PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	SCHNEIDER, H; SOLLNER, T; DIETMEIER, K; ECKERSKORN, C; LOTTSPEICH, F; TRULZSCH, B; NEUPERT, W; PFANNER, N				SCHNEIDER, H; SOLLNER, T; DIETMEIER, K; ECKERSKORN, C; LOTTSPEICH, F; TRULZSCH, B; NEUPERT, W; PFANNER, N			TARGETING OF THE MASTER RECEPTOR MOM19 TO MITOCHONDRIA	SCIENCE			English	Article							OUTER-MEMBRANE PROTEIN; PRECURSOR PROTEINS; IMPORT RECEPTOR; MATRIX; INSERTION; CARRIER; SITE	The targeting of proteins to mitochondria involves the recognition of the precursor proteins by receptors on the mitochondrial surface followed by insertion of the precursors into the outer membrane at the general insertion site GIP. Most mitochondrial proteins analyzed so far use a mitochondrial outer membrane protein of 19 kilodaltons (MOM19) as an import receptor. The gene encoding MOM19 has now been isolated. The deduced amino acid sequence predicts that MOM19 is anchored in the outer membrane by an NH2-terminal hydrophobic sequence, while the rest of the protein forms a hydrophilic domain exposed to the cytosol. MOM19 was targeted to the mitochondria via a pathway that is independent of protease-accessible surface receptors and controlled by direct assembly of the MOM19 precursor with GIP.	UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,W-8000 MUNICH 2,GERMANY; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	University of Munich; Max Planck Society	PFANNER, N (corresponding author), UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,W-8000 MUNICH 2,GERMANY.		Pfanner, Nikolaus/AAV-7878-2021					BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1988, TRENDS BIOCHEM SCI, V13, P165, DOI 10.1016/0968-0004(88)90140-5; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SOLLNER T, UNPUB; STEGER HF, 1990, J CELL BIOL, V111, P2355; STUART RA, 1987, EMBO J, V6, P2131, DOI 10.1002/j.1460-2075.1987.tb02480.x; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1991, J BIOL CHEM, V266, P6416; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	29	101	103	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1659	1662		10.1126/science.1661031	http://dx.doi.org/10.1126/science.1661031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1661031	Green Submitted			2022-12-24	WOS:A1991GV07300050
J	PEREIRA, JH; PALANDE, DD; SUBRAMANIAN, A; NARAYANAKUMAR, TS; CURTIS, J; TURK, JL				PEREIRA, JH; PALANDE, DD; SUBRAMANIAN, A; NARAYANAKUMAR, TS; CURTIS, J; TURK, JL			DENATURED AUTOLOGOUS MUSCLE GRAFT IN LEPROSY	LANCET			English	Note							PERIPHERAL-NERVE REPAIR	Autologous muscle grafts were used to repair 12 mixed peripheral nerves (9 posterior tibial, 3 median) in 10 patients with leprosy who had total anaesthesia and analgesia of the area supplied by the nerve. Postoperatively, 7 patients reported improved sensation in the foot or hand, with a return of vibration sense and joint position sense in 11 and of perception of a 10 g pin in 5; the ability to sweat in the affected area was also restored in 7.	ROYAL COLL SURG ENGLAND,DEPT PATHOL,35-43 LINCOLNS INN FIELDS,LONDON WC2A 3PN,ENGLAND; SACRED HEART LEPROSY CTR,TAMIL NADU 612401,INDIA	Royal College of Surgeons of England								ANTIA JH, 1970, INT J LEPROSY, V38, P12; FAWCETT JW, 1986, J NEUROSURG, V65, P354, DOI 10.3171/jns.1986.65.3.0354; GLASBY MA, 1986, NEURO-ORTHOPEDICS, V2, P21; GSCHMEISSNER SE, 1991, J BONE JOINT SURG BR, V73, P688, DOI 10.1302/0301-620X.73B4.2071663; NAPIER JR, 1949, BRAIN, V72, P63, DOI 10.1093/brain/72.1.63; NORRIS RW, 1988, J BONE JOINT SURG BR, V70, P530, DOI 10.1302/0301-620X.70B4.3403592; PEREIRA JH, 1990, J BONE JOINT SURG BR, V72, P874, DOI 10.1302/0301-620X.72B5.2170419; PEREIRA JH, IN PRESS J HAND SURG; Rao K S, 1987, Indian J Lepr, V59, P442	9	43	43	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1991	338	8777					1239	1240		10.1016/0140-6736(91)92105-B	http://dx.doi.org/10.1016/0140-6736(91)92105-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ166	1682647				2022-12-24	WOS:A1991GQ16600007
J	DESBOIS, C; AUBERT, D; LEGRAND, C; PAIN, B; SAMARUT, J				DESBOIS, C; AUBERT, D; LEGRAND, C; PAIN, B; SAMARUT, J			A NOVEL MECHANISM OF ACTION FOR V-ERBA - ABROGATION OF THE INACTIVATION OF TRANSCRIPTION FACTOR AP-1 BY RETINOIC ACID AND THYROID-HORMONE RECEPTORS	CELL			English	Article							RAT GROWTH-HORMONE; NEGATIVE REGULATION; RESPONSIVE ELEMENT; C-ERBA; GLUCOCORTICOID RECEPTOR; RETROVIRAL VECTORS; GENE-TRANSCRIPTION; FUNCTIONAL DOMAINS; JUN; EXPRESSION	Ligand-activated retinoic acid receptor-alpha (RAR-alpha) and c-ErbA-alpha repress the AP-1-mediated transcriptional activation of the interstitial collagenase gene promoter by specifically decreasing the activity of the AP-1 transcription factor. On the other hand, the v-ErbA oncoprotein fails to repress the AP-1 activity and acts as a dominant negative oncoprotein by overcoming the repression of the AP-1 activity induced by RAR-alpha and c-ErbA-alpha. This maintenance by v-ErbA of a fully active AP-1 complex is correlated with the abrogation by this same oncogene product of the growth-inhibitory response of chicken embryo fibroblasts to retinoic acid treatment. This new mechanism of action of v-ErbA together with its previously discovered dominant repressor effect on transcription of thyroid hormone-activated target genes may explain the contribution of the v-erbA oncogene to sarcomatogenic and leukemogenic transformation.	ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR49,F-69364 LYONS 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE	DESBOIS, C (corresponding author), UNIV CLAUDE BERNARD LYON 1,FAC MED ALEXIS CARREL,CNRS,UMR30,F-69372 LYONS 08,FRANCE.		Aubert, dominique/AAH-5854-2019; Samarut, Jacques/AAD-2587-2019; Morris, Christelle/M-8168-2014; Pain, Bertrand/A-7686-2015	Morris, Christelle/0000-0003-1575-4609; Pain, Bertrand/0000-0002-1210-8444; Aubert, Denise/0000-0002-1442-3384				AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, IN PRESS ONCOGENE; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIAZ JJ, 1989, ONCOL RES, V1, P163; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JANSSON M, 1987, ONCOGENE, V1, P167; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Oppenheimer J. H., 1983, MOL BASIS THYROID HO; PAIN B, 1990, New Biologist, V2, P284; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; URIER G, 1989, EMBO J, V8, P1447, DOI 10.1002/j.1460-2075.1989.tb03527.x; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	58	161	163	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					731	740		10.1016/0092-8674(91)90068-A	http://dx.doi.org/10.1016/0092-8674(91)90068-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1682056				2022-12-24	WOS:A1991GQ40700010
J	LEVINE, WC; SMART, JF; ARCHER, DL; BEAN, NH; TAUXE, RV				LEVINE, WC; SMART, JF; ARCHER, DL; BEAN, NH; TAUXE, RV			FOODBORNE DISEASE OUTBREAKS IN NURSING-HOMES, 1975 THROUGH 1987	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESCHERICHIA-COLI O157-H7; ROTAVIRUS INFECTION; SALMONELLA; GASTROENTERITIS; TRANSMISSION; SURVEILLANCE; FACILITIES; HOSPITALS; GUIDELINE	Objective. - To describe the epidemiology of foodborne disease outbreaks in nursing homes and to identify where preventive efforts might be focused. Data Sources. - Reports by state and local health departments of foodborne disease outbreaks occurring from January 1, 1975, through December 31, 1987. Study Selection. - Foodborne disease outbreaks reported to the Centers for Disease Control, Atlanta, Ga, on standard investigation forms. Data Extraction. - Each foodborne disease outbreak report was examined by an epidemiologist or statistician. Outbreaks were considered to have a known pathogen if confirmed by laboratory tests, and a known vehicle when an epidemiologic investigation implicated a specific food item. Data Synthesis. - From 1975 through 1987, 26 states reported 115 outbreaks of foodborne disease in nursing homes, causing illness in 4944 persons and death in 51. These outbreaks represented 2% of all reported foodborne disease outbreaks and 19% of outbreak-associated deaths in this period. Of 52 outbreaks with a known cause, Salmonella was the most frequently reported pathogen, accounting for 52% of outbreaks and 81% of deaths. Salmonella enteritidis outbreaks accounted for 56% of the Salmonella-associated deaths since 1981. The implicated food vehicles in S enteritidis outbreaks were made with eggs or prepared with equipment contaminated with eggs. Staphylococcal foodborne disease was the next most commonly identified cause, accounting for 23% of outbreaks. Conclusions. - Since the elderly are at high risk for serious morbidity from foodborne disease, nursing homes should practice careful food handling, preparation, and storage procedures; provide education for food handlers; and have active infection control programs to rapidly detect and control outbreaks of foodborne disease.	US FDA, CTR FOOD SAFETY & APPL NUTR, DIV MICROBIOL, WASHINGTON, DC 20204 USA	US Food & Drug Administration (FDA)	LEVINE, WC (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ENTER DIS BRANCH, ATLANTA, GA 30333 USA.							ASERKOFF B, 1969, NEW ENGL J MED, V281, P636, DOI 10.1056/NEJM196909182811202; AVORN J, 1981, NEW ENGL J MED, V305, P759, DOI 10.1056/NEJM198109243051309; BAINE WB, 1973, J INFECT DIS, V128, P357, DOI 10.1093/infdis/128.3.357; BARTLETT PC, 1982, PUBLIC HEALTH REP, V97, P258; Bean N H, 1990, MMWR CDC Surveill Summ, V39, P15; BLACK PH, 1960, NEW ENGL J MED, V262, P921, DOI 10.1056/NEJM196005052621806; BLACK PH, 1960, NEW ENGL J MED, V262, P864, DOI 10.1056/NEJM196004282621706; BLACK PH, 1960, NEW ENGL J MED, V262, P811, DOI 10.1056/NEJM196004212621606; BLASER MJ, 1981, J INFECT DIS, V143, P743, DOI 10.1093/infdis/143.5.743; BRYAN FL, 1968, J MILK FOOD TECHNOL, V31, P110, DOI 10.4315/0022-2747-31.4.110; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; CROSSLEY KB, 1985, JAMA-J AM MED ASSOC, V254, P2918, DOI 10.1001/jama.254.20.2918; CUBITT WD, 1981, J CLIN PATHOL, V34, P924, DOI 10.1136/jcp.34.8.924; CUBITT WD, 1980, J CLIN PATHOL, V33, P306, DOI 10.1136/jcp.33.3.306; GARIBALDI RA, 1981, NEW ENGL J MED, V305, P731, DOI 10.1056/NEJM198109243051304; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; GIANNELLA RA, 1971, AM J DIG DIS, V16, P1000, DOI 10.1007/BF02235012; GORDON SM, 1990, AM J EPIDEMIOL, V131, P702, DOI 10.1093/oxfordjournals.aje.a115554; GRIFFIN PM, 1988, ANN INTERN MED, V109, P705, DOI 10.7326/0003-4819-109-9-705; HOLMBERG SD, 1984, JAMA-J AM MED ASSOC, V251, P487, DOI 10.1001/jama.251.4.487; HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001; HONISH A, 1986, ALBERTA SOC SERV COM, V10, P363; JOSEPH CA, 1989, BRIT MED J, V298, P1161, DOI 10.1136/bmj.298.6681.1161; KAPLAN JE, 1982, AM J EPIDEMIOL, V116, P940, DOI 10.1093/oxfordjournals.aje.a113496; KAPLAN JE, 1982, AM J PUBLIC HEALTH, V72, P1329, DOI 10.2105/AJPH.72.12.1329; LEVINE WC, 1991, J INFECT DIS, V164, P81, DOI 10.1093/infdis/164.1.81; MARRIE TJ, 1982, ARCH INTERN MED, V142, P313, DOI 10.1001/archinte.142.2.313; NEILL MA, 1991, ANN INTERN MED, V114, P195, DOI 10.7326/0003-4819-114-3-195; NICOLLE LE, 1984, J AM GERIATR SOC, V32, P513, DOI 10.1111/j.1532-5415.1984.tb02236.x; PAVIA AT, 1990, J INFECT DIS, V161, P255, DOI 10.1093/infdis/161.2.255; REID JA, 1988, LANCET, V2, P321; RILEY LW, 1984, J INFECT DIS, V149, P878, DOI 10.1093/infdis/149.6.878; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SCHROEDER SA, 1968, NEW ENGL J MED, V279, P674, DOI 10.1056/NEJM196809262791303; SMITH PW, 1987, AM J INFECT CONTROL, V15, P97, DOI 10.1016/0196-6553(87)90162-3; STLOUIS ME, 1988, JAMA-J AM MED ASSOC, V259, P2103, DOI 10.1001/jama.259.14.2103; TAUXE RV, 1988, J INFECT DIS, V157, P370, DOI 10.1093/infdis/157.2.370; VLAHOV D, 1987, AM J INFECT CONTROL, V15, P47, DOI 10.1016/0196-6553(87)90001-0; WHITE KE, 1986, AM J EPIDEMIOL, V124, P120, DOI 10.1093/oxfordjournals.aje.a114356; WHITE KE, 1989, J INFECT DIS, V160, P298, DOI 10.1093/infdis/160.2.298; WILLIAMS WW, 1983, INFECT CONT HOSP EP, V4, P326; 1989, VITAL HLTH STAT 14, V33; 1990, MMWR, V38, P877; 1983, CAN DISEASE WEEKLY R, V9, P29	45	95	98	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2105	2109		10.1001/jama.266.15.2105	http://dx.doi.org/10.1001/jama.266.15.2105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1656108				2022-12-24	WOS:A1991GJ47400031
J	DOWDY, SF; FASCHING, CL; ARAUJO, D; LAI, KM; LIVANOS, E; WEISSMAN, BE; STANBRIDGE, EJ				DOWDY, SF; FASCHING, CL; ARAUJO, D; LAI, KM; LIVANOS, E; WEISSMAN, BE; STANBRIDGE, EJ			SUPPRESSION OF TUMORIGENICITY IN WILMS-TUMOR BY THE P15.5-P14 REGION OF CHROMOSOME-11	SCIENCE			English	Article							SHORT ARM; DELETION; ALLELES; CELLS; 11P13; GENES; LOCUS; DNA; HETEROZYGOSITY; CANCER	Wilms tumor has been associated with genomic alterations at both the 11p13 and 11p15 regions. To differentiate between the involvement of these two loci, a chromosome 11 was constructed that had one or the other region deleted, and this chromosome was introduced into the tumorigenic Wilms tumor cell line G401. When assayed for tumor-forming activity in nude mice, the 11p13-deleted, but not the 11p15.5-p14.1-deleted chromosome, retained its ability to suppress tumor formation. These results provide in vivo functional evidence for the existence of a second genetic locus (WT2) involved in suppressing the tumorigenic phenotype of Wilms tumor.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599	University of California System; University of California Irvine; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA044470] Funding Source: NIH RePORTER; NCI NIH HHS [CA19104, CA44470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BECKWITH JB, 1983, HUM PATHOL, V14, P481, DOI 10.1016/S0046-8177(83)80003-3; BEST LG, 1981, AM J MED GENET, V9, P291, DOI 10.1002/ajmg.1320090405; BROWN KW, 1989, BRIT J CANCER, V60, P25, DOI 10.1038/bjc.1989.213; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COMPTON DA, 1990, GENOMICS, V6, P309, DOI 10.1016/0888-7543(90)90571-B; DAVIS LM, 1988, GENOMICS, V3, P264, DOI 10.1016/0888-7543(88)90087-0; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; DOWDY SF, UNPUB; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LITTLE MH, 1988, HUM GENET, V79, P186, DOI 10.1007/BF00280564; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUNAGA E, 1981, HUM GENET, V57, P231; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P984; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; PLRITCHARDJONES K, 1990, NATURE, V364, P194; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROONEY CW, 1986, HUMAN CYTOGENETICS P; RUSSELL WC, 1975, NATURE, V253, P461, DOI 10.1038/253461a0; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SCOTT AF, 1979, P NATL ACAD SCI USA, V76, P4563, DOI 10.1073/pnas.76.9.4563; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; STANBRIDGE EJ, 1981, ISRAEL J MED SCI, V17, P563; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099	41	136	136	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					293	295		10.1126/science.1656527	http://dx.doi.org/10.1126/science.1656527			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1656527				2022-12-24	WOS:A1991GJ64200042
J	MACINTYRE, S; SOOMAN, A				MACINTYRE, S; SOOMAN, A			NON-PATERNITY AND PRENATAL GENETIC SCREENING	LANCET			English	Editorial Material							CYSTIC-FIBROSIS GENE				MACINTYRE, S (corresponding author), MRC,MED SOCIOL UNIT,6 LILYBANK GARDENS,GLASGOW G12 8QQ,SCOTLAND.		Macintyre, Sally/P-6246-2014; Ellaway, Anne/A-3065-2009					ASHTON GC, 1980, AM J HUM GENET, V32, P601; BELLIS MA, 1990, ANIM BEHAV, V40, P997, DOI 10.1016/S0003-3472(05)81008-5; EDWARDS J H, 1957, Br J Prev Soc Med, V11, P79; EMERY AEH, 1983, ELEMENTS MED GENETIC; GOODFELLOW PN, 1989, NATURE, V341, P102, DOI 10.1038/341102a0; Johnstone JM, 1954, BRIT J PREV SOC MED, V8, P117; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; SALMON D, 1980, AM J HUM GENET, V32, P432; SCHACHT LE, 1963, 2ND P INT C HUM GEN, P894; STEWART AD, 1989, NATURE, V341, P696, DOI 10.1038/341696b0; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; WOLSTENHOLME GEW, 1973, CIBA FDN S LOND DEC, P66	12	85	87	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1991	338	8771					869	871		10.1016/0140-6736(91)91513-T	http://dx.doi.org/10.1016/0140-6736(91)91513-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH945	1681226				2022-12-24	WOS:A1991GH94500015
J	PIACQUADIO, K; HOLLINGSWORTH, DR; MURPHY, H				PIACQUADIO, K; HOLLINGSWORTH, DR; MURPHY, H			EFFECTS OF INUTERO EXPOSURE TO ORAL HYPOGLYCEMIC DRUGS	LANCET			English	Article							DIABETIC MOTHERS; MALFORMATIONS; INFANTS; PREGNANCY	The observation that several Mexican-American women were taking oral hypoglycaemic agents while pregnant led to a study to confirm reports of associations between these agents and congenital abnormalities. 20 non-insulin-dependent (NIDDM) pregnant diabetic women with exposure to oral hypoglycaemic drugs during embryogenesis and 40 pregnant NIDDM women matched for age, race, parity, weight, and glycaemic control but not exposed to oral hypoglycaemic drugs were followed up. 10 infants (50%) in the exposed group had congenital malformations, compared with only 6 (15%) in the control group (p < 0.002). 5 (25%) infants in the exposed group had ear malformations, anomalies not commonly described in diabetic embryopathy. Hyperbilirubinemia (p < 0.04), polycythaemia, and hyperviscosity requiring partial exchange transfusions (p < 0.03) were commoner among babies in the exposed than in the control group. 3 babies in the exposed group but none in the comparison group had severe prolonged neonatal hypoglycaemia lasting 2, 4, and 7 days; 2 of the 3 had been exposed for 22 and 28 weeks during gestation, whereas the third had been exposed throughout the first trimester. Although exposure to oral hypoglycaemic drugs during fetal life seems to be associated with congenital malformations and neonatal hypoglycaemia, a large, prospective study is needed to exclude the confounding effect of maternal metabolic derangement secondary to diabetes.	UNIV CALIF SAN DIEGO,DEPT REPROD MED & MED 0802,LA JOLLA,CA 92093; USN HOSP,DEPT OBSTET & GYNECOL,SAN DIEGO,CA 92134	University of California System; University of California San Diego; United States Department of Defense; United States Navy			Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713				ADAM PAJ, 1968, PEDIATRICS, V42, P819; CALDERA R, 1970, Annales de Pediatrie (Paris), V17, P432; CAMPBELL GD, 1961, LANCET, V1, P891; Chung C S, 1975, Birth Defects Orig Artic Ser, V11, P1; COETZEE EJ, 1988, CONTROVERSIES DIABET, P56; DEMEYER R, 1958, SOC BELGE ENDOCRINOL, V19, P167; DEROT M, 1962, B MEM SOC MED HOP P, V113, P426; DOLGER H, 1962, DIABETES, V11, P97; FERNER RE, 1989, Q J MED, V73, P987; GHANEM MH, 1960, ALEXANDRIA MED J, V6, P14; GREENE MF, 1989, TERATOLOGY, V39, P225, DOI 10.1002/tera.1420390303; GRIX A, 1982, BIRTH DEFECTS-ORIG, V18, P55; JACKSON WPU, 1962, DIABETES, V11, P98; JOHNSON JP, 1982, AM J MED GENET, V13, P125, DOI 10.1002/ajmg.1320130204; KEMBALL ML, 1970, ARCH DIS CHILD, V45, P696, DOI 10.1136/adc.45.243.696; LARSSON Y, 1960, LANCET, V2, P1424; LAZAROW A, 1962, DIABETES, V11, P103; MALINS JM, 1964, BRIT MED J, V2, P187, DOI 10.1136/bmj.2.5402.187; MILLER DI, 1962, DIABETES, V11, P93; MILLS JL, 1979, DIABETES, V28, P292, DOI 10.2337/diabetes.28.4.292; MILLS JL, 1982, TERATOLOGY, V25, P385, DOI 10.1002/tera.1420250316; MOORE KL, 1973, DEV HUMAN CLIN ORIEN, P346; MOSS J M, 1965, Med Ann Dist Columbia, V34, P253; SCHIFF D, 1970, J PEDIATR-US, V77, P457, DOI 10.1016/S0022-3476(70)80015-4; STOWERS JM, 1975, CARBOHYD METABOL, P205; SUTHERLAND HW, 1973, BMJ-BRIT MED J, V3, P9, DOI 10.1136/bmj.3.5870.9; TUCHMANNDUPLESS.H, 1975, DRUG EFFECTS FETUS S, P198; Wilson JG, 1973, ENV BIRTH DEFECTS; ZUCKER P, 1968, PEDIATRICS, V42, P824	29	85	87	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1991	338	8771					866	869		10.1016/0140-6736(91)91512-S	http://dx.doi.org/10.1016/0140-6736(91)91512-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH945	1681225				2022-12-24	WOS:A1991GH94500014
J	HOEKMAN, K; VONBLOMBERGVANDERFLIER, BME; WAGSTAFF, J; DREXHAGE, HA; PINEDO, HM				HOEKMAN, K; VONBLOMBERGVANDERFLIER, BME; WAGSTAFF, J; DREXHAGE, HA; PINEDO, HM			REVERSIBLE THYROID-DYSFUNCTION DURING TREATMENT WITH GM-CSF	LANCET			English	Note							COLONY-STIMULATING FACTOR; ANTIGEN EXPRESSION; DENDRITIC CELLS; INDUCTION; INTERFERON; INVITRO; THERAPY	To investigate whether autoimmunity against thyroid antigens is induced or exacerbated by granulocyte-macrophage colony-stimulating factor, thyroid function and thyroid autoantibodies were studied in 14 patients with advanced breast cancer and 11 with soft-tissue sarcoma who received several cycles of doxorubicin and cyclophosphamide plus GM-CSF 250-mu-g/m2 intravenously daily for 10 days in every 21 day cycle. All patients had normal thyroid function before treatment. In 2 patients with pre-existing thyroid antibodies, thyroid dysfunction developed but disappeared after cessation of GM-CSF. No other autoimmune abnormalities appeared. Stimulation of antigen-presenting cells by GM-CSF may bring about this phenomenon.	FREE UNIV AMSTERDAM HOSP,DEPT MED ONCOL,DE BOELELAAN 1117,1007 MB AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,AMSTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT IMMUNOL,3000 DR ROTTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Erasmus University Rotterdam								ATKINS MB, 1988, NEW ENGL J MED, V318, P1557, DOI 10.1056/NEJM198806163182401; BURMAN P, 1986, J CLIN ENDOCR METAB, V63, P1086, DOI 10.1210/jcem-63-5-1086; HAZENBERG BPC, 1989, BLOOD, V74, P2769, DOI 10.1182/blood.V74.8.2769.2769; KUNG AWC, 1990, J CLIN ENDOCR METAB, V71, P1230, DOI 10.1210/jcem-71-5-1230; LIESCHKE GJ, 1989, ANN INTERN MED, V110, P357, DOI 10.7326/0003-4819-110-5-357; MARKOWICZ S, 1990, J CLIN INVEST, V85, P955, DOI 10.1172/JCI114525; MARTIN A, 1990, ENDOCRINOLOGY, V127, P651, DOI 10.1210/endo-127-2-651; SMITH PD, 1990, J IMMUNOL, V144, P3829; VOORBY HAM, 1990, CLIN IMMUNOL IMMUNOP, V55, P9, DOI 10.1016/0090-1229(90)90065-X; WEETMAN AP, 1985, J CLIN ENDOCR METAB, V61, P817, DOI 10.1210/jcem-61-5-817	10	57	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					541	542		10.1016/0140-6736(91)91103-2	http://dx.doi.org/10.1016/0140-6736(91)91103-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678803	Green Submitted			2022-12-24	WOS:A1991GD00200007
J	DEGRAEFFMEEDER, ER; VANDERZEE, R; RIJKERS, GT; SCHUURMAN, HJ; KUIS, W; BIJLSMA, JWJ; ZEGERS, BJM; VANEDEN, W				DEGRAEFFMEEDER, ER; VANDERZEE, R; RIJKERS, GT; SCHUURMAN, HJ; KUIS, W; BIJLSMA, JWJ; ZEGERS, BJM; VANEDEN, W			RECOGNITION OF HUMAN 60 KD HEAT-SHOCK PROTEIN BY MONONUCLEAR-CELLS FROM PATIENTS WITH JUVENILE CHRONIC ARTHRITIS	LANCET			English	Article							65-KILODALTON MYCOBACTERIAL ANTIGEN; RHEUMATOID-ARTHRITIS; TUBERCULOSIS; REACTIVITY; PATHOGENESIS; LYMPHOCYTES; THERAPY; CLONES	A postulated mechanism for autoimmune disorders is that the immunoreactivity develops against bacterial antigens which show a high degree of sequence homology with mammalian proteins. The mycobacterial 65 kD heat shock protein (hsp) has been implicated in several forms of arthritis. Substantial amounts of the human 60 kD homologue (hsp60) were produced by insertion of the gene into Escherichia coli. To investigate the hypothesis that T-cell reactivity is directed against the endogenous hsp, T-cell proliferation of synovial-fluid and peripheral-blood mononuclear cells in response to hsp60 was studied in samples from six patients with juvenile chronic arthritis (JCA) and nine adult patients with rheumatoid arthritis (RA). There was no T-lymphocyte proliferative response to purified fractions of hsp60 in mononuclear cells from RA patients or healthy children and young adults. However, both synovial-fluid and peripheral-blood mononuclear cells from JCA patients showed significant correlation between the stimulation indices for human hsp60 and for mycobacterial hsp65 (r = 0.948, p < 0.02). A similar correlation for hsp60 and mycobacterial hsp70 did not achieve significance. Immunohistochemistry showed that hsp65 and hsp70 homologues were expressed in the synovial membrane in these patients but not in controls. These findings suggest a sequence of events in which hsps become expressed during synovial inflammation and function as autoantigens. In JCA this may be manifested by specific T-cell reactivity which apparently is lost in the more bone-eroding and non-remitting adult disease.	NATL INST PUBL HLTH & ENVIRONM PROTECT,BILTHOVEN,NETHERLANDS; STATE UNIV UTRECHT HOSP,DEPT PATHOL,3511 GV UTRECHT,NETHERLANDS; STATE UNIV UTRECHT HOSP,DEPT INTERNAL MED,3511 GV UTRECHT,NETHERLANDS; STATE UNIV UTRECHT HOSP,DEPT RHEUMATOL,3511 GV UTRECHT,NETHERLANDS; STATE UNIV UTRECHT,FAC VET MED,INST INFECT DIS & IMMUNOL,UTRECHT,NETHERLANDS	Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University	DEGRAEFFMEEDER, ER (corresponding author), STATE UNIV UTRECHT,HET WILHELMINA KINDERZIEKENHUIS,DEPT IMMUNOL,POB 18009,3501 CA UTRECHT,NETHERLANDS.		Rijkers, Ger/AAW-6143-2020; van der Zee, Ruurd/O-5256-2015; Rijkers, Ger/R-7236-2019	van der Zee, Ruurd/0000-0002-4331-2755; Rijkers, Ger/0000-0001-6948-6123				ABRAHAMSEN TG, 1978, SCAND J IMMUNOL, V7, P81, DOI 10.1111/j.1365-3083.1978.tb00429.x; BAHR GM, 1988, CLIN EXP IMMUNOL, V74, P211; BILLINGHAM MEJ, 1990, J EXP MED, V171, P339, DOI 10.1084/jem.171.1.339; COHEN IR, 1986, IMMUNOL REV, V94, P5, DOI 10.1111/j.1600-065X.1986.tb01161.x; COHEN IR, 1985, ARTHRITIS RHEUM, V28, P841, DOI 10.1002/art.1780280802; DEGRAEFFMEEDER ER, 1990, AM J PATHOL, V137, P1013; DUDANI AK, 1989, INFECT IMMUN, V57, P2786, DOI 10.1128/IAI.57.9.2786-2793.1989; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; GASTON JSH, 1990, J EXP MED, V171, P831, DOI 10.1084/jem.171.3.831; GASTON JSH, 1989, J IMMUNOL, V143, P2492; HOLOSHITZ J, 1986, LANCET, V2, P305; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; JONES DB, 1990, LANCET, P583; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J; LYDYARD P, 1990, IMMUNOL TODAY, V2, P228; MEHLERT A, 1989, MOL MICROBIOL, V3, P125, DOI 10.1111/j.1365-2958.1989.tb01801.x; Munthe E, 1978, CARE RHEUMATIC CHILD, P47; OTTENHOFF THM, 1986, LANCET, V2, P310; PALACIOSBOIX AA, 1988, J IMMUNOL, V140, P1844; POPE RM, 1991, CELL IMMUNOL, V133, P95, DOI 10.1016/0008-8749(91)90182-B; RES PCM, 1988, LANCET, V2, P478, DOI 10.1016/S0140-6736(88)90123-7; RES PCM, 1990, LANCET, V336, P1406, DOI 10.1016/0140-6736(90)93104-W; STOKER NG, 1989, GENE, V78, P93, DOI 10.1016/0378-1119(89)90317-X; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; THOMPSON SJ, 1990, EUR J IMMUNOL, V20, P2479, DOI 10.1002/eji.1830201118; VANDENBROEK MF, 1989, J EXP MED, V170, P449, DOI 10.1084/jem.170.2.449; VANDENBROEK MF, 1989, APMIS, V97, P861; VANEDEN W, 1990, IMMUNOL RES, V9, P157, DOI 10.1007/BF02918175; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; VANEDENW, 1900, APMIS, V98, P383	30	173	180	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1368	1372		10.1016/0140-6736(91)93057-G	http://dx.doi.org/10.1016/0140-6736(91)93057-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674762				2022-12-24	WOS:A1991FP87000002
J	LITTLE, JM; AVRAMOVIC, J				LITTLE, JM; AVRAMOVIC, J			GALLSTONE FORMATION AFTER MAJOR ABDOMINAL-SURGERY	LANCET			English	Article							SLUDGE FORMATION; RISK-FACTORS; CHOLELITHIASIS; METABOLISM; COMPLICATION; VAGOTOMY; DISEASE	84 patients underwent multiple abdominal ultrasound examinations over a median of 36 months (range 6-140). 11 had gallstones at their first ultrasound examination, and were excluded from further analysis. Of the remaining 73 patients, 12 of 47 who underwent major abdominal surgery had gallstones within 14-36 months of operation, compared with 0 of 26 who did not undergo such surgery. The cumulative prevalence of new gallstones within 3 years of major surgery was 28%; no new gallstones were seen from 36 to up to 140 months postoperatively. By univariate and logistic regression analysis, age and major abdominal surgery were the only significant clinical determinants for the appearance of gallstones during follow-up. The findings of this retrospective study indicate that major abdominal surgery may accelerate the development of gallstones in some patients. If confirmed in a prospective study, it may be possible to define groups at high risk of gallstones after surgery and to institute prophylactic measures.	UNIV SYDNEY, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney	LITTLE, JM (corresponding author), WESTMEAD HOSP, DEPT SURG, WESTMEAD, NSW 2145, AUSTRALIA.							BENGMARK S, 1982, BILIARY TRACT, P270; BENNION LJ, 1978, NEW ENGL J MED, V299, P1221, DOI 10.1056/NEJM197811302992205; BENNION LJ, 1975, J CLIN INVEST, V56, P996, DOI 10.1172/JCI108180; BENNION LJ, 1978, NEW ENGL J MED, V299, P1161, DOI 10.1056/NEJM197811232992104; BOLONDI L, 1985, GUT, V26, P734, DOI 10.1136/gut.26.7.734; COWIE AGA, 1972, BRIT J SURG, V59, P365, DOI 10.1002/bjs.1800590508; DEITEL M, 1987, SURG GYNECOL OBSTET, V164, P549; DOTY JE, 1985, ANN SURG, V201, P76, DOI 10.1097/00000658-198520110-00011; DUANE WC, 1976, J LIPID RES, V17, P211; GOSBINK BR, 1976, SEMIN RADIOL, V11, P185; HARRISON EC, 1978, AM HEART J, V95, P483, DOI 10.1016/0002-8703(78)90240-5; HAUTERS P, 1988, BRIT J SURG, V75, P899, DOI 10.1002/bjs.1800750923; HEATON KW, 1969, BMJ-BRIT MED J, V3, P494, DOI 10.1136/bmj.3.5669.494; IHASZ M, 1981, AM J SURG, V141, P48, DOI 10.1016/0002-9610(81)90010-6; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LINDSTROM CG, 1977, SCAND J GASTROENTERO, V12, P341, DOI 10.3109/00365527709180938; LORUSSO D, 1988, SURGERY, V103, P579; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; MILLER MC, 1968, CAN MED ASSOC J, V98, P350; PITT HA, 1983, GASTROENTEROLOGY, V84, P1274; ROSLYN JJ, 1984, AM J SURG, V148, P58, DOI 10.1016/0002-9610(84)90289-7; SALEN G, 1975, GASTROENTEROLOGY, V69, P676; TOMPKINS RK, 1972, SURGERY, V71, P196	23	25	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	1991	337	8750					1135	1137		10.1016/0140-6736(91)92796-5	http://dx.doi.org/10.1016/0140-6736(91)92796-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674022				2022-12-24	WOS:A1991FL12400013
J	PALLESEN, G; HAMILTONDUTOIT, SJ; ROWE, M; YOUNG, LS				PALLESEN, G; HAMILTONDUTOIT, SJ; ROWE, M; YOUNG, LS			EXPRESSION OF EPSTEIN-BARR-VIRUS LATENT GENE-PRODUCTS IN TUMOR-CELLS OF HODGKINS-DISEASE	LANCET			English	Article							ESTABLISHED RODENT CELLS; MEMBRANE-PROTEIN; NASOPHARYNGEAL CARCINOMA; MALIGNANT-LYMPHOMAS; INFECTION; TRANSFORMATION; PATTERNS; TAMARINS; TISSUES; GENOMES	The Epstein-Barr virus (EBV)-encoded latent gene products, latent membrane protein (LMP) and EBV nuclear antigen 2 (EBNA 2), seem to have important roles in EBV-induced cell transformation in vitro, and have been implicated as important effector molecules in EBV-associated lymphomagenesis. Because up to 35% of Hodgkin's disease (HD) samples have been reported to contain EBV genomes, the expression of LMP and EBNA 2 in these tumours was investigated. 84 cases of HD were studied with monoclonal antibodies and immunohistochemical labelling of acetone-fixed cryostat sections. LMP, but not EBNA 2 was demonstrated in Reed-Sternberg (RS) cells of 40 cases (48%); the two proteins were easily detected in transformed lymphocytes of positive control acute infectious mononucleosis tonsils. LMP expression in RS cells varied according to the histological subtype of HD (1/10 cases [10%] of lymphocyte predominance subtype, 16/50 cases [32%] of nodular sclerosis, 23/24 [96%] cases of mixed cellularity type). That the LMP antibodies showed no substantial cross-reactivity with negative control tissues shows that they are useful probes for the diagnosis of latent EBV infection in tissue sections. The finding suggest that EBV is associated with more cases of HD than was previously recognised, that in positive cases RS cells express a latent infection protein phenotype (LMP +, EBNA 2-) which differs from that of other EBV-associated lymphomas, and the LMP expression is related to histologically aggressive subtypes of HD.	UNIV BIRMINGHAM,DEPT CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	PALLESEN, G (corresponding author), AARHUS UNIV,AARHUS KOMMUNE HOSP,INST PATHOL,IMMUNOHISTOL LAB,FINSENSGADE 12,DK-8000 AARHUS,DENMARK.		Rowe, Martin/B-2880-2009; Dutoit, Stephen Hamilton/E-1815-2013; Young, Lawrence S/B-7213-2009	Rowe, Martin/0000-0003-4139-7326; Young, Lawrence S/0000-0003-3919-4298; Hamilton-Dutoit, Stephen/0000-0003-2158-3885	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; CLEARY ML, 1985, SCIENCE, V228, P722, DOI 10.1126/science.2986287; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; EPSTEIN MA, 1986, LANCET, V1, P1425; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GUTENSOHN N, 1981, NEW ENGL J MED, V304, P135, DOI 10.1056/NEJM198101153040302; HARABUCHI Y, 1990, LANCET, V335, P128, DOI 10.1016/0140-6736(90)90002-M; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; JOHANSSO.B, 1970, INT J CANCER, V6, P450, DOI 10.1002/ijc.2910060316; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; LEVINE PH, 1971, CANCER-AM CANCER SOC, V27, P416, DOI 10.1002/1097-0142(197102)27:2<416::AID-CNCR2820270227>3.0.CO;2-W; MASIH A, 1990, LAB INVEST, V62, pA64; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; PALLESEN G, 1990, ORD M EUR ASS HAEM W, P1; PALLESEN G, 1990, 3RD M EUR ASS HAEM W, P1; POPPEMA S, 1985, AM J CLIN PATHOL, V84, P385, DOI 10.1093/ajcp/84.3.385; ROSDAHL N, 1974, BMJ-BRIT MED J, V2, P253, DOI 10.1136/bmj.2.5913.253; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; STAAL SP, 1989, AM J CLIN PATHOL, V91, P1; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEISS LM, 1987, AM J PATHOL, V129, P86; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; WOLF BC, 1990, AM J PATHOL, V136, P717; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; YOUNG LS, 1989, J VIROL, V63, P1967, DOI 10.1128/JVI.63.5.1967-1974.1989	30	658	663	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					320	322		10.1016/0140-6736(91)90943-J	http://dx.doi.org/10.1016/0140-6736(91)90943-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671232				2022-12-24	WOS:A1991EX36200003
J	WILCOCK, D; LANE, DP				WILCOCK, D; LANE, DP			LOCALIZATION OF P53, RETINOBLASTOMA AND HOST REPLICATION PROTEINS AT SITES OF VIRAL REPLICATION IN HERPES-INFECTED CELLS	NATURE			English	Article							SIMPLEX VIRUS TYPE-1; DNA-BINDING-PROTEIN; LARGE TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; GENE-PRODUCT; SV40-TRANSFORMED CELLS; SUSCEPTIBILITY GENE; AUXILIARY PROTEIN; POLYMERASE-DELTA; NUCLEAR ANTIGEN	REPLICATION of DNA occurs at DNA occurs at discrete sites in eukaryotic cell nuclei, where replication proteins are clustered into large complexes, or 'replicases' 1-3. Similarly, viral DNA replication is a highly structured process, notably in herpes simplex virus type-1 (HSV-1; reviewed in ref. 4) in which large globular "replication compartments' containing the viral replication machinery exist. Replicating cellular DNA redistributes to these compartments upon HSV-1 infection 5. We have now used antibodies raised against several cellular proteins to detect changes in their subnuclear localization on HSV-1 infection. We found that various proteins involved in cellular DNA replication move to sites of viral DNA synthesis, whereas a selection of non-replication proteins do not. The retinoblastoma protein and p53 (the products of two putative anti-oncogenes 6.7) relocate to the same sites as known DNA replication proteins, suggesting that they may be associated with DNA replication complexes in normal, uninfected cells.			WILCOCK, D (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BERNS KI, 1978, REPLICATION MAMMALIA, P13; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BROWN SM, 1973, J GEN VIROL, V18, P329, DOI 10.1099/0022-1317-18-3-329; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2187; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOX E, 1990, VIROLOGY, V176, P403, DOI 10.1016/0042-6822(90)90010-O; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KNIPE DM, 1987, J VIROL, V61, P276, DOI 10.1128/JVI.61.2.276-284.1987; KNIPE DM, 1989, ADV VIRUS RES, V37, P85; KOPS AD, 1988, CELL, V55, P857, DOI 10.1016/0092-8674(88)90141-9; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LERNER MR, 1980, NATURE, V283; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAO JCH, 1975, BIOCHEMISTRY-US, V14, P5475, DOI 10.1021/bi00696a015; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; OCHS R, 1983, EXP CELL RES, V146, P139, DOI 10.1016/0014-4827(83)90332-4; OLIVO PD, 1989, J VIROL, V63, P196, DOI 10.1128/JVI.63.1.196-204.1989; POWELL KL, 1981, J VIROL, V39, P894, DOI 10.1128/JVI.39.3.894-902.1981; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; QUINLAN MP, 1984, CELL, V36, P857, DOI 10.1016/0092-8674(84)90035-7; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; WALTON TH, 1989, J VIROL, V63, P3651, DOI 10.1128/JVI.63.9.3651-3660.1989; WASEEM NH, 1990, J CELL SCI, V96, P121; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLTER S, 1980, BIOCHIM BIOPHYS ACTA, V607, P420, DOI 10.1016/0005-2787(80)90152-5; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	42	249	252	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					429	431		10.1038/349429a0	http://dx.doi.org/10.1038/349429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1671528				2022-12-24	WOS:A1991EV51400056
J	VISKOCHIL, D; BUCHBERG, AM; XU, GF; CAWTHON, RM; STEVENS, J; WOLFF, RK; CULVER, M; CAREY, JC; COPELAND, NG; JENKINS, NA; WHITE, R; OCONNELL, P				VISKOCHIL, D; BUCHBERG, AM; XU, GF; CAWTHON, RM; STEVENS, J; WOLFF, RK; CULVER, M; CAREY, JC; COPELAND, NG; JENKINS, NA; WHITE, R; OCONNELL, P			DELETIONS AND A TRANSLOCATION INTERRUPT A CLONED GENE AT THE NEUROFIBROMATOSIS TYPE-1 LOCUS	CELL			English	Article									UNIV UTAH, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT HUMAN GENET, SALT LAKE CITY, UT 84132 USA; NCI, FREDERICK CANC RES & DEV CTR, APPL BIOSCI LABS, BASIC RES PROGRAM, FREDERICK, MD 21701 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	VISKOCHIL, D (corresponding author), UNIV UTAH, DEPT PEDIAT, SALT LAKE CITY, UT 84132 USA.			Buchberg, Arthur/0000-0002-0543-5631	PHS HHS [N01-CQ-74101] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BUCHBERG AM, 1990, IN PRESS MOL CELL BI; CAWTHON RM, 1990, IN PRESS GENOMICS; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOUNTAIN JW, 1989, SCIENCE, V244, P1085, DOI 10.1126/science.2543076; FRIEDMAN KD, 1988, NUCLEIC ACIDS RES, V16, P8718, DOI 10.1093/nar/16.17.8718; GARDINER K, 1986, SOMAT CELL MOLEC GEN, V12, P185, DOI 10.1007/BF01560665; GOLDGAR DE, 1989, AM J HUM GENET, V44, P6; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LEDBETTER DH, 1989, AM J HUM GENET, V44, P20; MENON AG, 1989, GENOMICS, V5, P245, DOI 10.1016/0888-7543(89)90053-0; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; OCONNELL P, 1989, AM J HUM GENET, V44, P51; OCONNELL P, 1989, SCIENCE, V244, P1087, DOI 10.1126/science.2543077; OCONNELL P, 1990, IN PRESS GENOMICS; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; SCHMIDT MA, 1987, AM J MED GENET, V28, P771, DOI 10.1002/ajmg.1320280333; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SEIZINGER BR, 1987, CELL, V49, P589, DOI 10.1016/0092-8674(87)90534-4; SELDEN RF, 1989, CURRENT PROTOCOLS MO	24	890	913	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	1990	62	1					187	192		10.1016/0092-8674(90)90252-A	http://dx.doi.org/10.1016/0092-8674(90)90252-A			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DN533	1694727				2022-12-24	WOS:A1990DN53300023
J	RONNETT, GV; HESTER, LD; NYE, JS; CONNORS, K; SNYDER, SH				RONNETT, GV; HESTER, LD; NYE, JS; CONNORS, K; SNYDER, SH			HUMAN CORTICAL NEURONAL CELL-LINE - ESTABLISHMENT FROM A PATIENT WITH UNILATERAL MEGALENCEPHALY	SCIENCE			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Nye, Jeffrey/G-6520-2012	Nye, Jeffrey/0000-0002-6056-281X	NIDA NIH HHS [DA 00074, DA 00266] Funding Source: Medline; NIMH NIH HHS [MH 18501] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		DAMBSKA M, 1984, BRAIN DEV-JPN, V6, P60, DOI 10.1016/S0387-7604(84)80012-1; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P175; GOODMAN R, 1986, DEV MED CHILD NEUROL, V28, P251; HOKFELT T, 1984, SCIENCE, V225, P1326, DOI 10.1126/science.6147896; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; MIKHAEL MA, 1978, J COMPUT ASSIST TOMO, V2, P291, DOI 10.1097/00004728-197807000-00009; PAHLMAN S, 1986, LAB INVEST, V54, P554; Sieber-Blum M, 1982, Prog Clin Biol Res, V85 Pt B, P485; SPEICHER DW, 1980, P NATL ACAD SCI-BIOL, V77, P5673, DOI 10.1073/pnas.77.10.5673	9	114	128	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 4	1990	248	4955					603	605		10.1126/science.1692158	http://dx.doi.org/10.1126/science.1692158			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB956	1692158				2022-12-24	WOS:A1990DB95600037
J	MONK, M; HOLDING, C				MONK, M; HOLDING, C			AMPLIFICATION OF A BETA-HEMOGLOBIN SEQUENCE IN INDIVIDUAL HUMAN OOCYTES AND POLAR BODIES	LANCET			English	Article											MONK, M (corresponding author), UNIV LONDON UNIV COLL, MRC, MAMMALIAN DEV UNIT, WOLFSON HOUSE, 4 STEPHENSON WAY, LONDON NW1 2HE, ENGLAND.							CAO A, 1989, MOL PROBES TECHNOLOG, P43; EMBURY SH, 1987, NEW ENGL J MED, V316, P656, DOI 10.1056/NEJM198703123161103; HOLDING C, 1989, LANCET, V2, P532; MARCOTTA C, 1977, J BIOL CHEM, V252, P5040; MONK M, 1987, LANCET, V2, P423; NICOLSON GL, 1975, J CELL BIOL, V66, P263, DOI 10.1083/jcb.66.2.263; Orkin S., 1987, MOL BASIS BLOOD DISE, P106; SERJEANT GR, 1985, SICKLE CELL DISEASE	8	62	63	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 28	1990	335	8696					985	988		10.1016/0140-6736(90)91060-N	http://dx.doi.org/10.1016/0140-6736(90)91060-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB072	1691429				2022-12-24	WOS:A1990DB07200001
J	SISODIA, SS; KOO, EH; BEYREUTHER, K; UNTERBECK, A; PRICE, DL				SISODIA, SS; KOO, EH; BEYREUTHER, K; UNTERBECK, A; PRICE, DL			EVIDENCE THAT BETA-AMYLOID PROTEIN IN ALZHEIMERS-DISEASE IS NOT DERIVED BY NORMAL PROCESSING	SCIENCE			English	Article									JOHNS HOPKINS UNIV, SCH MED, NEUROPATHOL LAB, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; UNIV HEIDELBERG, CTR MOLEC BIOL, W-6900 HEIDELBERG, GERMANY	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Ruprecht Karls University Heidelberg	SISODIA, SS (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE ON AGING [R35AG007914, P50AG005146, R01AG003359] Funding Source: NIH RePORTER; NIA NIH HHS [AG 05146, AG 07914, AG 03359] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; Maniatis T., 1982, MOL CLONING; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SISODIA SS, UNPUB; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WEIS JJ, 1988, J EXP MED, V167, P1047, DOI 10.1084/jem.167.3.1047; WISNIEWSKI HM, 1976, J NEUROL SCI, V27, P173, DOI 10.1016/0022-510X(76)90059-9; WONG CW, 1985, P NATL ACAD SCI USA, V82, P8729, DOI 10.1073/pnas.82.24.8729	28	857	888	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 27	1990	248	4954					492	495		10.1126/science.1691865	http://dx.doi.org/10.1126/science.1691865			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA756	1691865				2022-12-24	WOS:A1990DA75600047
J	EVERHART, JE; DIBISCEGLIE, AM; MURRAY, LM; ALTER, HJ; MELPOLDER, JJ; KUO, G; HOOFNAGLE, JH				EVERHART, JE; DIBISCEGLIE, AM; MURRAY, LM; ALTER, HJ; MELPOLDER, JJ; KUO, G; HOOFNAGLE, JH			RISK FOR NON-A, NON-B (TYPE-C) HEPATITIS THROUGH SEXUAL OR HOUSEHOLD CONTACT WITH CHRONIC CARRIERS	ANNALS OF INTERNAL MEDICINE			English	Note									CHIRON CORP, EMERYVILLE, CA USA; NIH, BETHESDA, MD 20205 USA	Novartis; National Institutes of Health (NIH) - USA								ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ARMITAGE P, 1971, STATISTICAL METHODS, P111; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; KAHN RA, 1982, AM J EPIDEMIOL, V115, P929, DOI 10.1093/oxfordjournals.aje.a113380; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467	10	259	260	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1990	112	7					544	545		10.7326/0003-4819-112-7-544	http://dx.doi.org/10.7326/0003-4819-112-7-544			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW001	1690526				2022-12-24	WOS:A1990CW00100010
J	MONACO, S; BONETTI, B; FERRARI, S; MORETTO, G; NARDELLI, E; TEDESCO, F; MOLLNES, TE; NOBILEORAZIO, E; MANFREDINI, E; BONAZZI, L; RIZZUTO, N				MONACO, S; BONETTI, B; FERRARI, S; MORETTO, G; NARDELLI, E; TEDESCO, F; MOLLNES, TE; NOBILEORAZIO, E; MANFREDINI, E; BONAZZI, L; RIZZUTO, N			COMPLEMENT-MEDIATED DEMYELINATION IN PATIENTS WITH IGM MONOCLONAL GAMMOPATHY AND POLYNEUROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV TRIESTE,IST PATOL GEN,TRIESTE,ITALY; UNIV VERONA,IST NEUROL,I-37134 VERONA,ITALY; UNIV VERONA,IST CHIM & MICROSCOPIA CLIN,I-37134 VERONA,ITALY; NATL HOSP NORWAY,INST IMMUNOL & RHEUMATOL,OSLO 1,NORWAY; UNIV MILAN,CTR DINO FERRARI,IST CLIN NEUROL,I-20122 MILAN,ITALY	University of Trieste; University of Verona; University of Verona; University of Oslo; National Hospital Norway; University of Milan			Monaco, Salvatore/K-4659-2018; Nobile-Orazio, Eduardo/B-7915-2013; Bonetti, Bruno/F-1431-2013; Tedesco, Francesco/F-1929-2011; Mollnes, Tom/ABI-5183-2020	Monaco, Salvatore/0000-0003-3191-8597; Nobile-Orazio, Eduardo/0000-0003-2624-8138; BONETTI, Bruno/0000-0002-3944-4165; ferrari, sergio/0000-0003-3855-5135				BRAUN PE, 1982, J NEUROCHEM, V39, P1261, DOI 10.1111/j.1471-4159.1982.tb12563.x; DALAKAS MC, 1981, ANN NEUROL, V10, P45, DOI 10.1002/ana.410100109; DYCK PJ, 1984, PERIPHERAL NEUROPATH, P760; FRAIL DE, 1984, MOL IMMUNOL, V21, P721, DOI 10.1016/0161-5890(84)90024-5; HAYS AP, 1987, NEUROLOGY, V37, P242, DOI 10.1212/WNL.37.2.242; HAYS AP, 1988, J NEUROIMMUNOL, V18, P231, DOI 10.1016/0165-5728(88)90101-4; IMAGAWA DK, 1983, P NATL ACAD SCI-BIOL, V80, P6647, DOI 10.1073/pnas.80.21.6647; JOHNSON AB, 1979, LAB INVEST, V40, P568; KELLY JJ, 1988, ARCH NEUROL-CHICAGO, V45, P1355, DOI 10.1001/archneur.1988.00520360073015; KELLY JJ, 1985, MUSCLE NERVE, V8, P138, DOI 10.1002/mus.880080210; KING RHM, 1984, ACTA NEUROPATHOL, V63, P319, DOI 10.1007/BF00687340; KOSKI CL, 1987, J CLIN INVEST, V80, P1492, DOI 10.1172/JCI113231; LATOV N, 1988, CRIT REV NEUROBIOL, V3, P301; LATOV N, 1987, POLYNEUROPATHIES ASS, P51; MENDELL JR, 1985, ANN NEUROL, V17, P243, DOI 10.1002/ana.410170305; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P183, DOI 10.1111/j.1365-3083.1985.tb01870.x; MOLLNES TE, 1987, SCAND J IMMUNOL, V26, P381, DOI 10.1111/j.1365-3083.1987.tb02270.x; MONACO S, 1985, P NATL ACAD SCI USA, V82, P920, DOI 10.1073/pnas.82.3.920; MORETTO G, 1987, ACTA NEUROPATHOL, V73, P344, DOI 10.1007/BF00688257; NOBILEORAZIO E, 1984, NEUROLOGY, V34, P1336, DOI 10.1212/WNL.34.10.1336; NOBILEORAZIO E, 1987, NEUROLOGY, V37, P1506, DOI 10.1212/WNL.37.9.1506; SHY ME, 1984, J IMMUNOL, V133, P2509; STECK AJ, 1983, NEUROLOGY, V33, P19, DOI 10.1212/WNL.33.1.19; STECK AJ, 1985, SPRINGER SEMIN IMMUN, V8, P29; STECK AJ, 1987, ANN NEUROL, V22, P764, DOI 10.1002/ana.410220614; STEFANSSON K, 1983, ACTA NEUROPATHOL, V59, P255, DOI 10.1007/BF00691490; STERNBERGER LA, 1978, IMMUNOCYTOCHEMISTRY; TAKATSU M, 1985, ANN NEUROL, V18, P173, DOI 10.1002/ana.410180203; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAPP BD, 1982, J CELL BIOL, V92, P877, DOI 10.1083/jcb.92.3.877	31	136	137	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	1990	322	10					649	652		10.1056/NEJM199003083221002	http://dx.doi.org/10.1056/NEJM199003083221002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR781	1689461				2022-12-24	WOS:A1990CR78100002
J	WILKINSON, DG; BHATT, S; HERRMANN, BG				WILKINSON, DG; BHATT, S; HERRMANN, BG			EXPRESSION PATTERN OF THE MOUSE T-GENE AND ITS ROLE IN MESODERM FORMATION	NATURE			English	Article									NATL INST MED RES,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research				Wilkinson, David/0000-0001-6757-7080				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEDDINGTON RSP, 1981, J EMBRYOL EXP MORPH, V64, P87; BEDDINGTON RSP, 1982, J EMBRYOL EXP MORPH, V69, P265; BEDDINGTON RSP, 1987, DEV MAMMALS, V5, P1; BELLAIRS R, 1986, ANAT EMBRYOL, V174, P1, DOI 10.1007/BF00318331; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIMOTO H, 1983, DIFFERENTIATION, V25, P44; Gluecksohn-Schoenheimer S, 1944, P NATL ACAD SCI USA, V30, P134, DOI 10.1073/pnas.30.6.134; GRUNEBERG H, 1958, J EMBRYOL EXP MORPH, V6, P424; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; PATERNO GD, 1989, DEVELOPMENT, V106, P79; SEARLE AG, 1966, GENET RES, V7, P86, DOI 10.1017/S0016672300009496; Slack J, 1983, EGG EMBRYO; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1988, DEVELOPMENT, V103, P591; SNELL GEORGE D., 1966, P205; TAM PPL, 1987, DEVELOPMENT, V99, P109; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YANAGISAWA KO, 1977, J EMBRYOL EXP MORPH, V40, P277; YANAGISAWA KO, 1981, DEV BIOL, V87, P242, DOI 10.1016/0012-1606(81)90147-0	24	708	727	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 15	1990	343	6259					657	659		10.1038/343657a0	http://dx.doi.org/10.1038/343657a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN989	1689462				2022-12-24	WOS:A1990CN98900069
J	TAN, JC; NOCKA, K; RAY, P; TRAKTMAN, P; BESMER, P				TAN, JC; NOCKA, K; RAY, P; TRAKTMAN, P; BESMER, P			THE DOMINANT W42 SPOTTING PHENOTYPE RESULTS FROM A MISSENSE MUTATION IN THE C-KIT RECEPTOR KINASE	SCIENCE			English	Article									SLOAN KETTERING MEM CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,MOLEC BIOL PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,DEPT CELL BIOL,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Cornell University				Traktman, Paula/0000-0002-6517-0225	NATIONAL CANCER INSTITUTE [P01CA016599, R01CA032926] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-16599, R01-CA-32926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJITA J, 1988, J CELL PHYSIOL, V134, P78, DOI 10.1002/jcp.1041340109; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LYON MF, 1984, GENET RES, V44, P161, DOI 10.1017/S0016672300026367; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MORAN MF, 1988, ONCOGENE, V3, P665; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, UNPUB; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Silvers W.K., 1979, COAT COLORS MICE, P206; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	22	274	282	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1990	247	4939					209	212		10.1126/science.1688471	http://dx.doi.org/10.1126/science.1688471			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH520	1688471				2022-12-24	WOS:A1990CH52000035
J	VERGE, CF; LAM, A; SIMPSON, JM; COWELL, CT; HOWARD, NJ; SILINK, M				VERGE, CF; LAM, A; SIMPSON, JM; COWELL, CT; HOWARD, NJ; SILINK, M			EFFECTS OF THERAPY IN X-LINKED HYPOPHOSPHATEMIC RICKETS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							D-RESISTANT RICKETS; VITAMIN-D; PRETERM INFANTS; PHOSPHATE; NEPHROCALCINOSIS; HEIGHT; CALCITRIOL; GROWTH	Background. Patients with X-linked hypophosphatemic rickets, which is clinically manifested by growth failure and bowing of the legs, are usually treated with phosphate and a vitamin D preparation. However, the efficacy of this treatment has been disputed, and nephrocalcinosis is a recognized complication of therapy. Methods. We studied 24 patients with X-linked hypophosphatemic rickets (9 boys and 15 girls) ranging in age from 1 to 16 years (median, 5.3). The duration of combination therapy ranged from 0.3 to 11.8 years (median, 3.0). We measured height as a standard-deviation (SD) score (the number of SDs from the mean height for chronologic age). Measurements made before the age of two years or after the onset of puberty were excluded. We compared the results with those reported in 1971 for 16 untreated prepubertal Australian patients. We also determined the severity of nephrocalcinosis (on a scale of 0 to 4, with 0 indicating no abnormalities and 4 stone formation) with renal ultrasonography and whether it could be related to the dosage of phosphate or vitamin D or to other factors. Results. Patients treated for at least two years before the onset of puberty (n = 19) had a mean height SD score of -1.08, as compared with -2.05 in the untreated historical controls. The 13 patients who had been treated with calcitriol and phosphate for at least two years had an increase in the mean height SD score of 0.33, from -1.58 to -1.25 (95 percent confidence interval, 0 to 0.67; P = 0.05). Nineteen of the 24 patients (79 percent) had nephrocalcinosis detected on renal ultrasonography. The grade of nephrocalcinosis was significantly correlated with the mean phosphate dose (r = 0.60, P = 0.002), but not with the dose of vitamin D or the duration of therapy. All patients had normal serum creatinine concentrations. Conclusions. Therapy with calcitriol and phosphate may increase the growth of children with X-linked hypophosphatemic rickets. Nephrocalcinosis in these children represents a complication of therapy and is associated with the dose of phosphate received.	CHILDRENS HOSP, RAY WILLIAMS INST PAEDIAT ENDOCRINOL DIABET & META, SYDNEY, AUSTRALIA; CHILDRENS HOSP, DEPT RADIOL, SYDNEY, AUSTRALIA; UNIV SYDNEY, DEPT PUBL HLTH, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney; University of Sydney; University of Sydney								ALON U, 1985, PEDIATRICS, V75, P754; BALSAN S, 1990, J PEDIATR-US, V116, P365, DOI 10.1016/S0022-3476(05)82822-7; CHAN JCM, 1985, J PEDIATR-US, V106, P533, DOI 10.1016/S0022-3476(85)80068-8; GLORIEUX FH, 1980, NEW ENGL J MED, V303, P1023, DOI 10.1056/NEJM198010303031802; GLORIEUX FH, 1972, NEW ENGL J MED, V287, P481, DOI 10.1056/NEJM197209072871003; GOODYER PR, 1987, J PEDIATR-US, V111, P700, DOI 10.1016/S0022-3476(87)80245-7; HAASE P, 1975, J ANAT, V119, P19; HITCHCOCK NE, 1986, MED J AUSTRALIA, V145, P373, DOI 10.5694/j.1326-5377.1986.tb112388.x; HOWARD CP, 1979, PEDIATR RES, V13, P380; HUFNAGLE KG, 1982, PEDIATRICS, V70, P360; KLEEREKOPER M, 1974, CLIN CHEM, V20, P369; PAK CYC, 1969, J CLIN INVEST, V48, P1914, DOI 10.1172/JCI106158; PATRIQUIN H, 1986, AM J ROENTGENOL, V146, P1253, DOI 10.2214/ajr.146.6.1253; POLISSON RP, 1985, NEW ENGL J MED, V313, P1, DOI 10.1056/NEJM198507043130101; RASMUSSEN H, 1981, J PEDIATR-US, V99, P16, DOI 10.1016/S0022-3476(81)80951-1; REUSZ GS, 1990, LANCET, V335, P1240, DOI 10.1016/0140-6736(90)91304-S; REUSZ GS, 1990, ARCH DIS CHILD, V65, P1125, DOI 10.1136/adc.65.10.1125; STEENDIJK R, 1971, HELV PAEDIATR ACTA, V26, P179; STICKLER GB, 1989, LANCET, V2, P902; STICKLER GB, 1988, AM J DIS CHILD, V142, P14, DOI 10.1001/archpedi.1988.02150010020009; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; TSURU N, 1987, AM J DIS CHILD, V141, P108, DOI 10.1001/archpedi.1987.04460010108039; WOOLFIELD N, 1988, ARCH DIS CHILD, V63, P86, DOI 10.1136/adc.63.1.86; 1976, PHS HRA761120 PUBL	24	169	176	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1991	325	26					1843	1848		10.1056/NEJM199112263252604	http://dx.doi.org/10.1056/NEJM199112263252604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW528	1660098				2022-12-24	WOS:A1991GW52800004
J	LEE, JA; LEE, HA; SADLER, PJ				LEE, JA; LEE, HA; SADLER, PJ			UREMIA - IS UREA MORE IMPORTANT THAN WE THINK	LANCET			English	Note							TRIMETHYLAMINE; ANTIDIURESIS; OSMOLYTES; KIDNEY; HUMANS	Urea is accumulated as an osmolyte by some groups of animals even though it impairs protein function. These organisms can withstand high internal urea concentrations because they also accumulate other low-molecular-weight osmolytes, the methylamines, which can offset the effects of urea on proteins. Methylamines have also been found in the medulla of the mammalian kidney (where urea concentrations are high) and in the plasma of human subjects with chronic renal failure. These findings suggest that previous investigations of the potential contribution of urea to the syndrome of uraemia may have been confounded because of the presence of variable concentrations of protective substances. That naturally occurring methylamines or related substances may prove to have a useful therapeutic role in uraemia is also possible.	ST MARYS HOSP,DEPT RENAL MED,PORTSMOUTH PO3 6AQ,HANTS,ENGLAND; UNIV LONDON BIRKBECK COLL,DEPT CHEM,CHRISTOPHER INGOLD LABS & GORDON HOUSE,LONDON WC1E 7HX,ENGLAND	University of London; Birkbeck University London	LEE, JA (corresponding author), UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT PATHOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							ALWAIZ M, 1987, CLIN PHARMACOL THER, V42, P608, DOI 10.1038/clpt.1987.207; ALWAIZ M, 1987, CLIN PHARMACOL THER, V42, P588, DOI 10.1038/clpt.1987.201; BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; BALABAN RS, 1987, KIDNEY INT, V31, P562, DOI 10.1038/ki.1987.36; BALABAN RS, 1983, AM J PHYSIOL, V245, pC438; BARSOTTI G, 1989, NUTR TREATMENT CHRON, P33; BATES JR, 1986, MAGNETIC RESONANCE M, V3, P849; BECK F, 1984, KIDNEY INT, V25, P397, DOI 10.1038/ki.1984.30; BELL JD, 1991, MAGN RESON MED, V17, P414, DOI 10.1002/mrm.1910170213; BELL JD, 1991, BIOCHIM BIOPHYS ACTA, V1096, P101, DOI 10.1016/0925-4439(91)90046-C; Bollman JL, 1927, P SOC EXP BIOL MED, V24, P923; BONAVENTURA J, 1974, SCIENCE, V186, P57, DOI 10.1126/science.186.4158.57; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BROWN JCC, 1989, MAGNET RESON MED, V11, P193, DOI 10.1002/mrm.1910110207; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; DAVIES SEC, 1988, CLIN CHIM ACTA, V178, P241, DOI 10.1016/0009-8981(88)90232-X; DIAMOND JR, 1990, AM J PHYSIOL, V258, pF1, DOI 10.1152/ajprenal.1990.258.1.F1; GILBOE DD, 1964, P SOC EXP BIOL MED, V115, P633; GUTMAN Y, 1971, BIOCHIM BIOPHYS ACTA, V233, P133, DOI 10.1016/0005-2736(71)90365-8; HUTCHINGS RH, 1966, ANN INTERN MED, V65, P275, DOI 10.7326/0003-4819-65-2-275; KNOCHEL JP, 1976, KIDNEY, P1448; MERRILL JP, 1953, AM J MED, V14, P519; SILIGARDI G, IN PRESS INT J PEPTI; Somero G. N., 1986, NEWS PHYSIOL SCI, V1, P9; SOMERO GN, 1986, AM J PHYSIOL, V251, pR197, DOI 10.1152/ajpregu.1986.251.2.R197; WILLS MR, 1978, METABOLIC CONSEQUENC; YANCEY PH, 1989, AM J PHYSIOL, V257, pF602, DOI 10.1152/ajprenal.1989.257.4.F602; YANCEY PH, 1979, BIOCHEM J, V183, P317, DOI 10.1042/bj1830317; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	29	25	26	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1991	338	8780					1438	1440		10.1016/0140-6736(91)92733-I	http://dx.doi.org/10.1016/0140-6736(91)92733-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT904	1683430				2022-12-24	WOS:A1991GT90400014
J	BUCHWALD, H				BUCHWALD, H			GASTRIC DECONTAMINATION IN PATIENT WITH GASTRIC STAPLING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BUCHWALD, H (corresponding author), UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3040	3040						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1687926				2022-12-24	WOS:A1991GR77500042
J	TAYLOR, JE; HENDERSON, IS; STEWART, WK; BELCH, JJF				TAYLOR, JE; HENDERSON, IS; STEWART, WK; BELCH, JJF			ERYTHROPOIETIN AND SPONTANEOUS PLATELET-AGGREGATION IN HEMODIALYSIS-PATIENTS	LANCET			English	Note							RECOMBINANT-HUMAN-ERYTHROPOIETIN; RENAL-FAILURE; BLOOD	Erythropoietin significantly, reversibly, and reproducibly increased in-vitro whole-blood spontaneous platelet aggregation in 15 patients on haemodialysis. During erythropoietin treatment, spontaneous platelet aggregation was significantly higher in these subjects than in non-uraemic controls; concomitant treatment with 300 mg aspirin daily reversed platelet hyperaggregability. Erythropoietin may promote thrombosis by an effect on platelet function.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT MED, DUNDEE DD1 9SY, SCOTLAND	University of Dundee	TAYLOR, JE (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, RENAL UNIT, DUNDEE DD1 9SY, SCOTLAND.		Belch, Jill/AAE-9189-2019	Belch, Jill/0000-0001-8280-6689				DIMINNO G, 1985, AM J MED, V79, P552, DOI 10.1016/0002-9343(85)90051-8; HEIDENREICH S, 1991, KIDNEY INT, V39, P259, DOI 10.1038/ki.1991.31; HOCKEN AG, 1982, NEPHRON, V32, P28, DOI 10.1159/000182727; KINDLER J, 1989, NEPHROL DIAL TRANSPL, V4, P345, DOI 10.1093/oxfordjournals.ndt.a091888; RAINE AEG, 1988, LANCET, V1, P97; SANIABADI AR, 1987, ATHEROSCLEROSIS, V66, P175, DOI 10.1016/0021-9150(87)90061-X; SANIABADI AR, 1989, ATHEROSCLEROSIS, V76, P149, DOI 10.1016/0021-9150(89)90098-1; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; VANGEET C, 1990, THROMB HAEMOSTASIS, V64, P7; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6	10	60	63	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 30	1991	338	8779					1361	1362		10.1016/0140-6736(91)92239-X	http://dx.doi.org/10.1016/0140-6736(91)92239-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682739				2022-12-24	WOS:A1991GR77300006
J	ROSENSTEIN, Y; PARK, JK; HAHN, WC; ROSEN, FS; BIERER, BE; BURAKOFF, SJ				ROSENSTEIN, Y; PARK, JK; HAHN, WC; ROSEN, FS; BIERER, BE; BURAKOFF, SJ			CD43, A MOLECULE DEFECTIVE IN WISKOTT-ALDRICH SYNDROME, BINDS ICAM-1	NATURE			English	Article								THE protein CD43 (also known as sialophorin, leukosialin, large sialoglycoprotein or gp115) is expressed on the surface of T lymphocytes, monocytes, neutrophils, platelets and some B lymphocytes 1-6. Expression of CD43 is deficient and/or defective in the X-chromosome-linked immunodeficiency disorder Wiscott-Aldrich syndrome 7, suggesting that CD43 might have a role in T-cell activation. We have shown that expression of human CD43 in an HLA-DR-specific murine T-cell hybridoma enhances the antigen-specific response to stimulation by the human lymphoblastoid cell line Daudi, and that Daudi cells bind specifically to purified immobilized CD43 (ref. 8). These data indicate that the specific interaction of CD43 with a ligand on the surface of Daudi cells might contribute to T-cell activation. Here we report evidence that intercellular adhesion molecule-1 (ICAM-1, or CD54), is a ligand for CD43.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CTR BLOOD RES, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	ROSENSTEIN, Y (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA.			Bierer, Barbara/0000-0001-6448-8170				ARDMAN B, 1990, J EXP MED, V172, P1151, DOI 10.1084/jem.172.4.1151; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BEYERS AD, 1989, IMMUNOL REV, V111, P59, DOI 10.1111/j.1600-065X.1989.tb00542.x; BIERER BE, 1988, P NATL ACAD SCI USA, V85, P1154; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CLARK EA, 1986, HUM IMMUNOL, V16, P100, DOI 10.1016/0198-8859(86)90039-X; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DORKEN B, 1989, LEUCOCYTE TYPING 4, P3; GAHMBERG CG, 1976, J CELL BIOL, V68, P642, DOI 10.1083/jcb.68.3.642; GOLDSTEIN SAN, 1986, J IMMUNOL, V137, P3383; GORGA JC, 1986, CELL IMMUNOL, V103, P160, DOI 10.1016/0008-8749(86)90077-8; HAHN WC, 1991, J IMMUNOL, V147, P14; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PARKMAN R, 1981, LANCET, V2, P1387; REMOLDODONNELL E, 1987, BLOOD, V70, P104; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1982, CELL IMMUNOL, V73, P1, DOI 10.1016/0008-8749(82)90431-2; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; SPRINGER TA, 1987, REV IMMUNOL, P223; STAUNTON DE, 1990, CELL, V61, P242; STOLL M, 1989, LEUCOCYTE TYPING 4, P605; TAKAI Y, 1987, P NATL ACAD SCI USA, V84, P6864, DOI 10.1073/pnas.84.19.6864; WICKEN M, 1988, SCAND J IMMUNOL, V28, P457	33	258	264	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1991	354	6350					233	235		10.1038/354233a0	http://dx.doi.org/10.1038/354233a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1683685				2022-12-24	WOS:A1991GQ94800050
J	KOTEN, JW; DENOTTER, W				KOTEN, JW; DENOTTER, W			ARE OMENTAL MILKY SPOTS AN INTESTINAL THYMUS	LANCET			English	Note								It is suggested that omental milky spots in young children, which in later life gradually transform into fatty tissue and only reappear during intraperitoneal infection, might influence the development of gastrointestinal immunity.	ACAD ZIEKENHUIS,DEPT EXPTL PATHOL,HEIDELBERGLAAN 100,3584 CX UTRECHT,NETHERLANDS									Dux K., 1988, OMENTUM RES CLIN APP, P19; Liebermann-Meffert D, 1983, GREATER OMENTUM ANAT, P1; LIEBERMANNMEFFE.D, 1991, 4TH INT S BIOL IMM S; SHIMOTSUMA M, 1989, ACTA ANAT, V136, P211; SHIMOTSUMA M, 1991, 4TH INT S BIOL IMM S	5	21	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1991	338	8776					1189	1190		10.1016/0140-6736(91)92043-2	http://dx.doi.org/10.1016/0140-6736(91)92043-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP034	1682602				2022-12-24	WOS:A1991GP03400015
J	WOOD, SA; PARK, JE; BROWN, WJ				WOOD, SA; PARK, JE; BROWN, WJ			BREFELDIN-A CAUSES A MICROTUBULE-MEDIATED FUSION OF THE TRANS-GOLGI NETWORK AND EARLY ENDOSOMES	CELL			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; I-CELL DISEASE; MHC CLASS-II; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; LYSOSOMAL-ENZYMES; COATED VESICLES; BETA-GLUCURONIDASE; SECRETORY PROTEINS; HUMAN-FIBROBLASTS	Brefeldin A (BFA) is a fungal metabolite that causes a redistribution of the stacked cisternae of the Golgi complex into the endoplasmic reticulum by inhibiting anterograde transport. We report that BFA also causes membrane tubules derived from the trans-Golgi network (TGN) to fuse with early endosomes. In the presence of BFA, a mannose-6-phosphate receptor (M6PR)-enriched tubular network rapidly forms from the TGN, not from the prelysosomal compartment, and can be labeled with endocytic tracers after only 5 min of uptake at either 20-degrees-C or 37-degrees-C, indicating that it is also functionally an early endosome. Formation of the TGN-early endosome network is microtubule dependent and may involve modification of membrane processes affected by microtubule-associated motor activity. Concomitant with the formation of the fused TGN-early endosome network, there is a > 5-fold increase in cell surface M6PRs. The data suggest that BFA has revealed a membrane transport cycle between the TGN and early endosomes, perhaps used for the secretion or delivery of molecules to the cell surface.			WOOD, SA (corresponding author), CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA.		Brown, William/GXN-2777-2022		NIADDK NIH HHS [AM 37249] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R23AM037249] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERGER EG, 1987, EXP CELL RES, V173, P267, DOI 10.1016/0014-4827(87)90352-1; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; BROWN WJ, 1990, EUR J CELL BIOL, V51, P201; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BROWN WJ, 1987, P NATL ACAD SCI USA, V84, P9001, DOI 10.1073/pnas.84.24.9001; CAMPBELL CH, 1983, J BIOL CHEM, V258, P3347; CAMPBELL CH, 1983, J BIOL CHEM, V258, P2628; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GONATAS NK, 1983, MOL CELL BIOL, V3, P91, DOI 10.1128/MCB.3.1.91; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1990, J CELL SCI, V95, P441; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; Handley D. A., 1989, COLLOIDAL GOLD PRINC, V1, P13; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; HO WC, 1989, EUR J CELL BIOL, V48, P250; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; JIN M, 1989, J BIOL CHEM, V264, P7675; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEMANSKY P, 1987, J CELL BIOL, V104, P1743, DOI 10.1083/jcb.104.6.1743; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NATOWICZ MR, 1979, P NATL ACAD SCI USA, V76, P4322, DOI 10.1073/pnas.76.9.4322; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1990, J CELL BIOL, V111, P1383, DOI 10.1083/jcb.111.4.1383; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1991, CELL, V64, P1183; PARK JE, 1991, J CELL BIOL, V112, P245, DOI 10.1083/jcb.112.2.245; PFEFFER SR, 1987, J CELL BIOL, V105, P229, DOI 10.1083/jcb.105.1.229; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SCHULZELOHOFF E, 1985, J CELL BIOL, V101, P824, DOI 10.1083/jcb.101.3.824; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; SWANSON J, 1987, J CELL BIOL, V104, P1217, DOI 10.1083/jcb.104.5.1217; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P6259, DOI 10.1073/pnas.80.20.6259; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WOODS JW, 1986, J CELL BIOL, V103, P277, DOI 10.1083/jcb.103.1.277; ZIJDERHANDBLEEKEMOLEN JE, 1987, J CELL BIOL, V104, P1647, DOI 10.1083/jcb.104.6.1647	68	379	380	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1991	67	3					591	600		10.1016/0092-8674(91)90533-5	http://dx.doi.org/10.1016/0092-8674(91)90533-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1657400				2022-12-24	WOS:A1991GN66400015
J	GOODRICH, DW; WANG, NP; QIAN, YW; LEE, EYHP; LEE, WH				GOODRICH, DW; WANG, NP; QIAN, YW; LEE, EYHP; LEE, WH			THE RETINOBLASTOMA GENE-PRODUCT REGULATES PROGRESSION THROUGH THE G1 PHASE OF THE CELL-CYCLE	CELL			English	Article							LARGE-T-ANTIGEN; SV40 LARGE-T; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; SUSCEPTIBILITY GENE; RB GENE; TERMINAL REGION; EXPRESSION; TUMORIGENICITY; IDENTIFICATION	The RB gene product is a nuclear phosphoprotein that undergoes cell cycle-dependent changes in its phosphorylation status. To test whether RB regulates cell cycle progression, purified RB proteins, either full-length or a truncated form containing the T antigen-binding region, were injected into cells. Injection of either protein early in G1 inhibits progression into S phase. Co-injection of anti-RB antibodies antagonizes this effect. Injection of RB into cells arrested at G1/S or late in G1 has no effect on BrdU incorporation, suggesting that RB does not inhibit DNA synthesis in S phase. These results indicate that RB regulates cell proliferation by restricting cell cycle progression at a specific point in G1 and establish a biological assay for RB activity. Neither co-injection of RB with a T antigen peptide nor injection into cells expressing T antigen prevents cells from progressing into S phase, which supports the hypothesis that T antigen binding has functional consequences for RB.			GOODRICH, DW (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,SAN ANTONIO,TX 78284, USA.							ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAMEL P, 1990, MOL CELL BIOL, V12, P6585; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HEINTZ NH, 1982, P NATL ACAD SCI-BIOL, V79, P4083, DOI 10.1073/pnas.79.13.4083; HENSEL CH, 1990, CANCER RES, V50, P3067; HONG F, 1991, IN PRESS BIOSCI REP; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Knudson A. G., 1973, ADV CANCER RES, V17, P317; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1990, TUMOR SUPPRESSOR GEN, V20, P159; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Maniatis T., 1982, MOL CLONING; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SOMPAYRAC L, 1988, VIROLOGY, V163, P391, DOI 10.1016/0042-6822(88)90279-6; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	62	725	736	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					293	302		10.1016/0092-8674(91)90181-W	http://dx.doi.org/10.1016/0092-8674(91)90181-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655277				2022-12-24	WOS:A1991GL47000009
J	LUNN, PG; NORTHROPCLEWES, CA; DOWNES, RM				LUNN, PG; NORTHROPCLEWES, CA; DOWNES, RM			INTESTINAL PERMEABILITY, MUCOSAL INJURY, AND GROWTH FALTERING IN GAMBIAN INFANTS	LANCET			English	Article							AUTOMATED ENZYMATIC ASSAYS; CATCH-UP GROWTH; DIARRHEA; LACTULOSE; MANNITOL; PROBES; URINE	There is controversy over whether children in developing countries can catch up on their growth rates after bouts of diarrhoea. A factor influencing catch-up growth is the extent and duration of mucosal injury. To explore the relation between intestinal disease and growth performance, a non-invasive test of intestinal integrity, the lactulose:mannitol permeability test, was done regularly on children aged 2-15 months, whose growth was monitored over a mean of 7.5 months. The study revealed persistent abnormalities in the small bowel mucosa of 2-15 month old Gambian infants and a negative correlation between these abnormalities and growth. Up to 43% of observed growth faltering can be explained on the basis of these long-term intestinal lesions.	MRC,DUNN NUTR CTR,KENEBA,SENEGAMBIA		LUNN, PG (corresponding author), MRC,DUNN NUTR CTR,CAMBRIDGE CB4 1XJ,ENGLAND.							BEHRENS RH, 1987, AM J CLIN NUTR, V45, P1433, DOI 10.1093/ajcn/45.6.1433; BRIEND A, 1990, LANCET, V335, P1157, DOI 10.1016/0140-6736(90)91159-8; BRIEND A, 1989, LANCET, V2, P319; BRUNSER O, 1990, NESTLE NUTR WORKS SE, V19, P261; ELIA M, 1987, CLIN SCI, V73, P197, DOI 10.1042/cs0730197; FORD RP, 1985, J PAEDIATRIC GASTROE, V4, P468; HAMMILL PVV, 1979, AM J CLIN NUTR, V32, P607; KEUSCH GT, 1990, NESTLE NUTR WORKS SE, V19, P37; LEBENTHAL E, 1986, NESTLE NUTRITION WOR, V6, P5; LIFSCHITZ C, 1985, J PEDIATR GASTR NUTR, V4, P520, DOI 10.1097/00005176-198508000-00003; LUNN PG, 1989, CLIN CHIM ACTA, V183, P163, DOI 10.1016/0009-8981(89)90332-X; LUNN PG, 1991, T ROY SOC TROP MED H, V85, P8, DOI 10.1016/0035-9203(91)90137-N; MOY RJD, 1990, LANCET, V335, P600; NORTHROP CA, 1990, CLIN CHIM ACTA, V187, P79, DOI 10.1016/0009-8981(90)90333-N; Prentice A., 1990, BREASTFEEDING NUTR I, P87; ROWLAND S G J G, 1985, Journal of Diarrhoeal Diseases Research, V3, P7; ROY SK, IN PRESS J PEDIATR G; SCHORLING JB, 1990, LANCET, V335, P599, DOI 10.1016/0140-6736(90)90378-I; SULLIVAN PB, IN PRESS J PEDIATR G; 1985, LANCET, V1, P256	20	266	271	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					907	910		10.1016/0140-6736(91)91772-M	http://dx.doi.org/10.1016/0140-6736(91)91772-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681266				2022-12-24	WOS:A1991GJ89900003
J	SALGAME, P; ABRAMS, JS; CLAYBERGER, C; GOLDSTEIN, H; CONVIT, J; MODLIN, RL; BLOOM, BR				SALGAME, P; ABRAMS, JS; CLAYBERGER, C; GOLDSTEIN, H; CONVIT, J; MODLIN, RL; BLOOM, BR			DIFFERING LYMPHOKINE PROFILES OF FUNCTIONAL SUBSETS OF HUMAN CD4 AND CD8 T-CELL CLONES	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; SUSCEPTIBLE BALB/C MICE; CHIMERA PRODUCE IL-5; HOST-REACTIVE CD4+; LYMPHOCYTE-T; IFN-GAMMA; INTERFERON-GAMMA; CUTANEOUS LEISHMANIASIS; MURINE LEISHMANIASIS; MONOCLONAL-ANTIBODY	Functional subsets of human T cells were delineated by analyzing patterns of lymphokines produced by clones from individuals with leprosy and by T cell clones of known function. CD4 clones from individuals with strong cell-mediated immunity produced predominantly interferon-gamma, whereas those clones that enhanced antibody formation produced interleukin-4. CD8 cytotoxic T cells secreted interferon-gamma. Interleukin-4 was produced by CD8 T suppressor clones from immunologically unresponsive individuals with leprosy and was found to be necessary for suppression in vitro. Both the classic reciprocal relation between antibody formation and cell-mediated immunity and resistance or susceptibility to certain infections may be explained by T cell subsets differing in patterns of lymphokine production.	DNAX RES INST MOLEC & CELLULAR BIOL INC, DEPT IMMUNOL, PALO ALTO, CA 94304 USA; INST BIOMED, CARACAS, VENEZUELA; STANFORD UNIV, MED CTR, DEPT CARDIOVASC SURG, PALO ALTO, CA 94304 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV DERMATOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SALGAME, P (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, BRONX, NY 10461 USA.		Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020111, P01AI026491] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07118, AI-26491, AI-20111] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE M, 1980, INT J LEPROSY, V51, P387; ABRAMS JM, UNPUB; ASHERSON GL, 1966, IMMUNOLOGY, V10, P179; AWWAD M, 1988, J EXP MED, V168, P2193, DOI 10.1084/jem.168.6.2193; BACCHETTA R, 1990, J IMMUNOL, V144, P902; BATTISTO JR, 1962, P SOC EXP BIOL MED, V111, P111; BLOOM BR, 1983, REV INFECT DIS, V5, P765; BOREL Y, 1966, J EXP MED, V123, P585, DOI 10.1084/jem.123.4.585; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; CLAYBERGER C, 1985, J EXP MED, V162, P1709, DOI 10.1084/jem.162.5.1709; Crowle A J, 1966, Clin Exp Immunol, V1, P323; DAMLE NK, 1984, J IMMUNOL, V132, P644; FERNANDEZBOTRAN R, 1988, J EXP MED, V168, P543, DOI 10.1084/jem.168.2.543; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GOLDSTEIN H, 1990, J IMMUNOL, V145, P952; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HILL JO, 1989, J EXP MED, V169, P1819, DOI 10.1084/jem.169.5.1819; HOWARD JG, 1981, J EXP MED, V153, P557, DOI 10.1084/jem.153.3.557; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KING CL, 1990, J CLIN INVEST, V85, P1810, DOI 10.1172/JCI114639; LAMB JR, 1982, J IMMUNOL, V128, P233; LEHN M, 1989, J IMMUNOL, V143, P3020; LI SG, 1990, EUR J IMMUNOL, V20, P1281, DOI 10.1002/eji.1830200613; MAGGI E, 1988, EUR J IMMUNOL, V18, P1045, DOI 10.1002/eji.1830180712; MAGGI E, 1991, J IMMUNOL, V146, P1169; MARTINEZ OM, 1990, J IMMUNOL, V144, P2211; MEHRA V, 1989, J IMMUNOL, V142, P2873; MODLIN RL, 1983, J AM ACAD DERMATOL, V8, P182, DOI 10.1016/S0190-9622(83)70021-6; MODLIN RL, 1988, P NATL ACAD SCI USA, V85, P1213, DOI 10.1073/pnas.85.4.1213; MODLIN RL, 1986, NATURE, V322, P459, DOI 10.1038/322459a0; MODLIN RL, 1986, J IMMUNOL, V137, P2831; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1991, IMMUNOPARASITOL TOD, pA49; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSSMANN TR, 1989, ANNU REV IMMUNOL, V145, P73; OTTENHOFF THM, 1986, NATURE, V322, P462, DOI 10.1038/322462a0; PALIARD X, 1988, J IMMUNOL, V141, P849; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; PELEMAN R, 1989, J EXP MED, V170, P1751, DOI 10.1084/jem.170.5.1751; POND L, 1989, J IMMUNOL, V143, P4232; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SALGAME P, 1991, P NATL ACAD SCI USA, V88, P2598, DOI 10.1073/pnas.88.6.2598; Salgame P, 1989, Int Immunol, V1, P121, DOI 10.1093/intimm/1.2.121; TITUS RG, 1985, J IMMUNOL, V135, P2108; UMETSU DT, 1988, J IMMUNOL, V140, P4211; VANVOORHIS WC, 1982, NEW ENGL J MED, V307, P1593, DOI 10.1056/NEJM198212233072601; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	53	1052	1076	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	1991	254	5029					279	282		10.1126/science.1681588	http://dx.doi.org/10.1126/science.1681588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1681588				2022-12-24	WOS:A1991GJ64200037
J	COHN, KH; WANG, FS; DESOTOLAPAIX, F; SOLOMON, WB; PATTERSON, LG; ARNOLD, MR; WEIMAR, J; FELDMAN, JG; LEVY, AT; LEONE, A; STEEG, PS				COHN, KH; WANG, FS; DESOTOLAPAIX, F; SOLOMON, WB; PATTERSON, LG; ARNOLD, MR; WEIMAR, J; FELDMAN, JG; LEVY, AT; LEONE, A; STEEG, PS			ASSOCIATION OF NM23-H1 ALLELIC DELETIONS WITH DISTANT METASTASES IN COLORECTAL-CARCINOMA	LANCET			English	Note							INDICATORS	A prospective study analysed the prognostic value of nm23-H1 allelic deletions in colorectal cancer. Of 21 patients with no evidence of distant metastases at initial operation, 11 showed nm23-H1 allelic deletions (including 1 homozygous deletion); 10 had no nm23-H1 deletions. After median follow-up of 25 months, distant metastases had developed in 8 of 11 (73%) patients with nm23-H1 deletions but in only 2 of 10 (20%) without nm23-H1 deletions (p < 0.03). Tests with probe YNZ 22.1, near p53, showed no significant association with distant metastases. nm23-H1 may be, or may be located near, a late-acting suppressor gene in colorectal carcinoma, in which deletions may have prognostic value.	SUNY HLTH SCI CTR,DEPT MED,BROOKLYN,NY; SUNY HLTH SCI CTR,DEPT SURG,BROOKLYN,NY; SUNY HLTH SCI CTR,DEPT PREVENT MED & COMMUNITY HLTH,BROOKLYN,NY; NCI,PATHOL LAB,BETHESDA,MD 20892; VET ADM MED CTR,DEPT PATHOL,BROOKLYN,NY 11209	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Department of Veterans Affairs; Veterans Health Administration (VHA)	COHN, KH (corresponding author), VET ADM MED CTR,DEPT SURG 112,800 POLY PL,BROOKLYN,NY 11209, USA.		leone, alvaro/AAQ-7051-2020; Leone, Alvaro/K-6410-2016	Leone, Alvaro/0000-0003-3815-9052				BEVILACQUA G, 1989, CANCER RES, V49, P5185; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HAMMSDAHL E, 1988, J SURG ONCOL, V37, P109; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1991, CANCER RES, V51, P2490; MEHTA CR, 1988, J AM STAT ASSOC, V83, P999; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; WIGGERS T, 1988, CANCER, V61, P386, DOI 10.1002/1097-0142(19880115)61:2<386::AID-CNCR2820610231>3.0.CO;2-J	10	154	164	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1991	338	8769					722	724		10.1016/0140-6736(91)91444-Y	http://dx.doi.org/10.1016/0140-6736(91)91444-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679868				2022-12-24	WOS:A1991GG10400005
J	FRIBERG, L; OLESEN, J; IVERSEN, HK; SPERLING, B				FRIBERG, L; OLESEN, J; IVERSEN, HK; SPERLING, B			MIGRAINE PAIN ASSOCIATED WITH MIDDLE CEREBRAL-ARTERY DILATATION - REVERSAL BY SUMATRIPTAN	LANCET			English	Article							BLOOD-FLOW; CLASSIC MIGRAINE; 5-HT1-LIKE RECEPTOR; COMMON MIGRAINE; ATTACKS; GR43175; ISCHEMIA; TOMOGRAPHY; HEADACHE; AGONIST	The combination of measurements of regional cerebral blood flow (rCBF) and blood velocity in the middle cerebral arteries (MCA) by transcranial doppler sonography was used to investigate cerebrovascular involvement in migraine. Ten migraine patients with unilateral headache were studied during an attack and when they had been free of attacks for 5 days (non-attack). On both occasions they were given an intravenous infusion of sumatriptan (2 mg), a 5-HT1-like receptor agonist, which relieved the symptoms within 30 min without affecting rCBF. The MCA velocity was normal on both sides on the non-attack day and on the unaffected side during the attack. However, during the attack the MCA velocity on the headache side was significantly lower than that on the nonheadache side (45 vs 61 cm/s:mean difference 16.3 [95% confidence interval 10.3-22.3]; p = 0.02). The MCA velocity on the headache side returned to normal after treatment with sumatriptan and recovery. Since rCBF in the MCA supply territory was unaffected, the lower velocity can be explained only by dilatation of the MCA. The mean MCA diameter increase was estimated to be 20%. Thus, headache was associated with intracranial large arterial dilatation on the headache side. Sumatriptan predominantly had effects on the distended artery, which suggests that the 5-HT receptor system has a role in the pathogenesis of migraine.	GENTOFTE HOSP,DEPT NEUROL,DK-2900 COPENHAGEN,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital	FRIBERG, L (corresponding author), BISWAS & ASSOCIATES,DEPT CLIN PHYSIOL & NUCL MED,OTTAWA K2H 5Y6,ONTARIO,CANADA.		Iversen, Helle Klingenberg/B-9154-2009; Iversen, Helle Klingenberg/P-5726-2019	Iversen, Helle Klingenberg/0000-0002-5880-6352; Olesen, Jes/0000-0002-6712-2702				AASLID R, TRANSCRANIAL DOPPLER, P19; ANDERSEN AR, 1988, ARCH NEUROL-CHICAGO, V45, P154, DOI 10.1001/archneur.1988.00520260040017; ATKINS HL, 1980, J NUCL MED, V21, P459; CELSIS P, 1981, J COMPUT ASSIST TOMO, V5, P641, DOI 10.1097/00004728-198110000-00006; DECLERCK F, 1985, SEROTONIN CARDIOVASC, P155; DOENICKE A, 1988, LANCET, V1, P1309; EDVINSSON L, 1989, CEPHALALGIA S10, V9, P39; FENIUK W, 1989, BRIT J PHARMACOL, V96, P83, DOI 10.1111/j.1476-5381.1989.tb11787.x; FRIBERG L, 1987, BRAIN, V110, P917, DOI 10.1093/brain/110.4.917; FRIBERG L, 1989, CEPHALALGIA S10, V9, P29; HARPER AM, 1977, J PHYSIOL-LONDON, V271, P735, DOI 10.1113/jphysiol.1977.sp012023; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HUMPHREY PPA, 1988, BRIT J PHARMACOL, V94, P1123, DOI 10.1111/j.1476-5381.1988.tb11630.x; IVERSEN HK, 1990, LANCET, V336, P837, DOI 10.1016/0140-6736(90)92339-J; JENSEN K, 1985, ACTA NEUROL SCAND, V72, P561; JENSEN K, 1987, ACTA NEUROL SCAND, V75, P310, DOI 10.1111/j.1600-0404.1987.tb05452.x; LASSEN NA, 1978, J COMPUT ASSIST TOMO, V2, P661, DOI 10.1097/00004728-197811000-00047; LAURITZEN M, 1983, ANN NEUROL, V13, P633, DOI 10.1002/ana.410130609; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; Moskowitz M., 1988, BASIC MECH HEADACHE, P429; OLESEN J, 1990, ANN NEUROL, V28, P791, DOI 10.1002/ana.410280610; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; OLESEN J, 1981, LANCET, V2, P438; OLSEN TS, 1987, ARCH NEUROL-CHICAGO, V44, P156, DOI 10.1001/archneur.1987.00520140028013; PARSONS AA, 1989, BRIT J PHARMACOL, V96, P434, DOI 10.1111/j.1476-5381.1989.tb11835.x; SKINHOJ E, 1973, ARCH NEUROL-CHICAGO, V29, P95, DOI 10.1001/archneur.1973.00490260039007; TFELTHANSEN P, 1989, CEPHALALGIA, V9, P73; THIE A, 1990, HEADACHE, V30, P209, DOI 10.1111/j.1526-4610.1990.hed3004209.x; YOUNG AR, 1987, NEURONAL MESSENGERS, P57	29	337	337	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					13	17		10.1016/0140-6736(91)90005-A	http://dx.doi.org/10.1016/0140-6736(91)90005-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676084				2022-12-24	WOS:A1991FV29600004
J	SCOTT, NA; LEINHARDT, DJ; OHANRAHAN, T; FINNEGAN, S; SHAFFER, JL; IRVING, MH				SCOTT, NA; LEINHARDT, DJ; OHANRAHAN, T; FINNEGAN, S; SHAFFER, JL; IRVING, MH			SPECTRUM OF INTESTINAL FAILURE IN A SPECIALIZED UNIT	LANCET			English	Article							HOME PARENTERAL-NUTRITION; FISTULAS; MANAGEMENT; TRACT	300 consecutive admissions over 7 years to a purpose-built intestinal failure unit are reviewed. The commonest underlying condition was Crohn's disease (42%), and the commonest complication precipitating admission was intestinal fistula (42%). Total parenteral nutrition was used in 85% and surgery in 50%. A multidisciplinary approach to management gave a high success rate-90% of patients were discharged from hospital, although nearly 25% needed home parental nutrition. These results suggest that chronic intestinal failure should be managed in specialised units in the same manner as other types of organ failure.	UNIV MANCHESTER, HOPE HOSP, DEPT SURG, NUTR UNIT, ECCLES OLD RD, SALFORD M6 8HD, LANCS, ENGLAND; UNIV MANCHESTER, HOPE HOSP, DEPT MED, SALFORD M6 8HD, LANCS, ENGLAND	University of Manchester; University of Manchester								BURY KD, 1971, AM J SURG, V121, P174, DOI 10.1016/0002-9610(71)90096-1; FISCHER JE, 1976, TOTAL PARENTERAL NUT, P127; FLEMING CR, 1981, CLIN SURGERY INT, P219; IRVING M, 1985, ANN ROY COLL SURG, V67, P2; KETTLEWELL MGW, 1983, BRIT MED J, V286, P1323; LEREBOURS E, 1988, JPEN-PARENTER ENTER, V12, P360, DOI 10.1177/0148607188012004360; LEVY E, 1988, BRIT J SURG, V75, P549, DOI 10.1002/bjs.1800750615; MCINTYRE PB, 1984, BRIT J SURG, V71, P293, DOI 10.1002/bjs.1800710416; MUGHAL M, 1986, LANCET, V2, P383; MUGHAL MM, 1989, BRIT J SURG, V76, P15, DOI 10.1002/bjs.1800760107; PADBERG FT, 1981, ANN SURG, V193, P264, DOI 10.1097/00000658-198103000-00002; PETTIGREW RA, 1985, BRIT J SURG, V72, P52, DOI 10.1002/bjs.1800720121; ROSE D, 1986, SURG GYNECOL OBSTET, V163, P345; STOKES MA, 1988, BRIT J SURG, V75, P481, DOI 10.1002/bjs.1800750524	14	33	33	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 23	1991	337	8739					471	473		10.1016/0140-6736(91)93403-V	http://dx.doi.org/10.1016/0140-6736(91)93403-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671480				2022-12-24	WOS:A1991EY88700014
J	HELFGOTT, SM; MOSCISCKI, RA; MARTIN, JS; LORENZO, C; KIEVAL, R; MCKENNA, M; NADOL, J; TRENTHAM, DE				HELFGOTT, SM; MOSCISCKI, RA; MARTIN, JS; LORENZO, C; KIEVAL, R; MCKENNA, M; NADOL, J; TRENTHAM, DE			CORRELATION BETWEEN ANTIBODIES TO TYPE-II COLLAGEN AND TREATMENT OUTCOME IN BILATERAL PROGRESSIVE SENSORINEURAL HEARING-LOSS	LANCET			English	Article							INNER-EAR DISEASE; RELAPSING POLYCHONDRITIS; RHEUMATOID-ARTHRITIS; SERUM ANTIBODIES; AUTOIMMUNITY	Our aim was to assess whether "idiopathic" bilateral progressive sensorineural hearing loss (BPSHL) has an immunological cause in some patients; antibodies to native type II collagen were sought by an ELISA in eighteen patients with BPSHL, before and after corticosteroid treatment, and in twelve patients with Meniere's disease, fifteen with otosclerosis, eighteen with rheumatoid arthritis, nine with fibrositis, and nine healthy controls. A positive result was defined as a mean dilution titre of 2 or more. Eight of eighteen BPSHL patients had positive titres - significantly (p < 0.005) more than in any other group (one Meniere's disease, two otosclerosis, and no others). The mean antibody titre was higher in the BPSHL group than in any other group (2.02[SEM 0.62] vs 0.17 [0.17]) Meniere's disease, 0.44 [0.32] otosclerosis, 0 all others; p < 0.005). The nine BPSHL patients who showed a clinical response to corticosteroids (improvement in at least one tone by audiogram or 25 db in speech discrimination score) had the highest mean antibody titre (3.46 [0.88] vs 0.59 [0.59] for the nine non-responsive patients; p < 0.04). We suggest that in some patients with BPSHL, immunity to type II collagen, a major constituent of the inner ear, may be important in the pathogenesis of the disorder.	MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; MASSACHUSETTS EYE & EAR HOSP,DIV OTORHINOLARYNGOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	HELFGOTT, SM (corresponding author), BETH ISRAEL HOSP,DEPT MED,RES E,ROOM 319,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							ADAMS RD, 1985, PRINCIPLES NEUROLOGY, P211; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; ARNOLD W, 1985, ACTA OTO-LARYNGOL, V99, P437, DOI 10.3109/00016488509108935; BOWMAN CA, 1987, LARYNGOSCOPE, V97, P7; CLAGUE RB, 1983, ANN RHEUM DIS, V42, P537, DOI 10.1136/ard.42.5.537; FOIDART JM, 1978, NEW ENGL J MED, V299, P1203, DOI 10.1056/NEJM197811302992202; HARRIS JP, 1986, ANN OTO RHINOL LARYN, V95, P176, DOI 10.1177/000348948609500214; HUGHES GB, 1986, LARYNGOSCOPE, V96, P502, DOI 10.1288/00005537-198605000-00006; HUGHES GB, 1984, LARYNGOSCOPE, V94, P758; KAKANI RS, 1990, J OTOLARYNGOL, V19, P100; LEUTJE CM, 1989, LARYNGOSCOPE, V99, P1137; MARKUSSE HM, 1988, ANN RHEUM DIS, V47, P600, DOI 10.1136/ard.47.7.600; MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501; MOLONEY JR, 1978, J LARYNGOL OTOL, V92, P9, DOI 10.1017/S0022215100084875; MOSCICKI R, 1990, Journal of Allergy and Clinical Immunology, V85, P149; PLESTER D, 1989, AM J OTOL, V10, P188; TRENTHAM DE, 1983, J IMMUNOL, V130, P2684; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; YOO TJ, 1985, AM J OTOLARYNG, V6, P209, DOI 10.1016/S0196-0709(85)80087-9; YOO TJ, 1983, SCIENCE, V222, P65, DOI 10.1126/science.6623056; YOO TJ, 1982, SCIENCE, V217, P1153, DOI 10.1126/science.7112122; YOO TJ, 1984, J LARYNGOL OTOL, V9, P220; YOO TJ, 1985, AM J OTOL, V6, P95	23	48	48	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					387	389		10.1016/0140-6736(91)91165-Q	http://dx.doi.org/10.1016/0140-6736(91)91165-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671423				2022-12-24	WOS:A1991EX60500003
J	AURELIUS, E; JOHANSSON, B; SKOLDENBERG, B; STALAND, A; FORSGREN, M				AURELIUS, E; JOHANSSON, B; SKOLDENBERG, B; STALAND, A; FORSGREN, M			RAPID DIAGNOSIS OF HERPES-SIMPLEX ENCEPHALITIS BY NESTED POLYMERASE CHAIN-REACTION ASSAY OF CEREBROSPINAL-FLUID	LANCET			English	Article							LINKED IMMUNOSORBENT-ASSAY; ENZYMATIC AMPLIFICATION; VIRUS ENCEPHALITIS; SERODIAGNOSIS; VIDARABINE; ACYCLOVIR; THERAPY; DNA	With the aim of improving early diagnosis of herpes simplex encephalitis a polymerase chain reaction (PCR) assay with two "nested" primer pairs was developed for the amplification of herpes simplex virus DNA in cerebrospinal fluid (CSF). Southern blotting was used to confirm the specificity of the amplification. The assay was applied to 151 CSF samples from 43 consecutive patients with herpes simplex encephalitis verified by the finding of herpes simplex virus/viral antigen in a brain biopsy sample or at necropsy (13) and/or intrathecal production of IgG antibody to the virus (40). As controls, 87 CSF samples from 60 patients with acute febrile focal encephalopathy (initially suspected to be herpes simplex encephalitis but excluded by the absence of intrathecal antibody synthesis) were tested. PCR detected herpes simplex virus DNA in 42 of the 43 patients with proven herpes simplex encephalitis; all but 1 were positive in the first CSF sample taken. The 1 PCR-negative patient had been treated with acyclovir from 20 h after the onset of symptoms. All the control subjects were PCR negative, as were 270 internal contamination controls. The PCR result remained positive in samples drawn up to 27 days after the onset of neurological symptoms. This method is a rapid and non-invasive means to diagnose herpes simplex encephalitis; it is highly sensitive and specific.	CENT MICROBIOL LAB,DEPT VIROL,STOCKHOLM,SWEDEN		AURELIUS, E (corresponding author), KAROLINSKA INST,DANDERYD HOSP,DEPT INFECT DIS,S-18288 DANDERYD,SWEDEN.							ANDERSON N E, 1989, Australian and New Zealand Journal of Medicine, V19, P635; AURELIUS E, 1989, SERODIAG IMMUN INF D, V3, P249, DOI 10.1016/0888-0786(89)90005-X; BOERMAN RH, 1989, J VIROL METHODS, V25, P189, DOI 10.1016/0166-0934(89)90032-3; BOS CA, 1987, J MED VIROL, V21, P169, DOI 10.1002/jmv.1890210209; FORSGREN M, 1989, SERODIAG IMMUN INF D, V3, P259, DOI 10.1016/0888-0786(89)90006-1; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; HIGUCHI R, 1989, AMPLIFICATIONS; JOHNSON RT, 1968, ARCH NEUROL-CHICAGO, V18, P260, DOI 10.1001/archneur.1968.00470330050004; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAKEMAN FD, 1987, J INFECT DIS, V155, P1172, DOI 10.1093/infdis/155.6.1172; LEVINE DP, 1978, JAMA-J AM MED ASSOC, V240, P356, DOI 10.1001/jama.240.4.356; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PORTERJORDAN K, 1990, J MED VIROL, V30, P85, DOI 10.1002/jmv.1890300202; POWELL KF, 1990, LANCET, V335, P357, DOI 10.1016/0140-6736(90)90648-O; ROWLEY AH, 1990, LANCET, V335, P440, DOI 10.1016/0140-6736(90)90667-T; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SKOLDENBERG B, 1984, LANCET, V2, P707; WHITLEY RJ, 1977, NEW ENGL J MED, V297, P289, DOI 10.1056/NEJM197708112970601; WHITLEY RJ, 1986, NEW ENGL J MED, V314, P144, DOI 10.1056/NEJM198601163140303	21	476	483	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					189	192		10.1016/0140-6736(91)92155-U	http://dx.doi.org/10.1016/0140-6736(91)92155-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670839				2022-12-24	WOS:A1991EU92400001
J	MASUKATA, H; TOMIZAWA, J				MASUKATA, H; TOMIZAWA, J			A MECHANISM OF FORMATION OF A PERSISTENT HYBRID BETWEEN ELONGATING RNA AND TEMPLATE DNA	CELL			English	Article									NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								APPLEYARD RK, 1954, GENETICS, V39, P440; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MASUKATA H, 1987, CELL, V51, P1123, DOI 10.1016/0092-8674(87)90598-8; MASUKATA H, 1986, CELL, V44, P125, DOI 10.1016/0092-8674(86)90491-5; MASUKATA H, 1984, CELL, V36, P513, DOI 10.1016/0092-8674(84)90244-7; OHMORI H, 1987, J MOL BIOL, V198, P223, DOI 10.1016/0022-2836(87)90308-1; SELZER G, 1983, CELL, V32, P119, DOI 10.1016/0092-8674(83)90502-0; TOMIZAWA J, 1987, CELL, V51, P623, DOI 10.1016/0092-8674(87)90131-0; TOMIZAWA J, 1982, CELL, V31, P575, DOI 10.1016/0092-8674(82)90313-0; TOMIZAWA J, 1985, CELL, V40, P527, DOI 10.1016/0092-8674(85)90201-6; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; ZVEREV VV, 1985, PLASMID, V14, P192, DOI 10.1016/0147-619X(85)90002-2	14	94	94	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 27	1990	62	2					331	338		10.1016/0092-8674(90)90370-T	http://dx.doi.org/10.1016/0092-8674(90)90370-T			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DR202	1695550				2022-12-24	WOS:A1990DR20200013
J	ALLEGRETTA, M; NICKLAS, JA; SRIRAM, S; ALBERTINI, RJ				ALLEGRETTA, M; NICKLAS, JA; SRIRAM, S; ALBERTINI, RJ			T-CELLS RESPONSIVE TO MYELIN BASIC-PROTEIN IN PATIENTS WITH MULTIPLE-SCLEROSIS	SCIENCE			English	Article									UNIV VERMONT,DEPT NEUROL,BURLINGTON,VT 05405	University of Vermont	ALLEGRETTA, M (corresponding author), UNIV VERMONT,GENET LAB,BURLINGTON,VT 05401, USA.				NATIONAL CANCER INSTITUTE [R01CA030688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K07NS000849] Funding Source: NIH RePORTER; NCI NIH HHS [CA30688-07] Funding Source: Medline; NINDS NIH HHS [NS00849] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHAORBEA H, 1989, ANNU REV IMMUNOL, V7, P371, DOI 10.1146/annurev.iy.07.040189.002103; ALBERTINI RJ, 1985, NATURE, V316, P369, DOI 10.1038/316369a0; ALBERTINI RJ, 1982, P NATL ACAD SCI-BIOL, V79, P6617, DOI 10.1073/pnas.79.21.6617; ALBERTINI RJ, IN PRESS MUTATION EN; ALLEGRETTA M, UNPUB; AMMENHEUSER MM, 1988, MUTAT RES, V204, P509, DOI 10.1016/0165-1218(88)90045-6; BERRICHE S, 1988, J NEUROL, V4, P234; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; BURNS FR, 1989, J EXP MED, V169, P27, DOI 10.1084/jem.169.1.27; FALLIS RJ, 1987, J NEUROIMMUNOL, V14, P205, DOI 10.1016/0165-5728(87)90055-5; HAFLER DA, 1987, J IMMUNOL, V139, P68; HAFLER DA, 1985, NEW ENGL J MED, V312, P1405, DOI 10.1056/NEJM198505303122201; KERMAN RH, 1988, J NEUROIMMUNOL, V18, P325, DOI 10.1016/0165-5728(88)90053-7; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; NICKLAS JA, 1988, ENVIRON MOL MUTAGEN, V12, P271, DOI 10.1002/em.2860120302; NICKLAS JA, 1986, MUTAT RES, V173, P65; ONEILL JP, 1989, ENVIRON MOL MUTAGEN, V13, P289, DOI 10.1002/em.2850130403; ONEILL JP, 1987, MUTAGENESIS, V2, P87, DOI 10.1093/mutage/2.2.87; OSHIRO Y, 1970, ARCH BIOCHEM BIOPHYS, V138, P392, DOI 10.1016/0003-9861(70)90361-9; RICHERT JR, 1988, NEUROLOGY, V38, P739, DOI 10.1212/WNL.38.5.739; SESHADRI R, 1983, MUTAT RES, V110, P141, DOI 10.1016/0027-5107(83)90023-4; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; Waksman B H, 1988, Ann N Y Acad Sci, V540, P13, DOI 10.1111/j.1749-6632.1988.tb27047.x; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0	24	402	417	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1990	247	4943					718	721		10.1126/science.1689076	http://dx.doi.org/10.1126/science.1689076			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CM843	1689076				2022-12-24	WOS:A1990CM84300041
J	KISERUD, T; EIKNES, SH; BLAAS, HGK; HELLEVIK, LR				KISERUD, T; EIKNES, SH; BLAAS, HGK; HELLEVIK, LR			ULTRASONOGRAPHIC VELOCIMETRY OF THE FETAL DUCTUS VENOSUS	LANCET			English	Article							PHYSIOLOGY; ANATOMY; LIVER; BLOOD; FLOWS; LAMBS	In fetal lambs, the ductus venosus shunts well-oxygenated blood directly to the heart, a pattern expected to be found also in the human fetus. We aimed to describe the human ductus venosus in a longitudinal sonographic study of two-dimensional imaging, colour flow mapping, and pulsed doppler velocimetry every 3-4 weeks during the second half of pregnancy. The fetuses of 29 healthy women were studied. The ductus venosus and its blood flow were identified and recorded for later analysis that included maximum velocity tracing. In the 184 examinations analysed, the ductus venosus appeared as a narrow vessel projecting a high-velocity jet posteriorly to reach the foramen ovale. The mean peak velocity in the ductus venosus increased from 65 cm/s in week 18 to 75 cm/s at term. Low values of the time-averaged maximum velocity were found in 2 fetuses with cardiovascular abnormalities (1 supraventricular tachycardia, 1 congestive heart failure), as a result of reversed flow in the ductus venosus during atrial systole. The high peak velocity in the ductus venosus, which is comparable with arterial velocities, probably gives the blood sufficient momentum to reach the foramen ovale without extensive mixing with deoxygenated blood. Velocimetry of the ductus venosus carries new diagnostic possibilities.			KISERUD, T (corresponding author), TRONDHEIM REG & UNIV HOSP,DEPT GYNECOL & OBSTET,NATL CTR FETAL DIAG & THERAPY,N-7006 TRONDHEIM,NORWAY.			Kiserud, Torvid/0000-0003-1825-1660				BARCLAY AE, 1942, BRIT J RADIOL, V15, P66; Barclay AE, 1944, FOETAL CIRCULATION C; Barcroft J., 1946, RESEARCHES PRENATAL; BEHRMAN RE, 1970, AM J OBSTET GYNECOL, V108, P956, DOI 10.1016/0002-9378(70)90341-8; CHAKO AW, 1953, ANAT REC, V115, P151; CHAMPETIER J, 1989, SURG RADIOL ANAT, V11, P53, DOI 10.1007/BF02102248; CHINN DH, 1982, RADIOLOGY, V144, P153, DOI 10.1148/radiology.144.1.7089248; DAWES GS, 1984, AM J OBSTET GYNECOL, V84, P1634; Dawes GS, 1968, FETAL NEONATAL PHYSL; EDELSTONE D I, 1980, Journal of Developmental Physiology (Eynsham), V2, P219; EDELSTONE DI, 1978, CIRC RES, V42, P426, DOI 10.1161/01.RES.42.3.426; EDELSTONE DI, 1979, AM J PHYSIOL, V237, pH724, DOI 10.1152/ajpheart.1979.237.6.H724; EIKNES SH, 1981, RECENT ADV PRENATAL, P113; GUDMUNDSSON S, 1991, AM J OBSTET GYNECOL, V164, P33, DOI 10.1016/0002-9378(91)90618-2; MEYER WW, 1966, ARCH DIS CHILD, V41, P597, DOI 10.1136/adc.41.220.597; NICOLINI U, 1989, AM J OBSTET GYNECOL, V160, P1139, DOI 10.1016/0002-9378(89)90176-2; REED KL, 1990, CIRCULATION, V81, P498, DOI 10.1161/01.CIR.81.2.498; STAUDACH A, 1987, SECTIONAL FETAL ANAT; WEINER CP, 1989, AM J OBSTET GYNECOL, V161, P714, DOI 10.1016/0002-9378(89)90387-6	19	199	215	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1991	338	8780					1412	1414		10.1016/0140-6736(91)92720-M	http://dx.doi.org/10.1016/0140-6736(91)92720-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT904	1683418				2022-12-24	WOS:A1991GT90400002
J	GRIGG, JM; SAVILL, JS; SARRAF, C; HASLETT, C; SILVERMAN, M				GRIGG, JM; SAVILL, JS; SARRAF, C; HASLETT, C; SILVERMAN, M			NEUTROPHIL APOPTOSIS AND CLEARANCE FROM NEONATAL LUNGS	LANCET			English	Article							CELL-DEATH; INFLAMMATION; MACROPHAGES; PHAGOCYTOSIS; ELASTASE	8 newborn babies with airways inflammation, who were mechanically ventilated, underwent bronchoalveolar lavage to examine the fate of neutrophils in the inflamed airways. Light microscopy and electronmicroscopy showed evidence of neutrophil apoptosis and ingestion of intact neutrophils by macrophages in specimens from all 8 infants. Neutrophil apoptosis, without the local release of intracellular contents that promote inflammation, might represent a mechanism by which tissue injury is reduced during the resolution of neonatal pulmonary inflammation.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOPATHOL,LONDON W12 0HS,ENGLAND; CITY HOSP EDINBURGH,DEPT RESP MED,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND	Imperial College London; Imperial College London	GRIGG, JM (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT PAEDIAT,DU CANE RD,LONDON W12 0NN,ENGLAND.			Grigg, Jonathan/0000-0003-3109-6028				HASLETT C, 1989, CURR OPIN IMMUNOL, V2, P10, DOI 10.1016/0952-7915(89)90091-5; HENSON PM, 1978, J IMMUNOL, V121, P851; MEAGHER L, 1989, BIOCHEM SOC T, V17, P608, DOI 10.1042/bst0170608; MERRITT TA, 1983, J CLIN INVEST, V72, P656, DOI 10.1172/JCI111015; NEWMAN SL, 1982, J EXP MED, V156, P430, DOI 10.1084/jem.156.2.430; OGDEN BE, 1984, AM REV RESPIR DIS, V130, P817; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SHELLITO J, 1987, AM J PATHOL, V129, P567; VARTIO T, 1981, J BIOL CHEM, V256, P471; Wyllie A H, 1980, Int Rev Cytol, V68, P251	10	189	190	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1991	338	8769					720	722		10.1016/0140-6736(91)91443-X	http://dx.doi.org/10.1016/0140-6736(91)91443-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679867				2022-12-24	WOS:A1991GG10400004
J	HOPPU, K; TIKANOJA, T; TAPANAINEN, P; REMES, M; SAARENPAAHEIKKILA, O; KOUVALAINEN, K				HOPPU, K; TIKANOJA, T; TAPANAINEN, P; REMES, M; SAARENPAAHEIKKILA, O; KOUVALAINEN, K			ACCIDENTAL ASTEMIZOLE OVERDOSE IN YOUNG-CHILDREN	LANCET			English	Note							TORSADE-DE-POINTES	6 cases of accidental astemizole poisoning in children have been reported to the Finnish Poison Information Center. The children were aged 1 year 7 months to 3 years 4 months and had taken doses of 2.5 to 16.7 mg/kg, at least twelve times that recommended. In 2 children the overdose was verified by measurement of drug concentrations. Despite measures to prevent drug absorption prolonged QT(c)-interval, a sign of cardiac toxicity, was found in all 5 children on whom an electrocardiogram was available for analysis, and severe ventricular arrhythmias developed in 1. Young children with accidental astemizole overdose should be carefully monitored in hospital. Similar precautions may be justified in cases of overdose with other selective H-1-histamine receptor antagonists.	UNIV KUOPIO,DEPT PAEDIAT,KUOPIO,FINLAND; UNIV OULU,DEPT PAEDIAT,SF-90100 OULU 10,FINLAND; UNIV TAMPERE,DEPT PAEDIAT,TAMPERE,FINLAND	University of Eastern Finland; University of Oulu; Tampere University	HOPPU, K (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,DEPT PAEDIAT 2,SF-00290 HELSINKI 29,FINLAND.		Hoppu, Kalle/A-2811-2009	Hoppu, Kalle/0000-0001-6775-0453				Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; CRAFT TM, 1986, BRIT MED J, V292, P660, DOI 10.1136/bmj.292.6521.660; DAVIES AJ, 1989, BRIT MED J, V298, P325, DOI 10.1136/bmj.298.6669.325; GARSON A, 1990, PEDIATRIC ARRHYTHMIA, P427; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; SIMONS FER, 1988, LANCET, V2, P624; SNOOK J, 1988, BRIT J CLIN PRACT, V42, P257; STRATMANN HG, 1987, AM HEART J, V113, P1470, DOI 10.1016/0002-8703(87)90664-8; WOESTENBORGHS R, 1986, DRUG DEVELOP RES, V8, P63, DOI 10.1002/ddr.430080108	10	66	68	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					538	540		10.1016/0140-6736(91)91101-Y	http://dx.doi.org/10.1016/0140-6736(91)91101-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678801				2022-12-24	WOS:A1991GD00200005
J	FALLON, AM				FALLON, AM			DNA-MEDIATED GENE-TRANSFER - APPLICATIONS TO MOSQUITOS	NATURE			English	Article							AEDES-ALBOPICTUS CELLS; ANOPHELES-GAMBIAE; TRANSIENT EXPRESSION; INTEGRATION; DROSOPHILA; VECTOR				FALLON, AM (corresponding author), UNIV MINNESOTA,ENTOMOL,1980 FOLWELL AVE,ST PAUL,MN 55108, USA.							BESANSKY NJ, 1990, MOL CELL BIOL, V10, P863, DOI 10.1128/MCB.10.3.863; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DOBENS L, 1991, MOL CELL BIOL, V11, P1846, DOI 10.1128/MCB.11.4.1846; DURBIN JE, 1985, GENE, V36, P173, DOI 10.1016/0378-1119(85)90082-4; DURBIN JE, 1988, BIOCHIM BIOPHYS ACTA, V950, P182, DOI 10.1016/0167-4781(88)90010-3; Fallon A. M., 1987, Advances in Cell Culture, V5, P97; GERENDAY A, 1989, INSECT BIOCHEM, V19, P679, DOI 10.1016/0020-1790(89)90104-2; HENDRICKS MB, 1989, BIO-TECHNOL, V7, P1271; JAMES AA, 1954, GENE, V75, P7389; KJER KM, 1991, ARCH INSECT BIOCHEM, V16, P189, DOI 10.1002/arch.940160305; MCGRANE V, 1988, AM J TROP MED HYG, V39, P502, DOI 10.4269/ajtmh.1988.39.502; MENTO SJ, 1978, SOMAT CELL GENET, V4, P179, DOI 10.1007/BF01538983; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; QIAN S, 1988, P NATL ACAD SCI USA, V85, P9601, DOI 10.1073/pnas.85.24.9601; ROMANS P, 1991, J MED ENTOMOL, V28, P147, DOI 10.1093/jmedent/28.1.147; SHOTKOSKI FA, IN PRESS EUR J BIOCH; SINGH KRP, 1967, CURR SCI INDIA, V36, P506; TATEM J, 1986, VIRUS RES, V5, P121, DOI 10.1016/0168-1702(86)90012-2; WHEELER DA, 1991, SCIENCE, V251, P1082, DOI 10.1126/science.1900131	21	17	18	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					828	829		10.1038/352828a0	http://dx.doi.org/10.1038/352828a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1679196				2022-12-24	WOS:A1991GC96400068
J	DAVIDSON, DR; CRAWLEY, A; HILL, RE; TICKLE, C				DAVIDSON, DR; CRAWLEY, A; HILL, RE; TICKLE, C			POSITION-DEPENDENT EXPRESSION OF 2 RELATED HOMEOBOX GENES IN DEVELOPING VERTEBRATE LIMBS	NATURE			English	Article							CHICK WING BUD; PATTERN-FORMATION; POLARIZING REGION; RETINOIC ACID; MOUSE; DROSOPHILA	MANY genes that control pattern formation in insects contain a conserved homeobox region which encodes a domain involved in DNA binding 1. One approach to understanding pattern formation in vertebrates is to examine the role of homeobox-containing genes in the developing limb 2. Two such genes, Hox-7.1 and Hox-8.1, are expressed in distal mesoderm, but not in the proximal core, of mouse forelimb (refs 3,4, and D.R.D., manuscript in preparation). The proximodistal cartilage pattern in the chick wing is progressively determined in the distal mesoderm, which is maintained as a 'progress zone' by the overlying apical ectodermal ridge 5. Indeed, proximal cells are reprogrammed to form distal structures when placed in the progress zone 6 and we therefore expect that genes involved in controlling limb pattern should be activated in such grafts. We tested this requirement for Hox-7.1 and Hox-8.1 in mouse limb mesoderm placed in chick wing buds. Our results reported here indicate that both genes are rapidly activated by a signal from the apical ectoderm. These properties, taken with the DNA-binding properties of the homeodomain, strongly suggest that Hox-7.1 and Hox-8.1 have fundamental roles in limb-pattern formation.	UNIV COLL & MIDDLESEX SCH MED,DEPT ANAT & DEV BIOL,LONDON W1P 6DB,ENGLAND	University of London; University College London	DAVIDSON, DR (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,DEV GENET GRP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							CAIRNS JM, 1965, DEV BIOL, V12, P36, DOI 10.1016/0012-1606(65)90019-9; COTTRILL CP, 1990, CELL DIFFER DEV, V29, P67, DOI 10.1016/0922-3371(90)90025-R; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DOLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HAMBURGER V, 1979, J MORPHOL, V50, P217; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JORQUERA B, 1971, CR ACAD SCI D NAT, V272, P1522; LYONS KM, 1990, DEVELOPMENT, V109, P833; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; SAUNDERS JW, 1959, DEV BIOL, V1, P281, DOI 10.1016/0012-1606(59)90030-2; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TICKLE C, 1976, NATURE, V259, P396, DOI 10.1038/259396a0; Wolpert L, 1975, Ciba Found Symp, V0, P95	20	188	191	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					429	431		10.1038/352429a0	http://dx.doi.org/10.1038/352429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1677742				2022-12-24	WOS:A1991FZ34600064
J	WEBER, GF; MAERTENS, P; MENG, X; PIPPENGER, CE				WEBER, GF; MAERTENS, P; MENG, X; PIPPENGER, CE			GLUTATHIONE-PEROXIDASE DEFICIENCY AND CHILDHOOD SEIZURES	LANCET			English	Note								4 children with intractable seizures, repeated infections, and intolerance to anticonvulsants had evidence of glutathione peroxidase deficiency. 2 had low intracellular enzyme activity but normal blood selenium and high plasma glutathione peroxidase concentrations. The other 2 had low intracellular glutathione peroxidase activity with low circulating glutathione peroxidase and selenium concentrations. The clinical state of the children improved after discontinuation of anticonvulsant medication and selenium substitution.	UNIV SO ALABAMA,MED CTR,DEPT NEUROL,MOBILE,AL 36617; CLEVELAND CLIN FDN,DEPT BIOCHEM,CLEVELAND,OH 44195	University of South Alabama; Cleveland Clinic Foundation	WEBER, GF (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT BIOL CHEM & MOLEC PHARMACOL,44 BINNEY ST,BOSTON,MA 02115, USA.							BAKER SS, 1983, J IMMUNOL, V130, P2856; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; HOLMES B, 1970, NEW ENGL J MED, V283, P217, DOI 10.1056/NEJM197007302830501; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PIPPENGER CE, 1989, ANTIEPILEPTIC DRUG I, P293; WILMORE LJ, 1981, NEUROLOGY, V31, P63	6	99	102	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1443	1444		10.1016/0140-6736(91)93130-2	http://dx.doi.org/10.1016/0140-6736(91)93130-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675321				2022-12-24	WOS:A1991FR06000007
J	OCALLAGHAN, E; SHAM, P; TAKEI, N; GLOVER, G; MURRAY, RM				OCALLAGHAN, E; SHAM, P; TAKEI, N; GLOVER, G; MURRAY, RM			SCHIZOPHRENIA AFTER PRENATAL EXPOSURE TO 1957 A2-INFLUENZA EPIDEMIC	LANCET			English	Article							INFLUENZA; BIRTH	The birth dates of schizophrenic inpatients in eight health regions in England and Wales were reviewed for any effect of the 1957 A2 influenza epidemic. 5 months after the peak infection prevalence, the number of births of individuals who later developed schizophrenia was 88% higher than the average number of such births in the corresponding periods of the 2 previous and the next 2 years. This finding is in accordance with a study from Helsinki and with clinical and neuropathological evidence of aberrant fetal brain development in the pathogenesis of schizophrenia.	INST PSYCHIAT,DEPT PSYCHOL MED,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND; WESTMINSTER MED SCH & HOSP,DEPT COMMUNITY MED,LONDON SW1P 2AP,ENGLAND; UNIV LONDON KINGS COLL HOSP,LONDON SE5 8RX,ENGLAND	University of London; King's College London; Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London			Murray, Robin M/F-8658-2012; Takei, Nori/AAC-8578-2019; Takei, Nori/GWZ-7464-2022	Murray, Robin M/0000-0003-0829-0519; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; BOGERTS B, 1985, ARCH GEN PSYCHIAT, V42, P784; BOWLER AE, 1990, ARCH GEN PSYCHIAT, V47, P877; COFFEY VP, 1959, LANCET, V2, P935; DEGREEF G, 1988, BIOL PSYCHIAT, V24, P461, DOI 10.1016/0006-3223(88)90186-2; GUY JD, 1983, SCHIZOPHRENIA BULL, V9, P571, DOI 10.1093/schbul/9.4.571; JAKOB H, 1989, J ROY SOC MED, V82, P466, DOI 10.1177/014107688908200808; JOHNSTONE EC, 1976, LANCET, V2, P924; KENDELL RE, 1989, ARCH GEN PSYCHIAT, V46, P878; LECK I, 1963, BRIT J PREV SOC MED, V17, P70; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; MCDONALD JC, 1958, P ROY SOC MED, V51, P1016; MEDNICK SA, 1990, ARCH GEN PSYCHIAT, V47, P875; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189, DOI 10.1001/archpsyc.1988.01800260109013; MENINGER KA, 1926, AM J PSYCHIAT, V82, P469; MURRAY RM, 1988, SCHIZOPHRENIA MAJOR, P90; MURRAY RM, 1985, GENETICS ASPECTS HUM, P63; OCALLAGHAN E, IN PRESS BR J PSYCHI; WEINBERGER DR, 1980, AM J PSYCHIAT, V137, P1410; ZIPURSKY RB, 1987, BIOL PSYCHIAT, V22, P1288, DOI 10.1016/0006-3223(87)90040-0; [No title captured]; 1958, REPORT REGISTRAR GEN	22	329	332	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1248	1250		10.1016/0140-6736(91)92919-S	http://dx.doi.org/10.1016/0140-6736(91)92919-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN047	1674062				2022-12-24	WOS:A1991FN04700003
J	VU, TKH; HUNG, DT; WHEATON, VI; COUGHLIN, SR				VU, TKH; HUNG, DT; WHEATON, VI; COUGHLIN, SR			MOLECULAR-CLONING OF A FUNCTIONAL THROMBIN RECEPTOR REVEALS A NOVEL PROTEOLYTIC MECHANISM OF RECEPTOR ACTIVATION	CELL			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN-PLATELETS; LIGAND-BINDING; HOMOLOGOUS DESENSITIZATION; BOVINE TRYPSINOGEN; EXPRESSION SYSTEM; INDUCED RELEASE; CDNA; PROTEIN; CELL	We isolated a cDNA encoding a functional human thrombin receptor by direct expression cloning in Xenopus oocytes. mRNA encoding this receptor was detected in human platelets and vascular endothelial cells. The deduced amino acid sequence revealed a new member of the seven transmembrane domain receptor family with a large amino-terminal extracellular extension containing a remarkable feature. A putative thrombin cleavage site (LDPR/S) resembling the activation cleavage site in the zymogen protein C (LDPR/I) was noted 41 amino acids carboxyl to the receptor's start methionine. A peptide mimicking the new amino terminus created by cleavage at R41 was a potent agonist for both thrombin receptor activation and platelet activation. "Uncleavable" mutant thrombin receptors failed to respond to thrombin but were responsive to the new amino-terminal peptide. These data reveal a novel signaling mechanism in which thrombin cleaves its receptor's amino-terminal extension to create a new receptor amino terminus that functions as a tethered ligand and activates the receptor.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	VU, TKH (corresponding author), UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043322, P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43322, HL 43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Baenziger N L, 1974, Methods Enzymol, V31, P149; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BERNDT MC, 1986, ANN NY ACAD SCI, V485, P374, DOI 10.1111/j.1749-6632.1986.tb34598.x; BERNDT MC, 1981, PLATELETS BIOL PATHO, P43; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; COLEMAN A, 1984, TRANSCRIPTION TRANSL, P271; DAHLBACK B, 1986, J BIOL CHEM, V261, P5111; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P282, DOI 10.1021/bi00726a017; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P2462, DOI 10.1021/bi00737a015; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; EIDT JF, 1989, J CLIN INVEST, V84, P18, DOI 10.1172/JCI114138; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FRASER CM, 1989, J BIOL CHEM, V264, P9266; GREENBERG SM, 1988, BLOOD, V72, P1968; GRONKE RS, 1987, J BIOL CHEM, V262, P3030; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HOGG DH, 1978, THROMB RES, V12, P953, DOI 10.1016/0049-3848(78)90051-8; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MARTIN BM, 1975, BIOCHEMISTRY-US, V14, P1308, DOI 10.1021/bi00677a032; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Muszbek L, 1984, THROMBIN, P83; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; PAPAYANNOPOULOU T, 1987, J CLIN INVEST, V79, P859, DOI 10.1172/JCI112895; PARIS S, 1988, J BIOL CHEM, V263, P11250; PHILLIPS DR, 1974, THROMB DIATH HAEMOST, V32, P207, DOI 10.1055/s-0038-1647686; PIPILISYNETOS E, 1990, BIOCHEM BIOPH RES CO, V171, P913, DOI 10.1016/0006-291X(90)90770-N; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERAGA HA, 1977, CHEM BIOL THROMBIN, P145; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SHUMAN MA, 1979, J CLIN INVEST, V63, P1211, DOI 10.1172/JCI109416; STENFLO J, 1982, J BIOL CHEM, V257, P2180; SUMIKAWA K, 1982, NUCLEIC ACIDS RES, V10, P5809, DOI 10.1093/nar/10.19.5809; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; VANOBBERGHENSCHILLING E, 1990, FEBS LETT, V262, P330, DOI 10.1016/0014-5793(90)80221-4; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; WORKMAN EF, 1977, J BIOL CHEM, V252, P7118	60	2845	2986	0	69	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1991	64	6					1057	1068		10.1016/0092-8674(91)90261-V	http://dx.doi.org/10.1016/0092-8674(91)90261-V			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1672265				2022-12-24	WOS:A1991FD55800004
J	WILSON, JB; WEINBERG, W; JOHNSON, R; YUSPA, S; LEVINE, AJ				WILSON, JB; WEINBERG, W; JOHNSON, R; YUSPA, S; LEVINE, AJ			EXPRESSION OF THE BNLF-1 ONCOGENE OF EPSTEIN-BARR-VIRUS IN THE SKIN OF TRANSGENIC MICE INDUCES HYPERPLASIA AND ABERRANT EXPRESSION OF KERATIN-6	CELL			English	Article									NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	WILSON, JB (corresponding author), PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544, USA.		Wilson, Joanna B/B-4466-2009		NCI NIH HHS [CA49271-02, CA38757-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049271, R01CA038757, R37CA038757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAMBAUGH T, 1980, P NATL ACAD SCI-BIOL, V77, P2999, DOI 10.1073/pnas.77.5.2999; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; Epstein M. A., 1986, EPSTEIN BARR VIRUS R; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; GREENHALGH DA, 1988, CARCINOGENESIS, V1, P134; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; KNAPP B, 1987, J BIOL CHEM, V262, P938; LIAU G, 1985, J BIOL CHEM, V260, P531; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; ROOP DR, 1985, ANN NY ACAD SCI, V455, P426, DOI 10.1111/j.1749-6632.1985.tb50426.x; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1984, J BIOL CHEM, V259, P8037; ROOP DR, 1983, P NATL ACAD SCI-BIOL, V80, P716, DOI 10.1073/pnas.80.3.716; SCHMIDT A, 1984, J BIOL CHEM, V229, P7411; SIXBEY JW, 1987, J GEN VIROL, V68, P805, DOI 10.1099/0022-1317-68-3-805; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TYNDALL C, 1981, NUCLEIC ACIDS RES, V9, P6231, DOI 10.1093/nar/9.23.6231; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397	37	221	227	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 29	1990	61	7					1315	1327		10.1016/0092-8674(90)90695-B	http://dx.doi.org/10.1016/0092-8674(90)90695-B			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DM156	1694724				2022-12-24	WOS:A1990DM15600019
J	DECKER, CJ; SOLLNERWEBB, B				DECKER, CJ; SOLLNERWEBB, B			RNA EDITING INVOLVES INDISCRIMINATE U CHANGES THROUGHOUT PRECISELY DEFINED EDITING DOMAINS	CELL			English	Article									JOHNS HOPKINS UNIV,SCH MED,HUMAN GENET PROGRAM,BALTIMORE,MD 21205	Johns Hopkins University	DECKER, CJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.				NIGMS NIH HHS [GM-34231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENNE R, 1983, NUCLEIC ACIDS RES, V11, P6925, DOI 10.1093/nar/11.20.6925; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; CAMPBELL DA, 1989, MOL BIOCHEM PARASIT, V36, P197, DOI 10.1016/0166-6851(89)90192-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DUNNING AM, 1988, NUCLEIC ACIDS RES, V16, P10393, DOI 10.1093/nar/16.21.10393; ENGLUND PT, 1982, ANNU REV BIOCHEM, V51, P695, DOI 10.1146/annurev.bi.51.070182.003403; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FEAGIN JE, 1988, MOL CELL BIOL, V8, P1259, DOI 10.1128/MCB.8.3.1259; GRUNBERGMANAGO M, 1963, PROGR NUCL ACIDS RES, P93; HEPPEL LA, 1963, J BIOL CHEM, V238, P357; HIRSCH M, 1974, CELL, V1, P31, DOI 10.1016/0092-8674(74)90152-4; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW JM, 1989, P NATL ACAD SCI USA, V86, P6220, DOI 10.1073/pnas.86.16.6220; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON L, 1986, INT REV CYTOL, V99, P119; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; STUART K, 1989, PARASITOL TODAY, V5, P5, DOI 10.1016/0169-4758(89)90211-1; Stuart K., 1988, Molecular genetics of parasitic protozoa., P143; STUART K, 1989, EXP PARASITOL, V68, P486, DOI 10.1016/0014-4894(89)90135-5; STUART K, 1989, GENE, V82, P155, DOI 10.1016/0378-1119(89)90040-1; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; VANDERSPEK H, 1988, EMBO J, V7, P2509, DOI 10.1002/j.1460-2075.1988.tb03098.x; VOLLOCH V, 1990, NATURE, V343, P482, DOI 10.1038/343482a0; WHITE TC, 1987, NUCLEIC ACIDS RES, V15, P3275, DOI 10.1093/nar/15.8.3275	32	122	124	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 15	1990	61	6					1001	1011		10.1016/0092-8674(90)90065-M	http://dx.doi.org/10.1016/0092-8674(90)90065-M			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DK145	1693545				2022-12-24	WOS:A1990DK14500010
J	WUCHERPFENNIG, KW; OTA, K; ENDO, N; SEIDMAN, JG; ROSENZWEIG, A; WEINER, HL; HAFLER, DA				WUCHERPFENNIG, KW; OTA, K; ENDO, N; SEIDMAN, JG; ROSENZWEIG, A; WEINER, HL; HAFLER, DA			SHARED HUMAN T-CELL RECEPTOR V-BETA USAGE TO IMMUNODOMINANT REGIONS OF MYELIN BASIC-PROTEIN	SCIENCE			English	Article									HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	WUCHERPFENNIG, KW (corresponding author), BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,DEPT MED,DIV NEUROL,BOSTON,MA 02115, USA.				NHLBI NIH HHS [1 K11 HL 02228-01] Funding Source: Medline; NINDS NIH HHS [NS 00981, R01 NS 24247] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024247, K08NS000981] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALLEGRETTA M, 1990, SCIENCE, V247, P718, DOI 10.1126/science.1689076; Alvord EC, 1984, EXPT ALLERGIC ENCEPH; BENNUN A, 1982, J IMMUNOL, V129, P303; BURNS FR, 1989, J EXP MED, V169, P27, DOI 10.1084/jem.169.1.27; CONCANNON P, 1986, P NATL ACAD SCI USA, V83, P6598, DOI 10.1073/pnas.83.17.6598; HAFLER DA, 1988, J EXP MED, V167, P1313, DOI 10.1084/jem.167.4.1313; HAFLER DA, 1989, IMMUNOL TODAY, V10, P104, DOI 10.1016/0167-5699(89)90236-3; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; KIMURA N, 1986, J EXP MED, V164, P739, DOI 10.1084/jem.164.3.739; KIMURA N, 1987, EUR J IMMUNOL, V17, P37; LAI E, 1988, NATURE, V331, P543, DOI 10.1038/331543a0; MARTIN R, 1990, NEUROLOGY, V40, P391; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; MOKHTARIAN F, 1984, NATURE, V309, P356, DOI 10.1038/309356a0; MORETTA A, 1983, J EXP MED, V157, P743, DOI 10.1084/jem.157.2.743; OLERUP O, 1989, P NATL ACAD SCI USA, V86, P7113, DOI 10.1073/pnas.86.18.7113; OTA K, 1990, FASEB J, V4, pA1857; SEBOUN E, 1989, CELL, V57, P1095, DOI 10.1016/0092-8674(89)90046-9; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; TILLINGHAST JP, 1986, SCIENCE, V233, P879, DOI 10.1126/science.3755549; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WINOTO A, 1986, NATURE, V324, P679, DOI 10.1038/324679a0; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	26	452	485	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 25	1990	248	4958					1016	1019		10.1126/science.1693015	http://dx.doi.org/10.1126/science.1693015			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF144	1693015				2022-12-24	WOS:A1990DF14400037
J	JOHNSON, IS; ROGERS, C; BISWAS, B; AHMEDZAI, S				JOHNSON, IS; ROGERS, C; BISWAS, B; AHMEDZAI, S			WHAT DO HOSPICES DO - A SURVEY OF HOSPICES IN THE UNITED-KINGDOM AND REPUBLIC-OF-IRELAND	BRITISH MEDICAL JOURNAL			English	Article											JOHNSON, IS (corresponding author), LEICESTERSHIRE HOSPICE,LEICESTER LE3 9QE,ENGLAND.		biswas, biswajit/N-8291-2019	biswas, biswajit/0000-0002-3448-3827; Ahmedzai, Sam/0000-0002-2028-8510				ALDERSON MR, 1973, BRIT MED J, V1, P170, DOI 10.1136/bmj.1.5846.170; [Anonymous], 1980, REPORT WORKING GROUP; Hill F, 1984, Health Trends, V16, P9; LUNT B, 1980, TERMINAL CANCER CARE; PORTER KRO, 1973, BRIT MED J, V1, P40, DOI 10.1136/bmj.1.5844.40; SMITH T, 1985, BRIT MED J, V291, P1670, DOI 10.1136/bmj.291.6510.1670; WARD AWM, 1985, HOME CARE SERVICES T; WILKES E, 1965, LANCET, V1, P799; 1988, 1988 DIRECTORY HOSPI	9	20	20	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 24	1990	300	6727					791	793		10.1136/bmj.300.6727.791	http://dx.doi.org/10.1136/bmj.300.6727.791			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW227	1691031	Bronze, Green Published			2022-12-24	WOS:A1990CW22700025
J	ODARCEDERLOF, I; THEODORSSON, E; ERICSSON, F; KJELLSTRAND, CM				ODARCEDERLOF, I; THEODORSSON, E; ERICSSON, F; KJELLSTRAND, CM			PLASMA-CONCENTRATIONS OF CALCITONIN GENE-RELATED PEPTIDE IN FLUID OVERLOAD	LANCET			English	Note							ATRIAL-NATRIURETIC-PEPTIDE	To investigate the hypothesis that calcitonin gene-related peptide (CGRP), a potent vasodilator, is an important physiological defence against fluid overload, plasma CGRP concentrations were measured in various degrees of fluid overload in 26 haemodialysis patients, for whom diuresis, mediated by atrial natriuretic peptide (ANP), is not a possible defence mechanism. Plasma CGRP concentrations were positively correlated with the degree of fluid excess (r = 0.815, p = 0.0001) and were significantly higher in 5 patients with severe fluid overload than in those less severely affected (143 [SE 14] vs 52 [11] pmol/l; p < 0.001). CGRP may be an effective defence against complications of fluid overload since if can increase capitance by vasodilatation.	KAROLINSKA HOSP,DEPT CLIN CHEM,S-10401 STOCKHOLM 60,SWEDEN; UNIV ALBERTA HOSP,DEPT MED,DIV NEPHROL,EDMONTON T6G 2B7,ALBERTA,CANADA	Karolinska Institutet; Karolinska University Hospital; University of Alberta	ODARCEDERLOF, I (corresponding author), KAROLINSKA HOSP,DEPT INTERNAL MED,DIV NEPHROL,BOX 60500,S-10401 STOCKHOLM 60,SWEDEN.		Theodorsson, Elvar/H-2096-2011	Theodorsson, Elvar/0000-0003-0756-7723				BERGLUND H, 1990, BRIT HEART J, V64, P9; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; ERICSSON F, 1983, NEPHRON, V33, P173, DOI 10.1159/000182937; GENNARI C, 1990, CARDIOVASC RES, V3, P239; GREENBERG B, 1987, BRIT J PHARMACOL, V92, P789, DOI 10.1111/j.1476-5381.1987.tb11382.x; LANG RE, 1985, NATURE, V314, P264, DOI 10.1038/314264a0; ODARCEDERLOF I, 1989, J INTERN MED, V226, P177, DOI 10.1111/j.1365-2796.1989.tb01376.x; TALARTSCHIK J, 1988, Z KARDIOL, V77, P72; YAMAMOTO A, 1988, BIOCHEM BIOPH RES CO, V155, P1452, DOI 10.1016/S0006-291X(88)81304-4	10	31	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					411	412		10.1016/0140-6736(91)91035-S	http://dx.doi.org/10.1016/0140-6736(91)91035-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678085				2022-12-24	WOS:A1991GB44600006
J	KAUFMAN, LD; GRUBER, BL; GREGERSEN, PK				KAUFMAN, LD; GRUBER, BL; GREGERSEN, PK			CLINICAL FOLLOW-UP AND IMMUNOGENETIC STUDIES OF 32 PATIENTS WITH EOSINOPHILIA-MYALGIA-SYNDROME	LANCET			English	Article								31 patients with L-tryptophan-associated eosinophilia-myalgia syndrome (EMS) that developed during the United States outbreak in 1989 were followed up prospectively at a university hospital outpatient rheumatology clinic for 16 to 24 months from the onset of their illness. Another patient with EMS associated with L-tryptophan in 1988 was followed up for 30 months. 93% of the 28 survivors from the 1989 cohort continue to have symptoms affecting 1-4 organ systems (median 3) and 3 have died, so the disorder produces considerable morbidity and mortality. The chronic sequelae most often associated with long-term disability are sclerodermatous skin thickening (54%), sensorimotor polyneuropathy (61%), proximal myopathy (36%), and severe episodic myalgias (64%). Thrombocytopenia developed in 1 patient. HLA-class II typing revealed a non-significant trend towards an association with HLA-DR4. Early therapy with corticosteroids did not seem to prevent the development of chronic manifestations.	CORNELL UNIV, N SHORE UNIV HOSP,COLL MED,DEPT MED,DIV MOLEC MED, MANHASSET, NY 11030 USA	Cornell University; Northwell Health; North Shore University Hospital	KAUFMAN, LD (corresponding author), SUNY STONY BROOK, HLTH SCI CTR T16040, DEPT MED, DIV ALLERGY RHEUMATOL & CLIN IMMUNOL, STONY BROOK, NY 11794 USA.							BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; CROFFORD LJ, 1990, J CLIN INVEST, V86, P1757, DOI 10.1172/JCI114902; EIDSON M, 1990, LANCET, V335, P645, DOI 10.1016/0140-6736(90)90421-Z; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAUFMAN LD, 1990, J RHEUMATOL, V17, P795; KAUFMAN LD, 1990, MEDICINE, V69, P187, DOI 10.1097/00005792-199007000-00001; KAUFMAN LD, 1990, J AM ACAD DERMATOL, V23, P1063, DOI 10.1016/0190-9622(90)70334-E; KAUFMAN LD, IN PRESS RHEUM DIS C; KILBOURNE EM, 1983, NEW ENGL J MED, V309, P1408, DOI 10.1056/NEJM198312083092302; LAKHANPAL S, 1988, SEMIN ARTHRITIS RHEU, V17, P221, DOI 10.1016/0049-0172(88)90008-X; MARTIN RW, 1990, ANN INTERN MED, V113, P124, DOI 10.7326/0003-4819-113-2-124; MEDSGER TA, 1968, ARTHRITIS RHEUM-US, V11, P554, DOI 10.1002/art.1780110405; SEIDMAN RJ, 1991, J NEUROPATH EXP NEUR, V50, P49, DOI 10.1097/00005072-199101000-00004; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; TAZELAAR HD, 1990, CHEST, V97, P1032, DOI 10.1378/chest.97.5.1032; TSOKOS GC, 1981, ARCH INTERN MED, V246, P766; VARGA J, 1990, SEMIN ARTHRITIS RHEU, V19, P313, DOI 10.1016/0049-0172(90)90069-R; VICARIO JL, 1982, LANCET, V1, P276; 1989, MMWR, V38, P765	20	71	72	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	1991	337	8749					1071	1074		10.1016/0140-6736(91)91717-9	http://dx.doi.org/10.1016/0140-6736(91)91717-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673503				2022-12-24	WOS:A1991FK20400014
J	HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; GREENWOOD, BM; MCMICHAEL, AJ				HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; GREENWOOD, BM; MCMICHAEL, AJ			HLA CLASS-I TYPING BY PCR - HLA-B27 AND AN AFRICAN B27 SUBTYPE	LANCET			English	Article							ANKYLOSING-SPONDYLITIS; POPULATION; ANTIGENS; DNA	We describe a rapid method of HLA class I typing using the polymerase chain reaction and oligonucleotide hybridisation that eliminates the requirements for viable lymphocytes and allows subtypes to be defined. We have used this to demonstrate that the predominant subtype of HLA-B27 in the Gambia, West Africa, is HLA-B*2703, which is very rare or absent in other racial groups. This subtype differs from the common Caucasian HLA-B27 subtypes in its recognition by cytotoxic T cells. We propose that HLA*B-2703, unlike other HLA-B27 subtypes, may not be associated with ankylosing spondylitis, thus accounting in part for the rarity of this condition in black populations.	MRC LABS,FAJARA,SENEGAMBIA		HILL, AVS (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.		HILL, Adrian V>S>/C-1306-2008	Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BREURVRIESENDORP BS, 1987, ANN RHEUM DIS, V46, P353, DOI 10.1136/ard.46.5.353; BREWERTON DA, 1973, LANCET, V1, P904; CALVO V, 1990, J IMMUNOL, V144, P4038; Cave L, 1965, Rhumatologie, V17, P153; CHERTKOFF LP, 1988, HUM IMMUNOL, V23, P241, DOI 10.1016/0198-8859(88)90060-2; CHOO SY, 1988, HUM IMMUNOL, V21, P209; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; DEWAAL L, 1987, J IMMUNOL, V139, P3396; DUTOIT ED, 1988, TISSUE ANTIGENS, V31, P109; FERNANDEZVINA M, 1990, HUM IMMUNOL, V28, P51, DOI 10.1016/0198-8859(90)90102-U; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GASTON JSH, 1990, CLIN EXP IMMUNOL, V82, P1; GREENWOOD BM, 1970, ANN RHEUM DIS, V29, P56, DOI 10.1136/ard.29.1.56; KALIDI I, 1988, TISSUE ANTIGENS, V31, P98, DOI 10.1111/j.1399-0039.1988.tb02070.x; KHAN MA, 1977, J RHEUMATOL, V4, P39; OKOYE RC, 1989, TISSUE ANTIGENS, V33, P445, DOI 10.1111/j.1399-0039.1989.tb01693.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; SCARF SJ, 1989, P NATL ACAD SCI USA, V86, P6215; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0	24	151	161	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					640	642		10.1016/0140-6736(91)92452-8	http://dx.doi.org/10.1016/0140-6736(91)92452-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1671992				2022-12-24	WOS:A1991FB73000004
J	SMIRNE, S; IANNACCONE, S; FERINISTRAMBI, L; COMOLA, M; COLOMBO, E; NEMNI, R				SMIRNE, S; IANNACCONE, S; FERINISTRAMBI, L; COMOLA, M; COLOMBO, E; NEMNI, R			MUSCLE-FIBER TYPE AND HABITUAL SNORING	LANCET			English	Article							OBSTRUCTIVE SLEEP-APNEA; SKELETAL-MUSCLES; STIMULATION; AIRWAY	Although anatomical abnormalities of the upper airway have been recorded in some patients with obstructive sleep apnoea (OSA), a muscle tone dysregulation also seems to have an important role in this disorder. Since habitual snoring is the initial stage of OSA, the structural characteristics of upper airway muscles (medium pharyngeal constrictor muscle [MPCM]) from 13 men (9 non-snorers and 4 habitual snorers) were studied. MPCM fibre structure in non-snorers was broadly similar to that in normal limb muscles, with the exception that fibre diameters were smaller for all fibre types. Compared with limb muscles, MPCM had a smaller proportion of type IIb fibres and a higher proportion of types I and IIa fibres. MPCM in habitual snorers had an abnormal distribution of fibre types (low percentage of type I and type IIb fibres and high percentage of type IIa fibres) compared with non-snorers (p < 0.001) and the type IIa fibres were hypertrophic. No myopathic or neurogenic changes were seen. Two possible hypotheses explain the abnormal distribution of fibre types in snorers. First, a constitutionally determined reduction of slow alpha-motor neurons induces an adaptive transformation of type IIb to type IIa fibres and a hypertrophy of type IIa fibres; or, second, motor neurons change their patterns of discharge and, hence, of activation, and modify fibre-type distribution of MPCM as an adaptation to the anatomical characteristic of upper airway and habitual snoring.	UNIV MILAN,CTR SLEEP DISORDERS,I-20122 MILAN,ITALY; HOSP NIGUARDA CA GRANDA,DEPT OTOLARYNGOL,MILAN,ITALY	University of Milan	SMIRNE, S (corresponding author), UNIV MILAN,SCI INST HS RAFFAELE,DEPT NEUROL,VIA PRINETTI 29,I-20127 MILAN,ITALY.		STRAMBI, Luigi FERINI/K-3620-2018; Iannaccone, sandro/K-4252-2018	STRAMBI, Luigi FERINI/0000-0003-2867-5424; Iannaccone, sandro/0000-0002-8333-3972				ALAMOOD WS, 1987, J PHYSIOL-LONDON, V392, P377, DOI 10.1113/jphysiol.1987.sp016786; Astrom K.E., 1981, DISORDERS VOLUNTARY, P151; BARNARD RJ, 1970, J APPL PHYSIOL, V28, P762, DOI 10.1152/jappl.1970.28.6.762; BASMAJIAN JV, 1955, ARCH NEURO PSYCHIATR, V73, P224, DOI 10.1001/archneurpsyc.1955.02330080102019; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; Buller AJ, 1974, DISORDERS VOLUNTARY, P20; COTTER M, 1986, EXP NEUROL, V93, P531, DOI 10.1016/0014-4886(86)90173-1; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI, P82; GRIMBY G, 1983, CLIN PHYSIOL, V3, P209, DOI 10.1111/j.1475-097X.1983.tb00704.x; GRIMBY G, 1982, ACTA PHYSL SCAND, V115, P124; GUILLEMINAULT C, 1978, EXP NEUROL, V62, P48, DOI 10.1016/0014-4886(78)90040-7; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HISHIKAWA Y, 1965, ELECTROEN CLIN NEURO, V18, P487, DOI 10.1016/0013-4694(65)90129-X; HORNER RL, 1989, EUR RESPIR J, V2, P613; LEESE G, 1986, ACTA ANAT, V127, P77; LEXELL J, 1983, ACTA PHYSIOL SCAND, V117, P115, DOI 10.1111/j.1748-1716.1983.tb07185.x; LUGARESI E, 1983, B EUR PHYSIOPATH RES, V19, P590; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; ROJEWSKI TE, 1984, OTOLARYNG HEAD NECK, V92, P127, DOI 10.1177/019459988409200201; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; SULLIVAN CE, 1987, SLEEP AGING RELATED, P47; SURATT PM, 1983, AM REV RESPIR DIS, V127, P487, DOI 10.1164/arrd.1983.127.4.487; TAUBER ES, 1977, ANN NEUROL, V2, P66, DOI 10.1002/ana.410020112; THORSTENSSON A, 1976, ACTA PHYSL SCAND S, V443, P7; WADE AJ, 1990, LANCET, V335, P805, DOI 10.1016/0140-6736(90)90933-V	25	89	92	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					597	599						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671953				2022-12-24	WOS:A1991FA70200014
J	CRAWFORD, CL; HOBBS, MJ				CRAWFORD, CL; HOBBS, MJ			INFANTILE PARALYSIS IN DEVELOPING-COUNTRIES - IS IT POLIOMYELITIS OR DIPLEGIA	LANCET			English	Editorial Material							SERIOUS PROBLEM				CRAWFORD, CL (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND.							ALLBROOK D, 1960, LANCET, V1, P459; BANNISTER R, 1985, BRAINS CLIN NEUROLOG, P328; BAZIN M, 1980, NATURE, V285, P7; BURNETT M, 1962, NATURAL HIST INFECTI, P91; CRAWFORD C L, 1968, Leprosy Review, V39, P9; HARRIES JR, 1973, TROPICAL NEUROLOGY, P213; HUCKSTEP RL, 1975, POLIOMYELITIS, P6; LAFORCE FM, 1980, B WORLD HEALTH ORGAN, V58, P609; MIMS CA, 1976, PATHOGENESIS INFECTI, P202; MODLIN JF, 1990, PRINCIPLES PRACTICE, P1359; NICHOLAS DD, 1977, BRIT MED J, V1, P1009, DOI 10.1136/bmj.1.6067.1009; OFOSUAMAAH S, 1977, BRIT MED J, V1, P1012, DOI 10.1136/bmj.1.6067.1012; POSKANZER DC, 1963, LANCET, V2, P917; SHARRARD WJW, 1955, J BONE JOINT SURG BR, V37, P540, DOI 10.1302/0301-620X.37B4.540; WALKER A J, 1956, East Afr Med J, V33, P169; WILSON SAK, 1954, NEUROLOGY, V2, P891; 1990, B WORLD HEALTH ORGAN, V68, P115	17	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					284	286		10.1016/0140-6736(91)90883-Q	http://dx.doi.org/10.1016/0140-6736(91)90883-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671124				2022-12-24	WOS:A1991EV71900016
J	PONCE, C; PONCE, E; MORRISON, A; CRUZ, A; KREUTZER, R; MCMAHONPRATT, D; NEVA, F				PONCE, C; PONCE, E; MORRISON, A; CRUZ, A; KREUTZER, R; MCMAHONPRATT, D; NEVA, F			LEISHMANIA-DONOVANI-CHAGASI - NEW CLINICAL VARIANT OF CUTANEOUS LEISHMANIASIS IN HONDURAS	LANCET			English	Article							INFANTUM SENSU-LATO; MONOCLONAL-ANTIBODIES; IDENTIFICATION	During surveillance for endemic visceral leishmaniasis on an island off the Pacific coast of Honduras, an unusual form of cutaneous leishmaniasis was encountered. By clinical and laboratory criteria, 17 cases were identified over 5 months; children aged 4 to 15 years were primarily affected. Lesions were generally few in number, small, always papular, and non-ulcerative, even when present for several years. Patients with skin lesions seemed otherwise healthy and were well nourished. Montenegro skin tests with Leishmania mexicana and L major antigens were positive in 10 of 17 patients tested, and lesions from 9 patients were positive by culture. Since the summer of 1988, cases of atypical cutaneous leishmaniasis continue to occur on the island (8) as well as on the mainland of southern Honduras (23). A total of 9 parasite isolates from skin lesions, 4 from bone marrow of patients with kala-azar, and 2 from sandflies were identified as L donovani chagasi and were indistinguishable from one another by isoenzyme analysis.	NIAID, PARASIT DIS LAB, BLDG 4, ROOM 126, BETHESDA, MD 20892 USA; YALE UNIV, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06520 USA; YOUNGSTOWN STATE UNIV, DEPT BIOL, YOUNGSTOWN, OH 44555 USA; HOSP ESCUELA TEGUCIGALPA, TEGUCIGALPA, HONDURAS; MINIST HLTH, CENT LAB, TEGUCIGAL, HONDURAS	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Yale University; University System of Ohio; Youngstown State University				Morrison, Amy/0000-0001-6224-5984				BELAZZOUG S, 1985, ANN PARASIT HUM COMP, V60, P1; CAHILL KM, 1964, AM J TROP MED HYG, V13, P794, DOI 10.4269/ajtmh.1964.13.794; GRAMICCIA M, 1989, T ROY SOC TROP MED H, V83, P76, DOI 10.1016/0035-9203(89)90713-X; GRAMICCIA M, 1987, T ROY SOC TROP MED H, V81, P235, DOI 10.1016/0035-9203(87)90225-2; GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270; JAFFE CL, 1984, J IMMUNOL, V133, P440; KILLICKKENDRICK R, 1980, ANN TROP MED PARASIT, V74, P563, DOI 10.1080/00034983.1980.11687385; KREUTZER RD, 1980, AM J TROP MED HYG, V29, P199, DOI 10.4269/ajtmh.1980.29.199; KREUTZER RD, 1983, AM J TROP MED HYG, V32, P703, DOI 10.4269/ajtmh.1983.32.703; KUMAR PV, 1989, AM J TROP MED HYG, V40, P150, DOI 10.4269/ajtmh.1989.40.150; LAINSON R, 1979, BIOL KINETOPLASTIDA, V2, P68; MANSONBAHR PEC, 1955, NATURE, V175, P433, DOI 10.1038/175433b0; NAVIN TR, 1987, AM J TROP MED HYG, V35, P1069; NETO MPO, 1986, ANN TROP MED PARASIT, V80, P587, DOI 10.1080/00034983.1986.11812072; NETO MPO, 1986, MEM I O CRUZ, V81, P303; PRATA A., 1956, Hospital (Rio de Janeiro, Brazil), V49, P481; REES PH, 1987, LEISHMANIASES BIOL M, V2, P605; ZELEDON R, 1989, T ROY SOC TROP MED H, V83, P786, DOI 10.1016/0035-9203(89)90328-3	18	85	90	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 12	1991	337	8733					67	70		10.1016/0140-6736(91)90734-7	http://dx.doi.org/10.1016/0140-6736(91)90734-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670724				2022-12-24	WOS:A1991ER47700002
J	STURM, NR; SIMPSON, L				STURM, NR; SIMPSON, L			KINETOPLAST DNA MINICIRCLES ENCODE GUIDE RNAS FOR EDITING OF CYTOCHROME-OXIDASE SUBUNIT-III MESSENGER-RNA	CELL			English	Article									UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	STURM, NR (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.				NIAID NIH HHS [AI09102] Funding Source: Medline; NIGMS NIH HHS [GM07104] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARROIS M, 1981, P NATL ACAD SCI-BIOL, V78, P3323, DOI 10.1073/pnas.78.6.3323; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BORST P, 1987, MOL BIOCHEM PARASIT, V23, P31, DOI 10.1016/0166-6851(87)90184-8; DONELSON JE, 1979, PLASMID, V2, P572, DOI 10.1016/0147-619X(79)90055-6; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FOUTS DL, 1979, NUCLEIC ACIDS RES, V6, P3785, DOI 10.1093/nar/6.12.3785; FRASCH ACC, 1980, BIOCHIM BIOPHYS ACTA, V607, P397, DOI 10.1016/0005-2787(80)90150-1; KIDANE GZ, 1984, GENE, V27, P265, DOI 10.1016/0378-1119(84)90071-4; MCCUTCHAN TF, 1984, SCIENCE, V225, P625, DOI 10.1126/science.6330899; MOREL C, 1980, P NATL ACAD SCI-BIOL, V77, P6810, DOI 10.1073/pnas.77.11.6810; MUHICH ML, 1986, NUCLEIC ACIDS RES, V14, P5531, DOI 10.1093/nar/14.13.5531; RAY DS, 1989, MOL CELL BIOL, V9, P1365, DOI 10.1128/MCB.9.3.1365; ROHRER SP, 1987, CELL, V49, P625, DOI 10.1016/0092-8674(87)90538-1; SIMPSON AM, 1985, NUCLEIC ACIDS RES, V13, P5977, DOI 10.1093/nar/13.16.5977; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1986, INT REV CYTOL, V99, P119; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; STUART K, 1983, MOL BIOCHEM PARASIT, V9, P93, DOI 10.1016/0166-6851(83)90103-2; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M	21	188	191	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 1	1990	61	5					879	884		10.1016/0092-8674(90)90198-N	http://dx.doi.org/10.1016/0092-8674(90)90198-N			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DG090	1693097				2022-12-24	WOS:A1990DG09000017
J	ENDOW, SA; HENIKOFF, S; SOLERNIEDZIELA, L				ENDOW, SA; HENIKOFF, S; SOLERNIEDZIELA, L			MEDIATION OF MEIOTIC AND EARLY MITOTIC CHROMOSOME SEGREGATION IN DROSOPHILA BY A PROTEIN RELATED TO KINESIN	NATURE			English	Article									FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	ENDOW, SA (corresponding author), DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710, USA.			Endow, Sharyn A./0000-0002-0907-8889; Henikoff, Steven/0000-0002-7621-8685				BAKER BS, 1975, GENETICS, V80, P267; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COOPER KW, 1964, P NATL ACAD SCI USA, V52, P1248, DOI 10.1073/pnas.52.5.1248; DAVIS DG, 1969, GENETICS, V61, P577; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; GORBSKY GJ, 1988, J CELL BIOL, V104, P9; HENIKOFF S, 1988, NUCLEIC ACIDS RES, V16, P6191, DOI 10.1093/nar/16.13.6191; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; STUDIER FW, IN PRESS METH ENZYM; Sturtevant AH, 1929, Z WISS ZOOL ABT A, V135, P323; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YAMAMOTO AH, 1989, EMBO J, V8, P3543, DOI 10.1002/j.1460-2075.1989.tb08526.x; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	24	227	229	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 3	1990	345	6270					81	83		10.1038/345081a0	http://dx.doi.org/10.1038/345081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB957	1691829				2022-12-24	WOS:A1990DB95700063
J	NIGHTINGALE, SL				NIGHTINGALE, SL			1-PERCENT HYDROCORTISONE PRODUCTS TO BE AVAILABLE OVER-THE-COUNTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3263	3263						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU964	1660082				2022-12-24	WOS:A1991GU96400005
J	HARRIS, PC; THOMAS, S; RATCLIFFE, PJ; BREUNING, MH; COTO, E; LOPEZLARREA, C				HARRIS, PC; THOMAS, S; RATCLIFFE, PJ; BREUNING, MH; COTO, E; LOPEZLARREA, C			RAPID GENETIC-ANALYSIS OF FAMILIES WITH POLYCYSTIC KIDNEY DISEASE-1 BY MEANS OF A MICROSATELLITE MARKER	LANCET			English	Article							CHROMOSOME-16; MAP; POLYMORPHISMS; DIAGNOSIS; LOCUS; PKD1	Presymptomatic diagnosis of polycystic kidney disease 1 (PKD1) is possible by genetic linkage analysis with markers from both sides of the disease locus. The existing proximal markers are not informative in many families, so such analysis is difficult and time-consuming. We sought more useful length polymorphisms on the proximal side of the locus among simple sequence repeats (microsatellites). We identified two microsatellite polymorphisms that lie closer to the PKD1 locus than any previously described highly variable marker. One, SM7, is especially informative; we have found fourteen alleles and the observed heterozygosity in caucasians is 62.7%. Genetic linkage analysis in PKD1 families suggests that both of the markers lie proximal to the disease gene, closer than existing flanking markers. These polymorphisms can be simply assayed by polymerase chain reaction amplification of the variable regions, which generates DNA fragments that can be separated on non-denaturing acrylamide gels and directly examined after gel staining. This rapid, inexpensive, and non-radioactive method of linkage analysis allows the complete study of DNA samples within 8 h.	HOSP COVADONGA,SERV IMMUNOL,OVIEDO,SPAIN; LEIDEN UNIV,DEPT HUMAN GENET,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	HARRIS, PC (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.		Breuning, Martijn H/E-3429-2010	Ratcliffe, Peter/0000-0002-2853-806X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BREUNING MH, 1990, J MED GENET, V27, P614, DOI 10.1136/jmg.27.10.614; BREUNING MH, 1990, J MED GENET, V27, P603, DOI 10.1136/jmg.27.10.603; GERMINO GG, 1990, AM J HUM GENET, V46, P925; GILLESPIE GA, 1990, NUCLEIC ACIDS RES, V18, P7071, DOI 10.1093/nar/18.23.7071; GILLESPIE GAJ, 1991, P NATL ACAD SCI USA, V88, P4289, DOI 10.1073/pnas.88.10.4289; HARRIS PC, 1990, GENOMICS, V7, P195, DOI 10.1016/0888-7543(90)90541-2; HIMMELBAUER H, 1991, AM J HUM GENET, V48, P325; LALLOZ MRA, 1991, LANCET, V338, P207, DOI 10.1016/0140-6736(91)90348-S; LITT M, 1989, AM J HUM GENET, V44, P397; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; RAVINE D, 1991, LANCET, V337, P127, DOI 10.1016/0140-6736(91)90797-S; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WEBER JL, 1989, AM J HUM GENET, V44, P388	16	74	79	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1991	338	8781					1484	1487		10.1016/0140-6736(91)92300-Q	http://dx.doi.org/10.1016/0140-6736(91)92300-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1683919				2022-12-24	WOS:A1991GV07700004
J	FLOYD, RA				FLOYD, RA			OXIDATIVE DAMAGE TO BEHAVIOR DURING AGING	SCIENCE			English	Editorial Material							GLUTAMINE-SYNTHETASE; FREE-RADICALS; ISCHEMIA; BRAIN				FLOYD, RA (corresponding author), OKLAHOMA MED RES FDN,MOLEC TOXICOL RES PROGRAM,OKLAHOMA CITY,OK 73104, USA.				NIA NIH HHS [AG09690] Funding Source: Medline; NINDS NIH HHS [NS23307] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009690] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CARNEY JM, NIH AG09690 GRANTS; CARNEY JM, 1985, J BIOL CHEM, V260, P12600; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; OLIVER CN, 1987, J AM GERIATR SOC, V35, P947, DOI 10.1111/j.1532-5415.1987.tb02297.x; RIVETT AJ, 1985, J BIOL CHEM, V260, P300	11	98	103	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1597	1597		10.1126/science.1684251	http://dx.doi.org/10.1126/science.1684251			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1684251				2022-12-24	WOS:A1991GV07300032
J	EYSTER, ME; ALTER, HJ; ALEDORT, LM; QUAN, S; HATZAKIS, A; GOEDERT, JJ				EYSTER, ME; ALTER, HJ; ALEDORT, LM; QUAN, S; HATZAKIS, A; GOEDERT, JJ			HETEROSEXUAL COTRANSMISSION OF HEPATITIS-C VIRUS (HCV) AND HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; HEPATOCELLULAR-CARCINOMA; III ANTIBODIES; LIVER-DISEASE; BELLE-GLADE; HEMOPHILIACS; PREVALENCE; AIDS; FLORIDA	Objectives: To determine the prevalence of antibodies to hepatitis C virus (HCV) in female sexual partners of multitransfused men with hemophilia and to compare the frequency of transmission of HCV and human immunodeficiency virus (HIV). Study Design: Cross-sectional measurement of HCV and HIV antibodies. Setting: Ten hemophilia treatment centers. Patients: A total of 234 female sexual partners of 231 multitransfused men with hemophilia. Measurements and Main Results: The prevalence of antibodies to HCV (anti-HCV) among female sexual partners of HCV-Positive men was 5 of 194 (2.6%). Anti-HIV prevalence among female sexual partners of HIV-positive men was 25 of 196 (12.8%). Five (3%) of the 164 female sexual partners of HIV-positive/HCV-positive men were infected with HCV compared with none of the 30 female sexual partners of HIV-negative/HCV-positive men. Twenty-one (13%) of the 164 female sexual partners of HIV-positive/HCV-positive men were infected with HIV compared with 4 (13%) of 32 female sexual partners of HIV-positive/HCV-indeterminate men. The co-infected men were five times more likely to transmit both viruses than would be expected by chance (P = 0.01). When a single virus was transmitted to a female sexual partner, it was more often HIV than HCV (18 of 164 compared with 2 of 164, P = 0.001; odds ratio, 8.5; 95% Cl, 2.2 to 33.1). Conclusions: The higher prevalence of HCV in female sexual partners of men with hemophilia than in blood donor and other low-risk groups suggests that there is a low level of sexual transmission. Male to female sexual transmission of HCV is less efficient than that of HIV. The frequency of HCV transmission to sexual partners is five times higher when HIV is also transmitted, suggesting that HIV may be a cofactor for the sexual transmission of HCV.			EYSTER, ME (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT MED, DIV HEMATOL, BOX 850, HERSHEY, PA 17033 USA.			, M. Elaine Eyster/0000-0001-8248-6793	NCI NIH HHS [N01-CP-85649] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP085649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		ALEDORT LM, 1985, BLOOD, V66, P367; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1975, LANCET, V2, P838, DOI 10.1016/S0140-6736(75)90234-2; ALTER HJ, 1991, IN PRESS 1990 INT S; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; BIANCHI L, 1987, SEMIN LIVER DIS, V7, P203, DOI 10.1055/s-2008-1040577; BRUIX J, 1989, LANCET, V2, P1004; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; ESTEBAN JI, 1989, LANCET, V2, P294; EVATT BL, 1985, NEW ENGL J MED, V312, P483, DOI 10.1056/NEJM198502213120805; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; EYSTER ME, 1985, JAMA-J AM MED ASSOC, V253, P2219, DOI 10.1001/jama.253.15.2219; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GOEDERT JJ, 1988, 4 INT C AIDS STOCKH, P264; KITCHEN LW, 1984, NATURE, V312, P367, DOI 10.1038/312367a0; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MAKRIS M, 1990, LANCET, V335, P1117, DOI 10.1016/0140-6736(90)91124-S; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; RAGNI MV, 1986, BLOOD, V67, P592; ROSENBLUM LS, 1990, J INFECT DIS, V161, P407, DOI 10.1093/infdis/161.3.407; RUMI MG, 1990, ANN INTERN MED, V112, P379, DOI 10.7326/0003-4819-112-5-379; SCHRAMM W, 1989, BLUT, V59, P390, DOI 10.1007/BF00321210; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; VANDERPOEL CL, 1989, LANCET, V2, P297; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; 1987, 51 US DEP HLTH HUM S, P19; 1989, 1ST P INT S HEP C VI, P31	32	281	287	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					764	768		10.7326/0003-4819-115-10-764	http://dx.doi.org/10.7326/0003-4819-115-10-764			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1656825				2022-12-24	WOS:A1991GP80000003
J	HYAMS, KC; BOURGEOIS, AL; MERRELL, BR; ROZMAJZL, P; ESCAMILLA, J; THORNTON, SA; WASSERMAN, GM; BURKE, A; ECHEVERRIA, P; GREEN, KY; KAPIKIAN, AZ; WOODY, JN				HYAMS, KC; BOURGEOIS, AL; MERRELL, BR; ROZMAJZL, P; ESCAMILLA, J; THORNTON, SA; WASSERMAN, GM; BURKE, A; ECHEVERRIA, P; GREEN, KY; KAPIKIAN, AZ; WOODY, JN			DIARRHEAL DISEASE DURING OPERATION-DESERT-SHIELD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOXIGENIC ESCHERICHIA-COLI; TRAVELERS DIARRHEA; NORWALK VIRUS; SOUTH-KOREA; TRIMETHOPRIM; SHIGELLA; ANTIGEN; SULFAMETHOXAZOLE; GASTROENTERITIS; CHILDREN	Background. Under combat conditions infectious disease can become a major threat to military forces. During Operation Desert Shield, there were numerous outbreaks of diarrhea among the U.S. forces. To evaluate the causes of and risk factors for diarrheal disease, we collected clinical and epidemiologic data from U.S. troops stationed in northeastern Saudi Arabia. Methods. Between September and December 1990, stool cultures for enteric pathogens were obtained from 432 military personnel who presented with diarrhea, cramps, vomiting, or hematochezia. In addition, a questionnaire was administered to 2022 soldiers in U.S. military units located in various regions of Saudi Arabia. Results. A bacterial enteric pathogen was identified in 49.5 percent of the troops with gastroenteritis. Enterotoxigenic Escherichia coli and Shigella sonnei were the most common bacterial pathogens. Of 125 E. coli infections, 39 percent were resistant to trimethoprim-sulfamethoxazole, 63 percent to tetracycline, and 48 percent to ampicillin. Of 113 shigella infections, 85 percent were resistant to trimethoprim-sulfamethoxazole, 68 percent to tetracycline, and 21 percent to ampicillin. All bacterial isolates were sensitive to norfloxacin and ciprofloxacin. After an average of two months in Saudi Arabia, 57 percent of the surveyed troops had at least one episode of diarrhea, and 20 percent reported that they were temporarily unable to carry out their duties because of diarrheal symptoms. Vomiting was infrequently reported as a primary symptom, but of 11 military personnel in whom vomiting was a major symptom, 9 (82 percent) had serologic evidence of infection with the Norwalk virus. Conclusions. Gastroenteritis caused by enterotoxigenic E coli and shigella resistant to a number of drugs was a major problem that frequently interfered with the duties of U.S. troops during Operation Desert Shield.	ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND; NIH,INFECT DIS LAB,BETHESDA,MD 20892; USN,MED RES & DEV COMMAND,BETHESDA,MD 20814; USN,MED RES INST DETACHMENT,LIMA,PERU; USN,ENVIRONM & PREVENT MED UNIT 7,NAPLES,ITALY; USA,MED DEPT ACT,PREVENT MED SERV,FT CAMPBELL,KY; USN,MED RES UNIT 3,DIV EPIDEMIOL,CAIRO,EGYPT; WILLIAM BEAUMONT ARMY MED CTR,DEPT PEDIAT,EL PASO,TX 79920	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); National Institutes of Health (NIH) - USA; United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Medical Research Unit - No. 3 (NAMRU-3); United States Department of Defense; United States Navy; William Beaumont Army Medical Center	HYAMS, KC (corresponding author), USN,MED RES INST,DIV EPIDEMIOL,12300 WASHINGTON AVE,ROCKVILLE,MD 20852, USA.							AUGUST MJ, 1987, J CLIN MICROBIOL, V25, P2233, DOI 10.1128/JCM.25.11.2233-2235.1987; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHATKAEOMORAKOT A, 1987, PEDIATR INFECT DIS J, V6, P735, DOI 10.1097/00006454-198708000-00008; CHUGH TD, 1985, J HYG-CAMBRIDGE, V95, P391, DOI 10.1017/S0022172400062811; COHEN D, 1991, LANCET, P993; DANIELL FD, 1985, MIL MED, V150, P171, DOI 10.1093/milmed/150.4.171; DAVIS H, 1988, AM J EPIDEMIOL, V128, P1312, DOI 10.1093/oxfordjournals.aje.a115084; DEAN AG, 1972, J INFECT DIS, V125, P407, DOI 10.1093/infdis/125.4.407; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; ECHEVERRIA P, 1979, AM J EPIDEMIOL, V109, P493, DOI 10.1093/oxfordjournals.aje.a112706; ECHEVERRIA P, 1979, J INFECT DIS, V139, P215, DOI 10.1093/infdis/139.2.215; ECHEVERRIA P, 1978, AM J EPIDEMIOL, V108, P68; ECHEVERRIA P, 1990, GENE PROBES BACTERIA, P95; ERICSSON CD, 1990, JAMA-J AM MED ASSOC, V263, P257, DOI 10.1001/jama.263.2.257; ERICSSON CD, 1987, ANN INTERN MED, V106, P216, DOI 10.7326/0003-4819-106-2-216; GARY GW, 1985, J CLIN MICROBIOL, V22, P274, DOI 10.1128/JCM.22.2.274-278.1985; GARY GW, 1987, J CLIN MICROBIOL, V25, P2001, DOI 10.1128/JCM.25.10.2001-2003.1987; GASSER RA, 1991, NEW ENGL J MED, V324, P859, DOI 10.1056/NEJM199103213241229; GOLDFIELD EC, 1991, REV INFECT DIS S3, V13, pS197; GOODMAN LJ, 1990, ARCH INTERN MED, V150, P541, DOI 10.1001/archinte.150.3.541; GRIFFIN MR, 1982, AM J EPIDEMIOL, V115, P178, DOI 10.1093/oxfordjournals.aje.a113289; HABERBERGER RL, 1991, MIL MED, V156, P27, DOI 10.1093/milmed/156.1.27; HEGGERS JP, 1978, MIL MED, V143, P390; Kapikian AZ, 1990, VIROLOGY, P1353; KAPIKIAN AZ, 1975, PERSPECT VIROL, V9, P9; KAPIKIAN AZ, 1990, VIROLOGY, V1, P671; KELLY MT, 1985, MANUAL CLIN MICROBIO, P00263; MARTIN DL, 1986, AM J EPIDEMIOL, V124, P299, DOI 10.1093/oxfordjournals.aje.a114388; MELDMAN IJ, 1978, BACTERIOLOGY ANAL MA; MIDTHUN K, 1989, J CLIN MICROBIOL, V27, P2799, DOI 10.1128/JCM.27.12.2799-2804.1989; MIKHAIL IA, 1990, J CLIN MICROBIOL, V28, P956, DOI 10.1128/JCM.28.5.956-961.1990; Morris G. K., 1985, MANUAL CLIN MICROBIO, P302; MURRAY BE, 1986, REV INFECT DIS, V8, pS172; OLDFIELD EC, 1987, AM J TROP MED HYG, V37, P616, DOI 10.4269/ajtmh.1987.37.616; OPRANDY JJ, 1988, J CLIN MICROBIOL, V26, P92, DOI 10.1128/JCM.26.1.92-95.1988; PAZZAGLIA G, 1982, MIL MED, V147, P27, DOI 10.1093/milmed/147.1.27; QUIN NE, 1982, MIL MED, V147, P728, DOI 10.1093/milmed/147.9.728; SACK DA, 1977, JOHNS HOPKINS MED J, V141, P63; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; SCOTT DA, 1990, AM J TROP MED HYG, V42, P160, DOI 10.4269/ajtmh.1990.42.160; SERENY B, 1955, Acta Microbiol Acad Sci Hung, V2, P293; TAYLOR DN, 1991, ANN INTERN MED, V114, P731, DOI 10.7326/0003-4819-114-9-731; TAYLOR WR, 1982, NEW ENGL J MED, V306, P1093, DOI 10.1056/NEJM198205063061807; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; YOLKEN RH, 1986, MANUAL CLIN LABORATO, P573; YOUSIF AA, 1989, J BAHRAIN MED SOC, V1, P52	47	218	226	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1423	1428		10.1056/NEJM199111143252006	http://dx.doi.org/10.1056/NEJM199111143252006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1656260				2022-12-24	WOS:A1991GP52400006
J	BAETEN, CGMI; KONSTEN, J; SPAANS, F; VISSER, R; HABETS, AMMC; BOURGEOIS, IM; WAGENMAKERS, AJM; SOETERS, PB				BAETEN, CGMI; KONSTEN, J; SPAANS, F; VISSER, R; HABETS, AMMC; BOURGEOIS, IM; WAGENMAKERS, AJM; SOETERS, PB			DYNAMIC GRACILOPLASTY FOR TREATMENT OF FECAL INCONTINENCE	LANCET			English	Article							FECAL INCONTINENCE; NEOANAL SPHINCTER; GRACILIS MUSCLE; SKELETAL-MUSCLE; CONSTRUCTION; TRANSFORMATION; TRANSPOSITION; NEOSPHINCTER; STIMULATION; NEORECTUM	Serious faecal incontinence due to anal sphincter damage should be treated by surgery. Graciloplasty has had limited success because the gracilis is a fast-twitch muscle and fatigues quickly. A favourable outcome in a patient who had dynamic (electrically stimulated) graciloplasty encouraged us to further assess this procedure. Gracilis muscle transposition was done in ten patients with complete anal incontinence due to anal atresia, sphincter damage, or neurogenic causes, and who had had several other unsuccessful treatments. 6 weeks after muscle transposition, intramuscular leads were implanted and connected to an implantable electric stimulator. Eight patients became continent, one patient still has a diverting colostomy, and a fistula developed in the other patient. Anal sphincter pressure improved from 35 mm Hg without stimulation to 62 mm Hg with stimulation at 8 weeks (mean increase 28 mm Hg [95% confidence interval 18, 36), p < 0.01). Retention time of a phosphate enema increased from 22 to 281 s (mean increase 259 s (82, 436], p < 0.01). Defaecography showed that the new sphincter was functioning. Defaecation was possible when the stimulator was turned "off" with a magnet. Dynamic graciloplasty can restore continence and it improves quality of life in faecally incontinent patients for whom other treatments have been unsuccessful.	UNIV LIMBURG HOSP,DEPT CLIN NEUROPHYSIOL,6202 AZ MAASTRICHT,NETHERLANDS; BAKKEN RES CTR,MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT HUMAN BIOL,6200 MD MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC); Medtronic Bakken Research Center B.V.; Hasselt University; Maastricht University	BAETEN, CGMI (corresponding author), UNIV LIMBURG HOSP,DEPT SURG,POB 5800,6202 AZ MAASTRICHT,NETHERLANDS.		Wagenmakers, Anton/H-7625-2014	Wagenmakers, Anton/0000-0003-1916-3822				BAETEN C, 1988, DIS COLON RECTUM, V31, P134, DOI 10.1007/BF02562646; BAETEN CGMI, 1990, BRIT J SURG, V77, P473, DOI 10.1002/bjs.1800770433; CARPENTIER A, 1986, BIOMECHANICAL CARDIA, P85; CAVINA E, 1990, INT J COLORECTAL DIS, V5, P6, DOI 10.1007/BF00496141; CHACHQUES JC, 1986, BIOMECHANICAL CARDIA, P59; CHRISTIANSEN J, 1990, BRIT J SURG, V77, P1039, DOI 10.1002/bjs.1800770928; CORMAN ML, 1979, DIS COLON RECTUM, V22, P290, DOI 10.1007/BF02609307; EDSTROM L, 1986, MUSCLE NERVE, V9, P104, DOI 10.1002/mus.880090203; EISENBERG BR, 1984, CELL TISSUE RES, V238, P221; HALLAN RI, 1990, BRIT J SURG, V77, P208, DOI 10.1002/bjs.1800770226; HAVENITH MG, 1990, HISTOCHEMISTRY, V93, P497, DOI 10.1007/BF00266407; LEIGH RJ, 1982, LANCET, V1, P1349; PETTE D, 1984, MED SCI SPORT EXER, V16, P517; PICKRELL KL, 1952, ANN SURG, V135, P853, DOI 10.1097/00000658-195206000-00010; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; WILLIAMS NS, 1989, BRIT J SURG, V76, P1191, DOI 10.1002/bjs.1800761124; WILLIAMS NS, 1990, ANN ROY COLL SURG, V72, P108	17	177	182	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1991	338	8776					1163	1165		10.1016/0140-6736(91)92030-6	http://dx.doi.org/10.1016/0140-6736(91)92030-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP034	1682590				2022-12-24	WOS:A1991GP03400002
J	WEST, JW; NUMANN, R; MURPHY, BJ; SCHEUER, T; CATTERALL, WA				WEST, JW; NUMANN, R; MURPHY, BJ; SCHEUER, T; CATTERALL, WA			A PHOSPHORYLATION SITE IN THE NA+ CHANNEL REQUIRED FOR MODULATION BY PROTEIN-KINASE-C	SCIENCE			English	Article							SODIUM-CHANNEL; RAT-BRAIN; ALPHA-SUBUNIT; GATING PROPERTIES; SKELETAL-MUSCLE; MESSENGER-RNAS; EXPRESSION; INACTIVATION; ACTIVATION; SEQUENCE	Voltage-gated sodium channels are responsible for generation of action potentials in excitable cells. Activation of protein kinase C slows inactivation of sodium channels and reduces peak sodium currents. Phosphorylation of a single residue, serine 1506, that is located in the conserved intracellular loop between domains III and IV and is involved in inactivation of the sodium channel, is required for both modulatory effects. Mutant sodium channels lacking this phosphorylation site have normal functional properties in unstimulated cells but do not respond to activation of protein kinase C. Phosphorylation of this conserved site in sodium channel alpha-subunits may regulate electrical activity in a wide range of excitable cells.			WEST, JW (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751, R01NS025704] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07270] Funding Source: Medline; NINDS NIH HHS [NS25704, NS15751] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BECKH S, 1989, EMBO J, V8, P3611, DOI 10.1002/j.1460-2075.1989.tb08534.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEGG C, 1977, J BIOL CHEM, V262, P13111; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; Hille B, 1984, IONIC CHANNELS EXCIT; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SARAO R, IN PRESS NUCLEIC ACI; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SCHEUER T, 1991, Biophysical Journal, V59, p262A; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	29	237	241	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					866	868		10.1126/science.1658937	http://dx.doi.org/10.1126/science.1658937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1658937				2022-12-24	WOS:A1991GN83300048
J	SARIOLA, H; SAARMA, M; SAINIO, K; ARUMAE, U; PALGI, J; VAAHTOKARI, A; THESLEFF, I; KARAVANOV, A				SARIOLA, H; SAARMA, M; SAINIO, K; ARUMAE, U; PALGI, J; VAAHTOKARI, A; THESLEFF, I; KARAVANOV, A			DEPENDENCE OF KIDNEY MORPHOGENESIS ON THE EXPRESSION OF NERVE GROWTH-FACTOR RECEPTOR	SCIENCE			English	Article							NEUROTROPHIC FACTOR; MOLECULAR-CLONING; FACTOR BINDING; MESSENGER-RNA; HIGH-AFFINITY; BRAIN; CELLS; PROTEIN; DIFFERENTIATION; TISSUES	Nerve growth factor receptor (NGFR) serves as the binding site for the neurotrophic growth factors. Although NGFR has been found in several embryonic tissues outside the nervous system, the function of NGFR in embryogenesis of non-neuronal organs remains unknown. NGFR is transiently synthesized by embryonic rat kidney and disappears from nephrons upon their terminal differentiation. Anti-sense oligonucleotide inhibition of NGFR expression inhibits kidney morphogenesis. Therefore, NGFR is required not only for development of the nervous system, but also for differentiation of the kidney tubules.	ACAD SCI ESSSR, INST CHEM PHYS & BIOPHYS, 200103 TALLINN, ESTONIA, USSR; UNIV HELSINKI, INST PEDODONT & ORTHODONT, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, DEPT PATHOL, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, INST BIOTECHNOL, SF-00100 HELSINKI 10, FINLAND	National Institute of Chemical Physics & Biophysics (NICPB); University of Helsinki; University of Helsinki; University of Helsinki	SARIOLA, H (corresponding author), UNIV HELSINKI, CHILDRENS HOSP, DEPT PAEDIAT PATHOL, STENBACKINKATU 11, SF-00290 HELSINKI 29, FINLAND.		Arumäe, Urmas/E-8290-2016	Arumäe, Urmas/0000-0003-3658-6464				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BENGTSTROM M, IN PRESS NUCLEIC ACI; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; CHESA PG, 1988, J HISTOCHEM CYTOCHEM, V36, P383, DOI 10.1177/36.4.2831267; COSTRINI NV, 1979, P NATL ACAD SCI USA, V76, P3242, DOI 10.1073/pnas.76.7.3242; ENFORS P, 1990, NEURON, V5, P511; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; ERNFORS P, 1991, INT J DEV NEUROSCI, V9, P57, DOI 10.1016/0736-5748(91)90073-U; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FROEHLER BC, 1986, NUCLEIC ACIDS RES, V14, P5399, DOI 10.1093/nar/14.13.5399; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GROB PM, 1985, J BIOL CHEM, V260, P8044; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; HEMSTEAD BL, 1991, NATURE, V350, P678; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KARAVANOV AA, 1983, EXPERIENTIA, V39, P1015, DOI 10.1007/BF01989779; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Maniatis T., 1982, MOL CLONING; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PARTANEN AM, 1987, DEV BIOL, V120, P186, DOI 10.1016/0012-1606(87)90117-5; PERSSON H, 1990, SCIENCE, V247, P704, DOI 10.1126/science.2154035; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SARIOLA H, 1989, DEV BIOL, V132, P271, DOI 10.1016/0012-1606(89)90224-8; SARIOLA H, UNPUB; Saxen L., 1987, ORGANOGENESIS KIDNEY; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7956, DOI 10.1021/bi00372a026; YAN Q, 1988, J NEUROSCI, V8, P3481	41	195	197	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					571	573		10.1126/science.1658930	http://dx.doi.org/10.1126/science.1658930			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1658930				2022-12-24	WOS:A1991GL79900049
J	DERR, LK; STRATHERN, JN; GARFINKEL, DJ				DERR, LK; STRATHERN, JN; GARFINKEL, DJ			RNA-MEDIATED RECOMBINATION IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST RETROTRANSPOSON TY; LONG TERMINAL REPEATS; VIRUS-LIKE PARTICLES; SACCHAROMYCES-CEREVISIAE; REVERSE TRANSCRIPTION; ELEMENT TRANSPOSITION; EUKARYOTIC GENOME; GENE-EXPRESSION; CDNA GENES; SPT3 GENE	The existence of pseudogenes and the observation of intron loss suggest that RNA can serve as an intermediate in recombination. We used a HIS3 reporter gene to show that RNA-mediated recombination occurs in yeast. His3+ prototroph formation required transcription and expression of the retrotransposon Ty. Two RNA-mediated recombination events were detected: homologous recombination between the cDNA and plasmid his3 sequences, resulting in intron loss, and insertion of the cDNA into the chromosome in the absence of HIS3 homology. The chromosomal His3+ prototrophs showed many hallmarks of naturally occurring pseudogenes. They integrated at novel sites in the chromosome, lacked introns, and possessed poly(A) tracts. Additionally, their 5' ends corresponded with the site of initiation of the GAL1 transcript.			DERR, LK (corresponding author), NCI, FREDERICK CANC RES FACIL, EUKARYOT GENE EXPRESS LAB, FREDERICK, MD 21701 USA.				PHS HHS [N01-C0-74101] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BOEKE JD, 1986, MOL CELL BIOL, V6, P3575, DOI 10.1128/MCB.6.11.3575; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOEKE JD, 1988, MOL CELL BIOL, V8, P1431; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; COLICELLI J, 1988, J VIROL, V62, P633, DOI 10.1128/JVI.62.2.633-636.1988; CURCIO MJ, 1990, MOL GEN GENET, V220, P213; CURCIO MJ, 1991, P NATL ACAD SCI USA, V88, P936, DOI 10.1073/pnas.88.3.936; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORNBURG R, 1990, J VIROL, V64, P886, DOI 10.1128/JVI.64.2.886-889.1990; DORNBURG R, 1988, MOL CELL BIOL, V8, P2328, DOI 10.1128/MCB.8.6.2328; DORNBURG R, 1990, MOL CELL BIOL, V10, P68, DOI 10.1128/MCB.10.1.68; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; GARFINKEL DJ, 1985, CELL, V42, P507, DOI 10.1016/0092-8674(85)90108-4; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HINNEBUSCH AG, 1983, J BIOL CHEM, V258, P5238; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LEVINE KL, 1990, MOL CELL BIOL, V10, P1891, DOI 10.1128/MCB.10.5.1891; LEVRAJUILLET E, 1989, MOL GEN GENET, V217, P168, DOI 10.1007/BF00330957; LINIAL M, 1987, CELL, V49, P93, DOI 10.1016/0092-8674(87)90759-8; MELLOR J, 1985, NATURE, V318, P583, DOI 10.1038/318583a0; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; PAQUIN CE, 1984, SCIENCE, V226, P53, DOI 10.1126/science.226.4670.53; SHERMAN F, 1986, LABORATORY COURSE MA; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; TEMIN HM, 1985, MOL BIOL EVOL, V2, P455; WEINSTOCK KG, 1990, MOL CELL BIOL, V10, P2882, DOI 10.1128/MCB.10.6.2882; WILKE CM, 1989, GENETICS, V123, P655; WINSTON F, 1984, CELL, V39, P675, DOI 10.1016/0092-8674(84)90474-4; XU H, 1990, MOL CELL BIOL, V10, P2695, DOI 10.1128/MCB.10.6.2695; YOSHIMATSU T, 1989, SCIENCE, V244, P1346, DOI 10.1126/science.2544026	36	115	119	2	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					355	364		10.1016/0092-8674(91)90187-4	http://dx.doi.org/10.1016/0092-8674(91)90187-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655280				2022-12-24	WOS:A1991GL47000015
J	PELLETIER, J; BRUENING, W; KASHTAN, CE; MAUER, SM; MANIVEL, JC; STRIEGEL, JE; HOUGHTON, DC; JUNIEN, C; HABIB, R; FOUSER, L; FINE, RN; SILVERMAN, BL; HABER, DA; HOUSMAN, D				PELLETIER, J; BRUENING, W; KASHTAN, CE; MAUER, SM; MANIVEL, JC; STRIEGEL, JE; HOUGHTON, DC; JUNIEN, C; HABIB, R; FOUSER, L; FINE, RN; SILVERMAN, BL; HABER, DA; HOUSMAN, D			GERMLINE MUTATIONS IN THE WILMS-TUMOR SUPPRESSOR GENE ARE ASSOCIATED WITH ABNORMAL UROGENITAL DEVELOPMENT IN DENYS-DRASH SYNDROME	CELL			English	Article							ZINC FINGER PROTEIN; P53 GENE; CHROMOSOME-11; DELETION; CANCER; LOCUS; DNA; PSEUDOHERMAPHRODITISM; BINDING; SRY	Denys-Drash syndrome is a rare human condition in which severe urogenital aberrations result in renal failure, pseudohermaphroditism, and Wilms' tumor (nephroblastoma). To investigate its possible role, we have analyzed the coding exons of the Wilms' tumor suppressor gene (WT1) for germline mutations. In ten independent cases of Denys-Drash syndrome, point mutations in the zinc finger domains of one WT1 gene copy were found. Nine of these mutations are found within exon 9 (zinc finger III); the remaining mutation is in exon 8 (zinc finger II). These mutations directly affect DNA sequence recognition. In two families analyzed, the mutations were shown to arise de novo. Wilms' tumors from three individuals and one juvenile granulosa cell tumor demonstrate reduction to homozygosity for the mutated WT1 allele. Our results provide evidence of a direct role for WT1 in Denys-Drash syndrome and thus urogenital system development.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,QUEBEC,CANADA; UNIV MINNESOTA,SCH MED,DEPT PEDIAT NEPHROL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201; HOP NECKER ENFANTS MALAD,INSERM,U73,F-75730 PARIS 15,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U192,F-75730 PARIS 15,FRANCE; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; SUNY STONY BROOK,DEPT PEDIAT,STONY BROOK,NY 11794; CHILDRENS MEM HOSP,DIV PEDIAT ENDOCRINOL,CHICAGO,IL 60614; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR CANC,BOSTON,MA 02114	McGill University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Oregon Health & Science University; Oregon Health & Science University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Ann & Robert H. Lurie Children's Hospital of Chicago; Harvard University; Harvard Medical School; Massachusetts General Hospital	PELLETIER, J (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [1K08CA 01356] Funding Source: Medline; NHGRI NIH HHS [HG00299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001356] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BECKWITH JB, 1989, PEDIATR PATHOL, V10, P1; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BOND JV, 1975, LANCET, V2, P482; BRESLOW N, 1988, CANCER RES, V48, P1653; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; DAO DD, 1987, AM J HUM GENET, V41, P202; DAVIS LM, 1991, GENOMICS, V10, P588, DOI 10.1016/0888-7543(91)90440-P; DENYS P, 1967, ARCH FR PEDIATR, V24, P729; DRASH A, 1970, J PEDIATR-US, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; FRASIER SD, 1964, J PEDIATR-US, V64, P740, DOI 10.1016/S0022-3476(64)80622-3; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLADE PR, 1976, PROG MED GENET, V1, P1; GREEN MR, 1983, CELL, V32, P681, DOI 10.1016/0092-8674(83)90054-5; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, IN PRESS P NATL ACAD; HABIB R, 1985, CLIN NEPHROL, V24, P269; HUFF V, 1991, AM J HUM GENET, V48, P997; JADRESIC L, 1991, HUM GENET, V86, P497; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LANGRIDGE J, 1980, ANAL BIOCHEM, V103, P264, DOI 10.1016/0003-2697(80)90266-3; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, IN PRESS MOL BASIS H; PELLETIER J, 1991, IN PRESS NATURE; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7; ZUNIN C, 1964, ANN PAEDIATR-BASEL, V203, P29	50	783	803	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					437	447		10.1016/0092-8674(91)90194-4	http://dx.doi.org/10.1016/0092-8674(91)90194-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655284				2022-12-24	WOS:A1991GL47000022
J	HARARI, M; SHANN, F; SPOONER, V; MEISNER, S; CARNEY, M; DECAMPO, J				HARARI, M; SHANN, F; SPOONER, V; MEISNER, S; CARNEY, M; DECAMPO, J			CLINICAL SIGNS OF PNEUMONIA IN CHILDREN	LANCET			English	Article							RESPIRATORY-TRACT INFECTIONS; DIAGNOSIS; CRITERIA	Clinical and chest radiographic findings were recorded prospectively in 185 children with cough who attended an outpatient clinic in Papua New Guinea. Children were studied if they were between 8 weeks and 6 years of age; patients with wheeze, stridor, measles, or pertussis were excluded. 56 children (30%) had radiological evidence of pneumonia. The presence of either a respiratory rate greater-than-or-equal-to 50/min or chest indrawing, or of both signs, was a good indication of pneumonia, with a predictive power of 46% for a positive test and 83% for a negative test. A more complex definition of tachypnoea, as a respiratory rate greater-than-or-equal-to 40/min in children over 12 months old and greater-than-or-equal-to 50/min in infants, showed little additional diagnostic benefit.	ROYAL CHILDRENS HOSP, INTENS CARE UNIT, FLEMINGTON RD, PARKVILLE, VIC 3052, AUSTRALIA; GOROKA BASE HOSP, GOROKA, PAPUA N GUINEA	Royal Children's Hospital Melbourne			Campbell, Harry/E-2959-2010; Shann, Frank/C-9510-2011	Campbell, Harry/0000-0002-6169-6262; 				CAMPBELL H, 1989, LANCET, V1, P297, DOI 10.1016/S0140-6736(89)91308-1; CAMPBELL H, 1988, LANCET, V2, P742; CHERIAN T, 1988, LANCET, V2, P125; GRISKA L, 1984, PNEUMONIAS CLIN APPR, P23; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Leowski J, 1986, World Health Stat Q, V39, P138; LEVENTHAL JM, 1982, CLIN PEDIATR, V21, P730, DOI 10.1177/000992288202101205; MANSKI CF, 1977, ECONOMETRICA, V45, P1977, DOI 10.2307/1914121; SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; ZUKIN DD, 1986, ANN EMERG MED, V15, P792	12	78	82	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	1991	338	8772					928	930		10.1016/0140-6736(91)91785-S	http://dx.doi.org/10.1016/0140-6736(91)91785-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681277				2022-12-24	WOS:A1991GJ89900015
J	VANDERMAST, RC; FEKKES, D; MOLEMAN, P; PEPPLINKHUIZEN, L				VANDERMAST, RC; FEKKES, D; MOLEMAN, P; PEPPLINKHUIZEN, L			IS POSTOPERATIVE DELIRIUM RELATED TO REDUCED PLASMA TRYPTOPHAN	LANCET			English	Note								The cause of postoperative delirium is unknown. In 7 patients with postcardiotomy delirium (6 men, 1 woman; mean age 67 years), we observed a plasma concentration of tryptophan and a plasma tryptophan ratio significantly lower than in 8 non-delirious postoperative control patients. We suggest that the mental symptoms of postcardiotomy delirium are the consequence of a reduced cerebral tryptophan availability due to a catabolic state.			VANDERMAST, RC (corresponding author), DIJKZIGT ACAD HOSP, DEPT PSYCHIAT, DR MOLEWATERPLEIN 40, 3015 GD ROTTERDAM, NETHERLANDS.							BRUINVELS J, 1984, J PSYCHIAT RES, V18, P307, DOI 10.1016/0022-3956(84)90021-9; FERNSTROM JD, 1972, SCIENCE, V178, P414, DOI 10.1126/science.178.4059.414; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; LEHMANN J, 1982, ACTA PSYCHIAT SCAND, V65, P1; Lipowski Z.J, 1990, DELIRIUM ACUTE CONFU; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; SKAUG OE, 1989, TIDSSKRIFT NORSKE LA, V104, P97; SMITH LW, 1989, AM J PSYCHIAT, V146, P452	8	47	49	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	1991	338	8771					851	852		10.1016/0140-6736(91)91504-N	http://dx.doi.org/10.1016/0140-6736(91)91504-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH945	1681217				2022-12-24	WOS:A1991GH94500006
J	GERSHON, PD; AHN, BY; GARFIELD, M; MOSS, B				GERSHON, PD; AHN, BY; GARFIELD, M; MOSS, B			POLY(A) POLYMERASE AND A DISSOCIABLE POLYADENYLATION STIMULATORY FACTOR ENCODED BY VACCINIA VIRUS	CELL			English	Article							THYMIDINE KINASE GENE; EARLY TRANSCRIPTION FACTOR; RNA-CAPPING ENZYME; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; BINDING-PROTEIN; FOWLPOX VIRUS; ACID; DNA	mRNA made in eukaryotic cells typically has a 3' poly(A) tail that is added posttranscriptionally. To investigate mechanisms by which 3' poly(A) is formed, we identified the genes for the two vaccinia virus-encoded polypeptides, VP55 and VP39. Primer-dependent polyadenylation activity was associated exclusively with purified VP55-VP39 heterodimer, which, although stable to column chromatography and glycerol gradient sedimentation, was readily dissociated by antibody to an N-terminal peptide of VP55. Poly(A) polymerase activity was associated with immunopurified VP55, but not with immunopurified or chromatographically purified VP39. VP39 was, however, required for the formation of long poly(A) molecules, in conjunction with either purified VP55 or low concentrations of the heterodimer, and was shown to bind free poly(A). Thus, a catalytic polypeptide and a dissociable poly(A)-binding stimulatory factor each contribute to poly(A) tail formation. No prokaryotic or eukaryotic homologs of either polypeptide were detected in sequence data bases, consistent with the absence of previously reported poly(A) polymerase genes from any source.	NIAID,BIOL RESOURCES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	GERSHON, PD (corresponding author), NIAID,VIRAL DIS LAB,BETHESDA,MD 20892, USA.			Moss, Bernard/0000-0002-2154-8564				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; BINNS MM, 1988, J GEN VIROL, V69, P1275, DOI 10.1099/0022-1317-69-6-1275; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRILLIEN R, 1987, VIROLOGY, V160, P203, DOI 10.1016/0042-6822(87)90061-4; EDMONDS M, 1990, METHOD ENZYMOL, V181, P161; GERSHON PD, 1989, J GEN VIROL, V70, P525, DOI 10.1099/0022-1317-70-3-525; GERSHON PD, 1990, P NATL ACAD SCI USA, V87, P4401, DOI 10.1073/pnas.87.11.4401; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACOB ST, 1983, ENZYMES NUCLEIC ACID, P135; JONES EV, 1987, J VIROL, V61, P1765, DOI 10.1128/JVI.61.6.1765-1771.1987; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KOIWAI O, 1986, NUCLEIC ACIDS RES, V14, P5777, DOI 10.1093/nar/14.14.5777; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; MOSS B, 1975, J BIOL CHEM, V250, P4722; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; NEVINS JR, 1975, VIROLOGY, V63, P1, DOI 10.1016/0042-6822(75)90365-7; NEVINS JR, 1977, J BIOL CHEM, V252, P6939; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLUCIENNICZAK A, 1985, NUCLEIC ACIDS RES, V13, P985, DOI 10.1093/nar/13.3.985; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; REGNIER P, 1987, J BIOL CHEM, V262, P63; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENBERG AH, 1987, GENE, V59, P191, DOI 10.1016/0378-1119(87)90327-1; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; Sambrook J., 1989, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SHUMAN S, 1988, J BIOL CHEM, V263, P8405; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P521, DOI 10.1093/nar/12.1Part2.521; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WEI CM, 1975, P NATL ACAD SCI USA, V72, P318, DOI 10.1073/pnas.72.1.318; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	50	111	116	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1269	1278		10.1016/0092-8674(91)90048-4	http://dx.doi.org/10.1016/0092-8674(91)90048-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1670500				2022-12-24	WOS:A1991GG55200020
J	FALANGA, V; KIRSNER, RS; EAGLSTEIN, WH; KATZ, MH; KERDEL, FA				FALANGA, V; KIRSNER, RS; EAGLSTEIN, WH; KATZ, MH; KERDEL, FA			STANOZOLOL IN TREATMENT OF LEG ULCERS DUE TO CRYOFIBRINOGENEMIA	LANCET			English	Note								Five consecutive patients with cryofibrinogenaemia in association with painful leg ulcers and intravascular dermal thrombi were treated with stanozolol, an androgenic steroid with fibrinolytic properties. In all patients treatment was followed by rapid and striking pain relief and healing of the ulcers. Cryofibrinogenaemia was not detected on subsequent laboratory evaluation, and dermal intravascular thrombi had resolved on repeat histological examination.			FALANGA, V (corresponding author), UNIV MIAMI,SCH MED,DEPT DERMATOL & CUTANEOUS SURG,POB 016250,MIAMI,FL 33136, USA.			Falanga, Vincent/0000-0003-2292-2017				AYRES ML, 1981, BRIT J SURG, V68, P51, DOI 10.1002/bjs.1800680117; COPEMAN PWM, 1979, BRIT J DERMATOL, V101, P57; JARRETT PEM, 1975, BRIT J SURG, V62, P654; KLEIN AD, 1991, ARCH DERMATOL, V127, P133; KLUFT C, 1984, THROMB HAEMOSTASIS, V51, P157; KORST DR, 1955, BLOOD, V10, P945, DOI 10.1182/blood.V10.9.945.945; MIALE JB, 1977, LABORATORY MED HEMAT, P1047; RACHMILEWITZ EA, 1970, ISRAEL J MED SCI, V6, P32; SMITH SB, 1972, AM J CLIN PATHOL, V58, P524; STATHAKIS NE, 1978, BLOOD, V51, P1211; ZLOTNICK A, 1969, ACTA HAEMATOL-BASEL, V42, P8, DOI 10.1159/000208756	11	50	50	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					347	348		10.1016/0140-6736(91)90483-6	http://dx.doi.org/10.1016/0140-6736(91)90483-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677702				2022-12-24	WOS:A1991GA60700008
J	KREMER, EJ; PRITCHARD, M; LYNCH, M; YU, S; HOLMAN, K; BAKER, E; WARREN, ST; SCHLESSINGER, D; SUTHERLAND, GR; RICHARDS, RI				KREMER, EJ; PRITCHARD, M; LYNCH, M; YU, S; HOLMAN, K; BAKER, E; WARREN, ST; SCHLESSINGER, D; SUTHERLAND, GR; RICHARDS, RI			MAPPING OF DNA INSTABILITY AT THE FRAGILE-X TO A TRINUCLEOTIDE REPEAT SEQUENCE P(CCG)N	SCIENCE			English	Article							NUCLEOTIDES; EXPRESSION	The sequence of a Pst I restriction fragment was determined that demonstrates instability in fragile X syndrome pedigrees. The region of instability was localized to a trinucleotide repeat p(CCG)n. The sequences flanking this repeat were identical in normal and affected individuals. The breakpoints in two somatic cell hybrids constructed to break at the fragile site also mapped to this repeat sequence. The repeat exhibits instability both when cloned in a nonhomologous host and after amplification by the polymerase chain reaction. These results suggest variation in the trinucleotide repeat copy number as the molecular basis for the instability and possibly the fragile site. This would account for the observed properties of this region in vivo and in vitro.	WASHINGTON UNIV,SCH MED,CTR GENET MED,ST LOUIS,MO 63110; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Washington University (WUSTL); Emory University; Emory University			Kremer, Eric J/D-3734-2013; Warren, Stephen T/A-2498-2012; Richards, Robert/ABE-6423-2020; Sutherland, Grant Robert/D-2606-2012; Kremer, EJ/P-9838-2019	Kremer, EJ/0000-0001-6114-7530; Richards, Robert Ian/0000-0002-5978-6453				BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; KREMER E, UNPUB; KREMER EJ, IN PRESS AM J HUM GE; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Sutherland G, 1985, FRAGILE SITES HUMAN; SUTHERLAND GR, 1986, AM J MED GENET, V23, P409, DOI 10.1002/ajmg.1320230133; SUTHERLAND GR, 1988, MUTAT RES, V200, P207, DOI 10.1016/0027-5107(88)90084-X; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WILLIAMSON R, 1990, CYTOGENET CELL GENET, V55, P457, DOI 10.1159/000133027; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; [No title captured]	13	834	866	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1711	1714		10.1126/science.1675488	http://dx.doi.org/10.1126/science.1675488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1675488				2022-12-24	WOS:A1991FT11400048
J	COLLINGE, J; PALMER, MS; DRYDEN, AJ				COLLINGE, J; PALMER, MS; DRYDEN, AJ			GENETIC PREDISPOSITION TO IATROGENIC CREUTZFELDT-JAKOB DISEASE	LANCET			English	Note							PRION	The spongiform encephalopathy Creutzfeldt-Jakob disease (CJD) has been transmitted to man via administration of growth hormone and gonadotropin extracted from large pooled batches of human cadaveric pituitary glands. In the UK, 1908 individuals were exposed to potentially contaminated growth hormone, of whom 6 have so far manifested CJD. Examination of the prion protein genes of all these cases and of a single case of gonadotropin-related CJD showed that 4 had the uncommon valine 129 homozygous genotype indicating genetic susceptibility to prion infection. Such genetic susceptibility may be important in the aetiology of sporadic CJD disease.			COLLINGE, J (corresponding author), ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,PRION DIS GRP,NORFOLK PL,LONDON W2 1PG,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUCHANAN CR, 1991, BRIT MED J, V302, P824, DOI 10.1136/bmj.302.6780.824; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; GOLDFARB L G, 1989, American Journal of Human Genetics, V45, pA189; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WU Y, 1987, NUCLEIC ACIDS RES, V15, P3191, DOI 10.1093/nar/15.7.3191	6	474	491	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1441	1442		10.1016/0140-6736(91)93128-V	http://dx.doi.org/10.1016/0140-6736(91)93128-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675319				2022-12-24	WOS:A1991FR06000005
J	LEE, HP; GOURLEY, L; DUFFY, SW; ESTEVE, J; LEE, J; DAY, NE				LEE, HP; GOURLEY, L; DUFFY, SW; ESTEVE, J; LEE, J; DAY, NE			DIETARY-EFFECTS ON BREAST-CANCER RISK IN SINGAPORE	LANCET			English	Article							CHINESE; POPULATION; FAT	It is suspected that diet influences the risk of getting breast cancer. A study of diet and breast cancer was done among 200 Singapore Chinese women with histologically confirmed disease and 420 matched controls. A quantitative food-frequency questionnaire was used to assess intakes of selected nutrients and foods 1 year before interview. Daily intakes were computed and risk analysed after adjustment for concomitant risk factors. In premenopausal women, high intakes of animal proteins and red meat were associated with increased risk. Decreased risk was associated with high intakes of polyunsaturated fatty acids (PUFA), beta-carotene, soya proteins, total soya products, a high PUFA to saturated fatty acid ratio, and a high proportion of soya to total protein. In multiple analysis, the variables which were significant after adjustment for each other were red meat (p < 0.001) as a predisposing factor, and PUFA (p = 0.02), beta-carotene (p = 0.003), and soya protein (p = 0.02) as protective factors. The analysis of dietary variables in postmenopausal women gave uniformly non-significant results. Our finding that soya products may protect against breast cancer in younger women is of interest since these foods are rich in phyto-oestrogens.	GLENEAGLES HOSP, SINGAPORE, SINGAPORE; MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND; INT AGCY RES CANC, F-69372 LYONS, FRANCE	MRC Biostatistics Unit; World Health Organization; International Agency for Research on Cancer (IARC)	LEE, HP (corresponding author), NATL UNIV SINGAPORE, DEPT COMMUNITY OCCUPAT & FAMILY MED, LOWER KENT RIDGE RD, SINGAPORE 0511, SINGAPORE.							ARMSTRONG BK, 1985, CANCER RISKS PREVENT, P68; BARNES S, 1990, PROG CLIN BIOL RES, V347, P239; Breslow N, 1980, STATISTICAL METHODS, V32; DEWAARD F, 1964, CANCER, V17, P141, DOI 10.1002/1097-0142(196402)17:2<141::AID-CNCR2820170202>3.0.CO;2-Z; GOURLEY L, 1988, EUR J CLIN NUTR, V42, P333; HIROHATA T, 1987, JNCI-J NATL CANCER I, V78, P595; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; ISCOVICH JM, 1989, INT J CANCER, V44, P770, DOI 10.1002/ijc.2910440504; La Vecchia C, 1987, Nutr Cancer, V10, P205; LEE HP, 1989, INT J CANCER, V43, P1007, DOI 10.1002/ijc.2910430609; LEE HP, 1988, INT J CANCER, V42, P159, DOI 10.1002/ijc.2910420204; LEMARCHAND L, 1988, AM J EPIDEMIOL, V128, P137; LUBIN F, 1986, JNCI-J NATL CANCER I, V77, P605, DOI 10.1093/jnci/77.3.605; ROHAN TE, 1988, INT J CANCER, V41, P390, DOI 10.1002/ijc.2910410312; ROHAN TE, 1988, AM J EPIDEMIOL, V128, P478, DOI 10.1093/oxfordjournals.aje.a114996; ROHAN TE, 1988, INT J CANCER, V41, P695, DOI 10.1002/ijc.2910410510; Setchell KDR, 1988, ROLE GUT FLORA TOXIC, P315; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; ZARIDZE DG, 1990, INT J CANCER, V45, P807, DOI 10.1002/ijc.2910450502; ZARIDZE DG, 1991, IN PRESS INT J CANCE	20	648	663	3	35	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1197	1200		10.1016/0140-6736(91)92867-2	http://dx.doi.org/10.1016/0140-6736(91)92867-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673746				2022-12-24	WOS:A1991FM26100011
J	LEVINE, B; CHAISSON, RE				LEVINE, B; CHAISSON, RE			MYCOBACTERIUM-KANSASII - A CAUSE OF TREATABLE PULMONARY-DISEASE ASSOCIATED WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNE-DEFICIENCY SYNDROME; AVIUM COMPLEX INFECTION; SYNDROME AIDS; TUBERCULOSIS; INTRACELLULARE; THERAPY	Objective: To assess the clinical features and response to therapy of Mycobacterium kansasii infection in patients with human immunodeficiency virus (HIV) infection. Design: We reviewed the records of all patients with M. kansasii and HIV infection treated between January 1985 and June 1990. Setting: The Johns Hopkins Hospital, Baltimore, Maryland. Results: Nineteen patients with M. kansasii and HIV infection were identified; 14 patients had exclusive pulmonary infection, 3 patients had pulmonary and extrapulmonary infection, and 2 patients had exclusive extrapulmonary infection. At the time of diagnosis of M. kansasii infection, the median CD4+ lymphocyte count was 49 cells/mu-L (range, 0 to 198 cells/mu-L), and 16 of 19 patients had a previous diagnosis of the acquired immunodeficiency syndrome (AIDS). All 17 patients with pulmonary infection presented with fever and cough of at least 2 weeks duration. Chest radiographs showed either focal upper lobe infiltrates (n = 8) or diffuse interstitial infiltrates (n = 9); 9 patients also had thin-walled cavitary lesions. Nine patients with pulmonary M. kansasii infection were treated with antituberculosis chemotherapy, with resolution of fever and respiratory symptoms, improvement of radiographic infiltrates, and sputum conversion; 1 patient with M. kansasii osteomyelitis also responsed to antituberculosis therapy. Autopsies done on 3 treated patients did not reveal any evidence of M. kansasii infection. Nine patients did not receive any antituberculosis chemotherapy; 2 untreated patients developed progressive cavitary pulmonary disease and died from M. kansasii pneumonia. Conclusions: Mycobacterium kansasii causes serious and potentially life-threatening pulmonary disease in patients with advanced HIV-related immunosuppression. In contrast to previous reports, our findings indicate that disease produced by M. kansasii in patients with HIV infection is responsive to antituberculosis chemotherapy.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University								AHN CH, 1982, AM REV RESPIR DIS, V125, P388; AHN CH, 1987, AM REV RESPIR DIS, V135, P10; [Anonymous], 1987, ANN INTERN MED, V106, P254, DOI 10.7326/0003-4819-106-2-254; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96; CHAN J, 1984, ANN INTERN MED, V101, P400, DOI 10.7326/0003-4819-101-3-400_1; CHAPMAN JS, 1977, ATYPICAL MYCOBACTERI; FOURNIER AM, 1988, CHEST, V93, P772, DOI 10.1378/chest.93.4.772; GREENE JB, 1982, ANN INTERN MED, V97, P539, DOI 10.7326/0003-4819-97-4-539; HAWKINS CC, 1986, ANN INTERN MED, V105, P184, DOI 10.7326/0003-4819-105-2-184; HIRASUNA JD, 1987, ANN INTERN MED, V107, P784, DOI 10.7326/0003-4819-107-5-784_1; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; JACOBSON MA, 1989, AM J CLIN PATHOL, V91, P236, DOI 10.1093/ajcp/91.2.236; PFUETZE KH, 1965, AM REV RESPIR DIS, V92, P470; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SANDERS WE, 1990, PRINCIPLES PRACTICE, P1914; SCHRAUFNAGEL DE, 1986, BRIT J DIS CHEST, V80, P131, DOI 10.1016/0007-0971(86)90033-1; SHERER R, 1986, ANN INTERN MED, V105, P710, DOI 10.7326/0003-4819-105-5-710; SNIDER DE, 1987, AM REV RESPIR DIS, V136, P492; TECSONTUMANG FT, 1984, ANN INTERN MED, V100, P461, DOI 10.7326/0003-4819-100-3-461_2; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; TSUKAMURA M, 1981, REV INFECT DIS, V3, P841; WALLACE JM, 1988, CHEST, V93, P926, DOI 10.1378/chest.93.5.926; WOLINSKY E, 1981, REV INFECT DIS, V3, P1025; WOLINSKY E, 1968, AM REV RESPIR DIS, V97, P1032; YOUNG LS, 1986, REV INFECT DIS, V8, P1024; YOUNG LS, 1988, J INFECT DIS, V157, P863, DOI 10.1093/infdis/157.5.863; 1987, MMWR, V36, pS3; 1981, AM REV RESPIR DIS, V123, P343; 1985, CTR DISEASE CONTROL, P165	32	100	100	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					861	868		10.7326/0003-4819-114-10-861	http://dx.doi.org/10.7326/0003-4819-114-10-861			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	1673053				2022-12-24	WOS:A1991FL65000005
J	STUART, AG; WREN, C; SHARPLES, PM; HUNTER, S; HEY, EN				STUART, AG; WREN, C; SHARPLES, PM; HUNTER, S; HEY, EN			HYPOPLASTIC LEFT HEART SYNDROME - MORE POTENTIAL TRANSPLANT RECIPIENTS THAN SUITABLE DONORS	LANCET			English	Article							ORTHOTOPIC CARDIAC TRANSPLANTATION; ANENCEPHALIC INFANTS; ORGAN DONORS; EXPERIENCE; DEATH	Neonatal cardiac transplantation offers the prospect of survival for babies with hypoplastic left heart syndrome-but only if suitable donors are available. In a retrospective survey in the Northern health region of England and Wales, the likely need for neonatal cardiac transplantation far outweighed the potential availability of donors. Over 8 years (1983-90) hypoplastic left heart syndrome was identified in 38 newborn babies and in 9 fetuses in utero. Of 41 live births (including 3 diagnosed prenatally) 31 would have been candidates for a cardiac transplant, but only 4 suitable donors could be identified (3 with anencephaly born alive during the same period and 1 who died between 1979 and 1986 after a head injury). Analysis of all infant deaths in 1987-89 revealed only 3 potential donors from 426 deaths in the 3 years. Although more widespread antenatal diagnosis may lead to fewer liveborn babies with hypoplastic left heart syndrome, these findings indicate that an alternative source of donors needs to be identified before neonatal cardiac transplantation can be widely used in the treatment of this disorder.	FREEMAN RD HOSP,DEPT PAEDIAT CARDIOL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT CHILD HLTH,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle Freeman Hospital; Newcastle University - UK				Stuart, Alan Graham/0000-0003-2789-2216				BAILEY LL, 1988, ANN SURG, V208, P279, DOI 10.1097/00000658-198809000-00004; BAILEY LL, 1990, PEDIATR CLIN N AM, V37, P137; Bailey LL., 1984, HEART TRANSPLANT, V3, P265; BOUCEK MM, 1990, J PEDIATR-US, V116, P171, DOI 10.1016/S0022-3476(05)82870-7; DAVID TJ, 1983, J MED GENET, V20, P338, DOI 10.1136/jmg.20.5.338; HARRISON MR, 1986, LANCET, V2, P1383; HOLZGREVE W, 1987, NEW ENGL J MED, V326, P1069; LLOYD TR, 1989, AM HEART J, V117, P1337, DOI 10.1016/0002-8703(89)90416-X; MAVROUDIS C, 1989, J THORAC CARDIOV SUR, V97, P389; MAVROUDIS C, 1988, J THORAC CARDIOV SUR, V96, P912; MEDEARIS DN, 1989, NEW ENGL J MED, V321, P391, DOI 10.1056/NEJM198908103210610; MORRIS CD, 1990, PEDIATRICS, V85, P977; NORWOOD WI, 1981, J THORAC CARDIOV SUR, V82, P511; PEABODY JL, 1989, NEW ENGL J MED, V321, P344, DOI 10.1056/NEJM198908103210602; PIGOTT JD, 1988, ANN THORAC SURG, V45, P122; SHEWMON DA, 1988, HASTINGS CENT REP, V18, P11, DOI 10.2307/3562217; STILLER CR, 1988, TRANSPL P, V20, P1; TRUOG RD, 1989, NEW ENGL J MED, V321, P388, DOI 10.1056/NEJM198908103210609; TUCKER WY, 1990, J THORAC CARDIOV SUR, V99, P885; 1988, C MED ROYAL COLLEGES	20	21	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					957	959		10.1016/0140-6736(91)91581-E	http://dx.doi.org/10.1016/0140-6736(91)91581-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678040				2022-12-24	WOS:A1991FH13100014
J	SAUNDERS, N; PATERSON, C				SAUNDERS, N; PATERSON, C			CAN WE ABANDON NAEGELE RULE	LANCET			English	Editorial Material								A pregnant woman may become anxious if she has not delivered by the date given to her by her physician. Much anxiety would be alleviated if a range of dates (38-42 weeks) was substituted for a specific date of delivery. 1			SAUNDERS, N (corresponding author), ST MARYS HOSP,SCH MED,DEPT OBSTET & GYNAECOL,NORFOLK PL,LONDON W2 1PG,ENGLAND.							DENMAN T, 1782, INTRO PRACTICE MIDWI; HENDERSON M, 1967, ARCH ENVIRON HEALTH, V14, P905; MONTGOMERY WF, 1837, EXPOSITION SIGNS SYM; NESBITT R E Jr, 1955, Obstet Gynecol Surv, V10, P311, DOI 10.1097/00006254-195506000-00001; PARK GL, 1968, LANCET, V2, P1388; SPEERT H, 1958, ESSAYS EPONYMY; STEWART HL, 1952, JAMA-J AM MED ASSOC, V148, P1079	7	20	20	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					600	601		10.1016/0140-6736(91)91653-C	http://dx.doi.org/10.1016/0140-6736(91)91653-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671954				2022-12-24	WOS:A1991FA70200015
J	JOYNER, AL; HERRUP, K; AUERBACH, BA; DAVIS, CA; ROSSANT, J				JOYNER, AL; HERRUP, K; AUERBACH, BA; DAVIS, CA; ROSSANT, J			SUBTLE CEREBELLAR PHENOTYPE IN MICE HOMOZYGOUS FOR A TARGETED DELETION OF THE EN-2 HOMEOBOX	SCIENCE			English	Article							DROSOPHILA ENGRAILED GENE; PROTO-ONCOGENE INT-1; BOX-CONTAINING GENES; DNA-BINDING; HOMOLOGOUS RECOMBINATION; SEQUENCE HOMOLOGY; MOUSE CEREBELLUM; GRANULE CELL; EXPRESSION; EMBRYOGENESIS	The two mouse genes, En-1 and En-2, that are homologs of the Drosophila segmentation gene engrailed, show overlapping spatially restricted patterns of expression in the neural tube during embryogenesis, suggestive of a role in regional specification. Mice homozygous for a targeted mutation that deletes the homeobox were viable and showed no obvious defects in embryonic development. This may be due to functional redundancy of En-2 and the related En-1 gene product during embryogenesis. Consistent with this hypothesis, the mutant mice showed abnormal foliation in the adult cerebellum, where En-2, and not En-1, is normally expressed.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA; EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC, WALTHAM, MA 02254 USA	University of Toronto	JOYNER, AL (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Herrup, Karl/C-5313-2014	Herrup, Karl/0000-0001-7786-5844	NICHD NIH HHS [HD25334] Funding Source: Medline; NINDS NIH HHS [NS18381, NS20591] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020591, R01NS018381] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1972, J COMP NEUROL, V146, P355, DOI 10.1002/cne.901460305; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BRIVANLOU AH, 1989, DEVELOPMENT, V106, P611; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; COLEMAN KG, 1987, GENE DEV, V1, P19, DOI 10.1101/gad.1.1.19; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DAVIS CA, IN PRESS DEVELOPMENT; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FJOSE A, 1988, FEBS LETT, V231, P355, DOI 10.1016/0014-5793(88)80849-4; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GARDNER CA, 1988, J NEUROSCI RES, V21, P426, DOI 10.1002/jnr.490210234; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GOLDOWITZ D, 1982, J NEUROSCI, V2, P1474; HEMMATIBRIVANLO.A, IN PRESS DEVELOPMENT; HERRUP K, 1987, NEUROSCIENCE, V23, P871, DOI 10.1016/0306-4522(87)90164-3; HOEY T, 1988, MOL CELL BIOL, V8, P4598, DOI 10.1128/MCB.8.11.4598; INGHAM P, 1985, NATURE, V317, P634, DOI 10.1038/317634a0; INOUYE M, 1980, J COMP NEUROL, V190, P357, DOI 10.1002/cne.901900209; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1984, EMBO J, V3, P2839, DOI 10.1002/j.1460-2075.1984.tb02217.x; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LITTLE JW, COMMUNICATION; LOGAN C, 1989, GENOMICS, V4, P206, DOI 10.1016/0888-7543(89)90301-7; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; NEUMANN PE, 1990, BRAIN RES, V524, P85, DOI 10.1016/0006-8993(90)90495-W; NJOLSTAD PR, 1988, BIOCHEM BIOPH RES CO, V157, P426, DOI 10.1016/S0006-291X(88)80266-3; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; REZAI Z, 1972, DEV BIOL, V29, P17, DOI 10.1016/0012-1606(72)90039-5; Sidman Richard L., 1971, ATLAS MOUSE BRAIN SP; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TREISMAN J, 1989, CELL, V59, P553; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	46	360	365	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1991	251	4998					1239	1243		10.1126/science.1672471	http://dx.doi.org/10.1126/science.1672471			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1672471				2022-12-24	WOS:A1991FA69100044
J	BRAHAMS, D				BRAHAMS, D			LATE BENOXAPROFEN CLAIMS	LANCET			English	Editorial Material																		1991, TIMES           0213	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					483	484		10.1016/0140-6736(91)93412-3	http://dx.doi.org/10.1016/0140-6736(91)93412-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671484				2022-12-24	WOS:A1991EY88700019
J	NAVARATNAM, DS; PRIDDLE, JD; MCDONALD, B; ESIRI, MM; ROBINSON, JR; SMITH, AD				NAVARATNAM, DS; PRIDDLE, JD; MCDONALD, B; ESIRI, MM; ROBINSON, JR; SMITH, AD			ANOMALOUS MOLECULAR-FORM OF ACETYLCHOLINESTERASE IN CEREBROSPINAL-FLUID IN HISTOLOGICALLY DIAGNOSED ALZHEIMERS-DISEASE	LANCET			English	Article							CSF ACETYLCHOLINESTERASE; HUMAN NEOCORTEX; NEURONS; HIPPOCAMPUS	The possibility that the different molecular forms of acetylcholinesterase (AChE) in cerebrospinal fluid (CSF) which can be revealed by isoelectric focusing may reflect changes in AChE in pathologically affected neurons in Alzheimer's disease was tested in a retrospective study. CSF samples obtained at necropsy from 33 patients with clinically diagnosed dementia, 9 with possible dementia, and 19 without a diagnosis of dementia were examined by isoelectric focusing. An additional band indicating an anomalous molecular form of AChE was present in CSF from 19 of 23 patients with a histological diagnosis of Alzheimer's disease and no other central nervous system disorder but in none of the 19 non-demented patients (without a histological diagnosis of Alzheimer's disease). The band was also present in 2 of 8 patients with histologically defined Alzheimer's disease plus other neurological disorders and in 4 of 8 patients with possible dementia who did not meet histopathological criteria for Alzheimer's disease. The absence of the anomalous form of AChE from the CSF of non-demented patients and its presence in the CSF of the majority of patients with Alzheimer's disease has implications for our understanding of the biological basis of the disease and might form the basis of an antemortem diagnostic test.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND; LITTLEMORE HOSP,OXFORD,ENGLAND	University of Oxford; Radcliffe Infirmary			Smith, Anthony D./A-4233-2010	Smith, Anthony D./0000-0002-1095-6722	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPLEYARD ME, 1987, NEUROCHEM INT, V11, P397, DOI 10.1016/0197-0186(87)90029-5; APPLEYARD ME, 1983, LANCET, V2, P452; APPLEYARD ME, 1987, BRAIN, V110, P1309, DOI 10.1093/brain/110.5.1309; ARENDT T, 1984, LANCET, V1, P173; CHUBB IW, 1976, NEUROSCIENCE, V1, P57, DOI 10.1016/0306-4522(76)90048-8; CHUBB IW, 1975, PROC R SOC SER B-BIO, V191, P245, DOI 10.1098/rspb.1975.0126; CROSS RB, 1982, MED LAB SCI, V39, P67; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GEULA C, 1989, BRAIN RES, V498, P185, DOI 10.1016/0006-8993(89)90419-8; GIULIAN GG, 1984, ANAL BIOCHEM, V142, P421, DOI 10.1016/0003-2697(84)90486-X; GREENFIELD SA, 1979, BRAIN RES, V177, P445, DOI 10.1016/0006-8993(79)90463-3; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LAMY C, 1989, NEUROPATH APPL NEURO, V15, P563, DOI 10.1111/j.1365-2990.1989.tb01255.x; MESULAM MM, 1988, ANN NEUROL, V24, P765, DOI 10.1002/ana.410240611; NAKAMURA S, 1985, NEUROSCI LETT, V61, P183, DOI 10.1016/0304-3940(85)90422-7; PERRY EK, 1986, BRIT MED BULL, V42, P63, DOI 10.1093/oxfordjournals.bmb.a072100; PERRY EK, 1981, METABOLIC DISORDERS, P382; SMITH AD, 1984, LANCET, V1, P513	18	60	64	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					447	450		10.1016/0140-6736(91)93391-L	http://dx.doi.org/10.1016/0140-6736(91)93391-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671469				2022-12-24	WOS:A1991EY88700002
J	AHMED, YF; GILMARTIN, GM; HANLY, SM; NEVINS, JR; GREENE, WC				AHMED, YF; GILMARTIN, GM; HANLY, SM; NEVINS, JR; GREENE, WC			THE HTLV-I REX RESPONSE ELEMENT MEDIATES A NOVEL FORM OF MESSENGER-RNA POLYADENYLATION	CELL			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; POLY(A) POLYMERASE; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; MULTIPLE FACTORS; 3' END; CLEAVAGE	HTLV-I structural gene expression is posttranscriptionally regulated by the Rex protein and the Rex response element (RexRE), a 255 nucleotide RNA stem-loop structure located in the retroviral 3' LTR. Independent of Rex, the RexRE also plays a critical role in the polyadenylation of all HTLV-I transcripts. Folding of the RexRE serves to spatially juxtapose the widely separated AAUAAA hexamer and GU-rich elements that are essential for polyadenylation. In turn, this folding promotes the cooperative and stable binding of two nuclear factors at these elements that commits this poly(A) site to 3' processing. These findings highlight a novel mechanism of 3' end formation in the HTLV family of retroviruses and underscore the general requirement for protein-protein interactions in the polyadenylation reaction.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University	AHMED, YF (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710, USA.							AHMED YF, 1990, GENE DEV, V4, P1014, DOI 10.1101/gad.4.6.1014; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BURNY A, 1980, BOVINE LEUKEMIA VIRU, P231; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHEN ISY, 1983, NATURE, V305, P502, DOI 10.1038/305502a0; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; DERSE D, 1988, J VIROL, V62, P1115, DOI 10.1128/JVI.62.4.1115-1119.1988; GALLO RC, 1985, CANCER RES, V45, P4524; GIL A, 1987, CELL, V49, P399, DOI 10.1016/0092-8674(87)90292-3; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KIM JH, 1991, J VIROL, V65, P405, DOI 10.1128/JVI.65.1.405-414.1991; LE SY, 1988, NUCLEIC ACIDS RES, V16, P5153, DOI 10.1093/nar/16.11.5153; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MCDEVITT MA, 1988, GENE DEV, V2, P588, DOI 10.1101/gad.2.5.588; MCDEVITT MA, 1986, EMBO J, V5, P2907, DOI 10.1002/j.1460-2075.1986.tb04586.x; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MOORE CL, 1986, EMBO J, V5, P1929, DOI 10.1002/j.1460-2075.1986.tb04446.x; OHTA M, 1988, J VIROL, V62, P4445, DOI 10.1128/JVI.62.12.4445-4451.1988; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROSENBLATT JD, 1988, SCIENCE, V240, P916, DOI 10.1126/science.2834826; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; SAGATA N, 1983, GENE, V26, P1, DOI 10.1016/0378-1119(83)90030-6; SAGATA N, 1984, P NATL ACAD SCI-BIOL, V81, P4741, DOI 10.1073/pnas.81.15.4741; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SHIMOTOHNO K, 1984, P NATL ACAD SCI-BIOL, V81, P1079, DOI 10.1073/pnas.81.4.1079; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WONGSTAAL F, 1985, CANCER RES, V45, P4539; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	51	97	97	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					727	737		10.1016/0092-8674(91)90502-P	http://dx.doi.org/10.1016/0092-8674(91)90502-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1671761				2022-12-24	WOS:A1991EZ47800008
J	PHILLIPS, HS; HAINS, JM; LARAMEE, GR; ROSENTHAL, A; WINSLOW, JW				PHILLIPS, HS; HAINS, JM; LARAMEE, GR; ROSENTHAL, A; WINSLOW, JW			WIDESPREAD EXPRESSION OF BDNF BUT NOT NT3 BY TARGET AREAS OF BASAL FOREBRAIN CHOLINERGIC NEURONS	SCIENCE			English	Article											PHILLIPS, HS (corresponding author), GENENTECH INC,DEPT DEV BIOL,S SAN FRANCISCO,CA 94080, USA.							AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; CAIN G, 1986, RAT BRAIN STEREOTAXI; DAVIES AM, 1988, TRENDS NEUROSCI, V11, P243, DOI 10.1016/0166-2236(88)90099-9; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; HARDY JA, 1986, NEUROBIOL AGING, V7, P489, DOI 10.1016/0197-4580(86)90086-2; HEFTI F, 1989, NEUROBIOL AGING, V10, P515, DOI 10.1016/0197-4580(89)90118-8; HEFTI F, 1989, SCIENCE, V243, P11; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; KNUSEL B, UNPUB; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARX J, 1990, SCIENCE, V247, P408, DOI 10.1126/science.2405484; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PEARSON RCA, 1985, P NATL ACAD SCI USA, V82, P4531, DOI 10.1073/pnas.82.13.4531; REYES PF, 1987, ARCH NEUROL-CHICAGO, V44, P644, DOI 10.1001/archneur.1987.00520180062017; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SHELTON DL, 1986, P NATL ACAD SCI USA, V83, P2714, DOI 10.1073/pnas.83.8.2714; TALAMO BR, 1989, NATURE, V337, P736, DOI 10.1038/337736a0; WHITEHOUSE PJ, 1981, ANN NEUROL, V10, P122, DOI 10.1002/ana.410100203	22	493	512	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 12	1990	250	4978					290	294		10.1126/science.1688328	http://dx.doi.org/10.1126/science.1688328			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC457	1688328				2022-12-24	WOS:A1990EC45700039
J	BORN, W; HALL, L; DALLAS, A; BOYMEL, J; SHINNICK, T; YOUNG, D; BRENNAN, P; OBRIEN, R				BORN, W; HALL, L; DALLAS, A; BOYMEL, J; SHINNICK, T; YOUNG, D; BRENNAN, P; OBRIEN, R			RECOGNITION OF A PEPTIDE ANTIGEN BY HEAT-SHOCK REACTIVE GAMMA-DELTA-LYMPHOCYTES-T	SCIENCE			English	Article									NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523; CTR DIS CONTROL,DIV BACTERIAL DIS,ATLANTA,GA 30333; HAMMERSMITH HOSP,MRC,TB & RELATED INFECT UNIT,LONDON W12 0HS,ENGLAND	National Jewish Health; Colorado State University; Centers for Disease Control & Prevention - USA; Imperial College London	BORN, W (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206, USA.							ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1989, CELL, V56, P27; BORN W, 1987, NATURE, V330, P572, DOI 10.1038/330572a0; BORN W, UNPUB; BORN W, 1989, IMMUNOL TODAY, V10, P40; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; CHIEN YH, 1987, NATURE, V327, P677, DOI 10.1038/327677a0; FISCH P, 1990, J EXP MED, V171, P1567, DOI 10.1084/jem.171.5.1567; Hall L.S., 2021, UNPUB; HAPP MP, 1989, NATURE, V342, P696, DOI 10.1038/342696a0; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HOLOSHITZ J, 1989, NATURE, V339, P226, DOI 10.1038/339226a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; JANIS EM, 1989, SCIENCE, V244, P713, DOI 10.1126/science.2524098; KYES S, COMMUNICATION; Lamb J R, 1989, Int Immunol, V1, P191, DOI 10.1093/intimm/1.2.191; LAMB JR, 1987, EMBO J, V6, P1245, DOI 10.1002/j.1460-2075.1987.tb02360.x; MATIS LA, 1987, NATURE, V330, P262, DOI 10.1038/330262a0; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGAI S, 1980, AM REV RESPIR DIS, V121, P551, DOI 10.1164/arrd.1980.121.3.551; OBRIEN R, UNPUB; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; OTTENHOFF THM, 1988, J EXP MED, V168, P1947, DOI 10.1084/jem.168.5.1947; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; RAMANUJAM R, 1990, P NATL ACAD SCI USA, V87, P1767; SAITO H, 1984, NATURE, V309, P757, DOI 10.1038/309757a0; SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987; SHINNICK TM, 1987, INFECT IMMUN, V55, P1932, DOI 10.1128/IAI.55.8.1932-1935.1987; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; WATSON JD, 1989, IMMUNOL TODAY, V10, P218, DOI 10.1016/0167-5699(89)90253-3	36	308	309	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 6	1990	249	4964					67	69		10.1126/science.1695022	http://dx.doi.org/10.1126/science.1695022			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DM384	1695022				2022-12-24	WOS:A1990DM38400041
J	PULLEN, AM; WADE, T; MARRACK, P; KAPPLER, JW				PULLEN, AM; WADE, T; MARRACK, P; KAPPLER, JW			IDENTIFICATION OF THE REGION OF T-CELL RECEPTOR BETA-CHAIN THAT INTERACTS WITH THE SELF-SUPERANTIGEN MLS-1A	CELL			English	Article									UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	PULLEN, AM (corresponding author), NATL JEWISH CTR,HOWARD HUGHES MED INST,DEPT MED,DIV BASIC IMMUNOL,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017134, R01AI018785, R56AI017134, R37AI018785, R01AI022259, R37AI017134] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22259, AI-18785, AI-17134] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; BECKER DM, 1985, NATURE, V317, P430, DOI 10.1038/317430a0; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BORN W, 1988, IMMUNOL RES, V7, P279, DOI 10.1007/BF02935533; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BURGERT HG, 1989, J EXP MED, V170, P1887, DOI 10.1084/jem.170.6.1887; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CHOU HS, 1987, P NATL ACAD SCI USA, V84, P1992, DOI 10.1073/pnas.84.7.1992; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FESTENSTEIN H, 1974, TRANSPLANTATION, V18, P555, DOI 10.1097/00007890-197412000-00016; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KABAT EA, 1987, INTRO SEQUENCES PROT; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LANGFORD MP, 1978, INFECT IMMUN, V22, P62, DOI 10.1128/IAI.22.1.62-68.1978; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NICOLAS JF, 1987, EUR J IMMUNOL, V17, P1561, DOI 10.1002/eji.1830171106; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; PEAVY DL, 1970, J IMMUNOL, V105, P1453; PECK AB, 1977, NATURE, V266, P840, DOI 10.1038/266840a0; PULLEN AM, 1990, J EXP MED, V171, P49, DOI 10.1084/jem.171.1.49; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; ROJO JM, 1988, J IMMUNOL, V140, P1081; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHIFFER M, 1986, P NATL ACAD SCI USA, V83, P4461, DOI 10.1073/pnas.83.12.4461; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TAYLOR BA, 1987, ORIGIN INBRED MICE, P423; TOMONARI K, 1988, IMMUNOGENETICS, V28, P445, DOI 10.1007/BF00355377; WEICKERT MJ, 1989, EDITORIAL COMMENTS, P5; WHITE J, 1983, J IMMUNOL, V130, P1033; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINOTO A, 1986, NATURE, V324, P679, DOI 10.1038/324679a0; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YAGUE J, 1985, CELL, V42, P81, DOI 10.1016/S0092-8674(85)80103-3	56	272	280	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 29	1990	61	7					1365	1374		10.1016/0092-8674(90)90700-O	http://dx.doi.org/10.1016/0092-8674(90)90700-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DM156	1694725				2022-12-24	WOS:A1990DM15600024
J	HIRSCH, RC; LAVINE, JE; CHANG, LJ; VARMUS, HE; GANEM, D				HIRSCH, RC; LAVINE, JE; CHANG, LJ; VARMUS, HE; GANEM, D			POLYMERASE GENE-PRODUCTS OF HEPATITIS-B VIRUSES ARE REQUIRED FOR GENOMIC RNA PACKAGING AS WELL AS FOR REVERSE TRANSCRIPTION	NATURE			English	Article									UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ADAM MA, 1988, J VIROL, V62, P3802, DOI 10.1128/JVI.62.10.3802-3806.1988; BARTENSCHLAGER R, 1988, EMBO J, V7, P4185, DOI 10.1002/j.1460-2075.1988.tb03315.x; BERG DE, 1989, MOBILE DNA, P185; BUSCHER M, 1985, CELL, V40, P717, DOI 10.1016/0092-8674(85)90220-X; CHANG LJ, 1989, NATURE, V337, P364, DOI 10.1038/337364a0; DICKSON C, 1982, RNA TUMOR VIRUSES, pCH6; EISENMAN RN, 1978, BIOCHIM BIOPHYS ACTA, V473, P187, DOI 10.1016/0304-419X(78)90014-8; ENDERS GH, 1987, J VIROL, V61, P35, DOI 10.1128/JVI.61.1.35-41.1987; FUETTERER J, 1987, TRENDS BIOCHEM SCI, V12, P92, DOI 10.1016/0968-0004(87)90044-2; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; HIRSCH R, 1988, VIROLOGY, V167, P136, DOI 10.1016/0042-6822(88)90062-1; LAVINE J, 1989, J VIROL, V63, P4257, DOI 10.1128/JVI.63.10.4257-4263.1989; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MERIC C, 1986, J VIROL, V60, P450; MOLNARKIMBER KL, 1983, J VIROL, V45, P165, DOI 10.1128/JVI.45.1.165-172.1983; MORISATO D, 1983, CELL, V32, P799, DOI 10.1016/0092-8674(83)90066-1; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; SCHLICHT HJ, 1989, CELL, V56, P85, DOI 10.1016/0092-8674(89)90986-0; SHIELDS A, 1978, CELL, V14, P601, DOI 10.1016/0092-8674(78)90245-3; SPRENGEL R, 1985, J MED VIROL, V15, P323, DOI 10.1002/jmv.1890150402	20	275	285	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 5	1990	344	6266					552	555		10.1038/344552a0	http://dx.doi.org/10.1038/344552a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX595	1690862				2022-12-24	WOS:A1990CX59500070
J	GRANFORS, K; JALKANEN, S; LINDBERG, AA; MAKIIKOLA, O; VONESSEN, R; LAHESMAARANTALA, R; ISOMAKI, H; SAARIO, R; ARNOLD, WJ; TOIVANEN, A				GRANFORS, K; JALKANEN, S; LINDBERG, AA; MAKIIKOLA, O; VONESSEN, R; LAHESMAARANTALA, R; ISOMAKI, H; SAARIO, R; ARNOLD, WJ; TOIVANEN, A			SALMONELLA LIPOPOLYSACCHARIDE IN SYNOVIAL-CELLS FROM PATIENTS WITH REACTIVE ARTHRITIS	LANCET			English	Article									KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN BACTERIOL,HUDDINGE,SWEDEN; RHEUMATISM FDN HOSP,HEINOLA,FINLAND; UNIV TURKU,DEPT MED,SF-20500 TURKU 50,FINLAND; LUTHERAN GEN HOSP,DIV MED,PK RIDGE,IL 60068	Karolinska Institutet; Rheumatism Foundation Hospital; University of Turku	GRANFORS, K (corresponding author), TURKU UNIV,DEPT MED MICROBIOL,SF-20520 TURKU,FINLAND.							BARTHOLOMEW LE, 1979, ARTHRITIS RHEUM, V22, P969, DOI 10.1002/art.1780220904; CARLIN NIA, 1987, MICROB PATHOGENESIS, V2, P171, DOI 10.1016/0882-4010(87)90019-2; FORD DK, 1985, ANN RHEUM DIS, V44, P701, DOI 10.1136/ard.44.10.701; GASTON JSH, 1989, CLIN EXP IMMUNOL, V76, P348; GRANFORS K, 1989, NEW ENGL J MED, V320, P216, DOI 10.1056/NEJM198901263200404; GRANFORS K, 1989, J INFECT DIS, V159, P1142, DOI 10.1093/infdis/159.6.1142; GRANFORS K, 1988, REACTIVE ARTHRITIS, P15; HOLLINGSWORTH JW, 1965, YALE J BIOL MED, V38, P241; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ISHIKAWA H, 1986, J BONE JOINT SURG AM, V68A, P777, DOI 10.2106/00004623-198668050-00024; ISOMAKI O, 1989, LANCET, V1, P1411; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN S, 1989, SPRINGER SEMIN IMMUN, V11, P187; KEAT A, 1987, LANCET, V1, P72; LAHESMAARANTALA R, 1987, ANN RHEUM DIS, V46, P121, DOI 10.1136/ard.46.2.121; LAHESMAARANTALA R, 1987, ANN RHEUM DIS, V46, P510, DOI 10.1136/ard.46.7.510; NURMINEN M, 1983, SCIENCE, V220, P1279, DOI 10.1126/science.6344216; SCHUMACHER HR, 1988, ARTHRITIS RHEUM, V31, P937; STIMPSON SA, 1987, J EXP MED, V165, P1688, DOI 10.1084/jem.165.6.1688; TAYLORROBINSON D, 1988, ANN RHEUM DIS, V47, P295, DOI 10.1136/ard.47.4.295; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; VANDENBROEK MF, 1988, ARTHRITIS RHEUM-US, V31, P1077, DOI 10.1002/art.1780310825	22	302	302	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 24	1990	335	8691					685	688		10.1016/0140-6736(90)90804-E	http://dx.doi.org/10.1016/0140-6736(90)90804-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV305	1690327				2022-12-24	WOS:A1990CV30500004
J	BREEUWER, M; GOLDFARB, DS				BREEUWER, M; GOLDFARB, DS			FACILITATED NUCLEAR TRANSPORT OF HISTONE H1 AND OTHER SMALL NUCLEOPHILIC PROTEINS	CELL			English	Article											BREEUWER, M (corresponding author), UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627, USA.							ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; BEAUERLE PA, 1988, SCIENCE, V242, P540; BONNER WM, 1975, J CELL BIOL, V64, P431, DOI 10.1083/jcb.64.2.431; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; COTTEN M, 1987, EMBO J, V6, P3945, DOI 10.1002/j.1460-2075.1987.tb02736.x; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1984, EMBO J, V3, P1933, DOI 10.1002/j.1460-2075.1984.tb02072.x; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; EBERHARDT NL, 1979, P NATL ACAD SCI USA, V76, P5005, DOI 10.1073/pnas.76.10.5005; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GOLDFARB DS, 1988, CELL BIOL INT REP, V12, P809, DOI 10.1016/0309-1651(88)90090-2; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; IMAMOTOSONOBE N, 1988, P NATL ACAD SCI USA, V85, P3426, DOI 10.1073/pnas.85.10.3426; Johns E W, 1977, Methods Cell Biol, V16, P183; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KUEHL L, 1985, J BIOL CHEM, V260, P361; LANDFORD RE, 1984, CELL, V37, P801; LANFORD RE, 1988, MOL CELL BIOL, V8, P2722, DOI 10.1128/MCB.8.7.2722; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; NESTOR JJ, 1988, J MED CHEM, V31, P65, DOI 10.1021/jm00396a011; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROARK DE, 1976, BIOCHEMISTRY-US, V15, P3019, DOI 10.1021/bi00659a013; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SUGAWA H, 1985, EXP CELL RES, V159, P419, DOI 10.1016/S0014-4827(85)80015-X; TSUNEOKA M, 1986, J BIOL CHEM, V261, P1829; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63; van Holde KE., 1989, SPRINGER SERIES MOL; WHITE EM, 1989, J CELL BIOL, V109, P1983, DOI 10.1083/jcb.109.5.1983; WU LH, 1986, J CELL BIOL, V103, P465, DOI 10.1083/jcb.103.2.465; YAMASAKI L, 1989, J MOL CELL BIOL, V9, P3028; YONEDA Y, 1988, SCIENCE, V242, P275, DOI 10.1126/science.3051382; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	47	258	263	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 23	1990	60	6					999	1008		10.1016/0092-8674(90)90348-I	http://dx.doi.org/10.1016/0092-8674(90)90348-I			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CW002	1690602	hybrid			2022-12-24	WOS:A1990CW00200014
J	BOLDOGH, I; ABUBAKAR, S; ALBRECHT, T				BOLDOGH, I; ABUBAKAR, S; ALBRECHT, T			ACTIVATION OF PROTO-ONCOGENES - AN IMMEDIATE EARLY EVENT IN HUMAN CYTOMEGALOVIRUS-INFECTION	SCIENCE			English	Article									UNIV TEXAS,MED BRANCH,DEPT MICROBIOL,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston			abubakar, sazaly/B-3957-2010	abubakar, sazaly/0000-0002-9267-1420				ALBRECHT T, 1976, J GEN VIROL, V30, P167, DOI 10.1099/0022-1317-30-2-167; ALBRECHT T, 1973, VIROLOGY, V55, P53, DOI 10.1016/S0042-6822(73)81007-4; ALBRECHT T, 1989, SUBCELLULAR BIOCH, V15, P153; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BOLDOGH I, 1978, ARCH VIROL, V58, P289, DOI 10.1007/BF01317821; BOLDOGH I, UNPUB; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEMARCHI JM, 1977, VIROLOGY, V82, P93, DOI 10.1016/0042-6822(77)90035-6; EPSTEIN RL, 1984, VIROLOGY, V133, P46, DOI 10.1016/0042-6822(84)90424-0; GEDER L, 1976, SCIENCE, V192, P1134, DOI 10.1126/science.179143; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HUANG ES, 1973, J VIROL, V12, P1473, DOI 10.1128/JVI.12.6.1473-1481.1973; HUNNINGHAKE GW, 1989, J VIROL, V63, P3026, DOI 10.1128/JVI.63.7.3026-3033.1989; KARN J, 1989, ONCOGENE, V4, P773; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; MACNAB JCM, 1987, J GEN VIROL, V68, P2525, DOI 10.1099/0022-1317-68-10-2525; Maniatis T., 1982, MOL CLONING; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MORIKE M, 1988, ONCOGENE, V3, P151; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OWEN TA, 1987, J BIOL CHEM, V262, P15111; PETRIE BL, 1988, PROG MED VIROL, V35, P21; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; REDFIELD DC, 1981, INFECT IMMUN, V32, P1216, DOI 10.1128/IAI.32.3.1216-1226.1981; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; ROESTER WJ, 1988, J BIOL CHEM, V163, P9063; ROSENBERG BH, 1981, J VIROL METHODS, V3, P167, DOI 10.1016/0166-0934(81)90051-3; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHEINFEST CW, 1988, MOL CELL BIOL, V8, P3080; Stagno S, 1984, Birth Defects Orig Artic Ser, V20, P65; STINSKI MF, 1976, J VIROL, V19, P594, DOI 10.1128/JVI.19.2.594-609.1976; STJEOR SC, 1974, J VIROL, V13, P353, DOI 10.1128/JVI.13.2.353-362.1974; TAYLOR HP, 1989, J VIROL, V63, P3991, DOI 10.1128/JVI.63.9.3991-3998.1989; VALYINAGY T, 1988, ARCH VIROL, V101, P199, DOI 10.1007/BF01311001; VRATI S, 1987, MOL BIOL REP, V1, P1; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WUNNER WH, 1984, J VIROL, V50, P691, DOI 10.1128/JVI.50.3.691-697.1984	50	153	155	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1990	247	4942					561	564		10.1126/science.1689075	http://dx.doi.org/10.1126/science.1689075			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CM419	1689075				2022-12-24	WOS:A1990CM41900029
J	STERN, CD; CANNING, DR				STERN, CD; CANNING, DR			ORIGIN OF CELLS GIVING RISE TO MESODERM AND ENDODERM IN CHICK-EMBRYO	NATURE			English	Article											STERN, CD (corresponding author), DEPT HUMAN ANAT, S PARKS RD, OXFORD OX1 3QX, ENGLAND.		Stern, Claudio/AAZ-7381-2021; Stern, Claudio D/C-6265-2008	Stern, Claudio/0000-0002-9907-889X; Stern, Claudio D/0000-0002-9907-889X				ABO T, 1981, J IMMUNOL, V127, P1024; AZAR Y, 1979, J EMBRYOL EXP MORPH, V52, P79; AZAR Y, 1981, J EMBRYOL EXP MORPH, V61, P133; CANNING DR, 1988, DEVELOPMENT, V104, P643; EYALGILADI H, 1976, DEV BIOL, V49, P321, DOI 10.1016/0012-1606(76)90178-0; EYALGILADI H, 1984, CELL DIFFER DEV, V14, P245, DOI 10.1016/0045-6039(84)90013-7; GOODMAN SL, 1981, J MICROSC-OXFORD, V123, P201, DOI 10.1111/j.1365-2818.1981.tb01295.x; GURDON JB, 1987, DEVELOPMENT, V99, P285; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUTSON JM, 1984, STAIN TECHNOL, V59, P105, DOI 10.3109/10520298409113839; MITRANI E, 1984, DIFFERENTIATION, V26, P107, DOI 10.1111/j.1432-0436.1984.tb01382.x; MITRANI E, 1981, NATURE, V289, P800, DOI 10.1038/289800a0; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; NIEUWKOOP PD, 1985, EPIGENETIC NATURE EA; RICKMANN M, 1985, J EMBRYOL EXP MORPH, V90, P437; SMITH JC, 1989, DEVELOPMENT, V105, P665; STERN CD, 1987, DEVELOPMENT, V99, P261; TUCKER GC, 1984, CELL DIFFER DEV, V14, P223, DOI 10.1016/0045-6039(84)90049-6; Waddington CH, 1933, ROUX ARCH DEV BIOL, V128, P502, DOI 10.1007/BF00649862	19	126	126	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	1990	343	6255					273	275		10.1038/343273a0	http://dx.doi.org/10.1038/343273a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ682	1689008				2022-12-24	WOS:A1990CJ68200075
J	SZASZ, T				SZASZ, T			DIAGNOSES ARE NOT DISEASES	LANCET			English	Editorial Material											SZASZ, T (corresponding author), SUNY HLTH SCI CTR,SYRACUSE,NY 13210, USA.							FREUDENHEIM M, 1991, WALL STREET J   0924; FREUDENHEIM M, 1991, NY TIMES        0629, pA1; FREUDENHEIM M, 1991, NY TIMES        0923, pD4; GOLDMAN MJ, 1991, AM J PSYCHIAT, V148, P986; KAREL R, 1991, PSYCHIATTRIC NEWS, V26, P16; Polanyi M., 1969, KNOWING BEING; ROGERS W, 1982, W ROGERS TREASURY RE, P256; Szasz T. S., 1974, MYTH MENTAL ILLNESS; Szasz T.S., 1987, INSANITY IDEA ITS CO; 1980, DIAGNOSTIC STATISTIC; 1987, DIAGNOSTIC STATISTIC; 1991, LANCET, V338, P785	12	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1574	1576		10.1016/0140-6736(91)92387-H	http://dx.doi.org/10.1016/0140-6736(91)92387-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683983				2022-12-24	WOS:A1991GW03600016
J	FISCH, A; SALVANET, A; PRAZUCK, T; FORESTIER, F; GERBAUD, L; COSCAS, G; LAFAIX, C				FISCH, A; SALVANET, A; PRAZUCK, T; FORESTIER, F; GERBAUD, L; COSCAS, G; LAFAIX, C			EPIDEMIOLOGY OF INFECTIVE ENDOPHTHALMITIS IN FRANCE	LANCET			English	Article							POST-OPERATIVE ENDOPHTHALMITIS; HUMAN AQUEOUS-HUMOR; LENS	Data from retrospective studies of endophthalmitis vary widely with respect to incidence and to the pathogens implicated. To see whether we could provide more accurate data, we have done a prospective multicentre national survey of endophthalmitis over one year in France. Records of 36 241 operations and 1148 cases of ocular trauma from 64 centres specialising in eye surgery were analysed. There were 167 cases of endophthalmitis; incidence of postoperative endophthalmitis was 0.31 per 100 operations, and the risk after penetrating ocular trauma was 2.8%. In contrast with most previous studies, Staphylococcus epidermidis was the most frequently isolated organism, with gram-negative organisms accounting for only a small proportion of cases. Patients infected with streptococci had the least favourable outcome. The survey confirms data from retrospective studies showing that the incidence of postoperative or post-injury endophthalmitis is low. The low frequency means that large numbers of patients would be required for a trial of antibiotic efficacy, but such a trial is worthwhile because there are now antibiotics with good ocular bioavailability that are effective against most of the bacteria that cause endophthalmitis.	UNIV HOSP VILLENEUVE ST GEORGES,DEPT OPHTHALMOL,F-94190 VILLENEUVE ST GEO,FRANCE		FISCH, A (corresponding author), UNIV HOSP VILLENEUVE ST GEORGES,ETUD EPIDEMIOL & PROPHYLACT GRP,40 ALLEE SOURCE,F-94190 VILLENEUVE ST GEO,FRANCE.		GERBAUD, Laurent/ABY-4952-2022					ALLEN HF, 1974, ARCH OPHTHALMOL-CHIC, V91, P3, DOI 10.1001/archopht.1974.03900060007002; ALLEN HF, 1978, OPHTHALMOLOGY, V85, P386; ALLEN HF, 1978, OPHTHALMOLOGY, V85, P317; BOHIGIAN GM, 1986, AM J OPHTHALMOL, V101, P323; BRINTON GS, 1984, ARCH OPHTHALMOL-CHIC, V102, P547; CAMERON ME, 1978, OPHTHALMIC SURG LAS, V9, P52; DRIEBE WT, 1986, OPHTHALMOLOGY, V93, P442; FAHMY JA, 1975, ACTA OPHTHALMOL, V53, P522; FISCH A, 1987, J ANTIMICROB CHEMOTH, V20, P453, DOI 10.1093/jac/20.3.453; Forster RK, 1981, CLIN OPHTHALMOL, P1; GLEICHER DA, 1973, AM J OPHTHALMOL, V75, P769, DOI 10.1016/0002-9394(73)90879-9; MELTZER DW, 1981, ARCH OPHTHALMOL-CHIC, V98, P100; OLSON JC, 1983, OPHTHALMOLOGY, V90, P692; PULIAFITO CA, 1982, OPHTHALMOLOGY, V89, P921; ROWSEY JJ, 1982, OPHTHALMOLOGY, V89, P1055; SALVANET A, 1986, J ANTIMICROB CHEMOTH, V18, P199, DOI 10.1093/jac/18.2.199; SHRADER SK, 1990, J INFECT DIS, V162, P115, DOI 10.1093/infdis/162.1.115; WEBER DJ, 1986, REV INFECT DIS, V8, P12	18	109	115	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1991	338	8779					1373	1376						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682746				2022-12-24	WOS:A1991GR77300013
J	ZOMERDIJK, JCBM; KIEFT, R; BORST, P				ZOMERDIJK, JCBM; KIEFT, R; BORST, P			EFFICIENT PRODUCTION OF FUNCTIONAL MESSENGER-RNA MEDIATED BY RNA POLYMERASE-I IN TRYPANOSOMA-BRUCEI	NATURE			English	Article							TRANSCRIPTION UNIT; GENE; EXPRESSION; PROMOTER; TRANS; IDENTIFICATION; PROVIDES; TUBULIN; CELLS; RDNA	THE unicellular eukaryote Trypanosoma brucei evades the immune defence of its mammalian host by antigenic variation 1. The genes for variant-specific surface glycoproteins (VSGs) are expressed within large multicistronic transcription units 2. Mature messenger RNAs are produced by trans-splicing and polyadenylation 3-5. A remarkable feature of the transcription of VSG genes is its insensitivity to the RNA polymerase II inhibitor alpha-amanitin 6. This has led to the speculation that RNA polymerase I, normally only involved in the transcription of ribosomal RNA genes, also mediates expression of these surface antigen genes. In higher eukaryotes, however, transcripts produced by RNA polymerase I were found to be poor substrates for processing into mature mRNAs 7-9. In contrast, we show here that the RNA polymerase I of T. brucei can mediate the efficient production of functional mRNA for neomycin phosphotransferase. The exceptional ability may be related to the unusual way in which pre-mRNAs are capped in trypanosomes. In most eukaryotes, mRNAs are modified at their 5' end by a capping activity associated with RNA polymerase II10; in trypanosomes, mRNAs acquire their 5'-cap from capped mini-exon donor RNA by trans-splicing 3-5, a process that could be independent of the RNA polymerase producing the pre-mRNA.			ZOMERDIJK, JCBM (corresponding author), NETHERLANDS CANC INST,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Zomerdijk, Joost/A-5142-2008	Zomerdijk, Joost/0000-0003-1865-729X				CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; GRIMALDI G, 1986, NUCLEIC ACIDS RES, V14, P6417, DOI 10.1093/nar/14.16.6417; GRUMMT I, 1985, P NATL ACAD SCI USA, V82, P722, DOI 10.1073/pnas.82.3.722; IMBODEN M, 1986, J MOL BIOL, V166, P393; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; JOVE R, 1982, P NATL ACAD SCI-BIOL, V79, P5842, DOI 10.1073/pnas.79.19.5842; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LAIRD PW, 1987, EMBO J, V6, P1055, DOI 10.1002/j.1460-2075.1987.tb04858.x; LOPATA MA, 1986, P NATL ACAD SCI USA, V83, P6677, DOI 10.1073/pnas.83.18.6677; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALDITTGEORGIEFF M, 1980, CELL, V19, P69, DOI 10.1016/0092-8674(80)90389-X; SATHER S, 1985, P NATL ACAD SCI USA, V82, P5695, DOI 10.1073/pnas.82.17.5695; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; XIONG Y, 1988, CELL, V55, P235, DOI 10.1016/0092-8674(88)90046-3; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P1359, DOI 10.1093/nar/19.7.1359	24	83	84	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					772	775		10.1038/353772a0	http://dx.doi.org/10.1038/353772a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1658658				2022-12-24	WOS:A1991GL69600074
J	PALMER, MS; DRYDEN, AJ; HUGHES, JT; COLLINGE, J				PALMER, MS; DRYDEN, AJ; HUGHES, JT; COLLINGE, J			HOMOZYGOUS PRION PROTEIN GENOTYPE PREDISPOSES TO SPORADIC CREUTZFELDT-JAKOB DISEASE	NATURE			English	Article							GERSTMANN-STRAUSSLER SYNDROME; GENE; DEMENTIA; MICE	THE human prion diseases, Creutzfeldt-Jakob disease (CJD) and Gerstmann-Straussler syndrome (GSS), are neurodegenerative diseases that are unique in being both infectious and genetic. Transmission of both diseases and the animal spongiform encephalopathies (for example, scrapie and bovine spongiform encephalopathy) to experimental animals by intracerebral inoculation with brain homogenates is well documented 1. Despite their experimental transmissibility, missense and insertional mutations in the prion protein gene are associated with both GSS and familial CJD, demonstrating that the human familial cases are autosomal dominant diseases 2-6. More that 80% of CJD cases occur sporadically, however, and are not known to be associated with mutations. Here we report that 21 of 22 sporadic CJD cases and a further 19 of 23 suspected sporadic CJD cases are homozygous at the polymorphic amino-acid residue 129; 51% of the normal population are heterozygous at this site. We argue that homozygosity predisposes towards sporadic CJD and that this directly supports the hypothesis that interaction between prion protein molecules underlies the disease process.	ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,PRION DIS GRP,NORFOLK PL,LONDON W2 1PG,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND	Imperial College London; Radcliffe Infirmary					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; GIBBS CJ, 1973, SCIENCE, V182, P67, DOI 10.1126/science.182.4107.67; GOLDFARB L G, 1989, American Journal of Human Genetics, V45, pA189; GOLDFARB LG, 1991, LANCET, V337, P15; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KITAMOTO T, 1989, J GEN VIROL, V70, P3371, DOI 10.1099/0022-1317-70-12-3371; MASTERS C L, 1987, P511; OWEN F, 1989, LANCET, V1, P51; PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WELLER RO, 1989, PSYCHOL MED, V19, P1, DOI 10.1017/S0033291700010965; WU Y, 1987, NUCLEIC ACIDS RES, V15, P3191, DOI 10.1093/nar/15.7.3191	21	736	757	0	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					340	342		10.1038/352340a0	http://dx.doi.org/10.1038/352340a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1677164				2022-12-24	WOS:A1991FY28900072
J	TREGASKIS, B; MAYBERRY, JF				TREGASKIS, B; MAYBERRY, JF			ELDERLY PEOPLE AT HOME WHO CANNOT COPE	LANCET			English	Editorial Material											TREGASKIS, B (corresponding author), LEICESTER GEN HOSP,LEICESTER LE5 4PW,ENGLAND.		Mayberry, John/AAP-2392-2020					FORSTER DP, 1980, BRIT MED J, V280, P739, DOI 10.1136/bmj.280.6215.739; GRAY JAM, 1990, J PUBLIC HEALTH MED, V12, P28, DOI 10.1093/oxfordjournals.pubmed.a042502; GRAY JAM, 1980, PUBLIC HEALTH, V94, P296, DOI 10.1016/S0033-3506(80)80078-3; Hoggett B., 1984, MENTAL HLTH LAW; MAYBERRY JF, 1991, THESIS U WALES; TOWLER JN, 1988, PUBLIC HEALTH, V102, P485, DOI 10.1016/S0033-3506(88)80087-8	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					47	47		10.1016/0140-6736(91)90026-L	http://dx.doi.org/10.1016/0140-6736(91)90026-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676095				2022-12-24	WOS:A1991FV29600019
J	LOCK, M				LOCK, M			CONTESTED MEANINGS OF THE MENOPAUSE	LANCET			English	Editorial Material							REPLACEMENT THERAPY; WOMEN				LOCK, M (corresponding author), MCGILL UNIV,DEPT HUMANITIES & SOCIAL STUDIES MED,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA.							ETTINGER B, 1987, AM J OBSTET GYNECOL, V156, P1298, DOI 10.1016/0002-9378(87)90168-2; Fedor-Freybergh P, 1977, Acta Obstet Gynecol Scand Suppl, V64, P1; GOSDEN RG, 1985, BIOL MENOPAUSE, P1; GREENBLATT RB, 1980, MENOPAUSE COMPREHENS, P151; KASE N, 1974, JAMA-J AM MED ASSOC, V227, P318, DOI 10.1001/jama.227.3.318; KAUFERT PA, 1984, SOC SCI MED, V18, P279, DOI 10.1016/0277-9536(84)90091-1; KAUFERT PA, 1986, CULT MED PSYCHIAT, V10, P7, DOI 10.1007/BF00053260; LOCK M, 1988, MATURITAS, V10, P317, DOI 10.1016/0378-5122(88)90067-9; LOCK M, 1988, BIOMEDICAL KNOWLEDGE; MCKINLAY SM, 1986, CLIMACTERIC PERSPECT, P59; NOTELOVITZ M, 1989, AM J OBSTET GYNECOL, V161, P8; THORNEYCROFT IH, 1989, AM J OBSTET GYNECOL, V160, P1306, DOI 10.1016/S0002-9378(89)80018-3; WEISS KM, 1981, OTHER WAYS GROWING O, P25; WRIGHT Peter, 1982, PROBLEM MED KNOWLEDG	14	100	106	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1270	1272		10.1016/0140-6736(91)92931-Q	http://dx.doi.org/10.1016/0140-6736(91)92931-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674073				2022-12-24	WOS:A1991FN04700014
J	HEDLEY, ML; MANIATIS, T				HEDLEY, ML; MANIATIS, T			SEX-SPECIFIC SPLICING AND POLYADENYLATION OF DSX PRE-MESSENGER-RNA REQUIRES A SEQUENCE THAT BINDS SPECIFICALLY TO TRA-2 PROTEIN INVITRO	CELL			English	Article							DROSOPHILA DOUBLESEX GENE; MELANOGASTER; SITE; DIFFERENTIATION; IDENTIFICATION; TRANSFORMER; EXPRESSION; INTRON; RECOGNITION; EFFICIENCY	Somatic sex determination in Drosophila involves a hierarchy of regulated alternative pre-mRNA processing. Female-specific splicing and/or polyadenylation of doublesex (dsx) pre-mRNA, the final gene in this pathway, requires transformer (tra) and transformer-2 (tra-2) proteins. The mechanism by which these proteins regulate RNA processing has not been characterized. In this paper we show that tra-2 produced in Escherichia coli binds specifically to a site within the female-specific exon of dsx pre-mRNA. This site, which contains six copies of a 13 nucleotide repeat, is required not only for female-specific splicing, but also for female-specific polyadenylation. These observations suggest that tra-2 is a positive regulator of dsx pre-mRNA processing.			HEDLEY, ML (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GM 42231, GM 13344] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1990, EMBO J, V9, P3619, DOI 10.1002/j.1460-2075.1990.tb07573.x; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; MCKEOWN M, 1987, CELL, V48, P489, DOI 10.1016/0092-8674(87)90199-1; McKeown M, 1990, Genet Eng (N Y), V12, P139; MCLAUCHLAN J, 1989, CELL, V59, P1093, DOI 10.1016/0092-8674(89)90765-4; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; PANDEY NB, 1990, NUCLEIC ACIDS RES, V18, P3161, DOI 10.1093/nar/18.11.3161; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SLEE R, 1990, Q REV BIOL, V65, P175, DOI 10.1086/416718; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	41	213	217	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					579	586		10.1016/0092-8674(91)90090-L	http://dx.doi.org/10.1016/0092-8674(91)90090-L			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1674449				2022-12-24	WOS:A1991FM03700008
J	CLEMENS, JD; VANLOON, F; SACK, DA; RAO, MR; AHMED, F; CHAKRABORTY, J; KAY, BA; KHAN, MR; YUNUS, M; HARRIS, JR; SVENNERHOLM, AM; HOLMGREN, J				CLEMENS, JD; VANLOON, F; SACK, DA; RAO, MR; AHMED, F; CHAKRABORTY, J; KAY, BA; KHAN, MR; YUNUS, M; HARRIS, JR; SVENNERHOLM, AM; HOLMGREN, J			BIOTYPE AS DETERMINANT OF NATURAL IMMUNIZING EFFECT OF CHOLERA	LANCET			English	Note							VACCINES; BANGLADESH	To test the hypothesis that clinical Vibrio cholerae O1 infections protect against recurrent cholera, treated cholera episodes in a rural Bangladesh population of 188 153 people who were followed between 1985 and 1988 were analysed. Of the 2214 people with initial episodes of cholera, 7 had a second episode. The incidence of cholera was 61% lower in subjects who had had an earlier episode than in those without such an episode. Whereas initial episodes of classical cholera were associated with complete protection against subsequent cholera, initial episodes of El Tor cholera were associated with negligible protection.	INT CTR DIARRHOEL DIS RES,DHAKA,BANGLADESH; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21218; CTR DIS CONTROL,ENTER INFECT BRANCH,ATLANTA,GA 30333; UNIV MARYLAND,CTR VACCINE DEV,BALTIMORE,MD 21201; GOTHENBURG UNIV,DEPT MED MICROBIOL,S-41124 GOTHENBURG,SWEDEN	International Centre for Diarrhoeal Disease Research (ICDDR); Johns Hopkins University; Centers for Disease Control & Prevention - USA; University System of Maryland; University of Maryland Baltimore; University of Gothenburg	CLEMENS, JD (corresponding author), NICHHD,PREVENT RES PROGRAM,EXECUT PLAZA N BLDG,ROOM 640,BETHESDA,MD 20892, USA.			Harris, Jeffrey/0000-0001-8728-7195				CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1988, LANCET, V1, P1375; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; Le vine MM, 1981, ACUTE ENTERIC INFECT, P443; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; ROTHMAN KJ, 1986, MODERN EPIDEMIOL; Ruzicka LT, 1978, DEMOGRAPHIC SURVEILL, V2; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; WOODWARD WE, 1971, J INFECT DIS, V123, P61, DOI 10.1093/infdis/123.1.61	10	52	52	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					883	884		10.1016/0140-6736(91)90207-6	http://dx.doi.org/10.1016/0140-6736(91)90207-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672971				2022-12-24	WOS:A1991FG04800006
J	PHILLIPS, AN; LEE, CA; ELFORD, J; JANOSSY, G; TIMMS, A; BOFILL, M; KERNOFF, PBA				PHILLIPS, AN; LEE, CA; ELFORD, J; JANOSSY, G; TIMMS, A; BOFILL, M; KERNOFF, PBA			SERIAL LYMPHOCYTE-CD4 COUNTS AND DEVELOPMENT OF AIDS	LANCET			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; NATURAL-HISTORY; HOMOSEXUAL MEN; HIV INFECTION; LYMPHADENOPATHY; SUBSETS; FOLLOW; COHORT	Low CD4 lymphocyte counts are associated with increased risk of progression to AIDS in human immunodeficiency virus (HIV) infection. We investigated the extent to which the timing of progression to AIDS can be explained solely in terms of decline of the CD4 lymphocyte count in 111 haemophiliacs followed for up to 11 years since infection with HIV. A median of 10 CD4 lymphocyte counts were made per patient. By applying a simple linear model for the decline in CD4 lymphocyte counts over time, we estimated the date of development of AIDs in 96 patients who had at least 5 determinations. 84% (81 of 96) of patients were correctly classified as to development of AIDS before Jan 1, 1990 (p < 0.0001), with this model. The results suggest that differences in the time at which patients with HIV will progress to AIDS can largely be explained by differences in rates of decline of CD4 lymphocyte counts.	ROYAL FREE HOSP, SCH MED, CTR HAEMOPHILIA, LONDON NW3 2PF, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT IMMUNOL, LONDON NW3 2PF, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	PHILLIPS, AN (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PUBL HLTH & PRIMARY CARE, ROWLAND HILL ST, LONDON NW3 2PF, ENGLAND.		Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807				CAMPANA D, 1987, J IMMUNOL, V138, P648; CROWE S, 1990, 6 INT C AIDS SAN FRA; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FABIO G, 1990, BRIT J HAEMATOL, V75, P531, DOI 10.1111/j.1365-2141.1990.tb07794.x; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GARDENER MJ, 1989, STATISTICS CONFIDENC; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; JANOSSY G, 1985, CLIN EXP IMMUNOL, V59, P257; KAPLAN JE, 1988, JAMA-J AM MED ASSOC, V260, P2694, DOI 10.1001/jama.260.18.2694; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LANGE JMA, 1989, AIDS, V3, pS153, DOI 10.1097/00002030-198901001-00023; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LEE CA, 1990, BRIT J HAEMATOL, V75, P623, DOI 10.1111/j.1365-2141.1990.tb07813.x; LEIBOVITZ E, 1990, NEW ENGL J MED, V323, P531, DOI 10.1056/NEJM199008233230807; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MOSS AR, 1989, AIDS, V3, P55, DOI 10.1097/00002030-198902000-00001; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PEDERSEN C, 1989, BRIT MED J, V299, P154, DOI 10.1136/bmj.299.6692.154; PHILLIPS A, 1989, AIDS, V3, P737, DOI 10.1097/00002030-198911000-00008; PHILLIPS AN, 1990, 6 INT C AIDS SAN FRA; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; VISSCHER B, 1990, 6 INT C AIDS SAN FRA; WAYNE WF, 1988, CYTOMETRY, V3, P23; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017	28	319	322	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 16	1991	337	8738					389	392						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671424				2022-12-24	WOS:A1991EX60500004
J	SAVIC, I; WIDEN, L; STONEELANDER, S				SAVIC, I; WIDEN, L; STONEELANDER, S			FEASIBILITY OF REVERSING BENZODIAZEPINE TOLERANCE WITH FLUMAZENIL	LANCET			English	Article							POSITRON EMISSION TOMOGRAPHY; RECEPTOR OCCUPANCY; RO 15-1788; ANTAGONIST; RO-15-1788; INVIVO; MICE; BINDING; BRAIN	To examine whether the benzodiazepine antagonist flumazenil can reverse tolerance to benzodiazepines but without precipitating withdrawal seizures, the antiepileptic effect of flumazenil itself and its ability to reverse tolerance at a dose that would leave sufficient receptors free for the binding of benzodiazepines were investigated. Electroencephalographic studies in 6 patients with partial and 6 with generalised seizures showed that flumazenil had a short (20 min) non-dose-dependent suppressant effect on epileptic discharges in those with partial seizures. Receptor occupancy studies in 12 patients showed that 1.5 mg flumazenil given intravenously occupied 55% receptors, whereas 15 mg occupied nearly all receptors. When 3 patients with partial seizures who had become tolerant to clonazepam were given 1.5 mg flumazenil, they were seizure-free for 6-21 days after the injection. The value of intermittent therapy with a benzodiazepine antagonist for preventing or reversing tolerance to benzodiazepine agonists ought to be investigated further.	KAROLINSKA PHARM,STOCKHOLM,SWEDEN	Karolinska Institutet	SAVIC, I (corresponding author), KAROLINSKA HOSP,DEPT CLIN NEUROPHYSIOL,POB 60500,S-10401 STOCKHOLM 60,SWEDEN.							BORMANN J, 1988, CHLORIDE CHANNELS TH, P47; ERIKSSON L, 1988, IEEE T NUCL SCI, V35, P703, DOI 10.1109/23.12815; GALLAGER DW, 1984, NATURE, V308, P74, DOI 10.1038/308074a0; GASTAUT H, 1985, J CLIN NEUROPHYSIOL, V2, P313, DOI 10.1097/00004691-198510000-00001; GELLER E, 1985, ANESTHESIOLOGY, V63, pA157; GLOOR P, 1982, H GASTAUT MARSEILLES, P45; GONSALVES SF, 1987, BRAIN RES, V405, P94, DOI 10.1016/0006-8993(87)90993-0; GONSALVES SF, 1985, EUR J PHARMACOL, V110, P163, DOI 10.1016/0014-2999(85)90208-0; GRECKSCH G, 1983, LIFE SCI, V32, P2579, DOI 10.1016/0024-3205(83)90241-2; Haefley W, 1988, CHLORIDE CHANNELS TH, P275; HAIGH JRM, 1988, TRENDS PHARMACOL SCI, V9, P361, DOI 10.1016/0165-6147(88)90255-6; HALLDIN C, 1988, APPL RADIAT ISOTOPES, V39, P993; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; JENSEN LH, 1983, LIFE SCI, V33, P393, DOI 10.1016/S0024-3205(83)80014-9; LUKAS SE, 1982, SCIENCE, V217, P1161, DOI 10.1126/science.6287579; MENNINI T, 1982, LIFE SCI, V31, P2025, DOI 10.1016/0024-3205(82)90094-7; MILLER LG, 1987, J PHARMACOL EXP THER, V240, P516; NUTT DJ, 1988, LIFE SCI, V43, P1045, DOI 10.1016/0024-3205(88)90199-3; PERSSON A, 1989, Human Psychopharmacology, V4, P215, DOI 10.1002/hup.470040307; POTIER MC, 1988, LIFE SCI, V43, P1287, DOI 10.1016/0024-3205(88)90583-8; ROBERTSON HA, 1983, BRAIN RES, V270, P380, DOI 10.1016/0006-8993(83)90619-4; SAVIC I, 1988, LANCET, V2, P863, DOI 10.1016/S0140-6736(88)92468-3; SAVIC I, IN PRESS EPILEPSIA; SCOLLOLAVIZZARI G, 1984, EUR NEUROL, V23, P1, DOI 10.1159/000115669; SHINOTOH H, 1989, PSYCHOPHARMACOLOGY, V99, P202, DOI 10.1007/BF00442808; SWAHN C-G, 1989, Human Psychopharmacology, V4, P297, DOI 10.1002/hup.470040410; THEODORSSON E, 1988, COMPUT METH PROG BIO, V26, P207, DOI 10.1016/0169-2607(88)90046-6	27	82	83	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					133	137		10.1016/0140-6736(91)90799-U	http://dx.doi.org/10.1016/0140-6736(91)90799-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670787				2022-12-24	WOS:A1991ET67900003
J	TRAYNELIS, SF; CULLCANDY, SG				TRAYNELIS, SF; CULLCANDY, SG			PROTON INHIBITION OF N-METHYL-D-ASPARTATE RECEPTORS IN CEREBELLAR NEURONS	NATURE			English	Article											TRAYNELIS, SF (corresponding author), UNIV LONDON UNIV COLL,DEPT PHARMACOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.			Cull-Candy, Stuart G/0000-0002-0831-8326	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALESTRINO M, 1988, J PHYSIOL-LONDON, V396, P247, DOI 10.1113/jphysiol.1988.sp016961; CHESLER M, 1988, NEUROSCIENCE, V27, P941, DOI 10.1016/0306-4522(88)90197-2; CIDON S, 1989, J BIOL CHEM, V264, P8281; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; CULLCANDY SG, 1988, J PHYSIOL-LONDON, V400, P189, DOI 10.1113/jphysiol.1988.sp017117; DINGLEDINE R, 1988, CRIT REV NEUROBIOL, V4, P1; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; GRANTYN R, 1988, NEUROSCI LETT, V89, P198, DOI 10.1016/0304-3940(88)90381-3; GRUOL DL, 1980, BRAIN RES, V183, P247, DOI 10.1016/0006-8993(80)90138-9; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOWE JR, 1988, PROC R SOC SER B-BIO, V233, P407, DOI 10.1098/rspb.1988.0030; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; KRISHTAL OA, 1980, NEUROSCIENCE, V5, P2325, DOI 10.1016/0306-4522(80)90149-9; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MAYER ML, 1989, J PHYSIOL-LONDON, V415, P329, DOI 10.1113/jphysiol.1989.sp017724; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MORAD M, 1988, Society for Neuroscience Abstracts, V14, P791; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PATLAK JB, 1988, J GEN PHYSIOL, V92, P413, DOI 10.1085/jgp.92.4.413; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; PIETROBON D, 1988, NATURE, V333, P373, DOI 10.1038/333373a0; TANG C M, 1989, Society for Neuroscience Abstracts, V15, P326; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121	30	469	484	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 24	1990	345	6273					347	350		10.1038/345347a0	http://dx.doi.org/10.1038/345347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF149	1692970				2022-12-24	WOS:A1990DF14900067
J	THUMMEL, CS; BURTIS, KC; HOGNESS, DS				THUMMEL, CS; BURTIS, KC; HOGNESS, DS			SPATIAL AND TEMPORAL PATTERNS OF E74 TRANSCRIPTION DURING DROSOPHILA DEVELOPMENT	CELL			English	Article									STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University				Burtis, Kenneth/0000-0002-9644-3265				ASHBURNER M, 1972, CHROMOSOMA, V38, P255, DOI 10.1007/BF00290925; ASHBURNER M, 1974, DEV BIOL, V39, P141, DOI 10.1016/S0012-1606(74)80016-3; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; ASHBURNER M, 1976, INSECT DEV, P203; Bodenstein D, 1965, BIOL DROSOPHILA, P275; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; BURTIS KC, 1985, THESIS STANFORD U ST; CHAO AT, 1986, EMBO J, V5, P143, DOI 10.1002/j.1460-2075.1986.tb04188.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; GIETZ RD, 1985, DEV BIOL, V107, P142, DOI 10.1016/0012-1606(85)90383-5; HAFEN E, 1986, DROSOPHILA PRACTICAL, P139; HANDLER AM, 1982, DEV BIOL, V93, P73, DOI 10.1016/0012-1606(82)90240-8; HODGETTS RB, 1977, DEV BIOL, V60, P310, DOI 10.1016/0012-1606(77)90128-2; Kafatos F C, 1972, Curr Top Dev Biol, V7, P125, DOI 10.1016/S0070-2153(08)60071-X; KRAMINSKY GP, 1980, P NATL ACAD SCI-BIOL, V77, P4175, DOI 10.1073/pnas.77.7.4175; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; RICHARDS G, 1981, BIOL REV, V56, P501, DOI 10.1111/j.1469-185X.1981.tb00358.x; RICHARDS G, 1976, DEV BIOL, V54, P264, DOI 10.1016/0012-1606(76)90304-3; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; RICHARDS G, 1976, DEV BIOL, V54, P256, DOI 10.1016/0012-1606(76)90303-1; RICHARDS G, 1982, ROUX ARCH DEV BIOL, V191, P103, DOI 10.1007/BF00848447; RICHARDS GP, 1976, DEV BIOL, V48, P191, DOI 10.1016/0012-1606(76)90057-9; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBB JA, 1969, J CELL BIOL, V41, P876, DOI 10.1083/jcb.41.3.876; SEED B, 1982, NUCLEIC ACIDS RES, V10, P1799, DOI 10.1093/nar/10.5.1799; SEGRAVES WA, 1990, IN PRESS GENES DEV; SEGRAVES WA, 1988, THESIS STANFORD U ST; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WHITE K, 1978, DEV BIOL, V65, P296, DOI 10.1016/0012-1606(78)90029-5; Wolfner M.F., 1988, Drosophila Information Service, V67, P104	32	224	226	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 6	1990	61	1					101	111		10.1016/0092-8674(90)90218-4	http://dx.doi.org/10.1016/0092-8674(90)90218-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CY382	1690603				2022-12-24	WOS:A1990CY38200013
J	SCOTT, JES; LEE, REJ; HUNTER, EW; COULTHARD, MG; MATTHEWS, JNS				SCOTT, JES; LEE, REJ; HUNTER, EW; COULTHARD, MG; MATTHEWS, JNS			ULTRASOUND SCREENING OF NEWBORN URINARY-TRACT	LANCET			English	Article							REFLUX; INFANTS	A non-invasive method to screen newborn babies for ureteric reflux might allow the possibility of appropriate action to prevent reflux nephropathy. We have tested the sensitivity of ultrasound screening of the urinary tract. 1061 unselected newborn infants born during 1986 were examined by ultrasound and the findings were recorded on videotape. Babies with dilated renal collecting systems underwent further investigations (micturating cystourethrography, intravenous urography, or radioisotope study). With these methods, 11 children were found to have renal disorders. A postal follow-up survey was carried out when the children were 3 years old. 657 (62%) families responded. We searched for non-responders among children born in 1986 who had subsequently had a renal radioisotope investigation: 5 nonresponders were found among these children. Of the total, 24 children had had a urinary-tract infection: 3 more children with ureteric reflux were found; their neonatal ultrasound scans had suggested no abnormality. Thus, mom than half the children of this cohort in whom hydronephrosis or ureteric reflux developed had only slight dilatation (less than 5 mm) on the neonatal scan. On review of the original videotapes there was no difference in internal dimension between left and right kidneys: the internal dimension was 5 mm or less in both kidneys in 96.5% of babies and 4 mm or less in 93.3%. Routine renal ultrasound scanning of newborn babies is of no value in detecting those who may have ureteric reflux: the number of other renal abnormalities likely to be detected is small.	ROYAL VICTORIA INFIRM,DEPT RADIOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; ROYAL VICTORIA INFIRM,DEPT CHILD HLTH,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DIV MED STAT,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK			Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X				ANDERSON PAM, 1991, BRIT J UROL, V67, P267, DOI 10.1111/j.1464-410X.1991.tb15132.x; DIARD F, 1987, PEDIATR RADIOL, V17, P154, DOI 10.1007/BF02388097; FALKOFF GE, 1987, RADIOLOGY, V162, P343, DOI 10.1148/radiology.162.2.3541028; GORDON AC, 1990, BRIT J UROL, V65, P407, DOI 10.1111/j.1464-410X.1990.tb14766.x; HODSON C J, 1960, Clin Radiol, V11, P219, DOI 10.1016/S0009-9260(60)80047-5; MARSHALL JL, 1990, RADIOLOGY, V175, P355, DOI 10.1148/radiology.175.2.2183279; PLACKETT RL, 1981, ANAL CATEGORICAL DAT, P79; SCOTT JES, 1987, BRIT J UROL, V59, P291, DOI 10.1111/j.1464-410X.1987.tb04634.x; SCOTT JES, 1990, ARCH DIS CHILD-FETAL, V65, P361, DOI 10.1136/adc.65.4_Spec_No.361; STEINHART JM, 1988, PEDIATRICS, V82, P609; 1991, LANCET, V338, P1050	11	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1571	1573		10.1016/0140-6736(91)92385-F	http://dx.doi.org/10.1016/0140-6736(91)92385-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683982				2022-12-24	WOS:A1991GW03600015
J	WANG, XF; LIN, HY; NGEATON, E; DOWNWARD, J; LODISH, HF; WEINBERG, RA				WANG, XF; LIN, HY; NGEATON, E; DOWNWARD, J; LODISH, HF; WEINBERG, RA			EXPRESSION CLONING AND CHARACTERIZATION OF THE TGF-BETA TYPE-III RECEPTOR	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MEMBRANE PROTEOGLYCAN; MOLECULAR-CLONING; GLYCOSAMINOGLYCAN CHAINS; EXTRACELLULAR-MATRIX; CELL PROLIFERATION; DOMAIN-STRUCTURE; LIGAND-BINDING; 2 FORMS; INHIBITION	The rat TGF-beta type III receptor cDNA has been cloned by overexpression in COS cells. The encoded receptor is an 853 amino acid protein with a large N-terminal extracellular domain containing at least one site for glycosaminoglycan addition, a single hydrophobic transmembrane domain, and a 41 amino acid cytoplasmic tail with no obvious signaling motif. Introduction of the cDNA into COS cells and L6 myoblasts induces expression of a heterogenously glycosylated 280-330 kd protein characteristic of the type III receptor that binds TGF-beta-1 specifically. In L6 myoblasts lacking the endogenous type III receptor, expression of the recombinant receptor leads to an increase in the amount of ligand bound and cross-linked to surface type II TGF-beta receptors. This indicates that the type III receptor may regulate the ligand-binding ability or surface expression of the type II receptor.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	WANG, XF (corresponding author), WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.			Downward, Julian/0000-0002-2331-4729	NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007287] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA39826] Funding Source: Medline; NHLBI NIH HHS [HL-41484] Funding Source: Medline; NIGMS NIH HHS [T 32 GM07287-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERNFIELD M, 1991, IN PRESS ANN NY ACAD; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CARR BI, 1986, CANCER RES, V46, P2330; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P3083, DOI 10.1021/bi00359a003; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P1699; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LIN HY, 1991, IN PRESS SCIENCE; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P7059; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOSES HL, 1985, CANCER CELL, V3, P65; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SHIPLEY GD, 1986, CANCER RES, V46, P2068; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	66	588	619	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1991	67	4					797	805		10.1016/0092-8674(91)90074-9	http://dx.doi.org/10.1016/0092-8674(91)90074-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657407				2022-12-24	WOS:A1991GQ40700016
J	CHAN, A; SHINDE, R; CHOW, CC; COCKRAM, CS; SWAMINATHAN, R				CHAN, A; SHINDE, R; CHOW, CC; COCKRAM, CS; SWAMINATHAN, R			INVIVO AND INVITRO SODIUM-PUMP ACTIVITY IN SUBJECTS WITH THYROTOXIC PERIODIC PARALYSIS	BRITISH MEDICAL JOURNAL			English	Article							OUABAIN-BINDING-SITES; NA+,K+-ATPASE ACTIVITY; RUBIDIUM CHLORIDE; CATION-TRANSPORT; SKELETAL-MUSCLE; THYROID-HORMONE; ATPASE ACTIVITY; GRAVES-DISEASE; POTASSIUM PUMP; HYPERTHYROIDISM	Objective - To examine whether sodium pump activity plays a part in the pathogenesis of thyrotoxic periodic paralysis. Design - Measurement of platelet sodium-potassium ATPase and in vivo sodium pump activities in healthy subjects and thyrotoxic subjects with and without paralysis. Setting - University hospital in Hong Kong. Subjects - 21 healthy subjects, 23 untreated thyrotoxic subjects, 13 untreated men with periodic paralysis, seven treated thyrotoxic subjects, and six treated men with periodic paralysis. Main outcome measures - Platelet Na+, K+-ATPase activity and plasma rubidium concentration after oral loading. Results - Median (range) platelet Na+, K+-ATPase activity in thyrotoxic subjects was 253 (169-821) mu-mol inorganic phosphate/h/g protein-significantly higher than that in healthy subjects (134 (81-180) mu-mol/h/g protein; p < 0.001). Na+, K+-ATPase activity in those with periodic paralysis was 374 (195-11%) mu-mol/h/g protein, again significantly higher than that in healthy subjects (p < 0.001) and that in other thyrotoxic subjects (p < 0.01) despite similar degrees of hyperthyroidism. Activities in treated thyrotoxic subjects with and without periodic paralysis were 148 (110-234) and 131 (86-173) mu-mol/h/g protein respectively. Mean (95% confidence interval) plasma rubidium concentration five hours after oral administration in thyrotoxic subjects (7.0 (6.6 to 7.5) mu-mol/l) was significantly lower than in healthy subjects (10.2 (9.5 to 10.9) mu-mol/l; p < 0.001) and higher than in those with periodic paralysis (6.0 (5.7 to 6.3) mu-mol/l; p < 0.01). Conclusions - Sodium pump activity in untreated subjects with periodic paralysis is higher than in other thyrotoxic subjects, and this may be responsible for the hypokalaemia.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT CHEM PATHOL,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital								ARNOTT RD, 1982, J CLIN ENDOCR METAB, V54, P1150, DOI 10.1210/jcem-54-6-1150; ARUMANAYAGAM M, 1990, J CLIN ENDOCR METAB, V71, P260, DOI 10.1210/jcem-71-1-260; ARUMANAYAGAM M, 1990, METABOLISM, V39, P952, DOI 10.1016/0026-0495(90)90307-X; ASANO Y, 1976, J CLIN INVEST, V57, P368, DOI 10.1172/JCI108288; BARON DN, 1985, CLIN SCI, V68, P143, DOI 10.1042/cs0680143; BERNSTEIN JC, 1970, J PHARMACOL EXP THER, V174, P323; BOON NA, 1984, CLIN SCI, V66, P569, DOI 10.1042/cs0660569; DALY JA, 1972, CLIN CHEM, V18, P263; ENGEL AG, 1972, MAYO CLIN PROC, V47, P919; FEELY J, 1981, POSTGRAD MED J, V57, P238, DOI 10.1136/pgmj.57.666.238; FIEVE RR, 1971, PSYCHOPHARMACOLOGIA, V20, P307, DOI 10.1007/BF00403562; HABER RS, 1984, ENDOCRINOLOGY, V115, P291, DOI 10.1210/endo-115-1-291; HALLIS KF, 1985, CLIN CHEM, V31, P274; HAWKINS BR, 1985, CLIN ENDOCRINOL, V23, P245, DOI 10.1111/j.1365-2265.1985.tb00220.x; ISMAILBEIGI F, 1988, AM ZOOL, V28, P363; KHAN FA, 1987, CLIN SCI, V72, P171, DOI 10.1042/cs0720171; KJELDSEN K, 1984, LANCET, V2, P8; LAM KSL, 1989, AUST NZ J MED, V19, P6, DOI 10.1111/j.1445-5994.1989.tb01664.x; LIN MH, 1978, J BIOL CHEM, V253, P723; MARX A, 1989, MUSCLE NERVE, V12, P810, DOI 10.1002/mus.880121005; MCFADZEAN AJ, 1967, BMJ-BRIT MED J, V1, P451, DOI 10.1136/bmj.1.5538.451; OH VMS, 1990, CLIN SCI, V78, P199, DOI 10.1042/cs0780199; OKINAKA S, 1957, J CLIN ENDOCR METAB, V17, P1454, DOI 10.1210/jcem-17-12-1454; RUBYTHON EJ, 1983, CLIN SCI, V64, P441, DOI 10.1042/cs0640441; SCHIZUME K, 1966, METABOLISM, V15, P138; TURAIHI K, 1989, METABOLISM, V38, P773, DOI 10.1016/0026-0495(89)90065-6; YEO PPB, 1978, BRIT MED J, V2, P930, DOI 10.1136/bmj.2.6142.930; YEUNG RTT, 1974, AM J MED, V57, P584, DOI 10.1016/0002-9343(74)90010-2; YEUNG RTT, 1987, OXFORD TXB MED, V10, P48	29	127	134	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1096	1099		10.1136/bmj.303.6810.1096	http://dx.doi.org/10.1136/bmj.303.6810.1096			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1660744	Green Published, Bronze			2022-12-24	WOS:A1991GN20900020
J	LIPPINCOTTSCHWARTZ, J; YUAN, L; TIPPER, C; AMHERDT, M; ORCI, L; KLAUSNER, RD				LIPPINCOTTSCHWARTZ, J; YUAN, L; TIPPER, C; AMHERDT, M; ORCI, L; KLAUSNER, RD			BREFELDIN-AS EFFECTS ON ENDOSOMES, LYSOSOMES, AND THE TGN SUGGEST A GENERAL MECHANISM FOR REGULATING ORGANELLE STRUCTURE AND MEMBRANE TRAFFIC	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; TRANS-GOLGI NETWORK; ENDOPLASMIC-RETICULUM; IMMUNOELECTRON MICROSCOPY; INTRACELLULAR-TRANSPORT; CARCINOMA A431-CELLS; SECRETORY PROTEINS; PLASMA-MEMBRANE; RAT PANCREAS; TRANSFERRIN	Addition of brefeldin A (BFA) to most cells results in both the formation of extensive, uncoated membrane tubules through which Golgi components redistribute into the ER and the failure to transport molecules out of this mixed ER/Golgi system. In this study we provide evidence that suggests BFA's effects are not limited to the Golgi apparatus but are reiterated throughout the central vacuolar system. Addition of BFA to cells resulted in the tubulation of the endosomal system, the trans-Golgi network (TGN), and lysosomes. Tubule formation of these organelles was specific to BFA, shared near identical pharmacologic characteristics as Golgi tubules and resulted in targeted membrane fusion. Analogous to the mixing of the Golgi with the ER during BFA treatment, the TGN mixed with the recycling endosomal system. This mixed system remained functional with normal cycling between plasma membrane and endosomes, but traffic between endosomes and lysosomes was impaired.	UNIV GENEVA, INST HISTOL & EMBRYOL, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	LIPPINCOTTSCHWARTZ, J (corresponding author), NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA.							ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BURKE B, 1984, CELL, V36, P847, DOI 10.1016/0092-8674(84)90034-5; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; ORCI L, 1973, J ULTRA MOL STRUCT R, V43, P270, DOI 10.1016/S0022-5320(73)80039-5; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; ORCI L, 1991, CELL, V64, P1183; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; SWANSON J, 1987, J CELL BIOL, V104, P1217, DOI 10.1083/jcb.104.5.1217; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEIBEL ER, 1979, STEREOLOGICAL METHOD, V1, P101; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	48	746	751	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1991	67	3					601	616		10.1016/0092-8674(91)90534-6	http://dx.doi.org/10.1016/0092-8674(91)90534-6			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1682055				2022-12-24	WOS:A1991GN66400016
J	MOTT, DD; LEWIS, DV				MOTT, DD; LEWIS, DV			FACILITATION OF THE INDUCTION OF LONG-TERM POTENTIATION BY GABA-B RECEPTORS	SCIENCE			English	Article							RAT DENTATE GYRUS; HIPPOCAMPAL-NEURONS; BACLOFEN; INHIBITION; DEPRESSION; 2-HYDROXY-SACLOFEN; INVITRO; STIMULATION; ANTAGONISTS; RESPONSES	Long-term potentiation (LTP), an in vitro model of learning, was induced in hippocampal slices by 5-hertz stimulation. During induction, gamma-aminobutyric acid A (GABA(A)) inhibition decreased, causing the N-methyl-D-aspartate receptor-mediated excitation to increase. 2-OH Saclofen, a GABA(B) receptor antagonist, prevented the reduction of inhibition, the increase of excitation, and the induction of LTP. Therefore, disinhibition caused by GABA(B) receptors is required for induction of LTP by 5-hertz stimulation. GABA(B) receptor modulation of synaptic plasticity occurs at frequencies in the range of the endogenous hippocampal theta rhythm, which has been shown to modulate LTP in vivo.	DUKE UNIV,MED CTR,DEPT PEDIAT NEUROL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Duke University; Duke University	MOTT, DD (corresponding author), DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710, USA.			Mott, David/0000-0003-0758-8006	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027488] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27488] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDAHAN MI, 1990, BRAIN RES, V526, P308, DOI 10.1016/0006-8993(90)91237-B; BONANNO G, 1989, EUR J PHARM-MOLEC PH, V172, P41, DOI 10.1016/0922-4106(89)90043-6; COLLINGRIDGE GL, 1989, NMDA RECEPTOR, pCH9; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; DUNWIDDIE T, 1978, J PHYSIOL-LONDON, V276, P353, DOI 10.1113/jphysiol.1978.sp012239; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; HERRON CE, 1985, NEUROSCI LETT, V60, P19, DOI 10.1016/0304-3940(85)90375-1; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; KERR DIB, 1988, NEUROSCI LETT, V92, P92, DOI 10.1016/0304-3940(88)90748-3; LAMBERT NA, 1989, NEUROSCI LETT, V107, P125, DOI 10.1016/0304-3940(89)90803-3; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; MISGELD U, 1989, PFLUG ARCH EUR J PHY, V414, P139, DOI 10.1007/BF00580955; MORRISETT RA, 1991, J NEUROSCI, V11, P203; MOTT D D, 1990, Society for Neuroscience Abstracts, V16, P945; MOTT DD, 1989, J PHARMACOL EXP THER, V249, P721; MOTT DD, 1990, NEUROSCI LETT, V113, P222, DOI 10.1016/0304-3940(90)90307-U; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLPE HR, 1990, N-S ARCH PHARMACOL, V342, P194, DOI 10.1007/BF00166964; PACELLI GJ, 1989, BRAIN RES, V486, P26, DOI 10.1016/0006-8993(89)91273-0; PAVLIDES C, 1988, BRAIN RES, V439, P383, DOI 10.1016/0006-8993(88)91499-0; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P524, DOI 10.1152/jn.1989.61.3.524; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0	25	262	264	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1718	1720		10.1126/science.1675489	http://dx.doi.org/10.1126/science.1675489			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1675489				2022-12-24	WOS:A1991FT11400050
J	SQUIRE, SB; ELFORD, J; BOR, R; TILSED, G; SALT, H; BAGDADES, EK; JANOSSY, G; GRIFFITHS, PD; JOHNSON, MA				SQUIRE, SB; ELFORD, J; BOR, R; TILSED, G; SALT, H; BAGDADES, EK; JANOSSY, G; GRIFFITHS, PD; JOHNSON, MA			OPEN ACCESS CLINIC PROVIDING HIV-I ANTIBODY RESULTS ON DAY OF TESTING - THE 1ST 12 MONTHS	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL; EARLY DIAGNOSIS; ZIDOVUDINE AZT; INFECTION; EFFICACY; SAFETY	Objectives - To determine the sociodemographic profile, risk category, and prevalence of HIV-1 infection among people attending a clinic providing counselling, medical advice, and results of HIV-1 antibody testing on the day of consultation; to determine the stage of infection and peripheral blood CD4 cell count among attenders with detectable HIV-1 antibodies. Design - Analysis of prospectively collected data for the 12 months from March 1989. Setting - Same day testing clinic run by the HIV/AIDS team at an urban teaching hospital. Patients - 561 consecutive people choosing to attend and proceeding to HIV-1 testing. Results - The demand for the service caused it to run to capacity within six months. The median age of those attending was 28 years and 65% (364 patients) were male. The overall prevalence of HIV-1 infection was 3.9% (22 patients). The greatest prevalence was in men reporting their primary risk as homosexual contact (11.9%, 13/109. The median CD4 cell count in the 22 patients who had detectable HIV-1 antibodies was 0.31 X 10(9) cells/l (normal range 0.5 X l0(9)/l to 1.2 X l0(9)/l). Twenty of these patients were asymptomatic (Centers for Disease Control stages 11 or 111), 14 had CD4 cell counts below 0.5 X l0(9)/l. Conclusions - There is a recognisable demand for a service providing rapid results of HIV-1 antibody testing in this setting. The overall seroprevalence of 3.9% is comparable with the 5.8% reported from freestanding clinics in the United States. Most patients with HIV-I antibodies detected in this way are asymptomatic but could benefit from early medical intervention because of low CD4 cell counts.			SQUIRE, SB (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND.			Squire, Stephen/0000-0001-7173-9038				BECK EJ, 1987, BRIT MED J, V295, P191, DOI 10.1136/bmj.295.6591.191; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GREEN J, 1987, CURRENT TOPICS AIDS, V1, P287; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LO B, 1989, ANN INTERN MED, V110, P727; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MOSS AR, 1989, AIDS, V3, P55, DOI 10.1097/00002030-198902000-00001; MURPHY FA, 1989, MMWR S5, V38, pS1; PHILLIPS AN, 1991, LANCET, V337, P389; SCHWARTZ JS, 1988, JAMA-J AM MED ASSOC, V259, P2574, DOI 10.1001/jama.259.17.2574; SONNEX C, 1987, BRIT MED J, V295, P193, DOI 10.1136/bmj.295.6591.193; SQUIRE SB, 1990, BRIT J HOSP MED, V44, P9; VOLBERDING P, 1989, J ACQ IMMUN DEF SYND, V2, P421; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, MMWR, V39, P137; 1987, MMWR S1, V36, pS3	17	27	27	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1991	302	6789					1383	1386		10.1136/bmj.302.6789.1383	http://dx.doi.org/10.1136/bmj.302.6789.1383			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR057	1676319	Green Published, Bronze			2022-12-24	WOS:A1991FR05700026
J	JAYNE, DRW; DAVIES, MJ; FOX, CJV; BLACK, CM; LOCKWOOD, CM				JAYNE, DRW; DAVIES, MJ; FOX, CJV; BLACK, CM; LOCKWOOD, CM			TREATMENT OF SYSTEMIC VASCULITIS WITH POOLED INTRAVENOUS IMMUNOGLOBULIN	LANCET			English	Article							ANTINEUTROPHIL CYTOPLASM ANTIBODIES; GAMMA-GLOBULIN; KAWASAKI SYNDROME; AUTOANTIBODIES; NEUTROPHILS; DIAGNOSIS; DISEASE; INVIVO	The therapeutic effect of a course of high-dose, pooled, intravenous immunoglobulin (IVIg) on disease activity and circulating antineutrophil cytoplasm antibodies (ANCA) was investigated in 7 patients with systemic vasculitis. 5 had active disease despite conventional immunosuppression, and 2 had not received any treatment. All 7 had clinical improvement, which was sustained in 6 and transient in 1. The fall in ANCA concentrations to a mean of 51% of the pre-treatment values was maintained during follow-up. C-reactive protein concentration also dropped considerably. IVIg seemed to confer a useful therapeutic effect without adverse reaction.	IPSWICH HOSP,DEPT MED,IPSWICH,SUFFOLK,ENGLAND; NORTHAMPTON GEN HOSP,DEPT MED,NORTHAMPTON NN1 5BD,ENGLAND; ROYAL FREE HOSP,DEPT RHEUMATOL,LONDON,ENGLAND	Ipswich Hospital NHS Trust; Ipswich Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	JAYNE, DRW (corresponding author), UNIV CAMBRIDGE,SCH CLIN MED,DEPT MED,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.		Davies, Michael/GWV-2527-2022	Jayne, David/0000-0002-1712-0637	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BASTA M, 1989, BLOOD, V74, P326; CHALOPIN JM, 1984, EUR J IMMUNOL, V14, P470, DOI 10.1002/eji.1830140516; COHEN J, 1982, Q J MED, V51, P1; DEREMEE RA, 1988, ARTHRITIS RHEUM, V31, P1068, DOI 10.1002/art.1780310821; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; GROTZ W, 1990, APMIS S19, V98, P54; HAYS WM, 1981, STATISTICS, P630; JAYNE DRW, 1989, CLIN NEPHROL, V32, P101; JORDAN SC, 1989, CLIN IMMUNOL IMMUNOP, V53, pS164, DOI 10.1016/0090-1229(89)90082-2; KIMBERLY RP, 1984, J IMMUNOL, V132, P745; LEUNG DYM, 1989, LANCET, V2, P1298; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; PALLA R, 1986, CLIN NEPHROL, V26, P314; ROSSI F, 1991, CLIN EXP IMMUNOL, V83, P298; ROSSI F, 1989, IMMUNOL REV, V110, P215; SAVAGE COS, 1989, ARCH DIS CHILD, V64, P360, DOI 10.1136/adc.64.3.360; SAVAGE COS, 1987, LANCET, V1, P1389; SCHIFFERLI J, 1991, LANCET, V335, P457; SCHWARTZ SA, 1990, J CLIN IMMUNOL, V10, P81, DOI 10.1007/BF00918189; SULTAN Y, 1984, LANCET, V2, P765; VANDERWOUDE FJ, 1985, LANCET, V1, P425	23	258	266	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1137	1139		10.1016/0140-6736(91)92797-6	http://dx.doi.org/10.1016/0140-6736(91)92797-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674023				2022-12-24	WOS:A1991FL12400014
J	SCHULMAN, KA; LYNN, LA; GLICK, HA; EISENBERG, JM				SCHULMAN, KA; LYNN, LA; GLICK, HA; EISENBERG, JM			COST-EFFECTIVENESS OF LOW-DOSE ZIDOVUDINE THERAPY FOR ASYMPTOMATIC PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE; AIDS	We did a cost-effectiveness analysis of zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. The incremental direct medical costs of zidovudine therapy were determined, and data on the effects of therapy were derived from the report of the Acquired Immunodeficiency Syndrome (AIDS) Clinical Trials Group Protocol 019. Zidovudine therapy has an annual incremental cost of $2653 per person. The cost per year of life saved ranges between $6553 and $70 526, depending on which epidemiologic model of potential long-term zidovudine effect is used (in sensitivity analyses, the cost per year of life saved ranges between $2649 and $250 546). Although expensive, zidovudine therapy has the potential to yield a substantial survival benefit to patients. The cost effectiveness of zidovudine therapy compares favorably with that of other common medical therapies.	UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania								EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HILTS PJ, 1989, NY TIMES        0819, pA1; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; SCITOVSKY AA, 1990, PUBLIC HLTH REP, V102, P5; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WINKENWERDER W, 1989, NEW ENGL J MED, V320, P1598, DOI 10.1056/NEJM198906153202406; 1982, MANUAL LABORATORY WO; 1990, MMWR, V39, P20; 1988, PUBLIC HLTH REP S1, V103, P35; 1989, MONTHLY VITAL STATIS, V37, P1; 1989, NY TIMES        0820, pE22; 1990, HIV AIDS SURVEILLANC, P1; 1989, ACTG 019 QUESTIONS A; 1989, JAMA-J AM MED ASSOC, V261, P75	21	114	114	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					798	802		10.7326/0003-4819-114-9-798	http://dx.doi.org/10.7326/0003-4819-114-9-798			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	1672806				2022-12-24	WOS:A1991FJ11700012
J	BRAHAMS, D				BRAHAMS, D			HYPOGLYCEMIA AND INTENT	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1030	1030		10.1016/0140-6736(91)92679-V	http://dx.doi.org/10.1016/0140-6736(91)92679-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673179				2022-12-24	WOS:A1991FJ13500018
J	BRILLIANT, MH; GONDO, Y; EICHER, EM				BRILLIANT, MH; GONDO, Y; EICHER, EM			DIRECT MOLECULAR-IDENTIFICATION OF THE MOUSE PINK-EYED UNSTABLE MUTATION BY GENOME SCANNING	SCIENCE			English	Article							RECOMBINANT-INBRED STRAINS; COAT-COLOR MUTATION; HUMAN DNA; MICE; GENE; CHROMOSOME-7; PROVIRUS; LINKAGE; RATES; LOCUS	DNA sequences associated with the mouse pink-eyed unstable mutation were identified in the absence of closely linked molecular markers and without prior knowledge of the encoded gene product. This was accomplished by "genome scanning," a technique in which high-resolution Southern blots of genomic DNAs were hybridized to a dispersed and moderately repetitive DNA sequence. In this assay, pink-eyed unstable DNA was distinguished from the DNA of wild-type and revertant mice by enhanced hybridization to one of several hundred resolved fragments. The fragments showing enhanced hybridization in pink-eyed unstable DNA was cloned and found to lie within a DNA duplication that is located close to, or within, the pink-eyed dilution locus. The duplication associated with the mouse pink-eyed unstable mutation may mediate the high reversion frequency characteristic of this mutation.	JACKSON LAB,BAR HARBOR,ME 04609	Jackson Laboratory	BRILLIANT, MH (corresponding author), FOX CHASE CANC INST,INST CANC RES,PHILADELPHIA,PA 19111, USA.		Gondo, Yoichi/A-5375-2016	Gondo, Yoichi/0000-0003-2184-6489	NCI NIH HHS [CA06927] Funding Source: Medline; NCRR NIH HHS [RR05529] Funding Source: Medline; NIGMS NIH HHS [GM43840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BAILEY DW, 1971, TRANSPLANTATION, V11, P325, DOI 10.1097/00007890-197103000-00013; BRILLIANT MH, 1987, J NEUROGENET, V4, P259, DOI 10.3109/01677068709102346; BURT DW, 1984, NUCLEIC ACIDS RES, V12, P8579, DOI 10.1093/nar/12.22.8579; COPELAND NG, 1983, CELL, V33, P379, DOI 10.1016/0092-8674(83)90419-1; DEOL MS, 1983, J EMBRYOL EXP MORPH, V78, P291; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GONDO Y, UNPUB; Haldane JBS, 1915, J GENET, V5, P133, DOI 10.1007/BF02985370; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JENKINS NA, 1981, NATURE, V293, P370, DOI 10.1038/293370a0; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KNOBLER R L, 1984, Experimental and Clinical Immunogenetics, V1, P217; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; MINTZ B, 1970, CONTROL MECHANISMS E, P15; ORKIN SH, 1986, CELL, V47, P854; PHILLIPS JS, 1977, MOUSE NEWS LETT, V56, P38; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SCHLAGER G, 1967, GENETICS, V57, P319; SEPERACK PK, 1988, P NATL ACAD SCI USA, V85, P189, DOI 10.1073/pnas.85.1.189; SILVER J, 1986, P NATL ACAD SCI USA, V83, P1423, DOI 10.1073/pnas.83.5.1423; SILVERS WK, 1979, COAT COLORS MICE, P90; SOUTHERN EM, 1975, J MOL BIOL, V98, P5503; Sturtevant AH, 1925, GENETICS, V10, P117; TARTOF KD, 1988, GENETICS, V120, P1; Taylor B. A., 1978, ORIGINS INBRED MICE, P423, DOI [10.1016/B978-0-12-507850-4.50032-9, DOI 10.1016/B978-0-12-507850-4.50032-9]; TAYLOR BA, 1984, MOL GEN GENET, V195, P491, DOI 10.1007/BF00341452; WHITNEY JB, 1982, J HERED, V73, P12, DOI 10.1093/oxfordjournals.jhered.a109567; WOLFE HG, 1963, 11TH P INT C GEN, P251	31	114	115	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					566	569		10.1126/science.1673574	http://dx.doi.org/10.1126/science.1673574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1673574				2022-12-24	WOS:A1991FJ12700047
J	CHISAKA, O; CAPECCHI, MR				CHISAKA, O; CAPECCHI, MR			REGIONALLY RESTRICTED DEVELOPMENTAL DEFECTS RESULTING FROM TARGETED DISRUPTION OF THE MOUSE HOMEOBOX GENE HOX-1.5	NATURE			English	Article							DROSOPHILA HOMEOTIC GENES; NEURAL CREST CELLS; MOLECULAR-GENETICS; DNA-SEQUENCE; STEM-CELLS; EXPRESSION; COMPLEX; ANTENNAPEDIA; EMBRYO; MURINE	Gene targeting in mouse embryo-derived stem cells has been used to disrupt the homeobox gene hox-1.5. Mice heterozygous at the hox-1.5 locus appear normal, whereas hox-1.5-/hox-1.5- mice die at or shortly after birth. These homozygotes are athymic, aparathyroid, have reduced thyroid and submaxillary tissue and exhibit a wide range of throat abnormalities. In addition, they often feature defects of the heart and arteries as well as craniofacial abnormalities. These deficiencies are remarkably similar to the pathology of the human congenital disorder DiGeorge's syndrome.			CHISAKA, O (corresponding author), UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1987, DEVELOPMENT, V101, P1; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BOCKMAN DE, 1989, ANAT RECORD, V225, P209, DOI 10.1002/ar.1092250306; BOCKMAN DE, 1984, SCIENCE, V223, P498, DOI 10.1126/science.6606851; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARRASCO AE, 1984, CELL, V37, P409, DOI 10.1016/0092-8674(84)90371-4; COULY G, 1988, DEVELOPMENT, V103, P101; DUBOULE D, 1990, GENOMICS, V7, P458, DOI 10.1016/0888-7543(90)90185-W; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FAINSOD A, 1987, DEV BIOL, V124, P125, DOI 10.1016/0012-1606(87)90465-9; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GAUNT SJ, 1986, NATURE, V324, P662, DOI 10.1038/324662a0; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GREENBERG F, 1988, AM J HUM GENET, V43, P605; HARDING K, 1985, SCIENCE, V229, P1236, DOI 10.1126/science.3898362; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5459, DOI 10.1073/pnas.86.14.5459; KAUFMAN TC, 1980, GENETICS, V94, P115; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; LEDOUARIN NM, 1980, NEURAL CREST; LELEIVRE CS, 1975, J EMBRYOL EXP MORPH, V34, P125; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN GR, 1987, NATURE, V325, P21, DOI 10.1038/325021b0; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V38, P675, DOI 10.1016/0092-8674(84)90262-9; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P916; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NODEN DM, 1975, DEV BIOL, V42, P106, DOI 10.1016/0012-1606(75)90318-8; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1990, ANN NY ACAD SCI, V588, P236, DOI 10.1111/j.1749-6632.1990.tb13214.x; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PULTZ MA, 1988, GENE DEV, V2, P901, DOI 10.1101/gad.2.7.901; RUSHLOW C, 1987, GENE DEV, V1, P1268, DOI 10.1101/gad.1.10.1268; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SCOTT MP, 1984, P NATL ACAD SCI USA, V81, P3115; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5	48	741	754	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					473	479		10.1038/350473a0	http://dx.doi.org/10.1038/350473a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1673020				2022-12-24	WOS:A1991FG14300041
J	YEUNG, ST; YOONG, C; SPINK, J; GALBRAITH, A; SMITH, PJ				YEUNG, ST; YOONG, C; SPINK, J; GALBRAITH, A; SMITH, PJ			FUNCTIONAL MYOCARDIAL IMPAIRMENT IN CHILDREN TREATED WITH ANTHRACYCLINES FOR CANCER	LANCET			English	Article							DOXORUBICIN CARDIOTOXICITY; ADRIAMYCIN; CARDIOMYOPATHY	A non-invasive exercise method was used to look for myocardial damage in apparently normal children who had received moderate doses of anthracyclines for treatment of cancer. 19 children (mean [SD] age 10.6 [4.3] years) who had received anthracyclines (mean total dose 230 [119] mg/m2) and 10 who had received other cytotoxic drugs (mean age 13.3 [4.9] years) were selected from 263 children attending routine follow-up examinations. They underwent measurement of heart rate, blood pressure, and left ventricular dimensions by echocardiography before and after exercise on a bicycle for a maximum of 10 min. All 29 were in remission. All the subjects showed normal fractional shortening (FS = left ventricular end-diastolic minus end-systolic diameter as a percentage of the end-diastolic diameter) at rest, but the increase in FS on exercise was significantly lower in the children who had received anthracyclines than in those who had not (3 [16]% vs 23 [17]%; p < 0.05). This difference remained significant after adjustment for age and drug exposure. However, there were no significant differences between the groups in the adjusted mean percentage changes on exercise in heart rate or systolic or diastolic blood pressure. Disease type had no effect on the cardiological indices. Thus, many children who have received anthracyclines may have suffered subclinical myocardial damage. Post-exercise echocardiography seems a useful noninvasive method for detecting such damage. Long-term cardiological follow-up of these patients is needed.	UNIV QUEENSLAND,SCH MED,DEPT PATHOL,HERSTON RD,HERSTON,QLD 4006,AUSTRALIA; ROYAL CHILDRENS HOSP,HERSTON,QLD,AUSTRALIA; PRINCE CHARLES HOSP,CHERMSIDE,QLD,AUSTRALIA	University of Queensland; Royal Children's Hospital Brisbane; Prince Charles Hospital								BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; BLUM RH, 1975, CANCER CHEMOTH REP 3, V6, P247; BRISTOW MR, 1981, AM HEART J, V102, P709, DOI 10.1016/0002-8703(81)90096-X; CARTER SK, 1975, J NATL CANCER I, V55, P1265, DOI 10.1093/jnci/55.6.1265; DEARTH J, 1984, MED PEDIATR ONCOL, V12, P54, DOI 10.1002/mpo.2950120113; HAUSDORF G, 1988, BRIT HEART J, V60, P309; MARCHANDISE B, 1989, AM HEART J, V118, P92, DOI 10.1016/0002-8703(89)90077-X; PRAGA C, 1979, CANCER TREAT REP, V63, P827; VONHOFF DD, 1977, AM J MED, V62, P200, DOI 10.1016/0002-9343(77)90315-1; VONHOFF DD, 1982, SEMIN ONCOL, V9, P23	10	82	82	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					816	818		10.1016/0140-6736(91)92516-5	http://dx.doi.org/10.1016/0140-6736(91)92516-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672914				2022-12-24	WOS:A1991FF22800004
J	HABIB, N; HOUSSIN, D; CAROL, C; CARDOSO, J; BOISSEAU, C; CALMUS, Y; OZIER, Y; QUERE, J; WOOD, C; MCINTYRE, N				HABIB, N; HOUSSIN, D; CAROL, C; CARDOSO, J; BOISSEAU, C; CALMUS, Y; OZIER, Y; QUERE, J; WOOD, C; MCINTYRE, N			EXPERIMENTAL REDUCTION OF PORTAL-HYPERTENSION BY MECHANICAL INCREASE OF LIVER PORTAL FLOW	LANCET			English	Note								Studies on the isolated perfused rat liver demonstrated that an increase in portal pressure is associated with an increase in the portal blood flow in normal and in cirrhotic livers. In two pigs with portal hypertension mesenteric portal pressure was lowered by mechanically increasing the liver portal blood flow by means of a balloon pump around the portal vein.	HAMMERSMITH HOSP,DEPT SURG,LONDON W12 0HS,ENGLAND; HOP COCHIN,SURG RES LAB,F-75674 PARIS 14,FRANCE; ECOLE NATL SUPER ARTS & METIERS,ANGERS,FRANCE	Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Arts et Metiers Institute of Technology	HABIB, N (corresponding author), ROYAL FREE HOSP,DEPT SURG,HEPATOBILIARY & LIVER TRANSPLANTAT UNIT,LONDON NW3 2QG,ENGLAND.								0	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					16	17		10.1016/0140-6736(91)93334-6	http://dx.doi.org/10.1016/0140-6736(91)93334-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670651				2022-12-24	WOS:A1991EQ60400008
J	BONIFACINO, JS; MCCARTHY, SA; MAGUIRE, JE; NAKAYAMA, T; SINGER, DS; KLAUSNER, RD; SINGER, A				BONIFACINO, JS; MCCARTHY, SA; MAGUIRE, JE; NAKAYAMA, T; SINGER, DS; KLAUSNER, RD; SINGER, A			NOVEL POSTTRANSLATIONAL REGULATION OF TCR EXPRESSION IN CD4+ CD8+ THYMOCYTES INFLUENCED BY CD4	NATURE			English	Article									NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BONIFACINO, JS (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.		Nakayama, Toshinori/E-1067-2017	Nakayama, Toshinori/0000-0002-1434-2007; Bonifacino, Juan S./0000-0002-5673-6370				BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; BONIFACINO JS, 1988, J BIOL CHEM, V263, P8965; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; COLLINS MKL, 1985, P NATL ACAD SCI USA, V82, P4503, DOI 10.1073/pnas.82.13.4503; CRISPE IN, 1987, J IMMUNOL, V139, P3585; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FURLEY AJ, 1986, CELL, V46, P75, DOI 10.1016/0092-8674(86)90861-5; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; LANIER LL, 1986, J IMMUNOL, V137, P2501; Maniatis T., 1982, MOL CLONING; MCCARTHY SA, 1988, NATURE, V336, P76, DOI 10.1038/336076a0; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PETTEY CL, 1987, J BIOL CHEM, V262, P4854; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROEHM N, 1984, CELL, V38, P577, DOI 10.1016/0092-8674(84)90512-9; ROYER HD, 1985, P NATL ACAD SCI USA, V82, P5510, DOI 10.1073/pnas.82.16.5510; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SAMELSON LE, 1985, NATURE, V315, P765, DOI 10.1038/315765a0; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDONGEN JJM, 1987, J IMMUNOL, V138, P1260; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	28	76	76	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 15	1990	344	6263					247	251		10.1038/344247a0	http://dx.doi.org/10.1038/344247a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU138	1690353				2022-12-24	WOS:A1990CU13800060
J	BLACHLYDYSON, E; PENG, SZ; COLOMBINI, M; FORTE, M				BLACHLYDYSON, E; PENG, SZ; COLOMBINI, M; FORTE, M			SELECTIVITY CHANGES IN SITE-DIRECTED MUTANTS OF THE VDAC ION CHANNEL - STRUCTURAL IMPLICATIONS	SCIENCE			English	Article									OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; UNIV MARYLAND,DEPT ZOOL,CELL BIOL LABS,COLLEGE PK,MD 20742	Oregon Health & Science University; University System of Maryland; University of Maryland College Park			Colombini, Marco/A-1540-2014		NIGMS NIH HHS [GM35759] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSBERGERMANGAN DM, 1987, J MEMBRANE BIOL, V98, P157, DOI 10.1007/BF01872128; BENZ R, 1989, J BIOENERG BIOMEMBR, V21, P439, DOI 10.1007/BF00762516; BLACHLYDYSON E, 1989, J BIOENERG BIOMEMBR, V21, P471, DOI 10.1007/BF00762519; Colombini M, 1980, Ann N Y Acad Sci, V341, P552, DOI 10.1111/j.1749-6632.1980.tb47198.x; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; Colombini M., 1986, ION CHANNEL RECONSTI, P533; DAUM G, 1982, J BIOL CHEM, V257, P3028; DIHANICH M, 1987, EMBO J, V6, P723, DOI 10.1002/j.1460-2075.1987.tb04813.x; DORING C, 1985, J MEMBRANE BIOL, V83, P81, DOI 10.1007/BF01868740; FORTE M, 1987, J MEMBRANE BIOL, V99, P65, DOI 10.1007/BF01870622; FORTE M, 1987, J BIOENERG BIOMEMBR, V19, P341, DOI 10.1007/BF00768537; FREITAG H, 1982, EUR J BIOCHEM, V123, P629; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; GUO XJ, 1986, YEAST, V2, pS138; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LINDEN M, 1983, BIOCHIM BIOPHYS ACTA, V736, P125, DOI 10.1016/0005-2736(83)90177-3; LINDEN M, 1982, BIOCHEM J, V208, P77, DOI 10.1042/bj2080077; LUDWIG O, 1988, EUR BIOPHYS J BIOPHY, V15, P269, DOI 10.1007/BF00256477; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; ZALMAN LS, 1980, J BIOL CHEM, V255, P1771	31	254	257	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 9	1990	247	4947					1233	1236		10.1126/science.1690454	http://dx.doi.org/10.1126/science.1690454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT096	1690454				2022-12-24	WOS:A1990CT09600046
J	DOLLE, P; CASTRILLO, JL; THEILL, LE; DEERINCK, T; ELLISMAN, M; KARIN, M				DOLLE, P; CASTRILLO, JL; THEILL, LE; DEERINCK, T; ELLISMAN, M; KARIN, M			EXPRESSION OF GHF-1 PROTEIN IN MOUSE PITUITARIES CORRELATES BOTH TEMPORALLY AND SPATIALLY WITH THE ONSET OF GROWTH-HORMONE GENE ACTIVITY	CELL			English	Article									FAC MED STRASBOURG, CNRS, GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE; UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of California System; University of California San Diego; University of California System; University of California San Diego			Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014718] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38527] Funding Source: Medline; NINDS NIH HHS [NS-14718] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BUGNON C, 1974, CR SOC BIOL, V168, P460; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHATELAIN A, 1979, CELL TISSUE RES, V196, P409; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COLOSI P, 1988, MOL ENDOCRINOL, V2, P579, DOI 10.1210/mend-2-6-579; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KARIN M, 1989, TISSUE SPECIFIC GENE; KEMPF J, 1982, MICROSC ACTA, V86, P215; KESSEL M, 1988, NATURE, V332, P117, DOI 10.1038/332117c0; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LEDOUARI.N, 1967, CR ACAD SCI D NAT, V264, P3027; LINZER DIH, 1985, J BIOL CHEM, V260, P9574; LOCKE M, 1966, MAJOR PROBLEMS DEV B; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MCCORMICK A, 1988, CELL, V55, P379, DOI 10.1016/0092-8674(88)90061-X; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; RUGH R, 1968, MOUSE ITS REPRODUCTI; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SETALO G, 1976, ENDOCRINOL EXP, V10, P155; SLABAUGH MB, 1982, ENDOCRINOLOGY, V110, P1489, DOI 10.1210/endo-110-5-1489; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; WATANABE YG, 1979, DEV BIOL, V68, P557, DOI 10.1016/0012-1606(79)90226-4; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	41	210	213	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 9	1990	60	5					809	820		10.1016/0092-8674(90)90095-V	http://dx.doi.org/10.1016/0092-8674(90)90095-V			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CV174	1690079				2022-12-24	WOS:A1990CV17400013
J	MAIONE, TE; GRAY, GS; PETRO, J; HUNT, AJ; DONNER, AL; BAUER, SI; CARSON, HF; SHARPE, RJ				MAIONE, TE; GRAY, GS; PETRO, J; HUNT, AJ; DONNER, AL; BAUER, SI; CARSON, HF; SHARPE, RJ			INHIBITION OF ANGIOGENESIS BY RECOMBINANT HUMAN-PLATELET FACTOR-IV AND RELATED PEPTIDES	SCIENCE			English	Article									HARVARD UNIV, SCH MED, DEPT DERMATOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	MAIONE, TE (corresponding author), REPLIGEN CORP, 1 KENDALL SQ, CAMBRIDGE, MA 02139 USA.							BARBER AJ, 1972, BIOCHIM BIOPHYS ACTA, V286, P312, DOI 10.1016/0304-4165(72)90267-X; BARONE AD, 1988, J BIOL CHEM, V263, P8710; DAMORE PA, 1988, SEMIN THROMB HEMOST, V14, P73, DOI 10.1055/s-2007-1002758; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; DEUEL TF, 1981, P NATL ACAD SCI-BIOL, V78, P4584, DOI 10.1073/pnas.78.7.4584; EISENSTEIN R, 1979, AM J OPHTHALMOL, V88, P1005, DOI 10.1016/0002-9394(79)90406-9; FILES JC, 1981, BLOOD, V58, P607; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1985, Important Adv Oncol, P42; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HORTON JE, 1980, BIOCHIM BIOPHYS ACTA, V630, P459, DOI 10.1016/0304-4165(80)90295-0; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; KATZ IR, 1986, P NATL ACAD SCI USA, V83, P3491, DOI 10.1073/pnas.83.10.3491; LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0; LEVINE SP, 1976, J BIOL CHEM, V251, P324; LUTTY GA, 1983, INVEST OPHTH VIS SCI, V24, P52; MOORE S, 1975, BIOCHIM BIOPHYS ACTA, V379, P370, DOI 10.1016/0005-2795(75)90144-0; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; PONCZ M, 1987, BLOOD, V69, P219; PRESTA M, 1988, HAEMOSTASIS, V18, P6; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SENIOR RM, 1983, J CELL BIOL, V96, P382, DOI 10.1083/jcb.96.2.382; SIDKY YA, 1987, CANCER RES, V47, P5155; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0	26	615	691	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	1990	247	4938					77	79		10.1126/science.1688470	http://dx.doi.org/10.1126/science.1688470			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG620	1688470				2022-12-24	WOS:A1990CG62000040
J	MACMAHON, EME; GLASS, JD; HAYWARD, SD; MANN, RB; BECKER, PS; CHARACHE, P; MCARTHUR, JC; AMBINDER, RF				MACMAHON, EME; GLASS, JD; HAYWARD, SD; MANN, RB; BECKER, PS; CHARACHE, P; MCARTHUR, JC; AMBINDER, RF			EPSTEIN-BARR-VIRUS IN AIDS-RELATED PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; INSITU HYBRIDIZATION; MEMBRANE-PROTEIN; GENE-EXPRESSION; INFECTED-CELLS; EBV; DISORDERS; THERAPY; DISEASE; GENOME	Primary central nervous system lymphoma occurs more often in patients with AIDS. Epstein-Barr virus (EBV) has been detected in these tumours, but the degree of association has not been defined because of both the highly restricted expression of EBV in malignant tissue and the lack of a technique that is reliable in formalin-fixed paraffin-embedded specimens. EBV-transformed lymphocytes contain short non-protein coding EBV transcripts (EBERs), which are expressed in much higher quantity than other EBV-latency transcripts. We describe a new strategy for detection of latent EBV with these transcripts as targets for in-situ hybridisation. 18 cases of AIDS-related primary CNS lymphoma from a consecutive necropsy series together with specimens from 3 further cases were studied. In each case, a strong positive signal over tumour cells indicated abundant expression of the EBV-EBER1 transcript. This 100% association suggests that the pathogenesis of these AIDS-associated lymphomas may differ from the systemic disease in which only 30-50% of tumours are associated with EBV. A pathogenetic role for EBV was further supported by showing expression of a viral protein (the latent membrane protein) that is implicated as an effector for EBV-associated lymphomagenesis. EBV might have a role as a tumour marker in the diagnosis and management of AIDS-related primary CNS lymphoma.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [R01 CA42245, R01 CA55529] Funding Source: Medline; NINDS NIH HHS [NS 07179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042245, R01CA055529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASHIR RM, 1989, NEUROLOGY, V39, P813, DOI 10.1212/WNL.39.6.813; BASHIR RM, 1990, MODERN PATHOL, V3, P429; BAUMGARTNER JE, 1990, J NEUROSURG, V73, P206, DOI 10.3171/jns.1990.73.2.0206; BIRX DL, 1986, NEW ENGL J MED, V314, P874, DOI 10.1056/NEJM198604033141403; CARTUN RW, 1989, J HISTOTECHNOL, V12, P273; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GLICKMAN JN, 1988, J VIROL, V62, P902, DOI 10.1128/JVI.62.3.902-911.1988; HAMILTONDUTOIT SJ, 1991, AM J PATHOL, V138, P149; HANTO DW, 1981, CANCER RES, V41, P4253; HOCHBERG FH, 1988, J NEUROSURG, V68, P835, DOI 10.3171/jns.1988.68.6.0835; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; LAWRENCE JB, 1988, CELL, V52, P51; LERNER MR, 1981, P NATL ACAD SCI USA, V78, P505; NAKHLEH RE, 1991, CANCER, V67, P444, DOI 10.1002/1097-0142(19910115)67:2<444::AID-CNCR2820670221>3.0.CO;2-W; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; ROSENBERG NL, 1986, ANN NEUROL, V20, P98, DOI 10.1002/ana.410200118; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; SHERMAN ME, 1991, AM J CLIN PATHOL, V95, P878, DOI 10.1093/ajcp/95.6.878; SUBAR M, 1988, BLOOD, V72, P667; TOCZYSKI DPW, 1991, EMBO J, V10, P459, DOI 10.1002/j.1460-2075.1991.tb07968.x; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WU TC, 1991, AM J PATHOL, V138, P1461; WU TC, 1990, INT J CANCER, V46, P801, DOI 10.1002/ijc.2910460509; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	26	441	455	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1991	338	8773					969	973		10.1016/0140-6736(91)91837-K	http://dx.doi.org/10.1016/0140-6736(91)91837-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK974	1681341				2022-12-24	WOS:A1991GK97400003
J	LUFKIN, T; DIERICH, A; LEMEUR, M; MARK, M; CHAMBON, P				LUFKIN, T; DIERICH, A; LEMEUR, M; MARK, M; CHAMBON, P			DISRUPTION OF THE HOX-1.6 HOMEOBOX GENE RESULTS IN DEFECTS IN A REGION CORRESPONDING TO ITS ROSTRAL DOMAIN OF EXPRESSION	CELL			English	Article							SEGMENT-SPECIFIC EXPRESSION; CENTRAL-NERVOUS-SYSTEM; MOUSE EMBRYOS; NEURAL CREST; FUNCTIONAL-ORGANIZATION; ANTENNAPEDIA-COMPLEX; INT-1 PROTOONCOGENE; HOMEOTIC GENES; RETINOIC ACID; MURINE	The Hox-1.6 gene disrupted in embryonic stem cells by homologous recombination was introduced into the mouse germline. Heterozygous mice were normal, but homozygous mice died at birth from anoxia and had numerous defects that were centered at the level of rhombomeres 4 to 7 and included delayed hindbrain neural tube closure, absence of certain cranial nerves and ganglia, and malformed inner ears and bones of the skull. Thus, Hox-1.6 is involved in regional specification along the rostrocaudal axis, but only in its most rostral domain of expression. Hox-1.6 appears to specify neurogenic neural crest cells prior to specification of mesenchymal neural crest cells by Hox-1.5. Thus, within the same region of the presumptive hindbrain, two HOX-1 genes are involved in the patterning of two different populations of neural crest cells. The implication of these results for the function of the Hox network during mouse embryogenesis is discussed.			LUFKIN, T (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,INSERM,U184,CNRS, GENET MOLEC LAB, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE.		Lufkin, Thomas/AAG-7476-2019; Lufkin, Thomas/B-5352-2011	Lufkin, Thomas/0000-0002-7902-4771; Lufkin, Thomas/0000-0002-7902-4771				AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; AWGULEWITSCH A, 1986, NATURE, V320, P328, DOI 10.1038/320328a0; BARON A, 1987, EMBO J, V6, P2977, DOI 10.1002/j.1460-2075.1987.tb02603.x; BRADLEY A, 1987, TERATOCARCINOMAS EMB; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; COULY G, 1990, DEVELOPMENT, V108, P543; DAVSON H, 1962, PRINCIPLES HUMAN PHY, P380; DEOL MS, 1966, NATURE, V209, P219, DOI 10.1038/209219a0; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; DO MS, 1988, GENOMICS, V3, P195, DOI 10.1016/0888-7543(88)90079-1; DRESSLER GR, 1989, DIFFERENTIATION, V41, P193, DOI 10.1111/j.1432-0436.1989.tb00747.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1986, NATURE, V324, P662, DOI 10.1038/324662a0; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; Goulding MD, 1989, CURR OPIN CELL BIOL, V1, P1088, DOI 10.1016/S0955-0674(89)80055-9; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HAMILTON WJ, 1946, HUMAN EMBRYOLOGY; HART C P, 1987, Genomics, V1, P182, DOI 10.1016/0888-7543(87)90011-5; HOLLAND PWH, 1988, DEVELOPMENT, V103, P17; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HOLTFRETER J, 1968, EPITHELIAL MESENCHYM, P1; HUNT P, 1991, DEVELOPMENT, V112, P43; HUNT P, 1991, DEVELOPMENT, P187; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; KOCHHAR DM, 1973, TERATOLOGY, V7, P289, DOI 10.1002/tera.1420070310; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEDOUARIN NM, 1986, TRENDS NEUROSCI, V9, P175, DOI 10.1016/0166-2236(86)90055-X; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; MOODY SA, 1983, J COMP NEUROL, V213, P344, DOI 10.1002/cne.902130309; MORRISSKAY G, 1987, TRENDS GENET, V3, P257, DOI 10.1016/0168-9525(87)90260-5; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NICHOLS DH, 1981, J EMBRYOL EXP MORPH, V64, P105; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1988, DEVELOPMENT, V103, P121; REID L, 1990, CELL, V63, P875, DOI 10.1016/0092-8674(90)90491-V; SCHUGHART K, 1989, GENOMICS, V5, P76, DOI 10.1016/0888-7543(89)90089-X; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; STUBBS L, 1990, GENOMICS, V7, P422, DOI 10.1016/0888-7543(90)90177-V; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; Theiler K., 1972, HOUSE MOUSE; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; VANDEWATER TR, 1988, DEVELOPMENT, V103, P185; VERWOERD CDA, 1979, ADV ANATOMY EMBRYOLO, V58; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WRIGHT C, 1991, NATURE, V350, P458, DOI 10.1038/350458a0	67	632	641	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1105	1119		10.1016/0092-8674(91)90034-V	http://dx.doi.org/10.1016/0092-8674(91)90034-V			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1680563				2022-12-24	WOS:A1991GG55200006
J	BROWNER, WS; SEELEY, DG; VOGT, TM; CUMMINGS, SR				BROWNER, WS; SEELEY, DG; VOGT, TM; CUMMINGS, SR			NONTRAUMA MORTALITY IN ELDERLY WOMEN WITH LOW BONE-MINERAL DENSITY	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; STROKE-ASSOCIATED MORTALITY; HIP FRACTURE; LONG-TERM; RISK; THIAZIDE; HYPERTENSION; OSTEOPOROSIS; POPULATION; MENOPAUSE	9704 ambulatory women aged 65 years or older were prospectively studied to determine whether low bone mineral density (osteopenia) was associated with mortality. Bone mineral density was measured at entry to the study by single-photon absorptiometry. 299 women died during a mean of 2.8 years' follow-up. Osteopenia was associated with increased non-trauma mortality, probably because it is a marker for several other adverse factors. Each standard deviation decrease in proximal radius bone mineral density (0.104 g/cm2) was associated with a 1.19-fold increase in mortality (95% confidence interval 1.04-1.36), adjusted for age and duration of follow-up. Diminished bone mineral density at the proximal radius was strongly associated with deaths from stroke (relative risk = 1.74; 95% Cl 1.12-2.70), an association that was not confounded by history of previous stroke, hypertension, postmenopausal use of oestrogen, thiazide diuretic treatment, diabetes mellitus, and smoking. Most deaths in women with low bone mineral density are unrelated to the occurrence of fractures-an observation that should be taken into account when estimating the need for and cost-effectiveness of bone-density screening and fracture prevention programmes.	VET AFFAIRS MED CTR,DEPT MED,GEN INTERNAL MED SECT,SAN FRANCISCO,CA; KAISER PERMANENTE CTR HLTH RES,PORTLAND,OR; UNIV CALIF SAN FRANCISCO,DEPT MED,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	US Department of Veterans Affairs; Veterans Health Administration (VHA); Kaiser Permanente; University of California System; University of California San Francisco	BROWNER, WS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,PREVENT SCI GRP,74 NEW MONTGOMERY,SUITE 600,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05407, AG05394] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AITKEN JM, 1987, OSTEOPOROSIS 1987, P45; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BOHANNON RW, 1986, ARCH PHYS MED REHAB, V67, P390; BRICKMAN AS, 1990, HYPERTENSION, V16, P515, DOI 10.1161/01.HYP.16.5.515; BUKOSKI RD, 1990, HYPERTENSION, V16, P523, DOI 10.1161/01.HYP.16.5.523; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Callaway CW., 1988, ANTHROPOMETRIC STAND, P39; CAULEY JA, 1990, AM J EPIDEMIOL, V132, P884, DOI 10.1093/oxfordjournals.aje.a115731; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DYKEN ML, 1985, 71022A AM HEART ASS; ETTINGER B, 1988, MATURITAS, V10, P271, DOI 10.1016/0378-5122(88)90063-1; FELSON DT, 1991, JAMA-J AM MED ASSOC, V265, P370, DOI 10.1001/jama.265.3.370; FRANKS AL, 1987, AM J OBSTET GYNECOL, V156, P20, DOI 10.1016/0002-9378(87)90196-7; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON BE, 1988, FERTIL STERIL, V49, pS9; JACOBSEN SJ, 1990, AM J EPIDEMIOL, V132, P755; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KHAW KT, 1984, STROKE, V15, P244, DOI 10.1161/01.STR.15.2.244; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LINDSAY R, 1976, LANCET, V1, P1038; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; SCRAGG R, 1990, INT J EPIDEMIOL, V19, P559, DOI 10.1093/ije/19.3.559; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; 1980, INT CLASSIFICATION D, V1	31	337	348	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					355	358		10.1016/0140-6736(91)90489-C	http://dx.doi.org/10.1016/0140-6736(91)90489-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677708				2022-12-24	WOS:A1991GA60700014
J	ROSENSTOCK, L; KEIFER, M; DANIELL, WE; MCCONNELL, R; CLAYPOOLE, K				ROSENSTOCK, L; KEIFER, M; DANIELL, WE; MCCONNELL, R; CLAYPOOLE, K			CHRONIC CENTRAL-NERVOUS-SYSTEM EFFECTS OF ACUTE ORGANOPHOSPHATE PESTICIDE INTOXICATION	LANCET			English	Article							HEALTH	Acute organophosphate pesticide poisonings cause substantial morbidity and mortality world wide; however, whether organophosphates cause chronic neurological sequelae has not been established. To see whether single episodes of acute unintentional organophosphate intoxication lead to chronic neuropsychological dysfunction, we carried out a retrospective study of agricultural workers in Nicaragua who had been admitted to hospital between July 1, 1986, and July 31, 1988, for occupationally related organophosphate intoxication. This "poisoned" group (36 men) was tested on average about two years after the episode of pesticide poisoning and compared with a matched control group. The poisoned group did much worse than the control group on all neuropsychological subtests, with significantly worse performance on five of six subtests of a World Health Organisation neuropsychological test battery and on 3 of 6 additional tests that assessed verbal and visual attention, visual memory, visuomotor speed, sequencing and problem solving, and motor steadiness and dexterity. Differences in neuropsychological performance could not be explained by other factors. The findings of a persistent decrease in neuropsychological performance among individuals with previous intoxication emphasise the importance of prevention of even single episodes of organophosphate poisoning.	UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,MT SINAI SCH MED,DIV OCCUPAT & ENVIRONM HLTH,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Icahn School of Medicine at Mount Sinai; University of Washington; University of Washington Seattle	ROSENSTOCK, L (corresponding author), UNIV WASHINGTON,OCCUPAT MED PROGRAM,ZA-66,SEATTLE,WA 98195, USA.							[Anonymous], 1990, PUBLIC HLTH IMPACT P; BURCHFIEL JL, 1976, TOXICOL APPL PHARM, V35, P365, DOI 10.1016/0041-008X(76)90296-9; COSTA LG, 1988, RECENT ADV NERVOUS S; Coye M J, 1985, J Public Health Policy, V6, P349, DOI 10.2307/3342402; Derogatis L.R., 1982, BRIEF SYMPTOM INDEX; DILLE JR, 1964, AEROSPACE MED, V35, P475; DUFFY FH, 1979, TOXICOL APPL PHARM, V47, P161, DOI 10.1016/0041-008X(79)90083-8; DURHAM WF, 1965, ARCH ENVIRON HEALTH, V10, P55, DOI 10.1080/00039896.1965.10663953; ESKANAZI B, 1988, MED NEUROPSYCHOLOGY, P223; GERCHON S, 1961, LANCET, V1, P1371; Hogstedt C, 1984, BIOL MONITORING SURV; HOLMES JH, 1957, T AM CLIN CLIMAT ASS, V68, P86; JEYARATNAM J, 1990, World Health Statistics Quarterly, V43, P139; JEYARATNAM J, 1985, SCAND J WORK ENV HEA, V11, P229, DOI 10.5271/sjweh.2230; JEYARATNAM J, 1985, BRIT J IND MED, V42, P505; KARCZMAR AG, 1984, FUND APPL TOXICOL, V4, pS1, DOI 10.1016/0272-0590(84)90133-7; LEWIS R, 1977, ANN M SE PSYCHOL ASS; MARONI M, 1986, TOXICOL LETT, V33, P115, DOI 10.1016/0378-4274(86)90076-7; MCCONNELL R, 1990, AM J PUBLIC HEALTH, V80, P1236, DOI 10.2105/AJPH.80.10.1236; Metcalf D R, 1969, Ann N Y Acad Sci, V160, P357, DOI 10.1111/j.1749-6632.1969.tb15857.x; MIDTLING JE, 1985, WESTERN J MED, V142, P514; Murphy DS, 1986, CASARETT DOULLS TOXI, P519; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan R. M., 1985, HALSTEAD REITAN NEUR, V4; Rey A, 1964, LEXAMEN CLINIQUE PSY; Rosenstock L., 1987, Toxicology of pesticides: experimental, clinical and regulatory perspectives., P197; SAVAGE EP, 1988, ARCH ENVIRON HEALTH, V43, P38, DOI 10.1080/00039896.1988.9934372; SENANAYAKE N, 1987, NEW ENGL J MED, V316, P761, DOI 10.1056/NEJM198703263161301; TABERSHAW IR, 1966, JOM-J OCCUP MED, V8, P5; Wechsler D., 1997, WAIS 3 WECHSLER ADUL, V3rd, DOI 10.1111/j.1749-6632.1989.tb21005.x; 1986, OPERATIONAL GUIDE WH; 1986, WHOVBC86926	32	364	381	0	29	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					223	227		10.1016/0140-6736(91)90356-T	http://dx.doi.org/10.1016/0140-6736(91)90356-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676786				2022-12-24	WOS:A1991FY50400011
J	DREWS, GN; BOWMAN, JL; MEYEROWITZ, EM				DREWS, GN; BOWMAN, JL; MEYEROWITZ, EM			NEGATIVE REGULATION OF THE ARABIDOPSIS HOMEOTIC GENE AGAMOUS BY THE APETALA2 PRODUCT	CELL			English	Article							FLOWER DEVELOPMENT; FLORAL DEVELOPMENT; ULTRABITHORAX TRANSCRIPTS; DROSOPHILA EMBRYOS; SPATIAL EXPRESSION; BITHORAX COMPLEX; ANTENNAPEDIA; THALIANA; PATTERN; PROTEIN	We characterized the distribution of AGAMOUS (AG) RNA during early flower development in Arabidopsis. Mutations in this homeotic gene cause the transformation of stamens to petals in floral whorl 3 and of carpels to another ag flower in floral whorl 4. We found that AG RNA is present in the stamen and carpel primordia but is undetectable in sepal and petal primordia throughout early wild-type flower development, consistent with the mutant phenotype. We also analyzed the distribution of AG RNA in apetela2 (ap2) mutant flowers. AP2 is a floral homeotic gene that is necessary for the normal development of sepals and petals in floral whorls 1 and 2. In ap2 mutant flowers, AG RNA is present in the organ primordia of all floral whorls. These observations show that the expression patterns of the Arabidopsis floral homeotic genes are in part established by regulatory interactions between these genes.			DREWS, GN (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Meyerowitz, Elliot M/A-7118-2009	Bowman, John/0000-0001-7347-3691	NIGMS NIH HHS [GM13100-03, 5T32-GM07616] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013100, T32GM007616] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM ME, 1983, EMBO J, V2, P2075, DOI 10.1002/j.1460-2075.1983.tb01703.x; AKAM ME, 1985, EMBO J, V4, P1689, DOI 10.1002/j.1460-2075.1985.tb03838.x; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BLASER HW, 1950, AM J BOT, V37, P297, DOI 10.2307/2437850; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1991, IN PRESS S SOC EXPT, V44; BOWMAN JL, 1991, IN PRESS DEVELOPMENT; BOWMAN JL, 1988, OXFORD SURV PLANT MO, V5, P57; CARROLL SB, 1986, CELL, V47, P113, DOI 10.1016/0092-8674(86)90372-7; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DERMEN H, 1947, AM J BOT, V34, P32, DOI 10.2307/2437192; DERMEN H, 1973, AM J BOT, V60, P283, DOI 10.2307/2441220; HAFEN E, 1984, NATURE, V307, P287, DOI 10.1038/307287a0; HARDING K, 1985, SCIENCE, V229, P1236, DOI 10.1126/science.3898362; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; INGHAM PW, 1986, NATURE, V324, P592, DOI 10.1038/324592a0; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; JACK T, 1990, EMBO J, V9, P1187, DOI 10.1002/j.1460-2075.1990.tb08226.x; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; LEVINE M, 1983, EMBO J, V2, P2037, DOI 10.1002/j.1460-2075.1983.tb01697.x; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1991, IN PRESS DEVELOPME S; Pruitt RE, 1987, GENETIC REGULATION D, P327; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; Satina S, 1941, AM J BOT, V28, P862, DOI 10.2307/2436864; Satina S, 1944, AM J BOT, V31, P493, DOI 10.2307/2437412; Satina S, 1940, AM J BOT, V27, P895, DOI 10.2307/2436558; Satina S, 1943, AM J BOT, V30, P453, DOI 10.2307/2437281; SATINA S, 1945, AM J BOT, V32, P72, DOI 10.2307/2437113; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	38	522	576	6	85	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					991	1002		10.1016/0092-8674(91)90551-9	http://dx.doi.org/10.1016/0092-8674(91)90551-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1675158				2022-12-24	WOS:A1991FR04700010
J	BRAVERMAN, AS				BRAVERMAN, AS			MEDICAL ONCOLOGY IN THE 1990S	LANCET			English	Editorial Material											BRAVERMAN, AS (corresponding author), SUNY HLTH SCI CTR,DEPT MED,DIV HEMATOL ONCOL,BOX 55,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; CHABNER BA, 1986, J CLIN ONCOL, V4, P625	2	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					901	902		10.1016/0140-6736(91)90218-E	http://dx.doi.org/10.1016/0140-6736(91)90218-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672980				2022-12-24	WOS:A1991FG04800015
J	[Anonymous]				[Anonymous]			THE HIV CATCH-22	LANCET			English	Editorial Material																		ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; ANDERSON RM, 1991, NATURE, V350, P356, DOI 10.1038/350356a0; RILEY VC, 1991, LANCET, V337, P183, DOI 10.1016/0140-6736(91)90853-H; 1990, LANCET, V336, P1501; 1990, LANCET, V335, P821	5	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					843	843						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672926				2022-12-24	WOS:A1991FF22800018
J	FIRTH, HV; BOYD, PA; CHAMBERLAIN, P; MACKENZIE, IZ; LINDENBAUM, RH; HUSON, SM				FIRTH, HV; BOYD, PA; CHAMBERLAIN, P; MACKENZIE, IZ; LINDENBAUM, RH; HUSON, SM			SEVERE LIMB ABNORMALITIES AFTER CHORION VILLUS SAMPLING AT 56-66 DAYS GESTATION	LANCET			English	Note								Among 289 pregnancies in which chorion villus sampling (CVS) was carried out at 56-66 days' gestation, 5 babies with severe limb abnormalities were subsequently identified. 4 had oromandibular-limb hypogenesis syndromes, and the other had a terminal transverse limb reduction defect. This high incidence raises the possibility that CVS was an aetiological factor for these developmental anomalies.	JOHN RADCLIFFE MATERN HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD,ENGLAND		FIRTH, HV (corresponding author), CHURCHILL HOSP,DEPT MED GENET,OXFORD OX3 7LJ,ENGLAND.							BOUWESBAVINCK JN, 1986, AM J MED GENET, V23, P903, DOI 10.1002/ajmg.1320230405; BOYD PA, 1990, PRENATAL DIAG, V10, P437, DOI 10.1002/pd.1970100705; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; GORLIN RJ, 1990, OXFORD MONOGRAPHS ME, V19, P666; HOYME HE, 1982, J PEDIATR-US, V101, P839, DOI 10.1016/S0022-3476(82)80343-0; JONES KL, 1988, SMITHS RECOGNISABLE, P588; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; WEBSTER WS, 1988, TERATOLOGY, V38, pA199; 1990, MB34 OFF POP CENS SU; 1991, MB35 OFF POP CENS SU	11	270	280	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					762	763		10.1016/0140-6736(91)91374-4	http://dx.doi.org/10.1016/0140-6736(91)91374-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672394				2022-12-24	WOS:A1991FD88400006
J	MILES, KA; HAYBALL, M; DIXON, AK				MILES, KA; HAYBALL, M; DIXON, AK			COLOR PERFUSION IMAGING - A NEW APPLICATION OF COMPUTED-TOMOGRAPHY	LANCET			English	Note							BLOOD-FLOW	We describe a new application for imaging with computed tomography (CT) in which a quantifiable map of tissue perfusion is created and displayed by means of a colour scale. A rapid sequence of images is acquired without table movement immediately after a bolus intravenous injection of radiographic contrast medium. The rate of enhancement in each pixel within the chosen slice can then be used to determine perfusion. The technique provides a quantifiable display of regional perfusion combined with the high spatial resolution afforded by CT.	ADDENBROOKES HOSP,DEPT NUCL MED,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES HOSP,DEPT MED PHYS,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	MILES, KA (corresponding author), ADDENBROOKES HOSP,DEPT RADIOL,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.			Miles, Kenneth/0000-0002-5920-381X				AXEL L, 1979, INVEST RADIOL, V14, P389; Hindmarsh T, 1975, Acta Radiol Suppl, V346, P45; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; MILES KA, 1990, BRIT J RADIOL, V63, P991; MILES KA, IN PRESS BR J RADIOL; PETERS AM, 1987, CARDIOVASC RES, V21, P830, DOI 10.1093/cvr/21.11.830; PETERS AM, 1987, NUCL MED COMMUN, V8, P823, DOI 10.1097/00006231-198710000-00009; RUSSELL SB, 1974, BRIT J RADIOL, V47, P268, DOI 10.1259/0007-1285-47-557-268	8	136	215	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					643	645		10.1016/0140-6736(91)92455-B	http://dx.doi.org/10.1016/0140-6736(91)92455-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1671994				2022-12-24	WOS:A1991FB73000006
J	RAVINE, D; WALKER, RG; GIBSON, RN; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM				RAVINE, D; WALKER, RG; GIBSON, RN; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM			TREATABLE COMPLICATIONS IN UNDIAGNOSED CASES OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE	LANCET			English	Article							INTRACRANIAL ANEURYSMS; BLOOD-PRESSURE; PROGRESSION; DIAGNOSIS; ONSET	In a study to determine the proportion of unrecognised cases and the prevalence of treatable complications of autosomal dominant polycystic kidney disease (ADPKD), 46 probands were identified through genetics and renal clinics in Melbourne, Australia. 321 offspring of the probands who were older than 15 years and had not been previously diagnosed as having ADPKD were identified. 68 (21%) had ultrasound evidence of polycystic kidney disease. Of this previously undiagnosed group, 25 (37%) had one or more treatable complications at the time of diagnosis. The complications included 20 cases of hypertension (diastolic blood pressure 95 mm Hg or above), 7 cases of impaired renal function (serum creatinine 0.12 mmol/l or above), and 4 cases of bacterial urinary tract infection. 8 people had several complications. ADPKD has an important treatable component which is not being treated in a substantial proportion of affected individuals, because the disease is not being diagnosed despite the presence of a positive family history.	UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT RADIOL,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT NEPHROL,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; University of Melbourne	RAVINE, D (corresponding author), ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA.		Ravine, David/A-6797-2008					BALDWIN DS, 1985, HYPERTENSION KIDNEY, pA57; BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BERGSTROM J, 1986, CLIN NEPHROL, V25, P1; CHURCHILL DN, 1984, KIDNEY INT, V26, P190, DOI 10.1038/ki.1984.154; COLEMAN AJ, 1966, J CLIN INVEST, V45, P1116, DOI 10.1172/JCI105418; DALGAARD O. Z., 1957, ACTA MED SCAND SUPPL, V158, P1; DISNEY APS, 1990, 13TH AUSTR NZ COMB D, P22; GARDNER KD, 1984, KIDNEY INT, V25, P244; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; KANNEL WB, 1976, STROKE, V7, P327, DOI 10.1161/01.STR.7.4.327; LEVEY AS, 1983, NEW ENGL J MED, V308, P986, DOI 10.1056/NEJM198304283081702; MCNAMARA JJ, 1965, AM J SURG, V109, P178; MILUTINOVIC J, 1980, AM J CLIN PATHOL, V73, P740; REEDERS ST, 1989, CLIN CHEM, V35, pB13; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; RYU SJ, 1990, STROKE, V21, P291, DOI 10.1161/01.STR.21.2.291; SIMON HB, 1955, JAMA-J AM MED ASSOC, V159, P657, DOI 10.1001/jama.1955.02960240023006; Tufveson G, 1989, NEPHROL DIAL TRAN S4, V4, P5; WAKABAYASHI T, 1983, J NEUROSURG, V58, P488, DOI 10.3171/jns.1983.58.4.0488; WERDER AA, 1984, J LAB CLIN MED, V103, P399; ZEIER M, 1988, NEPHRON, V49, P177, DOI 10.1159/000185052	22	22	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					127	129		10.1016/0140-6736(91)90797-S	http://dx.doi.org/10.1016/0140-6736(91)90797-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670785				2022-12-24	WOS:A1991ET67900001
J	KEW, MC; HOUGHTON, M; CHOO, QL; KUO, G				KEW, MC; HOUGHTON, M; CHOO, QL; KUO, G			HEPATITIS-C VIRUS-ANTIBODIES IN SOUTHERN AFRICAN BLACKS WITH HEPATOCELLULAR-CARCINOMA	LANCET			English	Article									CHIRON CORP,EMERYVILLE,CA	Novartis	KEW, MC (corresponding author), UNIV WITWATERSRAND,DEPT MED,7 YORK RD,JOHANNESBURG 2193,SOUTH AFRICA.			Houghton, Michael/0000-0003-3762-6771				BRUIX J, 1989, LANCET, V2, P1004; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; ESTEBAN JI, 1989, LANCET, V2, P294; KEW MC, 1982, MEDICINE, V61, P98, DOI 10.1097/00005792-198203000-00004; KEW MC, 1989, GASTROENTEROLOGY, V97, P136, DOI 10.1016/0016-5085(89)91426-1; KEW MC, 1984, SEMIN LIVER DIS, V4, P136, DOI 10.1055/s-2008-1040653; KEW MC, 1986, CANCER SURV, V5, P719; KEW MC, 1981, HEPATOLOGY, V1, P366, DOI 10.1002/hep.1840010415; KEW MC, 1984, BRIT MED J, V288, P1727, DOI 10.1136/bmj.288.6432.1727; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; PATERSON AC, 1985, HEPATOLOGY, V5, P72, DOI 10.1002/hep.1840050116	12	252	253	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 14	1990	335	8694					873	874		10.1016/0140-6736(90)90474-J	http://dx.doi.org/10.1016/0140-6736(90)90474-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CZ135	1691422				2022-12-24	WOS:A1990CZ13500002
J	WHITE, MB; AMOS, J; HSU, JMC; GERRARD, B; FINN, P; DEAN, M				WHITE, MB; AMOS, J; HSU, JMC; GERRARD, B; FINN, P; DEAN, M			A FRAME-SHIFT MUTATION IN THE CYSTIC-FIBROSIS GENE	NATURE			English	Article									BOSTON UNIV,MED CTR,BOSTON,MA; WAYNE STATE UNIV,SCH MED,DETROIT,MI 48201	Boston University; Wayne State University	WHITE, MB (corresponding author), NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701, USA.		Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; 				AMOS JA, 1989, CLIN INVEST MED, V13, P1; BARTELS I, 1986, AM J HUM GENET, V38, P280; BOAT TF, 1987, METABOLIC BASIS INHE, P2649; DEAN M, 1988, Genomics, V3, P93, DOI 10.1016/0888-7543(88)90138-3; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DISANTAGNESE PA, 1962, ANN NY ACAD SCI, V93, P555; ESTIVILL X, 1986, HUM GENET, V74, P320; ESTIVILL X, 1989, AM J HUM GENET, V44, P704; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; IANNUZZI MC, 1989, AM J HUM GENET, V44, P695; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LATHROP GM, 1988, AM J HUM GENET, V42, P38; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LITT M, 1989, AM J HUM GENET, V44, P397; Maniatis T., 1982, MOL CLONING; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENSTEIN BJ, 1984, CYSTIC FIBROSIS, P85; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TSUI LC, 1985, SCIENCE, V230, P1054, DOI 10.1126/science.2997931; WAINWRIGHT BJ, 1985, NATURE, V318, P384, DOI 10.1038/318384a0; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; WOLFF RK, 1988, GENOMICS, V3, P347, DOI 10.1016/0888-7543(88)90126-7	26	99	106	1	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 12	1990	344	6267					665	667		10.1038/344665a0	http://dx.doi.org/10.1038/344665a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY719	1691449				2022-12-24	WOS:A1990CY71900088
J	BACHMANN, M; PFEIFER, K; SCHRODER, HC; MULLER, WEG				BACHMANN, M; PFEIFER, K; SCHRODER, HC; MULLER, WEG			CHARACTERIZATION OF THE AUTOANTIGEN-LA AS A NUCLEIC-ACID DEPENDENT ATPASE DATPASE WITH MELTING PROPERTIES	CELL			English	Article											BACHMANN, M (corresponding author), UNIV MAINZ,INST PHYSIOL CHEM,DUESBERGWEG 6,W-6500 MAINZ,GERMANY.		Bachmann, Michael/AAA-5153-2020; Bachmann, Michael P/E-8850-2010; Müller, W. E. G./AAR-8651-2020	Bachmann, Michael/0000-0002-8029-5755; Bachmann, Michael P/0000-0002-8029-5755; Müller, W. E. G./0000-0002-8223-3689; Schroder, Heinz C./0000-0003-0992-6427				AKIZUKI M, 1977, J IMMUNOL, V119, P932; BACHMANN M, 1983, EUR J BIOCHEM, V136, P447, DOI 10.1111/j.1432-1033.1983.tb07762.x; BACHMANN M, 1988, CELL BIOL INT REP, V12, P765, DOI 10.1016/0309-1651(88)90088-4; BACHMANN M, 1989, MOL CELL BIOCHEM, V85, P103, DOI 10.1007/BF00577106; BACHMANN M, 1983, J BIOL CHEM, V258, P7033; BACHMANN M, 1989, J GEN VIROL, V70, P881, DOI 10.1099/0022-1317-70-4-881; BACHMANN M, 1986, BIOL CHEM H-S, V367, P671, DOI 10.1515/bchm3.1986.367.2.671; BACHMANN M, 1987, MOL BIOL REP, V12, P239, DOI 10.1007/BF00356918; BACHMANN M, 1986, P NATL ACAD SCI USA, V83, P7770, DOI 10.1073/pnas.83.20.7770; BACHMANN M, 1987, BIOCHEM J, V243, P189, DOI 10.1042/bj2430189; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLANCHARD KL, 1983, J BIOL CHEM, V258, P4091; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CARMOFONSECA M, 1989, EXP CELL RES, V185, P73, DOI 10.1016/0014-4827(89)90038-4; CHAMBERS JC, 1983, J BIOL CHEM, V258, P1438; CHAN EK, 1986, J IMMUNOL, V15, P3744; DAHLBERG JE, 1988, STRUCTURE FUNCTION M, P39; GALE A, 1986, ADV RHEUMATOL, V70, P237; GOTTLIEB E, 1987, MOL BIOL REP, V12, P243, DOI 10.1007/BF00356921; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; GRAMZOW M, 1986, J CELL BIOL, V102, P1344, DOI 10.1083/jcb.102.4.1344; GUIMARES RC, 1981, REV BRAS GENET 4, V3, P245; HAMELIN R, 1986, VIROLOGY, V152, P87, DOI 10.1016/0042-6822(86)90374-0; HARADA F, 1979, NUCLEIC ACIDS RES, V7, P909, DOI 10.1093/nar/7.4.909; HARADA F, 1980, NUCLEIC ACIDS RES, V8, P1273, DOI 10.1093/nar/8.6.1273; HARDIN JA, 1985, CLIN RHEUM DIS, V11, P485; HEYWOOD SM, 1986, NUCLEIC ACIDS RES, V14, P6771, DOI 10.1093/nar/14.16.6771; HOCH SO, 1984, J IMMUNOL, V133, P1397; HORI H, 1979, P NATL ACAD SCI USA, V76, P381, DOI 10.1073/pnas.76.1.381; JELINEK W, 1978, CELL, V15, P205, DOI 10.1016/0092-8674(78)90095-8; KATO N, 1982, BIOCHEM BIOPH RES CO, V99, P1477; KURATA N, 1976, ARTHRITIS RHEUM, V19, P574, DOI 10.1002/art.1780190309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; MADORE SJ, 1984, J BIOL CHEM, V259, P1929; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; MCNEILAGE LJ, 1984, J IMMUNOL METHODS, V66, P253, DOI 10.1016/0022-1759(84)90336-3; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RAUH AJG, 1988, EUR J IMMUNOL, V18, P2049, DOI 10.1002/eji.1830181227; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHRODER HC, 1986, J BIOL CHEM, V261, P663; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STUDIER FW, 1965, J MOL BIOL, V11, P373, DOI 10.1016/S0022-2836(65)80064-X; VENABLES PJW, 1983, CLIN EXP IMMUNOL, V54, P731	47	104	106	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1990	60	1					85	93		10.1016/0092-8674(90)90718-T	http://dx.doi.org/10.1016/0092-8674(90)90718-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CJ358	1688513				2022-12-24	WOS:A1990CJ35800011
J	RIGAUD, G; ROUX, J; PICTET, R; GRANGE, T				RIGAUD, G; ROUX, J; PICTET, R; GRANGE, T			INVIVO FOOTPRINTING OF RAT TAT GENE - DYNAMIC INTERPLAY BETWEEN THE GLUCOCORTICOID RECEPTOR AND A LIVER-SPECIFIC FACTOR	CELL			English	Article							TYROSINE AMINOTRANSFERASE GENE; STEROID-DEPENDENT INTERACTION; TRANSCRIPTION FACTORS; MMTV PROMOTER; TRYPTOPHAN OXYGENASE; ENHANCER SEQUENCES; NUCLEAR FACTOR; BINDING-SITE; DNA-BINDING; HORMONE	HNF5, a liver-specific DNA-binding protein, interacts with DNA in a manner that allows DNAase I cleavage in the middle of its recognition sequence. Using this property we have identified in vivo HNF5 bound to its sites within two glucocorticoid-responsive units of the rat tyrosine aminotransferase (TAT) gene. One HNF5-binding site is also a glucocorticoid receptor-binding site; glucocorticoid-dependent HNF5 binding could be detected at this site even though it is incompatible with glucocorticoid receptor binding. HNF5 binds within 10 min of hormone addition, indicating that it participates in transcriptional activation. In the TAT gene glucocorticoid-dependent HNF5 binding occurs where there is glucocorticoid-dependent disruption of nucleosomal structure; constitutive binding occurs in constitutively disrupted regions. These results suggest a hit-and-run mechanism of transcriptional activation by glucocorticoid receptor: the activated receptor binds its target sequence, modifies local chromatin structure, then leaves its site accessible to another factor.			RIGAUD, G (corresponding author), UNIV PARIS 07,CNRS,INST JACQUES MONOD,TOUR 43,2 PL JUSSIEU,F-75251 PARIS 05,FRANCE.			Grange, Thierry/0000-0001-8700-3092				ALTSCHMIED J, 1989, NUCLEIC ACIDS RES, V17, P4975, DOI 10.1093/nar/17.13.4975; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BAKKER O, 1988, MOL CELL BIOL, V8, P4557, DOI 10.1128/MCB.8.10.4557; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CORDINGLEY MG, 1988, NUCLEIC ACIDS RES, V16, P609, DOI 10.1093/nar/16.2.609; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; GRANGE T, 1989, EXP CELL RES, V180, P220, DOI 10.1016/0014-4827(89)90226-7; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRANNER DK, 1983, MOL CELL BIOCHEM, V53-4, P113; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACKSON DA, 1988, J CELL SCI, V90, P365; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ODDOS J, 1989, NUCLEIC ACIDS RES, V17, P8877, DOI 10.1093/nar/17.21.8877; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHERER G, 1982, P NATL ACAD SCI-BIOL, V79, P7205, DOI 10.1073/pnas.79.23.7205; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TANGUAY RL, 1990, NUCLEIC ACIDS RES, V18, P5902, DOI 10.1093/nar/18.19.5902; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WIJNHOLDS J, 1991, NUCLEIC ACIDS RES, V19, P33, DOI 10.1093/nar/19.1.33; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	47	244	244	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					977	986		10.1016/0092-8674(91)90370-E	http://dx.doi.org/10.1016/0092-8674(91)90370-E			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1683601				2022-12-24	WOS:A1991GT75500016
J	LIN, HY; HARRIS, TL; FLANNERY, MS; ARUFFO, A; KAJI, EH; GORN, A; KOLAKOWSKI, LF; LODISH, HF; GOLDRING, SR				LIN, HY; HARRIS, TL; FLANNERY, MS; ARUFFO, A; KAJI, EH; GORN, A; KOLAKOWSKI, LF; LODISH, HF; GOLDRING, SR			EXPRESSION CLONING OF AN ADENYLATE-CYCLASE COUPLED CALCITONIN RECEPTOR	SCIENCE			English	Article							G-PROTEINS	A calcitonin receptor complementary DNA (cDNA) was cloned by expression of a cDNA library from a porcine kidney epithelial cell line in COS cells. The 482-amino acid receptor has high affinity for salmon calcitonin (dissociation constant K(d) almost-equal-to 6 nM) and is functionally coupled to increases in intracellular cyclic adenosine monophosphate (cAMP). The receptor shows no sequence similarity to other reported G protein-coupled receptors but is homologous to the parathyroid hormone-parathyroid hormone-related peptide (PTH-PTHrP) receptor, indicating that the receptors for these hormones, which regulate calcium homeostasis, represent a new family of G protein-coupled receptors.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, MED SERV, ARTHRIT UNIT, BOSTON, MA 02114 USA; NEW ENGLAND DEACONESS HOSP, BOSTON, MA 02215 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital					NHLBI NIH HHS [HL-41484] Funding Source: Medline; NIADDK NIH HHS [AM 03564] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P01AM003564] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; COPP DH, 1962, ENDOCRINOLOGY, V70, P638, DOI 10.1210/endo-70-5-638; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOLDRING SR, 1978, BIOCHEM BIOPH RES CO, V83, P434, DOI 10.1016/0006-291X(78)91009-4; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOWALSKI LF, UNPUB; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LOREAU N, 1978, J ENDOCRINOL, V76, P533, DOI 10.1677/joe.0.0760533; MURAD F, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P446, DOI 10.1073/pnas.65.2.446; Sambrook J., 1989, MOL CLONING LAB MANU; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473	19	433	469	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1991	254	5034					1022	1024		10.1126/science.1658940	http://dx.doi.org/10.1126/science.1658940			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1658940				2022-12-24	WOS:A1991GP88300050
J	RUDENSKY, AY; PRESTONHURLBURT, P; HONG, SC; BARLOW, A; JANEWAY, CA				RUDENSKY, AY; PRESTONHURLBURT, P; HONG, SC; BARLOW, A; JANEWAY, CA			SEQUENCE-ANALYSIS OF PEPTIDES BOUND TO MHC CLASS-II MOLECULES	NATURE			English	Article							ANTIGEN-BINDING SITE; T-CELL RECOGNITION; HISTOCOMPATIBILITY MOLECULES; MONOCLONAL-ANTIBODIES; IA; SPECIFICITY; COMPLEX; CLONES; CHAIN; RESTRICTION	CD4 T cells recognize peptide fragments of foreign proteins bound to self class II molecules of the major histocompatibility complex (MHC). Naturally processed peptide fragments bound to MHC class II molecules are peptides of 13-17 amino acids which appear to be precessively truncated from the carboxy terminus, perhaps after binding to the MHC class II molecule. The finding of predominant self peptides has interesting implications for antigen processing and self-non-self discrimination.	YALE UNIV,SCH MED,PSYCHOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								ACHAORBEA H, 1987, P NATL ACAD SCI USA, V84, P2435, DOI 10.1073/pnas.84.8.2435; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BENOIST C, 1991, Current Biology, V1, P143, DOI 10.1016/0960-9822(91)90213-G; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Briner T. J., 1987, T CELL RECEPTORS, P309; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CEASE KB, 1986, J EXP MED, V164, P1779, DOI 10.1084/jem.164.5.1779; CRESSWELL P, 1989, COLD SH Q B, V54, P309; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINNEGAN A, 1986, J EXP MED, V164, P897, DOI 10.1084/jem.164.3.897; FOX BS, 1988, NATURE, V331, P538, DOI 10.1038/331538a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; M/ller G., 1988, IMMUNOL REV, V98, P1; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; R/tzschke O., 1990, NATURE, V348, P253; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SRINIVASAN M, 1990, P NATL ACAD SCI USA, V87, P919, DOI 10.1073/pnas.87.3.919; Stone K. L., 1988, MACROMOLECULAR SEQUE, P7; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAKAHASHI H, 1989, J IMMUNOL, V142, P2221; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANBLEEK GM, 1990, NATURE, V348, P213; vonBoehmer H., 1989, IMMUNOL TODAY, V10, P61; WATTS TH, 1984, P NATL ACAD SCI-BIOL, V81, P7564, DOI 10.1073/pnas.81.23.7564; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	49	1016	1062	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					622	627		10.1038/353622a0	http://dx.doi.org/10.1038/353622a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1656276				2022-12-24	WOS:A1991GK67200057
J	MATSUBARA, Y; NARISAWA, K; TADA, K; IKEDA, H; YAO, YQ; DANKS, DM; GREEN, A; MCCABE, ERB				MATSUBARA, Y; NARISAWA, K; TADA, K; IKEDA, H; YAO, YQ; DANKS, DM; GREEN, A; MCCABE, ERB			PREVALENCE OF K329E MUTATION IN MEDIUM-CHAIN ACYL-COA DEHYDROGENASE GENE DETERMINED FROM GUTHRIE CARDS	LANCET			English	Article							DEFICIENCY; DIAGNOSIS	Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is an autosomal recessive disorder that has been associated with sudden infant death syndrome and a condition resembling Reye's syndrome. The point mutation K329E is thought to be the commonest mutation causing MCAD deficiency in caucasian patients. The prevalence of this mutation was determined by use of dried blood spots on Guthrie cards obtained during neonatal screening programmes. 12 carriers were identified among 479 newborn babies in Britain, 5 among 353 in Australia, and 5 among 536 in North America but none among 500 in Japan. Since presymptomatic diagnosis and appropriate dietary management can prevent life-threatening episodes in MCAD deficiency, population-based DNA screening for this potentially fatal disorder might be justified in countries with a high frequency of this mutation.	TOHOKU UNIV,SCH MED,DEPT PEDIAT,SENDAI,MIYAGI 980,JAPAN; ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA; HOLLYMOOR HOSP,W MIDLANDS REG NEONATAL SCREENING LAB,BIRMINGHAM,ENGLAND; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Tohoku University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Baylor College of Medicine; Baylor College of Medicine	MATSUBARA, Y (corresponding author), TOHOKU UNIV,SCH MED,DEPT BIOCHEM GENET,1-1 SEIRYOMACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN.							BLAKEMORE AIF, 1991, LANCET, V337, P298, DOI 10.1016/0140-6736(91)90907-7; JINKS DC, 1989, HUM GENET, V81, P363, DOI 10.1007/BF00283692; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; MATSUBARA Y, 1990, LANCET, V335, P1589, DOI 10.1016/0140-6736(90)91413-5; MATSUBARA Y, 1990, BIOCHEM BIOPH RES CO, V171, P498, DOI 10.1016/0006-291X(90)91421-N; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; RINALDO P, 1988, NEW ENGL J MED, V319, P1308, DOI 10.1056/NEJM198811173192003; Roe C, 1989, METABOLIC BASIS INHE, P889; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; [No title captured]; 1986, LANCET, V2, P1073	11	105	106	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					552	553		10.1016/0140-6736(91)91110-G	http://dx.doi.org/10.1016/0140-6736(91)91110-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678810				2022-12-24	WOS:A1991GD00200014
J	NELSON, SR; HAWKINS, PN; RICHARDSON, S; LAVENDER, JP; SETHI, D; GOWER, PE; PUGH, CW; WINEARLS, CG; OLIVER, DO; PEPYS, MB				NELSON, SR; HAWKINS, PN; RICHARDSON, S; LAVENDER, JP; SETHI, D; GOWER, PE; PUGH, CW; WINEARLS, CG; OLIVER, DO; PEPYS, MB			IMAGING OF HEMODIALYSIS-ASSOCIATED AMYLOIDOSIS WITH I-123 SERUM AMYLOID-P COMPONENT	LANCET			English	Article							LONG-TERM HEMODIALYSIS; SYSTEMIC AMYLOIDOSIS; BETA-2-MICROGLOBULIN AMYLOIDOSIS; RENAL-TRANSPLANTATION; DEPOSITS; PROTEIN	Long-term haemodialysis is frequently complicated by amyloid deposition in which the fibrils consist of beta-2-microglobulin. Dialysis-related amyloid disease causes extensive morbidity and has been associated with deaths in some cases. All amyloid deposits contain amyloid P component that is derived from the normal circulating protein, serum amyloid P component (SAP). We have used scintigraphic imaging after injection of I-123-labelled SAP to assess the distribution of amyloidosis in 38 patients receiving long-term haemodialysis for end-stage renal failure. There was focal localisation of tracer at all sites where histological examination confirmed amyloid deposition. Splenic uptake was seen in 12 patients, indicating splenic amyloidosis, but there was no evidence of other visceral involvement. 6 control subjects who had been dialysed for under 1.5 years showed no localisation of tracer, nor was there any uptake of I-123-labelled human serum albumin in 3 long-term dialysis patients with histologically confirmed amyloidosis and positive I-123-SAP images. Negative scans were also obtained in 5 patients who had been transplanted 0.8-2.4 years previously, despite past evidence of dialysis arthropathy (5) and histologically proven amyloidosis (4). I-123-SAP scintigraphy may be helpful as a non-invasive method for both the diagnosis and monitoring of dialysis-associated amyloidosis.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,IMMUNOL MED UNIT,DU CANE RD,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT RADIOL,LONDON W12 0NN,ENGLAND; CHARING CROSS HOSP,DEPT MED,RENAL UNIT,LONDON W6 8RP,ENGLAND; CHURCHILL HOSP,RENAL UNIT,OXFORD OX3 7LJ,ENGLAND	Imperial College London; Imperial College London; Imperial College London; University of Oxford			Hawkins, Philip N/C-5573-2008	Pugh, Chris/0000-0002-5170-1662				BALTZ ML, 1986, CLIN EXP IMMUNOL, V66, P691; CHOI HSH, 1989, GASTROENTEROLOGY, V96, P230, DOI 10.1016/0016-5085(89)90785-3; DESTRIHOU CV, 1990, INT YB NEPHROLOGY, P217; FLOEGE J, 1989, NEPHRON, V51, P444, DOI 10.1159/000185351; FLOEGE J, 1990, KIDNEY INT, V38, P1169, DOI 10.1038/ki.1990.329; FUCHS A, 1987, AM J CLIN PATHOL, V88, P302, DOI 10.1093/ajcp/88.3.302; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GOREVIC PD, 1985, J CLIN INVEST, V76, P2425, DOI 10.1172/JCI112257; HAWKINS PN, 1988, J EXP MED, V167, P903, DOI 10.1084/jem.167.3.903; HAWKINS PN, 1988, LANCET, V1, P1413; HAWKINS PN, 1990, J CLIN INVEST, V86, P1862, DOI 10.1172/JCI114917; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; JADOUL M, 1989, CLIN NEPHROL, V32, P194; MAHER ER, 1988, BRIT MED J, V297, P265, DOI 10.1136/bmj.297.6643.265; MANTZOURANIS EC, 1985, J BIOL CHEM, V280, P7752; OHNISHI S, 1986, J BIOCHEM-TOKYO, V100, P849, DOI 10.1093/oxfordjournals.jbchem.a121797; ORFILA C, 1987, NEPHROL DIAL TRANSPL, V2, P448; Pepys M. B, 1988, IMMUNOLOGICAL DISEAS, V1, P631; PEPYS MB, CLIN EXP; PRELLI F, 1985, J BIOL CHEM, V260, P12865; SETHI D, 1989, AM J NEPHROL, V9, P173, DOI 10.1159/000167959; SHINODA T, 1989, CLIN NEPHROL, V32, P284; STONE WJ, 1989, AM J NEPHROL, V9, P177, DOI 10.1159/000167962; THEAKER JM, 1987, J CLIN PATHOL, V40, P1247, DOI 10.1136/jcp.40.10.1247	24	98	99	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					335	339		10.1016/0140-6736(91)90478-8	http://dx.doi.org/10.1016/0140-6736(91)90478-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677697				2022-12-24	WOS:A1991GA60700003
J	THALER, MM; PARK, CK; LANDERS, DV; WARA, DW; HOUGHTON, M; VEEREMANWAUTERS, G; SWEET, RL; HAN, JH				THALER, MM; PARK, CK; LANDERS, DV; WARA, DW; HOUGHTON, M; VEEREMANWAUTERS, G; SWEET, RL; HAN, JH			VERTICAL TRANSMISSION OF HEPATITIS-C VIRUS	LANCET			English	Note							INFANT TRANSMISSION	There is evidence that hepatitis C virus (HCV) may be vertically transmitted from infected mothers to their children. To test this hypothesis, we prospectively studied 10 pregnant women at high risk from parenterally or sexually transmitted diseases with the polymerase chain reaction. HCV RNA was found in 8 newborn babies delivered by women who were anti-HCV seropositive, and persisted for 2-19 months of follow-up. Anti-HCV detected in 7 infants cleared by 9 months and remained undetectable thereafter. Serum alanine aminotransferase was raised in 3 infants. The findings provide evidence of vertical transmission of HCV and suggest that perinatal infection may initiate a silent disease process or chronic carrier state.	CHIRON CORP,EMERYVILLE,CA; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; HALLYM UNIV,COLL MED,DEPT INTERNAL MED,CHUNCHON,SOUTH KOREA	Novartis; University of California System; University of California San Francisco; Hallym University	THALER, MM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,M680,BOX 0136,SAN FRANCISCO,CA 94143, USA.			Houghton, Michael/0000-0003-3762-6771	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01271] Funding Source: Medline; NICHD NIH HHS [NICHD 24640] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTER MJ, 1989, NEW ENGL J MED, V321, P1538, DOI 10.1056/NEJM198911303212208; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; CHOO QL, 1990, BRIT MED BULL, V46, P423, DOI 10.1093/oxfordjournals.bmb.a072408; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; REESINK HW, 1990, LANCET, V335, P1216, DOI 10.1016/0140-6736(90)92734-Y; WEINTRAUB S, 1990, J CLIN EXP NEUROPSYC, V12, P49	7	244	246	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					17	18		10.1016/0140-6736(91)90006-B	http://dx.doi.org/10.1016/0140-6736(91)90006-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676085				2022-12-24	WOS:A1991FV29600005
J	FOSTER, A				FOSTER, A			WHO WILL OPERATE ON AFRICA 3-MILLION CURABLY BLIND PEOPLE	LANCET			English	Article								About half the 6 million blind people in sub-Saharan Africa have surgically curable cataract. The available manpower and resources can only provide services for less than 10% of the new blind cataract patients each year, and little is being done for the estimated 3 million "cataract backlog". A serious limiting factor to the development of prevention of blindness programmes is lack of trained manpower. Despite an increase in the number of ophthalmologists trained in cataract surgery (which varies greatly from country to country), this number is not keeping pace with increased demand for eye-care services, especially in large rural populations. Initiatives that will help to overcome this dilemma are specific post-graduate courses in community ophthalmology in Africa, plans to develop a one-year diploma in ophthalmology course for English-speaking West African countries, and a proposal to upgrade a similar course in Zimbabwe. Additionally there is a need for the training of more ophthalmic assistants, cataract surgeons, and nurses in the diagnosis and management of common ophthalmic disorders. Experienced expatriate ophthalmologists also have an important role in the teaching of doctors and ophthalmic assistants how to select patients and carry out successful inexpensive cataract surgery with appropriate technology and limited facilities.			FOSTER, A (corresponding author), INT CTR EYE HLTH,27-29 CAYTON ST,LONDON EC1V 9EJ,ENGLAND.			Foster, Allen/0000-0003-2368-4436				FOSTER A, 1991, CLIN OPHTHALMOLOGY, V5; 1990, OPHTHALMIC MANPOWER; 1988, OPHTHALMIC MANPOWER	3	52	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1267	1269		10.1016/0140-6736(91)92929-V	http://dx.doi.org/10.1016/0140-6736(91)92929-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674072				2022-12-24	WOS:A1991FN04700013
J	LAWSON, HW; BRAUN, MM; GLASS, RIM; STINE, SE; MONROE, SS; ATRASH, HK; LEE, LE; ENGLENDER, SJ				LAWSON, HW; BRAUN, MM; GLASS, RIM; STINE, SE; MONROE, SS; ATRASH, HK; LEE, LE; ENGLENDER, SJ			WATERBORNE OUTBREAK OF NORWALK VIRUS GASTROENTERITIS AT A SOUTHWEST UNITED-STATES RESORT - ROLE OF GEOLOGICAL FORMATIONS IN CONTAMINATION OF WELL WATER	LANCET			English	Article							NONBACTERIAL GASTROENTERITIS	From April 17 to May 1, 1989, gastroenteritis developed in about 900 people during a visit to a new resort in Arizona, USA. Of 240 guests surveyed, 110 had a gastrointestinal illness that was significantly associated with the drinking of tap water from the resort's well (relative risk = 16.1, 95% confidence interval 14.5 to 17.8) and this risk increased significantly with the number of glasses of water consumed (p < 0.005). Three of seven paired sera tested for antibodies to the Norwalk agent had a four-fold or greater rise in titre. Water contaminated with faecal coliforms was traced back to the deep water well, which remained contaminated even after prolonged pumping. Effluent from the resort's sewage treatment facility seeped through fractures in the subsurface rock (with little filtration) directly into the resort's deep well. Although the latest technology was used to design the resort's water and sewage treatment plants, the region's unique geological conditions posed unexpected problems that may trouble developers faced with similar subsurface geological formations and arid climatic conditions in many parts of the world. In these areas, novel solutions are needed to provide adequate facilities for the treatment of sewage and supply of pure drinking water.	CTR DIS CONTROL,CTR CHRON DIS PREVENT & HLTH PROMOT,DIV REPROD HLTH,ATLANTA,GA 30333; ARIZONA DEPT HLTH SERV,PHOENIX,AZ 85007; CTR DIS CONTROL,CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Arizona Department of Health Services; Centers for Disease Control & Prevention - USA				Monroe, Stephan/0000-0002-5424-716X				CRAUN GF, 1988, J AM WATER WORKS ASS, V80, P40; GARY GW, 1985, J CLIN MICROBIOL, V22, P274, DOI 10.1128/JCM.22.2.274-278.1985; Gerba C., 1984, GROUNDWATER POLLUTIO, P65; GERBA CP, 1979, AM J PUBLIC HEALTH, V69, P1116, DOI 10.2105/AJPH.69.11.1116; GLASS RI, 1988, VIRUSES GUT, P87; KAPIKIAN AZ, 1972, J VIROL, V10, P1075, DOI 10.1128/JVI.10.5.1075-1081.1972; KAPLAN JE, 1982, J INFECT DIS, V146, P190, DOI 10.1093/infdis/146.2.190; KAPLAN JE, 1982, ANN INTERN MED, V96, P756, DOI 10.7326/0003-4819-96-6-756; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; WILSON R, 1982, AM J PUBLIC HEALTH, V72, P72, DOI 10.2105/AJPH.72.1.72; 1990, MMWR, V39, P1	13	79	81	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1200	1204						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673747				2022-12-24	WOS:A1991FM26100012
J	AKHRAS, F; JACKSON, G				AKHRAS, F; JACKSON, G			RAISED EXERCISE DIASTOLIC BLOOD-PRESSURE AS INDICATOR OF ISCHEMIC LEFT-VENTRICULAR DYSFUNCTION	LANCET			English	Article							CORONARY-ARTERY DISEASE; 2-DIMENSIONAL ECHOCARDIOGRAPHY	91 (16.8%) of 541 consecutive patients investigated for chest pain or after recent uncomplicated myocardial infarction had a rise in diastolic blood pressure (DBP) of more than 15 mm Hg during a symptom-limited treadmill test. 63 also had electrocardiographic evidence of ischaemia, but 28 did not have 1 mm ST segment depression, of whom 24 had angiographic evidence of more than 70% stenosis of two or more major coronary arteries. 55 of these 91 patients underwent coronary artery bypass surgery; repeat angiography in 22 at 12 months showed an improved left ventricular ejection fraction in 18 who had a normal postoperative DBP response, but no change in ejection fraction in the 4 who still had an abnormal rise in DBP on exercise. Exercise-induced ischaemia may cause a reversible fall in cardiac output that sometimes leads to reflex vasoconstriction and a rise in DBP before a fall in systolic blood pressure or ECG evidence of ST segment depression. An abnormal DBP response to exercise may identify some patients at high risk of myocardial infarction who might otherwise have false-negative exercise tests.	GUYS HOSP,DEPT CARDIOL,LONDON SE1 9RT,ENGLAND; LEWISHAM HOSP,DEPT CARDIOL,LONDON SE13 6LH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust								AKHRAS F, 1985, BRIT HEART J, V53, P598; AKHRAS F, 1988, J AM COLL CARDIOL, V11, P102; BOUCHARD RJ, 1971, CIRCULATION, V44, P1072, DOI 10.1161/01.CIR.44.6.1072; BRUCE R A, 1969, Progress in Cardiovascular Diseases, V11, P371, DOI 10.1016/0033-0620(69)90027-9; ELLESTAD MH, 1986, STRESS TESTING PRINC, P86; FOLLAND ED, 1979, CIRCULATION, V60, P760, DOI 10.1161/01.CIR.60.4.760; SCHILLER NB, 1979, CIRCULATION, V60, P547, DOI 10.1161/01.CIR.60.3.547; SHEPS DS, 1979, AM J CARDIOL, V43, P708, DOI 10.1016/0002-9149(79)90067-5; WEINER DA, 1982, AM J CARDIOL, V49, P1627, DOI 10.1016/0002-9149(82)90238-7; WOLTHUIS RA, 1977, CIRCULATION, V55, P153, DOI 10.1161/01.CIR.55.1.153	10	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					899	900		10.1016/0140-6736(91)90216-C	http://dx.doi.org/10.1016/0140-6736(91)90216-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672979				2022-12-24	WOS:A1991FG04800014
J	PAIN, B; WOODS, CM; SAEZ, J; FLICKINGER, T; RAINES, M; PEYROL, S; MOSCOVICI, C; MOSCOVICI, MG; KUNG, HJ; JURDIC, P; LAZARIDES, E; SAMARUT, J				PAIN, B; WOODS, CM; SAEZ, J; FLICKINGER, T; RAINES, M; PEYROL, S; MOSCOVICI, C; MOSCOVICI, MG; KUNG, HJ; JURDIC, P; LAZARIDES, E; SAMARUT, J			EGF-R AS A HEMATOPOIETIC GROWTH-FACTOR RECEPTOR - THE C-ERBB PRODUCT IS PRESENT IN CHICKEN ERYTHROCYTIC PROGENITORS AND CONTROLS THEIR SELF-RENEWAL	CELL			English	Article							THYROID-HORMONE RECEPTOR; AVIAN-LEUKOSIS VIRUS; TARGET-CELLS; ERYTHROBLASTOSIS; EXPRESSION; ACTIVATION; ONCOGENE; PROTEIN; INVITRO; DIFFERENTIATION	c-erbB, encoding the EGF receptor (EGF-R), was originally identified as the cellular homolog of a chicken leukemia oncogene. In humans, EGF-R is distributed widely except in hemopoietic tissues, and its amplification is associated with epidermal and glial malignancies. Here we show that c-erbB is present in normal chicken erythrocytic progenitors and transmits the mitogenic signal induced by TGF-alpha. Cells that contain high affinity EGF-R are at approximately the BFU-E stage, and their long-term renewal can be induced by TGF-alpha. Upon addition of insulin and erythropoietin, they can be induced to terminally differentiate into red cells. We previously demonstrated that v-erbA blocks differentiation of chicken erythrocytic progenitors but does not abrogate their growth factor dependence for proliferation. These data indicate that proliferation and differentiation are not necessarily coupled in these cells. They also demonstrate a direct role of c-erbB in the control of self-renewal of normal chicken erythrocytic progenitors and could account for the predominant leukemogenic potential of the chicken erbB gene.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; HOP DEBROUSSE, INSERM, F-69005 Lyon, FRANCE; CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA; PASTEUR INST, Lyon, FRANCE; VET ADM MED CTR, TUMOR VIROL LAB, GAINESVILLE, FL 32601 USA	California Institute of Technology; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	PAIN, B (corresponding author), ECOLE NORMALE SUPER LYON, INRA, CNRS, BIOL MOLEC & CELLULAIRE LAB, 46 ALLEE ITALIE, F-69364 Lyon 07, FRANCE.		Kung, Hsing-Jien/C-7651-2013; Samarut, Jacques/AAD-2587-2019; Pain, Bertrand/A-7686-2015	Pain, Bertrand/0000-0002-1210-8444	NATIONAL CANCER INSTITUTE [R37CA039207, R01CA039207] Funding Source: NIH RePORTER; NCI NIH HHS [CA39207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN TD, 1990, COLONY STIMULATING F, P1; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BERNIER M, 1986, ENDOCRINOLOGY, V118, P2254, DOI 10.1210/endo-118-6-2254; BEUG H, 1982, J CELL PHYSIOL, P195; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GAZZOLO L, 1980, CELL, V22, P683, DOI 10.1016/0092-8674(80)90544-9; GLINEUR C, 1989, ONCOGENE, V4, P1247; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; ISCOVE N, 1990, NATURE, V347, P126, DOI 10.1038/347126a0; KAZIMIERCZAK J, 1986, CELL TISSUE RES, V245, P487; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P4868, DOI 10.1128/MCB.8.11.4868; MAIHLE NJ, 1991, IN PRESS P NATL ACAD; MILLER M, 1990, ONCOGENE, V5, P1125; MURA CV, 1981, J BIOL CHEM, V256, P9767; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; NILSEN TW, 1985, JCELL, V41, P7149; PAIN B, 1990, New Biologist, V2, P284; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SAMARUT J, 1908, J CELL PHYSL, V105, P553; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WOODS CM, 1986, J CELL BIOL, V103, P1789, DOI 10.1083/jcb.103.5.1789; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	40	93	96	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					37	46		10.1016/0092-8674(91)90405-N	http://dx.doi.org/10.1016/0092-8674(91)90405-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1672832	Bronze			2022-12-24	WOS:A1991FF77300006
J	WILKINSON, SM; CARTWRIGHT, PH; ENGLISH, JSC				WILKINSON, SM; CARTWRIGHT, PH; ENGLISH, JSC			HYDROCORTISONE - AN IMPORTANT CUTANEOUS ALLERGEN	LANCET			English	Note							CONTACT-DERMATITIS	We have found a high incidence (4.8%) of allergy to hydrocortisone in patients with suspected allergic contact dermatitis. In view of this finding we would suggest that, in any condition that does not improve or that deteriorates after administration of hydrocortisone, allergy to this compound should be considered.			WILKINSON, SM (corresponding author), N STAFFORDSHIRE HOSP,CENT OUTPATIENTS DEPT,DEPT DERMATOL,STOKE ON TRENT ST4 7PA,ENGLAND.			Wilkinson, Stephen Mark/0000-0001-7253-3461				ALANI MD, 1972, ANN ALLERGY, V30, P181; CHURCH R, 1960, BRIT J DERMATOL, V72, P341, DOI 10.1111/j.1365-2133.1960.tb13814.x; COMAISH S, 1969, BRIT J DERMATOL, V81, P919, DOI 10.1111/j.1365-2133.1969.tb15974.x; DOOMSGOOSSENS A, 1986, CONTACT DERMATITIS, V14, P94, DOI 10.1111/j.1600-0536.1986.tb01168.x; ENGLISH JSC, 1990, CONTACT DERMATITIS, V23, P196, DOI 10.1111/j.1600-0536.1990.tb04789.x; KING RA, 1960, LANCET, V2, P1093; LAUERMA AI, 1990, BRIT J DERMATOL, V123, P699, DOI 10.1111/j.1365-2133.1990.tb04186.x; PARAMSOTHY Y, 1988, CONTACT DERMATITIS, V18, P30, DOI 10.1111/j.1600-0536.1988.tb05486.x; WILKINSON M, 1990, CONTACT DERMATITIS, V23, P120, DOI 10.1111/j.1600-0536.1990.tb03240.x; 1989, CONTACT DERMATITIS, V20, P158	10	70	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					761	762		10.1016/0140-6736(91)91373-3	http://dx.doi.org/10.1016/0140-6736(91)91373-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672393				2022-12-24	WOS:A1991FD88400005
J	NEWTON, CRJC; KIRKHAM, FJ; WINSTANLEY, PA; PASVOL, G; PESHU, N; WARRELL, DA; MARSH, K				NEWTON, CRJC; KIRKHAM, FJ; WINSTANLEY, PA; PASVOL, G; PESHU, N; WARRELL, DA; MARSH, K			INTRACRANIAL-PRESSURE IN AFRICAN CHILDREN WITH CEREBRAL MALARIA	LANCET			English	Article							EDEMA	Opening lumbar cerebrospinal fluid (CSF) pressure was measured with a paediatric spinal fluid manometer in 26 of 61 Kenyan children (mean age 39 months) with cerebral malaria. In all cases pressure was above normal (mean [SD] 22.6 [7.4] cm CSF, range 10.5-36). Clinical features of our patients suggest that intracranial hypertension is important in the pathogenesis of cerebral malaria in children, especially as a cause of death. We suggest that raised intracranial pressure is secondary to increased cerebral blood volume. Lowering intracranial pressure may significantly reduce the mortality and morbidity of cerebral malaria. The potential risks and benefits of lumbar puncture should be considered carefully in patients with suspected cerebral malaria.	INST CHILD HLTH, DEPT NEUROL, 30 GUILFORD ST, LONDON WC1N 2AP, ENGLAND; KENYA GOVT MED RES CTR, KILIFI COASTAL UNIT, KILIFI, KENYA; JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD OX3 9DU, ENGLAND	University of London; University College London; Kenya Medical Research Institute; University of Oxford			Kirkham, Fenella/C-2442-2009; Newton, Charles RJC/B-7578-2014; Newton, Charles/C-6222-2009; Pasvol, Geoffrey/B-7113-2009	Kirkham, Fenella/0000-0002-2443-7958; Newton, Charles RJC/0000-0002-6999-5507; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Commey J. O. O., 1980, Ghana Medical Journal, V19, P68; GOITEIN KJ, 1983, ARCH DIS CHILD, V58, P184, DOI 10.1136/adc.58.3.184; HASSLER W, 1988, J NEUROSURG, V68, P745; JENSEN MD, 1983, J PARASITOL, V69, P1060, DOI 10.2307/3280864; KINGSTON ME, 1971, J TROP MED HYG, V74, P249; KIRKHAM FJ, 1987, J NEUROL NEUROSUR PS, V50, P1504, DOI 10.1136/jnnp.50.11.1504; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LOOAREESUWAN S, 1983, LANCET, V1, P434; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; Miller J D, 1972, Prog Brain Res, V35, P411; MINNS RA, 1989, ARCH DIS CHILD, V64, P814, DOI 10.1136/adc.64.6.814; MOLYNEUX ME, 1989, Q J MED, V71, P441; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SCHMUTZHARD E, 1984, T ROY SOC TROP MED H, V78, P351, DOI 10.1016/0035-9203(84)90118-4; TASKER RC, 1988, ARCH DIS CHILD, V63, P888, DOI 10.1136/adc.63.8.888; THAPA B R, 1988, Indian Pediatrics, V25, P61; THOMAS JD, 1971, TROP GEOGR MED, V23, P232; WARRELL DA, 1988, LANCET, V2, P534; WARRELL DA, 1986, AM J TROP MED HYG, V35, P882, DOI 10.4269/ajtmh.1986.35.882; [No title captured]	23	169	171	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1991	337	8741					573	576		10.1016/0140-6736(91)91638-B	http://dx.doi.org/10.1016/0140-6736(91)91638-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671941				2022-12-24	WOS:A1991FA70200002
J	ECCLES, M; BRADSHAW, C				ECCLES, M; BRADSHAW, C			USE OF SECONDARY PROPHYLAXIS AGAINST MYOCARDIAL-INFARCTION IN THE NORTH OF ENGLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective - To record the use of secondary prophylactic drugs in patients discharged from hospital having had a myocardial infarction. Design - Prospective postal questionnaire survey of a random one in two sample of general practitioners in the region. Setting - The nine family practitioner committee areas within the Northern Regional Health Authority. Patients - Patients who had had a myocardial infarction and were discharged to their general practitioner. Main outcome measure - Whether beta-blockers or aspirin, or both, were given on discharge. Results - Of 267 patients, 158 (59%) were treated suboptimally in that they did not receive a secondary prophylactic drug to which they had no contraindication. For most patients this entailed underuse of one drug, but 17 (6%) of patients received no treatment. beta-blockers were 2.5 times less likely to be used than aspirin. Treatment was not associated with the age or sex of the patient, risk of further infarction, or hospital of discharge. Conclusions - Secondary prophylaxis after myocardial infarction is practised haphazardly. It should be offered to all patients who can tolerate it, after a trial period to assess any side effects of the drugs if necessary.	UNIV NEWCASTLE UPON TYNE, CTR HLTH SERV RES, NEWCASTLE UPON TYNE NE2 4AA, ENGLAND; MARSDEN RD HLTH CTR, S SHIELDS NE34 6RE, TYNE & WEAR, ENGLAND	Newcastle University - UK; Royal Marsden NHS Foundation Trust			Eccles, Martin P/AAD-4029-2020					[Anonymous], 1980, LANCET, V1, P1172; [Anonymous], 1988, LANCET, V2, P349; BLOOMFIELD P, 1987, BMJ-BRIT MED J, V3295, P1431; FRY J, 1979, COMMN DISEASES THEIR; HAMPTON JR, 1982, BRIT MED J, V285, P33, DOI 10.1136/bmj.285.6334.33; HANSTEEN V, 1982, BRIT MED J, V284, P155, DOI 10.1136/bmj.284.6310.155; JULIAN DG, 1988, BMJ-BRIT MED J, V297, P497, DOI 10.1136/bmj.297.6647.497; KAPLAN NM, 1987, ARCH INTERN MED, V147, P1160, DOI 10.1001/archinte.147.6.1160; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; ORME M, 1988, BRIT MED J, V296, P307, DOI 10.1136/bmj.296.6618.307; 1986, MORBIDITY STATISTICS; 1987, DRUG THER B, V25, P17; 1990, BRIT NATIONAL FORMUL; 1990, DRUG THER B, V28, P47	14	53	53	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 12	1991	302	6768					91	92		10.1136/bmj.302.6768.91	http://dx.doi.org/10.1136/bmj.302.6768.91			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1671652	Green Published, Bronze			2022-12-24	WOS:A1991ER95100022
J	MATHEW, CGP; EASTON, DF; NAKAMURA, Y; PONDER, BAJ				MATHEW, CGP; EASTON, DF; NAKAMURA, Y; PONDER, BAJ			PRESYMPTOMATIC SCREENING FOR MULTIPLE ENDOCRINE NEOPLASIA TYPE-2A WITH LINKED DNA MARKERS	LANCET			English	Article							MEDULLARY-THYROID CARCINOMA; GENETIC-LINKAGE MAP; CHROMOSOME 10; POLYMORPHISM; FAMILIES; LOCUS	Seven DNA markers from the pericentromeric region of chromosome 10 were tested for linkage to MEN 2A in a panel of 17 families. Four of the markers proved to be tightly linked and therefore suitable for predictive testing. The markers were used to estimate carrier risks for individuals who had a negative biochemical screening test for thyroid C-cell hyperplasia. The analysis substantially altered the carrier risks of most of these individuals, which suggests that typing with DNA markers should be introduced into the screening programme of MEN 2A families. Accurate prenatal diagnosis for this disorder is also now possible.	UNIV CAMBRIDGE,DEPT PATHOL,CANC RES CTR,HUMAN CANC GENET RES GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5PX,SURREY,ENGLAND; JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,TOKYO 170,JAPAN	University of Cambridge; University of London; Institute of Cancer Research - UK; Japanese Foundation for Cancer Research			Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK016684] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01 RR00054] Funding Source: Medline; NIADDK NIH HHS [5T32 AM0703910] Funding Source: Medline; NIDDK NIH HHS [5R37 DK16684] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CARTER C, 1987, CYTOGENET CELL GENET, V45, P33, DOI 10.1159/000132422; CHIN KS, 1988, NUCLEIC ACIDS RES, V16, P1645, DOI 10.1093/nar/16.4.1645; EASTON DF, 1989, AM J HUM GENET, V44, P208; EMERY AEH, 1976, METHODOLOGY MED GENE; GAGEL RF, 1988, NEW ENGL J MED, V318, P478, DOI 10.1056/NEJM198802253180804; GAGEL RF, 1982, J PEDIATR-US, V101, P941, DOI 10.1016/S0022-3476(82)80014-0; KAPLAN MM, 1989, 64TH M AM THYR ASS S; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LATHROP GM, 1988, GENOMICS, V2, P157; LIOU GI, 1987, NUCLEIC ACIDS RES, V15, P3196, DOI 10.1093/nar/15.7.3196; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MATHEW CGP, 1990, ANN HUM GENET, V54, P121, DOI 10.1111/j.1469-1809.1990.tb00368.x; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P374, DOI 10.1093/nar/16.1.374; NAKAMURA Y, 1988, GENOMICS, V3, P389, DOI 10.1016/0888-7543(88)90133-4; NAKAMURA Y, 1989, GENOMICS, V5, P199, DOI 10.1016/0888-7543(89)90046-3; NELKIN BD, 1989, JAMA-J AM MED ASSOC, V261, P3130, DOI 10.1001/jama.261.21.3130; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SOBOL H, 1988, LANCET, V1, P62; SOBOL H, 1989, NEW ENGL J MED, V321, P996, DOI 10.1056/NEJM198910123211502; TELENIUSBERG M, 1977, EUR J CLIN INVEST, V7, P7, DOI 10.1111/j.1365-2362.1977.tb01563.x; WHITE RL, 1990, GENOMICS, V6, P393, DOI 10.1016/0888-7543(90)90469-B; WU JS, 1989, HUM GENET, V83, P383, DOI 10.1007/BF00291386; YAMAMOTO M, 1989, HUM GENET, V82, P287, DOI 10.1007/BF00291173	26	71	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					7	11		10.1016/0140-6736(91)93329-8	http://dx.doi.org/10.1016/0140-6736(91)93329-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670689				2022-12-24	WOS:A1991EQ60400003
J	KASHLEV, M; LEE, JY; ZALENSKAYA, K; NIKIFOROV, V; GOLDFARB, A				KASHLEV, M; LEE, JY; ZALENSKAYA, K; NIKIFOROV, V; GOLDFARB, A			BLOCKING OF THE INITIATION-TO-ELONGATION TRANSITION BY A TRANSDOMINANT RNA-POLYMERASE MUTATION	SCIENCE			English	Article									COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; ACAD SCI USSR,INST MOLEC GENET,MOSCOW 123182,USSR	Columbia University; Russian Academy of Sciences					NIGMS NIH HHS [GM30717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; Buhler J.M., 1987, RNA POLYM REGULATION, P25; Burgess R.R., 1987, RNA POLYM REGULATION, P3; BURGESS RR, 1969, J BIOL CHEM, V244, P6168; CAI H, 1987, J BIOL CHEM, V262, P298; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; GLASS RE, 1986, MOL GEN GENET, V203, P487, DOI 10.1007/BF00422074; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; HEUMANN H, 1986, EUR J BIOCHEM, V158, P575, DOI 10.1111/j.1432-1033.1986.tb09793.x; HEUMANN H, 1988, J MOL BIOL, V201, P115, DOI 10.1016/0022-2836(88)90443-3; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; HUET J, 1983, EMBO J, V2, P1291, DOI 10.1002/j.1460-2075.1983.tb01583.x; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JOHNSTON DE, 1976, RNA POLYM, P101; KASHLEV MV, 1989, MOL GEN GENET, V216, P469, DOI 10.1007/BF00334392; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; MALIK S, 1985, J MOL BIOL, V185, P83, DOI 10.1016/0022-2836(85)90184-6; MALIK S, 1984, J BIOL CHEM, V259, P3292; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; MCKINNEY JD, 1987, GENE, V58, P13, DOI 10.1016/0378-1119(87)90024-2; NENE V, 1984, MOL GEN GENET, V194, P166, DOI 10.1007/BF00383512; NENE V, 1982, MOL GEN GENET, V88, P399; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; PUHLER G, 1989, NUCLEIC ACIDS RES, V17, P4517, DOI 10.1093/nar/17.12.4517; SCHULZ W, 1981, NUCLEIC ACIDS RES, V9, P6889, DOI 10.1093/nar/9.24.6889; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YURA T, 1979, ANNU REV GENET, V13, P59, DOI 10.1146/annurev.ge.13.120179.000423; ZALENSKAYA K, IN PRESS GENE; ZILLIG W, 1987, RNA POLYM REGULATION, P17	44	73	73	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 25	1990	248	4958					1006	1009		10.1126/science.1693014	http://dx.doi.org/10.1126/science.1693014			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DF144	1693014				2022-12-24	WOS:A1990DF14400034
J	MILBURN, MV; PRIVE, GG; MILLIGAN, DL; SCOTT, WG; YEH, J; JANCARIK, J; KOSHLAND, DE; KIM, SH				MILBURN, MV; PRIVE, GG; MILLIGAN, DL; SCOTT, WG; YEH, J; JANCARIK, J; KOSHLAND, DE; KIM, SH			3-DIMENSIONAL STRUCTURES OF THE LIGAND-BINDING DOMAIN OF THE BACTERIAL ASPARTATE RECEPTOR WITH AND WITHOUT A LIGAND	SCIENCE			English	Article							DIRECTED CROSS-LINKING; EPIDERMAL GROWTH-FACTOR; HUMAN INSULIN-RECEPTOR; ELECTRON-DENSITY MAP; ESCHERICHIA-COLI; MACROMOLECULAR CRYSTALLOGRAPHY; SIGNAL TRANSDUCTION; SECONDARY STRUCTURE; WEISSENBERG CAMERA; TAR CHEMORECEPTOR	The three-dimensional structure of an active, disulfide cross-linked dimer of the ligand-binding domain of the Salmonella typhimurium aspartate receptor and that of an aspartate complex have been determined by x-ray crystallographic methods at 2.4 and 2.0 angstrom (angstrom) resolution, respectively. A single subunit is a four-alpha-helix bundle with two long amino-terminal and carboxyl-terminal helices and two shorter helices that form a cylinder 20 angstrom in diameter and more than 70 angstrom long. The two subunits in the disulfide-bonded dimer are related by a crystallographic twofold axis in the apo structure, but by a noncrystallographic twofold axis in the aspartate complex structure. The latter structure reveals that the ligand binding site is located more than 60 angstrom from the presumed membrane surface and is at the interface of the two subunits. Aspartate binds between two alpha-helices from one subunit and one alpha-helix from the other in a highly charged pocket formed by three arginines. The comparison of the apo and aspartate complex structures shows only small structural changes in the individual subunits, except for one loop region that is disordered, but the subunits appear to change orientation relative to each other. The structures of the two forms of this protein provide a step toward understanding the mechanisms of transmembrane signaling.	UNIV CALIF BERKELEY, DEPT BIOCHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Privé, Gilbert G/A-3039-2008	Prive, Gilbert/0000-0002-0712-4319; Scott, William/0000-0002-9273-3564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009765, R01DK009765] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30725] Funding Source: Medline; NIDDK NIH HHS [DK09765] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN J, 1987, P NATL ACAD SCI USA, V84, P2532, DOI 10.1073/pnas.84.8.2532; ARGOS P, 1977, BIOCHEM BIOPH RES CO, V75, P83, DOI 10.1016/0006-291X(77)91292-X; BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; BIEMANN HP, UNPUB; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BRUNGER AT, 1990, XPLOR VERSION 21; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; IMAE Y, 1987, J BACTERIOL, V169, P371, DOI 10.1128/jb.169.1.371-379.1987; JANCARIK J, 1991, J MOL BIOL, V221, P31, DOI 10.1016/0022-2836(91)80198-4; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOSHLAND DE, 1988, BIOCHEMISTRY-US, V27, P5829, DOI 10.1021/bi00416a001; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; LEE L, 1988, J BACTERIOL, V170, P4769, DOI 10.1128/jb.170.10.4769-4774.1988; LYNCH BA, IN PRESS P NATL ACAD; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, IN PRESS SCIENCE; MILLIGAN DL, UNPUB; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MOE GR, 1986, MICROBIAL ENERGY TRA, P163; MOWBRAY SL, 1990, J BIOL CHEM, V265, P15638; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; STEIGEMANN W, 1982, PROTEIN PACKAGE CRYS; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TERWILLIGER TC, 1986, P NATL ACAD SCI USA, V83, P6707, DOI 10.1073/pnas.83.18.6707; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WARK KB, 1975, NATURE, V257, P818; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; YAMAMOTO T, 1984, CELL, V33, P615; 1979, SERK4 DAR LAB COLL C	47	395	399	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1991	254	5036					1342	1347		10.1126/science.1660187	http://dx.doi.org/10.1126/science.1660187			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1660187	Green Submitted			2022-12-24	WOS:A1991GR77700045
J	BRIGGS, DC; VAUGHAN, RW; WELSH, KI; MYERS, A; DUBOIS, RM; BLACK, CM				BRIGGS, DC; VAUGHAN, RW; WELSH, KI; MYERS, A; DUBOIS, RM; BLACK, CM			IMMUNOGENETIC PREDICTION OF PULMONARY FIBROSIS IN SYSTEMIC-SCLEROSIS	LANCET			English	Note							CLINICAL CORRELATIONS; ANTIGENS	75 systemic sclerosis patients were independently tested for pulmonary fibrosis, autoantibodies, and MHC class II genes. 24 of 42 (57%) patients with pulmonary fibrosis had either HLA DR3/DRw52a or anti-Scl-70 vs 2 of 33 (6%) patients without pulmonary fibrosis. The presence of DR3/DRw52a or anti-Scl-70 gives a relative risk of 16.7 for the development of pulmonary fibrosis in a patient with scleroderma-a risk substantial enough to require careful monitoring of these patients and treatment at an early stage of disease.	TEMPLE UNIV,HLTH SCI CTR,PHILADELPHIA,PA 19140; ROYAL BROMPTON HOSP,DEPT THORAC MED,LONDON,ENGLAND; ROYAL FREE HOSP,DEPT RHEUMATOL,LONDON,ENGLAND	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Royal Brompton Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	BRIGGS, DC (corresponding author), GUYS HOSP,DEPT IMMUNOGENET,TISSUE TYPING LAB,ST THOMAS ST,LONDON SE1 9RT,ENGLAND.			Briggs, David/0000-0002-6796-7086				BIDWELL J, 1988, IMMUNOL TODAY, V9, P18, DOI 10.1016/0167-5699(88)91351-5; CATOGGIO LJ, 1983, ANN RHEUM DIS, V42, P23, DOI 10.1136/ard.42.1.23; HARRISON NK, 1989, RESPIR MED, V83, P404; LEROY EC, 1988, J RHEUMATOL, V15, P202; LYNCH CJ, 1982, J CLIN IMMUNOL, V2, P314, DOI 10.1007/BF00915073; STEEN VD, 1988, ARTHRITIS RHEUM, V31, P196, DOI 10.1002/art.1780310207; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171; WEINER ES, 1990, ARTHRITIS RHEUM, V34, P68	8	112	114	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1991	338	8768					661	662		10.1016/0140-6736(91)91235-M	http://dx.doi.org/10.1016/0140-6736(91)91235-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF105	1679476				2022-12-24	WOS:A1991GF10500006
J	KENYON, K; CONTENTE, S; TRACKMAN, PC; TANG, J; KAGAN, HM; FRIEDMAN, RM				KENYON, K; CONTENTE, S; TRACKMAN, PC; TANG, J; KAGAN, HM; FRIEDMAN, RM			LYSYL OXIDASE AND RRG MESSENGER-RNA	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; SEQUENCE; CELLS		BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University	KENYON, K (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814, USA.		Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; Contente, Sara/0000-0002-8099-2817	NCI NIH HHS [R01 CA37351-04A1] Funding Source: Medline; NHLBI NIH HHS [P01 HL13262] Funding Source: Medline; NIAMS NIH HHS [R37 AR18880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037351] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P4863; BENSON D, 1990, GENOMICS, V6, P389, DOI 10.1016/0888-7543(90)90583-G; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; INDIK Z, 1990, ARCH BIOCHEM BIOPHYS, V280, P80, DOI 10.1016/0003-9861(90)90521-Y; KAGAN HM, 1984, J BIOL CHEM, V259, P1203; KAGAN HM, 1983, BIOCHEM BIOPH RES CO, V115, P186, DOI 10.1016/0006-291X(83)90987-7; KESHMIRIAN J, 1989, J NEUROCYTOL, V18, P491, DOI 10.1007/BF01474545; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; KUIVANIEMI H, 1986, BIOCHIM BIOPHYS ACTA, V883, P326, DOI 10.1016/0304-4165(86)90325-9; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; SCHUPPAN D, 1990, SEMIN LIVER DIS, V10, P1, DOI 10.1055/s-2008-1040452; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, IN PRESS BIOCHEMISTR	14	201	213	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					802	802		10.1126/science.1678898	http://dx.doi.org/10.1126/science.1678898			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1678898				2022-12-24	WOS:A1991GB29500045
J	KEATING, M; ATKINSON, D; DUNN, C; TIMOTHY, K; VINCENT, GM; LEPPERT, M				KEATING, M; ATKINSON, D; DUNN, C; TIMOTHY, K; VINCENT, GM; LEPPERT, M			LINKAGE OF A CARDIAC-ARRHYTHMIA, THE LONG QT SYNDROME, AND THE HARVEY RAS-1 GENE	SCIENCE			English	Article							ANIRIDIA-WILMS TUMOR; CANCER-PATIENTS; LOCALIZATION; C-HA-RAS1; ONCOGENE; PROTEINS; PRODUCT; LOCUS; CELLS	Genetic factors contribute to heart disease. In this study, linkage analyses have been performed in a family that is predisposed to sudden death from cardiac arrhythmias, the long QT syndrome (LQT). A DNA marker at the Harvey ras-1 locus (H-ras-1) was linked to LQT with a logarithm of the likelihood ratio for linkage (lod score) of 16.44 at theta = 0, which confirms the genetic basis of this trait and localizes this gene to the short arm of chromosome 11. As no recombination was observed between LQT and H-ras-1, and there is a physiological rationale for its involvement in this disease, ras becomes a candidate for the disease locus.	UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84132; LATTER DAY ST HOSP,DEPT MED,SALT LAKE CITY,UT 84143; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	KEATING, M (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,DIV CARDIOL,SALT LAKE CITY,UT 84132, USA.							Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; DAUSSET J, 1986, PRESSE MED, V15, P1801; DEMARTINVILLE B, 1983, NATURE, V305, P641, DOI 10.1038/305641a0; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GIUFFRE RM, 1990, AM J HUM GENET, V47; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HUERRE C, 1983, NATURE, V305, P638, DOI 10.1038/305638a0; ITOH S, 1962, CLIN PEDIATR PHILADE, V21, P20; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; JHANWAR SC, 1983, P NATL ACAD SCI-BIOL, V80, P4794, DOI 10.1073/pnas.80.15.4794; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KEATING MT, UNPUB; KLINGER HP, 1989, CYTOGENET CELL GENET, V51, P740; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LIDEREAU R, 1986, JNCI-J NATL CANCER I, V77, P697, DOI 10.1093/jnci/77.3.697; MCKUSICK VA, 1908, MENDELIAN INHERITANC; MELKI J, 1987, CYTOGENET CELL GENET, V40, P775; ROMANO C, 1965, LANCET, V1, P658; SCHATZKIN A, 1984, AM HEART J, V107, P1300, DOI 10.1016/0002-8703(84)90302-8; SCHWARTZ P J, 1989, Journal of the American College of Cardiology, V13, p20A; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523; VINCENT GM, 1989, CIRCULATION S2, V80, P654; WARD O C, 1964, J Ir Med Assoc, V54, P103; WEITKAMP LR, 1989, CYTOGENET CELL GENET, V51, P1106; WEITKAMP LR, 1985, CYTOGENET CELL GENET, V40, P775; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1988, SCIENCE, V241, P828, DOI 10.1126/science.2457252; YATANI A, 1990, SCIENCE, V249, P1163, DOI 10.1126/science.1697697	34	443	458	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					704	706		10.1126/science.1673802	http://dx.doi.org/10.1126/science.1673802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1673802				2022-12-24	WOS:A1991FK18500048
J	ALLAN, LD; COOK, A; SULLIVAN, I; SHARLAND, GK				ALLAN, LD; COOK, A; SULLIVAN, I; SHARLAND, GK			HYPOPLASTIC LEFT HEART SYNDROME - EFFECTS OF FETAL ECHOCARDIOGRAPHY ON BIRTH PREVALENCE	LANCET			English	Article							DISEASE	Hypoplastic left heart syndrome was diagnosed prenatally and confirmed in 105 fetuses since 1983 at a regional referral centre. An increased detection rate since 1988 is probably related to increased experience in the use of a four-chamber view of the fetal heart during routine obstetric ultrasound scanning. When the diagnosis was made sufficiently early, most parents chose to terminate the pregnancy after the prognosis and surgical options were explained. By contrast, after an increase in the mid 1980s, since 1988 there has been a striking fall in the number of newborn babies with hypoplastic left heart syndrome treated at a supraregional referral centre. More widespread use of four-chamber cardiac screening during routine fetal ultrasonography may reduce the number of newborn babies with hypoplastic left heart syndrome-a factor which should be taken into account when the likely requirements for neonatal cardiac transplantation facilities are calculated.	GUYS HOSP,DEPT PATHOL,LONDON SE1 9RT,ENGLAND; HOSP SICK CHILDREN,DEPT PAEDIAT CARDIOL,LONDON WC1N 3JH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	ALLAN, LD (corresponding author), GUYS HOSP,DEPT PERINATAL CARDIOL,ST THOMAS ST,LONDON SE1 9RT,ENGLAND.			Cook, Andrew/0000-0001-5079-7546				ALLAN LD, 1989, INT J CARDIOL, V25, P341, DOI 10.1016/0167-5273(89)90226-X; ALLAN LD, 1984, BRIT HEART J, V52, P542; ALLAN LD, 1986, BRIT MED J, V292, P1717, DOI 10.1136/bmj.292.6537.1717; BAILEY LL, 1990, PEDIATR CLIN N AM, V37, P137; BOUCEK MM, 1990, J PEDIATR-US, V116, P171, DOI 10.1016/S0022-3476(05)82870-7; CULLEN S, 1990, BRIT HEART J, V64, P90; FONTAN F, 1990, CIRCULATION, V81, P1520, DOI 10.1161/01.CIR.81.5.1520; JONAS R, 1990, AUG CARD SOC AUSTR N; MELIONES JN, 1990, CIRCULATION, V82, P151; MURDISON KA, 1990, CIRCULATION, V82, P199; PAHL E, 1990, J PEDIATR, V116, P117	11	62	63	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					959	961		10.1016/0140-6736(91)91582-F	http://dx.doi.org/10.1016/0140-6736(91)91582-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678041				2022-12-24	WOS:A1991FH13100015
J	MALCOLM, S; CLAYTONSMITH, J; NICHOLS, M; ROBB, S; WEBB, T; ARMOUR, JAL; JEFFREYS, AJ; PEMBREY, ME				MALCOLM, S; CLAYTONSMITH, J; NICHOLS, M; ROBB, S; WEBB, T; ARMOUR, JAL; JEFFREYS, AJ; PEMBREY, ME			UNIPARENTAL PATERNAL DISOMY IN ANGELMANS SYNDROME	LANCET			English	Article							PRADER-WILLI SYNDROME; PARENTAL ORIGIN; CHROMOSOME-15 DELETION	Angelman's syndrome and Prader-Willi syndrome are both causes of mental retardation with recognisable, but quite different, clinical phenotypes. Both are associated with deletions of chromosome 15q11-13, of maternal origin in Angelman's and paternal in Prader-Willi. Prader-Willi can arise by inheritance of two chromosomes 15 from the mother and none from the father (uniparental maternal disomy). In 2 patients with Angelman's syndrome we found evidence of uniparental paternal disomy. The phenotypic effects of maternal and paternal disomy of chromosome 15 are very different and inheritance of two normal 15s from one parent does not lead to normal development-strong evidence in man for genomic imprinting, in which the same gene has different effects dependent upon its parental origin.	UNIV BIRMINGHAM,DEPT CLIN GENET,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,ENGLAND; HOSP SICK CHILDREN,DEPT NEUROL,LONDON WC1N 3JH,ENGLAND	University of Birmingham; University of Leicester; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	MALCOLM, S (corresponding author), INST CHILD HLTH,MOTHERCARE DEPT PAEDIAT GENET,GUILFORD ST,LONDON WC1N 1EH,ENGLAND.			Armour, John/0000-0002-8558-8506				ANGELMAN H, 1965, DEV MED CHILD NEUROL, V7, P681; ARMOUR JAL, 1990, GENOMICS, V8, P501, DOI 10.1016/0888-7543(90)90037-U; BOYD SG, 1988, EUR J PEDIATR, V147, P508, DOI 10.1007/BF00441976; BUTLER MG, 1983, LANCET, V1, P1285; BUTLER MG, 1990, AM J MED GENET, V35, P319, DOI 10.1002/ajmg.1320350306; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CREASY MR, 1982, CHROMOSOME ABERRATIO, P122; DONLON TA, 1988, HUM GENET, V80, P322, DOI 10.1007/BF00273644; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; IMAIZUMI K, 1990, AM J MED GENET, V35, P314, DOI 10.1002/ajmg.1320350305; KAPLAN LC, 1987, AM J MED GENET, V28, P45, DOI 10.1002/ajmg.1320280107; KNOLL JHM, 1991, AM J HUM GENET, V48, P16; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; KNOLL JHM, 1989, HUM GENET, V83, P205, DOI 10.1007/BF00286723; LEDBETTER DH, 1988, PRADERWILLI SYNDROME, P13; MAGENIS RE, 1987, AM J MED GENET, V28, P829, DOI 10.1002/ajmg.1320280407; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MALCOLM S, 1990, AM J HUM GENET S, V47, pA227; NAKAMURA Y, 1988, GENOMICS, V3, P342, DOI 10.1016/0888-7543(88)90125-5; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; PEMBREY M, 1989, J MED GENET, V26, P73, DOI 10.1136/jmg.26.2.73; RICH DC, 1988, NUCLEIC ACIDS RES, V16, P8740, DOI 10.1093/nar/16.17.8740; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308; WILLIAMS CA, 1989, AM J MED GENET, V32, P339, DOI 10.1002/ajmg.1320320313	24	267	267	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					694	697		10.1016/0140-6736(91)90278-W	http://dx.doi.org/10.1016/0140-6736(91)90278-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672177				2022-12-24	WOS:A1991FD36700008
J	GARRARD, J; MAKRIS, L; DUNHAM, T; HESTON, LL; COOPER, S; RATNER, ER; ZELTERMAN, D; KANE, RL				GARRARD, J; MAKRIS, L; DUNHAM, T; HESTON, LL; COOPER, S; RATNER, ER; ZELTERMAN, D; KANE, RL			EVALUATION OF NEUROLEPTIC DRUG-USE BY NURSING-HOME ELDERLY UNDER PROPOSED MEDICARE AND MEDICAID REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSYCHOACTIVE MEDICATION; CARE; RESIDENTS; FACILITIES	Federal regulations for use of neuroleptic drugs in Medicare- and Medicaid-certified nursing homes throughout the United States were implemented October 1, 1990. These regulations constitute the first time that prescription drugs are required, by law, to be justified by indications documented in the medical chart. This study used extant data to estimate ineligible neuroleptic use at the individual and nursing home levels had these regulations been in effect in 1976 through 1985. Subjects, randomly sampled admissions (N = 5752) and residents (N = 3191), were followed up for up to 24 months in 60 nursing homes. One half of neuroleptic use in each cohort could be considered ineligible under the regulations; all but one of the nursing homes had one or more individuals who were treated with the ineligible use of neuroleptics. Improvements in documentation and/or prescription of neuroleptic drugs for nursing home elderly will be needed to ensure compliance with these new regulations.	UNIV MINNESOTA,SCH STAT,DEPT APPL STAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,COLL EDUC,DEPT EDUC PSYCHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,COLL PHARM,DEPT PHARM PRACTICE,MINNEAPOLIS,MN 55455; ST PAUL RAMSEY MED CTR,DEPT CLIN PHARM,ST PAUL,MN 55101; UNIV MINNESOTA,DIV BIOSTAT,MINNEAPOLIS,MN 55455; ABBOTT NW HOSP,MINNEAPOLIS,MN; UNIV WASHINGTON,WASHINGTON INST MENTAL ILLNESS TRAINING & RES,SEATTLE,WA 98195	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Saint Paul Ramsey Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle	GARRARD, J (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV HLTH SERV RES & POLICY,420 DELAWARE ST SE,BOX 729 MAYO,MINNEAPOLIS,MN 55455, USA.			Zelterman, Daniel/0000-0003-0711-8688	NATIONAL INSTITUTE ON AGING [K01AG000434] Funding Source: NIH RePORTER; NIA NIH HHS [1KO1-AG 000434-02] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1978, INT CLASSIFICATION D; AVORN J, 1989, NEW ENGL J MED, V320, P227, DOI 10.1056/NEJM198901263200406; BEARDSLEY RS, 1989, J AM GERIATR SOC, V37, P327, DOI 10.1111/j.1532-5415.1989.tb05499.x; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BUCK JA, 1988, J AM GERIATR SOC, V36, P409, DOI 10.1111/j.1532-5415.1988.tb02379.x; BUCK JA, 1989, AM J MENT RETARD, V93, P618; BURNS BJ, 1988, J FAM PRACTICE, V26, P155; DOANE KW, 1989, CONSULTANT PHARM, V4, P367; Goodman L.S., 1980, PHARM BASIS THERAPEU, V6th; HILL BK, 1985, PSYCHOPHARMACOL BULL, V21, P279; Institute of Medicine report, 1986, IMPROVING QUALITY CA; KANE RL, 1989, AM J PUBLIC HEALTH, V79, P1271, DOI 10.2105/AJPH.79.9.1271; KANE RL, 1989, NURSING HOMES NURSIN, P37; Kepferle L, 1983, J Long Term Care Adm, V11, P54; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; 1976, US DHEW MONOGRAPH, V2; 1988, ADVERSE DRUG REACT, P100; 1989, FED REG         0202, V54, P5316; 1986, DRUG EVALUATIONS	20	82	82	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	1991	265	4					463	467		10.1001/jama.265.4.463	http://dx.doi.org/10.1001/jama.265.4.463			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET377	1670645				2022-12-24	WOS:A1991ET37700023
J	POLTEN, A; FLUHARTY, AL; FLUHARTY, CB; KAPPLER, J; VONFIGURA, K; GIESELMANN, V				POLTEN, A; FLUHARTY, AL; FLUHARTY, CB; KAPPLER, J; VONFIGURA, K; GIESELMANN, V			MOLECULAR-BASIS OF DIFFERENT FORMS OF METACHROMATIC LEUKODYSTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARYLSULFATASE-A; PSEUDODEFICIENCY; JUVENILE	Background. Metachromatic leukodystrophy is an autosomal recessive inherited lysosomal storage disorder caused by a deficiency or arylsulfatase A. Three forms of the disease can be distinguished according to severity and the age at onset: late infantile (1 to 2 years), juvenile (3 to 16), and adult (> 16). Methods and Results. To understand the molecular basis of the different forms of the disease, we analyzed arylsulfatase A alleles associated with metachromatic leukodystrophy. Two alleles (termed I and A) were identified and accounted for about half of all arylsulfatase A alleles among 68 patients with metachromatic leukodystrophy whom we examined. Sufficient information was available for 66 of the patients to allow classification of their disease. Of the six instances of homozygosity for allele I, all were associated with the late-infantile form of the disease; of the eight instances of homozygosity for allele A, five were associated with the adult form and three with the juvenile form. When both alleles were present, the juvenile form resulted (seven of seven instances). Heterozygosity for allele I (with the other allele unknown) is usually associated with late-infantile disease, and heterozygosity for allele A with a later onset of the disease. The clinical variability can be explained by the different levels of residual arylsulfatase A activity associated with these genotypes. Conclusions. Like many lysosomal storage disorders, metachromatic leukodystrophy shows clinical heterogeneity that seems to reflect genetic heterogeneity. One of the known alleles (allele I) is associated with earlier and more severe disease than the other (allele A).	UNIV GOTTINGEN,DEPT BIOCHEM 2,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY	University of Gottingen								CLARKE JTR, 1989, AM J MED GENET, V33, P10, DOI 10.1002/ajmg.1320330104; GIESELMANN V, 1989, P NATL ACAD SCI USA, V86, P9436, DOI 10.1073/pnas.86.23.9436; GIESELMANN V, IN PRESS HUM GENET; GUSTAVSON KH, 1971, ACTA PAEDIATR SCAND, V60, P585, DOI 10.1111/j.1651-2227.1971.tb06994.x; HERZ B, 1984, HUM GENET, V66, P147, DOI 10.1007/BF00286589; HOHENSCHUTZ C, 1988, AM J MED GENET, V31, P169, DOI 10.1002/ajmg.1320310120; HOHENSCHUTZ C, 1989, HUM GENET, V82, P45, DOI 10.1007/BF00288270; KAPPLER J, IN PRESS HUM GENET; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KOLODNY EH, 1989, METABOLIC BASIS INHE, V2, P1721; KREYSING J, 1990, EUR J BIOCHEM, V191, P627, DOI 10.1111/j.1432-1033.1990.tb19167.x; KRIVIT W, 1990, NEW ENGL J MED, V322, P28, DOI 10.1056/NEJM199001043220106; STEIN C, 1989, J BIOL CHEM, V264, P1252; TABOR S, 1987, CURRENT PROTOCOLS MO; VONFIGURA K, 1983, P NATL ACAD SCI-BIOL, V80, P6066	15	229	234	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	1991	324	1					18	22		10.1056/NEJM199101033240104	http://dx.doi.org/10.1056/NEJM199101033240104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ503	1670590	Bronze			2022-12-24	WOS:A1991EQ50300004
J	LIGHT, DB; CORBIN, JD; STANTON, BA				LIGHT, DB; CORBIN, JD; STANTON, BA			DUAL ION-CHANNEL REGULATION BY CYCLIC-GMP AND CYCLIC GMP-DEPENDENT PROTEIN-KINASE	NATURE			English	Article									DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PHYSIOL,HANOVER,NH 03756; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Dartmouth College; Vanderbilt University								BEEBE SJ, 1986, ENZYMES, V17, P43; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; DEBOLD AJ, 1986, FED PROC, V45, P2081; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FESENKO EE, 1986, BIOCHIM BIOPHYS ACTA, V856, P661, DOI 10.1016/0005-2736(86)90162-8; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HEMMINGS HC, 1989, FASEB J, V3, P1583, DOI 10.1096/fasebj.3.5.2493406; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LIGHT DB, 1988, AM J PHYSIOL, V255, pF278, DOI 10.1152/ajprenal.1988.255.2.F278; LIGHT DB, 1989, J CLIN INVEST, V84, P352, DOI 10.1172/JCI114162; LIGHT DB, 1989, SCIENCE, V243, P383, DOI 10.1126/science.2463673; MAACK T, 1986, BIOCHEM PHARMACOL, V35, P2057, DOI 10.1016/0006-2952(86)90570-8; NAGATA K, 1989, BIOCHEM BIOPH RES CO, V160, P235, DOI 10.1016/0006-291X(89)91646-X; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PAUPARDINTRITSCH D, 1986, NATURE, V323, P812, DOI 10.1038/323812a0; STANTON BA, 1989, AM J PHYSIOL, V256, pF862, DOI 10.1152/ajprenal.1989.256.5.F862; TANAKA JC, 1987, P NATL ACAD SCI USA, V84, P724, DOI 10.1073/pnas.84.3.724; WALTER U, 1981, EUR J BIOCHEM, V118, P339; WOLFE L, 1987, J BIOL CHEM, V262, P16906; WOODY CD, 1986, BRAIN RES, V386, P379, DOI 10.1016/0006-8993(86)90175-7; YADA Y, 1989, FEBS LETT, V242, P368, DOI 10.1016/0014-5793(89)80503-4; ZEIDEL ML, 1988, J CLIN INVEST, V82, P1067, DOI 10.1172/JCI113663; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	28	175	176	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 22	1990	344	6264					336	339		10.1038/344336a0	http://dx.doi.org/10.1038/344336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV289	1690355				2022-12-24	WOS:A1990CV28900066
J	NAVA, E; PALMER, RMJ; MONCADA, S				NAVA, E; PALMER, RMJ; MONCADA, S			INHIBITION OF NITRIC-OXIDE SYNTHESIS IN SEPTIC SHOCK - HOW MUCH IS BENEFICIAL	LANCET			English	Note							HYPOTENSION	Hypotension in septic shock is often resistant to treatment with vasoconstrictors and appears to be mediated by production of nitric oxide (NO). Reversal of endotoxin-induced hypotension in rats was achieved by intravenous injection of 30 mg/kg NG-monomethyl-L-arginine (L-NMMA), an inhibitor of endogenous NO synthesis. A lower dose of 3 mg/kg L-NMMA was ineffective, but 300 mg/kg L-NMMA accelerated and enhanced the fall in blood pressure. NO synthase inhibitors may be helpful in the treatment of hypotension associated with sepsis or therapeutic use of cytokines, but complete inhibition of endogenous NO synthesis may be counterproductive.	WELLCOME RES LABS,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories				nava, eduardo/0000-0003-3259-0511				COHEN J, 1991, LANCET, V338, P736, DOI 10.1016/0140-6736(91)91453-2; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KLABUNDE RE, 1991, BIOCHEM BIOPH RES CO, V178, P1135, DOI 10.1016/0006-291X(91)91010-A; MONCADA S, 1991, PHARMACOL REV, V43, P109; SCOTTBURDEN T, IN PRESS BIOL NITRIC; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; VALLANCE P, 1989, LANCET, V2, P997; WRIGHT CE, IN PRESS CARDIOVASC	9	389	394	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1555	1557		10.1016/0140-6736(91)92375-C	http://dx.doi.org/10.1016/0140-6736(91)92375-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683974				2022-12-24	WOS:A1991GW03600006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FOSCARNET APPROVED FOR AIDS PATIENTS WITH CMV RETINITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3263	3263						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU964	1660082				2022-12-24	WOS:A1991GU96400004
J	SANTIBANEZKOREF, MF; BIRCH, JM; HARTLEY, AL; JONES, PHM; CRAFT, AW; EDEN, T; CROWTHER, D; KELSEY, AM; HARRIS, M				SANTIBANEZKOREF, MF; BIRCH, JM; HARTLEY, AL; JONES, PHM; CRAFT, AW; EDEN, T; CROWTHER, D; KELSEY, AM; HARRIS, M			P53 GERMLINE MUTATIONS IN LI-FRAUMENI SYNDROME	LANCET			English	Note							CANCER; FAMILY; GENE	Germline mutations within a defined region of the p53 gene have recently been found in families with the Li-Fraumeni syndrome (LFS). In the present study this region of p53 was sequenced in affected individuals from 8 families with LFS. In only 2 of them were such mutations detected. Our findings suggest that the p53 mutation could be the primary lesion in some but not all families with LFS, and confirm that there is a "hot spot" for these mutations at the CpG dinucleotide moiety of codon 248. Assigning risks and counselling families on the basis of presence of p53 mutations should be approached with caution.	CHRISTIE HOSP & HOLT RADIUM INST,CANC RES CAMPAIGN,PEDIAT & FAMILIAL CANC RES GRP,MANCHESTER M20 9BX,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST,CANC RES CAMPAIGN,DEPT CANC GENET,MANCHESTER M20 9BX,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,CANC RES CAMPAIGN,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,DEPT PATHOL,MANCHESTER M20 9BX,LANCS,ENGLAND; ROYAL MANCHESTER CHILDRENS HOSP,MANCHESTER M27 1HA,LANCS,ENGLAND; ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; ROYAL HOSP SICK CHILDREN,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND	Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital; Royal Manchester Children's Hospital; Newcastle University - UK	BIRCH, JM (corresponding author), CHRISTIE HOSP & HOLT RADIUM INST,CANC RES CAMPAIGN,PEDIAT & FAMILIAL CANC RES GRP,MANCHESTER M20 9BX,LANCS,ENGLAND.							BIRCH JM, 1990, CANCER-AM CANCER SOC, V66, P2239, DOI 10.1002/1097-0142(19901115)66:10<2239::AID-CNCR2820661034>3.0.CO;2-Q; DEANE M, 1990, EUR J IMMUNOL, V20, P2209, DOI 10.1002/eji.1830201009; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Sambrook J., 1989, MOL CLONING LAB MANU; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	10	136	136	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1991	338	8781					1490	1491		10.1016/0140-6736(91)92303-J	http://dx.doi.org/10.1016/0140-6736(91)92303-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1683921				2022-12-24	WOS:A1991GV07700007
J	FANNING, A; EDWARDS, S				FANNING, A; EDWARDS, S			MYCOBACTERIUM-BOVIS INFECTION IN HUMAN-BEINGS IN CONTACT WITH ELK (CERVUS-ELAPHUS) IN ALBERTA, CANADA	LANCET			English	Article								Human infection with Mycobacterium bovis is rare in developed countries because of milk pasteurisation and the slaughter of infected cattle. An epizootic of M bovis infection in domesticated elk (Cervus elaphus) in Alberta, Canada, which started in April, 1990, prompted us to seek human contacts of elk herds. There were 446 identified contacts, in 394 of whom tuberculin skin tests were done. Of 81 contacts who were skin-test positive, 50 had been in contact with culture-positive animals. 6 of 106 subjects tested a second time became tuberculin positive. 1 case of active M bovis infection was diagnosed by sputum culture. The mode of transmission of M bovis from these farm animals to man is likely to be aerosolisation of infected particles. Because of the apparent susceptibility of farmed Cervidae (deer) to M bovis infection, and the evidence of spread to man, control measures to prevent human infection should be developed.			FANNING, A (corresponding author), UNIV ALBERTA,DEPT MED,DIV INFECT DIS,2E4 11 WALTER MACKENZIE HLTH SCI CTR,EDMONTON T6G 2J3,ALBERTA,CANADA.							COLLINS CH, 1957, IRISH VET J, V41, P363; FANNING A, 1991, American Review of Respiratory Disease, V143, pA284; GEORGHIOU P, 1989, AUST NZ J MED, V19, P409, DOI 10.1111/j.1445-5994.1989.tb00289.x; KARLSON AG, 1970, ANN INTERN MED, V73, P979, DOI 10.7326/0003-4819-73-6-979; ROBINSON P, 1988, NZ J MED, V18, P701; Stumpff C. D., 1982, Proceedings of the American Animal Health Association, V86, P524; WIGLE WD, 1973, AM REV RESPIR DIS, V106, P528; YATES MD, 1986, J EPIDEMIOL COMMUN H, V40, P295, DOI 10.1136/jech.40.4.295	8	74	76	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1991	338	8777					1253	1255		10.1016/0140-6736(91)92113-G	http://dx.doi.org/10.1016/0140-6736(91)92113-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ166	1682654				2022-12-24	WOS:A1991GQ16600014
J	DRISCOLL, PC; CYSTER, JG; CAMPBELL, ID; WILLIAMS, AF				DRISCOLL, PC; CYSTER, JG; CAMPBELL, ID; WILLIAMS, AF			STRUCTURE OF DOMAIN-1 OF RAT LYMPHOCYTE-T CD2 ANTIGEN	NATURE			English	Article							IMMUNOGLOBULIN SUPERFAMILY; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; PROTEIN; FRAGMENT; SPECTROSCOPY; ACTIVATION; RESOLUTION; RECEPTORS; SEQUENCES	THE CD2 antigen is largely restricted to cells of the T-lymphocyte lineage and has been established as an important adhesion molecule in interactions between human T lymphocytes and accessory cells 1. In the adhesion reaction, CD2 on T cells binds to LFA-3 on other cells, with binding through domain 1 of CD2 (ref. 2). CD2 can also be a target for the delivery of mitogenic signals to T lymphocytes cultured with combinations of anti-CD2 antibodies 3,4. Two predictions that are contradictory have been made for the structure of CD2 domain 1. One suggests an immunoglobulin (Ig) fold, on the basis of sequence patterns conserved in the Ig-superfamily (IgSF) 5, whilst the other proposes a pattern of alternating alpha-helices and beta-strands, on the basis of secondary structure predictions 6. Thus CD2 domain 1 is an important test case for the validity of IgSF assignments based on sequence patterns. We report here the expression of domain 1 of rat CD2 in an Escherichia coli expression system and have determined a low-resolution solution structure by NMR spectroscopy.	UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, MRC, CELLULAR IMMUNOL RES UNIT, OXFORD OX1 3RE, ENGLAND	University of Oxford	DRISCOLL, PC (corresponding author), UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND.		Driscoll, Paul C/B-8007-2010	Driscoll, Paul C/0000-0002-4124-6950				AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BECKER JW, 1985, P NATL ACAD SCI USA, V82, P4225, DOI 10.1073/pnas.82.12.4225; BEYERS AD, 1989, IMMUNOL REV, V111, P59, DOI 10.1111/j.1600-065X.1989.tb00542.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; CLAYTON LK, 1987, EUR J IMMUNOL, V17, P1367, DOI 10.1002/eji.1830170922; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; KRAULIS P, IN PRESS J APPL CRYS; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; RECNY MA, 1990, J BIOL CHEM, V265, P8542; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAUL FA, 1978, J BIOL CHEM, V253, P585; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368	29	150	161	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1991	353	6346					762	765		10.1038/353762a0	http://dx.doi.org/10.1038/353762a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1682812				2022-12-24	WOS:A1991GL69600071
J	SUTTER, RW; PATRIARCA, PA; BROGAN, S; MALANKAR, PG; PALLANSCH, MA; KEW, OM; BASS, AG; COCHI, SL; ALEXANDER, JP; HALL, DB; SULEIMAN, AJM; ALGHASSANY, AAK; ELBUALY, MS				SUTTER, RW; PATRIARCA, PA; BROGAN, S; MALANKAR, PG; PALLANSCH, MA; KEW, OM; BASS, AG; COCHI, SL; ALEXANDER, JP; HALL, DB; SULEIMAN, AJM; ALGHASSANY, AAK; ELBUALY, MS			OUTBREAK OF PARALYTIC POLIOMYELITIS IN OMAN - EVIDENCE FOR WIDESPREAD TRANSMISSION AMONG FULLY VACCINATED CHILDREN	LANCET			English	Article								From January, 1988, to March, 1989, a widespread outbreak (118 cases) of poliomyelitis type 1 occurred in Oman. Incidence of paralytic disease was highest in children younger than 2 years (87/100 000) despite an immunisation programme that recently had raised coverage with 3 doses of oral poliovirus vaccine (OPV) among 12-month-old children from 67% to 87%. We did a case-control study (70 case-patients, 692 age-matched controls) to estimate the clinical efficacy of OPV, assessed the immunogenicity of OPV and extent of poliovirus spread by serology, retrospectively evaluated the cold chain and vaccine potency, and sought the origin of the outbreak strain by genomic sequencing. 3 doses of OPV reduced the risk of paralysis by 91%; vaccine failures could not be explained by failures in the cold chain nor on suboptimum vaccine potency. Cases and controls had virtually identical type 1 neutralising antibody profiles, suggesting that poliovirus type 1 circulation was widespread. Genomic sequencing indicated that the outbreak strain had been recently imported from South Asia and was distinguishable from isolates indigenous to the Middle East. Accumulation of enough children to sustain the outbreak seems to have been due to previous success of the immunisation programme in reducing spread of endemic strains, suboptimum efficacy of OPV, and delay in completing the primary immunisation series until 7 months of age. Additionally, the estimated attack rate of infection among children aged 9-23 months exceeded 25% in some regions, suggesting that a substantial proportion of fully vaccinated children had been involved in the chain of transmission.	CTR DIS CONTROL, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA; UNICEF, Muscat, OMAN; WHO, EXPANDED PROGRAMME IMMUNISAT, CH-1211 GENEVA 27, SWITZERLAND; MINIST HLTH, Muscat, OMAN	Centers for Disease Control & Prevention - USA; World Health Organization	SUTTER, RW (corresponding author), CTR DIS CONTROL, DIV IMMUNISAT E05, ATLANTA, GA 30333 USA.							BASS AG, 1989, REVIEW VACCINE OLD C; BERNIER RH, 1984, REV INFECT DIS, V6, pS371; De-Xiang D, 1986, B WORLD HEALTH ORGAN, V64, P853; DEMING MS, IN PRESS AM J EPIDEM; GAIL MH, 1981, BIOMETRIKA, V68, P703, DOI 10.1093/biomet/68.3.703; HANLON P, 1987, LANCET, V1, P800; JOHN TJ, 1984, REV INFECT DIS, V6, pS438; KIMFARLEY RJ, 1984, LANCET, V2, P1322; Melnick JL, 1979, DIAGNOSTIC PROCEDURE, V5th, P471; OTTEN MW, IN PRESS AM J EPIDEM; PATRIARCA PA, 1988, LANCET, V1, P429; PATRIARCA PA, IN PRESS REV INFECT; RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8; SABIN AB, 1960, JAMA-J AM MED ASSOC, V173, P1521, DOI 10.1001/jama.1960.03020320001001; SABIN AB, 1982, YALE J BIOL MED, V55, P383; SLATER PE, 1990, LANCET, V335, P1192, DOI 10.1016/0140-6736(90)92705-M; SUTTER RW, 1989, AM J PUBLIC HEALTH, V79, P495, DOI 10.2105/AJPH.79.4.495; SUTTER RW, 1989, 38TH ANN M AM SOC TR; TULCHINSKY T, 1989, AM J PUBLIC HEALTH, V79, P1648, DOI 10.2105/AJPH.79.12.1648; 1988, WHO TECH REP SER, V771; 1989, WEEKLY EPIDEMIOL REC, V64, P273; 1990, MMWR, V39, P557; 1985, TRAINING COURSE MID; 1988, WEEKLY EPIDEMIOL REC, V63, P161	24	81	81	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1991	338	8769					715	720		10.1016/0140-6736(91)91442-W	http://dx.doi.org/10.1016/0140-6736(91)91442-W			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679866				2022-12-24	WOS:A1991GG10400003
J	BRAHAMS, D				BRAHAMS, D			GROUP LITIGATION ON THE HORIZON	LANCET			English	Editorial Material							PORCINE INSULIN; HYPOGLYCEMIA											BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; DENISON S, 1991, INDEPENDENT     0807; GALE EAM, 1989, LANCET, V2, P1264; TEUSCHER A, 1987, LANCET, V2, P382	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					625	626		10.1016/0140-6736(91)90624-X	http://dx.doi.org/10.1016/0140-6736(91)90624-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1679162				2022-12-24	WOS:A1991GD80900015
J	SANJOSE, S; ROMAN, E; BERAL, V				SANJOSE, S; ROMAN, E; BERAL, V			LOW-BIRTH-WEIGHT AND PRETERM DELIVERY, SCOTLAND, 1981-84 - EFFECT OF PARENTS OCCUPATION	LANCET			English	Article							GESTATIONAL-AGE; PREGNANCY; REPRODUCTION; PREMATURITY; WORK	The relation between prematurity and parenteral occupation was examined in a national study of 252 147 liveborn babies delivered in Scotland between 1981 and 1984. Information about mothers' and fathers' work was routinely collected at the first antenatal visit, and birthweight and gestational age were recorded at delivery. Preterm delivery (< 37 weeks' gestation) and low birthweight (< 2500 g) were more frequent in the children of mothers and of fathers employed in manual rather than in non-manual jobs. The risk of preterm delivery and/or low birthweight was more than 50% higher in the children of women who worked with electrical, metal, or leather goods than in the children of other female manual workers. These findings were not explained by maternal age, gravidity, marital status, previous perinatal death, baby's sex, or father's social class. For male manual workers, only the children of ceramic workers had an increased risk of prematurity. The risk of a baby being small-for-gestational age (less-than-or-equal-to 5th gestation-specific birthweight percentile) varied little with mother's or father's occupation. Overall, the results suggest that parental occupational exposures do not have a pronounced effect on the risk of prematurity, and when there are adverse effects they are associated with maternal rather than paternal exposures.	RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND; INT AGCY RES CANC,F-69372 LYONS,FRANCE	Radcliffe Infirmary; University of Oxford; World Health Organization; International Agency for Research on Cancer (IARC)				Roman, Eve/0000-0001-7603-3704				[Anonymous], 1980, CLASSIFICATION OCCUP; ARMSTRONG BG, 1989, BRIT J IND MED, V46, P196; AXELSON O, 1989, BRIT J IND MED, V46, P505; CLARKE M, 1985, BRIT MED J, V290, P1235, DOI 10.1136/bmj.290.6477.1235; COLE SK, 1980, PERINATAL AUDIT SURV, P39; FLETCHER AC, 1985, REPRODUCTIVE HAZARDS; LIPSCOMB JA, 1991, J OCCUP ENVIRON MED, V33, P597; MAMELLE N, 1984, AM J EPIDEMIOL, V119, P309, DOI 10.1093/oxfordjournals.aje.a113750; MCDONALD AD, 1988, BRIT J IND MED, V45, P56; McDowall M. E., 1985, STUDIES MED POPULATI; ROSENBERG MJ, 1987, J OCCUP ENVIRON MED, V29, P584; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SANJOSE S, 1989, THESIS LONDON U; SAVITZ DA, 1989, AM J EPIDEMIOL, V129, P1201, DOI 10.1093/oxfordjournals.aje.a115241; 1987, BIRTHWEIGHT STATISTI; 1990, LANCET, V336, P1289	16	57	57	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					428	431		10.1016/0140-6736(91)91045-V	http://dx.doi.org/10.1016/0140-6736(91)91045-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB446	1678094				2022-12-24	WOS:A1991GB44600015
J	BOLLAG, U; BOLLAGALBRECHT, E				BOLLAG, U; BOLLAGALBRECHT, E			RECOMMENDATIONS DERIVED FROM PRACTICE AUDIT FOR THE TREATMENT OF ACUTE OTITIS-MEDIA	LANCET			English	Article							DOUBLE-BLIND; CHILDREN; MANAGEMENT	There is much disagreement about diagnostic criteria and optimum treatment for acute otitis media (OM). From a practice audit of the management of OM, we went on to develop and test a protocol in which we defined criteria for the diagnosis and treatment of this disorder. In a two-year study of 168 children aged 0-16 years with acute OM (and confirmed in a second study of another 62 children during the following year), we found that the main feature of otitis media is intense pain in the ear and is accompanied in 90% of cases by upper respiratory tract infection (URTI) at presentation. Hearing loss is common and otorrhoea develops in about 10% of children. Antibiotics, which are prescribed by most physicians, are not needed in the first instance, but we recommend vigorous treatment with analgesics. Supportive measures are similar to those used for the management of URTI. Follow-up evaluation is essential to detect the few refractory cases that must be referred to the specialist.										ARMSTRONG D, 1990, RES METHODS GENERAL; BLUESTONE CD, 1983, PEDIATRIC OTOLARYNGO; Bluestone CD., 2007, OTITIS MEDIA INFANTS, V4th; BOLLAG U, 1990, CLIN PEDIATR, V29, P244, DOI 10.1177/000992289002900410; BOLLAG U, 1984, HELV PAEDIATR ACTA, V39, P341; BOLLAG U, 1986, SPECTRUM, V27, P52; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; Chalmers D, 1989, CLIN DEV MED, V108, P1; FLEMING DM, 1989, INFLUENZA INFLUENZA, P213; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; FROOM J, 1982, J FAM PRACTICE, V15, P743; FRY J, 1961, CATARRHAL CHILD; HAYDEN GF, 1981, CLIN PEDIATR, V20, P99, DOI 10.1177/000992288102000203; KETTLETY A, 1907, BR J AUDIO, V21, P73; LOWE JF, 1963, LANCET, V2, P1129; PUKANDER J, 1983, ACTA OTO-LARYNGOL, V95, P117, DOI 10.3109/00016488309130924; SCHWARTZ DM, 1980, ANN OTOL RHINOL S68, V68, P211; SCHWARTZ RH, 1981, CLIN PEDIATR, V20, P549, DOI 10.1177/000992288102000901; SKINNER WM, 1978, OTOLARYNGOL CLIN N A, V11, P631; STOOL S, 1989, POSTGRAD MED, V85, P40; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883	22	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					96	99		10.1016/0140-6736(91)90086-5	http://dx.doi.org/10.1016/0140-6736(91)90086-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676479				2022-12-24	WOS:A1991FW16100014
J	CASTRILLO, JL; THEILL, LE; KARIN, M				CASTRILLO, JL; THEILL, LE; KARIN, M			FUNCTION OF THE HOMEODOMAIN PROTEIN GHF1 IN PITUITARY CELL-PROLIFERATION	SCIENCE			English	Article							HORMONE-RELEASING FACTOR; GENE; MICE; OLIGODEOXYNUCLEOTIDE; SOMATOTROPHS; REPLICATION; EXPRESSION; INHIBITION; ELEMENTS; INVITRO	Mutations that cause pituitary dwarfism in the mouse reside in the gene encoding the transcription factor growth hormone factor 1 (GHF1 or pit1). These dwarf mice (dw and dw(J)) are deficient in growth hormone (GH) and prolactin (PRL) synthesis and exhibit pituitary hypoplasia, suggesting a stem cell defect. With antisense oligonucleotide technology, a cell culture model of this genetic defect was developed. Specific inhibition of GHF1 synthesis by complementary oligonucleotides led to a marked decrease in GH and PRL expression and to a marked decrease in proliferation of somatotrophic cell lines. These results provide direct evidence that the homeodomain protein GHF1 is required not only for the establishment and maintenance of the differentiated phenotype but for cell proliferation as well.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038527] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38527] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTKE A, 1964, ANAT RECORD, V149, P225, DOI 10.1002/ar.1091490206; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CARACCIOLO D, 1989, SCIENCE, V245, P1107, DOI 10.1126/science.2672339; CASTRILLO JL, UNPUB; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; EICHER EM, 1976, J HERED, V67, P87, DOI 10.1093/oxfordjournals.jhered.a108682; Francis Torben, 1944, ACTA PATH ET MICROBIOL SCAND, V21, P928; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; ISHIKAWA K, 1986, NEUROENDOCRINOLOGY, V43, P537, DOI 10.1159/000124579; Karin M, 1990, CURR OPIN CELL BIOL, V2, P996, DOI 10.1016/0955-0674(90)90148-8; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; REYMOND MJ, 1984, ACTA ENDOCRINOL-COP, V106, P459, DOI 10.1530/acta.0.1060459; ROUX M, 1982, CELL TISSUE RES, V223, P415, DOI 10.1007/BF01258498; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Snell GD, 1929, P NATL ACAD SCI USA, V15, P274, DOI 10.1073/pnas.15.3.274; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; WILSON DB, 1981, J ANAT, V133, P407; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	32	236	239	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					197	199		10.1126/science.1677216	http://dx.doi.org/10.1126/science.1677216			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1677216				2022-12-24	WOS:A1991FW16000037
J	EVERALL, IP; LUTHERT, PJ; LANTOS, PL				EVERALL, IP; LUTHERT, PJ; LANTOS, PL			NEURONAL LOSS IN THE FRONTAL-CORTEX IN HIV-INFECTION	LANCET			English	Article							IMMUNE-DEFICIENCY SYNDROME; ARBITRARY PARTICLES; AIDS; VIRUS; NUMBER; NEUROPATHOLOGY; ENCEPHALOPATHY; PATHOLOGY; PROTEIN; BRAINS	In an attempt to elucidate the cause and mechanism of the dementia and other neurological disorders that can occur in HIV-1 infection, we have quantitatively assessed neuronal populations, by means of a stereological technique (the disector), in the frontal cortex of patients with HIV infection. Eleven of sixty-five brains in the Medical Research Council Central AIDS Brain Bank were selected for study. The selected patients died without opportunistic infection or neoplasm affecting the brain; they had HIV encephalitis or minimal changes. We compared their neuronal counts with those of eight control subjects (seven died of systemic illness, one of pontine haemorrhage which did not affect the cerebral hemispheres). The neuronal numerical density was significantly lower in the HIV group than in the control group (mean [SD] 307 [46] vs 499 [113] x 10(2) per mm3; p < 0.001). This difference represents a loss of about 38%. There was no significant difference between the HIV subgroups, which suggests that neuronal loss occurs in cases of minor pathology as well as in HIV encephalitis. This finding contributes to the understanding of dementia in AIDS patients and has important implications for their future treatment.			EVERALL, IP (corresponding author), INST PSYCHIAT,DEPT NEUROPATHOL,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.			Luthert, Philip/0000-0001-7276-6898				BRAENDGAARD H, 1990, J MICROSC-OXFORD, V157, P285, DOI 10.1111/j.1365-2818.1990.tb02967.x; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BUDKA H, 1989, ACTA NEUROPATHOL, V77, P225, DOI 10.1007/BF00687573; BUDKA H, 1987, ACTA NEUROPATHOL, V75, P185, DOI 10.1007/BF00687080; CIARDI A, 1990, ACTA NEUROPATHOL, V81, P51, DOI 10.1007/BF00662637; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; EPSTEIN LG, 1985, AIDS RES, V1, P447; EVERALL IP, 1991, IN PRESS NEUROPATHOL; GABUZDA DH, 1986, ANN NEUROL, V20, P289, DOI 10.1002/ana.410200304; GUNDERSEN HJG, 1981, J MICROSC-OXFORD, V121, P65, DOI 10.1111/j.1365-2818.1981.tb01199.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LANG W, 1989, ACTA NEUROPATHOL, V77, P379, DOI 10.1007/BF00687372; MARIO M, 1990, AIDS, V4, P831; Michaels J, 1988, Immunodefic Rev, V1, P71; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; WILEY CA, IN PRESS ANN NEUROL	21	465	467	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1119	1121		10.1016/0140-6736(91)92786-2	http://dx.doi.org/10.1016/0140-6736(91)92786-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674013				2022-12-24	WOS:A1991FL12400003
J	BRESSAC, B; KEW, M; WANDS, J; OZTURK, M				BRESSAC, B; KEW, M; WANDS, J; OZTURK, M			SELECTIVE G-MUTATION TO T-MUTATION OF P53 GENE IN HEPATOCELLULAR-CARCINOMA FROM SOUTHERN AFRICA	NATURE			English	Article							HEPATITIS-B VIRUS; CELL-LINE; LIVER; DNA; ESTABLISHMENT	HEPATOCELLULAR carcinoma (HCC) is a prevalent cancer in sub-Saharan Africa and eastern Asia 1. Hepatitis B virus and aflatoxins are risk factors for HCC 2, but the molecular mechanism of human hepatocellular carcinogenesis is largely unknown 3. Abnormalities in the structure and expression of the tumour-suppressor gene p53 are frequent in HCC cell lines 4, and allelic losses from chromosome 17p have been found in HCCs from China 5 and Japan 6. Here we report on allelic deletions from chromosome 17p and mutations of the p53 gene found in 50% of primary HCCs from southern Africa. Four of five mutations detected were G --> T substitutions, with clustering at codon 249. This mutation specificity could reflect exposure to a specific carcinogen, one candidate being aflatoxin B1 (ref. 7), a food contaminant in Africa 8, which is both a mutagen that induces G to T substitution 9 and a liver-specific carcinogen 10.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,MGH E,149 13TH ST,BOSTON,MA 02129; UNIV WITWATERSRAND,PARKTOWN 2193,SOUTH AFRICA	Harvard University; Massachusetts General Hospital; University of Witwatersrand			OZTURK, MEHMET/AAS-7241-2021; Paillerets, Brigitte Bressac-de/D-8954-2018; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; 				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; AMES BN, 1973, P NATL ACAD SCI USA, V70, P2281, DOI 10.1073/pnas.70.8.2281; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOSCH FX, 1989, LIVER CELL CARCINOMA, P3; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHIBA I, 1990, ONCOGENE, V5, P1603; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; FOSTER PL, 1983, P NATL ACAD SCI-BIOL, V80, P2695, DOI 10.1073/pnas.80.9.2695; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; FUJIMORI M, 1991, CANCER RES, V51, P89; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HE L, 1984, IN VITRO CELL DEV B, V20, P493, DOI 10.1007/BF02619623; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; MAKLIN D, 1990, SCIENCE, V250, P1233; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASHARANI U, 1988, NUCLEIC ACIDS RES, V16, P7757, DOI 10.1093/nar/16.15.7757; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NEWBERNE PM, 1969, CANCER RES, V29, P236; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SLAGLE BL, 1991, CANCER RES, V51, P49; VANRENSBURG SJ, 1985, BRIT J CANCER, V51, P713, DOI 10.1038/bjc.1985.107; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YANG SS, 1990, CANCER RES, V50, pS5658; YEH FS, 1989, CANCER RES, V49, P2506	29	1265	1304	0	76	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					429	431		10.1038/350429a0	http://dx.doi.org/10.1038/350429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1672732				2022-12-24	WOS:A1991FF04200052
J	VOLLBRECHT, E; VEIT, B; SINHA, N; HAKE, S				VOLLBRECHT, E; VEIT, B; SINHA, N; HAKE, S			THE DEVELOPMENTAL GENE KNOTTED-1 IS A MEMBER OF A MAIZE HOMEOBOX GENE FAMILY	NATURE			English	Article							DROSOPHILA; ANTENNAPEDIA; EXPRESSION; PROTEINS; HOMEODOMAIN; TRANSCRIPTS; SEQUENCES; REGION; LOCUS	THE Knotted-1 (Kn1) locus is defined by several dominant gain-of-function mutations that alter leaf development. Foci of cells along the lateral veins do not differentiate properly, but continue to divide, forming outpocketings or knots. The ligule, a fringe normally found at the junction of leaf blade and sheath, is often displaced and perpendicular to its normal position 1-3. The phenotype is manifested in all cell layers of the leaf blade, but is controlled by a subgroup of cells of the inner layer 4. Mutations result from the insertion of transposable elements 5 or a tandem duplication 6. We show that the Kn1 gene encodes a homeodomain-containing protein, the first identified in the plant kingdom. Sequence comparisons strongly suggest that Kn1 acts as a transcription factor. Here we use the Kn1 homeobox to isolate other expressed homeobox genes in maize. The Kn1 homeobox may permit the isolation of genes that, like animal and fungal counterparts 7, regulate cell fate determination.	USDA ARS,CTR PLANT GENE EXPRESS,800 BUCHANAN ST,ALBANY,CA 94710; UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	United States Department of Agriculture (USDA); University of California System; University of California Berkeley				Vollbrecht, Erik/0000-0003-4919-1365; Sinha, Neelima/0000-0002-1494-7065				Bryan AA, 1941, J HERED, V32, P343, DOI 10.1093/oxfordjournals.jhered.a104959; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; COLEMAN KG, 1987, GENE DEV, V1, P19, DOI 10.1101/gad.1.1.19; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FREELING M, 1985, GENETICS, V111, P617; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GELINAS D, 1969, AM J BOT, V56, P671, DOI 10.2307/2440442; HAKE S, 1989, EMBO J, V8, P15, DOI 10.1002/j.1460-2075.1989.tb03343.x; HAKE S, 1985, PLANT GENETICS, P61; HANLEY BA, 1988, NUCLEIC ACIDS RES, V16, P7159, DOI 10.1093/nar/16.14.7159; HARDING K, 1986, SCIENCE, V233, P953, DOI 10.1126/science.3755551; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LANGDALE JA, 1989, DEV BIOL, V133, P128, DOI 10.1016/0012-1606(89)90304-7; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SINHA N, 1990, DEV BIOL, V141, P203, DOI 10.1016/0012-1606(90)90115-Y; VEIT B, 1990, GENETICS, V125, P623; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3	34	573	633	3	76	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					241	243		10.1038/350241a0	http://dx.doi.org/10.1038/350241a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1672445				2022-12-24	WOS:A1991FC77900061
J	EPSTEIN, WV; HENKE, CJ; YELIN, EH; KATZ, PP				EPSTEIN, WV; HENKE, CJ; YELIN, EH; KATZ, PP			EFFECT OF PARENTERALLY ADMINISTERED GOLD THERAPY ON THE COURSE OF ADULT RHEUMATOID-ARTHRITIS	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; SODIUM THIOMALATE; HEALTH-STATUS; DISABILITY; MORTALITY; OUTCOMES; PLACEBO; DISEASE	Objective: To describe the course of rheumatoid arthritis over 5 years in adults and to evaluate the effect of parenterally administered gold salts on that course. Design: A prospective observational study of adults with rheumatoid arthritis. Data derived from annual interviews with patients from 1983 to 1988 and from physician surveys in 1983 and 1987. Setting: Rheumatology practices in the community. Patients: The study began in 1982 with 822 adults who had rheumatoid arthritis and were under the care of rheumatologists. Interventions: Those selected by rheumatologists in the management of their patients. Measurements: Information describing sociodemographic and clinical characteristics, course, and therapy was collected from patients and verified by physician reports. Functional status, measured by the Health Assessment Questionnaire, and the number of painful joints were used as outcome variables. Outcome variables were adjusted for age, sex, disease duration, baseline values of the outcome variable, and the use of four disease-remittive agents other than gold. Main Results: Multivariate repeated-measures analysis of variance showed no change in the course of rheumatoid arthritis over 5 years. The use of parenteral gold for at least 2 consecutive years at the start of the observation period produced, on average, no change in the course over 5 years in the two outcome variables. Conclusion: In our study of a community-based population of adults with rheumatoid arthritis who were under the care of community rheumatologists, we found that there was, on average, no statistically significant change in function or number of painful joints between 1983 and 1988. Patients receiving parenteral gold therapy for at least 2 consecutive years did not show a statistically significant difference in outcome when compared with those not receiving such therapy.	UNIV CALIF SAN FRANCISCO, ROSALIND RUSSELL ARTHRITIS CTR, SAN FRANCISCO, CA 94143 USA; KAISER PERMANENTE MED CTR, OAKLAND, CA USA	University of California System; University of California San Francisco; Kaiser Permanente					NIAMS NIH HHS [AR-20684] Funding Source: Medline; NIA NIH HHS [K04AG00273] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K04AG000273] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JJ, 1989, ARTHRITIS RHEUM, V32, P1093, DOI 10.1002/anr.1780320907; ANDERSON JJ, 1989, ARTHRITIS RHEUM, V32, P844; [Anonymous], 1960, ANN RHEUM DIS, V19, P95; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BOMBARDIER C, 1985, J RHEUMATOL, V12, P403; BOMBARDIER C, 1982, J RHEUMATOL, V9, P798; BRADLEY LA, 1989, ARTHRITIS RHEUM, V32, P1611, DOI 10.1002/anr.1780321220; BYE B, 1982, SSA1311745 PUBL, P1; EPSTEIN WV, 1989, J RHEUMATOL, V16, P1291; GABRIEL SE, 1988, MEDICINE, V67, P58, DOI 10.1097/00005792-198801000-00004; GOLDMAN AE, 1983, AM J MED, V75, P79, DOI 10.1016/0002-9343(83)90479-5; GORDON DA, 1989, TXB RHEUMATOLOGY, P804; IANNUZZI L, 1983, NEW ENGL J MED, V309, P1023, DOI 10.1056/NEJM198310273091704; KUSHNER I, 1989, J RHEUMATOL, V16, P1; LOUIS TA, 1988, STAT MED, V7, P29, DOI 10.1002/sim.4780070108; MEENAN RF, 1988, AM J PUBLIC HEALTH, V78, P1484, DOI 10.2105/AJPH.78.11.1484; NEVITT MC, 1986, ANN INTERN MED, V105, P421, DOI 10.7326/0003-4819-105-3-421; OREGLIA A, 1986, ABRIDGED LIFE TABLES; PINCUS T, 1984, ARTHRITIS RHEUM-US, V27, P864, DOI 10.1002/art.1780270805; PINCUS T, 1986, J RHEUMATOL, V13, P841; RAGAN C, 1951, B NEW YORK ACAD MED, V27, P63; SHARP JT, 1982, ARTHRITIS RHEUM, V25, P540, DOI 10.1002/art.1780250508; SHERRER YS, 1987, J RHEUMATOL, V14, P705; SIGLER JW, 1974, ANN INTERN MED, V80, P21, DOI 10.7326/0003-4819-80-1-21; VANDERHEIJDE MFM, 1988, SEMIN ARTHRITIS RHEU, V17, P284, DOI 10.1016/0049-0172(88)90013-3; WARD JR, 1983, ARTHRITIS RHEUM, V26, P1303, DOI 10.1002/art.1780261102; WILLIAMS HJ, 1988, ARTHRITIS RHEUM, V31, P702, DOI 10.1002/art.1780310602; WOLFE F, 1988, J RHEUMATOL, V15, P1480; WOLFE F, 1990, J RHEUMATOL, V17, P24; YELIN E, 1987, ARTHRITIS RHEUM, V30, P507, DOI 10.1002/art.1780300504; YELIN E, 1987, J RHEUMATOL, V14, P710; YELIN EH, 1985, NEW ENGL J MED, V312, P962, DOI 10.1056/NEJM198504113121506; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1961, ANN RHEUM DIS, V20, P315	34	54	55	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					437	444		10.7326/0003-4819-114-6-437	http://dx.doi.org/10.7326/0003-4819-114-6-437			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1671630				2022-12-24	WOS:A1991FB64000001
J	DEAN, JD; JONES, CJH; HUTCHISON, SJ; PETERS, JR; HENDERSON, AH				DEAN, JD; JONES, CJH; HUTCHISON, SJ; PETERS, JR; HENDERSON, AH			HYPERINSULINEMIA AND MICROVASCULAR ANGINA (SYNDROME-X)	LANCET			English	Note								Glucose and insulin responses to a glucose load in 11 patients with angina attributed to microvascular coronary dysfunction were compared with those in 11 healthy subjects matched for age, sex, and body mass. Stimulated hyperinsulinaemia was demonstrated in the microvascular angina group. The findings suggest a role for increased concentrations of insulin in coronary microvascular dysfunction.	UNIV COLL CARDIFF,DEPT CARDIOL,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES; UNIV COLL CARDIFF,DEPT MED,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University								CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; FACTOR SM, 1985, PROG CARDIOVASC DIS, V27, P395, DOI 10.1016/0033-0620(85)90002-7; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GELTMAN EM, 1990, J AM COLL CARDIOL, V16, P586, DOI 10.1016/0735-1097(90)90347-R; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; SAX FL, 1987, NEW ENGL J MED, V317, P1366, DOI 10.1056/NEJM198711263172202; STALDER M, 1981, DIABETOLOGIA, V21, P544; 1987, LANCET, V2, P1247	10	120	123	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					456	457						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671472				2022-12-24	WOS:A1991EY88700005
J	WAFFORD, KA; BURNETT, DM; DUNWIDDIE, TV; HARRIS, RA				WAFFORD, KA; BURNETT, DM; DUNWIDDIE, TV; HARRIS, RA			GENETIC-DIFFERENCES IN THE ETHANOL SENSITIVITY OF GABA-A RECEPTORS EXPRESSED IN XENOPUS OOCYTES	SCIENCE			English	Article									VET ADM MED CTR,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA)	WAFFORD, KA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262, USA.			Wafford, Keith/0000-0003-4537-4690	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006399, R37AA006399, P50AA003527] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06399, AA03527] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Allan A M, 1987, Recent Dev Alcohol, V5, P313; ALLAN AM, 1986, LIFE SCI, V39, P2005, DOI 10.1016/0024-3205(86)90324-3; ALLAN AM, 1987, PHARMACOL BIOCHEM BE, V27, P665, DOI 10.1016/0091-3057(87)90192-4; BELKNAP JK, 1983, BEHAV GENET, V13, P383, DOI 10.1007/BF01065776; CELENTANO JJ, 1989, BRAIN RES, V455, P337; GAGE PW, 1985, BRIT J PHARMACOL, V85, P675, DOI 10.1111/j.1476-5381.1985.tb10563.x; GALLAHER EJ, 1987, PSYCHOPHARMACOLOGY, V93, P25, DOI 10.1007/BF02439582; HARRIS DP, 1984, GEN PHARMACOL, V15, P449, DOI 10.1016/0306-3623(84)90198-8; HARRIS RA, 1989, BRAIN RES, V490, P26; HARRIS RA, 1989, FASEB J, V3, P1689, DOI 10.1096/fasebj.3.6.2467834; HARRIS RA, 1988, J PHARMACOL EXP THER, V247, P1012; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; HOUAMED KM, 1984, NATURE, V310, P318, DOI 10.1038/310318a0; HOWERTON TC, 1983, J PHARMACOL EXP THER, V227, P389; KIER WJ, IN PRESS SOC NEUR AB; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MANCILLAS JR, 1986, SCIENCE, V231, P161, DOI 10.1126/science.2867600; MCCLEARN GE, 1973, BEHAV GENET, V3, P409; MCQUILKIN SJ, 1990, LIFE SCI, V46, P527, DOI 10.1016/0024-3205(90)90009-G; MEHTA AK, 1988, J PHARMACOL EXP THER, V246, P558; NESTOROS JN, 1980, SCIENCE, V209, P708, DOI 10.1126/science.7394531; PALMER MR, 1988, J PHARMACOL EXP THER, V247, P1018; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SUZDAK PD, 1986, P NATL ACAD SCI USA, V83, P4071, DOI 10.1073/pnas.83.11.4071; SUZDAK PD, 1988, J PHARMACOL EXP THER, V245, P880; SUZDAK PD, 1986, SCIENCE, V234, P1243, DOI 10.1126/science.3022383; TAKADA R, 1989, ALCOHOL, V6, P115, DOI 10.1016/0741-8329(89)90035-9; TICKU MK, 1988, PHARMACOL BIOCHEM BE, V30, P501, DOI 10.1016/0091-3057(88)90487-X; WAFFORD KA, 1989, BRAIN RES, V505, P215, DOI 10.1016/0006-8993(89)91445-5; WILSON JR, 1986, SOC BIOL, V32, P162	32	146	147	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 20	1990	249	4966					291	293		10.1126/science.1695761	http://dx.doi.org/10.1126/science.1695761			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP599	1695761				2022-12-24	WOS:A1990DP59900038
J	YU, GL; BRADLEY, JD; ATTARDI, LD; BLACKBURN, EH				YU, GL; BRADLEY, JD; ATTARDI, LD; BLACKBURN, EH			INVIVO ALTERATION OF TELOMERE SEQUENCES AND SENESCENCE CAUSED BY MUTATED TETRAHYMENA-TELOMERASE RNAS	NATURE			English	Article									UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; BERNARDS A, 1983, NATURE, V303, P592, DOI 10.1038/303592a0; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1981, P NATL ACAD SCI-BIOL, V78, P2263, DOI 10.1073/pnas.78.4.2263; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1984, CELL, V37, P7, DOI 10.1016/0092-8674(84)90295-2; BROWN WRA, 1989, NATURE, V338, P774, DOI 10.1038/338774a0; BUDARF ML, 1986, J BIOL CHEM, V261, P363; BUDARF ML, 1986, NUCLEIC ACIDS RES, V15, P6273; CROSS SH, 1989, NATURE, V338, P771, DOI 10.1038/338771a0; DIFFLEY JFX, 1989, NATURE, V342, P24, DOI 10.1038/342024a0; FORNEY J, 1987, NUCLEIC ACIDS RES, V15, P9143, DOI 10.1093/nar/15.22.9143; FRANKEL J, 1977, DEV BIOL, V58, P255, DOI 10.1016/0012-1606(77)90091-4; FRANKEL J, 1976, J CELL BIOL, V71, P242, DOI 10.1083/jcb.71.1.242; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; KINGSTON RE, 1988, CURRENT PROTOCOLS MO; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABHART P, 1986, CELL, V45, P431, DOI 10.1016/0092-8674(86)90329-6; LARSON DD, 1987, CELL, V50, P477, DOI 10.1016/0092-8674(87)90501-0; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, IN PRESS CELL; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; PERROT M, 1987, MOL CELL BIOL, V7, P1725, DOI 10.1128/MCB.7.5.1725; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; RAGHURAMAN MK, 1989, CELL, V59, P719, DOI 10.1016/0092-8674(89)90018-4; RAGHURAMAN MK, 1989, NUCLEIC ACIDS RES, V17, P4235, DOI 10.1093/nar/17.11.4235; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SHOEMAN RL, 1988, J BIOL CHEM, V263, P18744; SHOEMAN RL, IN PRESS J BIOL CHEM; SPANGLER EA, 1988, NUCLEIC ACIDS RES, V16, P5569, DOI 10.1093/nar/16.12.5569; SUGEWARA N, 1986, YEAST S, V2, P373; TONDRAVI MM, 1986, P NATL ACAD SCI USA, V83, P4369, DOI 10.1073/pnas.83.12.4369; YU GL, 1989, P NATL ACAD SCI USA, V86, P8487, DOI 10.1073/pnas.86.21.8487; YU GL, 1988, P NATL ACAD SCI USA, V85, P5151, DOI 10.1073/pnas.85.14.5151; YU GL, IN PRESS MOL CELL BI; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	48	575	620	0	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 8	1990	344	6262					126	132		10.1038/344126a0	http://dx.doi.org/10.1038/344126a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT095	1689810				2022-12-24	WOS:A1990CT09500059
J	LEVINE, B; HARDWICK, JM; TRAPP, BD; CRAWFORD, TO; BOLLINGER, RC; GRIFFIN, DE				LEVINE, B; HARDWICK, JM; TRAPP, BD; CRAWFORD, TO; BOLLINGER, RC; GRIFFIN, DE			ANTIBODY-MEDIATED CLEARANCE OF ALPHAVIRUS INFECTION FROM NEURONS	SCIENCE			English	Article							AGE-DEPENDENT RESISTANCE; CENTRAL NERVOUS-SYSTEM; SINDBIS VIRUS; VIRAL-INFECTION; IMMUNE-RESPONSE; MICE; ENCEPHALITIS; PATHOGENESIS; ENCEPHALOMYELITIS; LYMPHOCYTES	Humoral immunity is important for protection against viral infection and neutralization of extracellular virus, but clearance of virus from infected tissues is thought to be mediated solely by cellular immunity. However, in a SCID mouse model of persistent alphavirus encephalomyelitis, adoptive transfer of hyperimmune serum resulted in clearance of infectious virus and viral RNA from the nervous system, whereas adoptive transfer of sensitized T lymphocytes had no effect on viral replication. Three monoclonal antibodies to two different epitopes on the E2 envelope glycoprotein mediated viral clearance. Treatment of alphavirus-infected primary cultured rat neurons with these monoclonal antibodies to E2 resulted in decreased viral protein synthesis, followed by gradual termination of mature infectious virion production. Thus, antibody can mediate clearance of alphavirus infection from neurons by restricting viral gene expression.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Crawford, Thomas/E-6307-2012	Bollinger, Robert/0000-0002-6798-6834	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029234, T32NS007000] Funding Source: NIH RePORTER; NINDS NIH HHS [T32-NS-07000, NS29234] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLAS ZK, 1986, J IMMUNOL, V137, P2380; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; FUJINAMI RS, 1989, J VIROL, V63, P2081, DOI 10.1128/JVI.63.5.2081-2087.1989; GRIFFIN DE, 1976, J INFECT DIS, V133, P456, DOI 10.1093/infdis/133.4.456; GRIFFIN DE, 1973, CELL IMMUNOL, V9, P426, DOI 10.1016/0008-8749(73)90057-9; JACKSON AC, 1987, LAB INVEST, V56, P418; JACKSON AC, 1988, LAB INVEST, V58, P503; JOHNSON RT, 1972, J INFECT DIS, V125, P257, DOI 10.1093/infdis/125.3.257; LEVINE B, UNPUB; MAUERHOFF T, 1988, J NEUROIMMUNOL, V18, P271, DOI 10.1016/0165-5728(88)90049-5; MCFARLAND HF, 1974, J IMMUNOL, V113, P173; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; MENDOZA QP, 1988, J GEN VIROL, V70, P3015; MOMBURG F, 1986, EUR J IMMUNOL, V16, P551, DOI 10.1002/eji.1830160516; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLMSTED RA, 1986, VIROLOGY, V148, P245, DOI 10.1016/0042-6822(86)90322-3; PERRY LL, 1991, J VIROL, V65, P3429, DOI 10.1128/JVI.65.7.3429-3434.1991; SCHMALJOHN AL, 1982, NATURE, V297, P70, DOI 10.1038/297070a0; SCHMALJOHN AL, 1983, VIROLOGY, V130, P305; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHERMAN LA, 1990, J VIROL, V64, P2041, DOI 10.1128/JVI.64.5.2041-2046.1990; STANLEY J, 1986, J VIROL, V58, P107, DOI 10.1128/JVI.58.1.107-115.1986; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; TYLER KL, 1989, J EXP MED, V170, P887, DOI 10.1084/jem.170.3.887	25	325	329	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					856	860		10.1126/science.1658936	http://dx.doi.org/10.1126/science.1658936			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1658936				2022-12-24	WOS:A1991GN83300045
J	ULLMAN, KS; FLANAGAN, WM; EDWARDS, CA; CRABTREE, GR				ULLMAN, KS; FLANAGAN, WM; EDWARDS, CA; CRABTREE, GR			ACTIVATION OF EARLY GENE-EXPRESSION IN LYMPHOCYTES-T BY OCT-1 AND AN INDUCIBLE PROTEIN, OAP40	SCIENCE			English	Article							RNA POLYMERASE-II; HISTONE H2B GENE; TRANSCRIPTION FACTOR; BINDING-PROTEIN; POU DOMAIN; CONTAINS; PURIFICATION; INTERACTS; COMPLEX; PROMOTERS	After antigenic stimulation of T lymphocytes, genes essential for proliferation and immune function, such as the interleukin-2 (IL-2) gene, are transcriptionally activated. In both transient transfections and T lymphocyte-specific in vitro transcription, the homeodomain-containing protein Oct-1 participated in the inducible regulation of transcription of the IL-2 gene. Oct-1 functioned in this context with a 40-kilodalton protein called Oct-1-associated protein (OAP40). In addition to interacting specifically with DNA, OAP40 reduced the rate of dissociation of Oct-I from its cognate DNA-binding site, suggesting that a direct interaction exists between Oct-1 and OAP40.	STANFORD UNIV,BECKMAN CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305; GENELABS INC,REDWOOD CITY,CA 94063; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University				Ullman, Katharine/0000-0003-3693-2830	NATIONAL CANCER INSTITUTE [R01CA039612, R37CA039612] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033942] Funding Source: NIH RePORTER; NCI NIH HHS [CA39612] Funding Source: Medline; NHLBI NIH HHS [HL33942] Funding Source: Medline; NIAID NIH HHS [AI07290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EDWARDS CM, UNPUB; FLANAGAN WM, IN PRESS J BIOL CHEM; FLANAGAN WP, UNPUB; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KEMP LM, 1988, EMBO J, V7, P4239, DOI 10.1002/j.1460-2075.1988.tb03321.x; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Ullman K.S., UNPUB; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113	37	153	155	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					558	562		10.1126/science.1683003	http://dx.doi.org/10.1126/science.1683003			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1683003				2022-12-24	WOS:A1991GL79900045
J	PIALOUX, G; YOULE, M; DUPONT, B; GAZZARD, B; CAUWENBERGH, GFMJ; STOFFELS, PAM; DAVIES, S; DESAINTMARTIN, J; JANSSEN, PAJ				PIALOUX, G; YOULE, M; DUPONT, B; GAZZARD, B; CAUWENBERGH, GFMJ; STOFFELS, PAM; DAVIES, S; DESAINTMARTIN, J; JANSSEN, PAJ			PHARMACOKINETICS OF R-82913 IN PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX	LANCET			English	Article							REPLICATION	R 82913, a tetrahydroimidazobenzodiazepinthione (TIBO) derivative with potent activity against human immunodeficiency virus 1 (HIV-1) in vitro, was given to 22 patients with AIDS or AIDS-related complex in a dose-escalating pilot study. Doses of 10 to 300 mg administered daily by intravenous infusion were well tolerated for up to 50 weeks, with no haematological or biochemical evidence of toxicity. Mean OKT4 cell count rose slightly during the second month of treatment when higher steady-state plasma concentrations of the drug were achieved. Median p24 antigen concentration fell by 41% during the first month of therapy. When the rise in p24 antigen before therapy was compared to the fall during treatment, end-point analysis showed a significant difference (p < 0.03). The combination of potent antiretroviral activity in vitro and the observed effect on H IV p24 antigen and absence of toxicity in vivo indicate that R 82913 and related TIBO derivatives merit further study in the treatment of retroviral infections.	WESTMINSTER MED SCH & HOSP,DEAN RYLE ST,LONDON SW1P 2AP,ENGLAND; HOP INST PASTEUR,PARIS,FRANCE; CHU NECKER ENFANTS MALAD,F-75730 PARIS 15,FRANCE; ST STEPHENS HOSP,LONDON SW10 9TH,ENGLAND; JANSSEN RES FDN,BEERSE,BELGIUM; INST PASTEUR,IMMUNOHAEMATOL UNIT,F-75724 PARIS 15,FRANCE	Imperial College London; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Johnson & Johnson; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; NAKASHIMA H, 1986, ANTIMICROB AGENTS CH, V30, P9033; PAUUWELS R, 1990, DESIGN ANTIAIDS DRUG, P103; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; YARCHOAN R, 1986, LANCET, V1, P575	5	36	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					140	143		10.1016/0140-6736(91)90135-C	http://dx.doi.org/10.1016/0140-6736(91)90135-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677064				2022-12-24	WOS:A1991FX42400003
J	EMMERSON, BT				EMMERSON, BT			IDENTIFICATION OF THE CAUSES OF PERSISTENT HYPERURICEMIA	LANCET			English	Article								Accurate identification of the factors that contribute to hyperuricaemia in an individual may enable some of these factors to be modified, and lead to permanent correction of the hyperuricaemia. A protocol is described which can supplement clinical assessment. Measurement of the effects on serum urate and urinary urate excretion of a low-purine diet for 7 days facilitates the identification of the contributions made by urate production (either endogenous or from purine consumption) and renal underexcretion of urate (either as a low urate clearance in the absence of renal disease or due to renal glomerular insufficiency).			EMMERSON, BT (corresponding author), UNIV QUEENSLAND,PRINCESS ALEXANDRA HOSP,DEPT MED,BRISBANE,QLD 4102,AUSTRALIA.							BATCH JA, 1984, AUST NZ J MED, V14, P852, DOI 10.1111/j.1445-5994.1984.tb03788.x; BROCHNERMORTENS.K, 1937, ACTA MED SCAND, V84, P127; EMMERSON BT, 1983, HYPERURICAEMIA GOUT; FOX IH, 1981, METABOLISM, V30, P616, DOI 10.1016/0026-0495(81)90142-6; KELLEY WN, 1967, P NATL ACAD SCI USA, V57, P1735, DOI 10.1073/pnas.57.6.1735; NUGENT CA, 1959, J CLIN INVEST, V38, P1890, DOI 10.1172/JCI103966; SEEGMILLER J, 1961, J CLIN INVEST, V40, P1304, DOI 10.1172/JCI104360; STAFFORD W, 1983, ADV EXP MED BIOL, V165, P309	8	30	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1461	1463		10.1016/0140-6736(91)93141-U	http://dx.doi.org/10.1016/0140-6736(91)93141-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675330				2022-12-24	WOS:A1991FR06000017
J	KEATING, JN; TRIMBLE, KC; MULCAHY, F; SCOTT, JM; WEIR, DG				KEATING, JN; TRIMBLE, KC; MULCAHY, F; SCOTT, JM; WEIR, DG			EVIDENCE OF BRAIN METHYLTRANSFERASE INHIBITION AND EARLY BRAIN INVOLVEMENT IN HIV-POSITIVE PATIENTS	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; COMBINED DEGENERATION; S-ADENOSYLMETHIONINE; L-HOMOCYSTEINE; L-METHIONINE; DEFICIENCY; ADENOSINE; AIDS	The myelopathy associated with human immunodeficiency virus (HIV) infection closely resembles that in subacute combined degeneration, a disorder of vitamin B-12 metabolism. To investigate whether the disorders share a pathogenetic mechanism, S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were measured in the cerebrospinal fluid (CSF) of 20 HIV-seropositive patients and 30 HIV-negative patients who were undergoing lumbar puncture for other medical reasons. The HIV-seropositive patients had significantly lower CSF concentrations of SAM (mean 77 [SD 25] vs 131 [35] nmol/l; p < 0.001) and significantly higher concentrations of SAH (30.5 [6.8] vs 19.0 [7.1] nmol/l; p < 0.001) than the controls. There was therefore a significant difference between the groups in the SAM/SAH (methylation) ratio (HIV 2.7 [1.0] vs control 7.6 [3.4]; p < 0.001). There were no correlations between SAM or SAH concentrations or methylation ratio and age or sex in both groups, or serum B-12 and folate concentrations, CSF folate, serum or CSF methylmalonic acid, risk factors, body mass index, specific drug treatment received, or disease stage in the HIV group. This finding suggests that HIV affects the brain from a very early stage of the infection. We suggest that, as in the pig, the CSF methylation ratio closely reflects that in the brain. In HIV-infected patients a reduced brain methylation ratio would inhibit methyltransferase enzymes, which would lead to hypomethylation in the central nervous system and ultimately to neurological lesions. In a pig model of subacute combined degeneration and in vitamin-B-12-deficient human beings, the primary cause of the low methylation ratio is impaired recycling of SAH back to SAM, a process which requires vitamin-B-12-dependent methionine synthase. The HIV patients in this study were vitamin B-12 and folate replete, which suggests a different cause for the low methylation ratio.	ST JAMES HOSP, MED SCH BLDG, DUBLIN 8, IRELAND; UNIV DUBLIN TRINITY COLL, DEPT CLIN MED, DUBLIN 2, IRELAND; UNIV DUBLIN TRINITY COLL, DEPT BIOCHEM, DUBLIN 2, IRELAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin								BARNES DM, 1987, SCIENCE, V235, P1574, DOI 10.1126/science.3103218; BEACH RS, 1988, JAMA-J AM MED ASSOC, V259, P519, DOI 10.1001/jama.1988.03720040017014; BOUDES P, 1990, LANCET, V335, P1401, DOI 10.1016/0140-6736(90)91279-J; DEFERRA F, 1984, CANCER RES, V44, P2297; DELAHABA G, 1959, J BIOL CHEM, V234, P603; EPSTEIN L G, 1984, AIDS Research, V1, P447; GHARIB A, 1982, J NEUROCHEM, V38, P810, DOI 10.1111/j.1471-4159.1982.tb08702.x; GRAY F, 1988, BRAIN, V111, P245, DOI 10.1093/brain/111.2.245; HERBERT V, 1990, AM J HEMATOL, V34, P132, DOI 10.1002/ajh.2830340210; Herbert V, 1961, FED PROC, V20, P453; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; HOFFMAN DR, 1980, J BIOL CHEM, V255, P822; HYLAND K, 1988, NEUROLOGY, V38, P459, DOI 10.1212/WNL.38.3.459; KELLEHER BP, 1990, MED LAB SCI, V47, P90; KUTZBACH C, 1967, BIOCHIM BIOPHYS ACTA, V139, P217, DOI 10.1016/0005-2744(67)90140-4; LAYZER RB, 1978, NEUROLOGY, V28, P504, DOI 10.1212/WNL.28.5.504; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; MCMURRAY CH, 1986, J CHROMATOGR, V378, P201, DOI 10.1016/S0378-4347(00)80713-6; MOLLOY A M, 1986, P505; MOLLOY AM, 1990, BIOMED CHROMATOGR, V4, P257, DOI 10.1002/bmc.1130040611; MOLLOY AM, 1989, CHEM BIOL PTERIDINES, P881; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; PETITO CK, 1985, NEW ENGL J MED, V312, P874, DOI 10.1056/NEJM198504043121402; SCOTT JM, 1974, AM J MED TECHNOL, V40, P125; SCOTT JM, 1981, LANCET, V2, P334; SURTEES R, 1990, LANCET, V335, P619, DOI 10.1016/0140-6736(90)90409-X; SURTEES R, 1990, J NEUROL NEUROSUR PS, V53, P569, DOI 10.1136/jnnp.53.7.569; WAGNER J, 1986, ANAL BIOCHEM, V154, P604, DOI 10.1016/0003-2697(86)90036-9; WEIR DG, 1988, J NEUROCHEM, V51, P1949, DOI 10.1111/j.1471-4159.1988.tb01184.x; WILSON MJ, 1984, BIOCHEM J, V218, P987, DOI 10.1042/bj2180987	31	65	65	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	1991	337	8747					935	939		10.1016/0140-6736(91)91570-K	http://dx.doi.org/10.1016/0140-6736(91)91570-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678030				2022-12-24	WOS:A1991FH13100003
J	VANDENBROUCKE, JP				VANDENBROUCKE, JP			POSTMENOPAUSAL ESTROGEN AND CARDIOPROTECTION	LANCET			English	Editorial Material							ESTROGEN USE; MORTALITY; DISEASE; THERAPY; WOMEN				VANDENBROUCKE, JP (corresponding author), LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BUSH TL, 1985, EPIDEMIOL REV, V7, P80, DOI 10.1093/oxfordjournals.epirev.a036287; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; CUMMINGS SR, 1990, ANN INTERN MED, V113, P565, DOI 10.7326/0003-4819-113-8-565; DAVIS ME, 1964, CLIN OBSTET GYNECOL, V7, P558; GAMBRELL RD, 1982, ACTA OBSTET GYNECO S, V106, P37; KNOPP RH, 1988, OBSTET GYNECOL, V72, pS23; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NORDIN BEC, 1990, LANCET, V336, P1327, DOI 10.1016/0140-6736(90)93018-K; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEVENSON JC, 1990, LANCET, V336, P1121, DOI 10.1016/0140-6736(90)92590-E; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; WEINSTEIN MC, 1980, NEW ENGL J MED, V303, P308, DOI 10.1056/NEJM198008073030604; WILSON RA, 1963, J AM GERIATR SOC, V11, P347, DOI 10.1111/j.1532-5415.1963.tb00068.x; 1970, JAMA-J AM MED ASSOC, V214, P1303; 1977, BRIT MED J, V1, P862	19	32	33	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					833	834		10.1016/0140-6736(91)92526-8	http://dx.doi.org/10.1016/0140-6736(91)92526-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672923				2022-12-24	WOS:A1991FF22800014
J	CHO, KWY; MORITA, EA; WRIGHT, CVE; DEROBERTIS, EM				CHO, KWY; MORITA, EA; WRIGHT, CVE; DEROBERTIS, EM			OVEREXPRESSION OF A HOMEODOMAIN PROTEIN CONFERS AXIS-FORMING ACTIVITY TO UNCOMMITTED XENOPUS EMBRYONIC-CELLS	CELL			English	Article							RETINOIC ACID; GROWTH-FACTORS; HOMEOBOX GENE; MESODERM; INDUCTION; LAEVIS; IDENTIFICATION; SPECIFICITY; DROSOPHILA; ORGANIZER	The anteroposterior character of mesoderm induced by a peptide growth factor (XTC-MIF) was tested by transplantation into host Xenopus gastrulae. Both retinoic acid and a homeodomain protein were able to override the anteriorizing effect of the growth factor. Microinjection of a posteriorly expressed homeobox mRNA can respecify anteroposterior identity, transforming head mesoderm into tail-inducing mesoderm. Unexpectedly, overexpression of XIHbox 6 protein in the transplanted cells, without addition of growth factors, caused the formation of tail-like structures. The cells overexpressing XIHbox 6 were able to recruit cells from the host into the secondary axis. The results suggest that vertebrate homeodomain proteins are part of the biochemical pathway leading to the generation of the body axis.			CHO, KWY (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.			De Robertis, Edward/0000-0002-7843-1869	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, R01HD021502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008243] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21502-06] Funding Source: Medline; NIGMS NIH HHS [GM-07104, GM08243] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTABA AR, 1989, NATURE, V341, P33; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; COOKE J, 1989, DEVELOPMENT, V107, P229; DALE L, 1987, DEVELOPMENT, V100, P279; DEROBERTIS EM, 1990, SCI AM, V263, P46, DOI 10.1038/scientificamerican0790-46; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1987, DEVELOPMENT, V99, P285; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARVEY RP, 1986, EMBO J, V5, P1237, DOI 10.1002/j.1460-2075.1986.tb04352.x; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HOLTFRETER J, 1955, ANAL DEV; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JONES EA, 1987, DEVELOPMENT, V101, P557; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nieuwkoop P. D., 1969, ROUX ARCH ENTW MECH, V162, P34; REUTER R, 1990, DEVELOPMENT, V110, P1031; ROSA F, 1988, SCIENCE, V239, P782; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; SPEMANN H, 1918, ROUX ARCH ENTW MECH, V43, P448; Spemann H., 1938, EMBRYONIC DEV INDUCT; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1989, DEVELOPMENT, V106, P691; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225	47	93	95	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					55	64		10.1016/0092-8674(91)90407-P	http://dx.doi.org/10.1016/0092-8674(91)90407-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1672833	Bronze			2022-12-24	WOS:A1991FF77300008
J	HANKEY, GJ; WARLOW, CP				HANKEY, GJ; WARLOW, CP			LACUNAR TRANSIENT ISCHEMIC ATTACKS - A CLINICALLY USEFUL CONCEPT	LANCET			English	Article							COMMUNITY STROKE PROJECT; ISCHEMIC ATTACKS; BASAL GANGLIA; INFARCTION; LESIONS; TOMOGRAPHY; OCCLUSION; FEATURES; ARTERY; RISK	Lacunar ischaemic stroke syndromes are clinically, pathophysiologically, and prognostically distinguishable from cortical ischaemic stroke syndromes. Could cerebrovascular transient ischaemic attacks (TIAs) share similar heterogeneity? 130 patients with TIAs were prospectively studied, 71 of whom underwent carotid angiography. Symptoms were associated with a 50% or greater stenosis of the ipsilateral internal carotid artery in 36 (67%) of 54 patients with presumed cortical TIAs, but in only 1 (6%) of 17 patients with presumed lacunar TIAs (p < 0.0001). These findings support the view that cortical TIAs are associated with ipsilateral extracranial internal carotid artery atheromatous disease, whereas patients with lacunar TIAs may have absent or insignificant large-vessel disease, and probably intracranial small-vessel disease. Accurate distinction between lacunar and cortical events may have implications for investigation and treatment of patients with TIAs.			HANKEY, GJ (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				ADAMS HP, 1983, STROKE, V14, P948, DOI 10.1161/01.STR.14.6.948; ALEKSIC SN, 1973, J NEUROL SCI, V19, P331, DOI 10.1016/0022-510X(73)90096-8; [Anonymous], 1989, Stroke, V20, P1407; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BOGOUSSLAVSKY J, 1986, ARCH NEUROL-CHICAGO, V43, P223, DOI 10.1001/archneur.1986.00520030015005; DAMASIO AR, 1982, ARCH NEUROL-CHICAGO, V39, P15, DOI 10.1001/archneur.1982.00510130017003; DEBONO DP, 1981, LANCET, V1, P343; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DONNAN GA, 1987, STROKE, V18, P296; DONNAN GA, 1982, NEUROLOGY, V32, P49, DOI 10.1212/WNL.32.1.49; FISHER CM, 1965, ARCH NEUROL-CHICAGO, V13, P30, DOI 10.1001/archneur.1965.00470010034005; FISHER CM, 1969, ACTA NEUROPATHOL, V12, P1, DOI 10.1007/BF00685305; GARDNER MJ, 1989, STATISTICS CONFIDENC; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HART RG, 1986, ARCH NEUROL-CHICAGO, V43, P71; HUANG CY, 1984, J NEUROL NEUROSUR PS, V47, P84, DOI 10.1136/jnnp.47.1.84; KAPPELLE LJ, 1988, STROKE, V19, P1093, DOI 10.1161/01.STR.19.9.1093; KASE CS, 1988, HDB CLIN NEUROLOGY, P353; LODDER J, 1990, STROKE, V21, P375, DOI 10.1161/01.STR.21.3.375; MILLER VT, 1983, ARCH NEUROL-CHICAGO, V40, P129, DOI 10.1001/archneur.1983.04050030023002; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; MORI E, 1985, STROKE, V16, P454, DOI 10.1161/01.STR.16.3.454; NELSON RF, 1980, STROKE, V11, P256, DOI 10.1161/01.STR.11.3.256; NORRVING B, 1989, STROKE, V20, P59, DOI 10.1161/01.STR.20.1.59; PESSIN MS, 1977, NEW ENGL J MED, V296, P358, DOI 10.1056/NEJM197702172960703; ROTHROCK JF, 1987, STROKE, V18, P781, DOI 10.1161/01.STR.18.4.781; ROTHROCK JF, 1988, NEUROLOGY, V38, P198, DOI 10.1212/WNL.38.2.198; SANTAMARIA J, 1983, STROKE, V14, P911, DOI 10.1161/01.STR.14.6.911; STILLER J, 1982, ARCH NEUROL-CHICAGO, V39, P660, DOI 10.1001/archneur.1982.00510220058014; WARLOW CP, 1982, TRANSIENT ISCHAEMIC, pR7; WIEBERS DO, 1982, NEUROLOGY, V32, P459, DOI 10.1212/WNL.32.5.459; WOLF PA, 1981, JAMA-J AM MED ASSOC, V245, P1442, DOI 10.1001/jama.245.14.1442	34	41	41	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 9	1991	337	8737					335	338		10.1016/0140-6736(91)90953-M	http://dx.doi.org/10.1016/0140-6736(91)90953-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671240				2022-12-24	WOS:A1991EX36200012
J	BROWN, P; GAJDUSEK, DC				BROWN, P; GAJDUSEK, DC			SURVIVAL OF SCRAPIE VIRUS AFTER 3 YEARS INTERNMENT	LANCET			English	Note								Supernatant fluid from a scrapie-infected hamster brain homogenate was mixed with soil, packed into perforated petri dishes that were then embedded within soil-containing pots, and buried in a garden for 3 years. Between 2 and 3 log units of the input infectivity of nearly 5 log units survived this exposure, with little leaching of virus into deeper soil layers. These results have implications for environmental contamination by scrapie and by similar agents, including those of bovine spongiform encephalopathy and Creutzfeldt-Jakob disease.			BROWN, P (corresponding author), NINCDS,CENT NERVOUS SYST STUDIES LAB,BETHESDA,MD 20892, USA.							BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; Brown P, 1980, Epidemiol Rev, V2, P113; Palsson P. A., 1979, Slow transmissible diseases of the nervous system. Volume 1., P357; TATEISHI J, 1987, PRIONS NOVEL INFECTI, P424; [No title captured]	5	177	179	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					269	270		10.1016/0140-6736(91)90873-N	http://dx.doi.org/10.1016/0140-6736(91)90873-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671114				2022-12-24	WOS:A1991EV71900006
J	BLUM, B; SIMPSON, L				BLUM, B; SIMPSON, L			GUIDE RNAS IN KINETOPLASTID MITOCHONDRIA HAVE A NONENCODED 3' OLIGO(U) TAIL INVOLVED IN RECOGNITION OF THE PREEDITED REGION	CELL			English	Article									UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	BLUM, B (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009102, R01AI009102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FEAGIN JE, 1988, MOL CELL BIOL, V8, P1259, DOI 10.1128/MCB.8.3.1259; LABBE D, 1990, J BIOL CHEM, V265, P2988; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MULLIGAN RM, 1988, P NATL ACAD SCI USA, V85, P7998, DOI 10.1073/pnas.85.21.7998; SHAW JM, 1989, P NATL ACAD SCI USA, V86, P6220, DOI 10.1073/pnas.86.16.6220; Silberklang M, 1979, Methods Enzymol, V59, P58; SIMPSON AM, 1985, NUCLEIC ACIDS RES, V13, P5977, DOI 10.1093/nar/13.16.5977; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; STUART K, 1989, PARASITOL TODAY, V5, P5, DOI 10.1016/0169-4758(89)90211-1; STUART K, 1989, GENE, V82, P155, DOI 10.1016/0378-1119(89)90040-1; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; VANDERSPEK H, 1990, EMBO J, V9, P257, DOI 10.1002/j.1460-2075.1990.tb08103.x; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	26	203	207	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 27	1990	62	2					391	397		10.1016/0092-8674(90)90375-O	http://dx.doi.org/10.1016/0092-8674(90)90375-O			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DR202	1695552				2022-12-24	WOS:A1990DR20200018
J	WALKER, DH; MALLER, JL				WALKER, DH; MALLER, JL			ROLE FOR CYCLIN-A IN THE DEPENDENCE OF MITOSIS ON COMPLETION OF DNA-REPLICATION	NATURE			English	Article							MATURATION-PROMOTING FACTOR; EMBRYONIC-CELL CYCLE; MESSENGER-RNA; XENOPUS OOCYTES; PROTEIN; INITIATION; EGGS; DEGRADATION; EXTRACTS; ENTRY	THE cyclins were first identified by their cell-cycle-dependent synthesis and destruction 1-3 and have a key role in the control of mitosis in Xenopus embryonic cell cycles 4-6. All higher eukaryotes have at least two types of cyclins, the A- and B-type, which can be distinguished by sequence motifs and the timing of their destruction in the cell cycle 2,7-10. The degradation of both cyclins is required for exit from mitosis 11, but the activation and destruction of cyclin A occur earlier in the cell cycle than with the B-type cyclins 9-11. This suggests that cyclin A has a distinct role in cell-cycle progression. We have used an antisense oligodeoxynucleotide directed against cyclin A to investigate this role. Ablation of cyclin A messenger RNA in cytostatic factor/metaphase-arrested extracts of Xenopus eggs, followed by in vitro progression into interphase, resulted in the premature appearance of cyclin B/cdc2-associated H1 kinase activity and premature entry into mitosis. Although cyclin A-ablated extracts could initiate DNA synthesis during interphase, S phase was not completed before entry into mitosis. The effects of cyclin A ablation were reversed by the addition of cyclin A mRNA or cyclin A protein to the extracts.			WALKER, DH (corresponding author), UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262, USA.							BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; COLMAN A, 1990, J CELL SCI, V97, P399; DAGLE JM, 1990, NUCLEIC ACIDS RES, V18, P4751, DOI 10.1093/nar/18.16.4751; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GABRIELLI GB, IN PRESS J BIOL CHEM; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MINSHULL J, 1987, NUCLEIC ACIDS RES, V16, P6343; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9	28	204	215	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					314	317		10.1038/354314a0	http://dx.doi.org/10.1038/354314a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1659666				2022-12-24	WOS:A1991GT20400050
J	EPSTEIN, DJ; VEKEMANS, M; GROS, P				EPSTEIN, DJ; VEKEMANS, M; GROS, P			SPLOTCH (SP2H), A MUTATION AFFECTING DEVELOPMENT OF THE MOUSE NEURAL-TUBE, SHOWS A DELETION WITHIN THE PAIRED HOMEODOMAIN OF PAX-3	CELL			English	Article							DEVELOPING EXCRETORY SYSTEM; CONSERVED LINKAGE; GENES; BOX; EXPRESSION; DROSOPHILA; DOMAIN; MUTANT	The molecular basis of the mouse mutation splotch (Sp), which is associated with spina bifida and exencephaly, was analyzed at three of its alleles, Sp, Sp2H, and Sp(r). We mapped the paired box gene Pax-3 within the Inha to Akp3 interval, near or at the Sp locus on chromosome 1, and found Pax-3 to be deleted in heterozygous Sp(r)/+ mice. Analysis of genomic DNA and cDNA clones constructed from Sp2H/Sp2H embryos identified a deletion of 32 nucleotides in the Pax-3 mRNA transcript and gene. This deletion maps within the paired homeodomain of PAX-3 and is predicted to create a truncated protein as a result of a newly created termination codon at the deletion breakpoint. Our study provides evidence for a causal link between deletion of the paired homeodomain of Pax-3 and the Sp2H mutation, and infers that Pax-3 plays a key role in normal neural development.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University	EPSTEIN, DJ (corresponding author), MCGILL UNIV,DEPT BIOL,MONTREAL H3G 1Y6,QUEBEC,CANADA.							ARIAS S, 1978, CYTOGENET CELL GENET, V22, P291, DOI 10.1159/000130956; ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; ASHER JH, 1991, AM J HUM GENET, V48, P43; AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; Beechey CV, 1986, MOUSE NEWS LETT, V75, P28; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DICKIE MM, 1964, J HERED, V55, P97, DOI 10.1093/oxfordjournals.jhered.a107317; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; Edmonds L D, 1990, MMWR CDC Surveill Summ, V39, P19; EPSTEIN DJ, 1991, GENOMICS, V10, P89, DOI 10.1016/0888-7543(91)90488-Z; EVANS EP, 1988, MOUSE NEWS LETT, V81, P66; FRANZ T, 1990, ACTA ANAT, V138, P246; FRANZ T, 1989, ANAT EMBRYOL, V1806, P4577; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HIRSCH MR, 1990, MOL CELL BIOL, V10, P1959, DOI 10.1128/MCB.10.5.1959; ISHIKIRIYAMA S, 1989, AM J MED GENET, V33, P505, DOI 10.1002/ajmg.1320330419; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Le Douarin N, 1980, Curr Top Dev Biol, V16, P31; MALO D, 1991, GENOMICS, V10, P356, DOI 10.1016/0888-7543(91)90320-E; MALO D, 1990, GENOMICS, V6, P697, DOI 10.1016/0888-7543(90)90507-Q; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P976; MOASE CE, 1990, TERATOLOGY, V42, P171, DOI 10.1002/tera.1420420208; MOASE CE, 1989, TERATOLOGY, V40, P67, DOI 10.1002/tera.1420400109; MOASE CE, 1991, IN PRESS DEVELOPMENT; MORRISSEY D, 1991, GENE DEV, V5, P1684, DOI 10.1101/gad.5.9.1684; NORNES HO, 1990, DEVELOPMENT, V109, P797; OLSON E, 1990, GENOMICS, V8, P427, DOI 10.1016/0888-7543(90)90028-S; PLACHOV D, 1990, DEVELOPMENT, V110, P643; RUSSELL WL, 1947, GENETICS, V32, P107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SCHURR E, 1990, GENOMICS, V8, P477, DOI 10.1016/0888-7543(90)90034-R; SKOW LC, 1988, BIOCHEM GENET, V26, P557, DOI 10.1007/BF02399601; SNELL GD, 1954, HEREDITY, V8, P271, DOI 10.1038/hdy.1954.23; STEEL KP, 1989, DEVELOPMENT, V107, P453; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594	46	620	628	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					767	774		10.1016/0092-8674(91)90071-6	http://dx.doi.org/10.1016/0092-8674(91)90071-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1682057				2022-12-24	WOS:A1991GQ40700013
J	JACKSON, CL; KONOPKA, JB; HARTWELL, LH				JACKSON, CL; KONOPKA, JB; HARTWELL, LH			SACCHAROMYCES-CEREVISIAE ALPHA-PHEROMONE RECEPTORS ACTIVATE A NOVEL SIGNAL TRANSDUCTION PATHWAY FOR MATING PARTNER DISCRIMINATION	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; A-FACTOR; ADENYLATE-CYCLASE; NUCLEAR-FUSION; CELL-FUSION; G-PROTEIN; PHOSPHOINOSITIDE TURNOVER; STRUCTURAL GENE; PLASMA-MEMBRANE; GAMMA-SUBUNITS	Wild-type S. cerevisiae cells of both mating types prefer partners producing high levels of pheromone and mate very infrequently to cells producing no pheromone. However, some mutants that are supersensitive to pheromone lack this ability to discriminate. In this study, we provide evidence for a novel role of alpha-pheromone receptors in mating partner discrimination that is independent of the known G protein-mediated signal transduction pathway. Furthermore, in response to pheromone, receptors become localized to the emerging region of morphogenesis that is positioned adjacent to the nucleus, suggesting that receptor localization may be involved in mating partner discrimination. Actin, myosin 2, and clathrin heavy chain are involved in mating partner discrimination, since strains carrying mutations in the genes encoding these proteins result in a small but significant defect in mating partner discrimination.			JACKSON, CL (corresponding author), UNIV WASHINGTON,DEPT GENET,SK-50,SEATTLE,WA 98195, USA.		Jackson, Catherine/A-3421-2013; Jackson, Catherine/T-5688-2019	Jackson, Catherine/0000-0002-0843-145X; Konopka, James/0000-0001-5989-4086	NIGMS NIH HHS [GM17709] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017709, R37GM017709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BABA M, 1989, J CELL SCI, V94, P207; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BENDER A, 1986, CELL, V47, P929, DOI 10.1016/0092-8674(86)90808-1; BENDER A, 1989, GENETICS, V121, P463; BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CLACK JW, 1988, P NATL ACAD SCI USA, V85, P9806, DOI 10.1073/pnas.85.24.9806; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, GENETICS, V126, P301; DELGADO MA, 1984, MOL GEN GENET, V193, P188, DOI 10.1007/BF00327435; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; FIELD C, 1980, J CELL BIOL, V86, P123, DOI 10.1083/jcb.86.1.123; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARTIG A, 1986, MOL CELL BIOL, V6, P2106, DOI 10.1128/MCB.6.6.2106; HASEK J, 1987, J GEN MICROBIOL, V133, P3355; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON CL, 1990, MOL CELL BIOL, V10, P2202, DOI 10.1128/MCB.10.5.2202; JACKSON CL, 1990, CELL, V63, P1039, DOI 10.1016/0092-8674(90)90507-B; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JAHNG KY, 1988, MOL CELL BIOL, V8, P2484, DOI 10.1128/MCB.8.6.2484; JENNESS DD, 1983, CELL, V35, P521, DOI 10.1016/0092-8674(83)90186-1; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KURJAN J, 1985, MOL CELL BIOL, V5, P787, DOI 10.1128/MCB.5.4.787; LEMMON SK, 1987, SCIENCE, V238, P504, DOI 10.1126/science.3116672; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LIPKE PN, 1989, MOL CELL BIOL, V9, P3155, DOI 10.1128/MCB.9.8.3155; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MIYAJIMA I, 1988, GENETICS, V119, P797; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MIYAJIMA I, 1989, MOL CELL BIOL, V9, P2289, DOI 10.1128/MCB.9.6.2289; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NAKAYAMA N, 1987, EMBO J, V6, P249, DOI 10.1002/j.1460-2075.1987.tb04746.x; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NOVICK P, 1989, GENETICS, V121, P659; OBRIEN DF, 1977, P NATL ACAD SCI USA, V74, P5222, DOI 10.1073/pnas.74.12.5222; OVCHINNIKOV YA, 1982, FEBS LETT, V148, P179, DOI 10.1016/0014-5793(82)80805-3; PAYNE GS, 1988, J CELL BIOL, V106, P1453, DOI 10.1083/jcb.106.5.1453; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PRAKASH L, 1973, J MOL BIOL, V79, P65, DOI 10.1016/0022-2836(73)90270-2; PRENDERGAST JA, 1990, GENETICS, V124, P81; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROSE MD, 1986, MOL CELL BIOL, V6, P3490, DOI 10.1128/MCB.6.10.3490; SCHOBERT B, 1982, J BIOL CHEM, V257, P306; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; STEIN R, 1988, EMBO J, V7, P3031, DOI 10.1002/j.1460-2075.1988.tb03167.x; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; TKACZ JS, 1979, J CELL BIOL, V80, P326, DOI 10.1083/jcb.80.2.326; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; TRUEHEART J, 1989, P NATL ACAD SCI USA, V86, P9916, DOI 10.1073/pnas.86.24.9916; WATZELE M, 1988, EMBO J, V7, P1483, DOI 10.1002/j.1460-2075.1988.tb02966.x; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	84	107	110	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					389	402		10.1016/0092-8674(91)90190-A	http://dx.doi.org/10.1016/0092-8674(91)90190-A			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655282				2022-12-24	WOS:A1991GL47000018
J	YANG, L; LI, R; MOHR, IJ; CLARK, R; BOTCHAN, MR				YANG, L; LI, R; MOHR, IJ; CLARK, R; BOTCHAN, MR			ACTIVATION OF BPV-1 REPLICATION INVITRO BY THE TRANSCRIPTION FACTOR E2	NATURE			English	Article							SV40 DNA-REPLICATION; SIMIAN VIRUS-40 DNA; T-ANTIGEN; HUMAN-CELLS; PROTEIN; ORIGIN; PHOSPHORYLATION; BINDING; COMPLEX	Soluble extracts from uninfected murine cells supplemented with purified viral E1 and E2 proteins support the replication of exogenously added papilloma virus DNA. The E2 transactivator stimulates the binding of the E1 replication protein to the minimal origin of replication and activates DNA replication. These results support the concept that transcription factors have a direct role in the initiation of DNA replication in eukaryotes by participating in the assembly of a complex at the origin of replication.			YANG, L (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA.							BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DODSON M, 1989, J BIOL CHEM, V264, P10719; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HATTON KS, 1988, CANCER CELL, V6, P335; HAUSEN HZ, 1988, PAPILLOMAVIRUSES, P245; HOWLEY PM, 1990, VIROLOGY, P1625; Hurst EW, 1933, J EXP MED, V58, P607, DOI 10.1084/jem.58.5.607; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; NAKANO N, 1966, TOHOKU J EXP MED, V88, P69, DOI 10.1620/tjem.88.69; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SHAW K, 1990, VIROLOGY, P1652; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUN S, 1990, J VIROL, V64, P5093, DOI 10.1128/JVI.64.10.5093-5105.1990; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WOBBE CR, 1986, P NATL ACAD SCI USA, V83, P4612, DOI 10.1073/pnas.83.13.4612	33	280	286	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	1991	353	6345					628	632		10.1038/353628a0	http://dx.doi.org/10.1038/353628a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1656277				2022-12-24	WOS:A1991GK67200058
J	SATOW, YI; HASHIDO, M; ISHIKAWA, KI; HONDA, H; MIZUNO, M; KAWANA, T; HAYAMI, M				SATOW, YI; HASHIDO, M; ISHIKAWA, KI; HONDA, H; MIZUNO, M; KAWANA, T; HAYAMI, M			DETECTION OF HTLV-I ANTIGEN IN PERIPHERAL AND CORD BLOOD-LYMPHOCYTES FROM CARRIER MOTHERS	LANCET			English	Note							T-CELL LEUKEMIA; TRANSMISSION; ANTIBODY; VIRUS	Vertical transmission of human T-cell lymphotropic virus type-I (HTLV-I) from an antibody-positive carrier mother to her infant has been reported, but it is not clear when and by what route such transmission occurs. Peripheral blood and cord blood lymphocytes from 40 antibody-positive carrier mothers were cultured for 2 months and HTLV-I antigen was sought by indirect immunofluorescence. Viral antigen was detected in 28 (70%) samples of peripheral blood lymphocytes and in 2 of cord blood lymphocytes, both from mothers positive for antigen in peripheral blood. From these data it is estimated that transplacental infection occurs at a rate of about 7%.	UNIV TOKYO,DEPT OBSTET & GYNAECOL,MEJIRODAI,JAPAN; MITSUI MEM HOSP,DEPT OBSTET & GYNAECOL,TOKYO 101,JAPAN; UNIV TOKYO,DEPT OBSTET & GYNAECOL,TOKYO 113,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ANIM PATHOL,SHIROGANEDAI,JAPAN; KYOTO UNIV,INST VIRUS RES,IMMUNODEFICIENCY VIRUS RES CTR,KYOTO 606,JAPAN	University of Tokyo; Mitsui Memorial Hospital; University of Tokyo; University of Tokyo; Kyoto University								HINO S, 1987, LANCET, V2, P158; HINO S, 1985, JPN J CANCER RES, V76, P474; HINUMA Y, 1982, GANN, V73, P341; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; ICHIJO M, 1988, OBSTET GYNECOL PRACT, V37, P45; KOMURO A, 1983, LANCET, V1, P240; MAEDA Y, 1989, JPN J CANCER RES, V80, P915, DOI 10.1111/j.1349-7006.1989.tb01625.x; SAITO S, 1990, JPN J CANCER RES, V81, P890, DOI 10.1111/j.1349-7006.1990.tb02663.x	8	28	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					915	916		10.1016/0140-6736(91)91775-P	http://dx.doi.org/10.1016/0140-6736(91)91775-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681269				2022-12-24	WOS:A1991GJ89900006
J	WILSON, P; LEESE, T; MORGAN, WP; KELLY, JF; BRIGG, JK				WILSON, P; LEESE, T; MORGAN, WP; KELLY, JF; BRIGG, JK			ELECTIVE LAPAROSCOPIC CHOLECYSTECTOMY FOR ALL-COMERS	LANCET			English	Article								Laparoscopic cholecystectomy is a safe and effective procedure in specialist centres, but its wider application will depend on the ability of general surgeons to become skilled in this technique. 180 patients underwent elective laparoscopic cholecystectomy during a nine-month period at a single district general hospital. All patients who would have been eligible for elective open cholecystectomy were offered the laparoscopic alternative. Laparoscopic cholecystectomy was abandoned in favour of an open procedure in 10 (6%) patients. Median operating time was 55 min. 2 patients had serious morbidity (right hepatic duct injury and a duodenal fistula) and there were no deaths. 3 patients required subsequent treatment for retained common duct stones. 90% of patients were discharged within 48 h of the operation and the median time to resume full activity after discharge was 12 days. Laparoscopic cholecystectomy is a safe and cost-effective technique in a district general hospital.	ROYAL LANCASTER INFIRM,DEPT SURG,LANCASTER LA1 4RP,ENGLAND									CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; DENT TL, 1991, AM J SURG, V161, P399, DOI 10.1016/0002-9610(91)90607-F; GRACE PA, 1991, BRIT J SURG, V78, P160, DOI 10.1002/bjs.1800780209; PATERSONBROWN S, 1991, BRIT J SURG, V78, P131, DOI 10.1002/bjs.1800780203; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; SULLIVAN DM, 1982, AM J SURG, V143, P218, DOI 10.1016/0002-9610(82)90072-1; TODD GJ, 1978, AM J SURG, V135, P622, DOI 10.1016/0002-9610(78)90121-6; 1991, AM J SURG, V161, P324	8	78	79	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1991	338	8770					795	797		10.1016/0140-6736(91)90674-E	http://dx.doi.org/10.1016/0140-6736(91)90674-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG979	1681169				2022-12-24	WOS:A1991GG97900013
J	EHRNST, A; LINDGREN, S; DICTOR, M; JOHANSSON, B; SONNERBORG, A; CZAJKOWSKI, J; SUNDIN, G; BOHLIN, AB				EHRNST, A; LINDGREN, S; DICTOR, M; JOHANSSON, B; SONNERBORG, A; CZAJKOWSKI, J; SUNDIN, G; BOHLIN, AB			HIV IN PREGNANT-WOMEN AND THEIR OFFSPRING - EVIDENCE FOR LATE TRANSMISSION	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VERTICAL TRANSMISSION; MATERNAL ANTIBODIES; CHILDREN BORN; INFECTION; TYPE-1; BLOOD; PLACENTA; INFANTS; MOTHERS	To assess the role of maternal viraemia in vertical transmission of HIV and the extent to which viraemia occurs during the various stages of pregnancy, we have attempted to detect human immunodeficiency virus (HIV) in 44 pregnant HIV-1 infected women during 47 pregnancies (30 continued, 17 aborted) and in 30 children and 12 fetuses. Infectious HIV was detected at some time during pregnancy in 59% of women from plasma and in 83% from either peripheral blood mononuclear cells or plasma. HIV was not isolated from any of the newborn babies (0/27) at birth. The mothers had a significantly higher frequency of viraemia during pregnancy than their children had by 6 months of age (p = 0.002); by this time HIV was recovered from 5 (26%) of 19 infants. HIV was not detected by virus isolation, in-situ hybridisation, or polymerase chain reaction (PCR) in 10 fetuses; the other 2 fetuses were positive either by in-situ hybridisation or by PCR but neither result could be confirmed in a second organ or by the other methods of detection. The findings show that there is no consistent spread of HIV across the placenta during maternal viraemia, and indicate that in most cases transmission occurs close to or at delivery.	HUDDINGE UNIV HOSP,DEPT OBSTET & GYNAECOL,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,DEPT PEDIAT,S-14186 HUDDINGE,SWEDEN; UNIV LUND HOSP,DEPT PATHOL,S-22185 LUND,SWEDEN	Karolinska Institutet; Karolinska Institutet; Lund University; Skane University Hospital	EHRNST, A (corresponding author), STOCKHOLM CTY COUNCIL,CENT MICROBIOL LAB,DEPT VIROL,BOX 70470,S-10726 STOCKHOLM,SWEDEN.		Sönnerborg, Anders/W-2011-2019	Sönnerborg, Anders/0000-0001-8928-3374				BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BROLIDEN PA, 1989, AIDS, V3, P577, DOI 10.1097/00002030-198909000-00004; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EHRNST A, 1988, J MED VIROL, V26, P23, DOI 10.1002/jmv.1890260105; GENDELMAN HE, 1986, IN SITU HYBRIDIZATIO, P203; GOEDERT JJ, 1989, LANCET, V2, P1351; GREENSPOON JS, 1989, AM J OBSTET GYNECOL, V161, P501, DOI 10.1016/0002-9378(89)90556-5; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOUSSET C, 1990, HUM PATHOL, V21, P404, DOI 10.1016/0046-8177(90)90202-G; JOVAISAS E, 1985, LANCET, V2, P1129; LYNMAN WD, 1990, AIDS, V4, P917; MARION RW, 1987, AM J DIS CHILD, V141, P429, DOI 10.1001/archpedi.1987.04460040087022; MARION RW, 1986, AM J DIS CHILD, V140, P429; MYERS G, 1990, HUMAN RETROVIRUSES A; PEUCHMAUR M, 1989, AM J OBSTET GYNECOL, V160, P765, DOI 10.1016/S0002-9378(89)80083-3; PIZZO PA, 1990, J INFECT DIS, V161, P316, DOI 10.1093/infdis/161.2.316; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RUBINSTEIN A, 1986, CLIN IMMUNOL IMMUNOP, V40, P115, DOI 10.1016/0090-1229(86)90074-7; Rubinstein A, 1986, Curr Probl Pediatr, V16, P361; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; SONNERBORG A, IN PRESS AIDS RES HU; SONNERBORG A, IN PRESS IMMUNOL INF; SPRECHER S, 1986, LANCET, V2, P288; 1991, LANCET, P253; [No title captured]	29	192	193	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					203	207		10.1016/0140-6736(91)90347-R	http://dx.doi.org/10.1016/0140-6736(91)90347-R			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676777				2022-12-24	WOS:A1991FY50400002
J	SETH, R; RAYMOND, FD; MAKGOBA, MW				SETH, R; RAYMOND, FD; MAKGOBA, MW			CIRCULATING ICAM-1 ISOFORMS - DIAGNOSTIC PROSPECTS FOR INFLAMMATORY AND IMMUNE DISORDERS	LANCET			English	Note							INTERCELLULAR-ADHESION MOLECULE-1; EXPRESSION; LIGAND; CELLS	Intercellular adhesion molecule-1 (ICAM-1, CD54) is an important early marker of immune activation and response. Evidence on its role has come from immunohistological staining of tissues, since no free circulating ICAM-1 has been detected. By means of monoclonal antibodies against ICAM-1 and a sensitive chemiluminescence technique, free circulating ICAM-1 was detected in serum from sixteen healthy young volunteers. The concentrations varied among the subjects. Non-denaturing gel separation methods showed that ICAM-1 circulates in at least three isoforms, the proportions of which also varied. These findings have important implications for the investigation, diagnosis, and therapeutic monitoring of various inflammatory, neoplastic, and immune disorders.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,DIV MOLEC ENDOCRINOL,DU CANE RD,LONDON W12 0NN,ENGLAND	Imperial College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS DH, 1989, LANCET, V2, P1122; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1987, CELL, V51, P831; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; VOGETSEDER W, 1989, INT J CANCER, V43, P768, DOI 10.1002/ijc.2910430504; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WEETMAN AP, 1989, J ENDOCRINOL, V122, P185, DOI 10.1677/joe.0.1220185	10	392	402	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					83	84		10.1016/0140-6736(91)90077-3	http://dx.doi.org/10.1016/0140-6736(91)90077-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676471				2022-12-24	WOS:A1991FW16100006
J	SHORT, RV; LEWIS, PR; RENFREE, MB; SHAW, G				SHORT, RV; LEWIS, PR; RENFREE, MB; SHAW, G			CONTRACEPTIVE EFFECTS OF EXTENDED LACTATIONAL AMENORRHEA - BEYOND THE BELLAGIO CONSENSUS	LANCET			English	Article								We have recorded the duration of lactational anovulation and amenorrhoea in a well-nourished group of Australian women who breastfed their babies throughout the study. The data enabled us to compare the theoretical cumulative probability of conception among breastfeeding women who had unprotected intercourse irrespective of their menstrual status with that of those who had unprotected intercourse only during lactational amenorrhoea. Breastfeeding alone is not an effective form of contraception, since all the women in our study resumed normal ovulation while still breastfeeding. However, among women who have unprotected intercourse only during lactational amenorrhoea but adopt other contraceptive measures when they resume menstruation, only 1.7% would have become pregnant during the first 6 months of amenorrhoea, only 7% after 12 months, and only 13% after 24 months. Thus for our women it would be possible to extend the Bellagio Consensus Conference guidelines which stated that lactational amenorrhoea can only be relied on as a contraceptive for the first 6 months post-partum in women who are fully or almost fully breastfeeding. The lactational amenorrhoea method can be relied on for excellent contraceptive protection in the first 6 months of breastfeeding, irrespective of when supplements are introduced into the baby's diet; for women who continue to breastfeed the method can also give good protection for up to 12 months post partum. Once menstruation has returned, other forms of contraception are essential to prevent pregnancy.	NURSING MOTHERS ASSOC AUSTRALIAL,NUNAWADING,AUSTRALIA; MONASH UNIV,DEPT ANAT,MELBOURNE,VIC 3004,AUSTRALIA	Monash University	SHORT, RV (corresponding author), MONASH UNIV,DEPT PHYSIOL,MELBOURNE 3168,AUSTRALIA.		Shaw, Geoff/A-6916-2012	Shaw, Geoff/0000-0002-7421-7136; Renfree, Marilyn/0000-0002-4589-0436				GRAY RH, 1990, LANCET, V335, P25, DOI 10.1016/0140-6736(90)90147-W; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; LEWIS PR, IN PRESS FERTIL STER; RODRIGUEZ G, 1988, BREASTFEEDING LENGTH; SIMPSONHEBERT M, 1981, STUD FAMILY PLANN, V12, P125, DOI 10.2307/1965593; THAPA S, 1988, NATURE, V335, P679, DOI 10.1038/335679a0; WOOD JW, 1989, OXFORD REV REPROD B, V11, P61; 1988, LANCET, V2, P1204	8	75	75	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					715	717		10.1016/0140-6736(91)90288-Z	http://dx.doi.org/10.1016/0140-6736(91)90288-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672186				2022-12-24	WOS:A1991FD36700018
J	VINCENT, A; HEITZ, D; PETIT, C; KRETZ, C; OBERLE, I; MANDEL, JL				VINCENT, A; HEITZ, D; PETIT, C; KRETZ, C; OBERLE, I; MANDEL, JL			ABNORMAL PATTERN DETECTED IN FRAGILE-X PATIENTS BY PULSED-FIELD GEL-ELECTROPHORESIS	NATURE			English	Article							MENTAL-RETARDATION; MUTATION; INHERITANCE; EXPRESSION; MARKERS; MALES	THE fragile-X syndrome is the most frequent inherited form of mental retardation, with an incidence of 1 in 1,500 males. It is characterized by the presence of a fragile site at Xq27.3 induced in vitro by folate deprivation or by inhibitors of deoxynucleotide synthesis 1. Its mode of inheritance is unusual for an X-linked trait, with incomplete penetrance in both males and females. Some phenotypically normal males transmit the mutation to all their daughters who rarely express any symptoms, but penetrance is high in sons and daughters of these carrier women 2. Genetic and physical mapping of the Xq27-q28 region has confirmed that the disease locus is located at or very near the fragile site 3-6. Hypotheses proposed to account for the abnormalities in the inheritance of the disease include sequence rearrangements by meiotic recombination 1,7,8 or a mutation that affects reactivation of an inactive X chromosome during differentiation of female germ cells 9,10. To detect such rearrangements, or methylation changes that may reflect a locally inactive X chromosome, we used pulsed-field gel analysis of DNA from fragile-X patients with probes close to the fragile-X locus. The probe Do33 (DXS465) detected abnormal patterns in fragile-X patients, but not in normal controls or in non-expressing male transmitters.	FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE; INST PASTEUR,UNITE RECOMBINAISON & EXPRESS GENET,F-75724 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Petit, Christine/0000-0002-9069-002X				BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; LAIRD CD, 1990, AM J HUM GENET, V46, P696; LAIRD CD, 1987, GENETICS, V117, P587; LEDBETTER DH, 1986, NATURE, V324, P161, DOI 10.1038/324161a0; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; OBERLE I, 1986, P NATL ACAD SCI USA, V83, P1016, DOI 10.1073/pnas.83.4.1016; PEMBREY ME, 1985, AM J MED GENET, V21, P709, DOI 10.1002/ajmg.1320210413; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SOUTHERN EM, 1987, NUCLEIC ACIDS RES, V15, P5925, DOI 10.1093/nar/15.15.5925; SUTHERS GK, 1990, AM J HUM GENET, V47, P187; SUTHERS GK, 1989, SCIENCE, V246, P1298, DOI 10.1126/science.2573953; SUTHERS GK, IN PRESS AM J HUM GE; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856	14	195	198	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					624	626		10.1038/349624a0	http://dx.doi.org/10.1038/349624a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1672039				2022-12-24	WOS:A1991EX57000064
J	CHART, H; SMITH, HR; SCOTLAND, SM; ROWE, B; MILFORD, DV; TAYLOR, CM				CHART, H; SMITH, HR; SCOTLAND, SM; ROWE, B; MILFORD, DV; TAYLOR, CM			SEROLOGICAL IDENTIFICATION OF ESCHERICHIA-COLI O157-H7 INFECTION IN HEMOLYTIC UREMIC SYNDROME	LANCET			English	Article							HEMOLYTIC UREMIC SYNDROME; CYTOTOXIN-PRODUCING STRAINS; POLYACRYLAMIDE GELS; ANTIBODIES; PROTEINS; PROBES	To test the value of serological tests as an adjunct to bacteriological methods and toxin testing in haemolytic uraemic syndrome (HUS), 60 patients with the disorder were examined for evidence of faecal Escherichia coli producing verocytotoxin (VTEC), particularly of serogroup O157. They were also tested for serum antibodies reacting with the lipopolysaccharide of E coli O157 by means of an enzyme-linked immunosorbent assay (ELISA) and immunoblotting; for faecal VTEC by means of DNA probes hybridising with the genes encoding verocytotoxins VT1 and VT2; and for "free" faecal VT. Strains of E coli serotype O157:H7 were isolated from 9 patients, and faecal VT2 was detected in 3 of them. Strains of E coli of serotypes O5:H -, O55:H10, O105ac:H18, and O163:H19 were isolated from 4 patients, but faecal VT was not detected. Faecal VT2 was present in 1 patient from whom VTEC were not isolated. Antibodies to the lipopolysaccharide of E coli O157 were detected in serum samples from 44 patients. The 9 patients with faecal O157:H7 all had high titres of these antibodies, but serum samples from 16 healthy control children were negative. Serological testing of patients with HUS for antibodies to the lipopolysaccharide of E coli O157 provides evidence of infection with E coli O157 when faecal bacteria or VT cannot be detected.	CHILDRENS HOSP,DEPT NEPHROL,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND		CHART, H (corresponding author), CENT PUBL HLTH LAB,DIV ENTER PATHOGENS,61 COLINDALE AVE,LONDON NW9 5HT,ENGLAND.							CHART H, 1989, J CLIN MICROBIOL, V27, P285, DOI 10.1128/JCM.27.2.285-290.1989; CHART H, 1989, J CLIN PATHOL, V42, P973, DOI 10.1136/jcp.42.9.973; Gross R. J., 1985, SPECIAL PUBLICATION, V13, P345; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KLEANTHOUS H, 1988, EPIDEMIOL INFECT, V101, P327, DOI 10.1017/S0950268800054261; KLEANTHOUS H, 1990, ARCH DIS CHILD, V65, P722, DOI 10.1136/adc.65.7.722; KONOWALCHUK J, 1977, INFECT IMMUN, V18, P775, DOI 10.1128/IAI.18.3.775-779.1977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN M, 1984, ARCH DIS CHILD, V59, P397, DOI 10.1136/adc.59.5.397; MILFORD DV, 1990, ARCH DIS CHILD, V65, P716, DOI 10.1136/adc.65.7.716; SCOTLAND SM, 1987, EPIDEMIOL INFECT, V99, P613, DOI 10.1017/S0950268800066462; SCOTLAND SM, 1985, LANCET, V2, P885; SCOTLAND SM, 1988, J MED MICROBIOL, V25, P237, DOI 10.1099/00222615-25-4-237; SMITH HR, 1984, LANCET, V1, P1242; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Von Gasser C, 1955, SCHWEIZ MED WOCHENSC, V85, P905; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WILLSHAW GA, 1987, J GEN MICROBIOL, V133, P1309; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	19	136	146	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					138	140		10.1016/0140-6736(91)90801-U	http://dx.doi.org/10.1016/0140-6736(91)90801-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670788				2022-12-24	WOS:A1991ET67900004
J	GORANSSON, M; SONDEN, B; NILSSON, P; DAGBERG, B; FORSMAN, K; EMANUELSSON, K; UHLIN, BE				GORANSSON, M; SONDEN, B; NILSSON, P; DAGBERG, B; FORSMAN, K; EMANUELSSON, K; UHLIN, BE			TRANSCRIPTIONAL SILENCING AND THERMOREGULATION OF GENE-EXPRESSION IN ESCHERICHIA-COLI	NATURE			English	Article									UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN	Umea University			Uhlin, Bernt Eric/AAO-6292-2021	Uhlin, Bernt Eric/0000-0002-2991-8072				BAGA M, 1985, EMBO J, V4, P3887, DOI 10.1002/j.1460-2075.1985.tb04162.x; BAGA M, 1988, CELL, V52, P197, DOI 10.1016/0092-8674(88)90508-9; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CUKIERKA.R, 1972, P NATL ACAD SCI USA, V69, P3643, DOI 10.1073/pnas.69.12.3643; DEFEZ R, 1981, GENETICS, V97, P11; DIDERICHSEN B, 1980, MOL GEN GENET, V180, P425, DOI 10.1007/BF00425858; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; FALCONI M, 1988, MOL MICROBIOL, V2, P323, DOI 10.1111/j.1365-2958.1988.tb00035.x; FORSMAN K, 1989, EMBO J, V8, P1271, DOI 10.1002/j.1460-2075.1989.tb03501.x; GORANSSON M, 1984, EMBO J, V3, P2885, DOI 10.1002/j.1460-2075.1984.tb02225.x; GORANSSON M, 1989, MOL MICROBIOL, V3, P1557, DOI 10.1111/j.1365-2958.1989.tb00141.x; GORANSSON M, 1989, GENE DEV, V3, P123, DOI 10.1101/gad.3.1.123; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HROMOCKYJ AE, 1989, J BACTERIOL, V171, P2879, DOI 10.1128/jb.171.5.2879-2881.1989; HUISMAN O, 1989, J BACTERIOL, V171, P3704, DOI 10.1128/jb.171.7.3704-3712.1989; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LAINE B, 1984, BIOCHEM BIOPH RES CO, V119, P1147, DOI 10.1016/0006-291X(84)90895-7; LUPSKI JR, 1984, MOL GEN GENET, V195, P391, DOI 10.1007/BF00341439; Maniatis T., 1982, MOL CLONING; PON CL, 1988, MOL GEN GENET, V212, P199, DOI 10.1007/BF00334684; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; RAIBAUD O, 1989, MOL MICROBIOL, V3, P455; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; SPEARS PA, 1986, J BACTERIOL, V168, P179, DOI 10.1128/jb.168.1.179-185.1986; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; TRAVERS A, 1974, FEBS LETT, V43, P86, DOI 10.1016/0014-5793(74)81111-7; TRAVERS A, 1989, NATURE, V341, P184, DOI 10.1038/341184a0; VARSHAVSKY AJ, 1977, NUCLEIC ACIDS RES, V4, P2725, DOI 10.1093/nar/4.8.2725; WADA M, 1988, J MOL BIOL, V204, P581, DOI 10.1016/0022-2836(88)90357-9	30	268	269	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 12	1990	344	6267					682	685		10.1038/344682a0	http://dx.doi.org/10.1038/344682a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY719	1691451				2022-12-24	WOS:A1990CY71900094
J	WINDLE, JJ; ALBERT, DM; OBRIEN, JM; MARCUS, DM; DISTECHE, CM; BERNARDS, R; MELLON, PL				WINDLE, JJ; ALBERT, DM; OBRIEN, JM; MARCUS, DM; DISTECHE, CM; BERNARDS, R; MELLON, PL			RETINOBLASTOMA IN TRANSGENIC MICE	NATURE			English	Article									SALK INST BIOL STUDIES,REGULATORY BIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HOWE LAB OPHTHALMOL,BOSTON,MA 02114; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR CANC,BOSTON,MA 02129	Salk Institute; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School; Massachusetts General Hospital				Bernards, Rene/0000-0001-8677-3423; Windle, Jolene/0000-0001-6690-385X	NICHD NIH HHS [R01 HD020377] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020377] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERT DM, 1978, JPN J OPHTHALMOL, V22, P358; BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EFRAT S, 1987, EMBO J, V6, P2699, DOI 10.1002/j.1460-2075.1987.tb02562.x; Flexner S, 1891, B J HOPKINS HOSP, V15, P115; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Hogan B., 1986, MANIPULATING MOUSE E; HSIEH CL, 1989, SOMAT CELL MOLEC GEN, V15, P461, DOI 10.1007/BF01534896; Jenkins N A, 1989, Important Adv Oncol, P61; KIVELA T, 1987, ANTIGENIC PROPERTIES, P51; KYRITSIS AP, 1984, NATURE, V307, P471, DOI 10.1038/307471a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; Maniatis T., 1982, MOL CLONING; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STONE JC, 1989, GENOMICS, V5, P70, DOI 10.1016/0888-7543(89)90088-8; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; TEDDER TF, 1988, J IMMUNOL, V141, P4388; TOOZE J, 1981, MOL BIOL TUMOR VIR 2; Ts'o M O, 1970, Am J Ophthalmol, V69, P339; Ts'o M O, 1970, Am J Ophthalmol, V69, P350; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WINTERSTEINER H, 1887, NEUROEPITHELIOMA RET; Wright JH, 1910, J EXP MED, V12, P556, DOI 10.1084/jem.12.4.556	35	203	213	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 15	1990	343	6259					665	669		10.1038/343665a0	http://dx.doi.org/10.1038/343665a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN989	1689463	Green Submitted			2022-12-24	WOS:A1990CN98900072
J	CHAMBERLAND, ME; CONLEY, LJ; BUSH, TJ; CIESIELSKI, CA; HAMMETT, TA; JAFFE, HW				CHAMBERLAND, ME; CONLEY, LJ; BUSH, TJ; CIESIELSKI, CA; HAMMETT, TA; JAFFE, HW			HEALTH-CARE WORKERS WITH AIDS - NATIONAL SURVEILLANCE UPDATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B VIRUS; OCCUPATIONAL RISK; TRANSMISSION; INFECTION; HIV	Objectives. - To characterize health care workers with the acquired immunodeficiency syndrome (AIDS) in the United States and to evaluate the role of occupational transmission of the human immunodeficiency virus (HIV). Data Source. - National AIDS surveillance data. Methods. - Health care workers with AIDS are reported to the Centers for Disease Control by state and local health departments. Health care workers who do not report a nonoccupational risk for HIV infection are termed undetermined risk cases and are investigated by health departments using a standard protocol. Results. - Through June 30, 1990, there were 5425 cases of AIDS in healthcare workers reported in the United States. Three of these workers developed AIDS following well-documented occupational exposure to HIV-infected blood. Of the 539 health care workers initially reported without a nonoccupational risk, follow-up investigations were completed for 303. Nonoccupational risk factors were established for 237 (78.2%) of the 303 investigated health care workers; 66 workers (21.8%) remained in the undetermined category. Follow-up information was incomplete for 236 health care workers who also remained in the undetermined category, resulting in 5120 health care workers (94.4%) with AIDS with nonoccupational risks for HIV infection. Overall, health care workers were more likely than non-health care workers with AIDS to have an undetermined risk for HIV infection (5.6% vs 2.8%; P < .001). While many of the 66 investigated health care workers had jobs involving contact with patients and/or potential contact with blood, none reported percutaneous, mucous membrane, or cutaneous exposures to blood or body fluids known to be infected with HIV. Conclusion. - Surveillance data suggest that most health care workers with AIDS acquired their HIV infection through a nonoccupational route.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; US PHS,WASHINGTON,DC	Centers for Disease Control & Prevention - USA; United States Public Health Service	CHAMBERLAND, ME (corresponding author), CTR DIS CONTROL,HOSP INFECT PROGRAM,1600 CLIFTON RD NE,MAIL STOP A-07,ATLANTA,GA 30333, USA.							BELL DM, 1991, AM J MED S3B, V91; BUEHLER J, 1989, 5 INT C AIDS MONTR, P124; CASTRO KG, 1988, JAMA-J AM MED ASSOC, V259, P1338, DOI 10.1001/jama.259.9.1338; Centers for Disease Control reports include, 1988, MMWR, V37, P229; CIESIELSKI CA, 1990, NEW ENGL J MED, V322, P1156; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; HADLER SC, 1985, INFECT CONT HOSP EP, V6, P24, DOI 10.1017/S0195941700062457; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; LIFSON AR, 1986, JAMA-J AM MED ASSOC, V256, P3231, DOI 10.1001/jama.256.23.3231; MARCUS R, 1989, B WORLD HEALTH ORGAN, V67, P577; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCCORMICK RD, 1981, AM J MED, V70, P928, DOI 10.1016/0002-9343(81)90558-1; Miller J W, 1989, Conn Med, V53, P457; TURNER SB, 1989, AM J PUBLIC HEALTH, V79, P1425, DOI 10.2105/AJPH.79.10.1425; 1991, MMWR, V40, P309; 1987, MMWR, V36, pS1; 1989, EMPLOY EARN, V36, P13; 1991, HIV AIDS SURVEILLANC, P1; 1988, MMWR, V37, P239; 1989, FED REG         0530, V54, P23042; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1	24	36	36	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3459	3462		10.1001/jama.266.24.3459	http://dx.doi.org/10.1001/jama.266.24.3459			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV878	1660544				2022-12-24	WOS:A1991GV87800032
J	HEDMAN, K; VAHERI, A; BRUMMERKORVENKONTIO, M				HEDMAN, K; VAHERI, A; BRUMMERKORVENKONTIO, M			RAPID DIAGNOSIS OF HANTAVIRUS DISEASE WITH AN IGG-AVIDITY ASSAY	LANCET			English	Article							NEPHROPATHIA EPIDEMICA; HEMORRHAGIC-FEVER; IMMUNOGLOBULIN-M; RENAL SYNDROME; INFECTION; ANTIBODY	Nephropathia epidemica (NE), due to Puumala virus, is endemic in eastern Europe and Scandinavia. Serodiagnosis of NE relies on conventional indirect immunofluorescence to detect IgG against Puumala virus. However, in conventional serology, most patients with acute NE have raised but stable non-diagnostic antibody titres. For better serodiagnosis of NE, we have developed a test that measures the avidity (functional affinity) of IgG antibodies against Puumala virus. This new assay was highly specific and sensitive; a diagnosis of NE could be confirmed or excluded rapidly from an early single serum sample. With this test we have now verified the diagnosis of NE in more than 1300 Finnish patients during 22 months in 1989-91. Our findings point to an incidence of confirmed hantavirus disease much higher than previously shown.			HEDMAN, K (corresponding author), UNIV HELSINKI, DEPT VIROL, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND.		Vaheri, Antti/AAV-1523-2020; Hedman, Klaus/D-5379-2009					[Anonymous], 1990, LANCET, V336, P407; ANTONIADIS A, 1989, REV INFECT DIS, V11, pS891; AVSICZUPANC T, 1989, ACTA VIROL, V33, P327; BRUMMERKORVENKONTIO M, 1980, J INFECT DIS, V141, P131, DOI 10.1093/infdis/141.2.131; BRUMMERKORVENKONTIO M, 1982, SCAND J INFECT DIS, P88; DESTRIHOU CV, 1989, Q J MED, V73, P941; HEDMAN K, 1989, J INFECT DIS, V159, P736, DOI 10.1093/infdis/159.4.736; KANGRO HO, 1991, J MED VIROL, V33, P100, DOI 10.1002/jmv.1890330207; LEE HW, 1989, PROG MED VIROL, V36, P62; LEE HW, 1978, J INFECT DIS, V137, P298, DOI 10.1093/infdis/137.3.298; LEE HW, 1989, REV INFECT DIS, V11, pS864; LEE PW, 1985, J CLIN MICROBIOL, V22, P940, DOI 10.1128/JCM.22.6.940-944.1985; NIKLASSON B, 1988, J CLIN MICROBIOL, V26, P1519, DOI 10.1128/JCM.26.8.1519-1523.1988; OSTERHAUS ADME, 1989, LANCET, V2, P338; PILASKI J, 1991, LANCET, V337, P111, DOI 10.1016/0140-6736(91)90765-H; PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1; SCHMALJOHN CS, 1985, SCIENCE, V227, P1041, DOI 10.1126/science.2858126; SETTERGREN B, 1987, J CLIN MICROBIOL, V25, P1134, DOI 10.1128/JCM.25.6.1134-1136.1987; SETTERGREN B, 1989, REV INFECT DIS, V11, P921; THOMAS HIJ, 1991, MED VIROL, V1, P41; YANAGIHARA R, 1990, REV INFECT DIS, V12, P449; ZOLLER L, 1991, LANCET, V338, P183, DOI 10.1016/0140-6736(91)90169-P	22	145	149	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 30	1991	338	8779					1353	1356		10.1016/0140-6736(91)92235-T	http://dx.doi.org/10.1016/0140-6736(91)92235-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682736				2022-12-24	WOS:A1991GR77300003
J	LO, YJ; POO, MM				LO, YJ; POO, MM			ACTIVITY-DEPENDENT SYNAPTIC COMPETITION INVITRO - HETEROSYNAPTIC SUPPRESSION OF DEVELOPING SYNAPSES	SCIENCE			English	Article							MOTOR UNIT SIZE; SKELETAL-MUSCLE; POLYNEURONAL INNERVATION; RAT MUSCLE; NEUROMUSCULAR-JUNCTIONS; EMBRYONIC NEURON; NEWBORN RATS; ELIMINATION; ACETYLCHOLINE; MECHANISMS	The development and stability of synaptic connections in the nervous system are influenced by the pattern of electrical activity and the competitive interaction between the adjacent nerve terminals. To investigate this influence, a culture system of nerve and muscle cells has been developed in which a single embryonic muscle cell is coinnervated by two spinal neurons. The effect of electrical activity on the synaptic efficacy was examined after repetitive electrical stimulation was applied to one or both neurons. Brief tetanic stimulation of one neuron resulted in immediate functional suppression of the synapse made by the unstimulated neuron innervating the same muscle cell. This heterosynaptic suppression was largely absent when the tetanic stimulation was applied concurrently to both neurons. This result demonstrates that activity-dependent synaptic competition can be studied in vitro at a cellular level.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University					NINDS NIH HHS [NS 22764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETZ WJ, 1989, J PHYSIOL-LONDON, V417, P25; BROW H, 1990, ANN REV NEUROSCI, V13, P475; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; BUCHANAN J, 1989, J NEUROSCI, V9, P1544; CALLAWAY EM, 1987, NATURE, V328, P357; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DECKER ER, 1990, J NEUROSCI, V10, P3413; DUNIA R, MOTONEURONAL PLASTIC; EVERS J, 1989, J NEUROSCI, V9, P1523; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hebb DO, 1949, ORG BEHAVIOR, P62; HERRERA AA, 1990, J NEUROBIOL, V21, P73, DOI 10.1002/neu.480210106; HERRERA AA, 1990, J NEUROBIOL, V21, P21; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; KUFFLER D, 1977, BRAIN RES, V138, P353, DOI 10.1016/0006-8993(77)90752-1; LOMO T, 1980, TRENDS NEUROSCI, V3, P126, DOI 10.1016/0166-2236(80)90047-8; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAGCHIELSE T, 1986, DEV BRAIN RES, V25, P211, DOI 10.1016/0165-3806(86)90210-5; NELSON PG, 1989, SCIENCE, V244, P585, DOI 10.1126/science.2717942; NELSON PG, 1990, J NEUROBIOL, V21, P138, DOI 10.1002/neu.480210110; OBRIEN RAD, 1978, J PHYSIOL-LONDON, V282, P571, DOI 10.1113/jphysiol.1978.sp012482; POO M, 1989, J NEUROBIOL, V21, P157; PURVES D, 1990, PRINCIPLES NEURAL DE, V5, P745; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RIBCHESTER RR, 1983, J PHYSIOL-LONDON, V344, P89, DOI 10.1113/jphysiol.1983.sp014926; RIBCHESTER RR, 1984, J PHYSIOL-LONDON, V347, P497, DOI 10.1113/jphysiol.1984.sp015078; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; RIDGE RMAP, 1984, J NEUROSCI, V4, P2614; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; SUN YA, 1987, P NATL ACAD SCI USA, V84, P2540, DOI 10.1073/pnas.84.8.2540; Tabti N., 1991, CULTURING NERVE CELL, P137; THOMPSON W, 1983, NATURE, V302, P614, DOI 10.1038/302614a0; VANESSEN DC, 1990, J NEUROBIOL, V21, P223, DOI 10.1002/neu.480210115; VANESSEN DC, 1982, NEURONAL DEV, P333; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	39	137	139	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					1019	1022		10.1126/science.1658939	http://dx.doi.org/10.1126/science.1658939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1658939				2022-12-24	WOS:A1991GP88300049
J	MOHR, G; LAMBOWITZ, AM				MOHR, G; LAMBOWITZ, AM			INTEGRATION OF A GROUP-I INTRON INTO A RIBOSOMAL-RNA SEQUENCE PROMOTED BY A TYROSYL-TRANSFER RNA-SYNTHETASE	NATURE			English	Article							NEUROSPORA MITOCHONDRIA; INVOLVEMENT; INVITRO	GROUP I and II introns are mobile elements that propagate by insertion into different genes 1. Some introns of both types self-splice in vitro by transesterification reactions catalysed by the intron RNA 2. These transesterifications are reversible 3-5, and it has been suggested that reverse splicing followed by reverse transcription and recombination with genomic DNA may be a mechanism for intron transposition 6-7. In vivo the splicing of many, if not all, group I and II introns requires protein factors, which may facilitate correct folding of the intron RNAs 8. Here we show that the Neurospora mitochondrial large rRNA intron, a group I intron that is not self-splicing in vitro 9, undergoes reverse splicing in a reaction promoted by the CYT-18 protein, the Neurospora mitochondrial tyrosyl-tRNA synthetase, which is required for splicing the intron in vivo 10. In contrast to known RNA-catalysed reverse splicing reactions, this protein-assisted reverse splicing is sufficiently rapid to compete with forward splicing at low RNA concentrations under physiologically relevant conditions, including high GTP and low Mg2+ concentrations. Our results indicate that proteins that promote splicing could contribute to intron mobility by promoting reverse splicing in vivo.	OHIO STATE UNIV,DEPT MOLEC GENET,484 W 12TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University				Mohr, Georg/0000-0002-6411-0685				AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BARTEL DP, 1991, MOL CELL BIOL, V11, P3390, DOI 10.1128/MCB.11.6.3390; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1985, INT REV CYTOL, V3, P3; COLLINS RA, 1985, J MOL BIOL, V184, P413, DOI 10.1016/0022-2836(85)90291-8; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GUO QB, 1991, J BIOL CHEM, V266, P1809; KITTLE JD, 1991, GENE DEV, V5, P109; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; MAJUMDER AL, 1989, MOL CELL BIOL, V9, P2089, DOI 10.1128/MCB.9.5.2089; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; WOODSON SA, 1991, BIOCHEMISTRY-US, V30, P2042, DOI 10.1021/bi00222a006; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9	17	23	26	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					164	167		10.1038/354164a0	http://dx.doi.org/10.1038/354164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1658660				2022-12-24	WOS:A1991GP88000065
J	RANDAZZO, PA; NORTHUP, JK; KAHN, RA				RANDAZZO, PA; NORTHUP, JK; KAHN, RA			ACTIVATION OF A SMALL GTP-BINDING PROTEIN BY NUCLEOSIDE DIPHOSPHATE KINASE	SCIENCE			English	Article							ADENYLATE-CYCLASE; NUCLEOTIDE BINDING; ADP-RIBOSYLATION; ESCHERICHIA-COLI; GS-ALPHA; TUMOR-METASTASIS; CHOLERA-TOXIN; 2 FORMS; EXPRESSION; NM23	Genes that encode nucleoside diphosphate kinases (NDKs) have been implicated as regulators of mammalian tumor metastasis and development in Drosophila melanogaster. However, the cellular pathways through which NDKs function am not known. One potential mechanism of regulation is phosphorylation of guanosine diphosphate (GDP) bound to regulatory guanosine triphosphate (GTP) binding proteins. NDK-catalyzed phosphorylation of bound GDP was investigated for the adenosine diphosphate ribosylation factor (ARF), a 21-kilodalton GTP-binding protein that functions in the protein secretion pathway. Bovine liver NDK, recombinant human NDK, and the protein product of the mouse gene nm23-1, which suppresses the metastatic potential of certain tumor cells, used ARF-GDP as a substrate, thereby allowing rapid and efficient production of activated ARF (ARF-GTP) in the absence of nucleotide exchange. These data are consistent with the proposed function of NDK as an activator of a small GTP-binding protein and provide a mechanism of activation for a regulatory GTP-binding protein that is independent of nucleotide exchange.	NCI,DIV CENT RES,BIOL CHEM LAB,BETHESDA,MD 20892; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06514	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yale University			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CHENG YC, 1971, BIOCHEMISTRY-US, V10, P2139; COLOMB MG, 1969, BIOCHEMISTRY-US, V8, P1926, DOI 10.1021/bi00833a024; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; GOFFEAU A, 1967, J BIOL CHEM, V242, P1845; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMURA N, 1979, J BIOL CHEM, V254, P3451; KIMURA N, 1983, J BIOL CHEM, V258, P2278; KREBS HA, 1953, BIOCHIM BIOPHYS ACTA, V12, P172, DOI 10.1016/0006-3002(53)90136-X; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOURAD N, 1966, J BIOL CHEM, V241, P271; OHTSUKI K, 1985, BIOCHEM INT, V11, P719; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; RANDAZZO PA, UNPUB; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; RULKA C, UNPUB; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SEDMARK J, 1971, J BIOL CHEM, V246, P53; SERAFINI T, IN PRESS CELL; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; UESAKA H, 1987, BIOCHEM BIOPH RES CO, V143, P552, DOI 10.1016/0006-291X(87)91389-1; WEISS O, 1989, J BIOL CHEM, V264, P21066; WILDMAN D, UNPUB	35	77	78	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					850	853		10.1126/science.1658935	http://dx.doi.org/10.1126/science.1658935			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1658935				2022-12-24	WOS:A1991GN83300043
J	SALTZ, BL; WOERNER, MG; KANE, JM; LIEBERMAN, JA; ALVIR, JMJ; BERGMANN, KJ; BLANK, K; KOBLENZER, J; KAHANER, K				SALTZ, BL; WOERNER, MG; KANE, JM; LIEBERMAN, JA; ALVIR, JMJ; BERGMANN, KJ; BLANK, K; KOBLENZER, J; KAHANER, K			PROSPECTIVE-STUDY OF TARDIVE-DYSKINESIA INCIDENCE IN THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVALENCE; MOVEMENTS; AGE	Objectives. - To investigate the incidence of tardive dyskinesia in elderly individuals beginning treatment with antipsychotic drugs and to identify risk factors for the development of tardive dyskinesia in the elderly. Design. - A cohort of previously neuroleptic-naive patients was identified at the time of initiation of antipsychotic drug treatment. Patients were evaluated at baseline and followed up at 3-month intervals for periods ranging from 3 to 119 weeks. Setting. - Subjects were recruited from the psychiatric and geriatric medical services of two medical centers, a geriatric institute, and three nursing homes in the metropolitan area of New York City, NY. Patients. - Two hundred fifteen individuals older than 55 years have entered the study thus far. Preliminary data are presented for 160 patients who were followed up for at least 1 month. Their age range was 57 to 99 years (mean, 77 years). Seventy-two percent were women and 87% were white. Sixty-seven percent of patients had a diagnosis of organic mental syndrome and 42% had a psychiatric diagnosis. Interventions. - A naturalistic, longitudinal, repeated assessment paradigm was employed. Assessments included abnormal involuntary movements, extrapyramidal signs, psychiatric symptoms, and medical and drug treatment histories. Main Outcome Measure. - The incidence of tardive dyskinesia was determined using a standardized rating instrument and survival analysis. Results. - The incidence of neuroleptic-induced dyskinesia was 31% (95% confidence interval, 20%, 42%) after 43 weeks of cumulative neuroleptic treatment. Psychiatric (as opposed to organic) diagnosis and presence of extrapyramidal signs early in treatment were associated with increased tardive dyskinesia vulnerability.	LONG ISL JEWISH MED CTR,DEPT NEUROL,NEW HYDE PK,NY 11042; PARKER JEWISH GERIATR CTR,NEW HYDE PK,NY; YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461; BETH ISRAEL MED CTR,DEPT PSYCHIAT,NEW YORK,NY 10003	Northwell Health; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Beth Israel Deaconess Medical Center	SALTZ, BL (corresponding author), LONG ISL JEWISH MED CTR,HILLSIDE HOSP,DEPT PSYCHIAT,BOX 38,GLEN OAKS,NY 11004, USA.		Lieberman, Jeffrey/AAY-8239-2020		NIMH NIH HHS [MH-41960, MH-40015, MH-32369] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH032369, P50MH041960, P30MH041960, R01MH040015, R01MH032369] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARNES TRE, 1983, J NEUROL NEUROSUR PS, V46, P540, DOI 10.1136/jnnp.46.6.540; BENEDETTI J, 1985, BMDP STATISTICAL SOF, P557; BOURGEOIS M, 1980, J NERV MENT DIS, V168, P177, DOI 10.1097/00005053-198003000-00009; BRANDON S, 1971, BRIT J PSYCHIAT, V118, P171, DOI 10.1192/bjp.118.543.171; CASEY DE, 1985, J CLIN PSYCHIAT, V46, P42; CHACKO RC, 1985, J CLIN PSYCHIAT, V46, P55; CRANE GE, 1974, ARCH GEN PSYCHIAT, V30, P314; DEGKWITZ R, 1969, PSYCHOTROPIC SIGNS D; DELWAIDE PJ, 1977, ACTA NEUROL SCAND, V56, P256; FINCH CE, 1973, BRAIN RES, V52, P261, DOI 10.1016/0006-8993(73)90663-X; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GARDOS G, 1983, TARDIVE DYSKINESIA A; GUY W, 1976, ADM76338 NAT I MENT; HOPKINS A, 1985, BMDP STATISTICAL SOF, P576; JESTE DV, 1982, UNDERSTANDING TREATI; JONES M, 1969, PSYCHOTROPIC DRUGS D, P53; KANE JM, 1982, ARCH GEN PSYCHIAT, V39, P473; KANE JM, 1982, PSYCHOPHARMACOLOGY, V77, P105, DOI 10.1007/BF00431929; KANE JM, 1986, DRUG DEVELOP RES, P41; KARSON CN, 1990, AM J PSYCHIAT, V147, P1646; LIEBERMAN J, 1984, PSYCHOPHARMACOL BULL, V20, P382; PRIEN RF, 1973, J AM GERIATR SOC, V21, P546; RABINS P, 1984, COMPR PSYCHIAT, V25, P290, DOI 10.1016/0010-440X(84)90060-9; RASKIND M, 1979, J AM GERIATR SOC, V27, P459, DOI 10.1111/j.1532-5415.1979.tb01727.x; SALZMAN C, 1987, PSYCHOPHARMACOLOGY 3, P1167; SCHOOLER NR, 1982, ARCH GEN PSYCHIAT, V39, P486; Simpson G M, 1970, Acta Psychiatr Scand Suppl, V212, P11; SIMPSON GM, 1979, PSYCHOPHARMACOLOGY, V64, P171, DOI 10.1007/BF00496058; SIRIS SG, 1982, ELECTROCONVULSIVE TH; SMITH JM, 1980, ARCH GEN PSYCHIAT, V37, P1368; SPIKER DG, 1985, AM J PSYCHIAT, V142, P430; TOENNIESSEN LM, 1985, ARCH GEN PSYCHIAT, V42, P278; UHRBRAND I, 1960, PSYCHOPHARMACOLOGIA, V1, P408; WOERNER MG, 1988, PSYCHOPHARMACOL BULL, V24, P112; WOERNER MG, 1991, J CLIN PSYCHOPHARM, V11, P34; YASSA R, 1985, PSYCHOSOMATICS, V26, P305, DOI 10.1016/S0033-3182(85)72863-0; 1987, DIAGNOSTIC STATISTIC	37	150	150	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2402	2406						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GM790	1681122				2022-12-24	WOS:A1991GM79000027
J	LI, JD; CARROLL, J; ELLAR, DJ				LI, JD; CARROLL, J; ELLAR, DJ			CRYSTAL-STRUCTURE OF INSECTICIDAL DELTA-ENDOTOXIN FROM BACILLUS-THURINGIENSIS AT 2.5-A RESOLUTION	NATURE			English	Article							BRUSH-BORDER MEMBRANE; VAR TENEBRIONIS; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN-STRUCTURE; SPECIFICITY; GENE; BINDING; PURIFICATION; COLEOPTERA; MECHANISM	The structure of the delta-endotoxin from Bacillus thuringiensis subsp. tenebrionis that is specifically toxic to Coleoptera insects (beetle toxin) has been determined at 2.5 angstrom resolution. It comprises three domains which are, from the N- to C-termini, a seven-helix bundle, a three-sheet domain, and a beta-sandwich. The core of the molecule encompassing all the domain interfaces is built from conserved sequence segments of the active delta-endotoxins. Therefore the structure represents the general fold of this family of insecticidal proteins. The bundle of long, hydrophobic and amphipathic helices is equipped for pore formation in the insect membrane, and regions of the three-sheet domain are probably responsible for receptor binding.	UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CB2 1QW, ENGLAND	University of Cambridge	LI, JD (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ADANG MJ, 1985, GENE, V36, P289, DOI 10.1016/0378-1119(85)90184-2; AHMAD W, 1990, FEMS MICROBIOL LETT, V68, P97, DOI 10.1111/j.1574-6968.1990.tb04130.x; ARNDT UW, 1985, METHOD ENZYMOL, V114, P472; BARTON KA, 1987, PLANT PHYSIOL, V85, P1103, DOI 10.1104/pp.85.4.1103; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CARROLL J, 1989, BIOCHEM J, V261, P99, DOI 10.1042/bj2610099; CHOMA CT, 1990, BIOCHEMISTRY-US, V29, P10971, DOI 10.1021/bi00501a015; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CHUNGJATUPORNCHAI W, 1988, EUR J BIOCHEM, V173, P9, DOI 10.1111/j.1432-1033.1988.tb13960.x; ELLAR DJ, 1985, MOL BIOL MICROBIAL D, P230; ENDO Y, 1980, J INVERTEBR PATHOL, V36, P90, DOI 10.1016/0022-2011(80)90140-8; GE AZ, 1989, P NATL ACAD SCI USA, V86, P4037, DOI 10.1073/pnas.86.11.4037; HAIDER MZ, 1987, BIOCHEM J, V248, P197, DOI 10.1042/bj2480197; Hodgman T. C, 1990, J DNA SEQU MAPPING, V1, P97; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HOFTE H, 1986, EUR J BIOCHEM, V161, P273, DOI 10.1111/j.1432-1033.1986.tb10443.x; HOFTE H, 1989, MICROBIOL REV, V53, P242; HOFTE H, 1987, NUCLEIC ACIDS RES, V15, P7183, DOI 10.1093/nar/15.17.7183; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; KNOWLES BH, 1986, J CELL SCI, V83, P89; KNOWLES BH, 1984, FEBS LETT, V168, P197, DOI 10.1016/0014-5793(84)80245-8; KRAULIS P, IN PRESS J APPL CRYS; KRIEG A, 1983, Z ANGEW ENTOMOL, V96, P500; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LI J, 1988, J MOL BIOL, V199, P543, DOI 10.1016/0022-2836(88)90625-0; MACINTOSH SC, 1990, BIOCHEM BIOPH RES CO, V170, P665, DOI 10.1016/0006-291X(90)92143-N; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; NICHOLLS CN, 1989, J BACTERIOL, V171, P5141, DOI 10.1128/jb.171.9.5141-5147.1989; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PERLAK FJ, 1991, P NATL ACAD SCI USA, V88, P3324, DOI 10.1073/pnas.88.8.3324; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHNEPF HE, 1985, J BIOL CHEM, V260, P6273; SCHNEPF HE, 1990, J BIOL CHEM, V265, P20923; SEKAR V, 1987, P NATL ACAD SCI USA, V84, P7036, DOI 10.1073/pnas.84.20.7036; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; VAECK M, 1987, NATURE, V328, P33, DOI 10.1038/328033a0; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; VISSER B, 1990, J BACTERIOL, V172, P6783, DOI 10.1128/jb.172.12.6783-6788.1990; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIDNER WR, 1990, J BACTERIOL, V172, P2826, DOI 10.1128/jb.172.6.2826-2832.1990; Wilcox D. R., 1986, PROTEIN ENG APPLICAT, P395	47	614	690	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					815	821		10.1038/353815a0	http://dx.doi.org/10.1038/353815a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1658659				2022-12-24	WOS:A1991GM73200050
J	NUDESHIMA, J				NUDESHIMA, J			OBSTACLES TO BRAIN-DEATH AND ORGAN-TRANSPLANTATION IN JAPAN	LANCET			English	Editorial Material											NUDESHIMA, J (corresponding author), MITSUBISHI KASEI INST LIFE SCI,LIFE SCI & SOC PROGRAMME,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							LOCK M, 1990, SOCIAL SCI PERSPECTI, P99; MANNINEN DL, 1985, JAMA-J AM MED ASSOC, V253, P3111, DOI 10.1001/jama.253.21.3111; PETERS TG, 1991, JAMA-J AM MED ASSOC, V265, P1302, DOI 10.1001/jama.265.10.1302; Yanagita Kunio, 1970, OUR ANCESTORS JAPANE; 1981, DEFINING DEATH	5	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1991	338	8774					1063	1064		10.1016/0140-6736(91)91912-E	http://dx.doi.org/10.1016/0140-6736(91)91912-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM253	1681367				2022-12-24	WOS:A1991GM25300015
J	YOKOUCHI, Y; SASAKI, H; KUROIWA, A				YOKOUCHI, Y; SASAKI, H; KUROIWA, A			HOMEOBOX GENE-EXPRESSION CORRELATED WITH THE BIFURCATION PROCESS OF LIMB CARTILAGE DEVELOPMENT	NATURE			English	Article							RETINOIC ACID; MORPHOGENESIS; CELLS	THE complex architecture of the limb cartilage pattern probably develops by the sequential segmentation and branching process of precartilaginous cell condensation under the control of positional signalling 1,2 provided by the zone of polarizing activity (anteroposterior) 3,4 and the apical ectodermal ridge (proximodistal) 5. This signalling is monitored and interpreted in the mesenchymal cells and induces the position-specific response of subsets of genes. Homeobox genes may be responsible for the interpretation of signalling 6-11. A correlation between limb pattern and expression domains of the homeobox genes in the upstream region of Hox/Chox-4 has been proposed 10-12. We have analysed the spatial expression pattern of the Chox-1 genes during development of chick limb buds. In contrast to genes in Hox/Chox-4 expressed coordinately along the anteroposterior axis 10,11, homeobox genes in Chox-1 have unique and mutually exclusive expression domains along the proximodistal axis. We report here that the expression domains of the Chox-1 genes are closely related to the segmental structure of cartilage along the proximodistal axis, whereas the expression domains of the Chox-4 genes are related to the cartilage branching pattern.	TOHOKU UNIV,TB & CANC RES INST,DEPT CELL BIOL,4-1 SEIRYOMACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,FAC SCI,INST BIOL,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University				Sasaki, Hiroshi/0000-0001-8752-6846; Kuroiwa, Atsushi/0000-0001-7710-4041				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AULTHOUSE AL, 1987, DEV BIOL, V120, P377, DOI 10.1016/0012-1606(87)90240-5; CRAWFORD K, 1988, DEVELOPMENT, V104, P703; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; NARDI JB, 1983, DIFFERENTIATION, V25, P27; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; OLIVER G, 1989, GENE DEV, V3, P641, DOI 10.1101/gad.3.5.641; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; OSTER GF, 1988, EVOLUTION, V42, P862, DOI 10.1111/j.1558-5646.1988.tb02508.x; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; YOKOUCHI Y, IN PRESS DEVELOPMENT, V113	20	295	298	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					443	445		10.1038/353443a0	http://dx.doi.org/10.1038/353443a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1680221				2022-12-24	WOS:A1991GH60600061
J	BRAHAMS, D				BRAHAMS, D			PERTUSSIS-VACCINE AND ENCEPHALOPATHY, AN IRISH CASE	LANCET			English	Editorial Material																			0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					305	305		10.1016/0140-6736(91)90437-T	http://dx.doi.org/10.1016/0140-6736(91)90437-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677124				2022-12-24	WOS:A1991FZ56500018
J	KUCK, KH; SCHLUTER, M; GEIGER, M; SIEBELS, J; DUCKECK, W				KUCK, KH; SCHLUTER, M; GEIGER, M; SIEBELS, J; DUCKECK, W			RADIOFREQUENCY CURRENT CATHETER ABLATION OF ACCESSORY ATRIOVENTRICULAR PATHWAYS	LANCET			English	Article							PARKINSON-WHITE SYNDROME; ELECTRODE CONFIGURATION; CONDUCTION; TACHYCARDIA; BLOCK	Tachyarrhythmias mediated by an accessory atrioventricular pathway and which are refractory to drug therapy have been treated surgically with variable success. Early results of direct-current catheter ablation were encouraging but were associated with complications such as barotrauma and the need for a general anaesthetic. We have investigated the endocardial application of radiofrequency current which is a potentially safer technique. Of 105 patients with an accessory atrioventricular pathway, 79 were located on the left side of the heart and 32 on the right side. Accessory pathway conduction was permanently abolished in 93 (89%) patients. Complications developed in 3 patients: thrombotic occlusion of a femoral artery, arteriovenous fistula formation at the site of groin puncture, and left ventricular rupture with cardiac tamponade after direct-current shocks. There were no deaths from the procedure. We conclude that radiofrequency current catheter ablation is both effective and safe for patients with symptomatic tachyarrhythmias mediated by accessory atrioventricular pathways.			KUCK, KH (corresponding author), UNIV HAMBURG,HOSP EPPENDORF,DEPT CARDIOL,W-2000 HAMBURG 20,GERMANY.		Poposka, Lidija/N-6851-2019	Poposka, Lidija/0000-0002-2539-6828				BECKER AE, 1978, CIRCULATION, V57, P870, DOI 10.1161/01.CIR.57.5.870; BORGGREFE M, 1987, J AM COLL CARDIOL, V10, P576, DOI 10.1016/S0735-1097(87)80200-0; COX JL, 1985, J THORAC CARDIOV SUR, V90, P490; EVANS GT, 1988, PACE, V11, P1621, DOI 10.1111/j.1540-8159.1988.tb06284.x; GALLAGHER JJ, 1982, NEW ENGL J MED, V306, P194, DOI 10.1056/NEJM198201283060402; JACKMAN W, 1990, CIRCULATION, V82, P689; JACKMAN WM, 1983, CIRCULATION, V68, P906, DOI 10.1161/01.CIR.68.5.906; JACKMAN WM, 1988, CIRCULATION, V78, P1288, DOI 10.1161/01.CIR.78.5.1288; JACKMAN WM, IN PRESS CIRCULATION; KUCK KH, 1990, CIRCULATION, V82, P407, DOI 10.1161/01.CIR.82.2.407; KUCK KH, 1989, PACE, V12, P1681, DOI 10.1111/j.1540-8159.1989.tb01847.x; KUCK KH, 1988, EUR HEART J, V9, P927, DOI 10.1093/oxfordjournals.eurheartj.a062589; KUCK KH, IN PRESS PACE; KUNZE KP, 1985, J AM COLL CARDIOL, V6, P1428, DOI 10.1016/S0735-1097(85)80236-9; LANGBERG JJ, 1991, AM J CARDIOL, V67, P142, DOI 10.1016/0002-9149(91)90436-O; MORADY F, 1990, CIRCULATION, V82, P689; MORADY F, 1989, CIRCULATION, V79, P1160, DOI 10.1161/01.CIR.79.6.1160; NATHAN AW, 1984, LANCET, V1, P1280; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; WARD DE, 1985, BRIT HEART J, V53, P64	20	333	343	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1557	1561		10.1016/0140-6736(91)93258-B	http://dx.doi.org/10.1016/0140-6736(91)93258-B			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675706				2022-12-24	WOS:A1991FU55100002
J	BRIDGES, BA; COLE, J; ARLETT, CF; GREEN, MHL; WAUGH, APW; BEARE, D; HENSHAW, DL; LAST, RD				BRIDGES, BA; COLE, J; ARLETT, CF; GREEN, MHL; WAUGH, APW; BEARE, D; HENSHAW, DL; LAST, RD			POSSIBLE ASSOCIATION BETWEEN MUTANT FREQUENCY IN PERIPHERAL LYMPHOCYTES AND DOMESTIC RADON CONCENTRATIONS	LANCET			English	Article							LEUKEMIA; CELLS; LUNG	To investigate whether previously found geographical correlations between leukaemia incidence and exposure to radon are reflected in a detectable mutagenic effect on individuals, the frequency of mutations in the hypoxanthine guanine phosphoribosyl transferase gene (hprt) in peripheral blood T lymphocytes was measured in subjects with known domestic radon concentrations. These concentrations were measured in December, 1989, in house in Street, Somerset, UK, by passive alpha-track radon detectors. 20 non-smoking subjects aged 36-55 years were selected from the patient list at the local health centre on the basis of the radon concentrations in their homes - the range selected varied by a factor of ten. Blood samples for preparation of T lymphocytes were taken in July, 1990. There was a significant association between the log mutant frequency and radon concentration (t = 3.47, p < 0.01). A second analysis of a further set of radon measurements (October, 1990, to January, 1991), in both living rooms and bedrooms, and repeated mutant frequency determinations also showed a significant relation, which remained significant even after exclusion of the highest frequency and adjustment for subject's age and cloning efficiency. These data must be regarded as preliminary and further more extensive studies should be done to determine whether the observed association is causal.	UNIV BRISTOL, HH WILLS PHYS LAB, BRISTOL BS8 1TL, AVON, ENGLAND; HLTH CTR, SOMERSET, ENGLAND	University of Bristol	BRIDGES, BA (corresponding author), UNIV SUSSEX, MRC, CELL MUTAT UNIT, BRIGHTON BN1 9RR, ENGLAND.							ALEXANDER FE, 1990, LANCET, V335, P1336; BAVERSTOCK KF, 1990, LANCET, V335, P1337; BRIDGES BA, 1989, LEUKEMIA, V3, P846; CLARKE RH, 1989, NATURE, V338, P197, DOI 10.1038/338197a0; COLE J, 1990, PROG CLIN BIOL RES, V340, P25; COLE J, 1988, MUTAT RES, V204, P493, DOI 10.1016/0165-1218(88)90044-4; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; HOLT PG, 1988, IMMUNOLOGY, V64, P649; HOLT PG, 1986, CLIN EXP IMMUNOL, V66, P188; LUCIE NP, 1989, LANCET, V2, P99; Pabst R, 1988, Adv Exp Med Biol, V237, P553; PABST R, 1989, IMMUNOL REV, V108, P83, DOI 10.1111/j.1600-065X.1989.tb00014.x; Pohl-Ruling J., 1988, BERZELIUS S, P103; RICHARDSON RB, IN PRESS BR J RADIOL; SANKARANARAYANAN K, 1988, AM J HUM GENET, V42, P651; THACKER J, IN PRESS ADV RAD BIO; WRIXON AD, 1988, R190 NAT RAD PROT BO; 1988, BIER4 REP	18	69	71	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1187	1189		10.1016/0140-6736(91)92859-Z	http://dx.doi.org/10.1016/0140-6736(91)92859-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673739				2022-12-24	WOS:A1991FM26100004
J	HURWITZ, B; ASSERSON, T				HURWITZ, B; ASSERSON, T			TAX-EXEMPTION FOR SEVERE MENTAL IMPAIRMENT	LANCET			English	Editorial Material											HURWITZ, B (corresponding author), THE SURGERY,1 ASHBY GROVE,LONDON N1 3PR,ENGLAND.							1991, MENTAL IMPAIRMENT SE, P7; 1989, PLCO8912 DEP HLTH ME; 1990, PLCO907 DEP HLTH MEM	3	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1147	1148		10.1016/0140-6736(91)92803-A	http://dx.doi.org/10.1016/0140-6736(91)92803-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FL124	1674026				2022-12-24	WOS:A1991FL12400017
J	TULPPALA, M; VIINIKKA, L; YLIKORKALA, O				TULPPALA, M; VIINIKKA, L; YLIKORKALA, O			THROMBOXANE DOMINANCE AND PROSTACYCLIN DEFICIENCY IN HABITUAL ABORTION	LANCET			English	Article							RECURRENT ABORTION; PREGNANCY; WOMEN	To evaluate the significance of vasoactive prostanoids in habitual abortion, we measured urinary excretion of prostacyclin metabolites (6-keto-PGF1-alpha and 2,3-dinor-6-keto-PGF1-alpha) and of thromboxane A2 metabolites (TxB2 and 2,3-dinor-TxB2) during 25 pregnancies in 22 women with recurrent spontaneous abortion (RSA). The control group were 16 pregnant women with no history of abortion. Ultrasound examination at first follow-up appointment showed a living fetus in 23 pregnancies of women with RSA. 9 of these pregnancies ended in abortion; 14 continued to term as did all the pregnancies in the control group. Compared with controls, women with RSA had a lower (p < 0.05) ratio of prostacyclin to thromboxane between weeks 4 and 7 of gestation and a lower (p < 0.01) output of 2,3-dinor-6-keto-PGF1-alpha between weeks 8 and 11. Women whose pregnancies ended in abortion had higher (p < 0.05) output of 2,3-dinor-TxB2 between weeks 4 and 7 of gestation and lower (p < 0.01) excretion of 2,3-dinor-6-keto-PGF1-alpha between weeks 8 and 11 compared with women whose pregnancies proceeded to term. We conclude that deficiency of vasodilatory prostacyclin may be a factor in habitual abortion.	UNIV CENT HOSP HELSINKI,DEP OBSTET & GYNAECOL 1,SF-00290 HELSINKI,FINLAND; UNIV CENT HOSP HELSINKI,CHILDRENS HOSP,SF-00290 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	TULPPALA, M (corresponding author), UNIV CENT HOSP HELSINKI,DEPT OBSTET & GYNAECOL 2,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							CASEY ML, 1986, SEMIN PERINATOL, V10, P270; DECASTELLARNAU C, 1988, EUR J OBSTET GYN R B, V29, P173, DOI 10.1016/0028-2243(88)90145-1; FRIEDMAN SA, 1988, OBSTET GYNECOL, V71, P122; GOLAN A, 1989, FERTIL STERIL, V51, P747; HILL JA, 1990, AM J REPROD IMMUNOL, V22, P33, DOI 10.1111/j.1600-0897.1990.tb01029.x; JOGEE M, 1983, BRIT J OBSTET GYNAEC, V90, P247, DOI 10.1111/j.1471-0528.1983.tb08618.x; MCNEELY MJ, 1988, FERTIL STERIL, V50, P1; MCPARLAND P, 1990, LANCET, V335, P1552, DOI 10.1016/0140-6736(90)91377-M; NOORT WA, 1990, EUR J OBSTET GYN R B, V35, P15, DOI 10.1016/0028-2243(90)90137-P; PARISI VM, 1986, SEMIN PERINATOL, V10, P288; PORTNOI MF, 1988, OBSTET GYNECOL, V72, P31; REGAN L, 1990, LANCET, V336, P1141, DOI 10.1016/0140-6736(90)92765-A; Rushton DI, 1988, EARLY PREGNANCY LOSS, P149; SCOTT JR, 1987, OBSTET GYNECOL, V70, P645; STIRRAT GM, 1990, LANCET, V336, P728, DOI 10.1016/0140-6736(90)92215-4; WALLENBURG HCS, 1986, LANCET, V1, P1; WALSH SW, 1990, SEMIN PERINATOL, V14, P152; YLIKORKALA O, 1986, J CLIN ENDOCR METAB, V63, P1307, DOI 10.1210/jcem-63-6-1307; YLIKORKALA O, 1985, AM J OBSTET GYNECOL, V152, P318, DOI 10.1016/S0002-9378(85)80221-0	19	56	56	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					879	881		10.1016/0140-6736(91)90205-4	http://dx.doi.org/10.1016/0140-6736(91)90205-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672969				2022-12-24	WOS:A1991FG04800004
J	OTA, K; MATSUI, M; MILFORD, EL; MACKIN, GA; WEINER, HL; HAFLER, DA				OTA, K; MATSUI, M; MILFORD, EL; MACKIN, GA; WEINER, HL; HAFLER, DA			T-CELL RECOGNITION OF AN IMMUNODOMINANT MYELIN BASIC-PROTEIN EPITOPE IN MULTIPLE-SCLEROSIS	NATURE			English	Article									BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,DIV NEUROL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,TISSUE TYPING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								ALLEGRETTA M, 1990, SCIENCE, V247, P718, DOI 10.1126/science.1689076; Alvord EC, 1984, EXPT ALLERGIC ENCEPH; ANTEL JP, 1979, ANN NEUROL, V5, P338, DOI 10.1002/ana.410050406; BACEVANIS CN, 1989, J NEUROIMMUN, V22, P23; BRINKMAN CJJ, 1981, ANN NEUROL, V11, P450; BROD SA, 1990, CELL IMMUNOL, V125, P426, DOI 10.1016/0008-8749(90)90096-A; CHOFFLON M, 1988, ANN NEUROL, V24, P185, DOI 10.1002/ana.410240203; CHOU FCH, 1976, J BIOL CHEM, V251, P2671; Dupont B, 1989, IMMUNOBIOLOGY HLA, V1st; ELIAN M, 1987, DIS MARKERS, V5, P89; FRANCIS DA, 1986, LANCET, V1, P211; HAFLER DA, 1987, J IMMUNOL, V139, P68; HAFLER DA, 1989, IMMUNOL TODAY, V10, P104, DOI 10.1016/0167-5699(89)90236-3; HAPP MP, 1988, J IMMUNOL, V141, P1489; HO HZ, 1981, IMMUNOGENETICS, V15, P509; JOHNSON D, 1986, J NEUROIMMUNOL, V13, P99, DOI 10.1016/0165-5728(86)90053-6; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; OFFNER H, 1989, J EXP MED, V170, P355, DOI 10.1084/jem.170.2.355; SAKAI K, 1988, J NEUROIMMUNOL, V19, P21, DOI 10.1016/0165-5728(88)90032-X; SCHLUESENER HJ, 1985, J IMMUNOL, V135, P3128; SPIELMAN RS, 1982, EPIDEMIOL REV, V4, P45, DOI 10.1093/oxfordjournals.epirev.a036251; VANDENBARK AA, 1985, J IMMUNOL, V135, P229; WAKSMAN BH, 1954, J EXP MED, V100, P451, DOI 10.1084/jem.100.5.451; YOSHIMURA T, 1985, J NEUROL SCI, V69, P47, DOI 10.1016/0022-510X(85)90006-1; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	25	782	826	2	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 12	1990	346	6280					183	187		10.1038/346183a0	http://dx.doi.org/10.1038/346183a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN424	1694970				2022-12-24	WOS:A1990DN42400064
J	STARZL, TE; FUNG, J; JORDAN, M; SHAPIRO, R; TZAKIS, A; MCCAULEY, J; JOHNSTON, J; IWAKI, Y; JAIN, A; ALESSIANI, M; TODO, S				STARZL, TE; FUNG, J; JORDAN, M; SHAPIRO, R; TZAKIS, A; MCCAULEY, J; JOHNSTON, J; IWAKI, Y; JAIN, A; ALESSIANI, M; TODO, S			KIDNEY-TRANSPLANTATION UNDER FK-506	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV PITTSBURGH,CTR HLTH,DEPT MED,PITTSBURGH,PA 15213; UNIV PITTSBURGH,CTR HLTH,DEPT PATHOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,VET ADM MED CTR,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)	STARZL, TE (corresponding author), UNIV PITTSBURGH,CTR HLTH,DEPT SURG,FALK CLIN,3601 5TH AVE,PITTSBURGH,PA 15213, USA.		Alessiani, Mario/AAC-3281-2019; FUNG, John Julian/A-2679-2012	Alessiani, Mario/0000-0003-2660-5780; FUNG, John Julian/0000-0002-3038-0441	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 29961, R01 DK029961-19] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEJANDRO R, 1989, DIABETES, V38, P698, DOI 10.2337/diabetes.38.6.698; BALLANTYNE CM, 1989, JAMA-J AM MED ASSOC, V262, P53, DOI 10.1001/jama.262.1.53; CARROLL PB, IN PRESS TRANSPLANTA; ENGFELDT P, 1986, TRANSPLANT P, V18, P65; FALK JA, 1985, TRANSPLANT P, V17, P1530; FARID NR, 1979, DIABETES, V28, P552, DOI 10.2337/diabetes.28.6.552; FUNG J, 1987, TRANSPLANT P, V19, P767; FUNG JJ, 1987, NEPHRON, V46, P19, DOI 10.1159/000184431; FUNG JJ, 1990, TRANSPLANT P, V22, P6; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; IWAKI Y, 1987, TRANSPLANT P, V19, P764; IWAKI Y, 1988, CLIN TRANSPLANT, V2, P81; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KERMAN RH, 1990, TRANSPLANTATION, V49, P52, DOI 10.1097/00007890-199001000-00011; KINO T, 1987, J ANTIBIOT, V40, P1256, DOI 10.7164/antibiotics.40.1256; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; LIN HY, 1989, NEW ENGL J MED, V321, P287, DOI 10.1056/NEJM198908033210504; MCCAULEY J, 1989, LANCET, V2, P1516; MCCAULEY J, 1990, LANCET, V335, P674, DOI 10.1016/0140-6736(90)90471-G; MCCAULEY J, 1990, TRANSPLANT P, V22, P17; MIELES L, 1990, TRANSPLANT P, V22, P41; NALESNIK MA, 1987, TRANSPLANT P, V19, P89; NALESNIK MA, 1990, TRANSPLANT P, V22, P87; RUIZ JO, 1973, SURGERY, V73, P759; SAWADA S, 1987, J IMMUNOL, V139, P1797; SHAPIRO R, 1990, TRANSPLANT P, V22, P35; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SOLOW H, 1979, DIABETES, V28, P1, DOI 10.2337/diabetes.28.1.1; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, IN PRESS TRANSPLANTA; STARZL TE, 1964, EXPERIENCE RENAL TRA, P177; STEGALL MD, 1989, TRANSPLANTATION, V48, P944, DOI 10.1097/00007890-198912000-00009; TAMURA K, 1987, TRANSPLANT P, V19, P23; TAYLOR CJ, 1989, TRANSPLANTATION, V48, P953, DOI 10.1097/00007890-198912000-00011; TODO S, 1987, TRANSPLANT P, V19, P57; TODO S, 1990, TRANSPLANT P, V22, P13; TODO S, 1988, SURGERY, V104, P239; TZAKIS A, 1988, TRANSPLANT P, V20, P92; TZE WJ, IN PRESS TRANSPLANTA; VANTHIEL DH, 1990, TRANSPLANT P, V22, P37; YAGISAWA T, 1986, TRANSPLANT P, V18, P1543; ZEEVI A, 1987, TRANSPLANT P, V19, P40	42	234	243	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	1990	264	1					63	67		10.1001/jama.264.1.63	http://dx.doi.org/10.1001/jama.264.1.63			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL320	1693970	Green Accepted			2022-12-24	WOS:A1990DL32000026
J	MYSLINSKI, E; SEGAULT, V; BRANLANT, C				MYSLINSKI, E; SEGAULT, V; BRANLANT, C			AN INTRON IN THE GENES FOR U3 SMALL NUCLEOLAR RNAS OF THE YEAST SACCHAROMYCES-CEREVISIAE	SCIENCE			English	Article									UNIV NANCY 1,CNRS,URA 457,ENZYMOL & GENIE GENET LAB,BP 239,F-54506 VANDOEUVRE NANCY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine				Branlant, Christiane/0000-0003-4728-5499				BRANLANT C, 1982, EMBO J, V1, P1259, DOI 10.1002/j.1460-2075.1982.tb00022.x; BRINGMANN P, 1983, EMBO J, V2, P1129, DOI 10.1002/j.1460-2075.1983.tb01557.x; BROW DA, 1989, NATURE, V337, P14, DOI 10.1038/337014a0; BUSCH H, 1982, ANNU REV BIOCHEM, V51, P617, DOI 10.1146/annurev.bi.51.070182.003153; CALVET JP, 1981, CELL, V26, P363, DOI 10.1016/0092-8674(81)90205-1; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; CHOI TSR, 1976, BIOCHEMISTRY-US, V15, P3823; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERBI SA, 1987, COLD SPRING HARB SYM, V52, P709, DOI 10.1101/SQB.1987.052.01.080; HUGHES JMX, 1987, EMBO J, V6, P2145, DOI 10.1002/j.1460-2075.1987.tb02482.x; KROL A, 1983, NUCLEIC ACIDS RES, V11, P8583, DOI 10.1093/nar/11.24.8583; LACROUTE F, 1968, J BACTERIOL, V95, P824, DOI 10.1128/JB.95.3.824-832.1968; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; MYSLINSKI E, UNPUB; PARKER KA, 1987, MOL CELL BIOL, V7, P2899, DOI 10.1128/MCB.7.8.2899; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PORTER GL, 1988, NUCLEIC ACIDS RES, V16, P10131, DOI 10.1093/nar/16.21.10131; QU LH, 1983, NUCLEIC ACIDS RES, V11, P5903, DOI 10.1093/nar/11.17.5903; RIEDEL N, 1986, P NATL ACAD SCI USA, V83, P8097, DOI 10.1073/pnas.83.21.8097; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAULT V, UNPUB; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STROKE IL, 1985, J MOL BIOL, V184, P183, DOI 10.1016/0022-2836(85)90372-9; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUH D, 1986, BIOCHEM BIOPH RES CO, V137, P1133, DOI 10.1016/0006-291X(86)90343-8; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; TEEM JL, 1984, NUCLEIC ACIDS RES, V12, P8295, DOI 10.1093/nar/12.22.8295; WATTS FZ, 1983, EMBO J, V2, P2085, DOI 10.1002/j.1460-2075.1983.tb01704.x; WISE JA, 1980, CELL, V22, P109, DOI 10.1016/0092-8674(80)90159-2	31	83	85	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 9	1990	247	4947					1213	1216		10.1126/science.1690452	http://dx.doi.org/10.1126/science.1690452			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT096	1690452				2022-12-24	WOS:A1990CT09600040
J	ELLIS, C; MORAN, M; MCCORMICK, F; PAWSON, T				ELLIS, C; MORAN, M; MCCORMICK, F; PAWSON, T			PHOSPHORYLATION OF GAP AND GAP-ASSOCIATED PROTEINS BY TRANSFORMING AND MITOGENIC TYROSINE KINASES	NATURE			English	Article									MT SINAI HOSP, RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; CETUS CORP, DEPT MOLEC BIOL, EMERYVILLE, CA 94608 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013					COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; LETWIN K, 1988, ONCOGENE, V3, P621; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAWSON T, 1988, ONCOGENE, V3, P491; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; SADOWSKI I, 1987, ONCOGENE, V1, P181; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989	25	744	762	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	1990	343	6256					377	381		10.1038/343377a0	http://dx.doi.org/10.1038/343377a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK918	1689011	Green Submitted			2022-12-24	WOS:A1990CK91800065
J	RIA, F; CHAN, BMC; SCHERER, MT; SMITH, JA; GEFTER, ML				RIA, F; CHAN, BMC; SCHERER, MT; SMITH, JA; GEFTER, ML			IMMUNOLOGICAL ACTIVITY OF COVALENTLY LINKED T-CELL EPITOPES	NATURE			English	Article									MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Di Sante, Gabriele/N-5280-2018; Ria, Francesco/AAD-1174-2022	Di Sante, Gabriele/0000-0001-6608-3388; Ria, Francesco/0000-0001-7455-4290				ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; ALLEN PM, 1985, J IMMUNOL, V135, P368; GAMMON G, 1986, NATURE, V319, P413, DOI 10.1038/319413a0; GUILLET JG, 1986, NATURE, V324, P260, DOI 10.1038/324260a0; GUILLET JG, 1987, SCIENCE, V235, P865, DOI 10.1126/science.2433769; KUISAKI J, 1986, EUR J IMMUNOL, V16, P236; LAI MZ, 1987, J IMMUNOL, V139, P3973; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; QUILL H, 1987, J IMMUNOL, V138, P3704; ROY S, 1989, SCIENCE, V244, P572, DOI 10.1126/science.2470147; SAUER RT, 1978, BIOCHEMISTRY-US, V17, P1092, DOI 10.1021/bi00599a024; SCHAEFFER EB, 1989, P NATL ACAD SCI USA, V86, P4649, DOI 10.1073/pnas.86.12.4649; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHASTRI N, 1986, J IMMUNOL, V136, P371; SHIMONKEWITZ R, 1974, J IMMUNOL, V133, P2067; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5	18	105	109	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1990	343	6256					381	383		10.1038/343381a0	http://dx.doi.org/10.1038/343381a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK918	1689012				2022-12-24	WOS:A1990CK91800066
J	MERCER, AR; EMPTAGE, NJ; CAREW, TJ				MERCER, AR; EMPTAGE, NJ; CAREW, TJ			PHARMACOLOGICAL DISSOCIATION OF MODULATORY EFFECTS OF SEROTONIN IN APLYSIA SENSORY NEURONS	SCIENCE			English	Article							GILL-WITHDRAWAL REFLEX; PRESYNAPTIC FACILITATION; INNERVATING TAIL; DISHABITUATION; MEMORY; LONG; SENSITIZATION; CAMP	In the mollusk Aplysia the neurotransmitter serotonin (5HT) has a fundamental modulatory role in several forms of learning and memory that involve an increase in the efficacy of synaptic transmission between tail sensory neurons (SNs) and motor neurons. The classical 5HT antagonist cyproheptadine (CYP) permits dissociation of three forms of serotonergic modulation in these SNs: (i) CYP reversibly blocks spike-broadening induced either by exogenous application of 5HT or by sensitizing stimulation of a tail nerve. (ii) CYP does not block 5HT-induced or tail input-induced increases in SN somatic excitability. (iii) Concomitant with its block of spike-broadening, CYP reversibly blocks 5HT-induced facilitation of synaptic transmission from SNs. These results suggest that endogenously released 5HT may act at different receptor subtypes that are coupled to different forms of neuromodulation in tail SNs of Aplysia.	YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520; UNIV OTAGO,DEPT ZOOL,DUNEDIN,NEW ZEALAND	Yale University; University of Otago	CAREW, TJ (corresponding author), YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520, USA.			Mercer, Alison/0000-0001-8110-4247	NIMH NIH HHS [MH 141083] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; BAXTER DA, 1989, J NEUROPHYSIOL, V62, P665, DOI 10.1152/jn.1989.62.3.665; BRAHA O, 1990, P NATL ACAD SCI USA, V87, P2040, DOI 10.1073/pnas.87.5.2040; BYRNE JH, 1987, PHYSIOL REV, V67, P329, DOI 10.1152/physrev.1987.67.2.329; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; CASTELLUCCI V, 1970, SCIENCE, V167, P1745, DOI 10.1126/science.167.3926.1745; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; GINGRICH KJ, 1985, J NEUROPHYSIOL, V53, P652, DOI 10.1152/jn.1985.53.3.652; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GOLDSMITH BA, 1991, P NATL ACAD SCI USA, V88, P9021, DOI 10.1073/pnas.88.20.9021; GREENBERG SM, 1987, J NEUROSCI, V7, P291; HAWKINS RD, 1987, HDB PHYSL 1, V6, P25; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8794, DOI 10.1073/pnas.83.22.8794; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; OCCOR KA, 1985, NEUROSCI LETT, V55, P65; OCCOR KA, 1986, BRAIN RES, V371, P190; PEROUTKA SJ, 1981, SCIENCE, V212, P827, DOI 10.1126/science.7221567; POLLOCK JD, 1985, J NEUROSCI, V5, P1862; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SUGITA S, 1991, Society for Neuroscience Abstracts, V17, P1590; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1522, DOI 10.1152/jn.1983.50.6.1522; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543	24	100	100	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1811	1813		10.1126/science.1662413	http://dx.doi.org/10.1126/science.1662413			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1662413				2022-12-24	WOS:A1991GW31600050
J	MITCHELL, MJ; WOODS, DR; TUCKER, PK; OPP, JS; BISHOP, CE				MITCHELL, MJ; WOODS, DR; TUCKER, PK; OPP, JS; BISHOP, CE			HOMOLOGY OF A CANDIDATE SPERMATOGENIC GENE FROM THE MOUSE Y-CHROMOSOME TO THE UBIQUITIN-ACTIVATING ENZYME-E1	NATURE			English	Article							SEX-DETERMINING REGION; L-CELL DEFECT; INSITU HYBRIDIZATION; DNA-REPLICATION; MICE; LOCALIZATION; EXPRESSION; ANTIGEN; DIFFERENTIATION; SEQUENCES	THE Sxr (sex-reversed) region, a fragment of the Y chromosome short arm, can cause chromosomally female XXSxr or XSxrO mice to develop as sterile males 1-3. The original Sxr region, termed Sxr(a), encodes: Tdy, the primary sex-determining gene; Hya, the controlling or structural locus for the minor transplantation antigen H-Y (ref. 4); gene(s) controlling the expression of the serologically detected male antigen (SDMA) 5; Spy, a gene(s) required for the survival and proliferation of A spermatogonia during spermatogenesis 6,7; Zfy-1/Zfy-2, zinc-finger-containing genes of unknown function 8; and Sry, which is probably identical to Tdy (ref. 9). A deletion variant 10 of Sxr(a), termed Sxr(b), which lacks Hya, SDMA expression, Spy and some Zfy-2 sequences, makes positional cloning of these genes possible. We report here the isolation of a new testis-specific gene, Sby, mapping to the DNA deleted from the Sxr(b) region (the DELTA-Sxr(b) interval). Sby has extensive homology to the X-linked human ubiquitin-activating enzyme E1 (ref. 11). The critical role of this enzyme in nuclear DNA replication 12 together with the testis-specific expression of Sby suggests Sby as a candidate for the spermatogenic gene Spy.	INST PASTEUR,INSERM,U276,UNITE IMMUNOGENET HUMAINE,PARIS 15,FRANCE; UNIV MICHIGAN,MUSEUM ZOOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MITCHELL, MJ (corresponding author), UNIV TENNESSEE,DEPT OBSTET GYNECOL,DIV REPROD GENET,MOLEC GENET RES LAB,MEMPHIS,TN 38105, USA.		Mitchell, Michael/I-3987-2016	Mitchell, Michael/0000-0003-2052-7347				AMAR L C, 1988, Genomics, V2, P220, DOI 10.1016/0888-7543(88)90006-7; AVNER P, 1987, P NATL ACAD SCI USA, V84, P5330, DOI 10.1073/pnas.84.15.5330; BISHOP CE, 1987, DEVELOPMENT, V101, P167; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; CATTANACH BM, 1971, CYTOGENETICS, V10, P318, DOI 10.1159/000130151; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, PCR PROTOCOLS; GOLDBERG EH, IN PRESS J REPROD IM; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P7456; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; MARDON G, 1989, SCIENCE, V243, P78, DOI 10.1126/science.2563173; MAYER A, 1989, J BIOL CHEM, V264, P2060; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MCLAREN A, 1988, P NATL ACAD SCI USA, V85, P6442, DOI 10.1073/pnas.85.17.6442; MCLAREN A, 1984, NATURE, V312, P552, DOI 10.1038/312552a0; MITCHELL M, 1989, GENETICS, V121, P803; MITCHELL MJ, IN PRESS GENOMICS; ROBERTS C, 1988, P NATL ACAD SCI USA, V85, P6446, DOI 10.1073/pnas.85.17.6446; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMPSON E, 1984, TRANSPLANTATION, V37, P17, DOI 10.1097/00007890-198401000-00007; SIMPSON EM, 1991, GENOMICS, V11, P601, DOI 10.1016/0888-7543(91)90067-O; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; TUCKER PK, IN PRESS MAMMALIAN G; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932; ZACKSENHAUS E, 1990, CYTOGENET CELL GENET, V53, P20, DOI 10.1159/000132887; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	33	150	156	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					483	486		10.1038/354483a0	http://dx.doi.org/10.1038/354483a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1684224	Green Published			2022-12-24	WOS:A1991GV07800062
J	KNAUS, UG; HEYWORTH, PG; EVANS, T; CURNUTTE, JT; BOKOCH, GM				KNAUS, UG; HEYWORTH, PG; EVANS, T; CURNUTTE, JT; BOKOCH, GM			REGULATION OF PHAGOCYTE OXYGEN RADICAL PRODUCTION BY THE GTP-BINDING PROTEIN RAC-2	SCIENCE			English	Article							RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; NEUTROPHIL NADPH OXIDASE; GUANINE-NUCLEOTIDES; CYTOSOLIC FACTOR; PLASMA-MEMBRANE; ACTIVATION; IDENTIFICATION; ASSOCIATION	A major action of the microbicidal system of human neutrophils is the formation of superoxide anion (O2-) by a multicomponent oxidase that transfers electrons from the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) to molecular oxygen. The mechanism of assembly and activation of the oxidase from its cytosolic and membrane-bound components is unknown, but may require the activity of a guanosine 5'-triphosphate (GTP)-binding component A cytosolic GTP-binding protein (G(ox)) that regulates the NADPH oxidase of neutrophils was identified. G(ox) was purified and shown to augment the rate of O2- production in a cell-free oxidase activation system. Sequence analysis of peptide fragments from G(ox) identified it as Rac 2, a member of the Ras superfamily of GTP-binding proteins. Antibody to a peptide derived from the COOH-terminus of Rac 2 inhibited O2- generation in a concentration-dependent manner. These results suggest that Rac 2 is a regulatory component of the human neutrophil NADPH oxidase, and provide new insights into the mechanism by which this oxygen radical-generating system is regulated.	Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; GENENTECH INC, DEPT CELL BIOL, S SAN FRANCISCO, CA 94080 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Roche Holding; Genentech; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; BOKOCH GM, 1988, FEBS LETT, V227, P66, DOI 10.1016/0014-5793(88)81415-7; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOKOCH GM, UNPUB; BOKOCH GM, IN PRESS J CLIN INVE; BOKOCH GM, IN PRESS SCIENCE; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1988, HEMATOL ONCOL CLIN N, V2, P241, DOI 10.1016/S0889-8588(18)30618-X; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GABIG TG, 1990, J IMMUNOL, V145, P945; KNAUS UG, UNPUB; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; LIGETI E, 1989, BIOCHEMISTRY-US, V28, P7116, DOI 10.1021/bi00443a050; PEVERI P, 1989, BLOOD, V74, pA107; PEVERI P, UNPUB; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SEIFERT R, 1986, FEBS LETT, V205, P161, DOI 10.1016/0014-5793(86)80886-9; SMITH RM, 1991, BLOOD, V77, P673	31	608	621	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1512	1515		10.1126/science.1660188	http://dx.doi.org/10.1126/science.1660188			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1660188				2022-12-24	WOS:A1991GT90300042
J	THUN, MJ; NAMBOODIRI, MM; HEATH, CW				THUN, MJ; NAMBOODIRI, MM; HEATH, CW			ASPIRIN USE AND REDUCED RISK OF FATAL COLON CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUG; AUTOCHTHONOUS INTESTINAL TUMORS; PROSTAGLANDIN SYNTHESIS; INDOMETHACIN TREATMENT; RATS; INHIBITION; CARCINOGENESIS; PIROXICAM; POLYPOSIS; SULINDAC	Background and Methods. Experiments in animals and two epidemiologic studies in humans suggest that aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs) may be protective against colon cancer. We tested this hypothesis in a prospective mortality study of 662,424 adults who provided information in 1982 on the frequency and duration of their aspirin use. Death rates from colon cancer were measured through 1988. The possible influence of other risk factors for colon cancer was examined in multivariate analyses for 598 case patients and 3058 matched control subjects drawn from the cohort. Results. Death rates from colon cancer decreased with more frequent aspirin use in both men and women. The relative risk among persons who used aspirin 16 or more times per month for at least one year was 0.60 in men (95 percent confidence interval, 0.40 to 0.89) and 0.58 in women (95 percent confidence interval, 0.37 to 0.90). The risk estimates were unaffected when we excluded persons who reported at entry into the study that they had cancer, heart disease, stroke, or another condition that might influence both their aspirin use and their mortality. Adjustment for dietary factors, obesity, physical activity, and family history did not alter the findings significantly. No association was found between the use of acetaminophen and the risk of colon cancer. Conclusions. Regular aspirin use at low doses may reduce the risk of fatal colon cancer. Whether this is due to a direct effect of aspirin, perhaps mediated by the inhibition of prostaglandin synthesis, or to other factors indirectly associated with aspirin use is unclear.			THUN, MJ (corresponding author), AMER CANC SOC, DEPT EPIDEMIOL & STAT, 1599 CLIFTON RD, ATLANTA, GA 30329 USA.							[Anonymous], 1988, BRIT MED J, V296, P320; CRAVEN PA, 1983, J CLIN INVEST, V72, P1365, DOI 10.1172/JCI111093; FLANDERS WD, 1984, J CHRON DIS, V37, P449, DOI 10.1016/0021-9681(84)90028-6; FURUTA Y, 1988, CANCER RES, V48, P3002; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P433; KUDO T, 1980, GANN, V71, P260; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LUBIN JH, 1984, BIOMETRICS, V40, P63, DOI 10.2307/2530744; LUPULESCU A, 1978, NATURE, V272, P634, DOI 10.1038/272634a0; LYNCH NR, 1978, BRIT J CANCER, V38, P503, DOI 10.1038/bjc.1978.237; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; METZGER U, 1984, DIS COLON RECTUM, V27, P366, DOI 10.1007/BF02553001; Moorghen M, 1990, Acta Histochem Suppl, V39, P195; NARISAWA T, 1983, CARCINOGENESIS, V4, P1225, DOI 10.1093/carcin/4.10.1225; NARISAWA T, 1981, CANCER RES, V41, P1954; NARISAWA T, 1984, J CANCER RES CLIN, V108, P239, DOI 10.1007/BF00402475; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PAGANINIHILL A, 1991, J NATL CANCER I, V83, P1182, DOI 10.1093/jnci/83.16.1182-a; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PLESCIA OJ, 1975, P NATL ACAD SCI USA, V72, P1848, DOI 10.1073/pnas.72.5.1848; POLLARD M, 1983, CANCER LETT, V21, P57, DOI 10.1016/0304-3835(83)90082-4; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; POLLARD M, 1983, J NATL CANCER I, V70, P1103; POLLARD M, 1981, P SOC EXP BIOL MED, V167, P161; REDDY BS, 1990, CANCER RES, V50, P2562; REDDY BS, 1987, CANCER RES, V47, P5340; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; ROSENBERG L, 1991, J NATL CANCER I, V83, P1183, DOI 10.1093/jnci/83.16.1183; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P230; STELLMAN SD, 1986, JNCI-J NATL CANCER I, V76, P1057; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119	35	1538	1593	2	78	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1991	325	23					1593	1596		10.1056/NEJM199112053252301	http://dx.doi.org/10.1056/NEJM199112053252301			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR770	1669840				2022-12-24	WOS:A1991GR77000001
J	GUBERSKI, DL; THOMAS, VA; SHEK, WR; LIKE, AA; HANDLER, ES; ROSSINI, AA; WALLACE, JE; WELSH, RM				GUBERSKI, DL; THOMAS, VA; SHEK, WR; LIKE, AA; HANDLER, ES; ROSSINI, AA; WALLACE, JE; WELSH, RM			INDUCTION OF TYPE-I DIABETES BY KILHAM RAT VIRUS IN DIABETES-RESISTANT BB/WOR RATS	SCIENCE			English	Article							MELLITUS	Type I diabetes mellitus is an autoimmune disease resulting from the interaction of genetic and environmental factors. A virus that was identified serologically as Kilham's rat virus (KRV) was isolated from a spontaneously diabetic rat and reproducibly induced diabetes in naive diabetes-resistant (DR) BB/Wor rats. Viral antigen was not identified in pancreatic islet cells, and beta-cell cytolysis was not observed until after the appearance of lymphocytic insulitis. KRV did not induce diabetes in major histocompatibility complex-concordant and discordant non-BB rats and did not accelerate diabetes in diabetes-prone BB/Wor rats unless the rats had been reconstituted with DR spleen cells. This model of diabetes may provide insight regarding the interagation of viruses and autoimmune disease.	UNIV MASSACHUSETTS, MED CTR, DEPT PATHOL, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, MED CTR, DEPT MED, WORCESTER, MA 01655 USA; CHARLES RIVER LAB, WILMINGTON, MA 01887 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019155, N01DK072287, T32DK007302, R37DK019155] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19155, DK7-2287, DK07302] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTLER L, 1988, FRONTIERS DIABETES R, V2, P74; CERRA MA, 1991, LAB ROBOTICS AUTOMAT, V2, P119; COLLE E, 1986, DIABETES, V35, P454, DOI 10.2337/diabetes.35.4.454; FORREST IM, 1969, PEDIATRICS, V44, P445; GAMBLE DR, 1969, BRIT MED J, V3, P627, DOI 10.1136/bmj.3.5671.627; GUBERSKI DL, UNPUB; JACOBY RO, 1987, ARCH VIROL, V95, P251, DOI 10.1007/BF01310784; LEITER EH, 1988, PATHOLOGY ENDOCRINE, P85; LIKE AA, 1991, DIABETES, V40, P259, DOI 10.2337/diabetes.40.2.259; LIKE AA, 1990, AM J PATHOL, V136, P565; LIKE AA, 1986, J IMMUNOL, V136, P3254; LIKE AA, 1985, J IMMUNOL, V134, P1583; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; NAKHOODA AF, 1977, DIABETES, V26, P100, DOI 10.2337/diabetes.26.2.100; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; ROSSINI AA, 1985, ANNU REV IMMUNOL, V3, P289; SIMPSON RW, 1984, SCIENCE, V223, P1425, DOI 10.1126/science.6701529; THOMAS VA, 1991, DIABETES, V40, P255, DOI 10.2337/diabetes.40.2.255; YOON JW, 1979, NEW ENGL J MED, V300, P1173, DOI 10.1056/NEJM197905243002102; YOON JW, 1991, CURR TOP MICROBIOL I, V160, P95	20	160	162	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1991	254	5034					1010	1013		10.1126/science.1658938	http://dx.doi.org/10.1126/science.1658938			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1658938				2022-12-24	WOS:A1991GP88300046
J	CLARKE, A				CLARKE, A			IS NONDIRECTIVE GENETIC-COUNSELING POSSIBLE	LANCET			English	Editorial Material											CLARKE, A (corresponding author), UNIV WALES COLL MED,INST MED GENET,CARDIFF CF4 4XN,S GLAM,WALES.							CLARKE A, 1990, LANCET, V335, P1145, DOI 10.1016/0140-6736(90)91139-2; GAVRILOV DK, 1991, STUDY FREQUENCIES AL; LIPPMAN A, 1991, AM J LAW MED, V17, P15; 1989, REPORT PRENATAL DIAG; 1991, NATURE, V351, P591	5	151	153	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1991	338	8773					998	1001		10.1016/0140-6736(91)91849-P	http://dx.doi.org/10.1016/0140-6736(91)91849-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK974	1681352				2022-12-24	WOS:A1991GK97400014
J	STANFORD, JL; GRANGE, JM; POZNIAK, A				STANFORD, JL; GRANGE, JM; POZNIAK, A			IS AFRICA LOST	LANCET			English	Editorial Material							PULMONARY TUBERCULOSIS; MYCOBACTERIUM-VACCAE; IMMUNOTHERAPY		ROYAL BROMPTON & NATL HEART HOSP,LONDON,ENGLAND; UNIV ZIMBABWE,DEPT MED,HARARE,ZIMBABWE	Imperial College London; University of Zimbabwe	STANFORD, JL (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,RIDING HOUSE ST,LONDON W1P 7LD,ENGLAND.							BAHR GM, 1990, TUBERCLE, V71, P259, DOI 10.1016/0041-3879(90)90038-A; BALASUBRAMANIAN R, 1990, TUBERCLE, V71, P253, DOI 10.1016/0041-3879(90)90037-9; Ferebee SH, 1969, ADV TUBERC RES, V17, P29; FESTENSTEIN F, 1991, J APPL BACTERIOL, V17, P19; MICHIHIKO S, 1989, LANCET, V1, P1206; Pozniak A, 1987, B INT UNION TUBERC L, V62, P39; ROOK GAW, 1981, TUBERCLE, V62, P63, DOI 10.1016/0041-3879(81)90038-6; ROOK GAW, 1991, TUBERCLE, V72, P13, DOI 10.1016/0041-3879(91)90019-O; SAIDI KG, 1989, INT J LEPROSY, V57, P45; STANFORD JL, 1991, APMIS, V99, P103, DOI 10.1111/j.1699-0463.1991.tb05127.x; STANFORD JL, 1990, TUBERCLE, V71, P87, DOI 10.1016/0041-3879(90)90002-P; 1988, AM REV RESPIR DIS, V137, P1147	12	54	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					557	558		10.1016/0140-6736(91)91113-9	http://dx.doi.org/10.1016/0140-6736(91)91113-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678812				2022-12-24	WOS:A1991GD00200016
J	DIAMOND, MS; STAUNTON, DE; MARLIN, SD; SPRINGER, TA				DIAMOND, MS; STAUNTON, DE; MARLIN, SD; SPRINGER, TA			BINDING OF THE INTEGRIN MAC-1 (CD11B/CD18) TO THE 3RD IMMUNOGLOBULIN-LIKE DOMAIN OF ICAM-1 (CD54) AND ITS REGULATION BY GLYCOSYLATION	CELL			English	Article								Both the integrins LFA-1 and Mac-1 bind to ICAM-1, an immunoglobulin superfamily member. Previously, we localized the binding sites of LFA-1 and the major group of human rhinoviruses to the first NH2-terminal immunoglobulin-like domain of ICAM-1. Here, we show that the binding site on ICAM-1 for Mac-1 is unexpectedly distinct from that for LFA-1 and maps to the third NH2-terminal immunoglobulin-like domain. These findings provide a function for the tandem duplication of immunoglobulin-like domains in ICAM-1 and have implications for other immunoglobulin superfamily members. Mutations at two sites in the third domain that destroy consensus sequences for N-linked glycosylation enhance binding to purified Mac-1. Agents that interfere with carbohydrate processing provide evidence that the size of the N-linked oligosaccharide side chains on ICAM-1 affects binding to Mac-1 but not to LFA- 1. Thus, we suggest that the extent of glycosylation on ICAM-1 may regulate adhesion to LFA-1 or Mac-1 in vivo.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CTR BLOOD RES, BOSTON, MA 02115 USA; BOEHRINGER INGELHEIM PHARMACEUT, RIDGEFIELD, CT 06877 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Boehringer Ingelheim	DIAMOND, MS (corresponding author), HARVARD UNIV, SCH MED, COMM CELL & DEV BIOL, 800 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Diamond, Michael/AAH-1733-2019	Diamond, Michael/0000-0002-8791-3165	NATIONAL CANCER INSTITUTE [R37CA031799, R01CA031799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NCI NIH HHS [CA31799] Funding Source: Medline; NIGMS NIH HHS [T32GM07753-11, T32 GM007753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BARTON RW, 1989, J IMMUNOL, V143, P1278; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BERNSTEIN ID, 1986, HUMAN MYELOID HEMATO, P1; BISCHOFF J, 1986, J BIOL CHEM, V261, P4766; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; DEFOUGEROLLES AR, 1991, IN PRESS J EXP MED; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUSTIN ML, 1989, COLD SPRING HARB SYM, V54, P753; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1986, J IMMUNOL, V137, P245; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; EDELMAN GM, 1970, BIOCHEMISTRY-US, V9, P3197, DOI 10.1021/bi00818a012; FLAVIN T, 1991, TRANSPLANT P, V23, P533; FLEIT HB, 1989, LEUKOCYTE TYPING, V4, P579; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; HARLAN JM, 1985, BLOOD, V66, P167; HASKARD D, 1986, J IMMUNOL, V137, P2901; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HSIEH P, 1984, J BIOL CHEM, V259, P2375; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KRENSKY AM, 1983, J IMMUNOL, V131, P611; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; LO SK, 1989, J IMMUNOL, V143, P3325; MAIO M, 1989, J IMMUNOL, V143, P181; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MILLER LJ, 1986, J IMMUNOL, V137, P2891; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; SPRINGER TA, 1987, CURRENT PROTOCOLS MO; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; SUMMER MD, 1988, MANUAL METHODS BACUL; TAKEI F, 1985, J IMMUNOL, V134, P1403; TOMASSINI JE, 1989, J BIOL CHEM, V264, P1656; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734	73	734	768	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					961	971		10.1016/0092-8674(91)90548-D	http://dx.doi.org/10.1016/0092-8674(91)90548-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1675157				2022-12-24	WOS:A1991FR04700007
J	AYA, T; KINOSHITA, T; IMAI, S; KOIZUMI, S; MIZUNO, F; OSATO, T; SATOH, C; OIKAWA, T; KUZUMAKI, N; OHIGASHI, H; KOSHIMIZU, K				AYA, T; KINOSHITA, T; IMAI, S; KOIZUMI, S; MIZUNO, F; OSATO, T; SATOH, C; OIKAWA, T; KUZUMAKI, N; OHIGASHI, H; KOSHIMIZU, K			CHROMOSOME-TRANSLOCATION AND C-MYC ACTIVATION BY EPSTEIN-BARR-VIRUS AND EUPHORBIA-TIRUCALLI IN LYMPHOCYTES-B	LANCET			English	Note								Dual exposure to Epstein-Barr virus and purified 4-deoxyphorbol ester derived from the plant Euphorbia tirucalli induced a high frequency of chromosomal rearrangements in human B lymphocytes in vitro. Rearrangements most commonly affected chromosome 8, the chromosome most often showing structural changes in Burkitt's lymphoma (BL) cells. E tirucalli is indigenous in parts of Africa where BL is endemic and may be an important risk factor for the disease.	HOKKAIDO UNIV, SCH MED, INST CANC, DEPT VIROL, SAPPORO, HOKKAIDO 060, JAPAN; KYOTO UNIV, FAC AGR, DEPT FOOD SCI & TECHNOL, KYOTO 606, JAPAN; HOKKAIDO UNIV, SCH MED, INST CANC, MOLEC GENET LAB, SAPPORO, HOKKAIDO 060, JAPAN	Hokkaido University; Kyoto University; Hokkaido University								EPSTEIN MA, 1979, EPSTEINBARR VIRUS, P1; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; OSATO T, 1987, LANCET, V1, P1257	3	30	32	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	1991	337	8751					1190	1190		10.1016/0140-6736(91)92861-U	http://dx.doi.org/10.1016/0140-6736(91)92861-U			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673740				2022-12-24	WOS:A1991FM26100005
J	HASTY, P; RAMIREZSOLIS, R; KRUMLAUF, R; BRADLEY, A				HASTY, P; RAMIREZSOLIS, R; KRUMLAUF, R; BRADLEY, A			INTRODUCTION OF A SUBTLE MUTATION INTO THE HOX-2.6 LOCUS IN EMBRYONIC STEM-CELLS	NATURE			English	Article							GERM-LINE TRANSMISSION; HOMOLOGOUS RECOMBINATION; ES CELLS; GENE; EXPRESSION; MURINE; ORGANIZATION; DISRUPTION; REGIONS	GENE targeting in embryonic stem (ES) cells is a powerful tool for generating mice with null alleles 1. Current methods of gene inactivation in ES cells introduce a neomycin gene (neo) cassette both as a mutagen and a selection marker for transfected cells 2-11. Although null alleles are valuable, changes at the nucleotide level of a gene are very important for functional analysis. One gene family in which subtle mutations would be particularly valuable are the clusters of Hox homeobox genes 12-16. Inactivation of genes in a cluster with a neo cassette that includes promoter/enhancer elements may deregulate transcription of neighbouring genes and generate a phenotype which is difficult to interpret. We describe here a highly efficient gene targeting method, termed the 'hit and run' procedure. This generates ES cells with subtle site-specific mutations with no selectable marker and may be useful for most genes. We have developed this procedure at the hypoxanthine phosphoribosyltransferase (hprt) locus and subsequently isolated ES cells with a premature stop codon in the homeobox of Hox-2.6 (ref. 14).	BAYLOR UNIV, INST MOLEC GENET, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Baylor College of Medicine; Baylor University; MRC National Institute for Medical Research			Krumlauf, Robb/AAH-5012-2019	Krumlauf, Robb/0000-0001-9102-7927; Bradley, Allan/0000-0002-2349-8839; Ramirez-Solis, Ramiro/0000-0003-4182-173X; Hasty, Paul/0000-0003-3046-0131				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAKER MD, 1988, P NATL ACAD SCI USA, V85, P6432, DOI 10.1073/pnas.85.17.6432; BAKER MD, 1989, MOL CELL BIOL, V9, P5500, DOI 10.1128/MCB.9.12.5500; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GRAHAM A, 1988, GENE DEV, V2, P1424, DOI 10.1101/gad.2.11.1424; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZIMMER A, 1989, NATURE, V338, P150, DOI 10.1038/338150a0	27	265	301	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	1991	350	6315					243	246		10.1038/350243a0	http://dx.doi.org/10.1038/350243a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1672446				2022-12-24	WOS:A1991FC77900062
J	KALK, WJ; VERIAVA, Y				KALK, WJ; VERIAVA, Y			HOSPITAL MANAGEMENT OF VOLUNTARY TOTAL FASTING AMONG POLITICAL PRISONERS	LANCET			English	Editorial Material								In 1989 20 political detainees, held without trial for up to 32 months, were admitted, on hunger strike, to the Johannesburg Hospital, South Africa. Most were held under the regulations of the State of Emergency (since revoked) and 5 were held incommunicado under section 29 of the Internal Security Act (still in force). Guidelines for ethical management were based on the Declaration of Tokyo, which included the understanding that such detentions constituted mental torture. Conditions of detention in hospital were complicated by police interference in medical and nursing care, and by the chaining of some prisoners to their beds. Doctors are in a unique position to protest against inhuman treatment of prisoners, and should use this authority.	CORONAT HOSP,DEPT MED,JOHANNESBURG,SOUTH AFRICA; NATL & MED DENT ASSOC DETAINEES SERV,PARKTOWN 2193,SOUTH AFRICA; UNIV WITWATERSRAND,SCH MED,JOHANNESBURG 2001,SOUTH AFRICA	University of Witwatersrand; University of Witwatersrand	KALK, WJ (corresponding author), UNIV WITWATERSRAND,SCH MED,DEPT MED,PARKTOWN 2193,SOUTH AFRICA.							FROMMEL D, 1984, LANCET, V1, P1451, DOI 10.1016/S0140-6736(84)91941-X; HARDING TW, 1989, LANCET, V1, P1191; LEVIN J, 1988, S AFR MED J, V74, P460; VERIAVA Y, 1989, CRITICAL HLTH, V26, P39; 1975, WORLD MED J, V22, P87; 1989, S89278 U WITW FM DOC; 1989, WEEKLY MAIL     0303; 1988, LANCET, V2, P1402; 1989, NATAL MERCURY   1028; 1981, HDB MED ETHICS	10	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					660	662		10.1016/0140-6736(91)92465-E	http://dx.doi.org/10.1016/0140-6736(91)92465-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB730	1672002				2022-12-24	WOS:A1991FB73000015
J	KINSELLA, J; CARTER, R; REID, WH; CAMPBELL, D; CLARK, CJ				KINSELLA, J; CARTER, R; REID, WH; CAMPBELL, D; CLARK, CJ			INCREASED AIRWAYS REACTIVITY AFTER SMOKE-INHALATION	LANCET			English	Article							BRONCHIAL HYPERREACTIVITY; ASTHMA; INJURY; SENSITIVITY; EXPOSURE; BURNS	13 fire victims who required treatment after smoke inhalation underwent lung function assessment within 3 days of injury and 3 months later. Initial airways hyperreactivity improved over this period, but FEV1 and airways specific conductance did not change significantly. There was a strong correlation between exposure carboxyhaemoglobin concentration (an indicator of smoke exposure) and initial airways specific conductance (r + 0.79; p = 0.006). Airways obstruction after smoke inhalation in house fires may be more common and more persistent than is generally recognised. Early lung function tests would allow the incidence of pulmonary complications after smoke inhalation and the potential benefits of early use of inhaled anti-inflammatory drugs to be assessed.	HAIRMYRES HOSP,DEPT RESP MED,GLASGOW G7S 8RG,SCOTLAND; UNIV GLASGOW,DEPT ANAESTHESIA,GLASGOW G12 8QQ,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT RESP MED,GLASGOW G4 0SF,SCOTLAND; GLASGOW ROYAL INFIRM,REG BURNS UNIT,GLASGOW G4 0SF,SCOTLAND	University Hospital Hairmyres; University of Glasgow; University of Glasgow; University of Glasgow			Kinsella, John/B-8252-2011					BARNES PJ, 1989, BRIT MED J, V299, P695, DOI 10.1136/bmj.299.6701.695; BOSCHETTO P, 1989, European Respiratory Journal, V2, p456S; BOULET LP, 1988, CHEST, V94, P476, DOI 10.1378/chest.94.3.476; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; CLARK CJ, 1981, LANCET, V1, P1332; CLARK CJ, 1986, BRIT MED J, V292, P1303, DOI 10.1136/bmj.292.6531.1303; CLARK CJ, 1988, LANCET, V2, P872, DOI 10.1016/S0140-6736(88)92471-3; CLARK CJ, 1988, THORAX, V43, P828; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DJUKANOVIC R, 1989, HOSP UPDATE, V16, P266; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; ISLAM MS, 1972, INT ARCH ARBEITSMED, V29, P221, DOI 10.1007/BF00539250; OLIVIERI D, 1989, European Respiratory Journal, V2, p540S; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; STENTON SC, 1988, BRIT J DIS CHEST, V82, P436, DOI 10.1016/0007-0971(88)90102-7; Sumi K., 1973, J FIRE FLAMMABILITY, V4, P15; TRUNKEY D, 1978, SURG CLIN N AM, V135, P250; VINCENT NJ, 1970, J APPL PHYSIOL, V29, P336; VIVORI E, 1977, BRIT MED J, V2, P1462, DOI 10.1136/bmj.2.6100.1462; 1970, BR PLASTICS, V44, P59; 1987, AM REV RESPIR DIS, V136, P225; 1986, UK FIRE STATISTICS 1	24	34	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					595	597		10.1016/0140-6736(91)91650-J	http://dx.doi.org/10.1016/0140-6736(91)91650-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671952				2022-12-24	WOS:A1991FA70200013
J	CRAVIOTO, A; TELLO, A; NAVARRO, A; RUIZ, J; VILLAFAN, H; URIBE, F; ESLAVA, C				CRAVIOTO, A; TELLO, A; NAVARRO, A; RUIZ, J; VILLAFAN, H; URIBE, F; ESLAVA, C			ASSOCIATION OF ESCHERICHIA-COLI HEP-2 ADHERENCE PATTERNS WITH TYPE AND DURATION OF DIARRHEA	LANCET			English	Article							DIFFUSE ADHERENCE; CELL ADHERENCE; ADHESION; PATHOGENS; CHILDREN; STRAINS; CULTURE; ASSAY	373 (59%) out of 636 faecal specimens obtained during the first 2 years of life of 72 Mexican children yielded adherent Escherichia coli (HEp-2 cells). Strains with localised adherence were significantly associated with acute non-bloody diarrhoea, whereas strains with aggregative adherence were significantly associated with persistent diarrhoea. Half the strains with localised adherence were not enteropathogenic E coli serotypes nor did they hybridise with an enteropathogenic E coli adherence factor DNA probe. All strains with localised adherence gave a positive fluorescent actin staining (FAS) assay, irrespective of serotype. One-third of children colonised by aggregative strains had bloody diarrhoea. Isolation of strains with diffuse adherence was not related to type or duration of diarrhoea but was generally associated with isolation of another pathogenic organism.			CRAVIOTO, A (corresponding author), INST NACL SALUD PUBL, CTR RES INFECT DIS, APARTADO POSTAL 16-116, MEXICO CITY 02000, DF, MEXICO.		Navarro, Armando/AAE-3832-2022; NAVARRO, ARMANDO/AAO-7368-2020	NAVARRO, ARMANDO/0000-0002-6693-7168				BAUDRY B, 1990, J INFECT DIS, V161, P1249, DOI 10.1093/infdis/161.6.1249; BENZ I, 1989, INFECT IMMUN, V57, P1506, DOI 10.1128/IAI.57.5.1506-1511.1989; BHAN MK, 1989, PEDIATR INFECT DIS J, V8, P499, DOI 10.1097/00006454-198908000-00005; BHAN MK, 1989, J INFECT DIS, V158, P70; BILGE SS, 1989, J BACTERIOL, V171, P4281, DOI 10.1128/JB.171.8.4281-4289.1989; CHATKAEOMORAKOT A, 1987, J INFECT DIS, V156, P669, DOI 10.1093/infdis/156.4.669; COBELJIC M, 1989, EPIDEMIOL INFECT, V103, P53, DOI 10.1017/S0950268800030351; CRAVIOTO A, 1988, EPIDEMIOL INFECT, V101, P123, DOI 10.1017/S0950268800029289; CRAVIOTO A, 1990, AM J EPIDEMIOL, V131, P886, DOI 10.1093/oxfordjournals.aje.a115579; CRAVIOTO A, 1979, CURR MICROBIOL, V3, P95, DOI 10.1007/BF02602439; FLEISS JL, 1973, STATISTICAL METHODS, P155; GOMES TAT, 1989, J CLIN MICROBIOL, V27, P266, DOI 10.1128/JCM.27.2.266-269.1989; KNUTTON S, 1987, INFECT IMMUN, V55, P78, DOI 10.1128/IAI.55.1.78-85.1987; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; KNUTTON S, 1987, INFECT IMMUN, V55, P69, DOI 10.1128/IAI.55.1.69-77.1987; LEVINE MM, 1988, J INFECT DIS, V158, P224, DOI 10.1093/infdis/158.1.224; LEVINE MM, 1987, J INFECT DIS, V155, P377, DOI 10.1093/infdis/155.3.377; MATHEWSON JJ, 1989, J INFECT DIS, V159, P1057, DOI 10.1093/infdis/159.6.1057; NATARO JP, 1985, J INFECT DIS, V152, P560, DOI 10.1093/infdis/152.3.560; ORSKOV F, 1975, AMPIS B, V83, P565; SAVARINO SJ, 1990, 90TH ANN M AM SOC MI, P45; SCOTLAND SM, 1989, J INFECTION, V19, P237, DOI 10.1016/S0163-4453(89)90729-9; VIAL PA, 1987, J INFECT DIS, V155, P377	23	262	266	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 2	1991	337	8736					262	264		10.1016/0140-6736(91)90868-P	http://dx.doi.org/10.1016/0140-6736(91)90868-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671111				2022-12-24	WOS:A1991EV71900003
J	KOLARS, JC; AWNI, WM; MERION, RM; WATKINS, PB				KOLARS, JC; AWNI, WM; MERION, RM; WATKINS, PB			1ST-PASS METABOLISM OF CYCLOSPORINE BY THE GUT	LANCET			English	Note							HUMAN-LIVER; IDENTIFICATION	Cyclosporin is thought to be exclusively metabolised in the liver. We instilled cyclosporin into the small bowel of 2 patients during the anhepatic phase of liver transplantation; cyclosporin metabolites were readily detected in portal venous blood. Our findings indicate that the small intestine is a major site of cyclosporin breakdown: such intestinal metabolism might help to explain the poor oral bioavailability and drug interactions of cyclosporin.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT SURG, ANN ARBOR, MI 48109 USA; HENNEPIN CTY MED CTR, DRUG EVALUAT UNIT, MINNEAPOLIS, MN 55415 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Hennepin County Medical Center	WATKINS, PB (corresponding author), UNIV MICHIGAN HOSP, KUGHN CLIN RES CTR, A7119 UNIV HOSP, ANN ARBOR, MI 48109 USA.			Kolars, Joseph/0000-0002-2603-188X				AOYAMA T, 1989, J BIOL CHEM, V264, P10388; AWNI WM, 1988, J CHROMATOGR-BIOMED, V425, P233, DOI 10.1016/0378-4347(88)80027-6; GUPTA SK, 1989, BRIT J CLIN PHARMACO, V27, P475, DOI 10.1111/j.1365-2125.1989.tb05396.x; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KOLARS JC, IN PRESS TRANSPLANTA; KRONBACH T, 1988, CLIN PHARMACOL THER, V43, P630, DOI 10.1038/clpt.1988.87; LUCEY MR, 1990, LANCET, V335, P11, DOI 10.1016/0140-6736(90)90137-T; PTACHCINSKI RJ, 1986, CLIN PHARMACOKINET, V11, P107, DOI 10.2165/00003088-198611020-00002; WATKINS PB, 1990, SEMIN LIVER DIS, V10, P235, DOI 10.1055/s-2008-1040480; WATKINS PB, 1987, J CLIN INVEST, V80, P1029, DOI 10.1172/JCI113156	10	387	404	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 14	1991	338	8781					1488	1490		10.1016/0140-6736(91)92302-I	http://dx.doi.org/10.1016/0140-6736(91)92302-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1683920	Green Submitted			2022-12-24	WOS:A1991GV07700006
J	YANG, XH; SEOW, KT; BAHRI, SM; OON, SH; CHIA, W				YANG, XH; SEOW, KT; BAHRI, SM; OON, SH; CHIA, W			2 DROSOPHILA RECEPTOR-LIKE TYROSINE PHOSPHATASE GENES ARE EXPRESSED IN A SUBSET OF DEVELOPING AXONS AND PIONEER NEURONS IN THE EMBRYONIC CNS	CELL			English	Article							HOMOPHILIC ADHESION MOLECULE; LEUKOCYTE-COMMON ANTIGEN; PROTO-ONCOGENE HOMOLOG; FASCICLIN-I; IMMUNOGLOBULIN SUPERFAMILY; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; PHOSPHORYLATION; GRASSHOPPER; SEQUENCE	Two Drosophila receptor-like tyrosine phosphatase genes, DPTP99A and DPTP10D, were characterized. Protein products of these genes show distinct expression patterns specific to subsets of developing CNS axons. DPTP99A expression coincides with the onset of axonogenesis and is expressed in several pioneer neurons, including aCC and RP2, which pioneer the intersegmental nerve; its proteins are transiently expressed in the intersegmental and segmental nerves, arguing for a role in the establishment of these nerves. Both genes produce complex sets of transcripts, owing to the alternative utilization of exons and polyadenylation sites. Each gene produces alternative protein forms, which differ in their C-terminal tails. The deduced proteins possess extracellular FN-III repeats and intracellular PTPase domain(s). We discuss the implications of these results and the role of protein tyrosine dephosphorylation in axon outgrowth and guidance.			YANG, XH (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, DROSOPHILA NEUROBIOL LAB, SINGAPORE 0511, SINGAPORE.							ALEXANDER D R, 1990, New Biologist, V2, P1049; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; HORTSCH M, 1990, J BIOL CHEM, V265, P15104; HSU S, 1988, NEUROSCI LETT, V85, P169; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LANDER AD, 1989, TRENDS NEUROSCI, V12, P189, DOI 10.1016/0166-2236(89)90070-2; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MANESS PF, 1990, CIBA F SYMP, V150, P57; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; SAMBROOK J, 1989, MOL CLONNING LABORAT; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SEEGER MA, 1988, CELL, V55, P589, DOI 10.1016/0092-8674(88)90217-6; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	52	174	181	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1991	67	4					661	673		10.1016/0092-8674(91)90062-4	http://dx.doi.org/10.1016/0092-8674(91)90062-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657401				2022-12-24	WOS:A1991GQ40700004
J	HUNT, P; GULISANO, M; COOK, M; SHAM, MH; FAIELLA, A; WILKINSON, D; BONCINELLI, E; KRUMLAUF, R				HUNT, P; GULISANO, M; COOK, M; SHAM, MH; FAIELLA, A; WILKINSON, D; BONCINELLI, E; KRUMLAUF, R			A DISTINCT HOX CODE FOR THE BRANCHIAL REGION OF THE VERTEBRATE HEAD	NATURE			English	Article							HOMEOBOX-CONTAINING GENE; MOUSE HINDBRAIN; EXPRESSION; MURINE; SEGMENTATION; ORGANIZATION; HOX-5.1; HOX-2.6; DOMAINS; HOX-1.5	THE branchial region of the vertebrate head forms through complex interactions involving rhombomeric segments, neural crest and branchial arches 1. It is thought that aspects of their patterning mechanisms are linked 2 and involve Hox-2 genes, whose overlapping and spatially restricted expression domains represent a combinatorial code for generating regional diversity 3-5. Vertebrates possess four Hox clusters of Antennapedia class homeobox genes, related to each other by duplication and divergence from a common ancestral complex 3,6-8. In consequence, at equivalent positions in different clusters there are highly related genes known as subfamilies or paralogous groups. As Hox-2 genes cannot fully account for patterning individual rhombomeres, we investigated whether offsets in expression limits of paralogous genes could account for the generation of regional diversity. We report here that, with the exception of the labial subfamily, paralogues show identical expression limits in rhombomeres, cranial ganglia and branchial arches, providing a combinatorial Hox code for the branchial region that seems to be different in organization to that of the trunk.	NATL INST MED RES, MRC, EUKARYOT MOLEC GENET LAB, RIDGEWAY, LONDON NW7 1AA, ENGLAND; CNR, INT INST GENET & BIOPHYS, NAPLES, ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Krumlauf, Robb/AAH-5012-2019; Gulisano, Massimo/F-6609-2012; Sham, Mai Har/AAX-3781-2020	Krumlauf, Robb/0000-0001-9102-7927; Gulisano, Massimo/0000-0001-8654-1745; Sham, Mai Har/0000-0003-1179-7839				BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1986, EMBO J, V5, P1973, DOI 10.1002/j.1460-2075.1986.tb04452.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GRAHAM A, 1991, DEVELOPMENT, V112, P255; GRAHAM A, 1988, GENE DEV, V2, P1424, DOI 10.1101/gad.2.11.1424; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HOLLAND P, 1990, EVOLUTION SEGMENTAL, V1, P135; HUNT P, 1991, DEVELOPMENT, V112, P43; HUNT P, 1991, DEVELOPMENT, P187; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, IN PRESS DEVELOPMENT; Lumsden A.G.S., 1990, Seminars in Developmental Biology, V1, P117; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NODEN DM, 1988, DEVELOPMENT, V103, P121; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; THOROGOOD P, 1988, DEVELOPMENT, V103, P141; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	39	456	463	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					861	864		10.1038/353861a0	http://dx.doi.org/10.1038/353861a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1682814				2022-12-24	WOS:A1991GM73200065
J	HIGGINS, GD; DAVY, M; RODER, D; UZELIN, DM; PHILLIPS, GE; BURRELL, CJ				HIGGINS, GD; DAVY, M; RODER, D; UZELIN, DM; PHILLIPS, GE; BURRELL, CJ			INCREASED AGE AND MORTALITY ASSOCIATED WITH CERVICAL CARCINOMAS NEGATIVE FOR HUMAN PAPILLOMAVIRUS RNA	LANCET			English	Article							PROGNOSTIC-SIGNIFICANCE; INVASIVE-CARCINOMA; DNA; MAINTENANCE; NEOPLASIA; CANCER	Attempts to relate presence and type of human papillomavirus in cervical carcinoma with prognosis have yielded conflicting results. To further investigate this relation, the association between survival of cervical cancer patients after diagnosis and the presence of human papillomavirus (HPV) RNA within the tumour was assessed retrospectively. Formalin-fixed biopsy specimens from 212 patients with cervical carcinoma who had been followed for up to 6 years were tested by in-situ hybridisation with I-125-labelled riboprobes. HPV-RNA-positive women were 11.9 years younger than HPV-negative women at diagnosis (p < 0.001). Case-fatality rates from cervical cancer rose with absence of HPV RNA, age at diagnosis, or FIGO stage. Multivariate analysis confirmed that absence of detectable HPV RNA and advanced FIGO stage were independent risk factors. No differences in survival between HPV types 16, 18, 31, or 33 were seen. These observations suggest that cervical carcinoma patients fall into two groups-a younger, HPV-RNA-positive group, with a better prognosis, and an older, HPV-RNA-negative group with poorer prognosis. Treatment regimens for the two groups may need to differ.	ROYAL ADELAIDE HOSP,INST MED & VET SCI,DIV TISSUE PATHOL,ADELAIDE,SA 5000,AUSTRALIA; ROYAL ADELAIDE HOSP,INST MED & VET SCI,DEPT GYNAECOL ONCOL,ADELAIDE,SA 5000,AUSTRALIA; UNIV ADELAIDE,S AUSTRALIAN HLTH COMM,EPIDEMIOL BRANCH,ADELAIDE,SA 5001,AUSTRALIA; UNIV ADELAIDE,DEPT MICROBIOL & IMMUNOL,ADELAIDE,SA 5001,AUSTRALIA	Institute Medical & Veterinary Science Australia; Royal Adelaide Hospital; Institute Medical & Veterinary Science Australia; Royal Adelaide Hospital; University of Adelaide; University of Adelaide	HIGGINS, GD (corresponding author), ROYAL ADELAIDE HOSP,INST MED & VET SCI,DIV MED VIROL,FROME RD,ADELAIDE,SA 5000,AUSTRALIA.		Roder, David/B-7038-2013; Phillips, Gael E/H-6321-2012	Roder, David/0000-0001-6442-4409; 				BARNES W, 1988, GYNECOL ONCOL, V29, P267, DOI 10.1016/0090-8258(88)90225-9; BONETT A, 1989, AUST NZ J OBSTET GYN, V29, P193, DOI 10.1111/j.1479-828X.1989.tb01717.x; BONETT P, 1988, MED J AUSTRALIA, V148, P556; CAMPO MS, 1985, EMBO J, V4, P1819, DOI 10.1002/j.1460-2075.1985.tb03856.x; COLLINS JE, 1988, J CLIN PATHOL, V41, P289, DOI 10.1136/jcp.41.3.289; CROOK T, 1991, ONCOGENE, V6, P873; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HIGGINS GD, 1991, J GEN VIROL, V72, P885, DOI 10.1099/0022-1317-72-4-885; HIGGINS GD, 1991, CANCER-AM CANCER SOC, V68, P561, DOI 10.1002/1097-0142(19910801)68:3<561::AID-CNCR2820680320>3.0.CO;2-R; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KING LA, 1989, CANCER, V63, P897, DOI 10.1002/1097-0142(19890301)63:5<897::AID-CNCR2820630517>3.0.CO;2-W; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; MORGAN D, 1990, J VIROL, V64, P969, DOI 10.1128/JVI.64.3.969-976.1990; RIOU G, 1990, LANCET, V335, P1171; ROSE BR, 1991, LANCET, V337, P489, DOI 10.1016/0140-6736(91)93422-6; WALKER J, 1989, OBSTET GYNECOL, V74, P781; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; [No title captured]	19	152	154	2	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					910	913		10.1016/0140-6736(91)91773-N	http://dx.doi.org/10.1016/0140-6736(91)91773-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681267				2022-12-24	WOS:A1991GJ89900004
J	GANGAR, KF; VYAS, S; WHITEHEAD, M; CROOK, D; MEIRE, H; CAMPBELL, S				GANGAR, KF; VYAS, S; WHITEHEAD, M; CROOK, D; MEIRE, H; CAMPBELL, S			PULSATILITY INDEX IN INTERNAL CAROTID-ARTERY IN RELATION TO TRANSDERMAL ESTRADIOL AND TIME SINCE MENOPAUSE	LANCET			English	Article							CORONARY HEART-DISEASE; BLOOD-FLOW; ESTROGEN; WOMEN; MORTALITY; THERAPY; DOPPLER; FETAL; RISK	The protection afforded by postmenopausal oestrogen replacement against cardiovascular disease is not fully explained by changes in plasma lipoproteins. To investigate the effect of oestrogen on arterial tone, doppler ultrasound was used to assess blood flow characteristics in the internal carotid arteries of 12 postmenopausal women. Patients were studied pretreatment and at weeks 4, 6, 9, and 22 of therapy with transdermal oestradiol 50-mu-g/day. The pulsatility index (PI), which is thought to represent impedance to blood flow distal to the point of sampling, was measured from the flow velocity waveform. 11 of the 12 patients were within 5 years of menopause; 1 was 8 years postmenopausal but had experienced bleeding 4 years after menopause. In the 11 women there was a highly significant correlation (r = 0.77) between time since menopause and baseline PI. A similar correlation (r = 0.74) was observed when the episode of postmenopausal bleeding was redefined as time of menopause in the twelfth patient. For all 12 patients, there was a significant negative correlation (r = -0.70) between change in PI during transdermal oestradiol therapy and mean of baseline plus week 22 PI value. For all correlations between changes in PI and time since menopause, the longer the time the greater the fall in PI. These results, and previous observations of a reduction in uterine artery PI with oestradiol treatment, suggest that oestrogen has a generalised effect on the arterial system.	UNIV LONDON KINGS COLL, SCH MED & DENT, MENOPAUSE CLIN, ACAD DEPT OBSTET & GYNAECOL, LONDON WC2R 2LS, ENGLAND; WYNN INST METAB RES, LONDON, ENGLAND; UNIV LONDON KINGS COLL HOSP, DEPT RADIOL, LONDON SE5 8RX, ENGLAND	University of London; King's College London; Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London				Crook, David/0000-0002-9587-3730				ANDERSON SG, 1977, AM J OBSTET GYNECOL, V127, P138, DOI 10.1016/S0002-9378(16)33239-2; BOURNE T, 1990, LANCET, V335, P1470, DOI 10.1016/0140-6736(90)91505-5; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CLARKSON TB, 1990, OBSTET GYNECOL, V75, P217; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; DOWSETT M, 1987, CANCER RES, V47, P1957; FARISH E, 1990, BRIT J OBSTET GYNAEC, V97, P78, DOI 10.1111/j.1471-0528.1990.tb01721.x; GILL JS, 1985, LANCET, V1, P567; GINSBURG J, 1989, BRIT MED J, V298, P1488, DOI 10.1136/bmj.298.6686.1488; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; Gosling RG., 1975, ARTERIES VEINS, P61; GRIFFIN D, 1983, CLIN OBSTET GYNAECOL, V10, P565; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; MATTA WHM, 1988, FERTIL STERIL, V49, P1083; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MEIRE HB, 1990, CLIN RADIOL, V41, P223, DOI 10.1016/S0009-9260(05)81651-4; MEIRE HB, 1983, RECENT ADV RADIOLOGY, P63; OLDHAM PD, 1968, MEASUREMENT MED INTE, P148; PADWICK ML, 1988, MENOPAUSE, P227; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; SARREL P, 1989, CIRCULATION FEMALE C, P117; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; VYAS S, 1990, BRIT J OBSTET GYNAEC, V97, P797, DOI 10.1111/j.1471-0528.1990.tb02573.x; VYAS S, 1989, AM J OBSTET GYNECOL, V161, P168, DOI 10.1016/0002-9378(89)90257-3; WAHL P, 1983, NEW ENGL J MED, V308, P862, DOI 10.1056/NEJM198304143081502; WOLINSKY H, 1972, CIRC RES, V30, P341, DOI 10.1161/01.RES.30.3.341; 1979, DHEW PHS7955071 PUBL	28	374	375	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	1991	338	8771					839	842						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH945	1681213				2022-12-24	WOS:A1991GH94500002
J	GARDOSI, JO; SCHRAM, CM; SYMONDS, EM				GARDOSI, JO; SCHRAM, CM; SYMONDS, EM			ADAPTATION OF PULSE OXIMETRY FOR FETAL MONITORING DURING LABOR	LANCET			English	Article							OXYGEN	Application of pulse oximetry to intrapartum monitoring was investigated in 105 women. No adequate reading could be obtained in 44 cases. Two major sources of artifact, related to probe apposition and signal processing, were identified and excluded. The average arterial oxygen saturation from the fetal scalp was 82% (SD 6%), which is higher than has been inferred from pO2 levels. Readings below 60% or the development of an unstable baseline suggest the presence of substantial hypoxia and acidosis.			GARDOSI, JO (corresponding author), QUEENS MED CTR,DEPT OBSTET & GYNAECOL,PERINATAL RES & MONITORING UNIT,NOTTINGHAM NG7 2UH,ENGLAND.		Gardosi, Jason/GXN-1375-2022	Gardosi, Jason/0000-0002-3230-1292				ANDREWS BF, 1965, AM J OBSTET GYNECOL, V91, P85, DOI 10.1016/0002-9378(65)90590-9; DAMIANOU D, 1991, IEE ABSTR, V89, P3; GARDOSI J, 1989, LANCET, V2, P692; HARRIS AP, 1988, J CLIN MONITOR, V4, P175, DOI 10.1007/BF01621812; JOHNSON N, 1991, BRIT J OBSTET GYNAEC, V98, P36, DOI 10.1111/j.1471-0528.1991.tb10308.x; JOHNSON SB, 1990, HEALTH PSYCHOL, V9, P493, DOI 10.1037/0278-6133.9.4.493; PEAT S, 1988, LANCET, V2, P213; ROSEN M, 1990, 1ST INT S INTR SURV; SCHRAM CMH, 1991, BRIT J OBSTET GYNAEC, V98, P113, DOI 10.1111/j.1471-0528.1991.tb10327.x; SOUTHALL DP, 1987, ARCH DIS CHILD, V62, P882, DOI 10.1136/adc.62.9.882; TREMPER KK, 1989, ANESTHESIOLOGY, V70, P98, DOI 10.1097/00000542-198901000-00019; 1990, LANCET, V335, P1130	12	68	73	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1265	1267		10.1016/0140-6736(91)92928-U	http://dx.doi.org/10.1016/0140-6736(91)92928-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674071				2022-12-24	WOS:A1991FN04700012
J	ROTHWELL, PM; UDWADIA, ZF; LAWLER, PG				ROTHWELL, PM; UDWADIA, ZF; LAWLER, PG			CORTISOL RESPONSE TO CORTICOTROPIN AND SURVIVAL IN SEPTIC SHOCK	LANCET			English	Note								Corticotropin stimulation tests were used to assess adrenocortical function in 32 patients with septic shock. 13 patients had a poor cortisol response (rise < 250 nmol/l) to corticotropin, all of whom died. However, there were only 6 deaths among the 19 patients with adequate responses (p < 0.001). These results suggest that some patients with septic shock may have relative adrenocortical insufficiency.	S CLEVELAND HOSP,INTENS THERAPY UNIT,MIDDLESBROUGH,ENGLAND				Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				FINLAY WEI, 1982, LANCET, V1, P1414; HERMAN AH, 1971, SURG GYNECOL OBSTETR, V132, P795; HINSHAW LB, 1985, CIRC SHOCK, V16, P265; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; NICHOLSON DP, 1989, CRIT CARE CLIN, V5, P151; SCHEIN RMH, 1990, CRIT CARE MED, V18, P259, DOI 10.1097/00003246-199003000-00002; SIBBALD WJ, 1977, ANN SURG, V186, P29, DOI 10.1097/00000658-197707000-00005	7	314	329	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					582	583		10.1016/0140-6736(91)91641-7	http://dx.doi.org/10.1016/0140-6736(91)91641-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671944				2022-12-24	WOS:A1991FA70200005
J	WIKTOR, SZ; JACOBSON, S; WEISS, SH; SHAW, GM; REUBEN, JS; SHORTY, VJ; MCFARLIN, DE; BLATTNER, WA				WIKTOR, SZ; JACOBSON, S; WEISS, SH; SHAW, GM; REUBEN, JS; SHORTY, VJ; MCFARLIN, DE; BLATTNER, WA			SPONTANEOUS LYMPHOCYTE-PROLIFERATION IN HTLV-II INFECTION	LANCET			English	Note								We measured lymphocyte proliferation in the absence of antigenic stimulation in 45 HTLV-II infected, 9 HTLV-I infected, and 19 HTLV-I seronegative intravenous drug users (IVDU). Lymphocyte proliferation was higher in IVDUs infected with HTLV-II than in seronegative IVDUs but lower than among those infected with HTLV-I. Higher rates of proliferation were also associated with needle sharing, CD4+ and IL2R+ lymphocyte counts, and HTLV-I antibody titres.	NIH,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; DESIRE NARCOT REHABIL CTR,NEW ORLEANS,LA; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PREVENT MED & COMMUNITY HLTH,NEWARK,NJ 07103; UNIV ALABAMA,SCH MED,DEPT MED,BIRMINGHAM,AL 35233	National Institutes of Health (NIH) - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Alabama System; University of Alabama Birmingham	WIKTOR, SZ (corresponding author), NCI,VIRAL EPIDEMIOL SECT,6130 EXECUT BLVD,EPN 434,ROCKVILLE,MD 20852, USA.		Reuben, Jayne/GWQ-6664-2022	Weiss, Stanley/0000-0002-5485-551X				BLATTNER WA, 1989, VIRAL INFECTIONS HUM, P545; GRIFFIN DE, 1989, NEW ENGL J MED, V320, P1667, DOI 10.1056/NEJM198906223202506; JACOBSON S, 1990, ANN NEUROL, V27, P149, DOI 10.1002/ana.410270209; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LILLEHOJ EP, IN PRESS J CLIN MICR; SOOP M, 1988, SCAND J IMMUNOL, V28, P659, DOI 10.1111/j.1365-3083.1988.tb01499.x	6	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					327	328		10.1016/0140-6736(91)90947-N	http://dx.doi.org/10.1016/0140-6736(91)90947-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671234				2022-12-24	WOS:A1991EX36200006
J	CHERNEVSKAYA, NI; OBUKHOV, AG; KRISHTAL, OA				CHERNEVSKAYA, NI; OBUKHOV, AG; KRISHTAL, OA			NMDA RECEPTOR AGONISTS SELECTIVELY BLOCK N-TYPE CALCIUM CHANNELS IN HIPPOCAMPAL-NEURONS	NATURE			English	Article							EXCITATORY AMINO-ACIDS; CHICK SENSORY NEURONS; GUINEA-PIG INVITRO; SYNAPTIC TRANSMISSION; OMEGA-CONOTOXIN; RAT HIPPOCAMPUS; CA1 NEURONS; CURRENTS; MODULATION; ACTIVATION	THE modulation of voltage-dependent calcium channels by various neurotransmitters had been demonstrated in many neurons 1-4,. Because of the critical role of Ca2+ in transmitter release and, more generally, in transmembrane signalling, this modulation has important functional implications. Hippocampal neurons posses low-threshold (T-type) Ca2+ channels and both L- and N-type high voltage-activated Ca2+ channels. 5-7 N-type Ca2+ channels are blocked selectively by omega-conotoxin 8, 9 and adenosine 10, 11. These substances both block excitatory synaptic transmission in the hippocampus 12-13, whereas dihydropyridines, which selectively block L-type channels 14, are ineffective 12. Excitatory synaptic transmission in the hippocampus displays a number of plasticity phenomena that are initiated by Ca2+ entry through ionic channels operated by N-methyl-D-aspartate (NMDA) receptors 15, 16. Here we report that NMDA receptor agonists selectively and effectively depress N-type Ca2+ channels which are involved in neurotransmitter release from presynaptic sites. The inhibitory effect is eliminated by the competitive NMDA antagonist D-2-amino-5-phosphonovalerate, does not require Ca2+ entry into the cell, and is probably receptor-mediated. This phenomenon may provide a negative feedback between the liberation of excitatory transmitter and entry of Ca2+ into the cell, and could be important in presynaptic inhibition and in the regulation of synaptic plasticity.	AA BOGOMOLETZ PHYSIOL INST,BOGOMOLETZ STR 4,KIEV 252024,UKRAINE,USSR	National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology			Obukhov, Alexander G/C-7246-2008; Krishtal, Oleg A/C-7739-2016	Obukhov, Alexander G/0000-0002-3862-6004; Krishtal, Oleg A/0000-0003-3342-9930				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BERTOLINO M, 1989, NEUROPHARMACOLOGY, V28, P453, DOI 10.1016/0028-3908(89)90078-6; CHIZHMAKOV IV, 1989, NEUROSCI LETT, V99, P131, DOI 10.1016/0304-3940(89)90277-2; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DEISZ RA, 1985, NEUROSCI LETT, V56, P205, DOI 10.1016/0304-3940(85)90130-2; DOCHERTY RJ, 1986, NEUROSCI LETT, V70, P110, DOI 10.1016/0304-3940(86)90447-7; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; GAHWILER BH, 1987, NEUROSCIENCE, V20, P731, DOI 10.1016/0306-4522(87)90236-3; GROSS RA, 1989, J PHYSIOL-LONDON, V411, P585, DOI 10.1113/jphysiol.1989.sp017592; HONORE T, 1982, J NEUROCHEM, V38, P173, DOI 10.1111/j.1471-4159.1982.tb10868.x; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; KASAI H, 1987, Neuroscience Research, V4, P228, DOI 10.1016/0168-0102(87)90014-9; KRISHTAL OA, 1988, NEUROSCI LETT, V85, P82, DOI 10.1016/0304-3940(88)90433-8; KRISHTAL OA, 1989, NEUROSCI LETT, V102, P197, DOI 10.1016/0304-3940(89)90078-5; KRISTAL SM, 1983, NEUROSCI LETT, V35, P41; OKADA Y, 1980, EUR J PHARMACOL, V68, P483; OZAWA S, 1989, BRAIN RES, V495, P329, DOI 10.1016/0006-8993(89)90225-4; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; SARVEY JM, 1989, J NEUROSCI METH, V28, P109, DOI 10.1016/0165-0270(89)90016-2; TAKAHASHI K, 1989, NEUROSCI LETT, V104, P229, DOI 10.1016/0304-3940(89)90359-5; TOSELLI M, 1989, PFLUG ARCH EUR J PHY, V415, P255, DOI 10.1007/BF00370874; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; ZORUMSKI CF, 1988, J NEUROSCI, V8, P4277	26	63	66	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					418	420		10.1038/349418a0	http://dx.doi.org/10.1038/349418a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1671527				2022-12-24	WOS:A1991EV51400052
J	YEUNG, CY; MA, YP; WONG, FHW; KWAN, HC; FUNG, KW; TAM, AYC				YEUNG, CY; MA, YP; WONG, FHW; KWAN, HC; FUNG, KW; TAM, AYC			AUTOMATIC END-EXPIRATORY AIR SAMPLING DEVICE FOR BREATH HYDROGEN TEST IN INFANTS	LANCET			English	Article							BOWEL TRANSIT-TIME; LACTOSE-MALABSORPTION; PREMATURE-INFANTS; H2 MEASUREMENTS; ABSORPTION; CHILDREN; H-2; EXCRETION; PRETERM	An automatic electronically operated end-expiratory air sampler has been developed for use in small infants. Upon expiration, which is detected by a hot-wire sensor, a small portion of the end-expiratory air is automatically collected into a syringe mounted on a syringe driver. The sampler obtained 87% of the end-expiratory air sample. Additionally, highly reproducible and consistent results were obtained for the respiratory gases (O2, N2, CO2). The sampler has been applied for studying breath hydrogen excretion to detect lactose malabsorption. It may also be applicable to study other expiratory gases in infants.	UNIV HONG KONG,ELECTR SERV UNIT,HONG KONG,HONG KONG; UNIV HONG KONG,DEPT CHEM,HONG KONG,HONG KONG	University of Hong Kong; University of Hong Kong	YEUNG, CY (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT PAEDIAT,HONG KONG,HONG KONG.							BOND JH, 1976, GASTROENTEROLOGY, V70, P1058; BOND JH, 1972, J CLIN INVEST, V51, P1219, DOI 10.1172/JCI106916; BOND JH, 1977, J LAB CLIN MED, V90, P30; BOND JH, 1975, J LAB CLIN MED, V85, P546; DOUWES AC, 1978, ARCH DIS CHILD, V53, P939, DOI 10.1136/adc.53.12.939; DUBOWSKI KM, 1974, CLIN CHEM, V20, P966; FERNANDES J, 1978, AM J CLIN NUTR, V31, P597, DOI 10.1093/ajcn/31.4.597; HOPPER AO, 1983, J PEDIATR GASTR NUTR, V2, P659, DOI 10.1097/00005176-198311000-00015; KIEN CL, 1987, J PEDIATR GASTR NUTR, V6, P286, DOI 10.1097/00005176-198703000-00022; KOCH G, 1968, BIOL NEONATORUM, V12, P136; LEVITT MD, 1970, J LAB CLIN MED, V75, P937; LEVITT MD, 1969, NEW ENGL J MED, V281, P122, DOI 10.1056/NEJM196907172810303; LIFSCHITZ CH, 1983, J PEDIATR GASTR NUTR, V2, P478, DOI 10.1097/00005176-198302030-00014; MACLEAN WC, 1980, J PEDIATR-US, V97, P383, DOI 10.1016/S0022-3476(80)80186-7; NIU HC, 1979, J LAB CLIN MED, V94, P755; NOSE O, 1979, ARCH DIS CHILD, V54, P436, DOI 10.1136/adc.54.6.436; OSTRANDER CR, 1983, J PEDIATR GASTR NUTR, V2, P525, DOI 10.1097/00005176-198302030-00022; ROGGERO P, 1986, J PEDIATR GASTR NUTR, V5, P214, DOI 10.1097/00005176-198605020-00009; Smith CA, 1976, PHYSL NEWBORN INFANT; STEVENSON DK, 1982, J PEDIATR GASTR NUTR, V1, P233, DOI 10.1097/00005176-198201020-00014; STEVENSON DK, 1982, J PEDIATR-US, V101, P607, DOI 10.1016/S0022-3476(82)80720-8; TADESSE K, 1986, HONG KONG J PEDIATR, V1, P75; VANDERKLEIVANMOORSEL JM, 1984, EUR J PEDIATR, V141, P221, DOI 10.1007/BF00572764; WILSON HK, 1986, SCAND J WORK ENV HEA, V12, P174, DOI 10.5271/sjweh.2159	24	4	5	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					90	93		10.1016/0140-6736(91)90746-C	http://dx.doi.org/10.1016/0140-6736(91)90746-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670735				2022-12-24	WOS:A1991ER47700013
J	BOLZ, J; NOVAK, N; GOTZ, M; BONHOEFFER, T				BOLZ, J; NOVAK, N; GOTZ, M; BONHOEFFER, T			FORMATION OF TARGET-SPECIFIC NEURONAL PROJECTIONS IN ORGANOTYPIC SLICE CULTURES FROM RAT VISUAL-CORTEX	NATURE			English	Article									MAX PLANCK INST BIOL CYBERNET,W-7400 TUBINGEN,GERMANY	Max Planck Society	BOLZ, J (corresponding author), MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,SPEMANNSTR 37-39,W-7400 TUBINGEN,GERMANY.		Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634; Gotz, Magdalena/0000-0003-1551-9203				ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; BERRY M, 1963, NATURE, V197, P984, DOI 10.1038/197984a0; BULLIER J, 1984, J COMP NEUROL, V228, P329, DOI 10.1002/cne.902280304; CAESER M, 1989, EXPL BRAIN RES, V77, P24; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CHUN JJM, 1987, NATURE, V325, P617, DOI 10.1038/325617a0; CHUN JJM, 1989, J COMP NEUROL, V282, P555, DOI 10.1002/cne.902820407; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; GILBERT CD, 1983, ANNU REV NEUROSCI, V6, P217, DOI 10.1146/annurev.ne.06.030183.001245; GODEMENT P, 1987, DEVELOPMENT, V101, P697; GOTZ M, 1989, NEUROSCI LETT, V107, P6, DOI 10.1016/0304-3940(89)90782-9; HARRIS WA, 1986, NATURE, V320, P266, DOI 10.1038/320266a0; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; HUBENER M, 1988, NEUROSCI LETT, V94, P76, DOI 10.1016/0304-3940(88)90273-X; KATZ LC, 1987, J NEUROSCI, V7, P1223; KLEIN BG, 1986, NEUROSCIENCE, V17, P57, DOI 10.1016/0306-4522(86)90225-3; LUMSDEN AGS, 1986, NATURE, V323, P538, DOI 10.1038/323538a0; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; MCCONNELL SK, 1989, SCIENCE, V245, P978, DOI 10.1126/science.2475909; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; MILLER MW, 1985, DEV BRAIN RES, V23, P187, DOI 10.1016/0165-3806(85)90040-9; OLAVARRIA J, 1983, BRAIN RES, V279, P233, DOI 10.1016/0006-8993(83)90182-8; OLEARY DDM, 1988, NEURON, V1, P901, DOI 10.1016/0896-6273(88)90147-X; SCHOFIELD BR, 1987, J COMP NEUROL, V261, P85, DOI 10.1002/cne.902610107; SEFTON AJ, 1981, BRAIN RES, V215, P1, DOI 10.1016/0006-8993(81)90487-X; SINGER M, 1979, J COMP NEUROL, V185, P1, DOI 10.1002/cne.901850102; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; SWADLOW HA, 1983, BRAIN RES REV, V6, P1, DOI 10.1016/0165-0173(83)90002-4; SYMONDS LL, 1984, J COMP NEUROL, V229, P1, DOI 10.1002/cne.902290103; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THONG IG, 1986, DEV BRAIN RES, V25, P227, DOI 10.1016/0165-3806(86)90212-9; VALVERDE F, 1989, J COMP NEUROL, V290, P118, DOI 10.1002/cne.902900108; WAHLE P, 1989, J COMP NEUROL, V282, P215, DOI 10.1002/cne.902820206; WISE SP, 1978, J COMP NEUROL, V178, P187, DOI 10.1002/cne.901780202; YAMAMOTO N, 1989, SCIENCE, V245, P192, DOI 10.1126/science.2749258	36	179	180	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 26	1990	346	6282					359	362		10.1038/346359a0	http://dx.doi.org/10.1038/346359a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ567	1695716				2022-12-24	WOS:A1990DQ56700060
J	FAHRAEUS, R; RYMO, L; RHIM, JS; KLEIN, G				FAHRAEUS, R; RYMO, L; RHIM, JS; KLEIN, G			MORPHOLOGICAL TRANSFORMATION OF HUMAN KERATINOCYTES EXPRESSING THE LMP GENE OF EPSTEIN-BARR-VIRUS	NATURE			English	Article									GOTHENBURG UNIV,DEPT MED CHEM,S-40033 GOTHENBURG,SWEDEN; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	University of Gothenburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	FAHRAEUS, R (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		fahraeus, robin/K-8726-2014	, robin/0000-0003-0402-8492				ANDERSSONANVRET M, 1977, INT J CANCER, V20, P486, DOI 10.1002/ijc.2910200403; ARRAND JR, 1981, NUCLEIC ACIDS RES, V9, P2999, DOI 10.1093/nar/9.13.2999; BAICHWAL VR, 1988, ONCOGENE, V2, P461; DILLNER J, 1988, ADV CANCER RES, V50, P95, DOI 10.1016/S0065-230X(08)60436-4; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1654; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P4737, DOI 10.1073/pnas.71.12.4737; KLEIN G, 1979, EPSTEINBARR VIRUS, P339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RICKSTEN A, 1987, J GEN VIROL, V68, P2407, DOI 10.1099/0022-1317-68-9-2407; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; RYMO L, 1985, P NATL ACAD SCI USA, V82, P3435, DOI 10.1073/pnas.82.10.3435; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SKARE J, 1985, J VIROL, V55, P268; Sun TT, 1984, CANCER CELLS, V1, P169; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	22	276	281	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 31	1990	345	6274					447	449		10.1038/345447a0	http://dx.doi.org/10.1038/345447a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DG082	1692971				2022-12-24	WOS:A1990DG08200066
J	LICHTER, P; WARD, DC				LICHTER, P; WARD, DC			IS NONISOTOPIC INSITU HYBRIDIZATION FINALLY COMING OF AGE	NATURE			English	Review									YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University	LICHTER, P (corresponding author), YALE UNIV,SCH MED,DEPT HUMAN GENET,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							ALBERTSON DG, 1988, EMBO J, V7, P2801, DOI 10.1002/j.1460-2075.1988.tb03135.x; ANASTASI J, 1990, AM J PATHOL, V136, P131; ARNOLDUS EPJ, 1989, HUM GENET, V83, P231, DOI 10.1007/BF00285162; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; CHERIF D, 1989, HUM GENET, V81, P358, DOI 10.1007/BF00283691; CREMER T, 1988, EXP CELL RES, V176, P199, DOI 10.1016/0014-4827(88)90325-4; CREMER T, 1986, HUM GENET, V74, P346, DOI 10.1007/BF00280484; CREMER T, 1988, HUM GENET, V80, P235, DOI 10.1007/BF01790091; DEVILEE P, 1988, CANCER RES, V48, P5825; EMMERICH P, 1989, EXP CELL RES, V181, P126, DOI 10.1016/0014-4827(89)90188-2; GARSON JA, 1987, NUCLEIC ACIDS RES, V15, P4761, DOI 10.1093/nar/15.12.4761; GRAY JW, 1990, CYTOMETRY, V11; HAASE AT, 1989, IN SITU HYBRIDIZATIO, P143; HOPMAN AHN, 1988, HISTOCHEMISTRY, V89, P307, DOI 10.1007/BF00500631; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LAWRENCE JB, 1988, CELL, V52, P51; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LICHTER P, 1989, CYTOGENET CELL GENET, V51, P1033; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LICHTER P, IN PRESS MOL GENETIC; LUX SE, IN PRESS NATURE; MANUELIDIS L, 1988, CHROMOSOMA, V96, P397, DOI 10.1007/BF00303033; NEDERLOF PM, 1989, CANCER GENET CYTOGEN, V42, P87, DOI 10.1016/0165-4608(89)90011-3; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; POPP S, IN PRESS EXP CELL RE; SHAW J, IN PRESS CYTOGENET C; TRASK B, 1988, HUM GENET, V78, P251, DOI 10.1007/BF00291672; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582	31	110	142	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 3	1990	345	6270					93	95		10.1038/345093a0	http://dx.doi.org/10.1038/345093a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB957	1691830				2022-12-24	WOS:A1990DB95700067
J	RAJAVASHISTH, TB; ANDALIBI, A; TERRITO, MC; BERLINER, JA; NAVAB, M; FOGELMAN, AM; LUSIS, AJ				RAJAVASHISTH, TB; ANDALIBI, A; TERRITO, MC; BERLINER, JA; NAVAB, M; FOGELMAN, AM; LUSIS, AJ			INDUCTION OF ENDOTHELIAL-CELL EXPRESSION OF GRANULOCYTE AND MACROPHAGE COLONY-STIMULATING FACTORS BY MODIFIED LOW-DENSITY LIPOPROTEINS	NATURE			English	Article									UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Rajavashisth, Tripathi/ABB-6379-2020					AVERILL LE, 1989, AM J PATHOL, V135, P369; AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; BAKER DP, 1984, ARTERIOSCLEROSIS, V4, P248, DOI 10.1161/01.ATV.4.3.248; BARRETT TB, 1987, P NATL ACAD SCI USA, V84, P1099, DOI 10.1073/pnas.84.4.1099; BERLINER JA, 1986, ARTERIOSCLEROSIS, V6, P254, DOI 10.1161/01.ATV.6.3.254; BERLINER JA, IN PRESS J CLIN INVE; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERRITY RG, 1979, AM J PATHOL, V95, P775; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; GOLDE DW, 1972, J CLIN INVEST, V52, P2981; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HOFF HF, 1982, ATHEROSCLEROSIS, V42, P273, DOI 10.1016/0021-9150(82)90157-5; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KOSUGI K, 1987, J CELL PHYSIOL, V130, P311, DOI 10.1002/jcp.1041300302; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LIBBY P, 1986, AM J PATHOL, V124, P179; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MORTON RE, 1986, J LIPID RES, V27, P1124; NAGATA S, 1986, NATURE, V324, P73; NAVAB M, 1988, J CLIN INVEST, V82, P1853, DOI 10.1172/JCI113802; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; RAJAVASHISTH TB, 1987, P NATL ACAD SCI USA, V84, P1157, DOI 10.1073/pnas.84.5.1157; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SALSER WA, 1985, LEUKEMIA RECENT ADV, P349; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TSUKADA T, 1986, ARTERIOSCLEROSIS, V6, P601, DOI 10.1161/01.ATV.6.6.601; WANG JM, 1988, J IMMUNOL, V141, P575; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	34	631	652	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 15	1990	344	6263					254	257		10.1038/344254a0	http://dx.doi.org/10.1038/344254a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU138	1690354				2022-12-24	WOS:A1990CU13800062
J	VOLLOCH, V; SCHWEITZER, B; RITS, S				VOLLOCH, V; SCHWEITZER, B; RITS, S			UNCOUPLING OF THE SYNTHESIS OF EDITED AND UNEDITED COIII RNA IN TRYPANOSOMA-BRUCEI	NATURE			English	Article									HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	VOLLOCH, V (corresponding author), BOSTON BIOMED RES INST,DEPT METAB REGULAT,BOSTON,MA 02114, USA.							ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENNE R, 1983, NUCLEIC ACIDS RES, V11, P6925, DOI 10.1093/nar/11.20.6925; EISEN H, 1988, CELL, V53, P331, DOI 10.1016/0092-8674(88)90150-X; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1985, NUCLEIC ACIDS RES, V13, P4577, DOI 10.1093/nar/13.12.4577; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FEAGIN JE, 1988, MOL CELL BIOL, V8, P1259, DOI 10.1128/MCB.8.3.1259; HENSGENS LAM, 1984, NUCLEIC ACIDS RES, V12, P7327, DOI 10.1093/nar/12.19.7327; LAMOND AI, 1988, TRENDS BIOCHEM SCI, V13, P283, DOI 10.1016/0968-0004(88)90117-X; MAIZELS N, 1988, NATURE, V334, P469, DOI 10.1038/334469a0; Maniatis T., 1982, MOL CLONING; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; STUART K, 1989, PARASITOL TODAY, V5, P5, DOI 10.1016/0169-4758(89)90211-1; VANDERSPEK H, 1988, EMBO J, V7, P2509, DOI 10.1002/j.1460-2075.1988.tb03098.x; VOLCKAERT G, 1977, ANAL BIOCHEM, V83, P222, DOI 10.1016/0003-2697(77)90530-9; VOLLOCH V, 1987, EXP CELL RES, V173, P38, DOI 10.1016/0014-4827(87)90329-6	20	14	14	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1990	343	6257					482	484		10.1038/343482a0	http://dx.doi.org/10.1038/343482a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL818	1689017				2022-12-24	WOS:A1990CL81800067
J	PICCIRILLI, JA; KRAUCH, T; MORONEY, SE; BENNER, SA				PICCIRILLI, JA; KRAUCH, T; MORONEY, SE; BENNER, SA			ENZYMATIC INCORPORATION OF A NEW BASE PAIR INTO DNA AND RNA EXTENDS THE GENETIC ALPHABET	NATURE			English	Article											PICCIRILLI, JA (corresponding author), SWISS FED INST TECHNOL,ORGAN CHEM LAB,CH-8092 ZURICH,SWITZERLAND.							BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BENNER SA, 1987, COLD SPRING HARB SYM, V52, P53, DOI 10.1101/SQB.1987.052.01.009; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CHEN JH, 1988, BIOCHEMISTRY-US, V27, P6032, DOI 10.1021/bi00416a031; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; COLEMAN JE, 1988, BIOCHEMISTRY-US, V27, P3966; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; GILBERT W, 1986, NATURE, V319, P818; GUERRIERTAKADA C, 1984, SCIENCE, V223, P285, DOI 10.1126/science.6199841; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; PICCIRILLI JA, 1989, THESIS HARVARD U; RICH A, 1962, HORIZONS BIOCH, V103, P103; ROY KB, 1983, NUCLEOS NUCLEOT, V2, P231, DOI 10.1080/07328318308078857; SCHRAMM G, 1961, ANGEW CHEM INT EDIT, V73, P619, DOI 10.1002/ange.19610731707; SWITZER C, 1989, J AM CHEM SOC, V111, P8322, DOI 10.1021/ja00203a067; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; USHER DA, 1976, P NATL ACAD SCI USA, V73, P1149, DOI 10.1073/pnas.73.4.1149; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468	24	532	622	13	92	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1990	343	6253					33	37		10.1038/343033a0	http://dx.doi.org/10.1038/343033a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG614	1688644				2022-12-24	WOS:A1990CG61400043
J	DREXLER, H; ZEIHER, AM; MEINZER, K; JUST, H				DREXLER, H; ZEIHER, AM; MEINZER, K; JUST, H			CORRECTION OF ENDOTHELIAL DYSFUNCTION IN CORONARY MICROCIRCULATION OF HYPERCHOLESTEROLEMIC PATIENTS BY L-ARGININE	LANCET			English	Article							CHOLESTEROL-FED RABBITS; DEPENDENT RELAXATION; NITRIC-OXIDE; ARTERIES	Hypercholesterolaemia impairs endothelial function, possibly by interference with the intracellular formation of endothelium-derived relaxing factor from its precursor L-arginine. Whether L-arginine reverses hypercholesterolaemia-induced endothelial dysfunction in the coronary circulation was thus investigated. Epicardial artery cross-sectional area and coronary blood flow velocity were measured in 8 hypercholesterolaemic patients (mean serum cholesterol 7.8 [SE 0.3] mmol/l) and 7 age-matched controls before and after graded intracoronary infusions of the endothelium-dependent agent acetylcholine (0.036, 0.36, 3.6-mu-g/min). The effect of intracoronary infusion of L-arginine (160-mu-mol/min via the guiding catheter) on these measurements was then examined. In controls, acetylcholine induced a moderate dose-dependent constriction of the epicardial artery segment of the left anterior descending artery and increased coronary blood flow (by 239% [SE 57] at the highest dose). In patients with hypercholesterolaemia, the vasoconstrictive effect of acetylcholine on epicardial segments was similar to that in controls, but the increase in coronary blood flow with acetylcholine was significantly attenuated (highest dose: 61% [19), p < 0.02 vs controls). L-arginine restored the acetylcholine-induced increase in blood flow in patients with hypercholesterolaemia (198% [61] vs baseline) but did not affect coronary blood flow in controls. The findings suggest that hypercholesterolaemia impairs endothelium-dependent dilatation of the coronary microcirculation and that this impairment can be restored by short-term administration of L-arginine. The possibility that L-arginine might form the basis of treatment for coronary endothelial abnormalities induced by hypercholesterolaemia could be worth investigating.			DREXLER, H (corresponding author), UNIV FREIBURG, MED KLIN 3, W-7800 FREIBURG, GERMANY.							CALVER A, 1990, LANCET, V336, P1016; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; COOKE JP, 1991, CIRCULATION, V83, P1057, DOI 10.1161/01.CIR.83.3.1057; DREXLER H, 1991, HYPERTENSION, V18, P90, DOI 10.1161/01.HYP.18.4_Suppl.II90; DREXLER H, 1989, CIRCULATION, V80, P466, DOI 10.1161/01.CIR.80.3.466; DREXLER H, IN PRESS CIRCULATION; GALLE J, 1991, ARTERIOSCLER THROMB, V11, P198, DOI 10.1161/01.ATV.11.1.198; GIRERD XJ, 1990, CIRC RES, V67, P1301, DOI 10.1161/01.RES.67.6.1301; GOLINO P, 1991, NEW ENGL J MED, V324, P641, DOI 10.1056/NEJM199103073241001; HENDERSON AH, 1991, BRIT HEART J, V65, P116; HOGAN JC, 1988, BRIT J PHARMACOL, V94, P1020, DOI 10.1111/j.1476-5381.1988.tb11616.x; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; OSBORNE JA, 1989, AM J PHYSIOL, V256, pC591, DOI 10.1152/ajpcell.1989.256.3.C591; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; ROSSITCH E, 1991, J CLIN INVEST, V87, P1295, DOI 10.1172/JCI115132; RUBANYI GM, 1991, CIRCULATION, V83, P1118, DOI 10.1161/01.CIR.83.3.1118; SCHMIDT HHHW, 1988, EUR J PHARMACOL, V148, P293, DOI 10.1016/0014-2999(88)90578-X; SCHMIDT HHHW, 1990, BRIT J PHARMACOL, V101, P145, DOI 10.1111/j.1476-5381.1990.tb12104.x; SELLKE FW, 1990, CIRCULATION, V81, P1586, DOI 10.1161/01.CIR.81.5.1586; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; TAGAWA H, 1991, CIRC RES, V68, P330, DOI 10.1161/01.RES.68.2.330; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; VERBEUREN TJ, 1986, CIRC RES, V58, P552, DOI 10.1161/01.RES.58.4.552; WERNS SW, 1989, CIRCULATION, V79, P287, DOI 10.1161/01.CIR.79.2.287; WOLLSCHLAGER H, 1986, COMPUT CARDIOL, P483; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; ZEIHER AM, 1991, CIRCULATION, V84, P1984, DOI 10.1161/01.CIR.84.5.1984; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391; ZEIHER AM, 1991, CIRCULATION S, V84, P652	31	719	791	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1991	338	8782-3					1546	1550		10.1016/0140-6736(91)92372-9	http://dx.doi.org/10.1016/0140-6736(91)92372-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683971				2022-12-24	WOS:A1991GW03600003
J	MOLLA, A; PAUL, AV; WIMMER, E				MOLLA, A; PAUL, AV; WIMMER, E			CELL-FREE, DENOVO SYNTHESIS OF POLIOVIRUS	SCIENCE			English	Article							TRANSLATION SYSTEM; INITIATION SITES; RNA-POLYMERASE; POLYPEPTIDE 2C; MESSENGER-RNA; HELA-CELLS; INVITRO; CLEAVAGE; MORPHOGENESIS; INTERMEDIATE	Cell-free translation of poliovirus RNA in an extract of uninfected human (HeLa) cells yielded viral proteins through proteolysis of the polyprotein. In the extract, newly synthesized proteins catalyzed poliovirus-specific RNA synthesis, and formed infectious poliovirus de novo. Newly formed virions were neutralized by type-specific antiserum, and infection of human cells with them was prevented by poliovirus receptor-specific antibodies. Poliovirus synthesis was increased nearly 70-fold when nucleoside triphosphates were added, but it was abolished in the presence of inhibitors of translation or viral genome replication. The ability to conduct cell-free synthesis of poliovirus will aid in the study of picornavirus proliferation and in the search for the control of picornaviral disease.			MOLLA, A (corresponding author), SUNY STONY BROOK,SCH MED,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.				NCI NIH HHS [CA-28146] Funding Source: Medline; NIAID NIH HHS [AI-15122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015122, R37AI015122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALTIMORE D, 1971, BACTERIOL REV, V35, P235, DOI 10.1128/MMBR.35.3.235-241.1971; BROWN BA, 1979, VIROLOGY, V97, P396, DOI 10.1016/0042-6822(79)90350-7; CALIGUIRI LA, 1973, SELECTIVE INHIBITORS, P257; CASJENS S, 1985, VIRUS STRUCTURE ASSE, P76; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DORNER AJ, 1982, J VIROL, V42, P1017, DOI 10.1128/JVI.42.3.1017-1028.1982; DORNER AJ, 1984, J VIROL, V50, P507, DOI 10.1128/JVI.50.2.507-514.1984; FERNANDEZTOMAS CB, 1973, J VIROL, V12, P1181, DOI 10.1128/JVI.12.5.1181-1183.1973; FERNANDEZTOMAS CB, 1973, J VIROL, V12, P1122, DOI 10.1128/JVI.12.5.1122-1130.1973; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; GRUBMAN MJ, 1985, J VIROL, V56, P120, DOI 10.1128/JVI.56.1.120-126.1985; HARBER JJ, 1991, J VIROL, V65, P326, DOI 10.1128/JVI.65.1.326-334.1991; HARRISON SC, 1990, VIROLOGY, P37; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KOCH G, 1973, CURR TOP MICROBIOL I, V2, P89; Kuhn R. J., 1987, The molecular biology of the positive strand RNA viruses, P17; LEE KAW, 1982, P NATL ACAD SCI-BIOL, V79, P3447, DOI 10.1073/pnas.79.11.3447; LURIA SE, 1967, GENERAL VIROLOGY, P5; MENDELSOHN C, 1986, P NATL ACAD SCI USA, V83, P7845, DOI 10.1073/pnas.83.20.7845; MOLLA A, UNPUB; NOBIS P, 1985, J GEN VIROL, V66, P2563, DOI 10.1099/0022-1317-66-12-2563; NOVAK JE, 1991, J VIROL, V65, P3384, DOI 10.1128/JVI.65.6.3384-3387.1991; PALMENBERG AC, 1982, J VIROL, V44, P900, DOI 10.1128/JVI.44.3.900-906.1982; PAUL AV, 1987, P NATL ACAD SCI USA, V84, P7827, DOI 10.1073/pnas.84.22.7827; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PEREZBERCOFF R, 1980, PROTEIN BIOSYNTHESIS; PESTOVA TV, 1991, J VIROL, V65, P6194, DOI 10.1128/JVI.65.11.6194-6204.1991; PINCUS SE, 1986, J VIROL, V57, P638, DOI 10.1128/JVI.57.2.638-646.1986; PINCUS SE, 1986, J VIROL, V60, P793, DOI 10.1128/JVI.60.2.793-796.1986; PINCUS SE, 1987, MOL BIOL RNA NEW PER, P175; PUTNAK JR, 1981, MICROBIOL REV, V45, P287, DOI 10.1128/MMBR.45.2.287-315.1981; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROTHBERG PG, 1981, THESIS STATE U NEW Y; RUECKERT RR, 1990, VIROLOGY, P507; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; SEMLER BL, 1988, RNA GENETICS, V1, P23; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; WALKER AI, 1985, THESIS U CAMBRIDGE; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YPMAWONG MF, 1987, NUCLEIC ACIDS RES, V15, P2069, DOI 10.1093/nar/15.5.2069; YPMAWONG MF, 1987, J VIROL, V61, P3181, DOI 10.1128/JVI.61.10.3181-3189.1987	44	309	326	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1647	1651		10.1126/science.1661029	http://dx.doi.org/10.1126/science.1661029			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1661029				2022-12-24	WOS:A1991GV07300046
J	ORTEGABARRIA, E; PEREIRA, MEA				ORTEGABARRIA, E; PEREIRA, MEA			A NOVEL TRYPANOSOMA-CRUZI HEPARIN-BINDING PROTEIN PROMOTES FIBROBLAST ADHESION AND PENETRATION OF ENGINEERED BACTERIA AND TRYPANOSOMES INTO MAMMALIAN-CELLS	CELL			English	Article							ENHANCE INFECTION; HIGH-DENSITY; BIOLOGY; INVITRO; NEURAMINIDASE; INHIBITION; INVASION; PEPTIDES	T. cruzi invades mammalian cells in various organs after migrating through the ECM. These activities appear to be mediated by a unique 60 kd protein exposed on the T. cruzi surface, which promotes selective adhesion of trypomastigotes to three ECM components: heparin, heparan sulfate, and collagen. The affinity-purified protein binds to host fibroblasts in a saturable and glycosaminoglycan- and collagen-inhibitable manner. When adsorbed to plastic, it promotes adhesion and spreading of fibroblasts, as does the recombinant protein expressed in E. coli. The endogenous protein, and reactive ECM proteins, are very effective in preventing T. cruzi invasion of culture cells. The recombinant protein localizes on the E. coli surface and induces the bacteria that express it to adhere to and penetrate nonphagocytic Vero cells in a proteoglycan-and collagen-inhibitable manner. Therefore, the protein, named penetrin, could play a critical role in T. cruzi binding to the ECM and to cells, and in host cell invasion.			ORTEGABARRIA, E (corresponding author), TUFTS UNIV,DEPT MED,DIV GEOG MED & INFECT DIS,750 WASHINGTON ST,BOSTON,MA 02111, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts B, 1989, MOL BIOL CELL, P802; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; COUGHLIN SR, 1988, J BIOL CHEM, V263, P928; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; HOWARD RJ, 1982, J PROTOZOOL, V29, P114, DOI 10.1111/j.1550-7408.1982.tb02891.x; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; LEWIN B, 1990, GENES, V4, P451; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; LU GY, 1991, MOL BIOCHEM PARASIT, V44, P109; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; OUAISSI MA, 1986, SCIENCE, V234, P603, DOI 10.1126/science.3094145; Pereira M. E. A., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P64; PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179; PRIOLI RP, 1987, P NATL ACAD SCI USA, V84, P3097, DOI 10.1073/pnas.84.10.3097; PRIOLI RP, 1990, MOL BIOCHEM PARASIT, V38, P191, DOI 10.1016/0166-6851(90)90022-E; PRIOLI RP, 1988, MOL BIOCHEM PARASIT, V28, P257, DOI 10.1016/0166-6851(88)90010-2; PRIOLI RP, 1990, J IMMUNOL, V144, P4384; PUGSLEY AP, 1987, PROTEIN TRANSFER ORG, P607; ROBERTS DD, 1989, J BIOL CHEM, V264, P9289; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1988, CELL, V55, P157, DOI 10.1016/0092-8674(88)90018-9; SCHENKMAN S, 1991, EXP PARASITOL, V72, P76, DOI 10.1016/0014-4894(91)90123-E; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STAATZ WD, 1991, J BIOL CHEM, V266, P7366; VELGE P, 1988, PARASITOLOGY, V97, P255, DOI 10.1017/S0031182000058467; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; 1990, WEEKLY EPIDEMIOL RES, V65, P257	35	192	197	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					411	421		10.1016/0092-8674(91)90192-2	http://dx.doi.org/10.1016/0092-8674(91)90192-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655283				2022-12-24	WOS:A1991GL47000020
J	BAGGIO, B; GAMBARO, G; MARCHINI, F; MARZARO, G; WILLIAMS, HE; BORSATTI, A				BAGGIO, B; GAMBARO, G; MARCHINI, F; MARZARO, G; WILLIAMS, HE; BORSATTI, A			CORRECTION OF ERYTHROCYTE ABNORMALITIES IN IDIOPATHIC CALCIUM-OXALATE NEPHROLITHIASIS AND REDUCTION OF URINARY OXALATE BY ORAL GLYCOSAMINOGLYCANS	LANCET			English	Article							PROTEIN-PHOSPHORYLATION; INHIBITION; TRANSPORT; EXCHANGE; CLONING; KINASE; FLUX; CDNA	Calcium-oxalate nephrolithiasis is associated with a defect in erythrocyte oxalate self-exchange and an abnormal rate of erythrocyte membrane protein phosphorylation. There is evidence that glycosaminoglycans (GAGs) have a regulatory effect on both of these processes. This study tested the hypothesis that modifications of erythrocyte oxalate self-exchange induced by oral GAGs are paralleled by similar changes in overall oxalate metabolism. 40 patients with idiopathic calcium-oxalate nephrolithiasis were treated for 15 days with 60 mg/day of a mixture of GAGs. By day 15 of treatment there were significant reductions from baseline in erythrocyte oxalate self-exchange (mean [SD] 1.67 [1.18] vs 2.59 [1.63] x 10(2) per min; p < 0.005) and erythrocyte membrane protein phosphorylation (55.8 [7.3] vs 72.9 [6.8] x 10(-3) cpm/mg protein; p < 0.005), but also in urinary oxalate excretion (0.24 [0.09] vs 0.31 [0.15) mmol/24 h; p < 0.005). This finding suggests similar changes in both erythrocytes and other cells more important in oxalate handling. The changes had reversed by 15 days after withdrawal of treatment. Acute intravenous administration of GAGs (60 mg) induced a fall in carbon-14-labelled oxalate renal clearance (143 [13] vs 169 [28] ml/min; p < 0.005), which strongly suggests the participation of the kidney. However, reduced oxalate absorption from the intestine, and even decreased synthesis of oxalate, cannot be ruled out.	UNIV PADUA,INST INTERNAL MED,DIV NEPHROL,I-35100 PADUA,ITALY; UNIV CALIF DAVIS,SCH MED,DAVIS,CA 95616	University of Padua; University of California System; University of California Davis				Gambaro, Giovanni/0000-0001-5733-2370				ALPER SL, 1987, KIDNEY INT       S23, V32, P117; BAGGIO B, 1984, LANCET, V2, P12, DOI 10.1016/S0140-6736(84)91998-6; BAGGIO B, 1986, IRCS MED SCI-BIOCHEM, V14, P368; BAGGIO B, 1984, LANCET, V2, P223; BAGGIO B, 1990, CLIN SCI, V79, P113, DOI 10.1042/cs0790113; BAGGIO B, 1986, NEW ENGL J MED, V314, P599, DOI 10.1056/NEJM198603063141002; BAGGIO B, 1988, INHIBITORS CRYSTALLI, P211; BIOVIN P, 1985, FEBS LETT, V186, P89; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CHOI HR, 1988, MOL CELL BIOL, V8, P4416; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; SUGIMOTO T, 1989, UROLITHIASIS, P431; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WILLIAMS HE, 1989, J UROLOGY, V141, P742, DOI 10.1016/S0022-5347(17)40999-2; WILLIAMS HE, 1971, CLIN SCI, V41, P213, DOI 10.1042/cs0410213; WISE BC, 1982, J BIOL CHEM, V257, P8489; WORCESTER EM, 1986, J CLIN INVEST, V77, P1888, DOI 10.1172/JCI112516	20	26	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					403	405		10.1016/0140-6736(91)91030-X	http://dx.doi.org/10.1016/0140-6736(91)91030-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678082				2022-12-24	WOS:A1991GB44600003
J	SORSCHER, EJ; HUANG, Z				SORSCHER, EJ; HUANG, Z			DIAGNOSIS OF GENETIC-DISEASE BY PRIMER-SPECIFIED RESTRICTION MAP MODIFICATION, WITH APPLICATION TO CYSTIC-FIBROSIS AND RETINITIS-PIGMENTOSA	LANCET			English	Article							ENZYMATICALLY AMPLIFIED DNA; OLIGONUCLEOTIDE PROBES; RHODOPSIN; MUTATION	Detection of small alterations or abnormalities in genomic DNA (eg, point mutations or small deletions) has become increasingly important in the diagnosis of genetic disease and polymorphism. When a mutation or polymorphism creates a new restriction endonuclease site, it can easily be identified by polymerase chain reaction (PCR) amplification of the DNA region of interest, followed by digestion with the restriction endonuclease. However, useful restriction sites are the exception, and a variety of specialised techniques have been developed to identify subtle DNA abnormalities. We have shown that where a DNA mutation does not create a useful novel restriction site, such a site can be introduced by PCR and specially chosen primers. The approach is simple and inexpensive and should be broadly applicable in the diagnosis of genetic polymorphism and mutation. The technique is illustrated here by the three base-pair deletion responsible for most cases of cystic fibrosis and by detection of the point mutation in the rhodopsin gene that has been associated with some cases of autosomal dominant retinitis pigmentosa.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	SORSCHER, EJ (corresponding author), UNIV ALABAMA,DEPT MED,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294, USA.			Sorscher, Eric J./0000-0001-9341-3354				[Anonymous], 1989, METABOLIC BASIS INHE, V34, P253; BALLABIO A, 1990, NATURE, V343, P220, DOI 10.1038/343220a0; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; Erlich HA, 1989, PCR TECHNOLOGY, P36; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P3606, DOI 10.1093/nar/17.9.3606; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1988, NEW ENGL J MED, V319, P537, DOI 10.1056/NEJM198809013190903; Sambrook J., 1989, MOL CLONING LAB MANU; SARKAR G, 1990, ANAL BIOCHEM, V186, P64, DOI 10.1016/0003-2697(90)90573-R	12	39	44	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1115	1118		10.1016/0140-6736(91)92785-Z	http://dx.doi.org/10.1016/0140-6736(91)92785-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674012				2022-12-24	WOS:A1991FL12400002
J	KOLLER, KJ; LOWE, DG; BENNETT, GL; MINAMINO, N; KANGAWA, K; MATSUO, H; GOEDDEL, DV				KOLLER, KJ; LOWE, DG; BENNETT, GL; MINAMINO, N; KANGAWA, K; MATSUO, H; GOEDDEL, DV			SELECTIVE ACTIVATION OF THE B-NATRIURETIC PEPTIDE RECEPTOR BY C-TYPE NATRIURETIC PEPTIDE (CNP)	SCIENCE			English	Article							GUANYLATE-CYCLASE; SEQUENCE-ANALYSIS; ATRIAL; BRAIN; PRECURSOR; CLONING; BINDING; PLASMA	The natriuretic peptides are hormones that can stimulate natriuretic, diuretic, and vasorelaxant activity in vivo, presumably through the activation of two known cell surface receptor guanylyl cyclases (ANPR-A and ANPR-B). Although atrial natriuretic peptide (ANP) and, to a lesser extent, brain natriuretic peptide (BNP) are efficient activators of the ANPR-A guanylyl cyclase, neither hormone can significantly stimulate ANPR-B. A member of this hormone family, C-type natriuretic peptide (CNP), potently and selectively activated the human ANPR-B guanylyl cyclase. CNP does not increase guanosine 3',5'-monophosphate accumulation in cells expressing human ANPR-A. The affinity of CNP for ANPR-B is 50- or 500-fold higher than ANP or BNP, respectively. This ligand-receptor pair may be involved in the regulation of fluid homeostasis by the central nervous system.	GENENTECH INC,DEPT IMMUNOL RES & ASSAY TECHNOL,S SAN FRANCISCO,CA 94080; NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 565,JAPAN; MIYAZAKI MED COLL,DEPT BIOCHEM,MIYAZAKI 88916,JAPAN	Roche Holding; Genentech; National Cerebral & Cardiovascular Center - Japan; University of Miyazaki	KOLLER, KJ (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080, USA.							ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; BAXTER JD, 1988, BIO-TECHNOL, V6, P529, DOI 10.1038/nbt0588-529; BOVY PR, 1990, MED RES REV, V10, P115, DOI 10.1002/med.2610100105; CHABOT JG, 1990, CURRENT ASPECTS NEUR, V1, pCH2; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; FULLER F, 1988, J BIOL CHEM, V263, P9395; FURUYA M, 1990, BIOCHEM BIOPH RES CO, V170, P201, DOI 10.1016/0006-291X(90)91260-Y; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; KAMBAYASHI Y, 1990, FEBS LETT, V259, P341, DOI 10.1016/0014-5793(90)80043-I; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; KOLLER KP, UNPUB; LOWE DA, UNPUB; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWE DG, 1990, NUCLEIC ACIDS RES, V18, P3412, DOI 10.1093/nar/18.11.3412; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MCGREGOR A, 1990, J CLIN ENDOCR METAB, V70, P1103, DOI 10.1210/jcem-70-4-1103; MINAMINO N, 1990, BIOCHEM BIOPH RES CO, V170, P973, DOI 10.1016/0006-291X(90)92187-5; MINAMINO N, UNPUB; MIYATA A, 1985, BIOCHEM BIOPH RES CO, V129, P248, DOI 10.1016/0006-291X(85)91429-9; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SONG DL, 1988, FEBS LETT, V232, P125, DOI 10.1016/0014-5793(88)80400-9; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUDOH T, 1989, BIOCHEM BIOPH RES CO, V159, P1427, DOI 10.1016/0006-291X(89)92269-9; WILCOX JD, UNPUB	31	729	754	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					120	123		10.1126/science.1672777	http://dx.doi.org/10.1126/science.1672777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	1672777				2022-12-24	WOS:A1991FE95200048
J	MAKI, M; AINE, L; LIPSANEN, V; KOSKIMIES, S				MAKI, M; AINE, L; LIPSANEN, V; KOSKIMIES, S			DENTAL ENAMEL DEFECTS IN 1ST-DEGREE RELATIVES OF CELIAC-DISEASE PATIENTS	LANCET			English	Note								To find out whether dental changes can be used to screen for coeliac disease among apparently healthy relatives of patients with the disorder, 56 healthy first-degree relatives of such patients were subjected to dental examination and small bowel biopsy. 25 had coeliac-type general permanent-tooth enamel lesions. All 7 who had histological evidence of coeliac disease also had enamel lesions. The finding that enamel defects may occur without small bowel changes must be borne in mind in screening. The coeliac-type enamel changes were strongly associated with HLA-DR3, and most of the DR3 alleles belonged to the extended haplotype A1; B8; DR3 group.	UNIV HOSP TAMPERE,DEPT ORAL & MAXILLOFACIAL SURG,TAMPERE,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,BLOOD TRANSFUS SERV,HELSINKI,FINLAND	Tampere University; Tampere University Hospital	MAKI, M (corresponding author), UNIV TAMPERE,DEPT CLIN SCI,SF-33520 TAMPERE,FINLAND.							AINE L, 1986, Proceedings of the Finnish Dental Society, V82, P1; AINE L, 1990, J ORAL PATHOL MED, V19, P241, DOI 10.1111/j.1600-0714.1990.tb00834.x; AMOS DB, 1969, TRANSPLANTATION, V7, P220, DOI 10.1097/00007890-196903000-00023; DUPONT B, 1989, IMMUNOBIOLOGY HLA IM, V2; MAKI M, 1990, ARCH DIS CHILD, V65, P1137, DOI 10.1136/adc.65.10.1137; MAKI M, IN PRESS GUT; Massier M, 1941, AM J DIS CHILD, V62, P33; NIKIFORUK G, 1981, J PEDIATR-US, V98, P888, DOI 10.1016/S0022-3476(81)80580-X	8	47	48	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					763	764		10.1016/0140-6736(91)91375-5	http://dx.doi.org/10.1016/0140-6736(91)91375-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672395				2022-12-24	WOS:A1991FD88400007
J	TRAPE, JF; DUPLANTIER, JM; BOUGANALI, H; GODELUCK, B; LEGROS, F; CORNET, JP; CAMICAS, JL				TRAPE, JF; DUPLANTIER, JM; BOUGANALI, H; GODELUCK, B; LEGROS, F; CORNET, JP; CAMICAS, JL			TICK-BORNE BORRELIOSIS IN WEST AFRICA	LANCET			English	Article								Reported cases of tick-borne relapsing fever due to the spirochaete Borrelia crocidurae are rare in West Africa, and few epidemiological data are available. To see how common relapsing fever is in Senegal thick blood smears from cases of fever of unknown origin and from randomly selected clinic outpatients from a rural dispensary were examined for Borrelia. The prevalence of Borrelia infections in small mammals was also assessed. Borrelia was seen in smears of 12 (0.9%) of 1340 children. All children who tested positive had complained of acute fever. Prevalence was 0% (0/496), 0.5% (2/417), 1.6% (5/308), and 4.2% (5/119) at ages 0-1, 2-4, 5-9, and 10-14, respectively. 26 other instances of borreliosis were seen in patients from different regions of Senegal. Blood samples from 7 of these patients were inoculated intraperitoneally into white mice; serious infection developed in all mice. Borrelia was seen in thick smears from 65 of 461 wild rodents or insectivores. Six rodents species were infected. From a sample of 93 rodents, 33.3% were infected, as judged by intraperitoneal inoculation of white mice, compared with 14.1% by direct smear examination. The findings suggest that borreliosis has a wide distribution and a high incidence in Senegal. This disease may be a major cause of morbidity in rural areas throughout much of West Africa.			TRAPE, JF (corresponding author), ORSTOM,BP 1386,DAKAR,SENEGAMBIA.							BALTAZARD M., 1954, BULL SOC PATHOL EXOT, V47, P878; BALTAZARD M., 1948, Bulletin de la Societe de Pathologie Exotique, V41, P399; BOIRON H., 1949, BULL SOC PATH EXOT, V42, P62; COLLIGNON R., 1989, SANTE POPULATION SEN; LEGER Andre, 1917, Bulletin de la Societe de Pathologie Exotique, V10, P280; Mathis C., 1934, Ann Inst Pasteur Paris T, V52, P166; MATHIS C., 1928, BULL SOC PATH EXOT, V21, P472; 1989, WHOVBC89967	8	52	52	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					473	475		10.1016/0140-6736(91)93404-W	http://dx.doi.org/10.1016/0140-6736(91)93404-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671481				2022-12-24	WOS:A1991EY88700015
J	MORTIMER, PP				MORTIMER, PP			THE FALLIBILITY OF HIV WESTERN-BLOT	LANCET			English	Editorial Material							RETROVIRUSES HTLV-III; AIDS				MORTIMER, PP (corresponding author), CENT PUBL HLTH LAB,VIRUS REFERENCE LAB,61 COLINDALE AVE,LONDON NW9 5HT,ENGLAND.							BENENSON AS, 1989, JAMA-J AM MED ASSOC, V262, P3435; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; EPSTEIN J, 1990, DIAGN CLIN TEST, V28, P50; GENESCA J, 1989, LANCET, V2, P1023; JORGENSEN A, 1990, SCAND J INFECT DIS, V22, P283, DOI 10.3109/00365549009027049; LEPINE DG, 1990, J CLIN MICROBIOL, V28, P1169, DOI 10.1128/JCM.28.6.1169-1171.1990; MORTIMER PP, 1985, LANCET, V2, P873; PARRY JV, 1990, STD9027 DEP HLTH; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937; SPIELBERG S, 1990, J CLIN MICROBIOL, V28, P303; 1990, MMWR, V39, P380; 1990, WEEK EPIDEMIOL REC; 1989, MMWR, V38, pS7	14	52	55	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					286	287						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671125				2022-12-24	WOS:A1991EV71900017
J	DURRANT, I				DURRANT, I			LIGHT-BASED DETECTION OF BIOMOLECULES	NATURE			English	Article											DURRANT, I (corresponding author), AMERSHAM INT PLC,DNA LABELLING & DETECT PROGRAMME,WHITE LION RD,AMERSHAM HP7 9LL,BUCKS,ENGLAND.							BONISZEWSKI ZAM, 1990, IN PRESS ELECTROPHOR; DURRANT I, 1990, BIOTECHNIQUES, V8, P564; EVANS MR, 1990, IN PRESS 6TH P INT C; HASHIDA S, 1984, Journal of Applied Biochemistry, V6, P56; HODGSON M, 1989, J BIOLUM CHEMILUM, V3, P21, DOI 10.1002/bio.1170030105; POLLARDKNIGHT D, 1990, ANAL BIOCHEM, V185, P84, DOI 10.1016/0003-2697(90)90259-C; POLLARDKNIGHT D, 1990, TECHNIQUES, V2, P1; RENZ M, 1984, NUCLEIC ACIDS RES, V12, P3435, DOI 10.1093/nar/12.8.3435; SORG R, 1990, IN PRESS LIFE SCI, V2; THORPE GHG, 1987, BIOLUMINESCENCE CHEM; WHITEHEAD TP, 1983, NATURE, V305, P158, DOI 10.1038/305158a0; 1990, ECL TECHNICAL MANUAL	12	71	74	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 19	1990	346	6281					297	298		10.1038/346297a0	http://dx.doi.org/10.1038/346297a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP456	1695714				2022-12-24	WOS:A1990DP45600075
J	OKABE, S; HIROKAWA, N				OKABE, S; HIROKAWA, N			TURNOVER OF FLUORESCENTLY LABELED TUBULIN AND ACTIN IN THE AXON	NATURE			English	Article											OKABE, S (corresponding author), UNIV TOKYO, SCH MED, DEPT ANAT & CELL BIOL, TOKYO 113, JAPAN.			Okabe, Shigeo/0000-0003-1216-8890				AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BAMBURG JR, 1986, NATURE, V321, P788, DOI 10.1038/321788a0; BLACK MM, 1980, J CELL BIOL, V86, P616, DOI 10.1083/jcb.86.2.616; GOLDENBERG SSS, 1983, J NEUROBIOL, V14, P195, DOI 10.1002/neu.480140304; HAMAGUCHI Y, 1987, CELL STRUCT FUNCT, V12, P43, DOI 10.1247/csf.12.43; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HIROKAWA N, 1985, J CELL BIOL, V101, P227, DOI 10.1083/jcb.101.1.227; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P223, DOI 10.1083/jcb.108.2.223; KEITH CH, 1987, SCIENCE, V235, P337, DOI 10.1126/science.2432662; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; KOSIK KS, 1987, J NEUROSCI, V7, P3142; KREIS TE, 1982, CELL, V29, P835, DOI 10.1016/0092-8674(82)90445-7; LIM SS, 1989, J CELL BIOL, V109, P253, DOI 10.1083/jcb.109.1.253; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; NIXON RA, 1986, J CELL BIOL, V102, P647, DOI 10.1083/jcb.102.2.647; OBLINGER MM, 1987, J NEUROSCI, V7, P453; OKABE S, 1989, J CELL BIOL, V109, P1581, DOI 10.1083/jcb.109.4.1581; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; OKABE S, 1989, P NATL ACAD SCI USA, V86, P4127, DOI 10.1073/pnas.86.11.4127; SALMON ED, 1984, J CELL BIOL, V99, P2157, DOI 10.1083/jcb.99.6.2157; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; TASHIRO T, 1989, J NEUROSCI, V9, P760; VIGERS GPA, 1988, J CELL BIOL, V107, P1011, DOI 10.1083/jcb.107.3.1011; VIKSTROM KL, 1989, P NATL ACAD SCI USA, V86, P549, DOI 10.1073/pnas.86.2.549; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WEISENBERG RC, 1987, SCIENCE, V238, P1119, DOI 10.1126/science.2446388; WILLARD M, 1974, P NATL ACAD SCI USA, V71, P2183, DOI 10.1073/pnas.71.6.2183; WOLF DE, 1989, METHOD CELL BIOL, V30, P271	30	152	152	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 1	1990	343	6257					479	482		10.1038/343479a0	http://dx.doi.org/10.1038/343479a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL818	1689016				2022-12-24	WOS:A1990CL81800066
J	KAJIWARA, K; HAHN, LB; MUKAI, S; TRAVIS, GH; BERSON, EL; DRYJA, TP				KAJIWARA, K; HAHN, LB; MUKAI, S; TRAVIS, GH; BERSON, EL; DRYJA, TP			MUTATIONS IN THE HUMAN RETINAL DEGENERATION SLOW GENE IN AUTOSOMAL DOMINANT RETINITIS-PIGMENTOSA	NATURE			English	Article							RHODOPSIN GENE; RDS; MICE	THE murine retinal degeneration slow (rds) gene is a semidominant mutation with a phenotype having rod and cone photoreceptors that develop abnormally and then slowly degenerate 1-3. The phenotype is a possible model for retinitis pigmentosa, one of the scores of hereditary human retinal degenerations, which is also characterized by photoreceptor degeneration. We report here three mutations of the human homologue of the rds gene (RDS) that cosegregate with autosomal dominant retinitis pigmentosa in separate families. Our results indicate that some cases of autosomal dominant retinitis pigmentosa are due to mutations at the RDS locus.	HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HOWE LAB OPHTHALMOL,243 CHARLES ST,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB STUDY RETINAL DEGENERAT,BOSTON,MA 02114; UNIV TEXAS,SW MED CTR,DEPT PSYCHIAT,DALLAS,TX 75237	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DRYJA, TP (corresponding author), HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HOWE LAB OPHTHALMOL,243 CHARLES ST,BOSTON,MA 02114, USA.		Travis, Gabriel Harvey/AIF-1062-2022	Travis, Gabriel Harvey/0000-0003-4020-9493				BEGY C, 1990, NUCLEIC ACIDS RES, V18, P3058, DOI 10.1093/nar/18.10.3058; BERSON EL, 1976, T AM ACAD OPHTHALMOL, V81, P659; COHEN AI, 1983, INVEST OPHTH VIS SCI, V24, P832; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; INGLEHEARN CF, 1991, AM J HUM GENET, V48, P26; KEEN TJ, 1991, GENOMICS, V11, P199, DOI 10.1016/0888-7543(91)90119-Y; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; REICHEL E, 1989, AM J OPHTHALMOL, V108, P540, DOI 10.1016/0002-9394(89)90431-5; SANYAL S, 1980, J COMP NEUROL, V194, P193, DOI 10.1002/cne.901940110; SHEFFIELD VC, 1991, AM J HUM GENET, V49, P699; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; VANNIE R, 1978, TISSUE ANTIGENS, V12, P106, DOI 10.1111/j.1399-0039.1978.tb01305.x; YANDELL DW, 1989, CANCER CEL, V7, P223	19	376	388	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					480	483		10.1038/354480a0	http://dx.doi.org/10.1038/354480a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1684223				2022-12-24	WOS:A1991GV07800061
J	WEINTRAUB, M; SINGH, S; BYRNE, L; MAHARAJ, K; GUTTMACHER, L				WEINTRAUB, M; SINGH, S; BYRNE, L; MAHARAJ, K; GUTTMACHER, L			CONSEQUENCES OF THE 1989 NEW-YORK-STATE TRIPLICATE BENZODIAZEPINE PRESCRIPTION REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABUSE	Objective. - Comparison of psychoactive medication prescribing and Medicaid expenditures before (1987 through 1988) and after (1989 through 1990) institution of the New York State triplicate benzodiazepine regulations. Data Sources. - The National Prescription Audit (IMS America, Plymouth Meeting, Pa), New York State Medicaid, and Blue Cross/Blue Shield of the Rochester (NY) Area. Results. - From 1988 to 1989, New York State benzodiazepine prescribing decreased by 44%, 60%, and 30% as assessed by IMS America, Medicaid, and Blue Cross/Blue Shield, respectively. Prescribing of the following alternative sedative-hypnotics increased in New York State compared with decreases nationally (IMS America data): meprobamate, + 125% vs - 9%; methyprylon, + 84% vs - 15%; ethchlorvynol, + 29% vs - 18%; butabarbital, + 31 % vs - 15%; hydroxyzine, + 15% vs - 1.1 %; and chloral hydrate, + 136% vs - 0.4%. increased prescribing of alternatives was also seen in the Medicaid and Blue Cross/Blue Shield data. Medicaid benzodiazepine expenditures decreased 52% from 1988 to 1989 ($21.7 million to $10.4 million). Alternative sedative expenditures increased 115% ($3.9 million to $8.4 million). Total Medicaid psychoactive medication expenditures remained nearly constant ($46.7 million to $45.6 million). Conclusion. - Although the triplicate regulations have decreased benzodiazepine prescribing, an undesirable increase has occurred in the prescribing of less acceptable medications. The wider public health, patient care, and financial implications of triplicate benzodiazepine regulations are of concern and require further study before other jurisdictions undertake similar programs.	UNIV ROCHESTER,SCH MED & DENT,DEPT PSYCHIAT,ROCHESTER,NY 14642	University of Rochester	WEINTRAUB, M (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT COMMUNITY & PREVENT MED,BOX 644,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.							BLACKWELL B, 1973, JAMA-J AM MED ASSOC, V223, P798, DOI 10.1001/jama.1973.03220070052017; BRAHAMS D, 1990, LANCET, V336, P1372, DOI 10.1016/0140-6736(90)92914-4; EADIE JL, 1988, DEC AM MED ASS NAT S; FINKLE BS, 1979, JAMA-J AM MED ASSOC, V242, P429, DOI 10.1001/jama.242.5.429; KAUFMAN A, 1972, J AMER MED ASSOC, V221, P1504, DOI 10.1001/jama.221.13.1504; KUNIN CM, 1973, ANN INTERN MED, V79, P555, DOI 10.7326/0003-4819-79-4-555; MADDALONI M A, 1990, Veterinary and Human Toxicology, V32, P355; MARKS J, 1985, BENZODIAZEPINES USE; PRESCOTT LP, 1983, BENZODIAZEPINES MOL, P252; RALL T W, 1990, P345; ROACHE JD, 1987, J PHARMACOL EXP THER, V243, P978; RODOS JJ, 1990, J AM OSTEOPATH ASSOC, V90, P26; SHENFIELD GM, 1980, BRIT MED J, V281, P651, DOI 10.1136/bmj.281.6241.651; WOODS JH, 1988, JAMA-J AM MED ASSOC, V260, P3476, DOI 10.1001/jama.260.23.3476; 1987, NEW YORK STAT R 0831; 1990, NEW YORK STATES REGU; 1989, EPIDEMIOL NOTES, P4; 1982, WHO6TH REP; 1990, EPIDEMIOL NOTES, P5; 1990, BENZODIAZEPINE DEPEN	20	123	127	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2392	2397		10.1001/jama.266.17.2392	http://dx.doi.org/10.1001/jama.266.17.2392			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1681121				2022-12-24	WOS:A1991GM79000025
J	BRAHAMS, D				BRAHAMS, D			TRIAZOLAM SUSPENDED	LANCET			English	Editorial Material																		BRAHAMS D, 1991, LANCET, V338, P502, DOI 10.1016/0140-6736(91)90565-7; BRAHAMS D, 1991, LANCET, V338, P243, DOI 10.1016/0140-6736(91)90367-X; OSWALD I, 1991, LANCET, V338, P516, DOI 10.1016/0140-6736(91)90592-D	3	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					938	938		10.1016/0140-6736(91)91792-S	http://dx.doi.org/10.1016/0140-6736(91)91792-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681280				2022-12-24	WOS:A1991GJ89900018
J	DOHERTY, P; ASHTON, SV; MOORE, SE; WALSH, FS				DOHERTY, P; ASHTON, SV; MOORE, SE; WALSH, FS			MORPHOREGULATORY ACTIVITIES OF NCAM AND N-CADHERIN CAN BE ACCOUNTED FOR BY G PROTEIN-DEPENDENT ACTIVATION OF L-TYPE AND N-TYPE NEURONAL CA2+ CHANNELS	CELL			English	Article							NERVE GROWTH-FACTOR; CELL-ADHESION MOLECULES; NEURITE OUTGROWTH; PC12 CELLS; KINASE-C; EXTRACELLULAR-MATRIX; EXPRESSION; CALCIUM; CAM; MUSCLE	We present evidence that the morphoregulatory activities of neural cell adhesion molecule (NCAM) and N-cadherin involve activation of intracellular second messenger pathways. PC12 cells were cultured on monolayers of control 3T3 cells or 3T3 cells expressing transfected N-cadherin or NCAM. NCAM and N-cadherin directly induced a transcription-independent change in the morphology of PC12 cells from an adrenal to neuronal phenotype and also specifically increased Thy-1, but not L1/NILE or low affinity NGF receptor, immunoreactivity. The morphological response was more rapid and, in the case of N-cadherin, more substantial than that induced by NGF. It could be fully inhibited by pertussis toxin and a combination of L- and N-type Ca2+ channel antagonists, but not by broad-specificity kinase inhibitors. It was blocked, however, by the kinase inhibitor K-252b. These studies suggest that cell adhesion molecules directly alter cell phenotype and provide direct evidence for transmembrane signaling mediating both the morphological and biochemical responses induced by NCAM and N-cadherin.			DOHERTY, P (corresponding author), UNIV MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT EXPTL PATHOL,LONDON BRIDGE,LONDON SE1 9RT,ENGLAND.		Doherty, Patrick/A-8752-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BIXBY JL, 1990, J CELL BIOL, V111, P2725, DOI 10.1083/jcb.111.6.2725; BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; CAMPENOT RB, 1989, NEURON, V3, P733, DOI 10.1016/0896-6273(89)90242-0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DOHERTY P, 1987, DEVELOPMENT, V101, P605; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1987, J NEUROCHEM, V49, P610, DOI 10.1111/j.1471-4159.1987.tb02907.x; DOHERTY P, 1988, EXP CELL RES, V179, P233, DOI 10.1016/0014-4827(88)90362-X; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; DOHERTY P, 1988, J CELL BIOL, V107, P333, DOI 10.1083/jcb.107.1.333; DOHERTY P, 1988, NEUROSCI LETT, V92, P222, DOI 10.1016/0304-3940(88)90065-1; Doherty P, 1989, CURR OPIN CELL BIOL, V1, P1102, DOI 10.1016/S0955-0674(89)80057-2; DOLPHIN AC, 1990, ANNU REV PHYSIOL, V52, P243; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; ERNSBERGER U, 1989, DEV BIOL, V135, P250, DOI 10.1016/0012-1606(89)90177-2; FUJIMOTO M, 1991, NEUROSCI LETT, V122, P9, DOI 10.1016/0304-3940(91)90180-2; GREENE LA, 1984, TRENDS NEUROSCI, V7, P91, DOI 10.1016/S0166-2236(84)80164-2; GREENE LA, 1982, DEV BIOL, V91, P305, DOI 10.1016/0012-1606(82)90037-9; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P424; GUNDERSEN RW, 1987, DEV BIOL, V121, P423, DOI 10.1016/0012-1606(87)90179-5; GUNNING PW, 1981, J NEUROSCI, V1, P1085; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; INOUE K, 1988, J BIOL CHEM, V263, P8157; KATER SB, 1991, J NEUROSCI, V11, P891; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LENDAHL U, 1990, TRENDS NEUROSCI, V13, P132, DOI 10.1016/0166-2236(90)90004-T; MANN DA, 1989, J NEUROCHEM, V53, P1581, DOI 10.1111/j.1471-4159.1989.tb08555.x; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; MATTHIES HJG, 1987, J NEUROSCI, V7, P1198; MOORE SE, 1987, J CELL BIOL, V105, P1377, DOI 10.1083/jcb.105.3.1377; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1177, DOI 10.1083/jcb.107.3.1177; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; PRENTICE HM, 1987, EMBO J, V6, P1859, DOI 10.1002/j.1460-2075.1987.tb02444.x; REBER BFX, 1991, J PHYSIOL-LONDON, V435, P145, DOI 10.1113/jphysiol.1991.sp018502; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SCOTT RH, 1990, MOL PHARMACOL, V38, P711; SEILHEIMER B, 1988, J CELL BIOL, V107, P341, DOI 10.1083/jcb.107.1.341; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1991, DEVELOPMENT, V251, P1451; TOGARI A, 1985, J NEUROSCI, V5, P307; WALSH FS, 1990, J NEUROCHEM, V55, P805, DOI 10.1111/j.1471-4159.1990.tb04563.x; WALSH FS, 1991, IN PRESS SEMIN NEURO, V3	57	388	395	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					21	33		10.1016/0092-8674(91)90569-K	http://dx.doi.org/10.1016/0092-8674(91)90569-K			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1680564				2022-12-24	WOS:A1991GJ32000004
J	MCKHANN, GM; CORNBLATH, DR; HO, T; LI, CY; BAI, AY; WU, HS; YEI, QF; ZHANG, WC; ZHAORI, Z; JIANG, Z; GRIFFIN, JW; ASBURY, AK				MCKHANN, GM; CORNBLATH, DR; HO, T; LI, CY; BAI, AY; WU, HS; YEI, QF; ZHANG, WC; ZHAORI, Z; JIANG, Z; GRIFFIN, JW; ASBURY, AK			CLINICAL AND ELECTROPHYSIOLOGICAL ASPECTS OF ACUTE PARALYTIC DISEASE OF CHILDREN AND YOUNG-ADULTS IN NORTHERN CHINA	LANCET			English	Article								Acute peripheral nervous system diseases leading to paralysis in children are rare in Europe and the USA, whereas epidemics of a Guillain-Barre-like syndrome occur annually among children in rural parts of northern China. To clarify the features of this disorder 36 patients, aged 15 months to 37 years (median 7) with this syndrome were investigated; 91% were from rural areas. In 47%, a prodromal illness was reported in the preceding 4 weeks. Leg weakness and resistance to neck flexion were the earliest symptoms. The weakness ascended rapidly and symmetrically to affect the arms and respiratory muscles, with maximum weakness occurring a mean of 6 days after onset of weakness. Bulbar weakness occurred in 61% of patients, but only 1 had extraocular paresis. Respiratory assistance was needed by 31% of patients. Tendon reflexes were lost as weakness developed. 42% of patients had raised concentrations of protein in the cerebrospinal fluid, and the mean cell count was 3 cells/mu-l (range 0-12/mu-l). Electrodiagnostic studies in 22 patients showed severe reductions in motor evoked amplitudes from distal stimulation. Sensory action potentials were normal. Electromyography revealed denervation potentials in limb muscles. The distinctive epidemiological, clinical, and neurophysiological characteristics of this illness suggest that the disorder is different from both Guillain-Barre syndrome and poliomyelitis. The neurophysiological findings support the hypothesis that the disorder is a reversible distal motor nerve terminal or anterior horn cell lesion.	HEBEI MED COLL,SECOND TEACHING HOSP,DEPT NEUROL,SHIJIAZHUANG,PEOPLES R CHINA; BEIJING CHILDRENS HOSP,DEPT NEUROL,BEIJING,PEOPLES R CHINA; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104	Capital Medical University; Johns Hopkins University; University of Pennsylvania			Ho, Tony W/F-1019-2011		NINDS NIH HHS [NS22849, NS23936] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023936, P01NS022849] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERS JW, 1985, MUSCLE NERVE, V8, P528, DOI 10.1002/mus.880080609; ALTER M, 1990, ANN NEUROL, V27, pS7, DOI 10.1002/ana.410270704; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; BROWN WF, 1984, BRAIN, V107, P219, DOI 10.1093/brain/107.1.219; CHIAE CK, 1986, CHINESE J PSYCHIATRY, V19, P149; CORNBLATH D R, 1990, Neurology, V40, P458; CORNBLATH DR, 1990, ANN NEUROL, V27, pS17, DOI 10.1002/ana.410270706; HUSHENG W, 1988, BRAIN DEV, V10, P147; PAULSON GW, 1970, DEV MED CHILD NEUROL, V12, P604; RAMOSALV.M, 1969, J AMER MED ASSOC, V207, P1481; SUN JY, 1991, CHINESE J NEUROL PSY, V15, P75; WADIA NH, 1983, J NEUROL NEUROSUR PS, V46, P599, DOI 10.1136/jnnp.46.7.599; WITTE JJ, 1966, AM J EPIDEMIOL, V83, P189, DOI 10.1093/oxfordjournals.aje.a120574; XUE G, 1980, ZHOGHUA YUFANGYIXUE, V14, P123; YOHANNAN MD, 1991, J INFECTION, V22, P129, DOI 10.1016/0163-4453(91)91503-P; ZHANG ZL, 1979, CHIN J NEUROL PSYCHI, V12, P17; ZHAO BX, 1981, ANN NEUROL, V9, P146, DOI 10.1002/ana.410090720	17	180	188	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					593	597		10.1016/0140-6736(91)90606-P	http://dx.doi.org/10.1016/0140-6736(91)90606-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1679153				2022-12-24	WOS:A1991GD80900003
J	TODD, JA; AITMAN, TJ; CORNALL, RJ; GHOSH, S; HALL, JRS; HEARNE, CM; KNIGHT, AM; LOVE, JM; MCALEER, MA; PRINS, JB; RODRIGUES, N; LATHROP, M; PRESSEY, A; DELARATO, NH; PETERSON, LB; WICKER, LS				TODD, JA; AITMAN, TJ; CORNALL, RJ; GHOSH, S; HALL, JRS; HEARNE, CM; KNIGHT, AM; LOVE, JM; MCALEER, MA; PRINS, JB; RODRIGUES, N; LATHROP, M; PRESSEY, A; DELARATO, NH; PETERSON, LB; WICKER, LS			GENETIC-ANALYSIS OF AUTOIMMUNE TYPE-1 DIABETES-MELLITUS IN MICE	NATURE			English	Article							DNA POLYMORPHISMS; NOD MOUSE; NONOBESE; INSULITIS; EXPRESSION; PREVENTION; LINKAGE; HETEROGENEITY; RECOMBINATION; CONSTRUCTION	Two genes, Idd-3 and Idd-4, that influence the onset of autoimmune type 1 diabetes in the nonobese diabetic mouse have been located on chromosomes 3 and 11, outside the chromosome 17 major histocompatibility complex. A genetic map of the mouse genome, analysed using the polymerase chain reaction, has been assembled specifically for the study. On the basis of comparative maps of the mouse and human genomes, the homologue of Idd-3 may reside on human chromosomes 1 or 4 and Idd-4 on chromosome 17.	CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND; CTR ETUD POLYMORPHISME HUMAINE,F-75010 PARIS,FRANCE; MERCK SHARP & DOHME LTD,DEPT CELLULAR & MOLEC PHARMACOL,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,AUTOIMMUNE DIS RES,RAHWAY,NJ 07065	Merck & Company; Merck & Company	TODD, JA (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND.		Todd, John A/A-3542-2010; Wicker, Linda S/F-7384-2010	Todd, John A/0000-0003-2740-8148; Prins, Jan-Bas/0000-0002-1831-8522; Aitman, Timothy/0000-0002-7875-4502	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; AITMAN TJ, IN PRESS MAMMALIAN G; BOTTAZZO GF, 1989, BRIT MED BULL, V45, P37, DOI 10.1093/oxfordjournals.bmb.a072319; CARTER TC, 1951, J GENET, V50, P307, DOI 10.1007/BF02996226; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CORNALL RJ, IN PRESS GENOMICS; FAUSTMAN D, 1989, DIABETES, V38, P1462, DOI 10.2337/diabetes.38.11.1462; HATAMORI N, 1990, DIABETES, V39, P1070, DOI 10.2337/diabetes.39.9.1070; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEARNE CM, IN PRESS MAMMALIAN G; HEROLD KC, 1990, DIABETES, V39, P815, DOI 10.2337/diabetes.39.7.815; HILLYARD AL, 1990, LOCUS MAP MOUSE COMP; JANSSEN LAJ, 1990, GENOMICS, V8, P237, DOI 10.1016/0888-7543(90)90277-2; KNIGHT AM, 1990, MOL CELL PROBE, V4, P497, DOI 10.1016/0890-8508(90)90008-N; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LATHROP GM, 1988, GENOMICS, V2, P157; LITT M, 1989, AM J HUM GENET, V44, P397; LIVINGSTONE A, 1991, J IMMUNOL, V146, P529; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; MIYAZAKI T, 1990, NATURE, V345, P722, DOI 10.1038/345722a0; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NEUMANN PE, IN PRESS P NATN ACAD; OLDSTONE MBA, 1988, SCIENCE, V239, P500, DOI 10.1126/science.3277269; OLMOS P, 1988, DIABETOLOGIA, V31, P747, DOI 10.1007/BF00274777; OTT J, 1985, ANAL HUMAN GENETIC L; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; PATERSON AH, 1991, GENETICS, V127, P181; PHILBRICK WM, 1990, EMBO J, V9, P2485, DOI 10.1002/j.1460-2075.1990.tb07427.x; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; RICE J, 1989, GENET EPIDEMIOL, V6, P161, DOI 10.1002/gepi.1370060130; RISCH N, 1987, AM J HUM GENET, V40, P1; SERREZE DV, 1988, J IMMUNOL, V140, P3801; SIBLEY RK, 1985, LAB INVEST, V53, P132; SLATTERY RM, 1990, NATURE, V345, P724, DOI 10.1038/345724a0; Suzuki T, 1987, IMMUNE DEFICIENT ANI, P112, DOI DOI 10.1159/000413303; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; THOMSON G, 1989, GENET EPIDEMIOL, V6, P155, DOI 10.1002/gepi.1370060129; THOMSON G, 1988, AM J HUM GENET, V43, P799; TODD JA, 1990, IMMUNOL TODAY, V11, P122, DOI 10.1016/0167-5699(90)90049-F; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE R, 1985, NATURE, V313, P101, DOI 10.1038/313101a0; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639; WICKER LS, 1989, J IMMUNOL, V142, P781; WICKER LS, IN PRESS P P S BIOME; WICKER LS, IN PRESS FRONTIERS D, V2; WILBERZ S, 1991, DIABETOLOGIA, V34, P2, DOI 10.1007/BF00404016	50	506	508	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					542	547		10.1038/351542a0	http://dx.doi.org/10.1038/351542a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1675432				2022-12-24	WOS:A1991FR03400049
J	HAMMANS, SR; SWEENEY, MG; BROCKINGTON, M; MORGANHUGHES, JA; HARDING, AE				HAMMANS, SR; SWEENEY, MG; BROCKINGTON, M; MORGANHUGHES, JA; HARDING, AE			MITOCHONDRIAL ENCEPHALOPATHIES - MOLECULAR GENETIC DIAGNOSIS FROM BLOOD-SAMPLES	LANCET			English	Article							DNA; MUTATION; DELETIONS; EPILEPSY; MERRF	Point mutations of mitochondrial DNA have been described in the muscle of patients with syndromes of myoclonic epilepsy and ragged red fibres (MERRF) and of mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS). We have found the MERRF mutation in members of 6 British kindreds; 2 of these had unusual phenotypes but all index patients had myoclonus. The MELAS mutation was detected in 17 patients from 16 families, who had a wide range of clinical features that particularly affected the central nervous system; stroke-like episodes were observed in 10.3 patients with mitochondrial DNA mutations did not have ragged red fibres on muscle biopsy, generally considered to be the morphological hallmark of mitochondrial diseases. In all 6 patients with the MERRF mutation, and 10 of 11 with the MELAS mutation, the genetic defect was easily detected in blood cells as well as muscle (blood samples were not available in 6 patients with MELAS mutations in muscle). Molecular genetic analysis of blood samples represents an inexpensive and reliable screening test for mitochondrial encephalopathies, and use of such techniques could influence diagnosis and genetic counselling in patients with seizure disorders and young-onset stroke.	UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,QUEEN SQ,LONDON WC1N 3BG,ENGLAND	University of London; University College London								AICARDI J, 1990, ANN NEUROL, V28, P113; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; HOLT IJ, 1990, AM J HUM GENET, V46, P428; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; POULTON J, 1989, LANCET, V1, P236; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; ZEVIANI M, 1991, AM J HUM GENET, V48, P203	11	173	175	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1991	337	8753					1311	1313		10.1016/0140-6736(91)92981-7	http://dx.doi.org/10.1016/0140-6736(91)92981-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674297				2022-12-24	WOS:A1991FP08400004
J	COURSAGET, P; YVONNET, B; GILKS, WR; WANG, CC; DAY, NE; CHIRON, JP; DIOPMAR, I				COURSAGET, P; YVONNET, B; GILKS, WR; WANG, CC; DAY, NE; CHIRON, JP; DIOPMAR, I			SCHEDULING OF REVACCINATION AGAINST HEPATITIS-B VIRUS	LANCET			English	Article							ENDEMIC AREA; ANTI-HBS; VACCINE; DIALYSIS; EFFICACY; INFANTS	Studies have shown that to maintain protection against infection after a primary course of hepatitis B immunisation, revaccination can be scheduled on the basis of an anti-hepatitis B virus surface antigen (anti-HBs) titre obtained 1 month after the booster dose. However, schemes which require post-booster testing may present practical difficulties. We applied a random-effects regression model to data from 118 Senegalese infants given three injections of hepatitis B vaccine about 6 weeks apart and a booster injection at 13 months, and show that revaccination can be scheduled on the basis of an anti-HBs titre recorded at the time of the booster dose. We also show that titre-at-booster is no less accurate in predicting future titre than 1-month post-booster titre. In several other studies the post-booster decline in anti-HBs conforms to the same mathematical description, indicating the generality of our findings.	FAC PHARM TOURS, INST VIROL TOURS, TOURS, FRANCE; FAC MED & PHARM DAKAR, DAKAR, SENEGAMBIA; ACAD SINICA, INST STAT, TAIPEI 115, TAIWAN; FAC PHARM TOURS, MICROBIOL LAB, TOURS, FRANCE	Academia Sinica - Taiwan								BENHAMOU E, 1986, NEW ENGL J MED, V314, P1710; COUROUCE AM, 1984, NEW ENGL J MED, V311, P1515; COURSAGET P, 1986, LANCET, V2, P1143; CROSNIER J, 1981, LANCET, V1, P455; DENTICO P, 1990, COLLOQ INSE, V194, P325; GELFAND AE, 1990, J AM STAT ASSOC, V85, P398, DOI 10.2307/2289776; GEMAN S, 1984, IEEE T PATTERN ANAL, V6, P721, DOI 10.1109/TPAMI.1984.4767596; GESEMANN M, 1989, LANCET, V2, P1274; GILKS WR, 1990, COLLOQ INSE, V194, P409; GILKS WR, 1989, LANCET, V2, P1273; GOUDEAU A, 1990, COLLOQ INSE, V194, P123; GROB PJ, 1990, COLLOQ INSE, V194, P437; GROB PJ, 1985, SCHWEIZ MED WSCHR, V115, P394; JILG W, 1990, LANCET, V335, P173, DOI 10.1016/0140-6736(90)90050-F; LAPLANCHE A, 1987, LANCET, V1, P1206; NOMMENSEN FE, 1990, LANCET, V335, P479, DOI 10.1016/0140-6736(90)90716-I; NOMMENSEN FE, 1989, LANCET, V2, P847; OON CJ, 1990, COLLOQ INSE, V194, P475; RAWAL BK, 1989, LANCET, V2, P1274; SIEGEL S, 1956, NONPARAMETRIC STAT, P47; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; YVONNET B, 1987, J MED VIROL, V22, P315, DOI 10.1002/jmv.1890220404; ZACHOVAL R, 1984, J INFECT DIS, V150, P112, DOI 10.1093/infdis/150.1.112; ZANETTI AR, 1990, COLLOQ INSE, V194, P79; 1988, LANCET, V1, P875	25	64	64	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1180	1183		10.1016/0140-6736(91)92857-X	http://dx.doi.org/10.1016/0140-6736(91)92857-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673737				2022-12-24	WOS:A1991FM26100002
J	MCKINNEY, RE; MAHA, MA; CONNOR, EM; FEINBERG, J; SCOTT, GB; WULFSOHN, M; MCINTOSH, K; BORKOWSKY, W; MODLIN, JF; WEINTRUB, P; ODONNELL, K; GELBER, RD; ROGERS, GK; LEHRMAN, SN; WILFERT, CM				MCKINNEY, RE; MAHA, MA; CONNOR, EM; FEINBERG, J; SCOTT, GB; WULFSOHN, M; MCINTOSH, K; BORKOWSKY, W; MODLIN, JF; WEINTRUB, P; ODONNELL, K; GELBER, RD; ROGERS, GK; LEHRMAN, SN; WILFERT, CM			A MULTICENTER TRIAL OF ORAL ZIDOVUDINE IN CHILDREN WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; INFECTION; AZT; SURVIVAL; TYPE-1	Background and Methods. Zidovudine has been shown to be an effective antiretroviral treatment in adults with human immunodeficiency virus (HIV) infection. We examined the safety of zidovudine and the tolerance of and therapeutic response to the drug in 88 children with advanced HIV disease. During a 24-week outpatient trial, zidovudine (180 mg per square meter of body-surface area per dose) was given by mouth every six hours and serial measurements were made of clinical, immunologic, and virologic indexes. Children who completed 24 weeks of treatment were permitted to continue receiving zidovudine. Results. Of the 88 children (mean age, 3.9 years; range, 4 months to 11 years), 61 completed the initial 24-week trial, and 49 continued to receive zidovudine for up to 90 weeks (median follow-up, 56 weeks). The patients generally tolerated zidovudine well. One or more episodes of hematologic toxicity occurred in 54 children (61 percent) - anemia (hemoglobin level, < 75 g per liter) in 23 children (26 percent) and neutropenia (neutrophil count, < 0.75 X 10(9) per liter) in 42 (48 percent). Many of these abnormalities resolved spontaneously, but 30 children required transfusions or a modification of the dose of zidovudine. Only three children had to stop receiving the drug because of hematologic toxicity. Kaplan-Meier analysis demonstrated that the probability of survival was 0.89 after 24 weeks and 0.79 after 52 weeks. There was marked improvement in weight gain, cognitive function (mainly in children < 3 years old), serum and cerebrospinal fluid concentrations of p24 antigen, and the proportion of cerebrospinal fluid cultures negative for HIV. CD4+ lymphocyte counts (mean at base line, 0.263 X 10(9) per liter) improved during the first 12 weeks, although the improvement was not sustained through the 24th week. Conclusions. Zidovudine in a dose of 180 mg per square meter every six hours can be safely administered to children with advanced HIV disease. The resultant clinical, immunologic, and virologic improvements in children are similar to those reported with zidovudine in adults.	BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709; NEW JERSEY CHILDRENS HOSP,NEWARK,NJ; NIAID,DIV AIDS,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT & EPIDEMIOL,BOSTON,MA 02115; UNIV MIAMI,SCH MED,DEPT PEDIAT,MIAMI,FL 33152; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,BOSTON,MA 02115; NYU,SCH MED,DEPT PEDIAT,NEW YORK,NY 10003; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Burroughs Wellcome Fund; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Miami; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; New York University; Johns Hopkins University	MCKINNEY, RE (corresponding author), DUKE UNIV,MED CTR,SCH MED,DEPT PEDIAT,BOX 3461,DURHAM,NC 27710, USA.			feinberg, judith/0000-0003-4206-7214				BALIS FM, 1989, J PEDIATR-US, V114, P880, DOI 10.1016/S0022-3476(89)80158-1; BALIS FM, 1989, ANN INTERN MED, V110, P279, DOI 10.7326/0003-4819-110-4-279; CHAISSON RE, 1988, ARCH INTERN MED, V148, P2151, DOI 10.1001/archinte.148.10.2151; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JACKSON GG, 1988, ANN INTERN MED, V108, P175, DOI 10.7326/0003-4819-108-2-175; KRASINSKI K, 1989, PEDIATR INFECT DIS J, V8, P216; MCKINNEY RE, 1990, J PEDIATR-US, V116, P640, DOI 10.1016/S0022-3476(05)81619-1; MICHALSKI FJ, 1989, YALE J BIOL MED, V62, P93; PARKS WP, 1988, J ACQ IMMUN DEF SYND, V1, P125; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; ROWE PC, 1987, H LANE HDB MANUAL PE, P325; SCHMITT FA, 1988, NEW ENGL J MED, V319, P1573, DOI 10.1056/NEJM198812153192404; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1987, MMWR S, V36, pS1; 1969, BAYLEY SCALES INFANT; 1989, MMWR, V38, P1; 1972, MCCARTHY SCALES CHIL	23	199	202	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1991	324	15					1018	1025		10.1056/NEJM199104113241503	http://dx.doi.org/10.1056/NEJM199104113241503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF771	1672443				2022-12-24	WOS:A1991FF77100003
J	CONNOR, E; BAGARAZZI, M; MCSHERRY, G; HOLLAND, B; BOLAND, M; DENNY, T; OLESKE, J				CONNOR, E; BAGARAZZI, M; MCSHERRY, G; HOLLAND, B; BOLAND, M; DENNY, T; OLESKE, J			CLINICAL AND LABORATORY CORRELATES OF PNEUMOCYSTIS-CARINII PNEUMONIA IN CHILDREN INFECTED WITH HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNE-DEFICIENCY SYNDROME; PROGNOSTIC FACTORS; LIFE EXPECTANCY; SURVIVAL; DISEASE; AIDS	The case histories of 27 children with Pneumocystis carinii pneumonia (PCP) who were followed up in the AIDS Program at the Children's Hospital of New Jersey, Newark, are reviewed. The mean and median age at PCP diagnosis were 10.8 and 7.7 months, respectively. All of the children had other clinical evidence of infection with the human immunodeficiency virus that was documented prior to the diagnosis of PCP or found at the time of PCP diagnosis. Most patients who presented to the hospital were acutely ill, and complications of treatment occurred in 70%. Overall, 89% of the patients died and 70% survived for less than 6 months after diagnosis of PCP. Median survival after the diagnosis of PCP was only 2.0 months and the median life span of children with PCP was only 14.4 months. Only 40% of children with PCP had CD4 lymphocyte counts at or below the threshold for institution of PCP prophylaxis in adults of 200 X 10(6) cells/L (200 cells/mm3).	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PEDIAT,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PREVENT MED,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	CONNOR, E (corresponding author), CHILDRENS HOSP NEW JERSEY,DEPT PEDIAT,AIDS PROGRAM,15 S 9TH ST,NEWARK,NJ 07107, USA.		Bagarazzi, Mark L/AAU-1383-2021; Oleske, James/C-1951-2016	Oleske, James/0000-0003-2305-5605; Denny, Thomas/0000-0002-7364-8276	NIAID NIH HHS [1 U01 AI25883-01] Funding Source: Medline; PHS HHS [U64/CCU202219-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025883] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN LJ, 1989, AM J DIS CHILD, V143, P775, DOI 10.1001/archpedi.1989.02150190025013; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; DENNY TN, 1990, PEDIATR RES, V27, P155; FALLOON J, 1989, J PEDIATR-US, V114, P1, DOI 10.1016/S0022-3476(89)80596-7; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; KALES CP, 1987, ARCH INTERN MED, V147, P1413; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; LEIBOVITZ E, 1990, NEW ENGL J MED, V323, P531, DOI 10.1056/NEJM199008233230807; MCCULLOUGH PC, 1986, RESPIRATION, V50, P286, DOI 10.1159/000194940; MCSHERRY G, 1988, 28TH INT C ANT AG CH; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; ROGERS MF, 1987, PEDIATRICS, V79, P1008; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; RUBINSTEIN A, 1986, J PEDIATR-US, V108, P498, DOI 10.1016/S0022-3476(86)80822-8; SANDERSLAUFER D, 1990, PEDIATR RES, V27, P183; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1989, MMWR S5, V38, P1; 1987, MMWR, V36, P225	25	53	53	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1693	1697		10.1001/jama.265.13.1693	http://dx.doi.org/10.1001/jama.265.13.1693			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1672168				2022-12-24	WOS:A1991FD65900024
J	MASUDA, T; SHIMURA, S; SASAKI, H; TAKISHIMA, T				MASUDA, T; SHIMURA, S; SASAKI, H; TAKISHIMA, T			SURFACTANT APOPROTEIN-A CONCENTRATION IN SPUTUM FOR DIAGNOSIS OF PULMONARY ALVEOLAR PROTEINOSIS	LANCET			English	Article							HUMAN AMNIOTIC-FLUID; MONOCLONAL-ANTIBODIES; IMMUNOASSAY; LAVAGE; MANAGEMENT	Pulmonary alveolar proteinosis (PAP), a disease characterised by accumulation of surfactant in alveoli, is diagnosed on the basis of invasive biopsy procedures. We have measured apoprotein A (SP-A) concentrations in sputum to see if this is useful for the diagnosis of PAP. Sputum samples from three patients with PAP and twenty patients with other pulmonary disease were assayed using monoclonal antibodies to SP-A. SP-A concentrations were 400 times higher in patients with PAP than in the controls, suggestions that this measurement is useful for the diagnosis of PAP, especially where lung biopsy is contraindicated.	TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,SENDAI,MIYAGI 980,JAPAN	Tohoku University								AKINO T, 1989, CLIN CHEM, V34, P1513; CLAYPOOL WD, 1984, CHEST, V85, P605; CORRIN B, 1970, THORAX, V25, P230, DOI 10.1136/thx.25.2.230; COSTELLO JF, 1975, THORAX, V30, P121, DOI 10.1136/thx.30.2.121; GONZALEZROTHI RJ, 1986, CHEST, V90, P656, DOI 10.1378/chest.90.5.656; HONDA Y, 1989, CLIN CHIM ACTA, V181, P11, DOI 10.1016/0009-8981(89)90312-4; KING RJ, 1972, AM J PHYSIOL, V223, P715, DOI 10.1152/ajplegacy.1972.223.3.715; KUROKI Y, 1985, BIOCHIM BIOPHYS ACTA, V836, P201; KUROKI Y, 1985, PEDIATR RES, V19, P1017, DOI 10.1203/00006450-198510000-00013; LARSON RK, 1965, ANN INTERN MED, V62, P292, DOI 10.7326/0003-4819-62-2-292; MARTIN RJ, 1980, AM REV RESPIR DIS, V121, P819; ROGERS RM, 1978, AM REV RESPIR DIS, V118, P255; SATO S, 1978, TOHOKU J EXP MED, V126, P257; SHIMIZU H, 1989, TOHOKU J EXP MED, V157, P269, DOI 10.1620/tjem.157.269; SINGH G, 1983, CHEST, V83, P82, DOI 10.1378/chest.83.1.82; SMITH LJ, 1980, CHEST, V78, P765, DOI 10.1378/chest.78.5.765; SNYDER JM, 1988, PEDIATR RES, V24, P728, DOI 10.1203/00006450-198812000-00016; VIDONE RA, 1966, DIS CHEST, V49, P326, DOI 10.1378/chest.49.3.326	18	33	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					580	582		10.1016/0140-6736(91)91640-G	http://dx.doi.org/10.1016/0140-6736(91)91640-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671943				2022-12-24	WOS:A1991FA70200004
J	RUSKIN, J; LARIVIERE, M				RUSKIN, J; LARIVIERE, M			LOW-DOSE COTRIMOXAZOLE FOR PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA IN HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE	LANCET			English	Article							SULFAMETHOXAZOLE; CHEMOPROPHYLAXIS; PENTAMIDINE; AIDS	The efficacy and tolerability of low, intermittent doses of co-trimoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole given Monday, Wednesday, Friday) for prophylaxis against Pneumocystis carinii pneumonia (PCP) was assessed retrospectively in 116 patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex at high risk of PCP. 92% were receiving concomitant zidovudine. 71 with previous episode(s) of PCP were followed a mean of 18.5 months (range 3-42). 45 without past PCP but with depletion of CD4 cells to < 200/mu-l were observed for a mean of 24.2 months (range 9-40). PCP did not develop in any patient on co-trimoxazole. 33 (28%) had side-effects, mainly rash, pruritus, and nausea. 15 discontinued co-trimoxazole, but only 11 (9%), who withdrew in the first month, were clearly drug-intolerant. Thus, low-dose, thrice weekly cotrimoxazole completely prevents AIDS-associated PCP, is cost-effective, and well tolerated by more than 85% of patients. Controlled comparisons of this regimen with other prophylactic agents are warranted.			RUSKIN, J (corresponding author), KAISER PERMANENTE MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,1505 N EDGEMONT ST,LOS ANGELES,CA 90027, USA.							BERNARD EM, 1989, 5 INT C AIDS MONTR; BIGBY TD, 1986, AM REV RESPIR DIS, V133, P515; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; GIRARD PM, 1989, LANCET, V1, P1348; GLUCKSTEIN D, 1988, 4 INT C AIDS STOCKH; GOLDEN JA, 1989, LANCET, V1, P654; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1979, ANTIMICROB AGENTS CH, V16, P333, DOI 10.1128/AAC.16.3.333; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; NICHOLAS P, 1990, 6 INT C AIDS SAN FRA; PESANTI EL, 1980, J INFECT DIS, V141, P775, DOI 10.1093/infdis/141.6.775; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; TELZAK EE, 1990, REV INFECT DIS, V12, P380; [No title captured]; 1989, AIDS WKLY SURV  0130, P1; 1989, MMWR, V38, P1	20	126	126	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					468	471		10.1016/0140-6736(91)93402-U	http://dx.doi.org/10.1016/0140-6736(91)93402-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671479				2022-12-24	WOS:A1991EY88700013
J	GRANDA, H; GISPERT, S; DORTICOS, A; MARTIN, M; CUADRAS, Y; CALVO, M; MARTINEZ, G; ZAYAS, MA; OLIVA, JA; HEREDERO, L				GRANDA, H; GISPERT, S; DORTICOS, A; MARTIN, M; CUADRAS, Y; CALVO, M; MARTINEZ, G; ZAYAS, MA; OLIVA, JA; HEREDERO, L			CUBAN PROGRAM FOR PREVENTION OF SICKLE-CELL DISEASE	LANCET			English	Article							DNA ANALYSIS; HEMOGLOBIN; DIAGNOSIS; ANEMIA	The percentage of carriers of the sickle cell gene in Cuba ranges from 3 to 7% in different regions. In 1983 the National Medical Genetics Centre initiated a programme for the control of sickle cell disease, which was started in Havana and later extended nationwide. The programme is based on mass education, screening and supportive genetic counselling, care of affected individuals, and availability of prenatal diagnosis. 806 935 pregnant women had been screened by the end of 1989: 29 913 (3.7%) were heterozygous, homozygous or doubly heterozygous for abnormal haemoglobin. 19 686 fathers (67%) were also tested: 1268 at-risk couples were detected. 531 elected to have prenatal diagnosis; 404 results were obtained and 98 affected fetuses (SS or SC) found. In 72 cases the pregnancy was terminated.	S PAEDIAT HOSP, DEPT PROV GENET, Santiago De Cuba, CUBA; MINIST PUBL HLTH CUBA, NATL INST HAEMATOL & IMMUNOL, HAVANA, CUBA; GYNECO OBSTET HOSP RAMON GONZALEZ CORO, PROV DEPT PRENATAL DIAG, HAVANA, CUBA; PAEDIAT HOSP GUANTANAMO, DEPT PROV GENET, GUANTANAMO, CUBA		GRANDA, H (corresponding author), NATL CTR MED GENET, HIGHER INST MED SCI,DEPT BIOCHEM,31 AVE,3102, PLAYA 16, HAVANA, CUBA.							BASSET P, 1978, BLOOD, V51, P971; CHANG JC, 1982, NEW ENGL J MED, V307, P30, DOI 10.1056/NEJM198207013070105; GRANDA-I H, 1987, American Journal of Human Genetics, V41, pA276; HEREDERO L, 1974, HUMANGENETIK, V21, P167, DOI 10.1007/BF00281035; HEREDERO L, 1976, CLIN CHIM ACTA, V71, P515; HEREDERO L, 1974, REV CUB PEDIATRIA, V46; KAN YW, 1978, LANCET, V2, P910; ORKIN SH, 1982, NEW ENGL J MED, V307, P32, DOI 10.1056/NEJM198207013070106; WAIKAN Y, 1978, P NATL ACAD SCI USA, V75, P5631, DOI 10.1073/pnas.75.11.5631	9	31	35	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 19	1991	337	8734					152	153						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670797				2022-12-24	WOS:A1991ET67900013
J	DEBATIN, KM; GOLDMANN, CK; BAMFORD, R; WALDMANN, TA; KRAMMER, PH				DEBATIN, KM; GOLDMANN, CK; BAMFORD, R; WALDMANN, TA; KRAMMER, PH			MONOCLONAL-ANTIBODY-MEDIATED APOPTOSIS IN ADULT T-CELL LEUKEMIA	LANCET			English	Article									GERMAN CANC RES CTR,DIV IMMUNOGENET,W-6900 HEIDELBERG 1,GERMANY; NCI,METAB BRANCH,BETHESDA,MD 20205	Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	DEBATIN, KM (corresponding author), UNIV HEIDELBERG,CHILDRENS HOSP,ONCOL IMMUNOL SECT,NEUENHEIMER FELD 150,W-6900 HEIDELBERG,GERMANY.		Debatin, Klaus-Michael/J-9704-2014; Waldmann, Thomas/AAT-5972-2021	Debatin, Klaus-Michael/0000-0002-8397-1886; Waldmann, Thomas/0000-0003-4500-6660				ARIMA N, 1986, BLOOD, V68, P779; BRODER S, 1984, ANN INTERN MED, V100, P543, DOI 10.7326/0003-4819-100-4-543; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; GREENE WC, 1986, ANN INTERN MED, V105, P560, DOI 10.7326/0003-4819-105-4-560; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UCHIYAMA T, 1988, BLOOD, V72, P1182; WALDMANN TA, 1988, BLOOD, V72, P1805; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	14	156	158	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 3	1990	335	8688					497	500		10.1016/0140-6736(90)90735-N	http://dx.doi.org/10.1016/0140-6736(90)90735-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT015	1689786				2022-12-24	WOS:A1990CT01500003
J	YAQOOB, M; MCCLELLAND, P; BELL, GM; AHMAD, R; BAKRAN, A				YAQOOB, M; MCCLELLAND, P; BELL, GM; AHMAD, R; BAKRAN, A			BLADDER-TUMORS IN PARAPLEGIC PATIENTS ON RENAL REPLACEMENT THERAPY	LANCET			English	Note							SPINAL-CORD INJURY; CANCER	Fourteen adult patients with end-stage renal disease due to spina bifida or spinal-cord injury underwent regular haemodialysis for 3-120 (mean 20) months. Seven of these patients received renal transplants. Urinary bladder tumours developed in four of the fourteen patients (three squamous-cell carcinoma in patients still on dialysis, one poorly differentiated transitional-cell carcinoma in a patient after successful transplantation). All four had widespread metastatic disease and died within 8 weeks of the diagnosis of cancer. We recommend regular urological evaluation for patients with neurogenic bladder even after initiation of dialysis treatment. Total cystectomy before transplantation might greatly reduce the risk of these rare tumours.			YAQOOB, M (corresponding author), ROYAL LIVERPOOL UNIV HOSP,RENAL UNIT,PRESCOT ST,LIVERPOOL L7 8XP,ENGLAND.							BROECKER BH, 1981, J UROLOGY, V125, P196, DOI 10.1016/S0022-5347(17)54963-0; ELMASRI WS, 1981, PARAPLEGIA, V19, P265, DOI 10.1038/sc.1981.52; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; GRUBER SA, 1991, TRANSPLANT P, V23, P1104; KAUFMAN JM, 1977, J UROLOGY, V118, P967, DOI 10.1016/S0022-5347(17)58266-X; Melzak J, 1966, Paraplegia, V4, P85; MIRAHMADI MK, 1982, PARAPLEGIA, V20, P43, DOI 10.1038/sc.1982.5; MURALIKRISHNA GS, 1989, BRIT MED J, V299, P1506, DOI 10.1136/bmj.299.6714.1506; PENN I, 1991, TRANSPLANT P, V23, P1101; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607	10	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1554	1555		10.1016/0140-6736(91)92374-B	http://dx.doi.org/10.1016/0140-6736(91)92374-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683973				2022-12-24	WOS:A1991GW03600005
J	SZABO, A; DALMAU, J; MANLEY, G; ROSENFELD, M; WONG, E; HENSON, J; POSNER, JB; FURNEAUX, HM				SZABO, A; DALMAU, J; MANLEY, G; ROSENFELD, M; WONG, E; HENSON, J; POSNER, JB; FURNEAUX, HM			HUD, A PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGEN, CONTAINS RNA-BINDING DOMAINS AND IS HOMOLOGOUS TO ELAV AND SEX-LETHAL	CELL			English	Article							GENE-PRODUCT; LUNG-CANCER; DROSOPHILA; PROTEINS; ANTIBODY; NEURONS	A neuronal antigen (HuD) recognized by the sera of patients with antibody-associated paraneoplastic encephalomyelitis has been isolated by screening a lambda cerebellar expression library. The recombinant antigen provides an unambiguous assay for this rare condition associated with small cell lung cancer. The recombinant antigen has been used to identify specific infiltrating lymphocytes in tumors and affected brain tissues of patients with antibody-associated paraneoplastic encephalomyelitis and sensory neuronopathy. HuD mRNA is uniquely expressed in brain tissue. The HuD protein shows a remarkable homology to the Drosophila proteins Elav and Sex-lethal and is likely to play a role in neuron-specific RNA processing.	MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	SZABO, A (corresponding author), MEM SLOAN KETTERING CANC CTR,MOLEC NEUROONCOL LAB,1275 YORK AVE,NEW YORK,NY 10021, USA.			furneaux, henry/0000-0003-2212-1017; Dalmau, Josep/0000-0001-5856-2813; Rosenfeld, Myrna/0000-0001-5095-2534	NATIONAL CANCER INSTITUTE [T32CA009512] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09512, CA 095-12-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BRAIN WR, 1965, BRAIN, V88, P465; CUNNINGHAM JM, 1985, J NEUROCHEM, V45, P159, DOI 10.1111/j.1471-4159.1985.tb05488.x; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; DALMAU J, 1991, IN PRESS NEUROLOGY; DENNYBROWN D, 1948, J NEUROL NEUROSUR PS, V11, P73, DOI 10.1136/jnnp.11.2.73; FURNEAUX H, 1990, RES PUBL ASSOC RES N, V68, P187; FURNEAUX HF, 1990, NEUROLOGY, V40, P1085, DOI 10.1212/WNL.40.7.1085; FURNEAUX HM, 1990, NEW ENGL J MED, V322, P1844, DOI 10.1056/NEJM199006283222604; GRAUS F, 1985, NEUROLOGY, V35, P538, DOI 10.1212/WNL.35.4.538; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; ONEILL JH, 1988, BRAIN, V111, P577, DOI 10.1093/brain/111.3.577; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBERTS A, 1985, NATURE, V317, P737, DOI 10.1038/317737a0; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X	22	526	541	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					325	333		10.1016/0092-8674(91)90184-Z	http://dx.doi.org/10.1016/0092-8674(91)90184-Z			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655278				2022-12-24	WOS:A1991GL47000012
J	NUMANN, R; CATTERALL, WA; SCHEUER, T				NUMANN, R; CATTERALL, WA; SCHEUER, T			FUNCTIONAL MODULATION OF BRAIN SODIUM-CHANNELS BY PROTEIN-KINASE-C PHOSPHORYLATION	SCIENCE			English	Article							RAT-BRAIN; ALPHA-SUBUNIT; GATING PROPERTIES; CLONED CDNA; EXPRESSION; NA+; ACTIVATION; INHIBITION; CELLS	Voltage-gated sodium channels, which are responsible for the generation of action potentials in the brain, are phosphorylated by protein kinase C (PKC) in purified form. Activation of PKC decreases peak sodium current up to 80 percent and slows its inactivation for sodium channels in rat brain neurons and for rat brain type IIA sodium channel alpha-subunits heterologously expressed in Chinese hamster ovary cells. These effects are specific for PKC because they can be blocked by specific peptide inhibitors of PKC and can be reproduced by direct application of PKC to the cytoplasmic surface of sodium channels in excised inside-out membrane patches. Modulation of brain sodium channels by PKC is likely to have important effects on signal transduction and synaptic transmission in the central nervous system.	UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025704, R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25704, NS15751] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; CHENG HC, 1986, J BIOL CHEM, V261, P989; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; DASCAL N, 1991, NEURON, V6, P165, DOI 10.1016/0896-6273(91)90131-I; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SCHEUER T, 1991, Biophysical Journal, V59, p262A; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; WESTENBROEK RE, 1989, NEURON, V3, P695, DOI 10.1016/0896-6273(89)90238-9; WESTENBROEK RE, UNPUB; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	28	284	287	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					115	118		10.1126/science.1656525	http://dx.doi.org/10.1126/science.1656525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1656525				2022-12-24	WOS:A1991GH60500042
J	RUTGEERTS, P; GOBOES, K; PEETERS, M; HIELE, M; PENNINCKX, F; AERTS, R; KERREMANS, R; VANTRAPPEN, G				RUTGEERTS, P; GOBOES, K; PEETERS, M; HIELE, M; PENNINCKX, F; AERTS, R; KERREMANS, R; VANTRAPPEN, G			EFFECT OF FECAL STREAM DIVERSION ON RECURRENCE OF CROHNS-DISEASE IN THE NEOTERMINAL ILEUM	LANCET			English	Article							FECAL STREAM; COLITIS; ILEOSTOMY; COLON; MANAGEMENT; RESECTION; SURGERY	Aphthous lesions recur in the neoterminal ileum within the first few months after curative resection of the distal ileum in patients with Crohn's disease. These lesions do not originate from microscopic disease that is already present at the time of surgery. To investigate the importance of faecal stream in the pathogenesis of recurrent Crohn's lesions, we have studied 5 patients with Crohn's disease who had ileal resection. After curative resection and ileocolonic anastomosis, a diverting terminal ileostomy was constructed 25-35 cm proximal to the anastomosis thereby excluding the neoterminal ileum, the anastomosis, and the colon from intestinal transit. After six months of exclusion, endoscopy of the ileocolon was undertaken and biopsy specimens were taken. Transit was then restored. Six months after reanastomosis further biopsy specimens were taken. These patients were compared with a control group of 75 patients with Crohn's disease who underwent a one-step ileal resection and ileocolonic anastomosis. None of the 5 patients had endoscopic lesions in the neoterminal ileum after six months of exclusion and biopsies did not show inflammatory changes characteristic of Crohn's disease. By contrast, 53 of 75 patients with one-step surgery had endoscopic recurrence in the neoterminal ileum within six months of surgery. All 5 patients had an important recurrence of disease, both endoscopically and histologically, at ileocolonoscopy six months after reanastomosis. Our findings strongly support the view that recurrence of Crohn's disease in the neoterminal ileum after curative ileal resection is dependent on faecal stream.	UNIV HOSP LEUVEN,DEPT MED,LOUVAIN,BELGIUM; UNIV HOSP LEUVEN,DEPT SURG,LOUVAIN,BELGIUM; UNIV HOSP LEUVEN,DEPT PATHOL,LOUVAIN,BELGIUM	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven			Peeters, Marc/C-5525-2013	Peeters, Marc/0000-0003-4969-2303				AUFSES AH, 1971, ANN SURG, V73, P91; BURMAN JH, 1971, GUT, V12, P11, DOI 10.1136/gut.12.1.11; GLOTZER DJ, 1981, GASTROENTEROLOGY, V80, P438; GREENSTEIN AJ, 1988, GUT, V29, P588, DOI 10.1136/gut.29.5.588; HARPER PH, 1985, GUT, V26, P279, DOI 10.1136/gut.26.3.279; HARPER PH, 1983, GUT, V24, P106, DOI 10.1136/gut.24.2.106; JONES JH, 1966, GUT, V7, P448, DOI 10.1136/gut.7.5.448; LESCUT D, 1990, GASTROENTEROL CLIN B, V4, pA20; MALCHOW H, 1987, GASTROINTEST ENDOSC, V33, P163; MCILRATH DC, 1971, ARCH SURG-CHICAGO, V103, P308; NUGENT FW, 1973, GASTROENTEROLOGY, V65, P398; OLAISON G, IN PRESS GUT; RUTGEERTS P, 1984, GUT, V25, P665, DOI 10.1136/gut.25.6.665; RUTGEERTS P, 1990, GASTROENTEROLOGY, V99, P950; TYTGAT GNJ, 1988, ENDOSCOPY, V20, P260, DOI 10.1055/s-2007-1018188; WILLIAMS JG, 1991, BRIT J SURG, V78, P10, DOI 10.1002/bjs.1800780106; WINSLET MC, 1988, GUT, V29, pA1475; ZELAS P, 1980, ANN SURG, V191, P164, DOI 10.1097/00000658-198002000-00006	18	582	588	0	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1991	338	8770					771	774		10.1016/0140-6736(91)90663-A	http://dx.doi.org/10.1016/0140-6736(91)90663-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG979	1681159				2022-12-24	WOS:A1991GG97900002
J	RADANOV, BP; DISTEFANO, G; SCHNIDRIG, A; BALLINARI, P				RADANOV, BP; DISTEFANO, G; SCHNIDRIG, A; BALLINARI, P			ROLE OF PSYCHOSOCIAL STRESS IN RECOVERY FROM COMMON WHIPLASH	LANCET			English	Article							SOMATIZATION; INJURIES; NECK	It is widely accepted that psychosocial factors are related to illness behaviour and there is some evidence that they may influence the rate of recovery from post-traumatic disorders. The abilities of psychosocial stress, somatic symptoms, and subjectively assessed cognitive impairment to predict delayed recovery from common whiplash were investigated in a follow-up study. 78 consecutive patients referred 7.2 (SD 4.5) days after they had sustained common whiplash in car accidents were assessed for psychosocial stress, negative affectivity, personality traits, somatic complaints, and cognitive impairment by semistructured interview and by several standardised tests. On examination 6 months later 57 patients were fully recovered and 21 had persisting symptoms. The groups' scores for the independent variables assessed at the baseline examination were compared. Stepwise regression analysis showed that psychosocial factors, negative affectivity, and personality traits were not significant in predicting the outcome. However, initial neck pain intensity, injury-related cognitive impairment, and age were significant factors predicting illness behaviour. This study, which was based on a random sample and which considered many other possible predictive factors as well as psychosocial status, does not support previous findings that psychosocial factors predict illness behaviour in post-trauma patients.	UNIV BERN,DEPT PSYCHOL,CH-3010 BERN,SWITZERLAND	University of Bern	RADANOV, BP (corresponding author), UNIV BERN,DEPT PSYCHIAT,MURTENSTR 21,CH-3010 BERN,SWITZERLAND.							BALLA JI, 1982, CULT MED PSYCHIAT, V6, P191, DOI 10.1007/BF00051428; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; COSTA PJ, 1988, J PERS, V55, P299; Fahrenberg J, 1984, FREIBURGER PERSONLIC; GAY JR, 1953, JAMA-J AM MED ASSOC, V152, P1698, DOI 10.1001/jama.1953.03690180020006; GOLDBERG DP, 1988, J PSYCHOSOM RES, V32, P137, DOI 10.1016/0022-3999(88)90048-7; HIRSCH SA, 1988, ORTHOP CLIN N AM, V19, P791; HODGE JR, 1971, PSYCHOSOMATICS, V12, P245; LEAVITT F, 1990, J PSYCHOSOM RES, V34, P447, DOI 10.1016/0022-3999(90)90068-F; LIPOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; MAIMARIS C, 1988, INJURY, V19, P393, DOI 10.1016/0020-1383(88)90131-3; MERSKEY H, 1984, CAN MED ASSOC J, V130, P1119; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MILLS H, 1986, NEW ZEAL MED J, V99, P373; MURPHY M, 1989, BRIT MED J, V298, P1331, DOI 10.1136/bmj.298.6684.1331; NORRIS SH, 1983, J BONE JOINT SURG BR, V65, P608, DOI 10.1302/0301-620X.65B5.6643566; PEARCE JMS, 1989, J NEUROL NEUROSUR PS, V52, P1329, DOI 10.1136/jnnp.52.12.1329; REINHERZ HZ, 1989, J AM ACAD CHILD PSY, V28, P942, DOI 10.1097/00004583-198911000-00021; RODGERS B, 1990, J CHILD PSYCHOL PSYC, V31, P393, DOI 10.1111/j.1469-7610.1990.tb01577.x; Von Zerssen D., 1976, BEFINDLICHKEITSSKALA; VONZERSSEN D, 1983, METHODOLOGY EVALUATI, P183; WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037/0033-295X.96.2.234; 1986, SPSS X	23	161	164	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1991	338	8769					712	715		10.1016/0140-6736(91)91441-V	http://dx.doi.org/10.1016/0140-6736(91)91441-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG104	1679865				2022-12-24	WOS:A1991GG10400002
J	BERATAN, DN; BETTS, JN; ONUCHIC, JN				BERATAN, DN; BETTS, JN; ONUCHIC, JN			PROTEIN ELECTRON-TRANSFER RATES SET BY THE BRIDGING SECONDARY AND TERTIARY STRUCTURE	SCIENCE			English	Article							TUNNELING PATHWAYS; CYTOCHROME-C; MOLECULES	The rate of long-distance electron transfer in proteins rapidly decreases with distance, which is indicative of an electron tunneling process. Calculations predict that the distance dependence of electron transfer in native proteins is controlled by the protein's structural motif. The helix and sheet content of a protein and the tertiary arrangement of these secondary structural units define the distance dependence of electronic coupling in that protein. The calculations use a tunneling pathway model applied previously with success to ruthenated proteins. The analysis ranks the average distance decay constant for electronic coupling in electron transfer proteins and identifies the amino acids that are coupled to the charge localization site more strongly or weakly than average for their distance.	CALTECH, BECKMAN INST, PASADENA, CA 91125 USA; UNIV CALIF SAN DIEGO, DEPT PHYS, LA JOLLA, CA 92093 USA	California Institute of Technology; University of California System; University of California San Diego	BERATAN, DN (corresponding author), CALTECH, JET PROP LAB, PASADENA, CA 91109 USA.		Beratan, David N/C-5098-2011	Beratan, David N/0000-0003-4758-8676				BALAJI V, 1987, J AM CHEM SOC, V109, P6957, DOI 10.1021/ja00257a010; BERATAN DN, 1984, J AM CHEM SOC, V106, P1584, DOI 10.1021/ja00318a008; BERATAN DN, 1987, J CHEM PHYS, V86, P4488, DOI 10.1063/1.452723; BERATAN DN, 1990, J AM CHEM SOC, V112, P7915, DOI 10.1021/ja00178a011; BERATAN DN, 1985, J CHEM PHYS, V83, P5325, DOI 10.1063/1.449694; BERATAN DN, 1989, PHOTOSYNTH RES, V22, P173, DOI 10.1007/BF00048296; BERATAN DN, 1991, MET IONS BIOL SYST, V27, P97; BOWLER BE, 1989, J AM CHEM SOC, V111, P8757, DOI 10.1021/ja00205a049; Broo A., 1989, INT J QUANTUM CHEM, V16, P185; CONRAD DW, 1989, J AM CHEM SOC, V111, P3461, DOI 10.1021/ja00191a070; COWAN JA, 1988, ANN NY ACAD SCI, V550, P68, DOI 10.1111/j.1749-6632.1988.tb35324.x; DEVAULT D, 1984, QUANTUM MECHANICAL T; DURHAM B, 1989, BIOCHEMISTRY-US, V28, P8659, DOI 10.1021/bi00447a057; FARVER O, 1989, FEBS LETT, V244, P379, DOI 10.1016/0014-5793(89)80567-8; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; JACKMAN MP, 1988, J AM CHEM SOC, V110, P5880, DOI 10.1021/ja00225a046; JACOBS BA, IN PRESS J AM CHEM S; JORTNER J, 1980, BIOCHIM BIOPHYS ACTA, V594, P193, DOI 10.1016/0304-4173(80)90001-4; KUKI A, 1987, SCIENCE, V236, P1647, DOI 10.1126/science.3603005; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; ONUCHIC JN, 1991, PHYS REV A, V43, P4500; PETERSONKENNEDY SE, 1986, J AM CHEM SOC, V108, P1739, DOI 10.1021/ja00268a004; THERIEN MJ, 1990, J AM CHEM SOC, V112, P2420, DOI 10.1021/ja00162a054	24	684	690	1	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1991	252	5010					1285	1288		10.1126/science.1656523	http://dx.doi.org/10.1126/science.1656523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1656523				2022-12-24	WOS:A1991FN85700032
J	HARRISON, PJ; MCLAUGHLIN, D; KERWIN, RW				HARRISON, PJ; MCLAUGHLIN, D; KERWIN, RW			DECREASED HIPPOCAMPAL EXPRESSION OF A GLUTAMATE RECEPTOR GENE IN SCHIZOPHRENIA	LANCET			English	Article							HYPOTHESIS	A striking and specific loss of the messenger RNA that encodes a non-N-methyl D-aspartate (non-NMDA) glutamate receptor was found in hippocampal tissue obtained at necropsy from 6 patients with schizophrenia, when compared to specimens from 8 controls without neurological or psychiatric signs or symptoms. These findings support suggestions of aberrant glutamatergic function in schizophrenia. Evidence that gene expression may be abnormal in schizophrenia, with decreased production of an excitatory neurotransmitter receptor, may have therapeutic as well as pathogenetic implications.	INST PSYCHIAT,DEPT NEUROSCI,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT PSYCHIAT,LONDON SE5 8AF,ENGLAND; ST MARYS HOSP,SCH MED,DEPT ANAT,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,SCH MED,DEPT PSYCHIAT,LONDON W2 1PG,ENGLAND	University of London; King's College London; University of London; King's College London; Imperial College London; Imperial College London			McLaughlin, Danny/J-6818-2013	McLaughlin, Daniel/0000-0002-7060-7321; Harrison, Paul/0000-0002-6719-1126	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSHULER LL, 1987, ARCH GEN PSYCHIAT, V44, P1094; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; DEAKIN JFW, 1989, J NEUROCHEM, V52, P1781, DOI 10.1111/j.1471-4159.1989.tb07257.x; DEUTSCH SI, 1989, CLIN NEUROPHARMACOL, V12, P1, DOI 10.1097/00002826-198902000-00001; FALKAI P, 1986, EUR ARCH PSY CLIN N, V236, P154, DOI 10.1007/BF00380943; Harrison P J, 1990, Neuroreport, V1, P149, DOI 10.1097/00001756-199010000-00017; HARRISON PJ, 1990, PROG NEUROBIOL, V34, P271, DOI 10.1016/0301-0082(90)90007-4; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; JESTE DV, 1989, ARCH GEN PSYCHIAT, V46, P1019; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KERWIN R, 1990, NEUROSCIENCE, V39, P25, DOI 10.1016/0306-4522(90)90219-T; KERWIN RW, 1988, LANCET, V1, P583; KERWIN RW, 1990, NEUROSCI LETT, V118, P164, DOI 10.1016/0304-3940(90)90617-I; KIM JS, 1980, NEUROSCI LETT, V20, P379, DOI 10.1016/0304-3940(80)90178-0; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MELDRUM B S, 1987, Journal of Psychopharmacology, V1, P217, DOI 10.1177/026988118700100401; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; OKADA F, IN PRESS J NEURAL TR; ROBERTS GW, 1990, TRENDS NEUROSCI, V13, P207, DOI 10.1016/0166-2236(90)90161-3; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; Spitzer RL, 1975, RES DIAGNOSTIC CRITE; STORMANN T, 1990, Society for Neuroscience Abstracts, V16, P959; VANTOL HHM, 1990, NEUROSCI LETT, V111, P303, DOI 10.1016/0304-3940(90)90279-I; WACHTEL H, 1990, TRENDS PHARMACOL SCI, V11, P219, DOI 10.1016/0165-6147(90)90243-2	25	217	219	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					450	452		10.1016/0140-6736(91)93392-M	http://dx.doi.org/10.1016/0140-6736(91)93392-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY887	1671470				2022-12-24	WOS:A1991EY88700003
J	ZHONG, Y; WU, CF				ZHONG, Y; WU, CF			ALTERED SYNAPTIC PLASTICITY IN DROSOPHILA MEMORY MUTANTS WITH A DEFECTIVE CYCLIC-AMP CASCADE	SCIENCE			English	Article							ADENYLATE-CYCLASE; SHORT-TERM; POTASSIUM CURRENTS; POTENTIATION; MELANOGASTER; CALCIUM; FACILITATION; HIPPOCAMPUS; DISSECTION; DEFICIENT	Synaptic transmission was examined in Drosophila mutants deficient in memory function. These mutants, dunce and rutabaga, are defective in different steps of the cyclic adenosine 3',5'-monophosphate (cAMP) cascade. In both dunce and rutabaga larvae, voltage-clamp analysis of neuromuscular transmission revealed impaired synaptic facilitation and post-tetanic potentiation as well as abnormal responses to direct application of dibutyryl cAMP. In addition, the calcium dependence of transmitter release was shifted in dunce. The results suggest that the cAMP cascade plays a role in synaptic facilitation and potentiation and indicate that synaptic plasticity is altered in Drosophila memory mutants.			ZHONG, Y (corresponding author), UNIV IOWA,DEPT BIOL,IOWA CITY,IA 52242, USA.			Wu, Chun-Fang/0000-0002-4973-2021; Zhong, Yi/0000-0001-7810-9899; Zhong, Yi/0000-0002-7927-5976				ANDERSON MS, 1988, J NEUROSCI, V8, P242; ATWOOD HL, UNPUB; BALLING A, 1987, J NEUROGENET, V4, P65, DOI 10.3109/01677068709102334; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CASTRO CA, 1989, NATURE, V342, P545, DOI 10.1038/342545a0; CORFAS G, 1990, J NEUROSCI, V10, P491; DAVIS RL, 1986, MOL CELL BIOL, V6, P1464, DOI 10.1128/MCB.6.5.1464; DELANEY KR, 1989, J NEUROSCI, V9, P3558; DEVAY P, 1987, J NEUROGENET, V4, P275; DIXON D, 1989, J NEUROSCI, V9, P4266; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; DUDAI Y, 1983, NEUROSCI LETT, V42, P207, DOI 10.1016/0304-3940(83)90408-1; DUERR JS, 1982, P NATL ACAD SCI-BIOL, V79, P3646, DOI 10.1073/pnas.79.11.3646; ELIOT LS, 1989, P NATL ACAD SCI USA, V86, P9564, DOI 10.1073/pnas.86.23.9564; Ganetzky B, 1983, J NEUROGENET, V1, P17, DOI 10.3109/01677068309107069; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GREENBERG SM, 1987, J NEUROSCI, V7, P291; HAUGLAND FN, 1990, J NEUROSCI, V10, P1357; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; JAN YN, 1978, P NATL ACAD SCI USA, V75, P515, DOI 10.1073/pnas.75.1.515; JOHANSEN J, 1989, J NEUROSCI, V9, P710; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; Kim Y, UNPUB; LANDFIELD PW, 1978, BRAIN RES, V150, P85, DOI 10.1016/0006-8993(78)90655-8; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; NELSON TJ, 1989, BIOESSAYS, V10, P75, DOI 10.1002/bies.950100209; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; STANLEY EF, 1986, J NEUROSCI, V6, P782; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1984, BEHAV GENET, V14, P527, DOI 10.1007/BF01065446; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; ZHONG Y, 1989, Society for Neuroscience Abstracts, V15, P1141; ZHONG Y, UNPUB; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	38	245	256	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					198	201		10.1126/science.1670967	http://dx.doi.org/10.1126/science.1670967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1670967				2022-12-24	WOS:A1991ET17300041
J	BIDART, JM; TROALEN, F; GHILLANI, P; ROUAS, N; RAZAFINDRATSITA, A; BOHUON, C; BELLET, D				BIDART, JM; TROALEN, F; GHILLANI, P; ROUAS, N; RAZAFINDRATSITA, A; BOHUON, C; BELLET, D			PEPTIDE IMMUNOGEN MIMICRY OF A PROTEIN-SPECIFIC STRUCTURAL EPITOPE ON HUMAN CHORIOGONADOTROPIN	SCIENCE			English	Article									INST GUSTAVE ROUSSY,DEPT BIOL CLIN,F-94805 VILLEJUIF,FRANCE; UNIV PARIS 05,FAC SCI PHARMACEUT & BIOL,IMMUNOL LAB,F-75270 PARIS 06,FRANCE	UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Cite								AVRAMEAS S, 1969, IMMUNOCHEMISTRY, V6, P67, DOI 10.1016/0019-2791(69)90179-7; BERGER P, 1987, NATURE, V326, P648, DOI 10.1038/326648a0; BIDART JM, 1987, J BIOL CHEM, V262, P15483; BIDART JM, 1987, MOL IMMUNOL, V24, P339, DOI 10.1016/0161-5890(87)90175-1; BIDART JM, 1987, J BIOL CHEM, V262, P8551; BIDART JM, UNPUB; BIRKEN S, 1977, J BIOL CHEM, V252, P5386; GOODFRIEND TL, 1964, SCIENCE, V144, P1344, DOI 10.1126/science.144.3624.1344; HOGREFE HH, 1989, J BIOL CHEM, V264, P10513; JONES WR, 1988, LANCET, V1, P1295; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLAR SE, 1989, SCIENCE, V246, P935, DOI 10.1126/science.2479101; MILLAR SE, 1989, SCIENCE, V246, P497; MOTTE P, 1987, J IMMUNOL, V138, P3332; OZTURK M, 1987, ENDOCRINOLOGY, V120, P549, DOI 10.1210/endo-120-2-549; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; STEVENS VC, 1986, IMMUNOL TODAY, V7, P369, DOI 10.1016/0167-5699(86)90029-0; TALWAR GP, 1988, CONTRACEPTION RES TO, P183; VANREGENMORTEL MHV, 1989, IMMUNOL TODAY, V10, P266, DOI 10.1016/0167-5699(89)90140-0; VANREGENMORTEL MHV, 1987, TRENDS BIOCHEM SCI, V12, P237, DOI 10.1016/0968-0004(87)90117-4; WALTER G, 1980, P NATL ACAD SCI-BIOL, V77, P5197, DOI 10.1073/pnas.77.9.5197; WEARE JA, 1979, J BIOL CHEM, V254, P6972; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	23	41	44	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 11	1990	248	4956					736	739		10.1126/science.1692160	http://dx.doi.org/10.1126/science.1692160			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC926	1692160				2022-12-24	WOS:A1990DC92600035
J	PETERSON, M; MILLER, J				PETERSON, M; MILLER, J			INVARIANT CHAIN INFLUENCES THE IMMUNOLOGICAL RECOGNITION OF MHC CLASS-II MOLECULES	NATURE			English	Article											PETERSON, M (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.							BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; GERMAIN RN, 1986, ANNU REV IMMUNOL, V4, P281, DOI 10.1146/annurev.iy.04.040186.001433; GLIMCHER LH, 1983, J IMMUNOL, V131, P2868; HARDING CV, 1989, J IMMUNOL, V142, P12; HOLT GD, 1985, J IMMUNOL, V135, P399; JENSEN PE, 1988, J IMMUNOL, V141, P2545; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOCH N, 1982, EUR J IMMUNOL, V12, P909, DOI 10.1002/eji.1830121103; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SIMONIS S, 1989, J IMMUNOL, V143, P3619; STOCKINGER B, 1989, CELL, V56, P683, DOI 10.1016/0092-8674(89)90590-4; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143	24	150	154	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 10	1990	345	6271					172	174		10.1038/345172a0	http://dx.doi.org/10.1038/345172a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC833	1692393				2022-12-24	WOS:A1990DC83300071
J	GENG, JG; BEVILACQUA, MP; MOORE, KL; MCINTYRE, TM; PRESCOTT, SM; KIM, JM; BLISS, GA; ZIMMERMAN, GA; MCEVER, RP				GENG, JG; BEVILACQUA, MP; MOORE, KL; MCINTYRE, TM; PRESCOTT, SM; KIM, JM; BLISS, GA; ZIMMERMAN, GA; MCEVER, RP			RAPID NEUTROPHIL ADHESION TO ACTIVATED ENDOTHELIUM MEDIATED BY GMP-140	NATURE			English	Article									UNIV OKLAHOMA, HLTH SCI CTR, ST FRANCIS MED RES INST, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, OKLAHOMA CITY, OK 73104 USA; OKLAHOMA MED RES FDN, OKLAHOMA CITY, OK 73104 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV VASC RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV UTAH, DEPT MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INS, SALT LAKE CITY, UT 84112 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah								BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; BRASS LF, 1989, METHOD ENZYMOL, V169, P355; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; HAMBURGER SA, 1990, BLOOD, V75, P550; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; JOHNSTON GI, 1989, J BIOL CHEM, V264, P1816; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEY K, 1989, BLOOD, V73, P1324; MARCHESI VT, 1985, ANDERSONS PATHOLOGY, P22; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313, DOI 10.1016/S0065-2776(08)60645-8; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	28	936	987	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1990	343	6260					757	760		10.1038/343757a0	http://dx.doi.org/10.1038/343757a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP807	1689464				2022-12-24	WOS:A1990CP80700061
J	SCHMALE, H; HOLTGREVEGREZ, H; CHRISTIANSEN, H				SCHMALE, H; HOLTGREVEGREZ, H; CHRISTIANSEN, H			POSSIBLE ROLE FOR SALIVARY-GLAND PROTEIN IN TASTE RECEPTION INDICATED BY HOMOLOGY TO LIPOPHILIC-LIGAND CARRIER PROTEINS	NATURE			English	Article											SCHMALE, H (corresponding author), UNIV HAMBURG, INST ZELLBIOCHEM & KLIN NEUROBIOL, MARTINISTR 52, W-2000 HAMBURG 20, GERMANY.							Baumgartner EA, 1917, AM J ANAT, V22, P365, DOI 10.1002/aja.1000220303; BIGNETTI E, 1985, EUR J BIOCHEM, V149, P227, DOI 10.1111/j.1432-1033.1985.tb08916.x; CAVAGGIONI A, 1987, FEBS LETT, V212, P225, DOI 10.1016/0014-5793(87)81349-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARDNER RJ, 1979, CHEM SENS FLAV, V4, P275, DOI 10.1093/chemse/4.4.275; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAND AR, 1970, J CELL BIOL, V44, P340, DOI 10.1083/jcb.44.2.340; HIGGINS GA, 1989, P NATL ACAD SCI USA, V86, P2074, DOI 10.1073/pnas.86.6.2074; Kinnamon J.C., 1987, P277; KINNAMON SC, 1988, TRENDS NEUROSCI, V11, P491, DOI 10.1016/0166-2236(88)90010-0; LANCET D, 1987, TRENDS BIOCHEM SCI, V12, P63, DOI 10.1016/0968-0004(87)90032-6; Lawless H. T, 1987, NEUROBIOLOGY TASTE S, P401; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PEVSNER J, 1985, P NATL ACAD SCI USA, V82, P3050, DOI 10.1073/pnas.82.9.3050; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; PEVSNER J, 1988, P NATL ACAD SCI USA, V85, P2383, DOI 10.1073/pnas.85.7.2383; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMALE H, 1989, EUR J BIOCHEM, V182, P621, DOI 10.1111/j.1432-1033.1989.tb14871.x; SCHOFIELD PR, 1988, TRENDS NEUROSCI, V11, P471, DOI 10.1016/0166-2236(88)90001-X; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561	23	136	141	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	1990	343	6256					366	369		10.1038/343366a0	http://dx.doi.org/10.1038/343366a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK918	1689010				2022-12-24	WOS:A1990CK91800061
J	OZTURK, M				OZTURK, M			P53 MUTATION IN HEPATOCELLULAR-CARCINOMA AFTER AFLATOXIN EXPOSURE	LANCET			English	Article							HEPATITIS-B VIRUS; EPIDEMIOLOGY; PREVALENCE; CANCER; JAPAN	Mutations of the p53 gene are found in hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Specific mutations might reflect exposure to specific carcinogens and we have screened HCC samples from patients in 14 different countries to determine the frequency of a hotspot mutation at codon 249 of the tumour suppressor p53 gene. We detected mutations in 17% of tumours (12/72) from four countries in south Africa and the southeast coast of Asia. There was no codon 249 mutation in 95 specimens of HCC from other geographical locations including North America, Europe, Middle East, and Japan. Worldwide, the presence of the codon 249 mutation in HCCs correlated with high risk of exposure to aflatoxins and the hepatitis B virus (HBV). Further studies were completed in two groups of HBV-infected patients at different risks of exposure to aflatoxins. 53% of patients (8/15) from Mozambique at high risk of aflatoxin exposure had a tumour with a codon 249 mutation, in contrast with 8% of patients from Transkei (1/12) who were at low risk. HCC is an endemic disease in Mozambique and accounts for up to two thirds of all tumours in men. A codon 249 mutation of the p53 gene identifies an endemic form of HCC strongly associated with dietary aflatoxin intake.			OZTURK, M (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,BOSTON,MA 02129, USA.		OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; Vyas, Girish/0000-0003-1090-4911; Kar, Siddhartha/0000-0001-9293-9274; Carr, Brian/0000-0002-6111-5077; PUISIEUX, Alain/0000-0002-9938-3798	NCI NIH HHS [CA35711, CA49832] Funding Source: Medline; NIAAA NIH HHS [AA00048] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA035711, R01CA035711, R29CA049832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K05AA000048] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BEASLEY RP, 1982, HEPATOLOGY, V2, pS21; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; DUSHEIKO GM, 1989, AM J EPIDEMIOL, V129, P138, DOI 10.1093/oxfordjournals.aje.a115102; GROOPMAN JD, 1988, CRC CR REV TOXICOL, V19, P113, DOI 10.3109/10408448809014902; HANN HWL, 1982, INT J CANCER, V30, P47, DOI 10.1002/ijc.2910300109; HAYWARD NK, 1991, NATURE, V352, P764, DOI 10.1038/352764a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Kew MC, 1984, ADV HEPATITIS RES, P203; LANGE W, 1987, POSTGRAD MED J, V63, P21; MAYANS MV, 1990, INT J CANCER, V46, P378, DOI 10.1002/ijc.2910460307; MIVECHI NF, 1990, CANCER RES, V50, P2877; MUIR CS, 1990, CANCER RES, V50, P6441; OKUDA K, 1987, CANCER RES, V47, P4967; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PUISIEUX A, IN PRESS CANCER RES; TANAKA T, 1986, AM J EPIDEMIOL, V124, P368, DOI 10.1093/oxfordjournals.aje.a114407; TOWNSEND TR, 1990, JAMA-J AM MED ASSOC, V263, P290; VANRENSBURG SJ, 1985, BRIT J CANCER, V51, P713, DOI 10.1038/bjc.1985.107; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YEH FS, 1989, CANCER RES, V49, P2506; YU SZ, 1985, SUBCLINICAL HEPATOCE, P189	22	415	424	0	24	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1991	338	8779					1356	1359						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682737				2022-12-24	WOS:A1991GR77300004
J	CAMPANELLI, JT; HOCH, W; RUPP, F; KREINER, T; SCHELLER, RH				CAMPANELLI, JT; HOCH, W; RUPP, F; KREINER, T; SCHELLER, RH			AGRIN MEDIATES CELL CONTACT INDUCED ACETYLCHOLINE-RECEPTOR CLUSTERING	CELL			English	Article							TORPEDO ELECTRIC ORGAN; CULTURED MUSCLE-CELLS; GENE-RELATED PEPTIDE; MESSENGER-RNA LEVELS; NEUROMUSCULAR-JUNCTION; BASAL LAMINA; AGGREGATING FACTOR; ALPHA-SUBUNIT; MOTOR NEURONS; PROTEIN	One of the important events in synapse formation is the accumulation of neurotransmitter receptors beneath the presynaptic nerve terminal. Agrin is a component of the synaptic basal lamina that induces the clustering of acetylcholine receptors when bath-applied to muscle fibers in culture. When a cDNA encoding a putative agrin protein is transfected into cells, the molecule is secreted and concentrated on the extracellular surface. Coculture of transfected cells with muscle fibers induces the formation of receptor patches at contact sites. These results demonstrate that expression of a single gene encoding agrin confers receptor clustering that is restricted to specific sites of cell-muscle contact.			CAMPANELLI, JT (corresponding author), STANFORD UNIV, HOWARD HUGHES MED INST, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA.							ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; ANDERSON MJ, 1983, J CELL BIOL, V97, P1396, DOI 10.1083/jcb.97.5.1396; BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; BEVAN S, 1977, J PHYSIOL-LONDON, V267, P195, DOI 10.1113/jphysiol.1977.sp011808; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DENNIS MJ, 1981, ANNU REV NEUROSCI, V4, P43, DOI 10.1146/annurev.ne.04.030181.000355; FALLON JR, 1985, NATURE, V315, P571, DOI 10.1038/315571a0; FERTUCK H C, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1376, DOI 10.1073/pnas.71.4.1376; FONTAINE B, 1987, J CELL BIOL, V105, P1337, DOI 10.1083/jcb.105.3.1337; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GETHING MJ, 1989, METHOD CELL BIOL, V32, P185; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; HALL ZW, 1973, J NEUROBIOL, V4, P343, DOI 10.1002/neu.480040404; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGILLSOLC C, 1990, J EXP BIOL, V153, P1; MAGILLSOLC C, 1988, J CELL BIOL, V107, P1825, DOI 10.1083/jcb.107.5.1825; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; NITKIN RM, 1990, J CELL BIOL, V111, P1161, DOI 10.1083/jcb.111.3.1161; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; PENG HB, 1991, NEURON, V6, P237; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; ROBERTS WM, 1990, J NEUROSCI, V10, P3664; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1986, J CELL BIOL, V102, P783, DOI 10.1083/jcb.102.3.783; WEINBERG CB, 1981, DEV BIOL, V84, P255, DOI 10.1016/0012-1606(81)90393-6	39	114	114	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					909	916		10.1016/0092-8674(91)90364-5	http://dx.doi.org/10.1016/0092-8674(91)90364-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1659950				2022-12-24	WOS:A1991GT75500010
J	NOKES, DJ; ANDERSON, RM				NOKES, DJ; ANDERSON, RM			VACCINE SAFETY VERSUS VACCINE EFFICACY IN MASS IMMUNIZATION PROGRAMS	LANCET			English	Article							MUMPS-MEASLES-VACCINES; JERYL-LYNN-MORATEN; RUBELLA VACCINE; YOUNG-CHILDREN; VIRUS-VACCINES; AGE; INFECTION; IMMUNOGENICITY; EPIDEMIOLOGY; IMMUNIZATION	In community-wide immunisation programmes against childhood infections there is a conflict between the interests of the individual (vaccine safety and efficacy) and the interests of the community (vaccine uptake and level of herd immunity). Studies suggesting that the complication rate is greater with the high efficacy Urabe Am 9 mumps vaccine than with the lower efficacy Jeryl Lynn vaccine, have led to concern about whether the higher efficacy mumps vaccine should be introduced or retained in nationwide mass immunisation programmes. We describe the use of a mathematical model to assess benefits and risks to both individual and community, and illustrate this method by reference to immunisation programmes based on these vaccines. On the basis of current epidemiological data on viral transmission and vaccine coverage in England and Wales, data on vaccine-associated and infection-associated complication rates, and vaccine efficacies estimated from clinical trials, our analyses suggest there is little to choose between the two vaccines, but that overall performance depends on the level of vaccine coverage in a defined population. In community-based programmes, the greater apparent safety of the Jeryl Lynn vaccine (fewer vaccine-induced complications) is offset by the greater apparent efficacy of the Urabe Am 9 vaccine (fewer complications due to natural infection). The findings suggest that it may not always be in the interests of the community to use the vaccine with the lowest complication rate.			NOKES, DJ (corresponding author), IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, PARASITE EPIDEMIOL RES GRP, LONDON SW7 2BB, ENGLAND.			Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON RM, 1985, J HYG-CAMBRIDGE, V94, P365, DOI 10.1017/S002217240006160X; ANDERSON RM, 1987, EPIDEMIOL INFECT, V99, P65, DOI 10.1017/S0950268800066875; ANDERSON RM, 1991, OXFORD TXB PUBLIC HL, V2, P225; BERGER R, 1988, J BIOL STAND, V16, P269, DOI 10.1016/0092-1157(88)90014-5; CAMPBELL AGM, 1990, IMMUNISATION INFECTI, P51; CHRISTENSON B, 1983, J BIOL STAND, V11, P323, DOI 10.1016/S0092-1157(83)80021-3; CHRISTENSON B, 1991, VACCINE, V9, P326, DOI 10.1016/0264-410X(91)90058-E; FARRINGTON CP, 1990, STAT MED, V9, P953, DOI 10.1002/sim.4780090811; FESCHAREK R, 1990, VACCINE, V8, P446, DOI 10.1016/0264-410X(90)90245-H; Furesz J, 1990, Can Dis Wkly Rep, V16, P253; GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419, DOI 10.1017/S0022172400062859; JUST M, 1987, MUNCHEN MED WOCHEN, V129, P446; JUST M, 1987, MUNCHEN MED WOCHEN, V129, P188; KAKAKIOS AM, 1990, MED J AUSTRALIA, V152, P472, DOI 10.5694/j.1326-5377.1990.tb125306.x; KIMFARLEY R, 1985, AM J EPIDEMIOL, V121, P593, DOI 10.1093/oxfordjournals.aje.a114037; LAVERGNE B, 1986, CAN DIS WEEKLY REP, V12, P85; MORGANCAPNER P, 1988, BRIT MED J, V297, P770, DOI 10.1136/bmj.297.6651.770; NALIN DR, 1989, LANCET, V2, P1396; NALIN DR, 1989, BRIT MED J, V299, P1219, DOI 10.1136/bmj.299.6709.1219-b; NOKES DJ, 1988, EPIDEMIOL INFECT, V101, P1, DOI 10.1017/S0950268800029186; NOKES DJ, 1990, EPIDEMIOL INFECT, V105, P175, DOI 10.1017/S0950268800047762; POPOWKRAUPP T, 1986, J MED VIROL, V18, P69, DOI 10.1002/jmv.1890180109; Quast U, 1979, Dev Biol Stand, V43, P269; VESIKARI T, 1983, ACTA PAEDIATR SCAND, V72, P41, DOI 10.1111/j.1651-2227.1983.tb09661.x; VESIKARI T, 1984, AM J DIS CHILD, V138, P843, DOI 10.1001/archpedi.1984.02140470043013; VESIKARI T, 1983, ACTA PAEDIATR SCAND, V72, P37, DOI 10.1111/j.1651-2227.1983.tb09660.x; 1974, J R COLL GEN PRACT, V24, P552; 1958, REGISTRAR GENERALS S; 1958, REPORTS HOSPITAL INP	29	23	23	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1991	338	8778					1309	1312		10.1016/0140-6736(91)92601-W	http://dx.doi.org/10.1016/0140-6736(91)92601-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR023	1682694				2022-12-24	WOS:A1991GR02300013
J	MULLER, W; CONNOR, JA				MULLER, W; CONNOR, JA			DENDRITIC SPINES AS INDIVIDUAL NEURONAL COMPARTMENTS FOR SYNAPTIC CA2+ RESPONSES	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL PYRAMIDAL CELLS; EXCITATORY AMINO-ACIDS; SYNAPSES; BLOCK	THE possibility that postsynaptic spines on neuronal dendrites are discrete biochemical compartments for Ca2+-activated processes involved in synaptic plasticity 1-6 is a widely proposed concept that has eluded experimental demonstration. Using microfluorometry on CA3 neurons in hippocampal slices, we show here that with weak presynaptic stimulation of associative/commissural fibres, Ca2+ accumulates in single postsynaptic spines but not in the parent dendrite. Stronger stimulation also promotes changes in dendrites. The NMDA-receptor antagonist AP-5 blocks changes in Ca2+ in spines. Sustained steep Ca2+ gradients between single spines and the parent dendrite, often lasting several minutes, develop with repeated stimulation. The observed compartmentalization allows for the specificity 7,8, cooperativity 9 and associativity 10-14 displayed by memory models such as long-term potentiation.			MULLER, W (corresponding author), ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT NEUROSCI,340 KINGSLAND ST,NUTLEY,NJ 07110, USA.							BARRIONUEVO G, 1983, P NATL ACAD SCI-BIOL, V80, P7347, DOI 10.1073/pnas.80.23.7347; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CONNOR JA, 1988, SCIENCE, V240, P649, DOI 10.1126/science.2452481; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.ne.11.030188.000425; DINGLEDINE R, 1983, J PHYSIOL-LONDON, V343, P385, DOI 10.1113/jphysiol.1983.sp014899; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HARRIS KM, 1989, J NEUROSCI, V9, P2982; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MULLER W, 1991, NEURON, V6, P901, DOI 10.1016/0896-6273(91)90230-W; MULLER W, 1988, EXP BRAIN RES, V72, P287; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.ne.12.030189.001303; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	23	413	418	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					73	76		10.1038/354073a0	http://dx.doi.org/10.1038/354073a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1682815				2022-12-24	WOS:A1991GN82900061
J	SERAFINI, T; ORCI, L; AMHERDT, M; BRUNNER, M; KAHN, RA; ROTHMAN, JE				SERAFINI, T; ORCI, L; AMHERDT, M; BRUNNER, M; KAHN, RA; ROTHMAN, JE			ADP-RIBOSYLATION FACTOR IS A SUBUNIT OF THE COAT OF GOLGI-DERIVED COP-COATED VESICLES - A NOVEL ROLE FOR A GTP-BINDING PROTEIN	CELL			English	Article							YPT1 GENE-PRODUCT; ADENYLATE-CYCLASE; ENDOPLASMIC-RETICULUM; CHOLERA-TOXIN; REGULATORY COMPONENT; SUCCESSIVE COMPARTMENTS; VESICULAR TRANSPORT; NUCLEOTIDE-BINDING; SECRETORY VESICLES; MOLECULAR-CLONING	ADP-ribosylation factor (ARF) is an abundant and highly conserved low molecular weight GTP-binding protein that was originally identified as a key element required for the action of cholera toxin in mammalian cells, but whose physiological role is unknown. We report that ARF family proteins are highly concentrated in non-clathrin-coated transport vesicles and are coat proteins. About three copies of ARF are present on the outside of coated vesicles per alpha-COP (and thus per coatomer). ARF is highly enriched in coated vesicles as compared with parental Golgi cisternae, as shown both by biochemical and morphological methods, and ARF is removed from transport vesicles through uncoating during transport. Furthermore, ARF binds to Golgi cisternae in a GTP-dependent manner independently of coated vesicle budding. These observations strongly suggest a new role for GTP-binding proteins: ARF proteins may modulate vesicle budding and uncoating through controlled GTP hydrolysis.	PRINCETON UNIV, DEPT MOLEC BIOL, LEWIS THOMAS LABS, PRINCETON, NJ 08544 USA; UNIV GENEVA, INST HISTOL & EMBRYOL, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND; NCI, DIV CANC TREATMENT, BIOL CHEM LAB, BETHESDA, MD 20892 USA	Princeton University; University of Geneva; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SERAFINI, T (corresponding author), STANFORD UNIV, BECKMAN CTR, DEPT BIOCHEM, STANFORD, CA 94305 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601; Brunner, Michael/0000-0001-9798-3047	NATIONAL CANCER INSTITUTE [R01CA047767] Funding Source: NIH RePORTER; NCI NIH HHS [CA47767-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMBRUSTER BL, 1982, J MICROSC-OXFORD, V126, P77, DOI 10.1111/j.1365-2818.1982.tb00358.x; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LITTLE SP, 1977, VIROLOGY, V81, P37, DOI 10.1016/0042-6822(77)90056-3; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; ORCI L, 1985, P NATL ACAD SCI USA, V82, P5385, DOI 10.1073/pnas.82.16.5385; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI SC, 1988, J BIOL CHEM, V263, P1768; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	69	519	529	2	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					239	253		10.1016/0092-8674(91)90176-Y	http://dx.doi.org/10.1016/0092-8674(91)90176-Y			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1680566				2022-12-24	WOS:A1991GL47000004
J	SHI, Y; SETO, E; CHANG, LS; SHENK, T				SHI, Y; SETO, E; CHANG, LS; SHENK, T			TRANSCRIPTIONAL REPRESSION BY YY1, A HUMAN GLI-KRUPPEL-RELATED PROTEIN, AND RELIEF OF REPRESSION BY ADENOVIRUS E1A PROTEIN	CELL			English	Article							MAMMALIAN-CELLS; RNA-POLYMERASE; DNA; EXPRESSION; GENE; ACTIVATION; PROMOTER; ELEMENT; PURIFICATION; DROSOPHILA	A sequence within the transcription control region of the adeno-associated virus P5 promoter has been shown to mediate transcriptional activation by the adenovirus E1A protein. We report here that this same element mediates transcriptional repression in the absence of E1A. Two cellular proteins have been found to bind to overlapping regions within this sequence element. One of these proteins, YY1, is responsible for the repression. E1A relieves repression exerted by YY1 and further activates transcription through its binding site. A YY1-specific cDNA has been isolated. Its sequence reveals YY1 to be a zinc finger protein that belongs to the GLI-Kruppel gene family. The product of the cDNA binds to YY1 sites. When fused to the GAL4 DNA-binding domain, it is capable of repressing transcription directed by a promoter that contains GAL4-binding sites, and E1A proteins can relieve the repression and activate transcription through the fusion protein.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,HOWARD HUGHES MED INST,PRINCETON,NJ 08544	Princeton University; Howard Hughes Medical Institute; Princeton University			Chang, Long-sheng/E-2871-2011		NATIONAL CANCER INSTITUTE [R37CA038965, R01CA038965] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38965] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HEARING P, 1983, CELL, V33, P695, DOI 10.1016/0092-8674(83)90012-0; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LEONG K, 1988, MOL CELL BIOL, V8, P1765, DOI 10.1128/MCB.8.4.1765; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTALVO EA, 1991, J VIROL, V65, P3647, DOI 10.1128/JVI.65.7.3647-3655.1991; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; ROONEY C, 1988, P NATL ACAD SCI USA, V85, P9801, DOI 10.1073/pnas.85.24.9801; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHENK T, 1979, COLD SPRING HARB SYM, V44, P367, DOI 10.1101/SQB.1980.044.01.041; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TAN S, 1988, EMBO J, V6, P2711; WANG J, 1987, NUCLEIC ACIDS RES, V15, P10105, DOI 10.1093/nar/15.24.10105; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	47	890	916	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					377	388		10.1016/0092-8674(91)90189-6	http://dx.doi.org/10.1016/0092-8674(91)90189-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655281				2022-12-24	WOS:A1991GL47000017
J	HILBERT, P; LINDPAINTNER, K; BECKMANN, JS; SERIKAWA, T; SOUBRIER, F; DUBAY, C; CARTWRIGHT, P; DEGOUYON, B; JULIER, C; TAKAHASI, S; VINCENT, M; GANTEN, D; GEORGES, M; LATHROP, GM				HILBERT, P; LINDPAINTNER, K; BECKMANN, JS; SERIKAWA, T; SOUBRIER, F; DUBAY, C; CARTWRIGHT, P; DEGOUYON, B; JULIER, C; TAKAHASI, S; VINCENT, M; GANTEN, D; GEORGES, M; LATHROP, GM			CHROMOSOMAL MAPPING OF 2 GENETIC-LOCI ASSOCIATED WITH BLOOD-PRESSURE REGULATION IN HEREDITARY HYPERTENSIVE RATS	NATURE			English	Article							RECOMBINANT INBRED STRAINS; INVITRO AMPLIFICATION; ANGIOTENSIN-I; RENIN GENE; DNA; HYBRIDIZATION; PROBES	The spontaneously hypertensive rat and the stroke-prone spontaneously hypertensive rat are useful models for human hypertension. In these strains hypertension is a polygenic trait, in which both autosomal and sex-linked genes can influence blood pressure 1-7. Linkage studies in crosses between the stroke-prone spontaneously hypertensive rat and the normotensive control strain Wistar-Kyoto have led to the localization of two genes, BP/SP-1 and BP/SP-2, that contribute significantly to blood pressure variation in the F2 population. BP/SP-1 and BP/SP-2 were assigned to rat chromosomes 10 and X, respectively. Comparison of the human and rat genetic maps indicates that BP/SP-1 could reside on human chromosome 17q in a region that also contains the angiotensin I-converting enzyme gene (ACE) 8. This encodes a key enzyme of the renin-angiotensin system 9, and is therefore a candidate gene in primary hypertension. A rat microsatellite marker of ACE was mapped to rat chromosome 10 within the region containing BP/SP-1.	CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE; CTR MOLEC MED,W-1115 BERLIN,GERMANY; INST RECH INTERDISCIPLINAIRE BIOL HUMAINE & NUCL,B-1070 BRUSSELS,BELGIUM; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; UNIV HEIDELBERG,GERMAN INST HIGH BLOOD PRESSURE,W-6900 HEIDELBERG,GERMANY; COLL FRANCE,MED EXPTL LAB,INSERM,U36,F-75231 PARIS 05,FRANCE; UNIV CLAUDE BERNARD,PHYSIOL LAB,F-69373 LYONS,FRANCE; UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132; GENMARK INC,SALT LAKE CITY,UT 84108; UNIV HEIDELBERG,DEPT PHARMACOL,W-6900 HEIDELBERG,GERMANY; KYOTO UNIV,FAC MED,INST LAB ANIM,KYOTO 606,JAPAN	Harvard University; Harvard Medical School; Ruprecht Karls University Heidelberg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Utah System of Higher Education; University of Utah; Ruprecht Karls University Heidelberg; Kyoto University			Beckmann, Jacques S/A-9772-2008; JULIER, Cécile/M-9824-2017	Beckmann, Jacques S/0000-0002-9741-1900; JULIER, Cécile/0000-0002-1538-0240				AOKI K, 1972, JPN CIRCULATION J, V36, P539, DOI 10.1253/jcj.36.539; BIOLLAZ J, 1986, HYPERTENSION, V8, P117, DOI 10.1161/01.HYP.8.2.117; COOKE NE, 1986, ENDOCRINOLOGY, V119, P2451, DOI 10.1210/endo-119-6-2451; DANNERBERG AL, 1987, HYPERTENSION, V10, P266; DIETZ R, 1984, J CARDIOVASC PHARM, V6, pS230, DOI 10.1097/00005344-198400061-00036; DIETZ R, 1982, HYPERTENSION, V4, P773, DOI 10.1161/01.HYP.4.6.773; DIXON WJ, 1988, BMDP STATISTICAL SOF; ELY DL, 1990, HYPERTENSION, V16, P277, DOI 10.1161/01.HYP.16.3.277; GEORGES M, 1988, CYTOGENET CELL GENET, V47, P127, DOI 10.1159/000132529; GRADIN K, 1987, ACTA PHYSIOL SCAND, V131, P273, DOI 10.1111/j.1748-1716.1987.tb08237.x; Guyton AC, 1980, ARTERIAL PRESSURE HY; HALL JE, 1986, AM J PHYSIOL, V250, pR960, DOI 10.1152/ajpregu.1986.250.6.R960; HARRAP SB, 1986, HYPERTENSION, V8, P572, DOI 10.1161/01.HYP.8.7.572; HILLYARD AL, 1991, LOCUS MAP MOUSE COMP; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; JULIER C, 1990, P NATL ACAD SCI USA, V87, P4585, DOI 10.1073/pnas.87.12.4585; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, GENOMICS, V2, P157; LEVAN G, IN PRESS GENOMCIS; LINDPAINTNER K, 1990, J HYPERTENS, V8, P763, DOI 10.1097/00004872-199008000-00011; LITT M, 1989, AM J HUM GENET, V44, P397; LOUIS WJ, 1969, LANCET, V1, P1035; LUFT FC, 1988, J CLI SCI, V74, P577; MATTEI MG, 1989, CYTOGENET CELL GENET, V51, P1041; PICKERING G, 1972, AM J MED, V52, P570, DOI 10.1016/0002-9343(72)90049-6; PRAVENEC M, 1991, HYPERTENSION, V17, P242, DOI 10.1161/01.HYP.17.2.242; PRAVENEC M, 1989, J HYPERTENS, V7, P217; PRAVENEC M, 1991, GENOMICS, V9, P466, DOI 10.1016/0888-7543(91)90412-8; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; RAPP JP, 1982, HYPERTENSION, V4, P459, DOI 10.1161/01.HYP.4.4.459; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SOLOMON E, 1989, CYTOGENET CELL GENET, V51, P319, DOI 10.1159/000132797; TANASE H, 1970, JPN CIRCULATION J, V34, P1197; TANASE H, 1987, JAP CIRC J, V51, P1184; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; VANDEVEN CJM, 1983, PFLUG ARCH EUR J PHY, V399, P74, DOI 10.1007/BF00652525; WARD R, 1990, PATHOPHYSIOLOGY DIAG, P81; WEBER JL, 1989, AM J HUM GENET, V44, P388; YAMORI Y, 1970, LAB INVEST, V22, P206; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6; YASUE Y, IN PRESS CYTOGENET C; YEN TT, 1974, HEREDITY, V33, P309, DOI 10.1038/hdy.1974.97	43	591	608	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					521	529		10.1038/353521a0	http://dx.doi.org/10.1038/353521a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1656270				2022-12-24	WOS:A1991GJ64300056
J	MAKI, M; HALLSTROM, O; MARTTINEN, A				MAKI, M; HALLSTROM, O; MARTTINEN, A			REACTION OF HUMAN NONCOLLAGENOUS POLYPEPTIDES WITH CELIAC-DISEASE AUTOANTIBODIES	LANCET			English	Note							IGA-CLASS RETICULIN; CELIAC-DISEASE; DERMATITIS-HERPETIFORMIS; ANTIBODY; RECOGNITION	We identified and purified six human noncollagenous protein molecules that specifically bind to serum IgA from patients with coeliac disease, and which as a combination can act as true antigen to reticulin antibodies. In affinity chromatography, the purified human protein molecules removed antibodies against reticulin and endomysium from serum samples of coeliac disease patients. We postulate that an autoimmune mechanism operates in generating the jejunal damage in gluten-sensitive enteropathy and that the human protein molecules described here act as self-antigens in the disease.			MAKI, M (corresponding author), UNIV TAMPERE,DEPT CLIN SCI,TEISKONTIE 35,POB 607,SF-33101 TAMPERE,FINLAND.							BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; CHORZELSKI TP, 1984, BRIT J DERMATOL, V111, P395, DOI 10.1111/j.1365-2133.1984.tb06601.x; HALLSTROM O, 1989, GUT, V30, P1225, DOI 10.1136/gut.30.9.1225; KARPATI S, 1990, LANCET, V336, P1335, DOI 10.1016/0140-6736(90)92893-M; KARPATI S, 1991, J INVEST DERMATOL, V96, P228, DOI 10.1111/1523-1747.ep12462097; LAMB JR, 1990, MOL BIOL MED, V7, P311; MAKI M, 1984, J PEDIATR-US, V105, P901, DOI 10.1016/S0022-3476(84)80074-8; MAKI M, IN PRESS GUT; SEAH PP, 1971, LANCET, V1, P834	9	72	72	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1991	338	8769					724	725		10.1016/0140-6736(91)91445-Z	http://dx.doi.org/10.1016/0140-6736(91)91445-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679869				2022-12-24	WOS:A1991GG10400006
J	DEPREZ, PH; GHOSH, P; GOODLAD, RA; LACEY, SL; MILLERSHIP, S; PLAYFORD, RJ; LEE, CY; CALAM, J				DEPREZ, PH; GHOSH, P; GOODLAD, RA; LACEY, SL; MILLERSHIP, S; PLAYFORD, RJ; LEE, CY; CALAM, J			HYPERGASTRINEMIA - A NEW MECHANISM	LANCET			English	Note							ACID	The mechanism by which lack of gastric acid causes hypergastrinaemia was investigated in seven patients with pernicious anaemia. Perfusion of gastric juice from the fasting patients (adjusted to pH 7.0) into the stomachs of conscious rats caused a significant rise in plasma gastrin (median 14 [range 2-20] pmol/l to 27 [12-65] pmol/l; p < 0.01), whereas perfusion of bicarbonate buffer (18 [13-23] pmol/l to 20 [9-25] pmol/l) or gastric juice from a duodenal ulcer patient (also pH 7.0; 13 [3-30] pmol/l to 17 [9-27] pmol/l) had no significant effect. During gastric lavage at pH 7.0 the median plasma gastrin concentration of the pernicious anaemia patients fell from 320 (63-1760) pmol/l to 125 (46-760) pmol/l (p < 0.03).	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,DU CANE RD,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT BACTERIOL,LONDON W12 0NN,ENGLAND; IMPERIAL CANC RES FUND,DEPT HISTOPATHOL,LONDON WC2A 3PX,ENGLAND	Imperial College London; Imperial College London; Cancer Research UK			Deprez, Pierre/AAC-5546-2019	Deprez, Pierre/0000-0001-8926-8967; Playford, Raymond/0000-0003-1235-8504; Goodlad, Robert/0000-0002-7660-4287				BORDI C, 1991, CANCER-AM CANCER SOC, V67, P663, DOI 10.1002/1097-0142(19910201)67:3<663::AID-CNCR2820670323>3.0.CO;2-L; BURLINSON B, 1990, LANCET, V335, P419, DOI 10.1016/0140-6736(90)90260-C; CALAM J, 1991, CLIN SCI, V80, P281, DOI 10.1042/cs0800281; FUKUOKA SI, 1990, PANCREAS, V5, P1, DOI 10.1097/00006676-199001000-00001; GOODLAD RA, 1987, GUT, V28, P177; HEATHCOTE JG, 1965, NATURE, V207, P941, DOI 10.1038/207941a0; YALOW RS, 1970, GASTROENTEROLOGY, V58, P1	7	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					410	411		10.1016/0140-6736(91)91034-R	http://dx.doi.org/10.1016/0140-6736(91)91034-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678084				2022-12-24	WOS:A1991GB44600005
J	LALLOZ, MRA; MCVEY, JH; PATTINSON, JK; TUDDENHAM, EGD				LALLOZ, MRA; MCVEY, JH; PATTINSON, JK; TUDDENHAM, EGD			HEMOPHILIA-A DIAGNOSIS BY ANALYSIS OF A HYPERVARIABLE DINUCLEOTIDE REPEAT WITHIN THE FACTOR-VIII GENE	LANCET			English	Article							HEMOPHILIA-A; INVITRO AMPLIFICATION; PRENATAL-DIAGNOSIS; DNA ANALYSIS; POLYMORPHISM; MICROSATELLITE; POLYMERASE; SEQUENCES; PROBE	The diagnosis of haemophilia A and the identification of carriers has greatly improved with knowledge of the structure of the gene for factor VIII. This has permitted the defect to be tracked in families by the study of restriction fragment length polymorphisms (RFLPs), irrespective of the nature of the molecular defect. However, this approach is time-consuming and the information yielded falls away as more polymorphisms are added. Within the factor VIII gene lies another source of polymorphism, a dinucleotide repeat sequence of varying length known as (CA)n. Conventional mapping localised this (CA)n repeat to intron 13. The polymerase chain reaction, used to examine (CA)n variability in genomic DNA from 25 males and 67 females, revealed eight allelic bands between n = 16 and n = 24. 91% of females were heterozygous for this repeat, and family studies showed X-linked mendelian inheritance with allelic frequencies ranging from 1% to 45%. The intron 13 (CA)n repeat is tightly linked with established RFLPs and tracks with haemophilia A in family studies. The analysis requires DNA from other family members, and relatives of sporadic cases of haemophilia A are only amenable to exclusion. Nonetheless, this intron 13 (CA)n repeat provides the most highly informative marker so far available for factor VIII gene tracking studies in haemophilia A kindreds and a result can be available within a day.			LALLOZ, MRA (corresponding author), CLIN RES CTR,HAEMOSTASIS RES GRP,HARROW HA1 3UJ,MIDDX,ENGLAND.		Tuddenham, Edward/AAS-6196-2020	Tuddenham, Edward/0000-0001-8955-2909; McVey, John/0000-0002-7416-533X				AHRENS P, 1987, HUM GENET, V76, P127, DOI 10.1007/BF00284907; ANTONARAKIS SE, 1985, NEW ENGL J MED, V313, P842, DOI 10.1056/NEJM198510033131402; GITSCHIER J, 1985, NATURE, V314, P738, DOI 10.1038/314738a0; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GRAHAM JB, 1990, BRIT J HAEMATOL, V76, P75, DOI 10.1111/j.1365-2141.1990.tb07839.x; HARPER K, 1984, LANCET, V2, P6; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LITT M, 1989, AM J HUM GENET, V44, P397; Maniatis T., 1982, MOL CLONING; MILLAR DS, 1990, HUM GENET, V86, P219; OBERLE I, 1985, NEW ENGL J MED, V312, P682, DOI 10.1056/NEJM198503143121103; PATTINSON JK, 1990, BLOOD, V76, P2242; ROTBLAT F, 1981, THROMB RES, V21, P931; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SURIN VL, 1990, NUCLEIC ACIDS RES, V18, P3432, DOI 10.1093/nar/18.11.3432; TANTRAVAHI U, 1986, CYTOGENET CELL GENET, V42, P75, DOI 10.1159/000132255; TAYLOR GR, 1989, LANCET, V2, P454; Tuddenham E G, 1989, Baillieres Clin Haematol, V2, P849, DOI 10.1016/S0950-3536(89)80049-6; WEBER JL, 1989, AM J HUM GENET, V44, P388; WION KL, 1986, NUCLEIC ACIDS RES, V14, P4535, DOI 10.1093/nar/14.11.4535; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; YOUSSOUFIAN H, 1987, NUCLEIC ACIDS RES, V15, P6312, DOI 10.1093/nar/15.15.6312	27	145	148	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					207	211		10.1016/0140-6736(91)90348-S	http://dx.doi.org/10.1016/0140-6736(91)90348-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676778				2022-12-24	WOS:A1991FY50400003
J	STOUT, RW; CRAWFORD, V				STOUT, RW; CRAWFORD, V			SEASONAL-VARIATIONS IN FIBRINOGEN CONCENTRATIONS AMONG ELDERLY PEOPLE	LANCET			English	Article							PLASMA; MORTALITY; PRESSURE; CORONARY; WINTER	Mortality and morbidity in elderly people are higher in winter than in summer months, with seasonal variations in rates of both fatal and non-fatal myocardial infarction and stroke. To identify factors that might contribute to the excess winter frequency of cardiovascular disease in the elderly, we studied 100 subjects aged 75 and over who lived in either their own homes or in sheltered or residential accommodation. Each person was visited each month for one year, body and environmental temperatures were noted, and cardiovascular risk factors were measured. 32 subjects withdrew from the study. Significant seasonal effects were found for fibrinogen, plasma viscosity, and HDL cholesterol (p < 0.003, Bonferroni adjustment). Plasma fibrinogen concentrations showed the greatest seasonal change and were 23% higher in the coldest six months compared with summer months. Fibrinogen was significantly (p < 0.05) and negatively related to core body temperature and all measures of environmental temperature. Those living in institutions had greater changes in plasma fibrinogen than those living in the community. The seasonal variation in plasma fibrinogen concentration is large enough to increase the risk of both myocardial infarction and stroke in winter.			STOUT, RW (corresponding author), QUEENS UNIV BELFAST, DEPT GERIATR MED, BELFAST BT7 9BL, NORTH IRELAND.							Alderson M. R., 1985, Health Trends, V4, P87; BASTOW MD, 1983, LANCET, V1, P143; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; BROOKE OG, 1973, J PHYSIOL-LONDON, V231, pP91; BULL G M, 1975, Age and Ageing, V4, P232, DOI 10.1093/ageing/4.4.232; BULL G M, 1975, Age and Ageing, V4, P19, DOI 10.1093/ageing/4.1.19; BULL G M, 1978, Age and Ageing, V7, P210, DOI 10.1093/ageing/7.4.210; BULL GM, 1979, J CLIN PATHOL, V32, P16, DOI 10.1136/jcp.32.1.16; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLINS KJ, 1986, AGE AGEING, V15, P212, DOI 10.1093/ageing/15.4.212; DIMINNO G, 1990, ARTERIOSCLEROSIS, V10, P1, DOI 10.1161/01.ATV.10.1.1; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; JARRETT RJ, 1984, DIABETOLOGIA, V27, P574, DOI 10.1007/BF00276970; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; KEATINGE WR, 1986, BRIT MED J, V293, P732, DOI 10.1136/bmj.293.6549.732-a; KEATINGE WR, 1989, INT J BIOMETEOROL, V33, P71, DOI 10.1007/BF01686280; MACMILLAN AL, 1967, LANCET, V2, P165; MARSHALL RJ, 1988, INT J EPIDEMIOL, V17, P325, DOI 10.1093/ije/17.2.325; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCKEE CM, 1989, EUR J EPIDEMIOL, V5, P178, DOI 10.1007/BF00156826; MEADE TW, 1980, LANCET, V1, P1050; WASSERTHEILSMOL.S, 1990, BIOSTATISTICS EPIDEM, P49	24	231	236	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	1991	338	8758					9	13		10.1016/0140-6736(91)90004-9	http://dx.doi.org/10.1016/0140-6736(91)90004-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676131				2022-12-24	WOS:A1991FV29600003
J	HENRY, I; BONAITIPELLIE, C; CHEHENSSE, V; BELDJORD, C; SCHWARTZ, C; UTERMANN, G; JUNIEN, C				HENRY, I; BONAITIPELLIE, C; CHEHENSSE, V; BELDJORD, C; SCHWARTZ, C; UTERMANN, G; JUNIEN, C			UNIPARENTAL PATERNAL DISOMY IN A GENETIC CANCER-PREDISPOSING SYNDROME	NATURE			English	Article							WIEDEMANN-BECKWITH SYNDROME; WILMS TUMOR; ADRENOCORTICAL CARCINOMA; CHROMOSOME-11; 11P15.5; ALLELES; TRISOMY; MARKERS; LOCUS	THE 11p15.5 region of human chromosome 11 seems to contain a locus or loci involved in congenital overgrowth anomalies as well as in the genesis of many tumours associated with the Beckwith-Wiedemann syndrome (BWS) 1-6. Given the unusual differential parental allele involvement in the different aetiological forms of BWS 5, 7 and the loss of maternal alleles in associated tumours 8-10, we have now used 11p15.5 markers to determine the parental origin of chromosome 11 in eight sporadic cases of BWS. Probands in three informative families had uniparental paternal disomy for region 11p15.5. Further, an overall greatly increased frequency of homozygosity for several 11p15.5 markers in 21 sporadic BWS patients suggest that isodisomy probably accounts for an even higher proportion of BWS sporadic cases. This demonstrates that uniparental paternal disomy can be associated with a genetic cancer-predisposing syndrome.	INSERM,U155,F-75016 PARIS,FRANCE; INSERM,U129,F-75014 PARIS,FRANCE; GREENWOOD GENET CTR,GREENWOOD,SC 29646; UNIV INNSBRUCK,A-6020 INNSBRUCK,AUSTRIA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Greenwood Genetic Center; University of Innsbruck	HENRY, I (corresponding author), INSERM,U73,CHATEAU LONGCHAMP,F-75016 PARIS,FRANCE.							ALECK K, 1985, ANN GENET-PARIS, V28, P102; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HENRY I, 1989, HUM GENET, V81, P273, DOI 10.1007/BF00279003; HENRY I, 1985, ANN HUM GENET, V49, P173, DOI 10.1111/j.1469-1809.1985.tb01691.x; JUNIEN C, 1989, CYTOGENET CELL GENET, V51, P226, DOI 10.1159/000132793; KNOLL JHM, 1990, AM J HUM GENET, V47, P149; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LUBINSKY M, 1974, LANCET, V1, P932; MANNENS M, 1988, AM J HUM GENET, V31, P41; MANNENS M, 1988, CYTOGENET CELL GENET, V46, P655; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NIIKAWA N, 1986, AM J MED GENET, V24, P41, DOI 10.1002/ajmg.1320240107; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PING AJ, 1989, AM J HUM GENET, V44, P720; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; TAKAHIKO Y, 1989, J NATL CANCER I, V81, P518; TURLEAU C, 1985, ANN GENET-PARIS, V28, P93; VOSS R, 1989, AM J HUM GENET, V45, P373; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807	23	369	375	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					665	667		10.1038/351665a0	http://dx.doi.org/10.1038/351665a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1675767				2022-12-24	WOS:A1991FT11200071
J	DESAI, KM; SESSA, WC; VANE, JR				DESAI, KM; SESSA, WC; VANE, JR			INVOLVEMENT OF NITRIC-OXIDE IN THE REFLEX RELAXATION OF THE STOMACH TO ACCOMMODATE FOOD OR FLUID	NATURE			English	Article							L-ARGININE; GLYCERYL TRINITRATE; GUANYLATE-CYCLASE; METHYLENE-BLUE; STIMULATION; NITROPRUSSIDE; INHIBITOR; MUSCLE	THE fundus of the guinea-pig stomach actively dilates in response to low increases in intragastric pressure 1. This physiological response, now called adaptive relaxation 2,3, accommodates the intake of liquid or food. It is independent of external innervation, resistant to ganglion blockade, but reflex in origin. The nerves involved are neither adrenergic nor cholinergic in nature. Non-adrenergic, non-cholinergic (NANC) nerves have now been recognized in many parts of the gastrointestinal tract 4 and have recently been linked with release of nitric oxide (NO) on electrical stimulation 5-7. Here we show that adaptive relaxation in isolated stomach of the guinea pig is mediated by a NANC neurotransmitter substance indistinguishable from NO derived from L-arginine 8. This is substantiated by inhibition of adaptive relaxation by N(G)-monomethyl-L-arginine or N-omega-nitro-L-arginine methyl ester, both inhibitors of NO synthesis 9,10, and by methylene blue, an inhibitor of soluble guanylate cyclase 11. There are two distinct neuronal pathways signalling NO-dependent adaptive relaxation, as evidenced by tetrodotoxin sensitivity. The first is a local reflex arc, the afferent fibres of which sense changes in intragastric pressure. The second is stimulated by an agonist for ganglionic nicotinic receptors. Thus, the functional significance of NO release from NANC nerves in the stomach is to bring about adaptive relaxation through a reflex response to increases in intragastric pressure.	ST BARTHOLOMEWS HOSP,COLL MED,WILLIAM HARVEY RES INST,LONDON EC1M 6BQ,ENGLAND	University of London; Queen Mary University London			Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Desai, Kaushik/0000-0001-9355-4528				ABRAHAMSSON H, 1973, ACTA PHYSL SCAND S, V390, P5; BOECKXSTAENS GE, 1991, BRIT J PHARMACOL, V102, P434, DOI 10.1111/j.1476-5381.1991.tb12191.x; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; GILLESPIE JS, 1982, MOTILIYT DIGESTIVE T; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LI CG, 1990, EUR J PHARMACOL, V191, P303; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MEYER JH, 1987, PHYSL GASTROINTESTIN; MOORE PK, 1990, BRIT J PHARMACOL, V99, P408, DOI 10.1111/j.1476-5381.1990.tb14717.x; MURPHY S, 1990, J NEUROCHEM, V55, P349, DOI 10.1111/j.1471-4159.1990.tb08860.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PATON WDM, 1963, J PHYSIOL-LONDON, V165, P10, DOI 10.1113/jphysiol.1963.sp007040; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x	18	507	519	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					477	479		10.1038/351477a0	http://dx.doi.org/10.1038/351477a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1675430				2022-12-24	WOS:A1991FP75800054
J	LITTLER, E; BAYLIS, SA; ZENG, Y; CONWAY, MJ; MACKETT, M; ARRAND, JR				LITTLER, E; BAYLIS, SA; ZENG, Y; CONWAY, MJ; MACKETT, M; ARRAND, JR			DIAGNOSIS OF NASOPHARYNGEAL CARCINOMA BY MEANS OF RECOMBINANT EPSTEIN-BARR-VIRUS PROTEINS	LANCET			English	Article							ANTIBODY; DNASE; TRANSCRIPTION; EXPRESSION	The immune response of patients with nasopharyngeal carcinoma to Epstein-Barr virus (EBV) antigens is diagnostic of the tumour. Existing tests use EBV antigens produced in EBV-infected lymphoblastoid cells, but the virus replicates poorly in these cells. Serum samples from 18 patients diagnosed as having nasopharyngeal carcinoma were screened by western blot analysis, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence tests for antibodies to the EBV-coded alkaline deoxyribonuclease (DNase), thymidine kinase, and membrane antigen (gp340/220) produced in recombinant baculovirus or bovine papillomavirus systems. Each protein was a useful diagnostic marker for nasopharyngeal carcinoma, although in the gp340/220 ELISAs there was substantial overlap for both IgG and IgA antibodies between serum samples from nasopharyngeal carcinoma patients and those from healthy donors seropositive for EBV. The EBV thymidine kinase was the most sensitive predictor of nasopharyngeal carcinoma; all such samples showed both IgG and IgA antibody responses to this protein and all gave clearly distinct titres from those of the EBV-seropositive donors in the IgA test. Each of the recombinant systems described is suitable for use in large-scale screening programmes for the early diagnosis of nasopharyngeal carcinoma.	CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,CANC RES CAMPAIGN LABS,MANCHESTER M20 9BX,LANCS,ENGLAND; CHINESE ACAD SCI,INST VIROL,BEIJING,PEOPLES R CHINA	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Chinese Academy of Sciences	LITTLER, E (corresponding author), WELLCOME RES LABS,DEPT MOLEC SCI,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND.							BAYLIS SA, 1989, NUCLEIC ACIDS RES, V17, P7609, DOI 10.1093/nar/17.19.7609; BAYLIS SA, 1991, VIROLOGY, V181, P390, DOI 10.1016/0042-6822(91)90511-9; CHEN JY, 1989, J MED VIROL, V27, P269, DOI 10.1002/jmv.1890270403; CHENG YC, 1980, P NATL ACAD SCI-BIOL, V77, P6162, DOI 10.1073/pnas.77.10.6162; CONWAY M, 1989, J GEN VIROL, V70, P729, DOI 10.1099/0022-1317-70-3-729; HENLE W, 1970, J NATL CANCER I, V44, P225; HENLE W, 1973, JNCI-J NATL CANCER I, V51, P361; LI SL, 1982, TUMOURS HEAD NECK, P251; LITTLER E, 1990, INT J CANCER, V45, P1028, DOI 10.1002/ijc.2910450608; LIU MY, 1989, J MED VIROL, V28, P101, DOI 10.1002/jmv.1890280209; NEILSEN NH, 1977, ACTA PATHOL MICROB A, V5, P850; RAABTRAUB N, 1983, J VIROL, V48, P580, DOI 10.1128/JVI.48.3.580-590.1983; SHANMUGARATNAM K, 1979, CANCER, V44, P1029, DOI 10.1002/1097-0142(197909)44:3<1029::AID-CNCR2820440335>3.0.CO;2-5; SHANMUGARATNAM K, 1972, IARC SCI PUBL, V2, P239; SIMMONS MJ, 1982, UICC71 TECHN REP; TAN RS, 1982, INT J CANCER, V30, P561, DOI 10.1002/ijc.2910300505; TUGWOOD JD, 1987, J GEN VIROL, V68, P1081, DOI 10.1099/0022-1317-68-4-1081; TURENNETESSIER M, 1989, INT J CANCER, V43, P45; Waterhouse JA, 1982, IARC SCI PUBLICATION, VIV; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZENG J, 1983, INT J CANCER, V31, P599, DOI 10.1002/ijc.2910310511; ZENG Y, 1983, INTERVIROLOGY, V20, P190, DOI 10.1159/000149391; ZENG Y, 1987, Chinese Journal of Virology, V3, P396; ZURHAUSEN H, 1970, NATURE, V228, P1956; 1950, NCI MONOGRAPH, V59	25	38	41	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					685	689		10.1016/0140-6736(91)90275-T	http://dx.doi.org/10.1016/0140-6736(91)90275-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672175				2022-12-24	WOS:A1991FD36700006
J	VANDIJK, JG; DORRESTEIJN, M; HAAN, J; FERRARI, MD				VANDIJK, JG; DORRESTEIJN, M; HAAN, J; FERRARI, MD			NO CONFIRMATION OF VISUAL EVOKED-POTENTIAL DIAGNOSTIC-TEST FOR MIGRAINE	LANCET			English	Note								We have attempted to replicate the results of studies on a diagnostic test reported to have 90% sensitivity and 89-96% specificity for migraine. The technique is based on peak-to-peak measurements of fast background electroencephalographic activity during a visual evoked potential (VEP) study. VEP latencies and amplitudes did not differ significantly, and showed substantial overlap, between a group of eight migraine patients and ten age-matched healthy controls. We could not recognise previously described fast activity or measure it objectively by peak-to-peak measurements. We cannot confirm that measurement of fast wave activity in the VEP background is useful in diagnosis of migraine.			VANDIJK, JG (corresponding author), LEIDEN UNIV HOSP,DEPT NEUROL CLIN NEUROPHYSIOL,POB 9600,2300 RC LEIDEN,NETHERLANDS.							MARSTERS JB, 1988, HEADACHE, V28, P526, DOI 10.1111/j.1526-4610.1988.hed2808526.x; MORTIMER MJ, 1990, LANCET, V335, P789, DOI 10.1016/0140-6736(90)90903-I; MORTIMER MJ, 1990, HEADACHE, V30, P285, DOI 10.1111/j.1526-4610.1990.hed3005285.x; MORTIMER MJ, 1990, LANCET, V335, P75, DOI 10.1016/0140-6736(90)90541-C; Regan D., 1989, HUMAN BRAIN ELECTROP; VANDIJK JG, 1990, LANCET, V335, P480; VANDIJK JG, 1989, NEW TRENDS CLIN NEUR, P107; WINTER AL, 1987, MIGRAINE CLIN THERAP, P485; 1988, CEPHALALGIA S, V7, P1	9	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					517	518		10.1016/0140-6736(91)91298-9	http://dx.doi.org/10.1016/0140-6736(91)91298-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671891				2022-12-24	WOS:A1991EZ87400005
J	HANES, SD; BRENT, R				HANES, SD; BRENT, R			A GENETIC MODEL FOR INTERACTION OF THE HOMEODOMAIN RECOGNITION HELIX WITH DNA	SCIENCE			English	Article							DROSOPHILA EMBRYO; TRANSCRIPTIONAL ACTIVATOR; ANTENNAPEDIA HOMEODOMAIN; BINDING-SPECIFICITY; ANTERIOR PATTERN; LAMBDA-REPRESSOR; BICOID PROTEIN; AMINO-ACID; SEQUENCE; OPERATOR	The Bicoid homeodomain protein controls anterior development in the Drosophila embryo by binding to DNA and regulating gene expression. With the use of genetic assays in yeast, the interaction between the Bicoid homeodomain and a series of mutated DNA sites was studied. These experiments defined important features of homeodomain binding sites, identified specific amino acid-base pair contacts, and suggested a model for interaction of the recognition alpha-helices of Bicoid and Antennapedia-class homeodomain proteins with DNA. The model is in general agreement with results of crystallographic and magnetic resonance studies, but differs in important details. It is likely that genetic studies of protein-DNA interaction will continue to complement conventional structural approaches.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	HANES, SD (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HANES SD, UNPUB; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HOCHSCHILD A, 1986, CELL, V44, P925, DOI 10.1016/0092-8674(86)90015-2; HOCHSCHILD A, 1986, CELL, V47, P807, DOI 10.1016/0092-8674(86)90523-4; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HORTON RM, 1990, BIOTECHNIQUES, V8, P538; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEHMING N, 1987, EMBO J, V6, P3145, DOI 10.1002/j.1460-2075.1987.tb02625.x; LEHMING N, 1990, NATURE, V9, P615; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; OHLENDORF DH, 1982, NATURE, V298, P718, DOI 10.1038/298718a0; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; SAMSON ML, 1989, CELL, V57, P1145; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STAACKE D, 1990, EMBO J, V9, P1963, DOI 10.1002/j.1460-2075.1990.tb08324.x; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TREISMAN J, 1989, CELL, V59, P553; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0	41	201	206	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					426	430		10.1126/science.1671176	http://dx.doi.org/10.1126/science.1671176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1671176				2022-12-24	WOS:A1991EU50400040
J	MCGILL, N; DIEPPE, PA; BOWDEN, M; GARDINER, DJ; HALL, M				MCGILL, N; DIEPPE, PA; BOWDEN, M; GARDINER, DJ; HALL, M			IDENTIFICATION OF PATHOLOGICAL MINERAL-DEPOSITS BY RAMAN MICROSCOPY	LANCET			English	Note							CRYSTAL DEPOSITION	Raman microscopy-the analysis of scattered photons after excitation-is well established in non-biological sciences for the identification of crystals. It shows promise in biological (clinical) specimens also, as demonstrated here in studies of synovial fluid, and gouty tophus, selected for their known content of sodium urate and calcium pyrophosphate crystals.	NEWCASTLE POLYTECH,DEPT CHEM & LIFE SCI,NEWCASTLE TYNE NE1 8ST,TYNE & WEAR,ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP,RHEUMATOL UNIT,BRISTOL BS2 8HW,AVON,ENGLAND	Northumbria University; Bristol Royal Infirmary								ANDERSON HC, 1988, RHEUM DIS CLIN N AM, V14, P303; BOWDEN M, 1990, 12TH P INT C RAM SPE, P844; DIEPPE P, 1988, RHEUM DIS CLIN N AM, V14, P415; DIEPPE P, 1985, CLIN RHEUM DIS, V11, P367; ETZ ES, 1986, MICROBEAM ANAL, V21, P39; Gardiner D., 1989, PRACTICAL RAMAN SPEC; GARDINER DJ, 1986, PHILOS T R SOC A, V320, P295, DOI 10.1098/rsta.1986.0118; HARRIES JE, 1983, ANN RHEUM DIS, V42, P100, DOI 10.1136/ard.42.Suppl_1.100	8	27	27	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					77	78		10.1016/0140-6736(91)90738-B	http://dx.doi.org/10.1016/0140-6736(91)90738-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670728				2022-12-24	WOS:A1991ER47700006
J	ROTZSCHKE, O; FALK, K; WALLNY, HJ; FAATH, S; RAMMENSEE, HG				ROTZSCHKE, O; FALK, K; WALLNY, HJ; FAATH, S; RAMMENSEE, HG			CHARACTERIZATION OF NATURALLY-OCCURRING MINOR HISTOCOMPATIBILITY PEPTIDES INCLUDING H-4 AND H-Y	SCIENCE			English	Article									MAX PLANCK INST BIOL, IMMUNGENET ABT, W-7400 TUBINGEN, GERMANY	Max Planck Society			Roetzschke, Olaf/GXH-0012-2022					BEVAN MJ, 1975, NATURE, V256, P419, DOI 10.1038/256419a0; BILLINGHAM RE, 1981, HUM GENET, V58, P9, DOI 10.1007/BF00284141; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; DAVIS AP, 1990, IMMUNOGENETICS, V31, P7, DOI 10.1007/BF00702483; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DEPLAEN E, 1988, P NATL ACAD SCI USA, V85, P2274; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; EICHWALD EJ, 1955, TRANSPLAN B, V2, P121; FALK K, UNPUB; GORDON RD, 1975, J EXP MED, V142, P1108, DOI 10.1084/jem.142.5.1108; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; GRAFF RJ, 1987, IMMUNOGENETICS, V26, P111, DOI 10.1007/BF00345464; KAUFMANN SHE, 1986, J EXP MED, V164, P363, DOI 10.1084/jem.164.1.363; LINDAHL KF, 1989, COLD SH Q B, V54, P563; LOVELAND B, 1986, IMMUNOL TODAY, V7, P223, DOI 10.1016/0167-5699(86)90109-X; MCMICHAEL AJ, COMMUNICATION; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; RAMMENSEE HG, 1983, IMMUNOGENETICS, V17, P637, DOI 10.1007/BF00366131; RAMMENSEE HG, 1989, IMMUNOGENETICS, V30, P296, DOI 10.1007/BF02421334; RAMMENSEE HG, 1986, NATURE, V319, P502, DOI 10.1038/319502a0; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; SCHILD H, 1990, SCIENCE, V247, P1587, DOI 10.1126/science.2321019; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SNELL GD, 1961, IMMUNOLOGY, V4, P366; SPEISER DE, 1990, P NATL ACAD SCI USA, V87, P2021, DOI 10.1073/pnas.87.5.2021; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; VONBOEHMER H, 1989, IMMUNOL TODAY, V10, P57, DOI 10.1016/0167-5699(89)90307-1; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; WETTSTEIN PJ, 1982, J IMMUNOL, V128, P2629; WETTSTEIN PJ, 1986, J IMMUNOL, V137, P2073; WETTSTEIN PJ, 1989, HUMAN IMMUNOGENETICS, P339; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	38	206	211	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 20	1990	249	4966					283	287		10.1126/science.1695760	http://dx.doi.org/10.1126/science.1695760			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP599	1695760				2022-12-24	WOS:A1990DP59900036
J	SIEGELMAN, MH; CHENG, IC; WEISSMAN, IL; WAKELAND, EK				SIEGELMAN, MH; CHENG, IC; WEISSMAN, IL; WAKELAND, EK			THE MOUSE LYMPH-NODE HOMING RECEPTOR IS IDENTICAL WITH THE LYMPHOCYTE CELL-SURFACE MARKER LY-22 - ROLE OF THE EGF DOMAIN IN ENDOTHELIAL BINDING	CELL			English	Article									UNIV FLORIDA, MED CTR, DEPT PATHOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida	SIEGELMAN, MH (corresponding author), STANFORD UNIV, MED CTR,SCH MED,HOWARD HUGHES MED INST, DEPT PATHOL, EXPTL ONCOL LAB, STANFORD, CA 94305 USA.			CHENG, IVAN-CHEN/0000-0002-0168-3902	NCI NIH HHS [CA42551] Funding Source: Medline; NIAID NIH HHS [AI09072, AI17966] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017966] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; ALTMAN PL, 1979, INBRED GENETICALLY 1, P16; APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAILEY D, 1981, MOUSE BIOMEDICAL RES; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOCK SC, 1985, CYTOGENET CELL GENET, V39, P67, DOI 10.1159/000132105; BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; BUTCHER EC, 1979, J IMMUNOL, V123, P1996; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CHAN MM, 1983, J IMMUNOL, V130, P2075; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN S, 1982, J BIOL CHEM, V257, P1523; DAILEY MO, 1985, J MOL CELL IMMUNOL, V2, P27; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; FINK PJ, 1985, NATURE, V313, P233, DOI 10.1038/313233a0; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KANSAS GS, 1985, J IMMUNOL, V134, P2995; KANSAS GS, 1985, J IMMUNOL, V134, P3003; KOMORIYA A, 1984, P NATL ACAD SCI-BIOL, V81, P1351, DOI 10.1073/pnas.81.5.1351; KREITMAN ME, 1986, GENETICS, V114, P93; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LIEBERMAN M, 1979, INT J CANCER, V24, P168, DOI 10.1002/ijc.2910240208; MARCHESI VT, 1964, PROC R SOC SER B-BIO, V159, P283, DOI 10.1098/rspb.1964.0002; MCCONNELL TJ, 1986, J IMMUNOL, V136, P3076; MCINTYRE BW, 1984, CELL, V38, P659, DOI 10.1016/0092-8674(84)90260-5; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PINK J, 1979, RES METHODS IMMUNOLO, V1, P169; REICHERT RA, 1983, J EXP MED, V157, P813, DOI 10.1084/jem.157.3.813; REICHERT RA, 1986, J IMMUNOL, V136, P3535; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; RICE MC, 1980, NATURE, V283, P157, DOI 10.1038/283157a0; RUDIKOFF S, 1976, P NATL ACAD SCI USA, V73, P2109, DOI 10.1073/pnas.73.6.2109; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; Seldin MF, 1988, GENOMICS, V2, P48, DOI 10.1016/0888-7543(88)90108-5; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; SIEGELMAN M, 1988, UBIQUITIN, P239; SIEGELMAN MH, 1989, P NATL ACAD SCI USA, V86, P5562, DOI 10.1073/pnas.86.14.5562; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SINGER PA, 1988, P NATL ACAD SCI USA, V85, P7729, DOI 10.1073/pnas.85.20.7729; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; STJOHN T, 1986, SCIENCE, V231, P845, DOI 10.1126/science.3003914; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; STOOLMAN LM, 1987, BLOOD, V70, P1842; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; TADA N, 1983, HYBRIDOMA, V2, P29, DOI 10.1089/hyb.1983.2.29; TAKADA S, 1989, J IMMUNOL, V142, P3038; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; USHIRO H, 1980, J BIOL CHEM, V255, P8363; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713; YEDNOCK TA, 1984, J CELL BIOL, V99, pA68; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725	68	112	121	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 18	1990	61	4					611	622		10.1016/0092-8674(90)90473-R	http://dx.doi.org/10.1016/0092-8674(90)90473-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DE904	1693096				2022-12-24	WOS:A1990DE90400007
J	MORIYAMA, T; GUILHOT, S; KLOPCHIN, K; MOSS, B; PINKERT, CA; PALMITER, RD; BRINSTER, RL; KANAGAWA, O; CHISARI, FV				MORIYAMA, T; GUILHOT, S; KLOPCHIN, K; MOSS, B; PINKERT, CA; PALMITER, RD; BRINSTER, RL; KANAGAWA, O; CHISARI, FV			IMMUNOBIOLOGY AND PATHOGENESIS OF HEPATOCELLULAR INJURY IN HEPATITIS-B VIRUS TRANSGENIC MICE	SCIENCE			English	Article									SCRIPPS CLIN & RES FDN,RES INST,LA JOLLA,CA 92037; NIAID,BETHESDA,MD 20205; LILLY RES LABS,LA JOLLA,CA 92037; UNIV PENN,PHILADELPHIA,PA 19104; UNIV WASHINGTON,SEATTLE,WA 98195	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Eli Lilly; University of Pennsylvania; University of Washington; University of Washington Seattle			Chisari, Francis V/A-3086-2008	Brinster, Ralph/0000-0003-1408-7656; Pinkert, Carl/0000-0001-7460-3881; Moss, Bernard/0000-0002-2154-8564; Chisari, Francis/0000-0002-4832-1044	NATIONAL CANCER INSTITUTE [R01CA034635, R01CA038635, R01CA040489, R37CA040489] Funding Source: NIH RePORTER; NCI NIH HHS [CA40489, CA38635, CA34635] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNABA V, 1989, J IMMUNOL, V143, P2650; CELIS E, 1988, J IMMUNOL, V140, P1808; CHENG KC, 1986, J VIROL, V60, P337, DOI 10.1128/JVI.60.2.337-344.1986; CHENG KC, 1987, J VIROL, V61, P1286, DOI 10.1128/JVI.61.4.1286-1290.1987; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; CHISARI FV, 1989, MICROB PATHOGENESIS, V6, P311, DOI 10.1016/0882-4010(89)90073-9; CHISARI FV, UNPUB; FERRARI C, 1987, J IMMUNOL, V139, P2050; FRANCO A, 1988, HEPATOLOGY, V8, P449, DOI 10.1002/hep.1840080302; HORDER M, 1981, SCAND J CLIN LAB INV, V41, P107, DOI 10.3109/00365518109092022; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEVY GA, 1981, SPRINGER SEMIN IMMUN, V3, P439, DOI 10.1007/BF01951492; MONDELLI M, 1982, J IMMUNOL, V129, P2773; MORIYAMA T, 1988, CELL IMMUNOL, V111, P482, DOI 10.1016/0008-8749(88)90111-6; MORIYAMA T, UNPUB, P37001; SI L, 1983, J CLIN IMMUNOL, V3, P408, DOI 10.1007/BF00915803; SKOSKIEWICZ MJ, 1985, J EXP MED, V162, P1645, DOI 10.1084/jem.162.5.1645; SMITH GL, 1983, NATURE, V302, P490, DOI 10.1038/302490a0; SPRENT J, 1986, NATURE, V322, P541, DOI 10.1038/322541a0; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOWNSEND ARM, 1983, IMMUNOGENETICS, V17, P283, DOI 10.1007/BF00364412	25	322	341	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 20	1990	248	4953					361	364		10.1126/science.1691527	http://dx.doi.org/10.1126/science.1691527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ837	1691527				2022-12-24	WOS:A1990CZ83700037
J	MERRIL, CR				MERRIL, CR			SILVER STAINING OF PROTEINS AND DNA	NATURE			English	Article											MERRIL, CR (corresponding author), NIMH,BLDG 10,BETHESDA,MD 20892, USA.							GOLDMAN D, 1980, CLIN CHEM, V26, P1317; HARRINGTON MG, 1986, NEW ENGL J MED, V315, P279, DOI 10.1056/NEJM198607313150502; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P412, DOI 10.1016/0003-2697(88)90208-4; MERRIL CR, 1986, ACTA HISTOCHEM CYTOC, V19, P655, DOI 10.1267/ahc.19.655; MERRIL CR, 1986, ANAL BIOCHEM, V156, P96, DOI 10.1016/0003-2697(86)90160-0; MERRIL CR, 1984, ELECTROPHORESIS, V5, P289, DOI 10.1002/elps.1150050509; MERRIL CR, 1988, P NATL ACAD SCI USA, V85, P453, DOI 10.1073/pnas.85.2.453; MERRIL CR, 1984, 2 DIMENSIONAL GEL EL, P93; MERRIL CR, 1987, ADV ELECTROPHORESIS, V1, P111; NIELSEN BL, 1984, ANAL BIOCHEM, V141, P311, DOI 10.1016/0003-2697(84)90047-2; OCHS D, 1983, ANAL BIOCHEM, V135, P470, DOI 10.1016/0003-2697(83)90714-5; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303	12	70	74	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1990	343	6260					779	780		10.1038/343779a0	http://dx.doi.org/10.1038/343779a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP807	1689465				2022-12-24	WOS:A1990CP80700068
J	SAVILL, J; DRANSFIELD, I; HOGG, N; HASLETT, C				SAVILL, J; DRANSFIELD, I; HOGG, N; HASLETT, C			VITRONECTIN RECEPTOR-MEDIATED PHAGOCYTOSIS OF CELLS UNDERGOING APOPTOSIS	NATURE			English	Article									IMPERIAL CANC RES FUND,MACROPHAGE LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	SAVILL, J (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0HS,ENGLAND.			Dransfield, Ian/0000-0001-5848-7059				BROWN DL, 1989, J CLIN INVEST, V84, P366, DOI 10.1172/JCI114166; BROWN EJ, 1988, J EXP MED, V167, P777, DOI 10.1084/jem.167.3.777; BURNS GF, 1986, CELL, V45, P269, DOI 10.1016/0092-8674(86)90391-0; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; MORGANELLI PM, 1988, J IMMUNOL, V140, P2296; MYONES BL, 1988, J CLIN INVEST, V82, P640, DOI 10.1172/JCI113643; NACHMAN RL, 1982, J CLIN INVEST, V69, P263, DOI 10.1172/JCI110448; NEWMAN SL, 1982, J EXP MED, V156, P430, DOI 10.1084/jem.156.2.430; PHILLIPS DR, 1988, BLOOD, V71, P831; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SAVILL JS, 1989, J CLIN INVEST, V84, P1518, DOI 10.1172/JCI114328; SAVILL JS, 1989, THESIS U LONDON; Wright S D, 1986, Methods Enzymol, V132, P204; WRIGHT SD, 1988, J CELL SCI S, V9, P251; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1984, J PATHOL, V142, P62	30	732	742	1	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1990	343	6254					170	173		10.1038/343170a0	http://dx.doi.org/10.1038/343170a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH527	1688647				2022-12-24	WOS:A1990CH52700060
J	MILLIGAN, DL; KOSHLAND, DE				MILLIGAN, DL; KOSHLAND, DE			INTRASUBUNIT SIGNAL TRANSDUCTION BY THE ASPARTATE CHEMORECEPTOR	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; DIRECTED CROSS-LINKING; HUMAN INSULIN-RECEPTOR; ESCHERICHIA-COLI; PROTEIN METHYLATION; PHOSPHORYLATION; DIMERIZATION; ADAPTATION; ACTIVATION; FAMILY	Receptors that transmit signals across cell membranes are typically composed of multiple subunits. To test whether subunit interactions are required for transmembrane signaling by the bacterial aspartate receptor, dimers were constructed with (i) two full-length subunits, (ii) one full-length subunit and one subunit lacking the cytoplasmic domain, or (iii) one full-length subunit and one subunit lacking both the cytoplasmic and the transmembrane domains. Methylation of the cytoplasmic domain of all three receptor constructs was stimulated by the binding of aspartate. These findings demonstrate that transmembrane signaling does not require interactions between cytoplasmic or transmembrane domains of adjacent subunits and suggest that signaling occurs via conformational changes transduced through a single subunit.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	MILLIGAN, DL (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.				NIDDK NIH HHS [DK 09765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, UNPUB; MOWBRAY SL, 1985, J BIOL CHEM, V260, P1711; PESSIN JE, 1985, MOL BASIS INSULIN AC, P3; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	25	82	82	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1651	1654		10.1126/science.1661030	http://dx.doi.org/10.1126/science.1661030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1661030				2022-12-24	WOS:A1991GV07300047
J	PATTERSON, DLH; TREASURE, T				PATTERSON, DLH; TREASURE, T			THE CULPRIT CORONARY-ARTERY LESION	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; DISEASE		ST GEORGE HOSP,DEPT CARDIOTHORAC,LONDON,ENGLAND	St Georges University London	PATTERSON, DLH (corresponding author), WHITTINGTON HOSP,DEPT CARDIAC,HIGHGATE HILL,LONDON N19 5NF,ENGLAND.							BROWN G, 1990, NEW ENGL J MED, V323, P1989; DETRE K, 1981, CIRCULATION, V63, P1329, DOI 10.1161/01.CIR.63.6.1329; HACKETT D, 1988, EUR HEART J, V9, P1317, DOI 10.1093/oxfordjournals.eurheartj.a062449; HAFT JI, 1988, CHEST, V94, P731, DOI 10.1378/chest.94.4.731; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MCHENRY PL, 1984, CIRCULATION, V70, P547, DOI 10.1161/01.CIR.70.4.547; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; RENTROP KP, 1988, AM J CARDIOL, V61, P677, DOI 10.1016/0002-9149(88)91048-X; 1980, LANCET, V2, P1173; 1983, CIRCULATION, V68, P939	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1991	338	8779					1379	1380		10.1016/0140-6736(91)92248-Z	http://dx.doi.org/10.1016/0140-6736(91)92248-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682748				2022-12-24	WOS:A1991GR77300015
J	NIMMANNIT, S; MALASIT, P; CHAOVAKUL, V; SUSAENGRAT, W; VASUVATTAKUL, S; NILWARANGKUR, S				NIMMANNIT, S; MALASIT, P; CHAOVAKUL, V; SUSAENGRAT, W; VASUVATTAKUL, S; NILWARANGKUR, S			PATHOGENESIS OF SUDDEN UNEXPLAINED NOCTURNAL DEATH (LAI TAI) AND ENDEMIC DISTAL RENAL TUBULAR-ACIDOSIS	LANCET			English	Editorial Material							ASIAN REFUGEES; SLEEP; THAILAND	Sudden unexplained nocturnal death (SUND), a disorder of unknown cause that occurs in otherwise healthy young adults, mostly male, during their sleep, is prevalent in the north-east region of Thailand, where it has been known for generations as lai tai. It occurs in the same population and area where hypokalaemic periodic paralysis (HPP), endemic distal renal tubular acidosis (EdRTA), and renal stones are also endemic. SUND has occurred in families of patients with EdRTA, and HPP can present as sudden onset of muscle paralysis with potentially lethal cardiac arrhythmias and respiratory failure from severe hypokalaemia occurring in the middle of the night. Surveys in which serum and urinary potassium have been measured indicate a deficiency of the electrolyte in the population. Potassium deficiency is probably the prime factor responsible for SUND and HPP. Low urinary citrate concentrations and the high prevalence of acidification defects in the population indicate that potassium deficiency is also responsible for the prevalence of EdRTA and for renal stones.	UBOLRAJATHANI HOSP,BANGKOK,THAILAND; KHONKAEN HOSP,BANGKOK,THAILAND		NIMMANNIT, S (corresponding author), MAHIDOL UNIV,SIRIRAJ HOSP,DEPT MED,RENAL UNIT,BANGKOK 10700,THAILAND.							ANDRES R, 1957, J CLIN INVEST, V36, P723, DOI 10.1172/JCI103475; APONTE GE, 1960, ANN INTERN MED, V52, P1258, DOI 10.7326/0003-4819-52-6-1258; CHAMBUMRUNG S, 1985, AM J CLIN NUTR, V41, P770; DEFONZO R, 1981, KIDNEY INT, V20, P83; GOH KT, 1990, LANCET, V335, P1154, DOI 10.1016/0140-6736(90)91153-2; HALPERIN M, 1991, CLIN DISORDER FLUID; HALPERIN ML, 1989, KIDNEY INT, V35, P1277, DOI 10.1038/ki.1989.122; HELFANT RH, 1986, AM J MED, V80, P13, DOI 10.1016/0002-9343(86)90336-0; KNEPPER MA, 1989, PHYSIOL REV, V69, P179, DOI 10.1152/physrev.1989.69.1.179; KNOCHEL JP, 1972, J CLIN INVEST, V51, P1750, DOI 10.1172/JCI106976; MOORE FJ, 1974, THAILAND ITS PEOPLE; MUNGER RG, 1986, LANCET, V2, P1093; MUNGER RG, 1987, AM J PUBLIC HEALTH, V77, P1187, DOI 10.2105/AJPH.77.9.1187; MUNGER RG, 1990, LANCET, V335, P1154, DOI 10.1016/0140-6736(90)91154-3; NATH KA, 1985, J CLIN INVEST, V76, P667, DOI 10.1172/JCI112020; NATH KA, 1989, KIDNEY INT, V36, pS52; NILWARANGKUR S, 1990, Q J MED, V74, P289; NILWARANGKUR S, 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P437; NIMMANNIT S, 1990, LANCET, V336, P116, DOI 10.1016/0140-6736(90)91631-J; NIMMANNIT S, 1989, 6TH P INT S UR NEW Y, P681; OTTO CM, 1984, ANN INTERN MED, V100, P45; TATSANAVIVAT A, 1991, 7TH ANN M ROYAL COLL, P101; WILLIAMS ME, 1985, NEW ENGL J MED, V312, P923; ZIERLER KL, 1957, J CLIN INVEST, V36, P730, DOI 10.1172/JCI103476; 1981, MMWR, V30, P581; 1948, J PHILIPP MED ASSOC, V24, P627	26	50	52	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					930	932		10.1016/0140-6736(91)91786-T	http://dx.doi.org/10.1016/0140-6736(91)91786-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681278				2022-12-24	WOS:A1991GJ89900016
J	TANG, CM; SHI, QY; KATCHMAN, A; LYNCH, G				TANG, CM; SHI, QY; KATCHMAN, A; LYNCH, G			MODULATION OF THE TIME COURSE OF FAST EPSCS AND GLUTAMATE CHANNEL KINETICS BY ANIRACETAM	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; QUISQUALATE RECEPTORS; DESENSITIZATION; CURRENTS; POTENTIATION	It is generally accepted that glutamate serves as the neurotransmitter at most excitatory synapses in the mammalian central nervous system (CNS). Synaptic release of glutamate may trigger a fast and a slow excitatory postsynaptic current (EPSC). The slow EPSC is mediated by N-methyl-D-aspartate (NMDA) receptor channels, whereas the fast EPSC is mediated by non-NMDA receptor channels. The nootropic agent aniracetam selectively and reversibly slows the desensitization kinetics of non-NMDA channels and lengthens their single-channel open times. Aniracetam also modulates the kinetics of the fast EPSC in a manner that mirrors its action on the kinetics of the non-NMDA channels. These results support the hypothesis that the properties of the non-NMDA glutamate channels rather than the rate of neurotransmitter clearance are the primary determinants of the kinetics of the fast EPSC in the mammalian CNS.	UNIV CALIF IRVINE,BONNEY CTR LEARNING & MEMORY,IRVINE,CA 92717; GRAD HOSP PHILADELPHIA,PHILADELPHIA,PA 19146	University of California System; University of California Irvine; University of Pennsylvania; Pennsylvania Medicine	TANG, CM (corresponding author), UNIV PENN,DEPT NEUROL,PHILADELPHIA,PA 19104, USA.				NINDS NIH HHS [NS28158] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028158] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; FROSTL W, 1989, PHARMACOPSYCHIATRY, V22, P54, DOI 10.1055/s-2007-1014626; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; ITO I, 1990, J PHYSIOL-LONDON, V424, P533, DOI 10.1113/jphysiol.1990.sp018081; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P173, DOI 10.1113/jphysiol.1972.sp009840; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; STAUBLI U, IN PRESS HIPPOCAMPUS; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; WESTBROOK GL, 1989, SEMINARS NEUROSCIENC, V1, P103; XIAO P, IN PRESS HIPPOCAMPUS; ZORUMSKI CF, 1989, CELL MOL NEUROBIOL, V9, P95, DOI 10.1007/BF00711446; ZORUMSKI CF, 1990, SOC NEUR ABSTR, V16, P547	16	183	185	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					288	290		10.1126/science.1681589	http://dx.doi.org/10.1126/science.1681589			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1681589				2022-12-24	WOS:A1991GJ64200040
J	DOCKRELL, HM; EASTCOTT, H; YOUNG, S; MACFARLANE, A; HUSSAIN, R; WATERS, MFR				DOCKRELL, HM; EASTCOTT, H; YOUNG, S; MACFARLANE, A; HUSSAIN, R; WATERS, MFR			POSSIBLE TRANSMISSION OF MYCOBACTERIUM-LEPRAE IN A GROUP OF UK LEPROSY CONTACTS	LANCET			English	Article							HOUSEHOLD CONTACTS; ANTIGEN; ANTIBODIES; SERODIAGNOSIS; TUBERCULOSIS; AGE	A case of infectious leprosy in residential accommodation in the UK prompted a study of the cellular and humoral response to Mycobacterium leprae in two groups of individuals who were in contact with the index case for almost a year. In the younger staff group (mean age 44 years) 23 of 30 individuals had positive Mitsuda skin tests, 25 showed lymphocyte transformation to a soluble sonicate of M leprae and 2 had slightly raised IgM antibody concentrations to the terminal disaccharide of M leprae phenolic glycolipid-1. In the older group of residents (mean age 83 years) 7 of 36 individuals were skin-test-positive, 25 of 33 were positive by lymphocyte transformation, but none had raised antibody levels. When retested on two further occasions, the same 2 individuals in the younger group still had raised antibody concentrations, 1 of whom had a persistent lepromin skin-test response for over 8 months and showed a pronounced increase in lymphocyte transformation to mycobacterial antigens. The findings suggest that transmission of M leprae may have occurred in these 2 contacts, who were therefore given 6 months' chemoprophylaxis with rifampicin.	MID DOWNS HLTH AUTHOR, HAYWARDS HEATH, W SUSSEX, ENGLAND; AGA KHAN UNIV, FAC HLTH SCI, DEPT MICROBIOL, KARACHI, PAKISTAN; HOSP TROP DIS, LONDON NW1 0PE, ENGLAND	Aga Khan University; University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	DOCKRELL, HM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT CLIN SCI, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Hussain, Rabia/E-9982-2015	Dockrell, Hazel/0000-0003-1869-9107				ADLER WH, 1990, PRINCIPLES GERIATRIC, P60; BAGSHAWE AF, 1990, INT J LEPROSY, V58, P25; BUCHANAN TM, 1983, INT J LEPROSY, V51, P638; CHANTEAU S, 1987, INT J LEPROSY, V55, P626; CHO SN, 1984, J INFECT DIS, V150, P311, DOI 10.1093/infdis/150.3.311; DESFORGES S, 1989, INT J LEPROSY, V57, P794; DOCKRELL HM, 1989, INFECT IMMUN, V57, P1979, DOI 10.1128/IAI.57.7.1979-1983.1989; DOUGLAS JT, 1987, INT J LEPROSY, V55, P718; GODAL T, 1973, BRIT MED J, V3, P557, DOI 10.1136/bmj.3.5880.557; GONZALEZABREU E, 1990, LEPROSY REV, V61, P145; HASAN R, 1989, INT J LEPROSY, V57, P766; HUNTER SW, 1982, J BIOL CHEM, V257, P5072; HUSSAIN R, 1990, INT J LEPROSY, V58, P491; JOPLING WH, 1991, LEPROSY REV, V62, P1; MacLeod JMH, 1925, BMJ-BRIT MED J, V1925, P107, DOI 10.1136/bmj.1.3342.107; Makinodan T, 1980, Adv Immunol, V29, P287, DOI 10.1016/S0065-2776(08)60047-4; STEAD WW, 1981, ANN INTERN MED, V94, P606, DOI 10.7326/0003-4819-94-5-606; STEAD WW, 1983, J INFECT DIS, V147, P951, DOI 10.1093/infdis/147.5.951; WATERS MFR, 1973, INT J LEPROSY, V41, P563; WILLIAMS DL, 1990, J INFECT DIS, V162, P193, DOI 10.1093/infdis/162.1.193; YOUNG DB, 1983, SCIENCE, V221, P1057, DOI 10.1126/science.6348948; 1980, BRIT MED J, V281, P895	22	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1991	338	8769					739	743		10.1016/0140-6736(91)91454-3	http://dx.doi.org/10.1016/0140-6736(91)91454-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679878				2022-12-24	WOS:A1991GG10400015
J	MARTIN, J; LANGER, T; BOTEVA, R; SCHRAMEL, A; HORWICH, AL; HARTL, FU				MARTIN, J; LANGER, T; BOTEVA, R; SCHRAMEL, A; HORWICH, AL; HARTL, FU			CHAPERONIN-MEDIATED PROTEIN FOLDING AT THE SURFACE OF GROEL THROUGH A MOLTEN GLOBULE-LIKE INTERMEDIATE	NATURE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; LIVER DIHYDROFOLATE-REDUCTASE; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; PRECURSOR PROTEINS; RIBULOSEBISPHOSPHATE-CARBOXYLASE; ATP HYDROLYSIS; RHODANESE; HSP60; MITOCHONDRIA	Folding of two monomeric enzymes mediated by groE has been reconstituted in vitro. The groEL protein stabilizes the polypeptides in a conformation resembling the 'molten globule' state. Mg-ATP and groES then promote the acquisition of ordered tertiary structure at the surface of groEL. Folding requires the hydrolysis of about 100 ATP molecules per protein monomer. This active process of surface-mediated chain folding might represent a general mechanism for the formation of protein structure in vivo.	UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,W-8000 MUNICH 2,GERMANY; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510; UNIV MUNICH,INST ZOOL,W-8000 MUNICH 2,GERMANY	University of Munich; Howard Hughes Medical Institute; Yale University; Yale University; University of Munich			Hartl, F. Ulrich/Y-8206-2019	Langer, Thomas/0000-0003-1250-1462				BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P327; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FAYET O, 1986, MOL GEN GENET, V202, P35; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2206; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GARVEY EP, 1989, PROTEINS, V6, P259, DOI 10.1002/prot.340060308; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTL FU, IN PRESS SEMIN IMMUN; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUANG SM, 1989, BIOCHEMISTRY-US, V28, P471, DOI 10.1021/bi00428a010; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KUMAR AA, 1980, BIOCHEMISTRY-US, V19, P667, DOI 10.1021/bi00545a010; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MATTHEWS DA, 1985, J BIOL CHEM, V260, P381; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OSTOASALOMA P, 1990, BIOCHIM BIOPHYS ACTA, V1041, P140; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1990, J BIOL CHEM, V265, P5967; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; VACHEREAU A, 1989, ANAL BIOCHEM, V179, P206, DOI 10.1016/0003-2697(89)90227-3; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257	54	810	817	0	38	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					36	42		10.1038/352036a0	http://dx.doi.org/10.1038/352036a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1676490				2022-12-24	WOS:A1991FV17800061
J	DWYER, T; PONSONBY, ALB; NEWMAN, NM; GIBBONS, LE				DWYER, T; PONSONBY, ALB; NEWMAN, NM; GIBBONS, LE			PROSPECTIVE COHORT STUDY OF PRONE SLEEPING POSITION AND SUDDEN-INFANT-DEATH-SYNDROME	LANCET			English	Article							COT DEATH	Studies of the link between prone sleeping position and sudden infant death syndrome have been criticised on grounds of recall bias and for not taking into account possible confounding effects. To avoid recall bias and to allow measurement of important biological factors a prospective cohort study of the cause of sudden infant death syndrome (SIDS) is being conducted. The infants included are those at high risk of the syndrome as assessed by a perinatal score. Of the 3110 members of the cohort born between January, 1988, and end of March, 1990, 23 infants later died of SIDS. Sleep position information was available for 15 of these. Matched analysis to control for the confounding effects of infant birthweight and maternal age indicated that prone sleeping position was associated with an increased risk of SIDS (OR 4.47 95% Cl [1.30-15.43]). The findings are strengthened by the results of a concurrent retrospective case-control study of 42 SIDS cases in which the prone position was also associated with an increased risk of SIDS (unadjusted OR 3.45 [1.59-7.49]).			DWYER, T (corresponding author), UNIV TASMANIA,MENZIES CTR POPULAT HLTH RES,43 COLLINS ST,HOBART,TAS 7000,AUSTRALIA.		Ponsonby, Anne-Louise/AAE-4351-2019	Ponsonby, Anne-Louise/0000-0002-6581-3657				BEAL S, 1988, MED J AUSTRALIA, V149, P562, DOI 10.5694/j.1326-5377.1988.tb120774.x; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; Breslow N, 1980, STATISTICAL METHODS, V32; Breslow N. E., 1987, STATISTICAL METHODS, VII; CAMERON MH, 1986, AUST PAEDIATR J, V22, P37; DAVIES DP, 1985, LANCET, V2, P1346; DEJONGE GA, 1989, BRIT MED J, V298, P722, DOI 10.1136/bmj.298.6675.722; DEJONGE GA, 1989, LANCET, V2, P1149; DESPAIGNET ET, 1990, TASMANIA PAED PERIN, V4, P422; EMERY JL, 1988, LANCET, V2, P738; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; ENGELBERTS AC, 1990, BRIT MED J, V301, P493; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FROGGATT P, 1970, SUDDEN INFANT DEATH, P40; GILLES FH, 1979, AM J DIS CHILD, V133, P30, DOI 10.1001/archpedi.1979.02130010036005; GUNTHEROTH WG, 1990, BRIT MED J, V301, P492; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; LEE M, 1988, LANCET, V1, P1332; MANTEL N, 1959, NAT CANCER I, V22, P819; MCGLASHAN ND, 1986, LANCET, V1, P106; MORRIS JA, 1989, BRIT MED J, V298, P958; NELSON EAS, 1989, LANCET, V1, P199; NEWMAN NM, 1986, AUST PAEDIATR J, V22, P111; NICHOLL JP, 1988, LANCET, V2, P106; SATERNUS KS, 1985, FESTSCHRIFT LEITHOFF, P67; SCOTT S, 1990, BRIT MED J, V301, P493, DOI 10.1136/bmj.301.6750.493-b; SENECAL J, 1987, ARCH FR PEDIATR, V44, P131; SOUTHALL D, 1990, BRIT MED J, V301, P492; TONKIN S, 1975, PEDIATRICS, V55, P650; TONKIN SL, 1986, NEW ZEAL MED J, V99, P324; TONKIN SL, 1979, PEDIATRICS, V63, P261; WAILOO MP, 1990, BRIT MED J, V301, P492, DOI 10.1136/bmj.301.6750.492-b; 1990, SUDDEN INFANT DEATH	33	279	283	1	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1244	1247		10.1016/0140-6736(91)92917-Q	http://dx.doi.org/10.1016/0140-6736(91)92917-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674061				2022-12-24	WOS:A1991FN04700002
J	OCARROLL, RE; HAYES, PC; EBMEIER, KP; DOUGALL, N; MURRAY, C; BEST, JJK; BOUCHIER, IAD; GOODWIN, GM				OCARROLL, RE; HAYES, PC; EBMEIER, KP; DOUGALL, N; MURRAY, C; BEST, JJK; BOUCHIER, IAD; GOODWIN, GM			REGIONAL CEREBRAL BLOOD-FLOW AND COGNITIVE FUNCTION IN PATIENTS WITH CHRONIC LIVER-DISEASE	LANCET			English	Article							HEPATOCELLULAR DISEASE; SCAN ABNORMALITIES; ENCEPHALOPATHY; SYSTEM; BRAIN	Subtle impairments of cognitive function may be an important cause of occupational and psychosocial morbidity in patients with chronic liver disease. Correlation of structural brain abnormalities with cognitive deficits has yielded inconsistent results. 10 patients with cirrhotic liver disease were compared with 10 age, education, and intelligence matched control subjects. Neuropsychological assessment revealed significant overall cognitive impairments in cirrhotic patients compared with controls (p = 0.02). Regional cerebral blood flow was measured by single photon emission computed tomography (SPET or SPECT) and showed increased uptake of radiotracer in the right and left posterior parts of the basal ganglia and right occipital lobe, together with reduced uptake in the right anterior cingulate region. The degree of cognitive impairment was directly correlated with functional abnormalities in the basal ganglia and limbic cortex (p < 0.05). Our results suggest that impaired cognitive status may be associated with abnormalities of regional brain function in patients with chronic liver disease. Since these deficits are clinically inapparent, our findings have important implications for identification and management of patients with chronic liver disease.	ROYAL INFIRM,DEPT MED,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT MED RADIOL,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh	OCARROLL, RE (corresponding author), ROYAL EDINBURGH & ASSOC HOSP,MRC,BRAIN METAB UNIT,EDINBURGH EH10 5HF,SCOTLAND.		O'Carroll, Ronan E/A-5040-2009; Dougall, Nadine J/O-8145-2015; Ebmeier, Klaus Peter/B-4789-2008	O'Carroll, Ronan E/0000-0002-5130-291X; Dougall, Nadine J/0000-0003-3462-6960; Ebmeier, Klaus Peter/0000-0002-5190-7038	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERNTHAL P, 1987, HEPATOLOGY, V7, P107, DOI 10.1002/hep.1840070122; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; DELONG MR, 1990, FUNCTION DYSFUNCTION; DUNK AA, 1989, DEV CLIN EXPT NEUROP, P39; GAMMAL SH, 1989, MED CLIN N AM, V73, P793, DOI 10.1016/S0025-7125(16)30639-3; HUNTER R, 1989, PSYCHOL MED, V19, P847, DOI 10.1017/S0033291700005560; LOCKWOOD AH, 1991, J CEREBR BLOOD F MET, V11, P331, DOI 10.1038/jcbfm.1991.66; MATSUI T, 1978, ATLAS HUMAN BRAIN CO; MOORE JW, 1989, J HEPATOL, V9, P319, DOI 10.1016/0168-8278(89)90140-2; NEIRINCKX RD, 1988, J CEREBR BLOOD F MET, V8, pS4, DOI 10.1038/jcbfm.1988.27; Nelson H.E., 1982, NATIONAL ADULT READI; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.neuro.13.1.25; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; SCHOMERUS H, 1981, DIGEST DIS SCI, V26, P622, DOI 10.1007/BF01367675; SOKOLOFF L, 1981, J CEREBR BLOOD F MET, V1, P7, DOI 10.1038/jcbfm.1981.4; TARTER RE, 1987, INT J NEUROSCI, V32, P901, DOI 10.3109/00207458709043346; TARTER RE, 1988, MED NEUROPSYCHOLOGY, P75	18	128	129	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1250	1253		10.1016/0140-6736(91)92920-W	http://dx.doi.org/10.1016/0140-6736(91)92920-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN047	1674063				2022-12-24	WOS:A1991FN04700004
J	BOWER, M; COLSTON, KW; STEIN, RC; HEDLEY, A; GAZET, JC; FORD, HT; COOMBES, RC				BOWER, M; COLSTON, KW; STEIN, RC; HEDLEY, A; GAZET, JC; FORD, HT; COOMBES, RC			TOPICAL CALCIPOTRIOL TREATMENT IN ADVANCED BREAST-CANCER	LANCET			English	Note							IMMUNOCYTOCHEMICAL DETECTION; 1,25-DIHYDROXYVITAMIN-D3; RECEPTOR; DIFFERENTIATION; PROLIFERATION; GROWTH	19 patients with locally advanced or cutaneous metastatic breast cancer were treated with the topical vitamin D analogue calcipotriol 100-mu-g daily. 14 patients completed 6 weeks' treatment; 3 showed a 50% reduction in the bidimensional diameter of treated lesions and 1 other patient showed a minimal response. 2 patients became hypercalcaemic during treatment. In all patients who responded the tumours contained receptors for 1,25-dihydroxyvitamin D3, shown by immunocytochemistry.	ST GEORGE HOSP,SCH MED,DEPT CELLULAR & MOLEC BIOL,CLIN ONCOL UNIT,LONDON,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT CLIN BIOCHEM,LONDON,ENGLAND; ST GEORGE HOSP,COMBINED BREAST CLIN,LONDON,ENGLAND	St Georges University London; St Georges University London; St Georges University London			Stein, Robert C/N-6679-2015	Stein, Robert C/0000-0003-2969-0415; Bower, Mark/0000-0002-4077-6351; Coombes, Raoul Charles/0000-0002-4811-1100				BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; BERGER U, 1987, CANCER RES, V47, P6793; BINDERUP L, 1988, BIOCHEM PHARMACOL, V37, P889, DOI 10.1016/0006-2952(88)90177-3; COLSTON K, 1986, ENDOCRINOLOGY, V119, P397, DOI 10.1210/endo-119-1-397; FRAMPTON RJ, 1983, CANCER RES, V43, P4443; HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F; KOGA M, 1988, CANCER RES, V48, P2734; MATSUI T, 1986, CANCER RES, V46, P5827; MCGUIRE WL, 1973, J CLIN ENDOCR METAB, V37, P986, DOI 10.1210/jcem-37-6-986; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506	10	113	115	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					701	702		10.1016/0140-6736(91)90280-3	http://dx.doi.org/10.1016/0140-6736(91)90280-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672178				2022-12-24	WOS:A1991FD36700010
J	IRELAND, A; HARTLEY, L; RYLEY, N; MCGEE, JOD; TROWELL, JM; CHAPMAN, RW				IRELAND, A; HARTLEY, L; RYLEY, N; MCGEE, JOD; TROWELL, JM; CHAPMAN, RW			RAISED GAMMA-GLUTAMYL-TRANSFERASE ACTIVITY AND THE NEED FOR LIVER-BIOPSY	BRITISH MEDICAL JOURNAL			English	Article									JOHN RADCLIFFE HOSP,DEPT GASTROENTEROL & HISTOPATHOL,OXFORD OX3 9DU,ENGLAND	University of Oxford								ATTERBURY CE, 1988, J CLIN GASTROENTEROL, V10, P605, DOI 10.1097/00004836-198812000-00003; LATCHAM RW, 1986, BRIT J PSYCHIAT, V149, P353, DOI 10.1192/bjp.149.3.353; NAKANO M, 1982, GASTROENTEROLOGY, V83, P777; TALLEY NJ, 1988, J CLIN GASTROENTEROL, V10, P647, DOI 10.1097/00004836-198812000-00015; WHITEHEAD TP, 1978, LANCET, V1, P978	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					388	389		10.1136/bmj.302.6773.388	http://dx.doi.org/10.1136/bmj.302.6773.388			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	1672259	Bronze, Green Published			2022-12-24	WOS:A1991EX85800028
J	KENDELL, RE				KENDELL, RE			CHRONIC FATIGUE, VIRUSES, AND DEPRESSION	LANCET			English	Editorial Material							POSTVIRAL FATIGUE; MAGNETIC-RESONANCE; MUSCLE; INFECTION; SYMPTOMS; PATIENT				KENDELL, RE (corresponding author), UNIV EDINBURGH,ROYAL EDINBURGH HOSP,DEPT PSYCHIAT,EDINBURGH EH10 5HF,SCOTLAND.							ANDREASEN NC, 1986, ARCH GEN PSYCHIAT, V43, P246; [Anonymous], 1989, ANN REPORT; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARNOLD DL, 1984, LANCET, V1, P1367; Beard GM, 1869, BOSTON MED SURG J, V80, P217; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; CALDER BD, 1987, J ROY COLL GEN PRACT, V37, P11; CHURCH AJ, 1980, MED J AUSTRALIA, V1, P307, DOI 10.5694/j.1326-5377.1980.tb134875.x; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JAMAL GA, 1985, J NEUROL NEUROSUR PS, V48, P961; KENDELL RE, 1983, HDB PSYCHIATRY, V4, P232; KENDLER KS, 1986, ARCH GEN PSYCHIAT, V43, P213; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; KRUESI MJP, 1989, J CLIN PSYCHIAT, V50, P53; MANU P, 1988, ANN INTERN MED, V109, P554, DOI 10.7326/0003-4819-109-7-554; SCHLEIFER SJ, 1983, JAMA-J AM MED ASSOC, V250, P374, DOI 10.1001/jama.250.3.374; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; YONGE RP, 1988, J ROY SOC MED, V81, P322, DOI 10.1177/014107688808100607; YOUSEF GE, 1988, LANCET, V1, P146; 1987, HLTH LIFESTYLE SURVE; 1989, WHO ICD10 DIV MENT H, pCH5	25	44	47	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					160	162						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ET679	1670800				2022-12-24	WOS:A1991ET67900016
J	JACOBSON, MA; BACCHETTI, P; KOLOKATHIS, A; CHAISSON, RE; SZABO, S; POLSKY, B; VALAINIS, GT; MILDVAN, D; ABRAMS, D; WILBER, J; WINGER, E; SACKS, HS; HENDRICKSEN, C; MOSS, A				JACOBSON, MA; BACCHETTI, P; KOLOKATHIS, A; CHAISSON, RE; SZABO, S; POLSKY, B; VALAINIS, GT; MILDVAN, D; ABRAMS, D; WILBER, J; WINGER, E; SACKS, HS; HENDRICKSEN, C; MOSS, A			SURROGATE MARKERS FOR SURVIVAL IN PATIENTS WITH AIDS AND AIDS RELATED COMPLEX TREATED WITH ZIDOVUDINE	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS TYPE-1; PLACEBO-CONTROLLED TRIAL; RECEIVING ZIDOVUDINE; SAN-FRANCISCO; INFECTION; SERUM; HIV; AZIDOTHYMIDINE; EXPERIENCE; EXPRESSION	Objective - To determine whether early effects of zidovudine treatment on CD4+ lymphocyte count and concentrations of beta-2 microglobulin, neopterin, or HIV p24 antigen or antibody are correlated with survival in patients with AIDS or AIDS related complex. Design - Retrospective study of changes in laboratory markers and survival. Setting - Multicentre trial at university hospital clinics. Subjects - '90 Patients with AIDS or AIDS related complex. Intervention - Patients started zidovudine 200 mg orally every four hours. Fifty six of the patients died a median 17 months after starting zidovudine; the remaining 34 patients were followed up for a median 25.5 months. Main outcome measures - Changes in CD4+ lymphocyte count and serum concentrations of p24 antigen and antibody, beta-2 microglobulin, and neopterin; survival of the patient. Results - The pretreatment characteristics that independently predicted poor survival were determined using a multivariate proportional hazards models: a diagnosis of AIDS (upsilon-AIDS related complex), age over 45 years, and the logarithm of serum neopterin concentration. When these baseline characteristics were controlled for the logarithm of CD4+ lymphocyte count at weeks 8-12 of treatment (p = 0.007) and an increase in serum beta-2 microglobulin concentration at weeks 8-12 (p = 0.05) also independently correlated with survival. In the 38 patients with a better pretreatment prognosis, 24 month survival estimated by the product-limit method was 88% for those with a good response on both surrogate markers during early treatment compared with only 50% for those with a poor response on either marker. In the 38 with a worse pretreatment prognosis, 24 month survival was estimated to be 49% for those with a good response on both surrogate markers compared with only 18% for those with a poor response on either. Conclusion - These data suggest that CD4+ lymphocyte count at 8-12 weeks and, perhaps, change in serum beta-2 microglobulin concentration could be surrogate end points for clinical outcome in trials of antiretroviral drugs for patients with HIV disease.	SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; BETH ISRAEL MED CTR,DEPT MED,NEW YORK,NY 10003; JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21218; MT SINAI MED CTR,DEPT MED,NEW YORK,NY 10029; MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021; TULANE UNIV,MED CTR,DEPT MED,NEW ORLEANS,LA 70118; BETH ISRAEL MED CTR,DIV INFECT DIS,NEW YORK,NY 10003; CALIF DEPT HLTH SERV,VIRAL & RICKETTSIAL DIS LAB,BERKELEY,CA 94704; IMMUNODIAGNOST LABS INC,SAN LEANDRO,CA; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOMATH,NEW YORK,NY 10029	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Cornell University; Tulane University; Harvard University; Beth Israel Deaconess Medical Center; California Department of Health Care Services; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	JACOBSON, MA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94110, USA.				NIAID NIH HHS [AI27663] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027663] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOWICZ M, 1986, MED LETT DRUGS THER, V28, P107; ANDERSON RE, 1990, ARCH INTERN MED, V150, P73, DOI 10.1001/archinte.150.1.73; BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; CHAISSON RE, 1988, ARCH INTERN MED, V148, P2151, DOI 10.1001/archinte.148.10.2151; COX DR, 1984, ANAL SURVIVAL DATA, P91; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOUDSMIT J, 1986, LANCET, V2, P177; HARRELL FE, 1986, 11TH P ANN SAS US GR; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; JACOBSON MA, 1989, J INFECT DIS, V159, P1029, DOI 10.1093/infdis/159.6.1029; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRAMER A, 1989, J ACQ IMMUN DEF SYND, V2, P291; KRUPPENBACHER JP, 1988, LANCET, V1, P298; Kubo R T, 1976, Contemp Top Immunobiol, V5, P267; Lehman EL, 1975, NONPARAMETRICS STATI, P120; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; STEINBERG JP, 1989, J ACQ IMMUN DEF SYND, V2, P229; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; Weiss R., 1990, SURROGATE ENDPOINTS; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; 1985, SUGI SUPPLEMENTAL LI	28	128	130	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					73	78		10.1136/bmj.302.6768.73	http://dx.doi.org/10.1136/bmj.302.6768.73			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1671651	Green Published, Bronze			2022-12-24	WOS:A1991ER95100015
J	SANDGREN, EP; LUETTEKE, NC; PALMITER, RD; BRINSTER, RL; LEE, DC				SANDGREN, EP; LUETTEKE, NC; PALMITER, RD; BRINSTER, RL; LEE, DC			OVEREXPRESSION OF TGF-ALPHA IN TRANSGENIC MICE - INDUCTION OF EPITHELIAL HYPERPLASIA, PANCREATIC METAPLASIA, AND CARCINOMA OF THE BREAST	CELL			English	Article									UNIV N CAROLINA,SCH MED,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27514; UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27514; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	SANDGREN, EP (corresponding author), UNIV PENN,SCH VET MED,REPROD PHYSIOL LAB,PHILADELPHIA,PA 19104, USA.			Brinster, Ralph/0000-0003-1408-7656	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA038635, R01CA043793] Funding Source: NIH RePORTER; NCI NIH HHS [CA38635, CA43793] Funding Source: Medline; NICHD NIH HHS [HD09172] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BLASBAND AJ, 1990, IN PRESS ONCOGENE; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CATTERTON WZ, 1979, PEDIATR RES, V13, P104, DOI 10.1203/00006450-197902000-00004; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COHEN S, 1962, J BIOL CHEM, V237, P1555; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DEMBINSKI AB, 1985, ENDOCRINOLOGY, V116, P90, DOI 10.1210/endo-116-1-90; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DICKSON RB, 1986, CANCER RES, V46, P1707; DIMARCO E, 1989, ONCOGENE, V4, P831; DOLLING M, 1983, J ANAT, V136, P656; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GOODLAD RA, 1987, GUT, V28, P37, DOI 10.1136/gut.28.Suppl.37; HAMMER RE, 1985, COLD SPRING HARB SYM, V50, P379, DOI 10.1101/SQB.1985.050.01.048; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; IBBOTSON KJ, 1986, P NATL ACAD SCI USA, V83, P2228, DOI 10.1073/pnas.83.7.2228; KOBRIN MS, 1986, J BIOL CHEM, V261, P4414; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEE DC, 1990, HDB EXPT PHARM, P611; LIU C, 1988, CANCER RES, V48, P850; LIU SC, 1987, MOL ENDOCRINOL, V1, P683, DOI 10.1210/mend-1-10-683; LONGNECKER DS, 1984, ENVIRON HEALTH PERSP, V56, P245, DOI 10.2307/3429850; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; Medina D., 1982, MOUSE BIOMEDICAL RES, VIV, P373; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MYDLO JH, 1989, CANCER RES, V49, P3407; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PRICE DOROTHY, 1963, NATL CANCER INST MONOGR, V12, P1; QUAIFE C, 1986, DEV BIOL, V118, P549, DOI 10.1016/0012-1606(86)90025-4; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RAYMOND VW, 1989, CANCER RES, V49, P3608; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1984, CANCER RES, V44, P4069; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SAMSOONDAR J, 1986, J BIOL CHEM, V261, P4408; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; SMITH JM, 1985, NATURE, V315, P515, DOI 10.1038/315515a0; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STERN PH, 1985, J CLIN INVEST, V76, P2016, DOI 10.1172/JCI112202; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUNDELL HW, 1980, AM J PATHOL, V100, P707; TAM JP, 1985, SCIENCE, V229, P673, DOI 10.1126/science.3860952; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; WRIGHT NA, 1990, NATURE, V343, P82, DOI 10.1038/343082a0; YEH YC, 1987, CANCER RES, V47, P896	77	678	687	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 15	1990	61	6					1121	1135		10.1016/0092-8674(90)90075-P	http://dx.doi.org/10.1016/0092-8674(90)90075-P			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DK145	1693546				2022-12-24	WOS:A1990DK14500020
J	LAZOVICH, D; WHITE, E; THOMAS, DB; MOE, RE				LAZOVICH, D; WHITE, E; THOMAS, DB; MOE, RE			UNDERUTILIZATION OF BREAST-CONSERVING SURGERY AND RADIATION-THERAPY AMONG WOMEN WITH STAGE-I OR STAGE-II BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPARING RADICAL-MASTECTOMY; CONSERVATIVE TREATMENT; AXILLARY DISSECTION; CHOICE; QUADRANTECTOMY; RADIOTHERAPY; LUMPECTOMY; PATIENT; AGE	Objective. - To identify time trends and factors associated with breast-conserving surgery (BCS) and delivery of postoperative radiation therapy among women with stage I or II breast cancer. Design. - Survey. Setting. - Population-based cancer registry in the Seattle-Puget Sound (Wash) region. Participants. - The study included 8095 women diagnosed with stage I or II breast cancer (American Joint Committee on Cancer staging criteria) from 1983 through 1989. Main Outcome Measures. - Breast-conserving surgery with or without radiation therapy vs mastectomy, and, among women with BCS, a comparison of radiation therapy vs no therapy. Results. - In 1985 when results from a US randomized clinical trial of BCS were published, the frequency of BCS peaked (46.3% of stage I; 30.1 % of stage II) followed by a return to levels before 1985 for women with stage II breast cancer and a more moderate decline for stage I breast cancer. The likelihood of BCS decreased with increasing age (P < .001), with stage II disease, and with residence outside the region's major urban center, and it increased with education (P < .001) or median income (P < .001) by census tract. The proportion of women who received radiation therapy after BCS decreased with age (P < .001), was lower for women with stage II than stage I disease, and was lowest in counties without radiation therapy facilities. Conclusions. - Despite scientific evidence of the equivalent efficacy of BCS with radiation therapy and mastectomy, BCS is not performed on the majority of women with stage I or II breast cancer as recommended by the National Institutes of Health, and factors are associated with its use that differ from selection criteria outlined by the National Institutes of Health.	UNIV WASHINGTON,DEPT OCEANOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	LAZOVICH, D (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,1124 COLUMBIA ST,MAILSTOP MP-702,SEATTLE,WA 98104, USA.				NCI NIH HHS [5-P01-CA34847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034847] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHCROFT JJ, 1985, J ROY SOC MED, V78, P43; BRESLOW NE, 1980, STATISTICAL METHODS, V2; CAWLEY M, 1990, CANCER NURS, V13, P90; CHU J, 1987, J GERONTOL, V42, P185, DOI 10.1093/geronj/42.2.185; DEBER RB, 1987, ARCH INTERN MED, V147, P1543, DOI 10.1001/archinte.147.9.1543; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; FISHER B, 1985, WORLD J SURG, V9, P655, DOI 10.1007/BF01655177; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P1766; HELLMAN S, 1987, CANCER RES, V47, P339; KLEINMAN JC, 1983, MED CARE, V21, P1232, DOI 10.1097/00005650-198312000-00010; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LIBERATI A, 1987, TUMORI J, V73, P601, DOI 10.1177/030089168707300609; LIBERATI A, 1990, AM J PUBLIC HEALTH, V81, P38; MANN BA, 1988, JAMA-J AM MED ASSOC, V259, P3413; MARGOLIS GJ, 1989, PSYCHOSOMATICS, V30, P192, DOI 10.1016/S0033-3182(89)72300-8; MCKINLAY JB, 1981, MILBANK FUND Q, V59, P374, DOI 10.2307/3349685; MORRIS J, 1989, J ROY SOC MED, V82, P12, DOI 10.1177/014107688908200105; MUNOZ E, 1986, ARCH SURG-CHICAGO, V121, P1297, DOI 10.1001/archsurg.121.11.1297; SAMET J, 1986, JAMA-J AM MED ASSOC, V255, P3385, DOI 10.1001/jama.255.24.3385; SARRAZIN D, 1984, CANCER, V53, P1209, DOI 10.1002/1097-0142(19840301)53:5<1209::AID-CNCR2820530531>3.0.CO;2-Y; SARRAZIN D, 1989, RADIOTHER ONCOL, V14, P177, DOI 10.1016/0167-8140(89)90165-5; SILLIMAN RA, 1989, J GERONTOL, V44, pM46, DOI 10.1093/geronj/44.2.M46; Tinker M A, 1987, Surg Annu, V19, P279; Valanis B G, 1985, Cancer Nurs, V8, P167; VERONESI U, 1986, EUR J CANCER CLIN ON, V22, P1085, DOI 10.1016/0277-5379(86)90011-8; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; WARD S, 1989, CANCER NURS, V12, P344; WILSON RE, 1984, SURG GYNECOL OBSTET, V159, P309; WOLBERG WH, 1987, J CLIN ONCOL, V5, P68, DOI 10.1200/JCO.1987.5.1.68; YANCIK R, 1989, CANCER, V63, P976, DOI 10.1002/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A; 1991, JAMA-J AM MED ASSOC, V265, P391; 1983, PHC802329 US DEP COM; 1988, MANUAL STAGING CANCE; 1986, 872789 US DEP HLTH H; 1991, CANCER FACTS FIGURES; 1988, BRIT J CANCER, V57, P630; 1990, MEMBERSHIP DIRECTORY; 1983, PHC802347 US DEP COM	40	315	315	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3433	3438		10.1001/jama.266.24.3433	http://dx.doi.org/10.1001/jama.266.24.3433			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV878	1688350				2022-12-24	WOS:A1991GV87800027
J	HANNINGTONKIFF, JG				HANNINGTONKIFF, JG			DOES FAILED NATURAL OPIOID MODULATION IN REGIONAL SYMPATHETIC-GANGLIA CAUSE REFLEX SYMPATHETIC DYSTROPHY	LANCET			English	Article							ENKEPHALIN	Early features of reflex sympathetic dystrophy in a limb resemble the general effects of autonomic arousal associated with opioid withdrawal. It is suggested that natural opioid peptide modulation in regional sympathetic ganglia normally rises to prevent excessive autonomic activity in an injured limb. After an injury (especially a trivial one) to a susceptible subject, this localised increase in opioid modulation may fail or may rapidly wane so that autonomic features of opioid withdrawal appear in the affected limb. Florid dystrophic changes may then occur because of passive complications of disuse associated with pain, or as a result of more active processes. Preservation of an appropriate opioid bias in the regional sympathetic ganglia might be an important factor in the successful management and prevention of reflex sympathetic dystrophy.			HANNINGTONKIFF, JG (corresponding author), FRIMLEY PK HOSP,CTR PAIN RELIEF,PORTSMOUTH RD,CAMBERLEY GU16 5UJ,SURREY,ENGLAND.							AN HS, 1988, J HAND SURG-AM, V13A, P458, DOI 10.1016/S0363-5023(88)80032-7; ARIAS LM, 1989, REGION ANESTH, V14, P90; Crile GW, 1913, LANCET, V2, P7; DIGIULIO AM, 1978, NEUROPHARMACOLOGY, V17, P989, DOI 10.1016/0028-3908(78)90144-2; HANNINGTONKIFF JG, 1990, J ROY SOC MED, V83, P373, DOI 10.1177/014107689008300612; HANNINGTONKIFF JG, 1988, LANCET, V1, P1404; HELEN P, 1984, NEUROSCIENCE, V12, P907, DOI 10.1016/0306-4522(84)90178-7; Janig W, 1990, PAIN SYMPATHETIC NER, P17; KONISHI S, 1981, NATURE, V294, P80, DOI 10.1038/294080a0; MAYS KS, 1981, J NEUROL NEUROSUR PS, V44, P189, DOI 10.1136/jnnp.44.2.189; NEELY J C, 1956, Br J Ophthalmol, V40, P636, DOI 10.1136/bjo.40.10.636; RIOS L, 1983, EUR J PHARMACOL, V86, P277; ROBERTS WJ, 1986, PAIN, V24, P297, DOI 10.1016/0304-3959(86)90116-8; SCHULTZBERG M, 1979, NEUROSCIENCE, V4, P249, DOI 10.1016/0306-4522(79)90087-3; THOREN P, 1990, MED SCI SPORT EXER, V22, P417; WALL PD, 1979, PAIN, V7, P103, DOI 10.1016/0304-3959(79)90002-2	16	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1991	338	8775					1125	1127		10.1016/0140-6736(91)91974-Y	http://dx.doi.org/10.1016/0140-6736(91)91974-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM784	1682552				2022-12-24	WOS:A1991GM78400014
J	CROOK, T; TIDY, JA; VOUSDEN, KH				CROOK, T; TIDY, JA; VOUSDEN, KH			DEGRADATION OF P53 CAN BE TARGETED BY HPV E6 SEQUENCES DISTINCT FROM THOSE REQUIRED FOR P53 BINDING AND TRANSACTIVATION	CELL			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN FORESKIN KERATINOCYTES; RETINOBLASTOMA GENE-PRODUCT; LARGE TUMOR-ANTIGEN; OPEN READING FRAME; CERVICAL-CARCINOMA; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODIES; TRANSFORMING GENE; E7 ONCOPROTEIN	Human papillomavirus (HPV) types 16 and 18 appear to play a role in the development of ano-genital malignancies, whereas HPV 6 and 11 are usually associated with benign lesions. One HPV16 oncoprotein, E6, complexes with and promotes degradation of the cellular tumor suppressor p53. Here we show that E6 proteins of both oncogenic and benign HPV types associate in vitro with p53, but binding by E6 proteins of benign HPV types cannot target p53 for degradation. A C-terminal region of E6 conserved among all HPV types is important for p53 binding. However, N-terminal sequences of E6 conserved only between oncogenic HPV types are necessary to direct p53 degradation. p53 binding by E6 appears necessary but not sufficient for this activity. All E6 proteins tested showed comparable transcriptional trans-activating activity, a property that does not require the ability to bind or direct degradation of p53.	SAMARITAN HOSP WOMEN, DEPT GYNECOL ONCOL, LONDON NW1 5YE, ENGLAND		CROOK, T (corresponding author), ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON W2 1PG, ENGLAND.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARBOSA MS, 1991, J VIROL, V65, P292, DOI 10.1128/JVI.65.1.292-298.1991; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, IN PRESS ONCOGENE; DANOS O, 1987, CANCER CELL, V5, P145; DARMANN K, 1986, VIROLOGY, V151, P124, DOI 10.1016/0042-6822(86)90110-8; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GIUS D, 1988, J VIROL, V62, P665, DOI 10.1128/JVI.62.3.665-672.1988; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL CV, 1983, J BIOL CHEM, V258, P14120; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KANDA T, 1988, J VIROL, V62, P610, DOI 10.1128/JVI.62.2.610-613.1988; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RAWLS JA, 1990, J VIROL, V64, P6121, DOI 10.1128/JVI.64.12.6121-6129.1990; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, IN PRESS P NATL ACAD; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1983, EMBO J, V2, P2341, DOI 10.1002/j.1460-2075.1983.tb01744.x; SEDMAN SA, 1991, IN PRESS J VIROL; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Vousden K H, 1990, Semin Cancer Biol, V1, P415; VOUSDEN KH, 1989, J VIROL, V63, P2340, DOI 10.1128/JVI.63.5.2340-2342.1989; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILKINSON D, 1988, J EXP MED, V167, P1442, DOI 10.1084/jem.167.4.1442; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	53	486	521	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1991	67	3					547	556		10.1016/0092-8674(91)90529-8	http://dx.doi.org/10.1016/0092-8674(91)90529-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1657399				2022-12-24	WOS:A1991GN66400011
J	LI, H; BINGHAM, PM				LI, H; BINGHAM, PM			ARGININE SERINE-RICH DOMAINS OF THE SU(WA) AND TRA RNA PROCESSING REGULATORS TARGET PROTEINS TO A SUBNUCLEAR COMPARTMENT IMPLICATED IN SPLICING	CELL			English	Article							DROSOPHILA-MELANOGASTER; NUCLEOLAR LOCALIZATION; BINDING PROTEINS; MESSENGER-RNA; GENE; SEX; SEQUENCES; SIMILARITY; EXPRESSION; ENCODES	Two unrelated pre-mRNA splicing regulators-suppressor-of-white-apricot (su(w(a))) and transformer (tra)-contain distinctive, approximately 120 amino acid arginine/serine (RS)-rich domains. Deletion of the su(w(a)) RS domain eliminates function. Replacement with the tra RS domain restores su(w(a)) function to nearly wild-type levels. Replacement with a 10 amino acid simple nuclear entry signal allows partial, inefficient function. Thus, the su(w(a)) RS domain apparently serves a generic function(s) subsuming nuclear entry. Moreover, immunocytochemical studies demonstrate that both RS domains specifically direct localization of a fused reporter protein to a punctate subnuclear compartment shown previously to be enriched in several constitutive splicing components. We propose that RS domains are a new class of targeting signals directing concentration of proteins in a subnuclear compartment implicated in splicing metabolism.			LI, H (corresponding author), SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794, USA.				PHS HHS [32003] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GE H, 1991, IN PRESS CELL; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KRAINER AR, 1991, IN PRESS CELL; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RIO DC, 1988, P NATL ACAD SCI USA, V85, P2904, DOI 10.1073/pnas.85.9.2904; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SMITH HC, 1985, J CELL BIOL, V101, P560, DOI 10.1083/jcb.101.2.560; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; ZACHAR Z, 1987, MOL CELL BIOL, V7, P2498, DOI 10.1128/MCB.7.7.2498; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x	29	201	204	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					335	342		10.1016/0092-8674(91)90185-2	http://dx.doi.org/10.1016/0092-8674(91)90185-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655279				2022-12-24	WOS:A1991GL47000013
J	RAY, R; AGGARWAL, R; SALUNKE, PN; MEHROTRA, NN; TALWAR, GP; NAIK, SR				RAY, R; AGGARWAL, R; SALUNKE, PN; MEHROTRA, NN; TALWAR, GP; NAIK, SR			HEPATITIS-E VIRUS GENOME IN STOOLS OF HEPATITIS PATIENTS DURING LARGE EPIDEMIC IN NORTH-INDIA	LANCET			English	Note							NON-B HEPATITIS; TRANSMITTED NON-A	Stool samples from patients affected during a large epidemic of hepatitis in north India were examined for the presence of hepatitis E virus (HEV) genome by means of reverse transcription-polymerase chain reaction. 6 to 10 samples studied were positive for the HEV genome, which suggests that HEV caused this large epidemic.	SANJAY GANDHI POSTGRAD INST MED SCI,DEPT GASTROENTEROL,PB 375,RAEBARELI RD,LUCKNOW 226001,INDIA; NATL INST IMMUNOL,NEW DELHI,INDIA; CENT DRUG RES INST,LUCKNOW 226001,UTTAR PRADESH,INDIA	Sanjay Gandhi Postgraduate Institute of Medical Sciences; Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)			Aggarwal, Rakesh/D-1583-2009	Aggarwal, Rakesh/0000-0001-9689-494X				ARANKALLE VA, 1988, LANCET, V2, P550; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRADLEY DW, 1987, P NATL ACAD SCI USA, V84, P6277, DOI 10.1073/pnas.84.17.6277; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Khuroo M S, 1991, Indian J Gastroenterol, V10, P96; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4; RAMALINGASWAMI V, 1988, LANCET, V1, P571; REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574; Viswanathan R., 1957, INDIAN J MED RES S, V45, P1; ZUCKERMAN AJ, 1990, BRIT MED J, V300, P1475, DOI 10.1136/bmj.300.6738.1475	10	70	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1991	338	8770					783	784		10.1016/0140-6736(91)90667-E	http://dx.doi.org/10.1016/0140-6736(91)90667-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG979	1681163				2022-12-24	WOS:A1991GG97900006
J	LANDAY, AL; JESSOP, C; LENNETTE, ET; LEVY, JA				LANDAY, AL; JESSOP, C; LENNETTE, ET; LEVY, JA			CHRONIC FATIGUE SYNDROME - CLINICAL CONDITION ASSOCIATED WITH IMMUNE ACTIVATION	LANCET			English	Article							BARR VIRUS-INFECTION; LYMPHOCYTE-T SUBSETS; IMMUNOLOGICAL ABNORMALITIES; EARLY ANTIGEN; MONONUCLEOSIS; PERSISTENT; DYSFUNCTION; ANTIBODIES	There is much conflicting immunological and viral data about the causes of chronic fatigue syndrome (CFS); some findings support the notion that CFS may be due to one or more immune disorders that have resulted from exposure to an infectious agent. In the present study, flow cytometry and several different monoclonal antibodies recognising T, B, and natural killer (NK) cell populations as well as activation and cell adhesion antigens were used to study 147 individuals with CFS. Compared with healthy controls, a reduced CD8 suppressor cell population and increased activation markers (CD38, HLA-DR) on CD8 cells were found. The differences were significant (p = 0.01) in patients with major symptoms of the disease. These immunological indices were not observed in 80 healthy individuals, in 22 contacts of CFS patients, or in 43 patients with other diseases. No correlation of these findings in CFS patients with any known human viruses could be detected by serology. The findings suggest that immune activation is associated with many cases of CFS.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,ROOM S1280,3RD & PARNASSUS,SAN FRANCISCO,CA 94143; VIROLAB,BERKELEY,CA; UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT IMMUNOL MICROBIOL,CHICAGO,IL 60612	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rush University								ALTAY HT, 1990, INT J PSYCHIAT MED, V20, P141, DOI 10.2190/T6GX-JJ2L-VCVV-T81B; AOKI T, 1987, NAT IMMUN CELL GROW, V6, P116; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BORYSIEWICZ LK, 1986, Q J MED, V58, P111; BUCHWALD D, 1991, REV INFECT DIS, V13, P512; CALIGIURI M, 1987, J IMMUNOL, V139, P3306; CARNEY WP, 1981, J IMMUNOL, V126, P2114; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; COON J, 1987, LAB INVEST, V15, P453; DEFREITAS E, 1991, P NATL ACAD SCI USA, V88, P2922, DOI 10.1073/pnas.88.7.2922; GRATAMA JW, 1987, BLOOD, V70, P516; HELLINGER WC, 1988, JAMA-J AM MED ASSOC, V260, P971; HENLE W, 1981, CANCER RES, V41, P4222; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; KIBLER R, 1985, J CLIN IMMUNOL, V5, P46, DOI 10.1007/BF00915168; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; LANDAY AL, 1990, 6TH INT C AIDS SAN F, P141; LENNETTE ET, 1982, J CLIN MICROBIOL, V15, P69, DOI 10.1128/JCM.15.1.69-73.1982; LEVY JA, 1990, LANCET, V335, P1047, DOI 10.1016/0140-6736(90)92628-U; LLOYD AR, 1989, MED J AUSTRALIA, V151, P122, DOI 10.5694/j.1326-5377.1989.tb139594.x; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; NOTKINS AL, 1970, ANNU REV MICROBIOL, V24, P525, DOI 10.1146/annurev.mi.24.100170.002521; PRIETO J, 1989, SCAND J IMMUNOL, V30, P13, DOI 10.1111/j.1365-3083.1989.tb01183.x; ROUSE BT, 1986, REV INFECT DIS, V8, P850; Siegel S., 1956, NONPARAMETRIC STAT B; STRAUS SE, 1989, J INFECT DIS, V160, P1085, DOI 10.1093/infdis/160.6.1085; STRAUS SE, 1991, REV INFECT DIS, V13, pS2; TOBI M, 1982, LANCET, V1, P61; TOMKINSON BE, 1987, J IMMUNOL, V139, P3802; TOSATO G, 1985, J IMMUNOL, V134, P3082	33	263	271	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1991	338	8769					707	712		10.1016/0140-6736(91)91440-6	http://dx.doi.org/10.1016/0140-6736(91)91440-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679864				2022-12-24	WOS:A1991GG10400001
J	PIETERS, R; HUISMANS, DR; LOONEN, AH; HAHLEN, K; VANDERDOESVANDENBERG, A; VANWERING, ER; VEERMAN, AJP				PIETERS, R; HUISMANS, DR; LOONEN, AH; HAHLEN, K; VANDERDOESVANDENBERG, A; VANWERING, ER; VEERMAN, AJP			RELATION OF CELLULAR-DRUG RESISTANCE TO LONG-TERM CLINICAL OUTCOME IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Article							DYE EXCLUSION ASSAY; MTT-ASSAY; LEUKEMIA-CELLS; CANCER-CHEMOTHERAPY; CHEMOSENSITIVITY; INVITRO; CHILDREN; INVIVO; SENSITIVITY	The clinical relevance of cellular drug resistance in children with acute lymphoblastic leukaemia (ALL) is unknown. The relation between in-vitro sensitivity to chemotherapeutic drugs at initial diagnosis and long-term clinical outcome was investigated in 44 children with ALL. The short-term MTT assay was used to assess sensitivity to prednisolone, vincristine, colaspase (asparaginase), daunorubicin, and thioguanine (instead of mercaptopurine which is unstable in vitro). For vincristine and colaspase there was no difference in outcome (probability of continuous complete remission) between sensitive and resistant patients. However, the probability of continuous complete remission was significantly lower in patients with resistant cells than in those with sensitive cells for thioguanine (p < 0.01), daunorubicin (p < 0.02), and prednisolone (p < 0.05). For prednisolone there was a significant worsening of the prognosis (p < 0.05) from the extremely sensitive patients through an intermediate group to the most resistant group. The prognostic significance of cellular drug resistance was independent of white-blood-cell count, age, sex, and hepatosplenomegaly. Leukaemic cells from boys were more resistant to thioguanine than those from girls. Thus, the short-term highly efficient MTT assay can help to predict long-term response to chemotherapy in childhood ALL.	ERASMUS UNIV,SOPHIA CHILDRENS HOSP,SUBDIV HAEMATO ONCOL,3000 DR ROTTERDAM,NETHERLANDS; DUTCH CHILDHOOD LEUKEMIA STUDY GRP,THE HAGUE,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital	PIETERS, R (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT PEDIAT,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS.		Veerman, Anjo/AAT-2443-2020	Veerman, Anjo JP/0000-0002-9309-301X				ASSELIN BL, 1989, CANCER RES, V49, P4363; BIRD MC, 1985, HEMATOL ONCOL, V3, P1, DOI 10.1002/hon.2900030102; CAMPLING BG, 1988, LEUKEMIA RES, V12, P823, DOI 10.1016/0145-2126(88)90036-7; EVANS WE, 1989, PEDIATR CLIN N AM, V36, P1199; HONGO T, 1990, CANCER-AM CANCER SOC, V65, P1263, DOI 10.1002/1097-0142(19900315)65:6<1263::AID-CNCR2820650602>3.0.CO;2-S; HONGO T, 1987, JPN J CANC CHEMOTHER, V14, P472; KERN DH, 1990, J NATL CANCER I, V82, P582, DOI 10.1093/jnci/82.7.582; KIRKPATRICK DL, 1990, LEUKEMIA RES, V14, P459, DOI 10.1016/0145-2126(90)90033-6; LENNARD L, 1987, CLIN PHARMACOL THER, V41, P18, DOI 10.1038/clpt.1987.4; LENNARD L, 1989, J CLIN ONCOL, V7, P1816, DOI 10.1200/JCO.1989.7.12.1816; LILLEYMAN JS, 1984, BRIT J CANCER, V49, P703, DOI 10.1038/bjc.1984.111; MATTERN J, 1982, CANCER TREAT REV, V9, P267, DOI 10.1016/S0305-7372(82)80041-8; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIETERS R, 1988, CANCER LETT, V41, P323, DOI 10.1016/0304-3835(88)90294-7; PIETERS R, 1989, BRIT J CANCER, V59, P217, DOI 10.1038/bjc.1989.44; PIETERS R, 1990, BLOOD, V76, P2327; PIETERS R, 1991, THESIS FREE U AMSTER; RIEHM H, 1987, ACUTE LEUKEMIAS PROG, P139; ROTHENBERG ML, 1989, BLOOD, V74, P1388; SANTINI V, 1989, HEMATOL ONCOL, V7, P287, DOI 10.1002/hon.2900070405; SARGENT JM, 1989, BRIT J CANCER, V60, P206, DOI 10.1038/bjc.1989.252; TAWA A, 1990, JPN J PEDIATR HEMATO, V4, P38; Thompson E B, 1986, Adv Exp Med Biol, V196, P111; TIDEFELT U, 1989, EUR J HAEMATOL, V43, P374; TWENTYMAN PR, 1989, BRIT J HAEMATOL, V71, P19, DOI 10.1111/j.1365-2141.1989.tb06268.x; TWENTYMAN PR, 1985, BRIT J CANCER, V51, P295, DOI 10.1038/bjc.1985.42; VANDENDOEL LJ, 1988, EUR J HAEMATOL, V41, P170; VEERMAN AJP, 1990, BRIT J HAEMATOL, V74, P381, DOI 10.1111/j.1365-2141.1990.tb06323.x; WEISENTHAL LM, 1986, CANCER TREAT REP, V70, P1283; WEISENTHAL LM, 1985, CANCER TREAT REP, V69, P615	30	217	220	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					399	403		10.1016/0140-6736(91)91029-T	http://dx.doi.org/10.1016/0140-6736(91)91029-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678081				2022-12-24	WOS:A1991GB44600002
J	BOROK, Z; BUHL, R; GRIMES, GJ; BOKSER, AD; HUBBARD, RC; HOLROYD, KJ; ROUM, JH; CZERSKI, DB; CANTIN, AM; CRYSTAL, RG				BOROK, Z; BUHL, R; GRIMES, GJ; BOKSER, AD; HUBBARD, RC; HOLROYD, KJ; ROUM, JH; CZERSKI, DB; CANTIN, AM; CRYSTAL, RG			EFFECT OF GLUTATHIONE AEROSOL ON OXIDANT-ANTIOXIDANT IMBALANCE IN IDIOPATHIC PULMONARY FIBROSIS	LANCET			English	Note							LOWER RESPIRATORY-TRACT; INTERSTITIAL LUNG-DISEASES; CHRONIC INFLAMMATION; UNKNOWN CAUSE; DEFICIENCY; FLUID	Idiopathic pulmonary fibrosis (IPF) is characterised by alveolar inflammation, exaggerated release of oxidants, and subnormal concentrations of the antioxidant glutathione in respiratory epithelial lining fluid (ELF). Glutathione (600 mg twice daily for 3 days) was given by aerosol to 10 patients with IPF. Total ELF glutathione rose transiently, ELF oxidised glutathione concentrations increased, and there was a decrease in spontaneous superoxide anion release by alveolar macrophages. Thus, glutathione by aerosol could be a means of reversing the oxidant-antioxidant imbalance in IPF.	NHLBI,PULM BRANCH,BLDG 10 ROOM 6D03,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT PHARM,BETHESDA,MD 20892; CHU SHERBROOKE,SERV PNEUMOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of Sherbrooke				Borok, Zea/0000-0001-8673-8177; Holroyd, Kenneth/0000-0001-6050-3935				BUHL R, 1990, P NATL ACAD SCI USA, V87, P4063, DOI 10.1073/pnas.87.11.4063; BUHL R, 1989, LANCET, V2, P1294; CANTIN AM, 1989, AM REV RESPIR DIS, V139, P370, DOI 10.1164/ajrccm/139.2.370; CANTIN AM, 1987, J CLIN INVEST, V79, P1665, DOI 10.1172/JCI113005; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P235, DOI 10.1056/NEJM198401263100406; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P154, DOI 10.1056/NEJM198401193100304; FORMAN HJ, 1990, AM J PHYSIOL, V259, pL102, DOI 10.1152/ajplung.1990.259.2.L102; MEISTER A, 1988, J BIOL CHEM, V263, P17205; SIES H, 1984, METHOD ENZYMOL, V105, P445; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171	10	169	176	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					215	216		10.1016/0140-6736(91)90350-X	http://dx.doi.org/10.1016/0140-6736(91)90350-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676780				2022-12-24	WOS:A1991FY50400005
J	LUPSKI, JR; DEOCALUNA, RM; SLAUGENHAUPT, S; PENTAO, L; GUZZETTA, V; TRASK, BJ; SAUCEDOCARDENAS, O; BARKER, DF; KILLIAN, JM; GARCIA, CA; CHAKRAVARTI, A; PATEL, PI				LUPSKI, JR; DEOCALUNA, RM; SLAUGENHAUPT, S; PENTAO, L; GUZZETTA, V; TRASK, BJ; SAUCEDOCARDENAS, O; BARKER, DF; KILLIAN, JM; GARCIA, CA; CHAKRAVARTI, A; PATEL, PI			DNA DUPLICATION ASSOCIATED WITH CHARCOT-MARIE-TOOTH DISEASE TYPE-1A	CELL			English	Article							NEUROPATHY TYPE-I; MULTILOCUS LINKAGE ANALYSIS; PERICENTROMERIC REGION; INTERSTITIAL DELETION; GEL-ELECTROPHORESIS; HEREDITARY MOTOR; GENETIC-LINKAGE; CHROMOSOME-17; RECEPTOR; LOCUS	Charcot-Marie-Tooth disease type 1A (CMT1A) was localized by genetic mapping to a 3 cM interval on human chromosome 17p. DNA markers within this interval revealed a duplication that is completely linked and associated with CMT1A. The duplication was demonstrated in affected individuals by the presence of three alleles at a highly polymorphic locus, by dosage differences at RFLP alleles, and by two-color fluorescence in situ hybridization. Pulsed-field gel electrophoresis of genomic DNA from patients of different ethnic origins showed a novel SacII fragment of 500 kb associated with CMT1A. A severely affected CMT1A offspring from a mating between two affected individuals was demonstrated to have this duplication present on each chromosome 17. We have demonstrated that failure to recognize the molecular duplication can lead to misinterpretation of marker genotypes for affected individuals, identification of false recombinants, and incorrect localization of the disease locus.	BAYLOR UNIV,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR UNIV,DEPT NEUROL,HOUSTON,TX 77030; LOUISIANA STATE UNIV,MED CTR,DEPT PATHOL,NEW ORLEANS,LA 70112; BAYLOR UNIV,CTR HUMAN GENOME,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT HUMAN GENET,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15260; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,DIV BIOMED SCI,LIVERMORE,CA 94550; UNIV UTAH,SCH MED,DEPT MED INFORMAT,SALT LAKE CITY,UT 84130; LOUISIANA STATE UNIV,MED CTR,DEPT NEUROL,NEW ORLEANS,LA 70112	Baylor University; Baylor University; Louisiana State University System; Baylor University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Utah System of Higher Education; University of Utah; Louisiana State University System	LUPSKI, JR (corresponding author), BAYLOR UNIV,INST MOLEC GENET,HOUSTON,TX 77030, USA.		Barker, David/HHZ-0471-2022; Patel, Pragna/H-9129-2017	Barker, David/0000-0002-1438-4100; Patel, Pragna/0000-0003-3584-1072	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000774] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000344, R01HG000256] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG-00256-01, HG 00344] Funding Source: Medline; NICHD NIH HHS [HD00774] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BEDFORD MT, 1990, BIOTECHNIQUES, V9, P744; BEESON D, 1990, ANN HUM GENET, V54, P199, DOI 10.1111/j.1469-1809.1990.tb00378.x; BIRD TD, 1978, CLIN GENET, V14, P43; BIRD TD, 1982, AM J HUM GENET, V34, P388; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Bridges CB, 1936, SCIENCE, V83, P210, DOI 10.1126/science.83.2148.210; CHANCE PF, 1990, AM J HUM GENET, V47, P915; Charcot JM, 1886, REV MED-PARIS, V6, P97; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; DAUSSET J, 1986, PRESSE MED, V15, P1801; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FAIN P R, 1987, Genomics, V1, P340, DOI 10.1016/0888-7543(87)90034-6; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FRANCO B, 1990, NUCLEIC ACIDS RES, V18, P7196, DOI 10.1093/nar/18.23.7196-a; GREEN MC, 1989, GENETIC VARIANTS STR; GRUNDY HO, 1989, IMMUNOGENETICS, V29, P331, DOI 10.1007/BF00352843; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; KILLIAN JM, 1979, ANN NEUROL, V5, P515, DOI 10.1002/ana.410050604; KORNREICH R, 1990, J BIOL CHEM, V265, P9319; LATHROP GM, 1988, AM J HUM GENET, V42, P498; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LINDSLEY DL, 1985, DROS INF SERV, V62; LITT M, 1989, AM J HUM GENET, V44, P397; LUPSKI JR, 1991, CURRENT NEUROLOGY, P1; MAGENIS RE, 1986, AM J MED GENET, V24, P415, DOI 10.1002/ajmg.1320240304; MCALPINE PJ, 1990, GENOMICS, V7, P408, DOI 10.1016/0888-7543(90)90175-T; McKusick VA, 1990, MENDELIAN INHERITANC; MIDDLETONPRICE HR, 1990, AM J HUM GENET, V46, P92; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORTON NE, 1956, AM J HUM GENET, V8, P80; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P10073, DOI 10.1093/nar/15.23.10073; Nakamura Y, 1988, GENOMICS, V2, P302, DOI 10.1016/0888-7543(88)90018-3; OTT J, 1978, ANN HUM GENET, V42, P255, DOI 10.1111/j.1469-1809.1978.tb00657.x; OTT J, 1985, ANAL HUMAN GENETIC L; PATEL PI, 1990, AM J HUM GENET, V47, P926; PATEL PI, 1990, AM J HUM GENET, V46, P801; RAEYMAEKERS P, 1989, AM J HUM GENET, V45, P953; RAY R, 1990, NUCLEIC ACIDS RES, V18, P4958, DOI 10.1093/nar/18.16.4958; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ CE, 1986, CYTOGENET CELL GENET, V43, P117, DOI 10.1159/000132307; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SHYAMALA V, 1990, EMBO J, V9, P939, DOI 10.1002/j.1460-2075.1990.tb08192.x; SKRE H, 1974, CLIN GENET, V6, P98; SMITH ACM, 1986, AM J MED GENET, V24, P393, DOI 10.1002/ajmg.1320240303; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRATTON RF, 1986, AM J MED GENET, V24, P421, DOI 10.1002/ajmg.1320240305; SULLIVAN DE, 1987, BIOTECHNIQUES, V5, P672; TIMMERMAN V, 1990, AM J HUM GENET, V47, P680; TRASK BJ, 1991, AM J HUM GENET, V48, P1; TSUBOTA SI, 1989, GENETICS, V122, P881; VANCE JM, 1989, EXP NEUROL, V104, P186, DOI 10.1016/S0014-4886(89)80013-5; VANCE JM, 1991, GENOMICS, V9, P623, DOI 10.1016/0888-7543(91)90355-I; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, GENOME ANAL, V1, P157; WESTERVELD A, 1971, NATURE-NEW BIOL, V234, P20, DOI 10.1038/newbio234020a0; WRIGHT EC, 1990, GENOMICS, V7, P103, DOI 10.1016/0888-7543(90)90524-X; ZOGHBI HY, 1989, AM J HUM GENET, V44, P255	62	1133	1152	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					219	232		10.1016/0092-8674(91)90613-4	http://dx.doi.org/10.1016/0092-8674(91)90613-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1677316				2022-12-24	WOS:A1991FY71200004
J	BLUMBERG, B; WRIGHT, CVE; DEROBERTIS, EM; CHO, KWY				BLUMBERG, B; WRIGHT, CVE; DEROBERTIS, EM; CHO, KWY			ORGANIZER-SPECIFIC HOMEOBOX GENES IN XENOPUS-LAEVIS EMBRYOS	SCIENCE			English	Article							DNA-BINDING SPECIFICITY; EARLY DROSOPHILA EMBRYO; BICOID PROTEIN; HOMEODOMAIN PROTEINS; ANTERIOR STRUCTURES; EXPRESSION VECTOR; GROWTH-FACTORS; MESODERM; AXIS; TRANSCRIPTION	The dorsal blastopore lip of the early Xenopus laevis gastrula can organize a complete secondary body axis when transplanted to another embryo. A search for potential gene regulatory components specifically expressed in the organizer was undertaken that resulted in the identification of four types of complementary DNAs from homeobox-containing genes that fulfill this criterion. The most abundant of these encodes a DNA-binding specificity similar to that of the Drosophila melanogaster anterior morphogen bicoid. The other three are also homologous to developmentally significant Drosophila genes. These four genes may participate in the regulation of the developmental potential of the organizer.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869	NICHD NIH HHS [HD-21502, HD-07273] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, F32HD007273, R01HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1990, TRENDS GENET, V6, P57; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; Cho K., UNPUB; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; Dawid I.B., 1990, Current Topics in Developmental Biology, V24, P261, DOI 10.1016/S0070-2153(08)60090-3; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GURDON JB, 1987, DEVELOPMENT, V99, P285; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HAN JH, 1988, NUCLEIC ACIDS RES, V16, P11837, DOI 10.1093/nar/16.24.11837; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARVEY RP, 1986, EMBO J, V5, P1237, DOI 10.1002/j.1460-2075.1986.tb04352.x; HOLTFRETER HB, 1965, THESIS U ROCHESTER; JAYNES JB, 1990, GENETICS OF PATTERN FORMATION AND GROWTH CONTROL, P47; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; NAKAMURA O, 1978, ORG MILESTONE HALF C; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; Spemann H, 1931, Wilhelm Roux Arch Entwickl Mech Org, V123, P389, DOI 10.1007/BF01380646; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEWART RM, 1990, DEVELOPMENT, V109, P363; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TREISMAN J, 1989, CELL, V59, P553; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1	45	342	349	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					194	196		10.1126/science.1677215	http://dx.doi.org/10.1126/science.1677215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1677215				2022-12-24	WOS:A1991FW16000036
J	BADWE, RA; GREGORY, WM; CHAUDARY, MA; RICHARDS, MA; BENTLEY, AE; RUBENS, RD; FENTIMAN, IS				BADWE, RA; GREGORY, WM; CHAUDARY, MA; RICHARDS, MA; BENTLEY, AE; RUBENS, RD; FENTIMAN, IS			TIMING OF SURGERY DURING MENSTRUAL-CYCLE AND SURVIVAL OF PREMENOPAUSAL WOMEN WITH OPERABLE BREAST-CANCER	LANCET			English	Article							CLINICAL-TRIALS; SURGICAL CURE; GROWTH; REGRESSION; AUTOCRINE	Timing of operation in relation to menstrual phase might affect outlook in premenopausal women with operable breast cancer. We examined the records of 249 such women treated between 1975 and 1985, and compared overall and recurrence-free survival in those whose operation was 3-12 days after their last menstrual period (LMP) (group 1, n = 75) with those in whom it was 0-2 or 13-32 days after LMP (group 2, n = 174). Overall and recurrence-free survival were greatly reduced in group 1 women (p < 0.001 for both). Actuarial survival at 10 years was 54% in group 1 versus 84% in group 2. This effect was independent of other factors, was of much the same importance as nodal status in multivariate analysis, was largely confined to histologically node-positive cases, seemed to be greater in women with small tumours (less-than-or-equal-to 2 cm), and was seen in patients with oestrogen-receptor positive and negative tumours. Thus phase of menstrual cycle at operation is of great importance for long-term outlook in premenopausal women with breast cancer.	GUYS HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust			Fentiman, Ian/AAB-9886-2020; Fentiman, Ian S/I-7644-2019					ANDERSEN PK, 1982, BIOMETRICS, V38, P67, DOI 10.2307/2530289; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1989, CANCER RES, V49, P1996; GELBER RD, 1989, LANCET, V2, P1344; HANNA N, 1982, J IMMUNOL, V130, P974; HISSOM JR, 1987, BIOCHEM BIOPH RES CO, V145, P706, DOI 10.1016/0006-291X(87)91022-9; HOEWITZ KB, 1985, CANCER RES, V45, P167; HRUSHESKY WJM, 1989, LANCET, V2, P949; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P70; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIPPMAN ME, 1986, BREAST CANCER RES TR, V7, P59, DOI 10.1007/BF01806790; MANNI A, 1990, BREAST CANCER RES TR, V15, P73, DOI 10.1007/BF01810779; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POWLES TJ, 1989, LANCET, V2, P1343; RATAJCZAK HV, 1988, J EXP MED, V168, P88; RICHARDS MA, 1990, J CLIN ONCOL, V8, P2032, DOI 10.1200/JCO.1990.8.12.2032; ROCHEFORT H, 1988, BIOCHIMIE, V70, P943, DOI 10.1016/0300-9084(88)90236-2; RUBENS RD, 1983, LANCET, V1, P839, DOI 10.1016/S0140-6736(83)91385-5; SENIE R T, 1990, Breast Cancer Research and Treatment, V16, P146; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; VILLE Y, 1990, BREAST CANCER RES TR, V16, P119, DOI 10.1007/BF01809296; YEN S, 1986, REPROD ENDOCRINOLOGY, P126	22	166	166	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1261	1264		10.1016/0140-6736(91)92927-T	http://dx.doi.org/10.1016/0140-6736(91)92927-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674070				2022-12-24	WOS:A1991FN04700011
J	MAGOS, AL; BAUMANN, R; LOCKWOOD, GM; TURNBULL, AC				MAGOS, AL; BAUMANN, R; LOCKWOOD, GM; TURNBULL, AC			EXPERIENCE WITH THE 1ST 250 ENDOMETRIAL RESECTIONS FOR MENORRHAGIA	LANCET			English	Article							ND-YAG LASER; ABLATION; SURGERY	234 patients with menorrhagia were treated hysteroscopically by transcervical resection of the endometrium (TCRE) instead of hysterectomy. 250 procedures were performed under general anaesthesia (63%) or under sedation plus local anaesthesia (38%). The endometrium was excised either totally (91%) or partially (9%) in all but one case, and 56 (22%) of the patients underwent simultaneous resection of submucous fibroids. Surgical time (range 10-100 min) varied with the gynaecologist's experience. 479 ml was the average volume of uterine irrigant absorbed by the patient. Blood loss was usually slight. Operative complications were uncommon, but 4 (2%) women sustained a uterine perforation (without serious sequelae), 7 (3%) absorbed more than 2 litres of fluid, and 1 required tamponade to control postoperative bleeding. Hospital stay was short and full recovery usual by 1-2 weeks. Menstrual symtoms improved in over 90% of the patients throughout the follow-up of up to 2 1/2 years; 27-42% of the women became amenorrhoeic at some time after total TCRE. Results were best in women > 35 years of age, but was not influenced by the presence of fibroids or pretreatment dysmenorrhoea. 10 (4%) women later underwent hysterectomy. Hysteroscopy 3 and 12 months after surgery revealed a small, fibrotic uterine cavity in the majority.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND	University of Oxford	MAGOS, AL (corresponding author), ROYAL FREE HOSP,ACAD DEPT OBSTET & GYNAECOL,LONDON NW3 2QG,ENGLAND.							ASHERMAN JG, 1950, J OBSTET GYN BRIT EM, V57, P892; BAGGISH MS, 1988, AM J OBSTET GYNECOL, V159, P287, DOI 10.1016/S0002-9378(88)80069-3; BAUMANN R, 1990, BRIT MED J, V300, P304, DOI 10.1136/bmj.300.6720.304; DANIELL JF, 1986, COLP GYNECOL LAS SUR, V2, P43; DAVIS JA, 1989, BRIT J OBSTET GYNAEC, V96, P928, DOI 10.1111/j.1471-0528.1989.tb03347.x; DECHERNEY A, 1983, OBSTET GYNECOL, V61, P392; GIMPELSON RJ, 1988, J REPROD MED, V33, P872; GOLDFARB HA, 1990, OBSTET GYNECOL, V76, P833, DOI 10.1097/00006250-199011000-00022; GOLDRATH MH, 1981, AM J OBSTET GYNECOL, V140, P14, DOI 10.1016/0002-9378(81)90251-9; GOLDRATH MH, 1990, J REPROD MED, V35, P91; GOLDRATH MH, 1986, GYNAECOLOGICAL LASER, P253; GORDON AG, 1989, BAILLIERE CLIN OB GY, V3, P429, DOI 10.1016/S0950-3552(89)80003-3; LOCKWOOD M, 1990, BRIT J OBSTET GYNAEC, V97, P656, DOI 10.1111/j.1471-0528.1990.tb02562.x; LOMANO JM, 1986, J REPROD MED, V31, P148; LOMANO JM, 1988, AM J OBSTET GYNECOL, V159, P152, DOI 10.1016/0002-9378(88)90512-1; MAGOS AL, 1990, LANCET, V335, P44, DOI 10.1016/0140-6736(90)90165-2; MAGOS AL, 1989, LANCET, V2, P925; MAGOS AL, 1989, BRIT MED J, V298, P1209, DOI 10.1136/bmj.298.6682.1209; MAGOS AL, 1990, ADV REP END, V2, P97; NEUWIRTH RS, 1978, AM J OBSTET GYNECOL, V131, P91, DOI 10.1016/0002-9378(78)90481-7; PERRY CP, 1990, J GYNECOL SURG, V6, P199, DOI 10.1089/gyn.1990.6.199; PHIPPS JH, 1990, OBSTET GYNECOL, V76, P876, DOI 10.1097/00006250-199011000-00032; PHIPPS JH, 1990, LANCET, V335, P374, DOI 10.1016/0140-6736(90)90207-L; TOWNSEND DE, 1990, OBSTET GYNECOL, V76, P310; VANCAILLIE TG, 1989, OBSTET GYNECOL, V74, P425	25	248	253	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1074	1078		10.1016/0140-6736(91)91718-A	http://dx.doi.org/10.1016/0140-6736(91)91718-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673504				2022-12-24	WOS:A1991FK20400015
J	KOVACS, A; FREDERICK, T; CHURCH, J; ELLER, A; OXTOBY, M; MASCOLA, L				KOVACS, A; FREDERICK, T; CHURCH, J; ELLER, A; OXTOBY, M; MASCOLA, L			CD4 LYMPHOCYTE-T COUNTS AND PNEUMOCYSTIS-CARINII PNEUMONIA IN PEDIATRIC HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN; CHEMOPROPHYLAXIS; RATIO	The relationship between CD4 T-lymphocyte counts and infection with the human immunodeficiency virus (HIV) is retrospectively investigated for 266 HIV-infected and uninfected children who were born to infected women, including 39 with Pneumocystis carinii pneumonia (PCP), in a population-based surveillance study. Of 21 perinatally HIV-infected children with PCP only 10 (48%) had CD4 T-lymphocyte counts that were less than 500 X 10(6) cells/L (500 cells/mm3), compared with all 18 who were infected via blood transfusions or clotting factors. Among 68 children who were 1 year or younger, 18 (90%) of 20 PCP cases had CD4 T-lymphocyte counts that were less than 1500 X 10(6) cells/L (1500 cells/mm3) compared with only five (10%) of 48 children who did not have the acquired immunodeficiency syndrome (odds ratio, 77.4; 95% confidence interval, 19.7 to 313.4). The mean CD4 T-lymphocyte count was lower for the 39 PCP cases when compared with the 188 children who were at different stages of HIV infection and did not have the acquired immunodeficiency syndrome (AIDS) independent of age. The majority of perinatally HIV-infected children with PCP were 6 months or younger and 50% were previously unknown to be infected. Thus, HIV-positive children should be identified early and followed closely. CD4 T-lymphocyte counts may be useful in monitoring HIV-positive children and determining when to begin PCP prophylaxis.	LOS ANGELES CTY DEPT HLTH SERV,PEDIAT AIDS SURVEILLANCE STUDY,LOS ANGELES,CA; CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA; UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033; CTR DIS CONTROL,ATLANTA,GA 30333; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; University of Southern California; Centers for Disease Control & Prevention - USA; University of Southern California	KOVACS, A (corresponding author), UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT PATHOL,PEDIAT PAVIL,1129 N STATE S,ROOM 3D14,LOS ANGELES,CA 90033, USA.				PHS HHS [U64-CCU903273-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERNSTEIN LJ, 1989, AM J DIS CHILD, V143, P775, DOI 10.1001/archpedi.1989.02150190025013; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; DENNY TN, 1990, PEDIATR RES, V27, P155; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; HSU H, 1990, 30TH ICAAC ATL; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; KOVACS JA, 1989, J INFECT DIS, V160, P882, DOI 10.1093/infdis/160.5.882; LEIBOVITZ E, 1990, NEW ENGL J MED, V323, P531, DOI 10.1056/NEJM199008233230807; MASUR H, 1989, ANN INTERN MED, V111, P813, DOI 10.7326/0003-4819-111-10-813; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; SANDERSLAUFER D, 1990, PEDIATR RES, V27, P183; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; VERNON DD, 1988, PEDIATRICS, V82, P223; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1987, MMWR, V36, P225; 1987, MMWR, V36, P235; 1989, MMWR S5, V38, pS1; 1987, MMWR S15, V36, pS1	24	43	43	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1698	1703						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1672169				2022-12-24	WOS:A1991FD65900025
J	FOX, K; DAW, N; SATO, H; CZEPITA, D				FOX, K; DAW, N; SATO, H; CZEPITA, D			DARK-REARING DELAYS THE LOSS OF NMDA-RECEPTOR FUNCTION IN KITTEN VISUAL-CORTEX	NATURE			English	Article							METHYL-D-ASPARTATE; OCULAR DOMINANCE COLUMNS; CAT; PLASTICITY; NEURONS	SOME features of the visual cortex develop postnatally in mammals 1,2. For example, geniculocortical axons that initially overlap throughout cortical layer IV segregate postnatally into two sets of interleaved eye-specific bands 3,4. NMDA (N-methyl-D-aspartate) receptors are necessary for eye-specific axon-segregation in the frog tectum 5, and as NMDA receptors play a greater part in synaptic transmission in early life 6,7 and decrease in function during the period of axon segregation, they may be involved in the segregation of geniculocortical axons: they are well placed to do so as they transduce 8 retinally derived signals essential for segregation 9. Rearing animals in the dark in early life delays segregation 10,11 and prolongs the critical period for plasticity 12. We now report that dark-rearing of kittens also delays the loss of NMDA receptor function in the visual cortex, supporting the view that they play an important part in neuronal development and plasticity.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,MCDONNELL CTR STUDIES HIGHER BRAIN FUNCT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Fox, Kevin/E-8836-2010	Fox, Kevin/0000-0002-2563-112X				BODEGREUEL KM, 1989, DEV BRAIN RES, V46, P197, DOI 10.1016/0165-3806(89)90283-6; CLINE HT, 1990, J NEUROSCI, V10, P1197; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; FLATMAN JA, 1986, BRAIN RES, V363, P62, DOI 10.1016/0006-8993(86)90659-1; FOX K, 1989, J NEUROSCI, V9, P2443; FOX K, 1990, J NEUROPHYSIOL, V64, P1413, DOI 10.1152/jn.1990.64.5.1413; FREEMAN RD, 1979, SCIENCE, V206, P1093, DOI 10.1126/science.493996; GORDON B, 1990, SOC NEUR ABSTR, V17, P986; HAGIHARA K, 1988, EXP BRAIN RES, V69, P407; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; Mitchell DE, 1984, HDB PHYSL 1 1, V3, P507; MOWER GD, 1985, J COMP NEUROL, V235, P448, DOI 10.1002/cne.902350404; REYNOLDS IJ, IN PRESS EXPL BRAIN; SHATZ CJ, 1988, CEREB CORTEX, V7, P35; STRYKER MP, 1986, J NEUROSCI, V6, P2117; SWINDALE NV, 1988, J COMP NEUROL, V267, P47; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0	22	105	107	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					342	344		10.1038/350342a0	http://dx.doi.org/10.1038/350342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1672557				2022-12-24	WOS:A1991FD83800093
J	MULKEY, RM; ZUCKER, RS				MULKEY, RM; ZUCKER, RS			ACTION-POTENTIALS MUST ADMIT CALCIUM TO EVOKE TRANSMITTER RELEASE	NATURE			English	Article							NEUROTRANSMITTER RELEASE; NERVE TERMINALS; FACILITATION; DEPOLARIZATION; CRAYFISH; ENTRY; INFLUX	THERE are two hypotheses to explain how neurons release transmitter. The calcium hypothesis proposes that membrane depolarization is necessary only for opening calcium channels and increasing internal calcium concentration ([Ca2+]i) near membrane transmitter-release sites 1-3. These calcium ions trigger a transient release of neurotransmitter 4,5. The calcium-voltage hypothesis postulates that voltage induces a conformational change in a membrane protein rendering it sensitive to calcium such that, in the presence of high [Ca2+]i, depolarization directly triggers transmitter release 6-9. Here we report that when calcium influx is blocked by cobalt or manganese ions in a calcium-free Ringer, as measured with Fura-2, and [Ca2+]i is elevated by liberation from a caged calcium compound, transmitter release at the crayfish neuromuscular junction is unaffected by presynaptic action potentials. These results support the calcium hypothesis.			MULKEY, RM (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720, USA.		Zucker, Robert S/J-9995-2012	Zucker, Robert S/0000-0003-1068-2343				BITTNER GD, 1988, J NEUROBIOL, V20, P386; DELANEY KR, 1990, J PHYSIOL-LONDON, V426, P473, DOI 10.1113/jphysiol.1990.sp018150; DELANEY KR, 1989, J NEUROSCI, V9, P3558; DUDEL J, 1983, PFLUG ARCH EUR J PHY, V399, P1, DOI 10.1007/BF00652515; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; FOGELSON AL, 1985, BIOPHYS J, V48, P1003, DOI 10.1016/S0006-3495(85)83863-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1988, BIOCHEM J, V255, P179, DOI 10.1042/bj2550179; HOCHNER B, 1989, NATURE, V342, P433, DOI 10.1038/342433a0; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; Katz B., 1969, RELEASE NEURAL TRANS; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MILEDI R, 1973, PROC R SOC SER B-BIO, V183, P421, DOI 10.1098/rspb.1973.0026; NARITA K, 1990, BRAIN RES, V510, P289, DOI 10.1016/0006-8993(90)91379-U; PARNAS H, 1986, PFLUG ARCH EUR J PHY, V406, P121, DOI 10.1007/BF00586672; PARNAS I, 1986, PFLUG ARCH EUR J PHY, V406, P131, DOI 10.1007/BF00586673; ZUCKER RS, 1986, J PHYSIOL-PARIS, V81, P237; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1986, SCIENCE, V231, P574, DOI 10.1126/science.2868525; ZUCKER RS, 1988, NATURE, V335, P360, DOI 10.1038/335360a0	20	104	104	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					153	155		10.1038/350153a0	http://dx.doi.org/10.1038/350153a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1672444				2022-12-24	WOS:A1991FB64500058
J	GOATE, A; CHARTIERHARLIN, MC; MULLAN, M; BROWN, J; CRAWFORD, F; FIDANI, L; GIUFFRA, L; HAYNES, A; IRVING, N; JAMES, L; MANT, R; NEWTON, P; ROOKE, K; ROQUES, P; TALBOT, C; PERICAKVANCE, M; ROSES, A; WILLIAMSON, R; ROSSOR, M; OWEN, M; HARDY, J				GOATE, A; CHARTIERHARLIN, MC; MULLAN, M; BROWN, J; CRAWFORD, F; FIDANI, L; GIUFFRA, L; HAYNES, A; IRVING, N; JAMES, L; MANT, R; NEWTON, P; ROOKE, K; ROQUES, P; TALBOT, C; PERICAKVANCE, M; ROSES, A; WILLIAMSON, R; ROSSOR, M; OWEN, M; HARDY, J			SEGREGATION OF A MISSENSE MUTATION IN THE AMYLOID PRECURSOR PROTEIN GENE WITH FAMILIAL ALZHEIMERS-DISEASE	NATURE			English	Article							SECONDARY STRUCTURE; LINKAGE; CHROMOSOME-21; CDNA; PREDICTION; MARKERS; DEFECT; LOCUS; DNA	A LOCUS segregating with familial Alzheimer's disease (AD) has been mapped to chromosome 21 (ref. 1), close to the amyloid precursor protein (APP) gene 2-5. Recombinants between the APP gene and the AD locus have been reported 6-8 which seemed to exclude it as the site of the mutation causing familial AD. But recent genetic analysis of a large number of AD families has demonstrated that the disease is heterogeneous 9. Families with late-onset AD do not show linkage to chromosome 21 markers 9,10. Some families with early-onset AD show linkage to chromosome 21 markers, but some do not 8,9,11. This has led to the suggestion that there is non-allelic genetic heterogeneity even within early onset familial AD 8,9. To avoid problems that heterogeneity poses for genetic analysis, we have examined the cosegregation of AD and markers along the long arm of chromosome 21 in a single family with AD confirmed by autopsy. Here we demonstrate that in this kindred, which shows linkage to chromosome 21 markers, there is a point mutation in the APP gene. This mutation causes an amino-acid substitution (Val --> Ile) close to the carboxy terminus of the beta-amyloid peptide. Screening other cases of familial AD revealed a second unrelated family in which this variant occurs. This suggests that some cases of AD could be caused by mutations in the APP gene.	ST MARYS HOSP, SCH MED, DEPT BIOCHEM, ALZHEIMERS DIS RES GRP, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, SCH MED, DEPT NEUROL, LONDON W2 1PG, ENGLAND; YALE UNIV, SCH MED, DEPT HUMAN GENET, NEW HAVEN, CT 06510 USA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; UNIV COLL CARDIFF, DEPT PSYCHOL MED, CARDIFF CF4 4XN, S GLAM, WALES; UNIV COLL CARDIFF, DEPT MED GENET, CARDIFF CF4 4XN, S GLAM, WALES	Imperial College London; Imperial College London; Yale University; Duke University; Cardiff University; Cardiff University			Chartier-Harlin, Marie-Christine/L-4527-2018; Rossor, Martin/C-1598-2008; Hardy, John/C-2451-2009	Chartier-Harlin, Marie-Christine/0000-0001-6416-6526; Hardy, John/0000-0002-3122-0423; Mullan, Michael/0000-0002-1473-7527; Goate, Alison/0000-0002-0576-2472; Rossor, Martin/0000-0001-8215-3120	NIA NIH HHS [AG-05128] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARGOS P, 1982, EUR J BIOCHEM, V128, P565; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE AM, 1989, LANCET, V1, P352; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GUO Z, 1990, NUCLEIC ACIDS RES, V18, P4967, DOI 10.1093/nar/18.16.4967-a; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEWIS JG, 1990, GENOMICS, V8, P400, DOI 10.1016/0888-7543(90)90300-J; LIM VI, 1974, J MOL BIOL, V88, P857, DOI 10.1016/0022-2836(74)90404-5; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; TANZI R E, 1988, Genomics, V3, P129, DOI 10.1016/0888-7543(88)90143-7; TANZI RE, 1987, NATURE, V329, P156, DOI 10.1038/329156a0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; VAN BROECKHOVEN C, 1987, NATURE, V329, P153; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; WARREN AC, 1989, GENOMICS, V4, P579, DOI 10.1016/0888-7543(89)90282-6; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N; [No title captured]	30	3712	3897	7	501	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					704	706		10.1038/349704a0	http://dx.doi.org/10.1038/349704a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1671712				2022-12-24	WOS:A1991EY62700050
J	MCELVANEY, NG; HUBBARD, RC; BIRRER, P; CHERNICK, MS; CAPLAN, DB; FRANK, MM; CRYSTAL, RG				MCELVANEY, NG; HUBBARD, RC; BIRRER, P; CHERNICK, MS; CAPLAN, DB; FRANK, MM; CRYSTAL, RG			AEROSOL ALPHA-1-ANTITRYPSIN TREATMENT FOR CYSTIC-FIBROSIS	LANCET			English	Note							HUMAN NEUTROPHIL ELASTASE	In cystic fibrosis neutrophil-dominated inflammation on the respiratory epithelial surface results in a chronic epithelial burden of the destructive enzyme, neutrophil elastase. Alpha-1-antitrypsin (alpha-1AT), the main inhibitor of neutrophil elastase in lung, was given in aerosol form to 12 cystic fibrosis patients. It suppressed neutrophil elastase in the respiratory epithelial lining fluid (ELF) and restored the ELF anti-neutrophil elastase capacity when ELF alpha-1AT reached 8-mu-mol/l. This treatment also reversed the inhibitory effect of cystic fibrosis ELF on pseudomonas killing by neutrophils, which suggests that it may augment host defence in cystic fibrosis.	NHLBI,PULM BRANCH,BLDG 10,ROOM 6DO3,BETHESDA,MD 20892; NIDDKD,PEDIAT METAB BRANCH,BETHESDA,MD; NIAID,CLIN INVEST LAB,BETHESDA,MD 20892; EMORY UNIV,SCH MED,DEPT PEDIAT,DIV GASTROENTEROL & CYST FIBROSIS,ATLANTA,GA 30322	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emory University			McElvaney, Noel/A-6809-2010	mcelvaney, Noel/0000-0002-0152-4370				BERGER M, 1989, J CLIN INVEST, V84, P1302, DOI 10.1172/JCI114298; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BREUER R, 1989, AM REV RESPIR DIS, V139, P779, DOI 10.1164/ajrccm/139.3.779; FICK RB, 1984, J CLIN INVEST, V74, P236, DOI 10.1172/JCI111407; LUCEY EC, 1988, EXP LUNG RES, V14, P671, DOI 10.3109/01902148809087836; SUTER S, 1989, PSEUDOMONAS AERUGINO, P158; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	7	297	307	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					392	394		10.1016/0140-6736(91)91167-S	http://dx.doi.org/10.1016/0140-6736(91)91167-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671425				2022-12-24	WOS:A1991EX60500005
J	SCHMID, A; DEHLINGERKREMER, M; SCHULZ, I; GOGELEIN, H				SCHMID, A; DEHLINGERKREMER, M; SCHULZ, I; GOGELEIN, H			VOLTAGE-DEPENDENT INSP3- INSENSITIVE CALCIUM CHANNELS IN MEMBRANES OF PANCREATIC ENDOPLASMIC-RETICULUM VESICLES	NATURE			English	Article											SCHMID, A (corresponding author), MAX PLANCK INST BIOPHYS,KENNEDY ALLEE 70,W-6000 FRANKFURT 70,GERMANY.							BAYERDORFFER E, 1984, J MEMBRANE BIOL, V81, P69, DOI 10.1007/BF01868811; CRIADO M, 1987, FEBS LETT, V224, P172, DOI 10.1016/0014-5793(87)80442-8; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GILL DL, 1989, CELL CALCIUM, V10, P363, DOI 10.1016/0143-4160(89)90062-6; GOGELEIN H, 1987, PFLUG ARCH EUR J PHY, V410, P288, DOI 10.1007/BF00580279; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; KEMMER TP, 1987, J BIOL CHEM, V262, P13758; KOSTYUK PG, 1989, J MEMBRANE BIOL, V110, P11, DOI 10.1007/BF01870988; LEE KS, 1984, J PHYSIOL-LONDON, V354, P253, DOI 10.1113/jphysiol.1984.sp015374; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; NILIUS B, 1985, NATURE, V316, P443, DOI 10.1038/316443a0; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SCHMID A, 1988, J MEMBRANE BIOL, V104, P275, DOI 10.1007/BF01872329; SCHMID A, 1989, J MEMBRANE BIOL, V111, P264; SCHULZ I, 1980, AM J PHYSIOL, V239, pG335, DOI 10.1152/ajpgi.1980.239.5.G335; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; STREB H, 1984, J MEMBRANE BIOL, V81, P241, DOI 10.1007/BF01868717; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856	25	83	83	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 26	1990	346	6282					374	376		10.1038/346374a0	http://dx.doi.org/10.1038/346374a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ567	1695718				2022-12-24	WOS:A1990DQ56700065
J	FINEGOLD, AA; SCHAFER, WR; RINE, J; WHITEWAY, M; TAMANOI, F				FINEGOLD, AA; SCHAFER, WR; RINE, J; WHITEWAY, M; TAMANOI, F			COMMON MODIFICATIONS OF TRIMERIC-G PROTEINS AND RAS PROTEIN - INVOLVEMENT OF POLYISOPRENYLATION	SCIENCE			English	Article									UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELLULAR BIOL, BERKELEY, CA 94720 USA; NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, GENET ENGN SECT, MONTREAL H4P 2R2, QUEBEC, CANADA	University of Chicago; University of California System; University of California Berkeley; National Research Council Canada				Schafer, William/0000-0002-6676-8034	NATIONAL CANCER INSTITUTE [R01CA041996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183, R01GM035827] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41996] Funding Source: Medline; NIGMS NIH HHS [GM 35827, GM 07183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINEGOLD AA, UNPUB; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERSKOWITZ I, 1987, CELL, V50, P995, DOI 10.1016/0092-8674(87)90162-0; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; MIYAJIMA I, 1987, CELL, V50, P11; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P5410, DOI 10.1128/MCB.8.12.5410; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SERRANO R, 1978, MOL CELL BIOCHEM, V22, P51; SHERMAN F, 1986, LABORATORY COURSE MA, P117; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAMANOI F, 1988, J CELL BIOCHEM, V36, P261, DOI 10.1002/jcb.240360307; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, UNPUB; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILSON KL, 1987, GENETICS, V155, P441; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	39	111	114	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	1990	249	4965					165	169		10.1126/science.1695391	http://dx.doi.org/10.1126/science.1695391			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DN539	1695391				2022-12-24	WOS:A1990DN53900035
J	MATSUDA, M; MAYER, BJ; FUKUI, Y; HANAFUSA, H				MATSUDA, M; MAYER, BJ; FUKUI, Y; HANAFUSA, H			BINDING OF TRANSFORMING PROTEIN, P47GAG-CRK, TO A BROAD RANGE OF PHOSPHOTYROSINE-CONTAINING PROTEINS	SCIENCE			English	Article									ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University			Fukui, Yasuhisa/E-8806-2010	Matsuda, Michiyuki/0000-0002-5876-9969	NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007233] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356] Funding Source: Medline; NIAID NIH HHS [AI 07233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; EMORI Y, 1989, J BIOL CHEM, V264, P21885; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; Marshall C., UNPUB; MATSUDA M, IN PRESS J BIOL CHEM; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MAYER BJ, IN PRESS J VIROL; MCCARLEY DJ, 1987, J VIROL, V61, P1927, DOI 10.1128/JVI.61.6.1927-1937.1987; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; PAWSON T, 1988, ONCOGENE, V3, P491; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; REICHMAN C, UNPUB; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEFTON BM, 1982, J VIROL, V41, P813, DOI 10.1128/JVI.41.3.813-820.1982; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934	34	385	399	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 22	1990	248	4962					1537	1539		10.1126/science.1694307	http://dx.doi.org/10.1126/science.1694307			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DK408	1694307				2022-12-24	WOS:A1990DK40800035
J	HILL, RE; FAVOR, J; HOGAN, BLM; TON, CCT; SAUNDERS, GF; HANSON, IM; PROSSER, J; JORDAN, T; HASTIE, ND; VANHEYNINGEN, V				HILL, RE; FAVOR, J; HOGAN, BLM; TON, CCT; SAUNDERS, GF; HANSON, IM; PROSSER, J; JORDAN, T; HASTIE, ND; VANHEYNINGEN, V			MOUSE SMALL EYE RESULTS FROM MUTATIONS IN A PAIRED-LIKE HOMEOBOX-CONTAINING GENE	NATURE			English	Article							DEVELOPING EXCRETORY SYSTEM; BOX; DROSOPHILA; DELETION; DOMAIN; PAX-1; OCT-1; DNA	SMALL eye (Sey) in mouse is a semidominant mutation which in the homozygous condition results in the complete lack of eyes and nasal primordia. On the basis of comparative mapping studies and on phenotypic similarities, Sey bas been suggested to be homologous to congenital aniridia (lack of iris) in human 1,2. A candidate gene for the aniridia (AN) locus at 11p13 bas been isolated by positional cloning 3 and its sequence and that of the mouse homologue has been established (C.T., manuscript in preparation). This gene belongs to the paired-like class of developmental genes first described in Drosophila which contain two highly conserved motifs, the paired box and the homeobox 4,5. In vertebrates, genes which encode the single paired domain as well as those which express both motifs have been described as the Pax multigene family 6-10. A Pax gene recently described as Pax-6 11,12 is identical to the mouse homologue of the candidate aniridia gene. Here we report the analysis of three independent Sey alleles and show that indeed this gene is mutated and that the mutations would predictably interrupt gene function.	GESELL STRAHLEN & UMWELTFORSCH MBH,INST SAUGETIERGENET,W-8042 NEUHERBERG,GERMANY; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	HILL, RE (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		VAN HEYNINGEN, Veronica/GYE-0531-2022; van Heyningen, Veronica/B-8039-2008	van Heyningen, Veronica/0000-0003-0359-0141; Hanson, Isabel/0000-0002-1878-0530				BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARTH RK, 1982, P NATL ACAD SCI-BIOL, V79, P500, DOI 10.1073/pnas.79.2.500; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; COTE S, 1987, EMBO J, V6, P2793, DOI 10.1002/j.1460-2075.1987.tb02575.x; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DILELLA AG, 1986, NATURE, V322, P799, DOI 10.1038/322799a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; ESUMI H, 1983, P NATL ACAD SCI-BIOL, V80, P95, DOI 10.1073/pnas.80.1.95; FAVOR J, 1988, MUTAT RES, V198, P269, DOI 10.1016/0027-5107(88)90003-6; FAVOR J, 1982, MUTAT RES, V92, P181; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Green MC., 1989, GENETIC VARIANTS STR, P12; HASTIE ND, IN PRESS CURR BIOL; HOGAN BLM, 1988, DEVELOPMENT, V103, P115; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; JOSTES B, 1991, MECH DEVELOP, V33, P27; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; MEYEROWITZ R, 1988, P NATL ACAD SCI USA, V85, P3955; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; PLACHOV D, 1990, DEVELOPMENT, V110, P643; PROSSER J, 1990, ONCOGENE, V5, P1573; RESS DJG, 1985, NATURE, V316, P643; ROBERTS RC, 1967, GENET RES, V9, P121, DOI 10.1017/S0016672300010387; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TON CCT, IN PRESS CELL, V67; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; VANDERMEERDEJONG R, 1990, GENOMICS, V7, P270, DOI 10.1016/0888-7543(90)90550-E; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, IN PRESS DEVELOPMENT; [No title captured]	37	1156	1174	2	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					522	525		10.1038/354522a0	http://dx.doi.org/10.1038/354522a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1684639				2022-12-24	WOS:A1991GW75100014
J	STONEBRIDGE, PA; BROPHY, CM				STONEBRIDGE, PA; BROPHY, CM			SPIRAL LAMINAR-FLOW IN ARTERIES	LANCET			English	Note							AORTA	Spiral blood-flow patterns in infrainguinal blood-vessels were observed at angioscopy in 54 patients who underwent peripheral vascular reconstruction; the endoluminal surface had spiral folds in 51 of 75 arteries examined. Spiral flow patterns, congruous with inherent endoluminal anatomical features, might more accurately represent blood-flow in infrainguinal arteries than current models of laminar flow.	YALE UNIV,SCH MED,DIV VASC SURG,NEW HAVEN,CT 06510	Yale University	STONEBRIDGE, PA (corresponding author), ROYAL INFIRM,VASC SURG UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							FRAZIN L, 1990, CLIN RES, V38, pA331; Fung YC, 1984, BIODYNAMICS CIRCULAT, P77; HUNT TH, 1989, CARDIOVASCULAR SCI T, P124; KARINO T, 1987, ANN NY ACAD SCI, V516, P422; LOGERFO FW, 1985, J VASC SURG, V2, P263, DOI 10.1067/mva.1985.avs0020263; MILLER A, 1991, SURGERY, V109, P286; SEGADAL L, 1987, CIRCULATION, V76, P90, DOI 10.1161/01.CIR.76.1.90; UCHIDA Y, 1987, AM HEART J, V114, P1216, DOI 10.1016/0002-8703(87)90199-2	8	101	113	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1991	338	8779					1360	1361		10.1016/0140-6736(91)92238-W	http://dx.doi.org/10.1016/0140-6736(91)92238-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682738				2022-12-24	WOS:A1991GR77300005
J	WALD, NJ				WALD, NJ			COUPLE SCREENING FOR CYSTIC-FIBROSIS	LANCET			English	Article											WALD, NJ (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1M 6BQ,ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					BROCK DJH, 1991, ANTENATAL DIAGNOSIS, P59; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1989, OBSTETRICS, P269; 1988, BRIT MED J, V297, P1599	6	80	80	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1991	338	8778					1318	1320		10.1016/0140-6736(91)92605-2	http://dx.doi.org/10.1016/0140-6736(91)92605-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR023	1682697				2022-12-24	WOS:A1991GR02300016
J	HEALY, JMS; HEFFRON, JJA; LEHANE, M; BRADLEY, DG; JOHNSON, K; MCCARTHY, TV				HEALY, JMS; HEFFRON, JJA; LEHANE, M; BRADLEY, DG; JOHNSON, K; MCCARTHY, TV			DIAGNOSIS OF SUSCEPTIBILITY TO MALIGNANT HYPERTHERMIA WITH FLANKING DNA MARKERS	BRITISH MEDICAL JOURNAL			English	Article							RYANODINE RECEPTOR GENE; MYOTONIC-DYSTROPHY GENE; SARCOPLASMIC-RETICULUM; LINKAGE GROUP; CHROMOSOME-19; CALCIUM; PIGS; LOCALIZATION; CANDIDATE; RELEASE	Objective - To define the region on human chromosome 19 carrying the gene for malignant hyperthermia susceptibility and to evaluate the use of flanking DNA markers in diagnosing susceptibility. Design - Prospective molecular genetic linkage studies in a large malignant hyperthermia pedigree. Setting - Irish malignant hyperthermia testing centre. Subjects - A large Irish malignant hyperthermia pedigree. Main outcome measures - Routine diagnosis of susceptibility to malignant hyperthermia with in vitro contracture test on muscle biopsy specimens and genetic linkage between susceptibility and polymorphic DNA markers in a malignant hyperthermia family. Results - Genetic typing of polymorphic DNA markers in a large Irish malignant hyperthermia pedigree generated a lod score of > 3 for the marker D19S9 and showed that the gene for susceptibility is flanked by the markers D19S9 and D19S16. These tightly linked flanking markers allowed non-invasive presymptomatic diagnosis of susceptibility in five untested subjects in the large pedigree with an accuracy of > 99.7%. Conclusions - DNA markers flanking the gene for susceptibility to malignant hyperthermia can be used with high accuracy to diagnose susceptibility in subjects in large known malignant hyperthermia pedigrees and may replace the previous in vitro contracture test for diagnosing this inherited disorder in large families with malignant hyperthermia.	NATL UNIV IRELAND UNIV COLL CORK,DEPT BIOCHEM,CORK,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND; CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND	University College Cork; Trinity College Dublin; Imperial College London			Bradley, Daniel G/A-3240-2012; Healy, Sandra J/D-5256-2013	McCarthy, Tommie/0000-0003-4884-6972; Bradley, Daniel G/0000-0001-7335-7092				BRITT BA, 1969, CAN ANAESTH SOC J, V16, P89, DOI 10.1007/BF03005788; BRITT BA, 1970, CAN ANAESTH SOC J, V17, P293, DOI 10.1007/BF03004694; BRITT BA, 1987, MALIGNANT HYPERTHERM, P325; BROOK JD, 1984, HUM GENET, V68, P282, DOI 10.1007/BF00292584; BRUNNER HG, 1989, GENOMICS, V5, P589, DOI 10.1016/0888-7543(89)90027-X; DAVIES KE, 1988, MOL BASIS INHERITED; ELLIS FR, 1985, RECENT ADV ANAESTHES, P173; ENGEL AG, 1986, MYOLOGY, V2, pR4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRONERT GA, 1986, MYOLOGY, V2, P1763; HARLEY HG, 1989, CYTOGENET CELL GENET, V51, P1011; HEFFRON JJA, 1988, BRIT J ANAESTH, V60, P274, DOI 10.1093/bja/60.3.274; Humphries S E, 1983, Mol Biol Med, V1, P463; IAIZZO PA, 1988, PFLUG ARCH EUR J PHY, V411, P648, DOI 10.1007/BF00580861; KALOW W, 1987, MALIGNANT HYPERTHERM, P155; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEVITT RC, 1990, NATURE, V345, P297, DOI 10.1038/345297b0; LEVITT RC, 1990, J NEUROL SCI S, P513; LOPEZ JR, 1985, MUSCLE NERVE, V8, P355, DOI 10.1002/mus.880080502; MACKENZIE AE, 1990, AM J HUM GENET, V46, P1082; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; McCarthy T V, 1990, Acta Anaesthesiol Belg, V41, P107; MCCARTHY TV, 1990, NATURE, V343, P562, DOI 10.1038/343562a0; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; NAKAMURA Y, 1988, Genomics, V3, P67, DOI 10.1016/0888-7543(88)90161-9; NELSON TE, 1983, J CLIN INVEST, V72, P862, DOI 10.1172/JCI111057; OHNISHI ST, 1983, FEBS LETT, V161, P103; ORDING H, 1987, MALIGNANT HYPERTHERM, P267; OTT J, 1985, ANAL HUMAN GENETIC L; ROPERS HH, 1990, CYTOGENET CELL GENET, V55, P218, DOI 10.1159/000133015; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEPENS J, 1987, NUCLEIC ACIDS RES, V15, P3192, DOI 10.1093/nar/15.7.3192; SCHONK D, 1989, GENOMICS, V4, P384, DOI 10.1016/0888-7543(89)90346-7; SCHONK D, 1990, HUMAN CYTOGENET CELL, V55, P1075; WAINWRIGHT BJ, 1985, NUCLEIC ACIDS RES, V13, P4610, DOI 10.1093/nar/13.12.4610; 1984, BRIT J ANAESTH, V56, P1267	36	21	21	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1225	1228		10.1136/bmj.303.6812.1225	http://dx.doi.org/10.1136/bmj.303.6812.1225			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1684123	Bronze, Green Published			2022-12-24	WOS:A1991GQ34200019
J	KILPI, T; ANTTILA, M; KALLIO, MJT; PELTOLA, H				KILPI, T; ANTTILA, M; KALLIO, MJT; PELTOLA, H			SEVERITY OF CHILDHOOD BACTERIAL-MENINGITIS AND DURATION OF ILLNESS BEFORE DIAGNOSIS	LANCET			English	Article							INFLUENZAE TYPE-B; C-REACTIVE PROTEIN; CEREBROSPINAL-FLUID; PNEUMOCOCCAL MENINGITIS; CHILDREN; INFECTIONS; SEQUELAE; ASSOCIATION; BLOOD	Rapid diagnosis of childhood bacterial meningitis (BM) is generally believed to be essential to avoid poor outcome. To see whether duration of illness before admission to hospital was related to the severity of illness, data from children with BM diagnosed in 18 paediatric hospitals in Finland from 1984 to 1989 were collected prospectively. We divided 286 cases with culture-positive cerebrospinal fluid (CSF) into three groups: BM with a history of up to 24 h (short-history group, n = 141), of more than 24 h and up to 48 h (intermediate-history group, n = 75), and of more than 48 h (long-history group, n = 70). The longer the history, the better the clinical condition of the child. If symptoms or signs of BM lasted 48 h or less, the child did significantly worse, as judged by seven variables, than if the history was longer than 48 h (level of consciousness, p < 0.001; seizures, p < 0.01; CSF protein concentration, p < 0.001; positive CSF gram-stain, p < 0.01; positive blood culture, p < 0.05 in Haemophilus influenzae meningitis, serum C-reactive reactive protein, p < 0.01 between intermediate-history and long-history groups, and urine sodium concentration, p < 0.001 ). The differences were not affected by causative organism, sex, age, or preadmission oral antimicrobial agents. The findings show that if BM follows an insidious pattern of disease, diagnostic delay may be unavoidable, which may have medicolegal implications.	UNIV HELSINKI, CHILDRENS HOSP, STENBACKINKATU 11, SF-00290 HELSINKI 29, FINLAND	University of Helsinki								BAIRD DR, 1976, LANCET, V2, P1344; DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806; DODGE PR, 1965, NEW ENGL J MED, V272, P1003, DOI 10.1056/NEJM196505132721906; EDWARDS MS, 1981, J PEDIATR-US, V99, P540, DOI 10.1016/S0022-3476(81)80250-8; FEIGIN RD, 1976, J PEDIATR-US, V88, P542, DOI 10.1016/S0022-3476(76)80002-9; FELDMAN WE, 1982, J PEDIATR-US, V100, P209, DOI 10.1016/S0022-3476(82)80636-7; GARY N, 1989, AM J DIS CHILD, V143, P307, DOI 10.1001/archpedi.1989.02150150061018; JARVIS CW, 1972, CLIN PEDIATR, V11, P201, DOI 10.1177/000992287201100406; KAPLAN SL, 1986, PEDIATR INFECT DIS J, V5, P626, DOI 10.1097/00006454-198611000-00005; KAPLAN SL, 1978, J PEDIATR-US, V92, P758, DOI 10.1016/S0022-3476(78)80144-9; KAPLAN SL, 1985, BACTERIAL MENINGITIS, P83; KLEIN JO, 1986, PEDIATRICS, V75, P959; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; LASCOLEA LJ, 1984, J CLIN MICROBIOL, V19, P187, DOI 10.1128/JCM.19.2.187-190.1984; LAXER RM, 1977, AM J DIS CHILD, V131, P850, DOI 10.1001/archpedi.1977.02120210028004; NIEMOLLER UM, 1989, EUR J CLIN MICROBIOL, V8, P109, DOI 10.1007/BF01963892; OLCEN P, 1979, SCAND J INFECT DIS, V11, P111, DOI 10.3109/inf.1979.11.issue-2.03; PELTOLA H, 1988, J PEDIATR-US, V113, P641, DOI 10.1016/S0022-3476(88)80372-X; PELTOLA HO, 1982, LANCET, V1, P980; QUAGLIARELLO VJ, 1986, J CLIN INVEST, V77, P1084, DOI 10.1172/JCI112407; ROMER FK, 1977, LANCET, V2, P345; SMALES ORC, 1979, BMJ-BRIT MED J, V1, P588, DOI 10.1136/bmj.1.6163.588; SWARTZ MN, 1965, NEW ENGL J MED, V272, P779, DOI [10.1056/NEJM196504152721506, 10.1056/NEJM196504222721607]; SWARTZ MN, 1965, NEW ENGL J MED, V272, P725, DOI 10.1056/NEJM196504082721406; SYROGIANNOPOULOS GA, 1988, J INFECT DIS, V157, P237, DOI 10.1093/infdis/157.2.237; VALMARI P, 1987, EUR J PEDIATR, V146, P515, DOI 10.1007/BF00441607; VALMARI P, 1987, INFECT MED, V4, P308	27	70	72	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 17	1991	338	8764					406	409		10.1016/0140-6736(91)91032-P	http://dx.doi.org/10.1016/0140-6736(91)91032-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678083				2022-12-24	WOS:A1991GB44600004
J	WENGER, JD; PIERCE, R; DEAVER, KA; PLIKAYTIS, BD; FACKLAM, RR; BROOME, CV				WENGER, JD; PIERCE, R; DEAVER, KA; PLIKAYTIS, BD; FACKLAM, RR; BROOME, CV			EFFICACY OF HAEMOPHILUS-INFLUENZAE TYPE-B POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE VACCINE IN UNITED-STATES CHILDREN AGED 18-59 MONTHS	LANCET			English	Article							RISK-FACTORS; BACTERIAL-MENINGITIS; PROTECTIVE EFFICACY; IMMUNOGENICITY; DISEASE; INFANTS; SAFETY; COUNTY	Vaccines prepared from the polyribosylribitol phosphate (PRP) capsule of Haemophilus influenzae b (Hib) have not consistently shown good efficacy in protecting children aged over 18 months from invasive Hib disease. To evaluate the efficacy of conjugate-PRP vaccines in this age-group, and to compare their effect with that of PRP vaccines, a post-marketing case-control study was conducted among 10 400 000 persons. Between Oct 1, 1988, and Feb 28, 1990, 75 patients with Hib disease and 161 control children between 18 and 60 months of age were enrolled. To minimise potentially confounding socioeconomic variables, controls were selected either from among patients' classmates at their day-care centre or from among family acquaintances. 9 of the 75 patients had received the diphtheria toxoid conjugate Hib vaccine more than 2 weeks before onset of illness. After adjusting for age and household crowding, the efficacy of PRP Hib vaccine was 64% (95% Cl = -20, 89) and efficacy of the diphtheria toxoid conjugate Hib vaccine was 74% (95% Cl = 30, 90). The study shows that the protective efficacy of this conjugate vaccine is less than ideal and highlights the need for additional post-licensing studies to confirm and expand understanding of the efficacy of these new products.	CTR DIS CONTROL, RESP DIS BRANCH, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, MENINGITIS & SPECIAL PATHOGENS BRANCH, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, BIOSTAT & INFORMAT MANAGEMENT BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								[Anonymous], 1991, MMWR Recomm Rep, V40, P1; BERKOWITZ CD, 1987, J PEDIATR-US, V110, P509, DOI 10.1016/S0022-3476(87)80540-1; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; COCHI SL, 1986, J PEDIATR-US, V108, P887, DOI 10.1016/S0022-3476(86)80922-2; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GREENBERG DP, 1991, JAMA-J AM MED ASSOC, V265, P987, DOI 10.1001/jama.265.8.987; HARRISON LH, 1988, JAMA-J AM MED ASSOC, V260, P1413, DOI 10.1001/jama.260.10.1413; ISTRE GR, 1985, J PEDIATR-US, V106, P190, DOI 10.1016/S0022-3476(85)80285-7; MADORE DV, 1990, PEDIATRICS, V86, P527; MURPHY TV, 1990, CLIN RES, V38, pA183; NOAH ND, 1987, BACTERIAL MENINGITIS, P93; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; OSTERHOLM MT, 1989, 29TH INT C ANT AG CH; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; REDMOND SR, 1984, JAMA-J AM MED ASSOC, V252, P2581, DOI 10.1001/jama.252.18.2581; SHAPIRO ED, 1989, J INFECT DIS, V160, P1064, DOI 10.1093/infdis/160.6.1064; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; SHAPIRO ED, 1990, 30TH INT C ANT AG CH; WARD JI, 1988, PEDIATRICS, V81, P887; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316	21	40	41	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 17	1991	338	8764					395	398						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678080				2022-12-24	WOS:A1991GB44600001
J	CRABTREE, JE; TAYLOR, JD; WYATT, JI; HEATLEY, RV; SHALLCROSS, TM; TOMPKINS, DS; RATHBONE, BJ				CRABTREE, JE; TAYLOR, JD; WYATT, JI; HEATLEY, RV; SHALLCROSS, TM; TOMPKINS, DS; RATHBONE, BJ			MUCOSAL IGA RECOGNITION OF HELICOBACTER-PYLORI 120-KDA PROTEIN, PEPTIC-ULCERATION, AND GASTRIC PATHOLOGY	LANCET			English	Article							CAMPYLOBACTER-PYLORIDIS; C-PYLORIDIS; ULCERS; DISEASE	The gastric IgA response to Helicobacter pylori was examined in 100 dyspeptic patients by means of immunoblotting of supernatants from antral biopsy and gastric mononuclear cell cultures. 76 of 78 patients with chronic gastritis, 2 of 8 with reactive gastritis, and 1 of 14 subjects with normal mucosa showed positive responses. Of patients with chronic gastritis, 75%, 83%, 97%, and 76%, respectively, showed responses to the 120 kDa, 90 kDa, 61 kDa, and 31 kDa proteins. None of the 19 patients with chronic gastritis who did not recognise the 120 kDa protein had peptic ulcers, whereas 25 of 57 with positive recognition had peptic ulcers (p < 0.001). Mucosal recognition of the H pylori 120 kDa protein was also positively associated with the activity of gastritis (polymorph infiltration) (p < 0.002) and with the extent of surface degeneration (p < 0.01). These findings suggest that 120-kDa-positive strains of H pylori have pathogenic features associated with active gastritis and peptic ulceration. infection with 120-kDa-negative strains may explain why peptic ulceration develops in only a proportion of subjects infected with H pylori.	BRADFORD ROYAL INFIRM,DEPT MICROBIOL,BRADFORD,ENGLAND; ST JAMES UNIV HOSP,DEPT PATHOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Bradford Royal Infirmary; Saint James's University Hospital	CRABTREE, JE (corresponding author), ST JAMES UNIV HOSP,DEPT MED,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.		Crabtree, Jean E/A-3549-2010					APEL I, 1988, ZBL BAKT-INT J MED M, V268, P271; ARMITAGE P, 1987, STATISTICAL METHODS; COGHLAN JG, 1987, LANCET, V2, P1109; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; CRABTREE JE, 1989, GUT, V30, P347, DOI 10.1136/gut.30.3.347; CRABTREE JE, 1991, J CLIN PATHOL, V44, P768, DOI 10.1136/jcp.44.9.768; CRABTREE JE, 1991, DIGEST DIS SCI, V44, P768; CRABTREE JE, 1991, GUT, V44, P768; EIDT S, 1990, HELICOBACTER PYLORI, P228; EMERY AEH, 1976, METHODOLOGY MED GENE, P98; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; FIGURA N, 1990, REV ESP ENF DIGES S1, V78, P7; GOODWIN CS, 1987, J INFECT DIS, V155, P488, DOI 10.1093/infdis/155.3.488; HESSEY SJ, 1990, GUT, V31, P134, DOI 10.1136/gut.31.2.134; KALOGEROPOULOS NK, 1988, J CLIN PATHOL, V41, P1093, DOI 10.1136/jcp.41.10.1093; Keenan D.R, 1990, WATSONS BAY LINE SYD; MARSHALL BJ, 1984, LANCET, V1, P1311; MORGAN DR, 1989, CAMPYLOBACTER PYLORI, P115; NEWELL DG, 1987, J GEN MICROBIOL, V133, P163; OMAHONY S, 1991, GUT, V32, P29, DOI 10.1136/gut.32.1.29; RASKOV H, 1987, SCAND J GASTROENTERO, V22, P568, DOI 10.3109/00365528708991899; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SHALLCROSS TM, 1989, CAMPYLOBACTER PYLORI, P155; SOBALA GM, 1991, LANCET, P94; VONWULFFEN H, 1988, J CLIN PATHOL, V41, P653, DOI 10.1136/jcp.41.6.653; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841	27	593	613	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					332	335		10.1016/0140-6736(91)90477-7	http://dx.doi.org/10.1016/0140-6736(91)90477-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677696				2022-12-24	WOS:A1991GA60700002
J	RUPP, RAW; WEINTRAUB, H				RUPP, RAW; WEINTRAUB, H			UBIQUITOUS MYOD TRANSCRIPTION AT THE MIDBLASTULA TRANSITION PRECEDES INDUCTION-DEPENDENT MYOD EXPRESSION IN PRESUMPTIVE MESODERM OF X-LAEVIS	CELL			English	Article							EARLY XENOPUS-EMBRYOS; POLYMERASE CHAIN-REACTION; FIBROBLAST GROWTH-FACTOR; HOMEOBOX GENE XHOX3; MESSENGER-RNA; DNA-BINDING; DEVELOPMENTAL REGULATION; CELLS; FAMILY; EMBRYOGENESIS	We have used a quantitative reverse transcription-polymerase chain reaction assay to detect MyoD mRNA during early embryonic development of Xenopus laevis. We find that during a short period of time following the midblastula transition MyoD becomes transcriptionally activated at a low level ubiquitously throughout the embryo. Restriction of MyoD expression to muscle precursor cells appears as a subsequent event, in which the process of mesoderm induction stabilizes transcription only in the marginal zone of the embryo, the presumptive mesoderm.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	RUPP, RAW (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT GENET,SEATTLE,WA 98104, USA.			rupp, ralph/0000-0002-8068-9957				ALTABA ARI, 1990, DEVELOPMENT, V108, P595; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; Chamberlain J.S., 1990, PCR PROTOCOLS GUIDE, P272; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; DWORKINRASTL E, 1986, J EMBRYOL EXP MORPH, V91, P153; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; GURDON JB, 1987, DEVELOPMENT, V99, P285; HARVEY RP, 1990, DEVELOPMENT, V108, P669; Holtzer H., 1978, STEM CELLS TISSUE HO, P1; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JONES EA, 1987, DEVELOPMENT, V101, P557; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRIEG PA, 1985, EMBO J, V4, P3463, DOI 10.1002/j.1460-2075.1985.tb04105.x; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LASSAR AB, 1991, TRANSCRIPTIONAL REGU; LEWIN B, 1980, GENE EXPRESSION, V2; MARTINEZSALAS E, 1989, GENE DEV, V3, P1493, DOI 10.1101/gad.3.10.1493; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OCHMAN H, 1988, GENETICS, V120, P621; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SMITH JC, 1989, DEVELOPMENT, V105, P665; SYMES K, 1987, DEVELOPMENT, V101, P339; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WORMINGTON WM, 1983, DEV BIOL, V99, P248, DOI 10.1016/0012-1606(83)90273-7; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	55	238	238	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					927	937		10.1016/0092-8674(91)90545-A	http://dx.doi.org/10.1016/0092-8674(91)90545-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1675156				2022-12-24	WOS:A1991FR04700004
J	HELMAN, CG				HELMAN, CG			LIMITS OF BIO-MEDICAL EXPLANATION	LANCET			English	Article							DISORDERS				HELMAN, CG (corresponding author), UNIV COLL & MIDDLESEX SCH MED, WHITTINGTON HOSP, DEPT PRIMARY HLTH CARE, HIGHGATE HILL, LONDON N19 5NF, ENGLAND.							BRABIN L, 1985, AM J EPIDEMIOL, V122, P725, DOI 10.1093/oxfordjournals.aje.a114155; COOPER JE, 1969, AM J PSYCHIAT, V125, P21, DOI 10.1176/ajp.125.10S.21; Eisenberg L, 1977, Cult Med Psychiatry, V1, P9, DOI 10.1007/BF00114808; ELLIOTTBINNS CP, 1986, J ROY COLL GEN PRACT, V36, P542; Goffman E., 1961, ENCOUNTERS 2 STUDIES; Good B J, 1977, Cult Med Psychiatry, V1, P25, DOI 10.1007/BF00114809; Greeley A. M., 1978, MED ANTHROPOL, V2, P31, DOI [10.1080/01459740.1978.9986961, DOI 10.1080/01459740.1978.9986961]; Helman C G, 1981, J R Coll Gen Pract, V31, P548; HELMAN C G, 1978, Culture Medicine and Psychiatry, V2, P107, DOI 10.1007/BF00054580; Helman C. G., 1990, CULTURE HLTH ILLNESS; HELMAN CG, 1981, SOC SCI MED-MED ANTH, V15, P521, DOI 10.1016/0160-7987(81)90026-0; HELMAN CG, 1985, CULT MED PSYCHIAT, V9, P1; HELMAN CG, 1988, ANTHR TODAY, V14, P14; Kark S. L., 1981, PRACTICE COMMUNITY O; Keesing R. M., 1981, CULTURAL ANTHR; Kleinman A., 1980, PATIENTS HEALERS CON; Lock M, 1988, BIOMEDICINE EXAMINED; MULL JD, 1988, SOC SCI MED, V27, P53, DOI 10.1016/0277-9536(88)90163-3; OBrien B., 1984, PATTERNS EUROPEAN DI; Payer Lynn, 1989, MED CULTURE; PEACOCK J, 1986, ANTHR LENS; PICHOT P, 1982, PSYCHOL MED, V12, P475, DOI 10.1017/S0033291700055586; SKULTANS V, 1970, MAN, V5, P639, DOI 10.2307/2799108; Stacey M., 1988, SOCIOLOGY HLTH HEALI; VAYDA E, 1982, ARCH SURG-CHICAGO, V117, P846; WEISS MG, 1988, SOC SCI MED, V27, P5, DOI 10.1016/0277-9536(88)90159-1	26	21	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	1991	337	8749					1080	1083		10.1016/0140-6736(91)91720-F	http://dx.doi.org/10.1016/0140-6736(91)91720-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673506				2022-12-24	WOS:A1991FK20400017
J	KAWAMOTO, F				KAWAMOTO, F			RAPID DIAGNOSIS OF MALARIA BY FLUORESCENCE MICROSCOPY WITH LIGHT-MICROSCOPE AND INTERFERENCE FILTER	LANCET			English	Article							PARASITES; PROBES	Fluorochrome staining to detect malaria parasites in bloodfilms is more sensitive, is easier to do, and is less time-consuming than Giemsa staining. However, standard epi-illuminated, mercury vapour, fluorescence microscopes are expensive, especially for tropical countries where malaria is endemic. Fluorescence microscopy with a standard light microscope and a new interference filter specially designed for the fluorochrome stain, acridine orange, was used to detect malaria parasites in thick and thin bloodfilms. In this system two fluorescence colours, green (nuclei) and red (cytoplasm), were emitted from stained parasites. Thick and thin bloodfilms from patients with malaria were examined with this system. Bloodfilms had been fixed and stored for 1-5 years. Rapid scanning of both thick and thin bloodfilms was possible at a magnification of x 200 with standard lenses, indicating that this may be a useful economic system for rapid diagnosis of malarias.			KAWAMOTO, F (corresponding author), NAGOYA UNIV,SCH MED,DEPT MED ZOOL,NAGOYA,AICHI 466,JAPAN.							BARKER RH, 1986, SCIENCE, V231, P1434, DOI 10.1126/science.3513309; BRUCECHWATT LJ, 1987, LANCET, V2, P1509; KAWAMOTO F, 1987, PARASITOL TODAY, V3, P284, DOI 10.1016/0169-4758(87)90110-4; KAWAMOTO F, 1987, JPN J MED SCI BIOL, V40, P35, DOI 10.7883/yoken1952.40.35; RICKMAN LS, 1989, LANCET, V1, P68; ROST FWD, 1980, HISTOCHEMISTRY THEOR, V1, P346; RYGAARD J, 1969, ACTA PATHOL MIC SC, V76, P146; SPIELMAN A, 1988, AM J TROP MED HYG, V39, P337, DOI 10.4269/ajtmh.1988.39.337; VOLLER A, 1982, BRIT MED BULL, V38, P173, DOI 10.1093/oxfordjournals.bmb.a071755; 1977, FLUORESCENT ANTIBODY, P95	10	98	112	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					200	202		10.1016/0140-6736(91)92159-Y	http://dx.doi.org/10.1016/0140-6736(91)92159-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670842				2022-12-24	WOS:A1991EU92400004
J	YOSHIDA, A; KAN, YW				YOSHIDA, A; KAN, YW			ORIGIN OF FUSED GLUCOSE-6-PHOSPHATE-DEHYDROGENASE	CELL			English	Note									UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT LAB MED,SAN FRANCISCO,CA 94145	Howard Hughes Medical Institute; University of California System; University of California San Francisco	YOSHIDA, A (corresponding author), CITY HOPE NATL MED CTR,BECKMAN RES INT,DEPT BIOCHEM GENET,DUARTE,CA 91010, USA.							HENIKOFF S, 1989, CELL, V58, P1021, DOI 10.1016/0092-8674(89)90498-4; KANNO H, 1989, CELL, V58, P595, DOI 10.1016/0092-8674(89)90440-6; YOSHIDA A, 1966, J BIOL CHEM, V241, P4966; YOSHIDA A, 1986, GLUCOSE 6 PHOSPHATE, P473	4	14	15	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 13	1990	62	1					11	12		10.1016/0092-8674(90)90233-5	http://dx.doi.org/10.1016/0092-8674(90)90233-5			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DN533	1694726				2022-12-24	WOS:A1990DN53300005
J	TSCHUDI, C; ULLU, E				TSCHUDI, C; ULLU, E			DESTRUCTION OF U2, U4, OR U6 SMALL NUCLEAR-RNA BLOCKS TRANS SPLICING IN TRYPANOSOME CELLS	CELL			English	Article									YALE UNIV,SCH MED,YALE MACARTHUR CTR MOLEC PARASITOL,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University	TSCHUDI, C (corresponding author), YALE UNIV,SCH MED,YALE MACARTHUR CTR MOLEC PARASITOL,DEPT INTERNAL MED,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008614] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BENAMAR MF, 1988, MOL CELL BIOL, V8, P2166, DOI 10.1128/MCB.8.5.2166; BERGET SM, 1986, CELL, V46, P691, DOI 10.1016/0092-8674(86)90344-2; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BOOTHROYD JC, 1982, GENE, V20, P281, DOI 10.1016/0378-1119(82)90046-4; BOOTHROYD JC, 1985, ANNU REV MICROBIOL, V39, P475, DOI 10.1146/annurev.mi.39.100185.002355; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BOZZONI I, 1984, J MOL BIOL, V180, P1173, DOI 10.1016/0022-2836(84)90276-6; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; FILIPOWICZ W, 1978, FEBS LETT, V96, P1, DOI 10.1016/0014-5793(78)81049-7; FRADIN A, 1984, CELL, V37, P927, DOI 10.1016/0092-8674(84)90427-6; FREISTADT MS, 1987, NUCLEIC ACIDS RES, V15, P9861, DOI 10.1093/nar/15.23.9861; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; KOOTER JM, 1984, EMBO J, V3, P2387, DOI 10.1002/j.1460-2075.1984.tb02144.x; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; LAIRD PW, 1987, EMBO J, V6, P1055, DOI 10.1002/j.1460-2075.1987.tb04858.x; LAIRD PW, 1985, NUCLEIC ACIDS RES, V13, P4253, DOI 10.1093/nar/13.12.4253; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SATHER S, 1985, P NATL ACAD SCI USA, V82, P5695, DOI 10.1073/pnas.82.17.5695; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHIMOTOHNO K, 1977, P NATL ACAD SCI USA, V74, P2734, DOI 10.1073/pnas.74.7.2734; SUTTON RE, 1988, EMBO J, V7, P1431, DOI 10.1002/j.1460-2075.1988.tb02960.x; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; SUTTON RE, 1988, MOL CELL BIOL, V8, P494, DOI 10.1128/MCB.8.1.494; TSCHUDI C, 1986, NUCLEIC ACIDS RES, V14, P8893, DOI 10.1093/nar/14.22.8893; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; TSCHUDI C, 1988, NUCLEIC ACIDS RES, V16, P11375, DOI 10.1093/nar/16.23.11375; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; TSCHUDI C, 1990, IN PRESS GENE; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P3591, DOI 10.1093/nar/10.12.3591	40	116	118	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 4	1990	61	3					459	466		10.1016/0092-8674(90)90527-L	http://dx.doi.org/10.1016/0092-8674(90)90527-L			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DC934	1692263				2022-12-24	WOS:A1990DC93400009
J	EGUCHI, Y; TOMIZAWA, J				EGUCHI, Y; TOMIZAWA, J			COMPLEX FORMED BY COMPLEMENTARY RNA STEM-LOOPS AND ITS STABILIZATION BY A PROTEIN - FUNCTION OF COLE1 ROM PROTEIN	CELL			English	Article											EGUCHI, Y (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; CASTAGNOLI L, 1989, EMBO J, V8, P621, DOI 10.1002/j.1460-2075.1989.tb03417.x; CESARENI G, 1985, TRENDS BIOCHEM SCI, V10, P303, DOI 10.1016/0968-0004(85)90168-9; CESARENI G, 1982, P NATL ACAD SCI-BIOL, V79, P6313, DOI 10.1073/pnas.79.20.6313; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; DOOLEY TP, 1987, PLASMID, V18, P24, DOI 10.1016/0147-619X(87)90075-8; GROSJEAN H, 1976, J MOL BIOL, V103, P499, DOI 10.1016/0022-2836(76)90214-X; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; LACATENA RM, 1981, NATURE, V294, P623, DOI 10.1038/294623a0; LACATENA RM, 1983, J MOL BIOL, V170, P635, DOI 10.1016/S0022-2836(83)80125-9; LACATENA RM, 1984, CELL, V37, P4009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUKATA H, 1987, CELL, V51, P1123, DOI 10.1016/0092-8674(87)90598-8; MASUKATA H, 1986, CELL, V44, P125, DOI 10.1016/0092-8674(86)90491-5; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; SOM T, 1983, P NATL ACAD SCI-BIOL, V80, P3232, DOI 10.1073/pnas.80.11.3232; TOMIZAWA J, 1981, P NATL ACAD SCI-BIOL, V78, P1421, DOI 10.1073/pnas.78.3.1421; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1986, CELL, V47, P89, DOI 10.1016/0092-8674(86)90369-7; TOMIZAWA J, 1987, CELL, V51, P623, DOI 10.1016/0092-8674(87)90131-0; TOMIZAWA J, 1985, CELL, V40, P527, DOI 10.1016/0092-8674(85)90201-6; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; TOMIZAWA JI, 1981, P NATL ACAD SCI-BIOL, V78, P6096, DOI 10.1073/pnas.78.10.6096; TOMIZAWA JI, 1990, IN PRESS J MOL BIOL; VLASSOV VV, 1981, EUR J BIOCHEM, V119, P51, DOI 10.1111/j.1432-1033.1981.tb05575.x; WONG EM, 1985, CELL, V42, P959, DOI 10.1016/0092-8674(85)90292-2	29	116	117	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1990	60	2					199	209		10.1016/0092-8674(90)90736-X	http://dx.doi.org/10.1016/0092-8674(90)90736-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CL816	1688738				2022-12-24	WOS:A1990CL81600005
J	CHO, KWY; BLUMBERG, B; STEINBEISSER, H; DEROBERTIS, EM				CHO, KWY; BLUMBERG, B; STEINBEISSER, H; DEROBERTIS, EM			MOLECULAR NATURE OF SPEMANNS ORGANIZER - THE ROLE OF THE XENOPUS HOMEOBOX GENE GOOSECOID	CELL			English	Article							RETINOIC ACID; POSITIONAL INFORMATION; INSITU HYBRIDIZATION; MESODERMAL PATTERN; DORSAL DEVELOPMENT; PROSPECTIVE AREAS; MESSENGER-RNAS; GROWTH-FACTORS; AXIS FORMATION; FROG EMBRYOS	This study analyzes the function of the homeobox gene goosecoid in Xenopus development. First, we find that goosecoid mRNA distribution closely mimics the expected localization of organizer tissue in normal embryos as well as in those treated with LiCl and UV light. Second, goosecoid mRNA accumulation is induced by activin, even in the absence of protein synthesis. it is not affected by bFGF and is repressed by retinoic acid. Lastly, microinjection of goosecoid mRNA into the ventral side of Xenopus embryos, where goosecoid is normally absent, leads to the formation of an additional complete body axis, including head structures and abundant notochordal tissue. The results suggest that the goosecoid homeodomain protein plays a central role in executing Spemann's organizer phenomenon.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, R01HD021502, F32HD007273] Funding Source: NIH RePORTER; NICHD NIH HHS [R37 HD021502-13, R37 HD021502, R01 HD021502, HD 21502-06, HD 07273] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; COOKE J, 1989, DEVELOPMENT, V107, P229; COOKE J, 1987, DEVELOPMENT, V101, P893; COOKE J, 1972, J EMBRYOL EXP MORPH, V28, P27; DENT JA, 1989, DEVELOPMENT, V105, P61; DEROBERTIS EM, 1991, DEVELOPMENT, V112, P669; DEROBERTIS EM, 1990, SCI AM, V263, P46, DOI 10.1038/scientificamerican0790-46; DIXON JE, 1989, DEVELOPMENT, V106, P749; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; ELINSON RP, 1989, DEV GROWTH DIFFER, V31, P423; FRITZ AF, 1989, DEV BIOL, V131, P584, DOI 10.1016/S0012-1606(89)80029-6; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KLEIN SL, 1987, DEV BIOL, V120, P299, DOI 10.1016/0012-1606(87)90127-8; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEHRS C, 1991, IN PRESS EMBO J; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SLACK JMW, 1989, DEVELOPMENT, V107, P141; SMITH JC, 1985, J EMBRYOL EXP MORPH, V89, P317; SMITH JC, 1989, DEVELOPMENT, V107, P149; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; Spemann H., 1938, EMBRYONIC DEV INDUCT; STEWART RM, 1990, DEVELOPMENT, V109, P363; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WOLPERT L, 1989, DEVELOPMENT, V107, P3; YUGE M, 1990, DEVELOPMENT, V110, P1051	56	740	749	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1111	1120		10.1016/0092-8674(91)90288-A	http://dx.doi.org/10.1016/0092-8674(91)90288-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1684739	Green Accepted			2022-12-24	WOS:A1991GX16400010
J	STANOJEVIC, D; SMALL, S; LEVINE, M				STANOJEVIC, D; SMALL, S; LEVINE, M			REGULATION OF A SEGMENTATION STRIPE BY OVERLAPPING ACTIVATORS AND REPRESSORS IN THE DROSOPHILA EMBRYO	SCIENCE			English	Article							GENE-EXPRESSION; GAP PROTEINS; HUNCHBACK; MORPHOGEN; PATTERNS; ELEMENTS; PROMOTER; KRUPPEL	Gene expression stripes in Drosophila melanogaster embryos provide a model for how eukaryotic promoters are turned on and off in response to combinations of transcriptional regulators. Genetic studies suggested that even-skipped (eve) stripe 2 is controlled by three gap genes, hunchback (hb), Kruppel (Kr), and giant (gt), and by the maternal morphogen bicoid (bcd). A direct link is established between binding sites for these regulatory proteins in the stripe 2 promoter element and the expression of the stripe during early embryogenesis. The bcd and hb protein binding sites mediate activation, whereas neighboring gt and Kr protein sites repress expression and establish the stripe borders. The stripe 2 clement has the properties of a genetic on-off switch.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,BONNER HALL,LA JOLLA,CA 92093; COLUMBIA UNIV,FAIRCHILD CTR,DEPT BIOL SCI,NEW YORK,NY 10027	University of California System; University of California San Diego; Columbia University				Levine, Michael/0000-0001-7629-0081	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; GAUL U, 1989, DEVELOPMENT, V107, P651; GOTO T, 1989, CELL, V57, P413, DOI 10.1016/0092-8674(89)90916-1; HARDING K, 1989, EMBO J, V8, P1205, DOI 10.1002/j.1460-2075.1989.tb03493.x; JACKLE H, 1986, NATURE, V324, P668, DOI 10.1038/324668a0; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MISMER D, 1987, GENETICS, V116, P565; NUSSLEINVOLHARD C, 1985, COLD SPRING HARB SYM, V50, P145, DOI 10.1101/SQB.1985.050.01.020; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STANOJEVIC D, UNPUB; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WARRIOR R, 1990, DEVELOPMENT, V110, P759	17	266	270	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1991	254	5036					1385	1387		10.1126/science.1683715	http://dx.doi.org/10.1126/science.1683715			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1683715				2022-12-24	WOS:A1991GR77700059
J	GALE, RP; BUTTURINI, A				GALE, RP; BUTTURINI, A			MAINTENANCE CHEMOTHERAPY AND CURE OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Article							LYMPHOCYTIC-LEUKEMIA; PROGNOSTIC FACTOR; DRUG-RESISTANCE; THERAPY; CHILDREN; 6-MERCAPTOPURINE; METHOTREXATE; LYMPHOMA; CELLS	Maintenance chemotherapy with 6-mercapto-purine and methotrexate, widely believed an essential contribution to the high cure rates achieved in children with acute lymphoblastic leukaemia (ALL), is thought to work by killing the leukaemia cells that remain after intensive chemotherapy. We suggest instead that ALL commonly arises in precursor B cells normally programmed to die, and that maintenance chemotherapy does not kill these cells but controls growth of the leukaemia clone so that programmed death can occur. A similar approach may apply to other cancers in which programmed death is intrinsic to the normal counterparts of the neoplastic cells.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL & ONCOL, LOS ANGELES, CA 90024 USA; UNIV PARMA, DEPT PAEDIAT, DIV HEMATOL & ONCOL, I-43100 PARMA, ITALY	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Parma					NCI NIH HHS [CA 23175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLOGIE B, 1989, BLOOD, V73, P865; BEISHUIZEN A, 1991, NEW ENGL J MED, V324, P772; BORZY MS, 1989, BLOOD, V73, P1608; CHESSELLS JM, 1986, J CLIN ONCOL, V4, P1758, DOI 10.1200/JCO.1986.4.12.1758; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; FREI E, 1961, BLOOD, V18, P431, DOI 10.1182/blood.V18.4.431.431; GALLAGHER RB, 1991, IMMUNOL TODAY, V12, P1, DOI 10.1016/0167-5699(91)90102-Y; GAYNON PS, 1988, LANCET, V2, P921; GOLDIE JH, 1984, CANCER RES, V44, P3643; GREAVES MF, 1988, LEUKEMIA, V2, P120; HANN IM, 1990, BRIT J HAEMATOL, V76, P359, DOI 10.1111/j.1365-2141.1990.tb06368.x; HOROWITZ MM, 1990, BLOOD, V75, P555; JERMY A, 1987, EUR J CANCER CLIN ON, V23, P1365, DOI 10.1016/0277-5379(87)90121-0; KOIZUMI S, 1988, CANCER, V61, P1292, DOI 10.1002/1097-0142(19880401)61:7<1292::AID-CNCR2820610703>3.0.CO;2-O; KOREN G, 1990, NEW ENGL J MED, V323, P17, DOI 10.1056/NEJM199007053230104; LAYWARD L, 1981, BRIT J HAEMATOL, V49, P251, DOI 10.1111/j.1365-2141.1981.tb07221.x; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LONSDALE D, 1975, CANCER, V36, P341, DOI 10.1002/1097-0142(197508)36:2<341::AID-CNCR2820360208>3.0.CO;2-3; MAUER AM, 1980, BLOOD, V56, P1; MOKYR MB, 1987, CANCER INVEST, V5, P31, DOI 10.3109/07357908709020304; Osmond D G, 1990, Semin Immunol, V2, P173; PATTE C, 1986, J CLIN ONCOL, V4, P1219, DOI 10.1200/JCO.1986.4.8.1219; PETO J, 1986, LANCET, V1, P408; PIETERS R, 1991, LANCET, V338, P399, DOI 10.1016/0140-6736(91)91029-T; PINKEL D, 1987, CANCER, V59, P1683, DOI 10.1002/1097-0142(19870515)59:10<1683::AID-CNCR2820591002>3.0.CO;2-G; PINKEL D, 1971, CANCER-AM CANCER SOC, V27, P247, DOI 10.1002/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C; POCHEDLY C, 1990, HEMATOL ONCOL CLIN N, V4, P871; RAPSON NT, 1980, BRIT J HAEMATOL, V45, P41, DOI 10.1111/j.1365-2141.1980.tb03809.x; Riehm H, 1987, Haematol Blood Transfus, V30, P139; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; STRYCKMANS PA, 1983, BLOOD, V62, P606; TERRY WD, 1982, IMMUNOTHERAPY HUMAN; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; WHITEHEAD VM, 1990, BLOOD, V76, P44; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705	36	58	59	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	1991	338	8778					1315	1318		10.1016/0140-6736(91)92604-Z	http://dx.doi.org/10.1016/0140-6736(91)92604-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR023	1682696				2022-12-24	WOS:A1991GR02300015
J	NOWAK, MA; ANDERSON, RM; MCLEAN, AR; WOLFS, TFW; GOUDSMIT, J; MAY, RM				NOWAK, MA; ANDERSON, RM; MCLEAN, AR; WOLFS, TFW; GOUDSMIT, J; MAY, RM			ANTIGENIC DIVERSITY THRESHOLDS AND THE DEVELOPMENT OF AIDS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 REVERSE-TRANSCRIPTASE; ZIDOVUDINE; DISEASE; TYPE-1; INFECTION; EVOLUTION; MUTATIONS; NEUTRALIZATION; REPLICATION	Longitudinal studies of patients infected with HIV-1 reveal a long and variable incubation period between infection and the development of AIDS. Data from a small number of infected patients show temporal changes in the number of genetically distinct strains of the virus throughout the incubation period, with a slow but steady rise in diversity during the progression to disease. A mathematical model of the dynamic interaction between viral diversity and the human immune system suggests the existence of an antigen diversity threshold, below which the immune system is able to regulate viral population growth but above which the virus population induces the collapse of the CD4+ lymphocyte population. The model suggests that antigenic diversity is the cause, not a consequence, of immunodeficiency disease. The model is compared with available data, and is used to assess how the timing of the application of chemotherapy or immunotherapy influences the rate of progress to disease.	DEPT VIROL, HUMAN RETROVIRUS LAB, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV LONDON IMPERIAL COLL SCI & TECHNOL, DEPT BIOL, LONDON SW7 2AZ, ENGLAND	Imperial College London	NOWAK, MA (corresponding author), UNIV OXFORD, DEPT ZOOL, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Nowak, Martin A/A-6977-2008	Anderson, Roy/0000-0002-9528-3175				ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x; ANDERSON RM, 1989, CELL TO CELL SIGNALLING : FROM EXPERIMENTS TO THEORETICAL MODELS, P335; ANDERSON RM, 1991, J ANIM ECOL, V60, P1, DOI 10.2307/5443; ASJO B, 1986, LANCET, V2, P660; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; CASTRO BA, 1988, AIDS, V2, pS17, DOI 10.1097/00002030-198800001-00004; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; DEWOLF F, IN PRESS VIROLOGY; DEWOLF F, 1991, LANCET, V337, P389; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; DOURNON E, 1988, LANCET, V2, P1297; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; EIGEN M, 1989, ADV CHEM PHYS, V75, P149; FENYO EM, 1989, AIDS, V3, pS5, DOI 10.1097/00002030-198901001-00002; FENYO EM, 1988, J VIROL, V62, P4414; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISHER AG, 1988, NATURE, V334, P444, DOI 10.1038/334444a0; GAINES H, 1990, AIDS, V4, P995, DOI 10.1097/00002030-199010000-00008; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GORY RF, 1989, LANCET S1, V3, P683; HAASE AT, 1986, NATURE, V322, P130, DOI 10.1038/322130a0; HAMMING RW, 1986, CODING INFORMATION T; HAVERKOS HW, 1987, J INFECT DIS, V156, P251, DOI 10.1093/infdis/156.1.251; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEIDER JM, 1988, J VIROL, V62, P3084, DOI 10.1128/JVI.62.9.3084-3091.1988; LEVY JA, 1990, AIDS, V4, P1051, DOI 10.1097/00002030-199011000-00001; LO SC, 1989, AM J TROP MED HYG, V41, P364, DOI 10.4269/ajtmh.1989.41.364; LOONEY DJ, 1988, SCIENCE, V241, P357, DOI 10.1126/science.3388046; LULLEY R, 1983, J GEN VIROL, V64, P1433; MAY RM, 1981, THEORETICAL ECOLOGY, pCH11; MCKEETING JA, 1989, AIDS, V4, P535; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; NOWAK M, 1989, J THEOR BIOL, V137, P375, DOI 10.1016/S0022-5193(89)80036-0; NOWAK M, 1990, NATURE, V347, P522, DOI 10.1038/347522a0; NOWAK MA, 1990, AIDS, V4, P1095, DOI 10.1097/00002030-199011000-00007; NOWAK MA, IN PRESS MATH BIOSCI; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; PECKHAM CS, 1991, LANCET, V337, P253; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RATNER L, 1989, AIDS RES HUM RETROV, V5, P115, DOI 10.1089/aid.1989.5.115; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SHRODA T, 1991, NATURE, V349, P167; VICKERMAN K, 1978, NATURE, V273, P613, DOI 10.1038/273613a0; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WAINHOBSON S, 1989, AIDS, V3, pS13, DOI 10.1097/00002030-198901001-00003; WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938; WOLFS TFW, IN PRESS VIROLOGY	52	446	453	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1991	254	5034					963	969		10.1126/science.1683006	http://dx.doi.org/10.1126/science.1683006			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1683006				2022-12-24	WOS:A1991GP88300033
J	WOTHERSPOON, AC; ORTIZHIDALGO, C; FALZON, MR; ISAACSON, PG				WOTHERSPOON, AC; ORTIZHIDALGO, C; FALZON, MR; ISAACSON, PG			HELICOBACTER-PYLORI-ASSOCIATED GASTRITIS AND PRIMARY B-CELL GASTRIC LYMPHOMA	LANCET			English	Note							CAMPYLOBACTER-PYLORI; IMMUNE-RESPONSE; MUCOSA; TISSUE	Although lymphoid tissue is absent in normal gastric mucosa, primary lymphomas arise in the stomach and most of these recapitulate the features of mucosa-associated lymphoid tissue (MALT). Gastric lymphoid tissue is known to be acquired in response to local infection by Helicobacter pylori, and we have confirmed this in 450 patients with H pylori-associated gastritis of whom 125 showed mucosal lymphoid follicles. In 8 patients, B lymphocytes infiltrated epithelium, which is a feature characteristic of MALT. We also examined 110 cases of gastric MALT lymphoma and found H pylori infection in 101 of these (92%). We conclude that gastric MALT is acquired in H pylori infection and that this provides the necessary background in which MALT lymphoma might develop.	UNIV COLL & MIDDLESEX SCH MED,DEPT HISTOPATHOL,UNIV ST,LONDON WC1E 6JJ,ENGLAND	University of London; University College London								CHAN JKC, 1990, AM J PATHOL, V136, P1153; CRABTREE JE, 1991, LANCET, P332; HYJEK E, 1988, HUM PATHOL, V19, P766, DOI 10.1016/S0046-8177(88)80259-4; HYJEK E, 1988, HUM PATHOL, V19, P1315, DOI 10.1016/S0046-8177(88)80287-9; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; SHALLCROSS TM, 1989, CAMPYLOBACTER PYLORI, P155; SPENCER JO, 1986, GUT, V27, P405, DOI 10.1136/gut.27.4.405; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712; WYATT JI, 1991, SEMIN DIAGN PATHOL, V8, P137	11	1539	1582	2	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1991	338	8776					1175	1176		10.1016/0140-6736(91)92035-Z	http://dx.doi.org/10.1016/0140-6736(91)92035-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP034	1682595				2022-12-24	WOS:A1991GP03400007
J	MARU, Y; WITTE, ON				MARU, Y; WITTE, ON			THE BCR GENE ENCODES A NOVEL SERINE THREONINE KINASE-ACTIVITY WITHIN A SINGLE EXON	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; MUSCLE PYRUVATE-KINASE; ACUTE LYMPHOCYTIC-LEUKEMIA; C-ABL PROTEIN; PHILADELPHIA-CHROMOSOME; FUSED TRANSCRIPT; TYROSINE; PRODUCT; REGION	Sequences encoded by the first exon of BCR that bind to the ABL SH2 domain are essential for the activation of the ABL tyrosine kinase and transforming potential of the chimeric BCR-ABL oncogene. The normal cellular BCR gene encodes a 160,000 dalton phosphoprotein associated with a serine/threonine kinase activity, but it shows only weak dispersed homologies to protein kinases. p160c-BCR Was purified to apparent homogeneity as an oligomer of > 600,000 daltons that contains autophosphorylation activity and transphosphorylation activity for several protein substrates. A region containing paired cysteine residues within the 426 amino acids encoded by the first exon of BCR is essential for its novel phosphotransferase activity, which overlaps with the strong SH2-binding regions. The recent demonstration of a GTPase-activating function within the C-terminal portion of BCR suggests that the protein kinase and SH2-binding domains may work in concert with other regions of the molecule in intracellular signaling processes.	UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	MARU, Y (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [R35CA053867, R01CA027507] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA53867, R01 CA27507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSON RB, 1989, ONCOGENE, V4, P243; ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; BASU M, 1984, NATURE, V311, P477, DOI 10.1038/311477a0; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ESCH FS, 1978, J BIOL CHEM, V253, P6100; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P2674, DOI 10.1073/pnas.81.9.2674; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HARTWELL LH, 1973, GENETICS, V74, P267; HEISTERKAMP N, 1989, NUCLEIC ACIDS RES, V17, P8821, DOI 10.1093/nar/17.21.8821; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LI WJ, 1989, ONCOGENE, V4, P127; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OHYA Y, 1986, J BACTERIOL, V165, P28, DOI 10.1128/jb.165.1.28-33.1986; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PENDERGAST AM, 1989, ONCOGENE, V4, P759; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PENDERGAST AM, 1991, IN PRESS P NATL ACAD; QUILLIAM LA, 1990, MOL CELL BIOL, V11, P1804; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REISLER E, 1974, BIOCHEMISTRY-US, V13, P3837, DOI 10.1021/bi00716a001; RON D, 1991, NEW BIOL, V3, P372; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHAH NP, 1991, MOL CELL BIOL, V11, P1854, DOI 10.1128/MCB.11.4.1854; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Summers MD, 1987, TEXAS AGR EXPT STATI; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; TIMMONS MS, 1989, ONCOGENE, V4, P559; TOGASHI CT, 1982, J BIOL CHEM, V257, P112; TOMICH JM, 1981, BIOCHEMISTRY-US, V20, P6711, DOI 10.1021/bi00526a029; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2	59	227	237	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					459	468		10.1016/0092-8674(91)90521-Y	http://dx.doi.org/10.1016/0092-8674(91)90521-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1657398				2022-12-24	WOS:A1991GN66400003
J	RUDENSKY, AY; RATH, S; PRESTONHURLBURT, P; MURPHY, DB; JANEWAY, CA				RUDENSKY, AY; RATH, S; PRESTONHURLBURT, P; MURPHY, DB; JANEWAY, CA			ON THE COMPLEXITY OF SELF	NATURE			English	Article							ANTIGEN	SELF peptides bound to self major histocompatibility complex (MHC) molecules have been implicated both in positive 1,2 and in negative 3,4 selection of T cells during intrathymic development. We report here that the novel MHC-restricted monoclonal antibody Y-Ae (ref. 5) detects the MHC class II bound form of a major self peptide 6. Y-Ae binds approximately 12% of the relevant MHC class II molecules on self antigen presenting cells. The peptide detected by Y-Ae is one of several major peptides eluted from the MHC molecule 6. These data suggest that self peptides presented by self MHC class II molecules at densities sufficient to signal a CD4 T cell are of very limited complexity. Furthermore, as Y-Ae stains antigen presenting cells that mediate negative selection but not thymic cortical epithelial cells 5 that drive positive selection 3, differential expression of self peptide:self MHC class II complexes may be a key feature of intrathymic selection.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute								BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; JANEWAY CA, 1984, J IMMUNOL, V132, P662; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; RUDENSKY AY, NATURE, V353, P622; vonBoehmer H., 1989, IMMUNOL TODAY, V10, P61	11	252	255	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					660	662		10.1038/353660a0	http://dx.doi.org/10.1038/353660a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1656278				2022-12-24	WOS:A1991GK67200070
J	KLEUSS, C; HESCHELER, J; EWEL, C; ROSENTHAL, W; SCHULTZ, G; WITTIG, B				KLEUSS, C; HESCHELER, J; EWEL, C; ROSENTHAL, W; SCHULTZ, G; WITTIG, B			ASSIGNMENT OF G-PROTEIN SUBTYPES TO SPECIFIC RECEPTORS INDUCING INHIBITION OF CALCIUM CURRENTS	NATURE			English	Article							GTP-BINDING-PROTEIN; PITUITARY CELL-LINE; ANTI-SENSE RNA; MESSENGER-RNA; ALPHA-SUBUNIT; MOLECULAR-CLONING; GENETIC-ANALYSIS; 2 FORMS; ANTISENSE; CHANNELS	The inhibition of voltage-dependent Ca2+ channels in secretory cells by plasma membrane receptors is mediated by pertussis toxin-sensitive G proteins. Multiple forms of G proteins have been described, differing principally in their alpha-subunits, but it has not been possible to establish which G-protein subtype mediates inhibition by a specific receptor. By intranuclear injection of antisense oligonucleotides into rat pituitary GH3 cells, the essential role of the G(o)-type G proteins in Ca2+-channel inhibition is established: the subtypes G(o1) and G(o2) mediate inhibition through the muscarinic and somatostatin receptors, respectively.	FREE UNIV BERLIN, INST PHARMAKOL, W-1000 BERLIN 33, GERMANY	Free University of Berlin	KLEUSS, C (corresponding author), FREE UNIV BERLIN, INST MOLEK BIOL & BIOCHEM, ARNIMALLEE 22, W-1000 BERLIN 33, GERMANY.							ASANO T, 1988, J NEUROCHEM, V50, P1164, DOI 10.1111/j.1471-4159.1988.tb10588.x; BERTRAND P, 1990, J BIOL CHEM, V265, P18576; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BIRNBAUMER LA, 1990, REV PHARM TOX, V30, P675; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; COLLU R, 1988, ENDOCRINOLOGY, V122, P1176, DOI 10.1210/endo-122-3-1176; CORNISHBOWDEN A, 1985, EUR J BIOCHEM, V150, P1; DREYER C, 1982, ROUX ARCH DEV BIOL, V191, P228, DOI 10.1007/BF00848409; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FINDLAY J, 1990, TRENDS PHARMACOL SCI, V11, P492, DOI 10.1016/0165-6147(90)90050-I; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HSU WH, 1990, J BIOL CHEM, V265, P11220; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JACKSON DA, 1988, J CELL SCI, V90, P365; JONES DT, 1987, J BIOL CHEM, V262, P14241; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MATTERA R, 1989, J BIOL CHEM, V264, P465; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MINSHULL J, 1986, NUCLEIC ACIDS RES, V14, P6433, DOI 10.1093/nar/14.16.6433; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; OFFERMANNS S, 1991, J BIOL CHEM, V266, P3365; OFFERMANNS S, 1989, EUR J BIOCHEM, V180, P283, DOI 10.1111/j.1432-1033.1989.tb14645.x; OFFERMANNS S, 1991, MOL ENDOCRINOL, V5, P995, DOI 10.1210/mend-5-7-995; PAULSSEN EJ, 1991, MOL CELL ENDOCRINOL, V76, P45, DOI 10.1016/0303-7207(91)90258-T; ROSENTHAL W, 1988, EMBO J, V7, P1627, DOI 10.1002/j.1460-2075.1988.tb02989.x; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SHUTTLEWORTH J, 1988, EMBO J, V7, P427, DOI 10.1002/j.1460-2075.1988.tb02830.x; SILBERT S, 1990, J BIOL CHEM, V265, P3102; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TOSELLI M, 1989, PFLUG ARCH EUR J PHY, V415, P255, DOI 10.1007/BF00370874; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; WEINTRAUB H, 1985, TRENDS GENET, V1, P22, DOI 10.1016/0168-9525(85)90010-1; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	47	562	563	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 5	1991	353	6339					43	48		10.1038/353043a0	http://dx.doi.org/10.1038/353043a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1679199				2022-12-24	WOS:A1991GD80500050
J	BRISSONNOEL, A; AZNAR, C; CHUREAU, C; NGUYEN, S; PIERRE, C; BARTOLI, M; BONETE, R; PIALOUX, G; GICQUEL, B; GARRIGUE, G				BRISSONNOEL, A; AZNAR, C; CHUREAU, C; NGUYEN, S; PIERRE, C; BARTOLI, M; BONETE, R; PIALOUX, G; GICQUEL, B; GARRIGUE, G			DIAGNOSIS OF TUBERCULOSIS BY DNA AMPLIFICATION IN CLINICAL-PRACTICE EVALUATION	LANCET			English	Article							POLYMERASE CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; IDENTIFICATION; SEQUENCE; COMPLEX; IS6110	Various polymerase chain reaction (PCR) assays have been devised for the rapid identification of mycobacteria in clinical specimens. To assess the value of such assays in routine laboratory work the results obtained by PCR were compared with those obtained by standard microbiological methods for 514 specimens collected for investigation of mycobacterial infection. Specimens were tested for the presence of Mycobacterium tuberculosis complex and atypical mycobacteria in two assays, one based on amplification of the 65 kDa gene and the other on the IS6110 insertion sequence. For the 489 samples that did not contain inhibitors of the amplification reaction PCR findings correlated well with bacteriological and/or clinical data in 476 (97.4%). 6 PCR results turned out to be false negatives, 3 to be false positives and 4 to be mis-identification of strains. Pre-treatment of samples with guanidium thiocyanate reduced the proportion of false-negative results and of samples that contained inhibitors. This study confirms the potential of DNA amplification for early diagnosis of mycobacterial infections.	HOP DESGENETTES,LYONS,FRANCE; HOP LOUIS PASTEUR,PARIS,FRANCE; INST PASTEUR,UNITE GENIE MICROBIOL,CNRS,URA 1300,F-75724 PARIS 15,FRANCE; CTR MED EDOUARD RIST,PARIS,FRANCE; INST PASTEUR,DEV BIOL MED LAB,F-75724 PARIS 15,FRANCE; HOP ST ANNE,TOULON,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	BRISSONNOEL, A (corresponding author), DIAGNOST PASTEUR,3 BLVD RAYMOND POINCARE,F-92430 MARNES COQUETTE,FRANCE.							BODDINGHAUS B, 1990, J CLIN MICROBIOL, V28, P1751; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRISSONNOEL A, 1989, LANCET, V2, P1069; DEWIT D, 1990, J CLIN MICROBIOL, V28, P2437, DOI 10.1128/JCM.28.11.2437-2441.1990; EISENACH KD, 1990, J INFECT DIS, V161, P977, DOI 10.1093/infdis/161.5.977; HANCE AJ, 1989, MOL MICROBIOL, V3, P843, DOI 10.1111/j.1365-2958.1989.tb00233.x; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P1204, DOI 10.1128/JCM.28.6.1204-1213.1990; Maniatis T., 1984, MOL CLONING; MANJUNATH N, 1991, TUBERCLE, V72, P21, DOI 10.1016/0041-3879(91)90020-S; MULLIS KB, 1987, METHOD ENZYMOL, V155, P355; PAO CC, 1990, J CLIN MICROBIOL, V28, P1877, DOI 10.1128/JCM.28.9.1877-1880.1990; SHANKAR P, 1990, LANCET, V335, P423, DOI 10.1016/0140-6736(90)90268-A; SJOBRING U, 1990, J CLIN MICROBIOL, V28, P2200; THIERRY D, 1990, J CLIN MICROBIOL, V28, P2668, DOI 10.1128/JCM.28.12.2668-2673.1990; THIERRY D, 1990, NUCLEIC ACIDS RES, V18, P188, DOI 10.1093/nar/18.1.188	15	273	282	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					364	366		10.1016/0140-6736(91)90492-8	http://dx.doi.org/10.1016/0140-6736(91)90492-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677709				2022-12-24	WOS:A1991GA60700016
J	JOSLYN, G; CARLSON, M; THLIVERIS, A; ALBERTSEN, H; GELBERT, L; SAMOWITZ, W; GRODEN, J; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R				JOSLYN, G; CARLSON, M; THLIVERIS, A; ALBERTSEN, H; GELBERT, L; SAMOWITZ, W; GRODEN, J; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R			IDENTIFICATION OF DELETION MUTATIONS AND 3 NEW GENES AT THE FAMILIAL POLYPOSIS LOCUS	CELL			English	Article							ADENOMATOUS POLYPOSIS; COLORECTAL CANCERS; SHORT ARM; CHROMOSOME-5; LOCALIZATION; FRAGMENTS; RNA	Small (100-260 kb), nested deletions were characterized in DNA from two unrelated patients with familial adenomatous polyposis coli (APC). Three candidate genes located within the deleted region were ascertained and a previous candidate gene, MCC, was shown to be located outside the deleted region. One of the new genes contained sequence identical to SRP19, the gene coding for the 19 kd component of the ribosomal signal recognition particle. The second, provisionally designated DP1 (deleted in polyposis 1), was found to be transcribed in the same orientation as MCC. Two other cDNAs, DP2 and DP3, were found to overlap, forming a single gene, DP2.5, that is transcribed in the same orientation as SRP19.	UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT PATHOL,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT MED,DIV GASTROENTEROL,SALT LAKE CITY,UT 84132; ST MARKS HOSP,SALT LAKE CITY,UT 84117; UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of California System; University of California Irvine	JOSLYN, G (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132, USA.		McPherson, John D/D-2633-2017	McPherson, John D/0000-0001-8049-9347; Le Paslier, Denis/0000-0003-4335-9956	NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040886] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09602] Funding Source: Medline; NHGRI NIH HHS [HG-00320] Funding Source: Medline; NIGMS NIH HHS [R01-GM40886-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BURT RW, 1988, GASTROENTEROL CLIN N, V17, P657; CIRULLO RE, 1983, MOL CELL BIOL, V3, P892, DOI 10.1128/MCB.3.5.892; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GARDINER K, 1986, SOMAT CELL MOLEC GEN, V12, P185, DOI 10.1007/BF01560665; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KINZLER K, 1991, IN PRESS SCIENCE; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; MANIATIS T, 1982, MOL CLONING LABORATO, P150; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OVERHAUSER J, 1986, AM J HUM GENET, V39, P562; OVERHAUSER J, 1987, NUCLEIC ACIDS RES, V15, P4617, DOI 10.1093/nar/15.11.4617; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	24	685	706	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					601	613		10.1016/0092-8674(81)90022-2	http://dx.doi.org/10.1016/0092-8674(81)90022-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1678319				2022-12-24	WOS:A1991GA94100020
J	HAHM, JO; LANGDON, RB; SUR, M				HAHM, JO; LANGDON, RB; SUR, M			DISRUPTION OF RETINOGENICULATE AFFERENT SEGREGATION BY ANTAGONISTS TO NMDA RECEPTORS	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; VISUAL-CORTEX; CAT; INFUSION; FERRET; TETRODOTOXIN; PROJECTION; POTENTIALS; CELLS; FIELD	AFFERENT activity has an important role in the formation of connections in the developing mammalian visual system 1,2. But the extent to which the activity of target neurons shapes patterns of afferent termination and synaptic contact is not known. In the ferret's visual pathway, retinal ganglion cell axons from each eye segregate early in development into eye-specific laminae in the lateral geniculate nucleus (LGN)3. The dorsal laminae (termed laminae A and A1) then segregate further into inner and outer sublaminae that retain input from on-centre and off-centre retinal axons, respectively 4,5. Thus, individual retinogeniculate axons form terminal arbors within laminae A and A1 that are restricted to one inner or outer sublamina 6. We report here that blockade of N-methyl-D-aspartate (NMDA) receptors on LGN cells with specific antagonists during the period of sublamina formation prevents retinal afferents from segregating into 'On' and 'Off' sublaminae. Retinogeniculate axons have arbors that are not restricted appropriately, or are restricted in size but inappropriately positioned within the eye-specific laminae. NMDA receptor antagonists may specifically disrupt a mechanism by which LGN neurons detect correlated afferent and target activity 7, and have been shown to reduce retinogeniculate transmission more generally 8-10, causing LGN cells to have markedly reduced levels of activity. These results therefore indicate that the activity of postsynaptic cells can significantly influence the patterning of inputs and the structure of presynaptic afferents during development.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								BEAR MF, 1990, J NEUROSCI, V10, P909; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1990, J NEUROSCI, V10, P1197; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONSTANTINEPATO.M, 1990, REV NEUROSCI, V13, P129; ESGUERRA M, 1990, NEUR ABST, V16, P159; ESGUERRA M, 1989, NEUR ABSTR, V15, P175; FOX K, 1989, J NEUROSCI, V9, P2443; HAHM J, 1988, NEUR ABSTR, V14, P460; HEGGELUND P, 1990, J NEUROPHYSIOL, V63, P1347, DOI 10.1152/jn.1990.63.6.1347; KWON YH, IN PRESS J NEUROPHYS; LANGDON RB, 1990, J NEUROPHYSIOL, V64, P1484, DOI 10.1152/jn.1990.64.5.1484; LINDEN DC, 1981, J COMP NEUROL, V203, P189, DOI 10.1002/cne.902030204; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; MOVSHON JA, 1981, ANNU REV PSYCHOL, V32, P477, DOI 10.1146/annurev.ps.32.020181.002401; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; ROE AW, 1989, J COMP NEUROL, V288, P208, DOI 10.1002/cne.902880203; SCHERER WJ, 1989, J NEUROSCI, V9, P3837; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHERMAN SM, 1982, PHYSIOL REV, V62, P740; SILLITO AM, 1990, J NEUROPHYSIOL, V63, P347, DOI 10.1152/jn.1990.63.2.347; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; STRYKER MP, 1983, J NEUROSCI, V3, P1943; ZAHS KR, 1985, J COMP NEUROL, V241, P210, DOI 10.1002/cne.902410208	24	225	229	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					568	570		10.1038/351568a0	http://dx.doi.org/10.1038/351568a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1675433				2022-12-24	WOS:A1991FR03400059
J	[Anonymous]				[Anonymous]			HOW CUBA CONTROLS HIV-INFECTION	LANCET			English	Editorial Material																		PEREZSTABLE EJ, 1991, AM J PUBLIC HEALTH, V81, P563, DOI 10.2105/AJPH.81.5.563	1	0	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	1991	337	8753					1340	1341						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674309				2022-12-24	WOS:A1991FP08400024
J	JAMES, MR; MARSHALL, H; CAREWMCCOLL, M				JAMES, MR; MARSHALL, H; CAREWMCCOLL, M			PULSE OXIMETRY DURING APPARENT TONIC-CLONIC SEIZURES	LANCET			English	Note								A pulse oximeter was used to monitor arterial oxygen saturations in 11 patients during apparent tonic-clonic seizures. 8 had a clinical diagnosis of genuine fits, 6 of whom showed striking falls in oxygen saturation during the seizures. 3 had a clinical diagnosis of pseudoseizures, none of whom had hypoxia during these episodes. Pulse oximetry during apparent tonic-clonic seizures may help to identify patients with low arterial oxygen tension who need immediate intervention.	HOPE HOSP,DEPT ACCID & EMERGENCY,SALFORD M6 8HD,LANCS,ENGLAND		JAMES, MR (corresponding author), ROYAL PRESTON HOSP,DEPT ACCID & EMERGENCY,PRESTON PR2 4HT,ENGLAND.							SADEH M, 1983, J NEUROL NEUROSUR PS, V46, P566, DOI 10.1136/jnnp.46.6.566	1	29	32	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					394	395						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671426				2022-12-24	WOS:A1991EX60500006
J	HERXHEIMER, A				HERXHEIMER, A			HOW MUCH DRUG IN THE TABLET	LANCET			English	Editorial Material								Many recommended drug doses are higher than necessary, for two reasons. Drugs are often introduced at a dose that will be effective in around 90% of the target population, because this helps market penetration. Doses are also partly determined by an irrational preference for round numbers. The dose excess due to such digit preference may be as much as 70% of the correct dose and on average is probably 25%. Needlessly high doses are bound to cause avoidable unwanted effects in a proportion of patients. Rigorous methods must be used to determine the doses recommended and the amount of drug to be put into a tablet or other dosage form.			HERXHEIMER, A (corresponding author), CHARING CROSS HOSP,CHARING CROSS & WESTMINSTER MED SCH,DEPT CLIN PHARMACOL & THERAPEUT,LONDON W6 8RF,ENGLAND.							ALEXANDER GR, 1989, AM J PUBLIC HEALTH, V79, P600, DOI 10.2105/AJPH.79.5.600; HERXHEIMER A, 1987, LANCET, V1, P32; ROSE GA, 1964, LANCET, V1, P296; 1990, BRIT NATIONAL FORMUL; 1990, DRUG THER B, V28, P71	5	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					346	348		10.1016/0140-6736(91)90958-R	http://dx.doi.org/10.1016/0140-6736(91)90958-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EX362	1671244				2022-12-24	WOS:A1991EX36200016
J	SOFRONIEW, MV; GALLETLY, NP; ISACSON, O; SVENDSEN, CN				SOFRONIEW, MV; GALLETLY, NP; ISACSON, O; SVENDSEN, CN			SURVIVAL OF ADULT BASAL FOREBRAIN CHOLINERGIC NEURONS AFTER LOSS OF TARGET NEURONS	SCIENCE			English	Article											SOFRONIEW, MV (corresponding author), UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE CB2 3DY,ENGLAND.			Isacson, Ole/0000-0001-8091-8302	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AMARAL DG, 1985, J COMP NEUROL, V240, P37, DOI 10.1002/cne.902400104; ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; APPEL SH, 1981, ANN NEUROL, V10, P499, DOI 10.1002/ana.410100602; ARENDT T, 1985, NEUROSCIENCE, V14, P1, DOI 10.1016/0306-4522(85)90160-5; AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BJERRE B, 1975, BRAIN RES, V94, P263, DOI 10.1016/0006-8993(75)90061-X; CAMPENOT RB, 1981, SCIENCE, V214, P579, DOI 10.1126/science.7292000; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; GAGE FH, 1986, NEUROSCIENCE, V19, P241, DOI 10.1016/0306-4522(86)90018-7; GAHWILER BH, 1987, NEUROSCI LETT, V75, P6, DOI 10.1016/0304-3940(87)90066-8; GOEDERT M, 1986, MOL BRAIN RES, V1, P85, DOI 10.1016/0169-328X(86)90023-9; GOLDSCHMIDT RB, 1980, J COMP NEUROL, V189, P359, DOI 10.1002/cne.901890210; HARTIKKA J, 1988, J NEUROSCI, V8, P2967; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; HEFTI F, 1986, J NEUROSCI, V6, P2155; HEFTI F, 1983, ANN NEUROL, V13, P109, DOI 10.1002/ana.410130127; JOHNSON EM, 1986, TRENDS NEUROSCI, V9, P33, DOI 10.1016/0166-2236(86)90012-3; KALEN P, 1989, EXP BRAIN RES, V75, P401; KORSCHING S, 1986, TRENDS NEUROSCI, V9, P570, DOI 10.1016/0166-2236(86)90179-7; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LAMS BE, 1988, BRAIN RES, V475, P401, DOI 10.1016/0006-8993(88)90635-X; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; LINDSAY RM, 1979, NATURE, V282, P80, DOI 10.1038/282080a0; NIETOSAMPEDRO M, 1984, P NATL ACAD SCI-BIOL, V81, P6250, DOI 10.1073/pnas.81.19.6250; OTTO D, 1989, J NEUROSCI RES, V22, P83, DOI 10.1002/jnr.490220111; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PEARSON RCA, 1983, BRAIN RES, V289, P375, DOI 10.1016/0006-8993(83)90046-X; PURVES D, 1988, NATURE, V336, P123, DOI 10.1038/336123a0; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; SCHEFF S, 1977, SCIENCE, V197, P795, DOI 10.1126/science.887924; Sofroniew M V, 1988, J Chem Neuroanat, V1, P327; SOFRONIEW MV, 1987, BRAIN RES, V411, P310, DOI 10.1016/0006-8993(87)91084-5; SOFRONIEW MV, IN PRESS BRAIN RES; SWANSON LW, 1987, HDB CHEM NEUROANAT 1, V5; VILLEGAS-PEREZ M P, 1988, Society for Neuroscience Abstracts, V14, P673; VILLEGASPEREZ MP, 1988, J NEUROSCI, V8, P265; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231	43	257	257	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1990	247	4940					338	342		10.1126/science.1688664	http://dx.doi.org/10.1126/science.1688664			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ669	1688664				2022-12-24	WOS:A1990CJ66900042
J	MEEK, TD; LAMBERT, DM; DREYER, GB; CARR, TJ; TOMASZEK, TA; MOORE, ML; STRICKLER, JE; DEBOUCK, C; HYLAND, LJ; MATTHEWS, TJ; METCALF, BW; PETTEWAY, SR				MEEK, TD; LAMBERT, DM; DREYER, GB; CARR, TJ; TOMASZEK, TA; MOORE, ML; STRICKLER, JE; DEBOUCK, C; HYLAND, LJ; MATTHEWS, TJ; METCALF, BW; PETTEWAY, SR			INHIBITION OF HIV-1 PROTEASE IN INFECTED LYMPHOCYTES-T BY SYNTHETIC PEPTIDE ANALOGS	NATURE			English	Article									SK&F LABS,DEPT ANTIINFECT,KING OF PRUSSIA,PA 19406; SK&F LABS,DEPT PEPTIDE CHEM,KING OF PRUSSIA,PA 19406; SK&F LABS,DEPT MACROMOLEC SCI,KING OF PRUSSIA,PA 19406; SK&F LABS,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Duke University	MEEK, TD (corresponding author), SK&F LABS,DEPT MED CHEM,709 SWEDELAND RD,KING OF PRUSSIA,PA 19406, USA.							CRAWFORD S, 1985, J VIROL, V53, P899, DOI 10.1128/JVI.53.3.899-907.1985; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; DREYER GB, IN PRESS P NATN ACAD; GALLO RC, 1988, SCI AM, V259, P40, DOI 10.1038/scientificamerican1088-40; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; HENDERSON LE, 1987, HUMAN RETROVIRUSES C, P135; HOLLADAY MW, 1987, J MED CHEM, V30, P374, DOI 10.1021/jm00385a020; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; KATOH I, 1985, VIROLOGY, V145, P280, DOI 10.1016/0042-6822(85)90161-8; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT DM, 1983, VIROLOGY, V130, P204, DOI 10.1016/0042-6822(83)90128-9; MATTHEWS TJ, 1987, P NATL ACAD SCI USA, V84, P5424, DOI 10.1073/pnas.84.15.5424; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MOORE ML, 1989, BIOCHEM BIOPH RES CO, V159, P420, DOI 10.1016/0006-291X(89)90008-9; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612; Szelke M., 1983, PEPTIDES STRUCTURE F, P579; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	30	247	326	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1990	343	6253					90	92		10.1038/343090a0	http://dx.doi.org/10.1038/343090a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG614	1688646				2022-12-24	WOS:A1990CG61400063
J	FIETE, D; SRIVASTAVA, V; HINDSGAUL, O; BAENZIGER, JU				FIETE, D; SRIVASTAVA, V; HINDSGAUL, O; BAENZIGER, JU			A HEPATIC RETICULOENDOTHELIAL CELL-RECEPTOR SPECIFIC FOR SO4-4GAINAC-BETA-1,4GLCNAC-BETA-1,2MAN-ALPHA THAT MEDIATES RAPID CLEARANCE OF LUTROPIN	CELL			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; PITUITARY GLYCOPROTEIN HORMONES; LIVER ENDOTHELIAL-CELLS; RAT-LIVER; HYALURONIC-ACID; SIALYLATED OLIGOSACCHARIDES; BOVINE LUTROPIN; STRUCTURAL ELUCIDATION; ENDOCYTOSIS; HEPATOCYTES	We have identified a receptor in hepatic endothelial and Kupffer cells that binds oligosaccharides terminating with the sequence SO4-4GalNAc-beta-1,4GlcNAc-beta-1,2-Man-alpha (S4GGnM). This receptor can account for the rapid removal of the glycoprotein hormone lutropin, which bears unique Asn-linked oligosaccharides terminating in S4GGnM, from the circulation. Hepatic endothelial cells express 579,000 S4GGnM receptors at their surface and bind lutropin with an apparent K(d) of 1.63 x 10(-7) M. Bound ligand is rapidly internalized. Binding does not require divalent cations, is reversed by incubation at pH 5.0 or below, and is inhibited by fucoidin but not by hyaluronate, heparin, chondroitin sulfate, or dextran sulfate. We propose that the S4GGnM-specific receptor represents a major mechanism for clearance of certain sulfated glycoproteins from the blood, including members of the glycoprotein hormone family.	UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,ALBERTA,CANADA	University of Alberta	FIETE, D (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110, USA.		Baenziger, Jacques U/E-9430-2012		NCI NIH HHS [R37-CA-21923] Funding Source: Medline; NIDDK NIH HHS [R01-DK-41738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BAENZIGER JU, 1991, IN PRESS P NATL ACAD; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BREITFELD PP, 1985, INT REV CYTOL, V97, P47, DOI 10.1016/S0074-7696(08)62348-7; DAMM JBL, 1990, EUR J BIOCHEM, V189, P175, DOI 10.1111/j.1432-1033.1990.tb15474.x; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; GREEN ED, 1986, MOL CELL BIOCHEM, V72, P81; HINDSGAUL V, 1987, CAN J CHEM, V65, P1645; KNOOK DL, 1976, EXP CELL RES, V99, P444, DOI 10.1016/0014-4827(76)90605-4; KNOOK DL, 1977, EXP CELL RES, V109, P317, DOI 10.1016/0014-4827(77)90011-8; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4076, DOI 10.1021/ja00847a035; MATSUI T, 1991, BIOCHEM BIOPH RES CO, V174, P940, DOI 10.1016/0006-291X(91)91509-B; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MIAN AJ, 1973, CARBOHYD RES, V304, P449; MURPHY BD, 1991, ENDOCR REV, V12, P27, DOI 10.1210/edrv-12-1-27; PARSONS TF, 1980, P NATL ACAD SCI-BIOL, V77, P7089, DOI 10.1073/pnas.77.12.7089; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SMEDSROD B, 1985, J LEUKOCYTE BIOL, V38, P213, DOI 10.1002/jlb.38.2.213; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1990, J BIOL CHEM, V265, P874; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SMITH PL, 1991, IN PRESS P NATL ACAD	30	264	270	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1103	1110		10.1016/0092-8674(91)90287-9	http://dx.doi.org/10.1016/0092-8674(91)90287-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1662117				2022-12-24	WOS:A1991GX16400009
J	STEINMEYER, K; KLOCKE, R; ORTLAND, C; GRONEMEIER, M; JOCKUSCH, H; GRUNDER, S; JENTSCH, TJ				STEINMEYER, K; KLOCKE, R; ORTLAND, C; GRONEMEIER, M; JOCKUSCH, H; GRUNDER, S; JENTSCH, TJ			INACTIVATION OF MUSCLE CHLORIDE CHANNEL BY TRANSPOSON INSERTION IN MYOTONIC MICE	NATURE			English	Article							RECESSIVE GENERALIZED MYOTONIA; MOUSE MUTANT ADR; SEQUENCE; ETN; CONDUCTANCE; EXPRESSION; PROTEIN; RAT	MYOTONIA (stiffness and impaired relaxation of skeletal muscle) is a symptom of several diseases caused by repetitive firing of action potentials in muscle membranes 1. Purely myotonic human diseases are dominant myotonia congenita (Thomsen) and recessive generalized myotonia (Becker), whereas myotonic dystrophy is a systemic disease. Muscle hyperexcitability was attributed to defects in sodium channels 2,3 and/or to a decrease in chloride conductance (in Becker's myotonia 4 and in genetic animal models 5-10). Experimental blockage of Cl- conductance (normally 70-85% of resting conductance in muscle") in fact elicits myotonia 1,9. ADR (ref. 12) mice are a realistic animal model 5-7,12-18 for recessive autosomal myotonia. In addition to Cl- conductance 5, many other parameters 6,12,16 are changed in muscles of homozygous animals. We have now cloned the major mammalian skeletal muscle chloride channel (ClC-1) 19. Here we report that in ADR mice a transposon of the ETn family 20-23 has inserted into the corresponding gene, destroying its coding potential for several membrane-spanning domains. Together with the lack of recombination between the Clc-1 gene and the adr locus, this strongly suggests a lack of functional chloride channels as the primary cause of mouse myotonia.	UNIV HAMBURG,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY; UNIV BIELEFELD,DEV BIOL UNIT,W-4800 BIELEFELD 1,GERMANY	University of Hamburg; University of Bielefeld			Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883; Jentsch, Thomas/0000-0002-3509-2553				ADRIAN RH, 1974, J PHYSIOL-LONDON, V240, P505, DOI 10.1113/jphysiol.1974.sp010620; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; BRINKMEIER H, 1987, BIOCHEM BIOPH RES CO, V148, P1383, DOI 10.1016/S0006-291X(87)80285-1; BRULET P, 1985, P NATL ACAD SCI USA, V82, P2054, DOI 10.1073/pnas.82.7.2054; BRULET P, 1983, P NATL ACAD SCI-BIOL, V80, P5641, DOI 10.1073/pnas.80.18.5641; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P367, DOI 10.1113/jphysiol.1971.sp009667; BUCAN M, 1986, EMBO J, V5, P2899, DOI 10.1002/j.1460-2075.1986.tb04585.x; CAMERINO DC, 1989, PFLUG ARCH EUR J PHY, V413, P568, DOI 10.1007/BF00594192; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; FRANKE C, 1991, MUSCLE NERVE, V14, P762, DOI 10.1002/mus.880140811; FRIEDMAN JM, 1991, MAMM GENOME, V1, P130, DOI 10.1007/BF00351059; FUCHTBAUER EM, 1988, P NATL ACAD SCI USA, V85, P3880, DOI 10.1073/pnas.85.11.3880; HELLER AH, 1982, J NEUROSCI, V2, P924; Iaizzo P A, 1991, Neuromuscul Disord, V1, P47, DOI 10.1016/0960-8966(91)90042-Q; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; JOCKUSCH H, 1988, EUR J BIOCHEM, V171, P101, DOI 10.1111/j.1432-1033.1988.tb13764.x; JOCKUSCH H, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P429; JOCKUSCH H, 1990, MOUSE GENOME, V86, P216; KOLTGEN D, 1991, MUSCLE NERVE, V14, P775, DOI 10.1002/mus.880140813; LIPICKY RJ, 1971, J CLIN INVEST, V50, P2091, DOI 10.1172/JCI106703; LIPICKY RJ, 1966, J GEN PHYSIOL, V50, P89, DOI 10.1085/jgp.50.1.89; MEHRKE G, 1988, MUSCLE NERVE, V11, P440, DOI 10.1002/mus.880110505; MEYERS JC, 1981, P NATL ACAD SCI USA, V78, P3516; NEUMANN P, 1989, MOUSE NEWS LETT, V83, P157; QUINTO C, 1982, P NATL ACAD SCI-BIOL, V79, P31, DOI 10.1073/pnas.79.1.31; REININGHAUS J, 1988, MUSCLE NERVE, V11, P433, DOI 10.1002/mus.880110504; RUDEL R, 1990, TRENDS NEUROSCI, V13, P1, DOI 10.1016/0166-2236(90)90049-G; RUDEL R, 1988, MUSCLE NERVE, V11, P202, DOI 10.1002/mus.880110303; RUDEL R, 1985, PHYSIOL REV, V65, P310, DOI 10.1152/physrev.1985.65.2.310; SHELL B, 1987, MOL CELL BIOL, V7, P1364, DOI 10.1128/MCB.7.4.1364; SONIGO P, 1987, P NATL ACAD SCI USA, V84, P3768, DOI 10.1073/pnas.84.11.3768; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; WATKINS WJ, 1984, LAB ANIM, V18, P1, DOI 10.1258/002367784780865036; WILKE TM, 1987, MOL CELL BIOL, V57, P1646; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	35	319	325	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					304	308		10.1038/354304a0	http://dx.doi.org/10.1038/354304a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1659665				2022-12-24	WOS:A1991GT20400047
J	SMITH, JC; ELLENBERGER, HH; BALLANYI, K; RICHTER, DW; FELDMAN, JL				SMITH, JC; ELLENBERGER, HH; BALLANYI, K; RICHTER, DW; FELDMAN, JL			PRE-BOTZINGER COMPLEX - A BRAIN-STEM REGION THAT MAY GENERATE RESPIRATORY RHYTHM IN MAMMALS	SCIENCE			English	Article							SPINAL-CORD PREPARATION; INSPIRATORY DRIVE; NUCLEUS AMBIGUUS; NEWBORN RAT; INVITRO; NEURONS; MEDULLA; PATTERN; MOTONEURONS; MODULATION	The location of neurons generating the rhythm of breathing in mammals is unknown. By microsection of the neonatal rat brainstem in vitro, a limited region of the ventral medulla (the pre-Botzinger Complex) that contains neurons essential for rhythmogenesis was identified. Rhythm generation was eliminated by removal of only this region. Medullary slices containing the pre-Botzinger Complex generated respiratory-related oscillations similar to those generated by the whole brainstem in vitro, and neurons with voltage-dependent pacemaker-like properties were identified in this region. Thus, the respiratory rhythm in the mammalian neonatal nervous system may result from a population of conditional bursting pacemaker neurons in the pre-Botzinger Complex.	UNIV GOTTINGEN,INST PHYSIOL,W-3400 GOTTINGEN,GERMANY	University of Gottingen	SMITH, JC (corresponding author), UNIV CALIF LOS ANGELES,DEPT KINESIOL,SYST NEUROBIOL LAB,LOS ANGELES,CA 90024, USA.		feldman, jack/AAO-7505-2021	feldman, jack/0000-0003-3692-9412	NHLBI NIH HHS [R01 HL070029-01A1, HL02204, R01 HL070029, HL4095, K30 HL004095, R01 HL040959] Funding Source: Medline; NINDS NIH HHS [R01 NS024742, NS24742] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K30HL004095, R01HL040959, R01HL070029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024742] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIEGER D, 1987, J COMP NEUROL, V262, P546, DOI 10.1002/cne.902620408; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; COHEN MI, 1979, PHYSIOL REV, V59, P1105, DOI 10.1152/physrev.1979.59.4.1105; ELLENBERGER HH, 1990, J COMP NEUROL, V294, P202, DOI 10.1002/cne.902940205; EZURE K, 1990, PROG NEUROBIOL, V35, P429, DOI 10.1016/0301-0082(90)90030-K; Feldman J, 1990, EUR J NEUROSCI, V3, P171; FELDMAN JL, 1990, AM J PHYSIOL, V259, pR879, DOI 10.1152/ajpregu.1990.259.5.R879; FELDMAN JL, 1989, ANN NY ACAD SCI, V563, P114, DOI 10.1111/j.1749-6632.1989.tb42194.x; FELDMAN JL, 1986, HDB PHYSL 1, V4, P463; FLUORENS P, 1851, CR HEBD ACAD SCI, V33, P437; GREER JJ, 1991, J PHYSIOL-LONDON, V437, P727, DOI 10.1113/jphysiol.1991.sp018622; HARADA Y, 1985, J PHYSIOL-LONDON, V368, P679, DOI 10.1113/jphysiol.1985.sp015883; HILAIRE G, 1989, BRAIN RES, V485, P325, DOI 10.1016/0006-8993(89)90577-5; LIU GS, 1990, J NEUROPHYSIOL, V64, P423, DOI 10.1152/jn.1990.64.2.423; MCCRIMMON DR, 1989, J NEUROSCI, V9, P1910; ONIMARU H, 1988, BRAIN RES, V445, P314, DOI 10.1016/0006-8993(88)91194-8; ONIMARU H, 1987, NEUROSCI LETT, V78, P151, DOI 10.1016/0304-3940(87)90624-0; OTAKE K, 1990, J COMP NEUROL, V302, P485, DOI 10.1002/cne.903020306; Richter DW, 1986, NEWS PHYSIOL SCI, V1, P109; SCHWARZACHER S W, 1991, Pfluegers Archiv European Journal of Physiology, V418, pR17; SMITH J C, 1989, Society for Neuroscience Abstracts, V15, P505; SMITH J C, 1990, Society for Neuroscience Abstracts, V16, P1130; Smith J. C., 1987, RESPIRATORY MUSCLES, P27; SMITH JC, 1986, FASEB J, V45, P518; SMITH JC, 1987, J NEUROSCI METH, V21, P321, DOI 10.1016/0165-0270(87)90126-9; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149, DOI 10.1152/jn.1990.64.4.1149; SUZUE T, 1984, J PHYSIOL-LONDON, V354, P173, DOI 10.1113/jphysiol.1984.sp015370	27	1588	1633	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					726	729		10.1126/science.1683005	http://dx.doi.org/10.1126/science.1683005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1683005	Green Accepted			2022-12-24	WOS:A1991GN47400047
J	ODELL, TJ; KANDEL, ER; GRANT, SGN				ODELL, TJ; KANDEL, ER; GRANT, SGN			LONG-TERM POTENTIATION IN THE HIPPOCAMPUS IS BLOCKED BY TYROSINE KINASE INHIBITORS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; SRC GENE-PRODUCT; RAT-BRAIN; PHORBOL ESTERS; PHOSPHORYLATION; RECEPTOR; SLICES; CELLS	LONG-TERM potentiation (LTP) in the hippocampus is thought to contribute to memory formation. In the Ca1 region, LTP requires the NMDA (N-methyl-D-aspartate) receptor-dependent influx of Ca2+ and activation of serine and threonine protein kinases. Because of the high amount of protein tyrosine kinases in hippocampus and cerebellum 1,2, two regions implicated in learning and memory, we examined the possible additional requirement of tyrosine kinase activity in LTP. We first examined the specificity in brain of five inhibitors of tyrosine kinase 3-5 (Table 1) and found that two of them, lavendustin A and genistein, showed substantially greater specificity for tyrosine kinase from hippocampus 6 than for three serine-threonine kinases: protein kinase A, protein kinase C, and Ca2+/calmodulin kinase II. Lavendustin A and genistein selectively blocked the induction of LTP when applied in the bath or injected into the postsynaptic cell. By contrast, the inhibitors had no effect on the established LTP, on normal synaptic transmission, or on the neurotransmitter actions attributable to the actions of protein kinase A or protein kinase C. These data suggest that tyrosine kinase activity could be required postsynaptically for long-term synaptic plasticity in the hippocampus. As Ca2+ calmodulin kinase II or protein kinase C seem also to be required 7,8, the tyrosine kinases could participate postsynaptically in a kinase network together with serine and threonine kinases.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	ODELL, TJ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032, USA.			Grant, Seth/0000-0001-8732-8735				AKIYAMA T, 1986, J BIOL CHEM, V261, P4797; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AURICCHIO F, 1987, METHOD ENZYMOL, V139, P731; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MADISON DV, 1982, NATURE, V299, P636, DOI 10.1038/299636a0; MALENKA RC, 1986, J NEUROSCI, V6, P475; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MIGLIACCIO A, 1984, P NATL ACAD SCI-BIOL, V81, P5921, DOI 10.1073/pnas.81.19.5921; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; NICOLL RA, 1988, NEURON, V1, P7; ODELL TJ, IN PRESS P NATN ACAD; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TERLAU H, 1990, EUR J NEUROSCI, V2, P973, DOI 10.1111/j.1460-9568.1990.tb00009.x; TERLAU H, 1989, BRAIN RES, V484, P352, DOI 10.1016/0006-8993(89)90380-6; WALAAS SI, 1988, MOL BRAIN RES, V3, P215, DOI 10.1016/0169-328X(88)90044-7	29	510	523	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					558	560		10.1038/353558a0	http://dx.doi.org/10.1038/353558a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1656271				2022-12-24	WOS:A1991GJ64300067
J	CARTWRIGHT, KAV; JONES, DM; SMITH, AJ; STUART, JM; KACZMARSKI, EB; PALMER, SR				CARTWRIGHT, KAV; JONES, DM; SMITH, AJ; STUART, JM; KACZMARSKI, EB; PALMER, SR			INFLUENZA-A AND MENINGOCOCCAL DISEASE	LANCET			English	Article							NEISSERIA-MENINGITIDIS; INFECTIONS; EPIDEMIC; VIRUSES	There are several anecdotal accounts of the association between outbreaks of influenza and meningococcal disease. The exceptional increase in the number of cases of meningococcal infection 2 weeks after an influenza A outbreak in England and Wales during November and December, 1989, provided an opportunity to investigate the relation between the two events. Patients with meningococcal disease in December, 1989, were more likely than age-matched controls to show serological evidence of recent influenza A infection (odds ratio 3.9, 95% CI 1.2-13.9). The most likely explanation for the association is immune suppression induced by influenza A, though a lowering of mucosal resistance to meningococcal invasion may also be a factor. Public health authorities should be aware of the association and should be prepared to alert medical practitioners and the public to the increased risk of meningococcal disease when influenza A outbreaks occur.	WITHINGTON HOSP,PUBL HLTH LAB,MANCHESTER M20 8LR,LANCS,ENGLAND; ST LUKES HOSP,PUBL HLTH LAB,GUILDFORD,ENGLAND; GLOUCESTER HLTH AUTHOR,DEPT PUBL HLTH MED,GLOUCESTER,ENGLAND; COMMUNICABLE DIS SURVEILLANCE CTR WELSH UNIT,CARDIFF,WALES		CARTWRIGHT, KAV (corresponding author), GLOUCESTER ROYAL HOSP,PUBL HLTH LAB,GREAT WESTERN RD,GLOUCESTER GL1 3NN,ENGLAND.		Smith, Ashley/GZB-0298-2022					ABRAMSON JS, 1988, PERSPECT BIOL MED, V32, P63; ARTENSTEIN MS, 1967, J AMER MED ASSOC, V201, P1004; BLAKEBROUGH IS, 1982, J INFECT DIS, V146, P626, DOI 10.1093/infdis/146.5.626; CAMBRIDGE G, 1976, INFECT IMMUN, V13, P36, DOI 10.1128/IAI.13.1.36-43.1976; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; DEWALS P, 1983, J INFECTION, V6, P147, DOI 10.1016/S0163-4453(83)92756-1; EDWARDS EA, 1977, SCAND J INFECT DIS, V9, P105, DOI 10.3109/inf.1977.9.issue-2.09; FIJEN CAP, 1989, LANCET, V2, P585; Fleming D M, 1985, Health Trends, V17, P13; FLEMING DM, 1990, BRIT J GEN PRACT, V40, P495; FLEMING DM, 1988, J ROY COLL GEN PRACT, V38, P159; KLEINERMAN ES, 1975, LANCET, V2, P1063; LAL H B, 1963, J Indian Med Assoc, V40, P113; LARSON HE, 1976, LANCET, V1, P283, DOI 10.1016/S0140-6736(76)91407-0; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; OLCEN P, 1979, SCAND J INFECT DIS, V11, P111, DOI 10.3109/inf.1979.11.issue-2.03; OXFORD JS, 1990, TOPLEY WILSONS PRINC, V4, P305; PALMER DF, 1975, ADV LABORATORY TECHN, P44; PARKER MT, 1979, J INFECT S2, V1, P9; PETHER JVS, 1982, LANCET, V1, P804; SCHUBIGER G, 1986, SCHWEIZ MED WSCHR, V116, P1172; SWEET C, 1990, TOPLEY WILSONS PRINC, V4, P105; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; 1990, IMMUNISATION INFECTI, P90; 1988, LANCET, V1, P95	25	159	160	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					554	557		10.1016/0140-6736(91)91112-8	http://dx.doi.org/10.1016/0140-6736(91)91112-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678811				2022-12-24	WOS:A1991GD00200015
J	GOSSEYE, S; VANOBBERGH, L; WEYNAND, B; SCHEIFF, JM; MOULIN, D; DEGOYET, JD; OTTE, JB				GOSSEYE, S; VANOBBERGH, L; WEYNAND, B; SCHEIFF, JM; MOULIN, D; DEGOYET, JD; OTTE, JB			PLATELET AGGREGATES IN SMALL LUNG VESSELS AND DEATH DURING LIVER-TRANSPLANTATION	LANCET			English	Article							SCREEN FILTRATION; BLOOD FILTRATION; PREVENTION; TRANSFUSION	10 children who died suddenly during liver transplantation were found at necropsy to have extensive obstruction of small lung vessels by platelet aggregates. In 7 of these patients pulmonary artery pressure changes before death were consistent with acute obstruction of the pulmonary vascular bed. Platelet aggregates were not strikingly increased in blood vessels in other tissues. No single obvious cause for these unusual histological findings could be identified, although the presence of intravascular catheters, perioperative blood and platelet concentrate transfusions, and cellular debris from the liver forced into the circulation during surgery might predispose to platelet aggregation.	CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT INTENS CARE,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT PAEDIAT SURG,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT PATHOL,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT ANAESTHESIOL,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT HAEMATOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc			Goyet, Jean de Ville de/I-6913-2019; Weynand, Birgit/H-9587-2019; Goyet, Jean de Ville de/A-1708-2014	Goyet, Jean de Ville de/0000-0001-7681-6178; Goyet, Jean de Ville de/0000-0001-7681-6178				BARRETT J, 1978, ARCH SURG-CHICAGO, V113, P947; CARLIER M, 1987, TRANSPLANT P, V19, P3333; DERIAN CK, 1990, THROMB RES, V57, P393, DOI 10.1016/0049-3848(90)90255-B; DURTSCHI MB, 1979, AM J SURG, V138, P8, DOI 10.1016/0002-9610(79)90235-6; ELMER O, 1988, AM J SURG, V155, P289, DOI 10.1016/S0002-9610(88)80716-5; GRIFFITH EM, 1977, LANCET, V1, P1010; HARKER LA, 1977, ANN SURG, V186, P594, DOI 10.1097/00000658-197711000-00009; HOAR PF, 1978, ANESTHESIOLOGY, V48, P445, DOI 10.1097/00000542-197806000-00014; MCNAMARA JJ, 1978, SURG GYNECOL OBSTET, V147, P507; MILLER RD, 1990, ANESTHESIA, P1467; MOSELEY RV, 1970, ANN SURG, V171, P329, DOI 10.1097/00000658-197003000-00002; REUL GJ, 1973, ARCH SURG-CHICAGO, V106, P386; REUL GJ, 1974, CHEST, V66, P4, DOI 10.1378/chest.66.1.4; SNYDER EL, 1983, TRANSFUSION, V23, P460, DOI 10.1046/j.1537-2995.1983.23684074264.x	14	21	21	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					532	534		10.1016/0140-6736(91)91099-G	http://dx.doi.org/10.1016/0140-6736(91)91099-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678799				2022-12-24	WOS:A1991GD00200003
J	FUNGLEUNG, WP; SCHILHAM, MW; RAHEMTULLA, A; KUNDIG, TM; VOLLENWEIDER, M; POTTER, J; VANEWIJK, W; MAK, TW				FUNGLEUNG, WP; SCHILHAM, MW; RAHEMTULLA, A; KUNDIG, TM; VOLLENWEIDER, M; POTTER, J; VANEWIJK, W; MAK, TW			CD8 IS NEEDED FOR DEVELOPMENT OF CYTOTOXIC T-CELLS BUT NOT HELPER T-CELLS	CELL			English	Article							MLSA-ENCODED ANTIGENS; STEM-CELLS; HOMOLOGOUS RECOMBINATION; TYROSINE PHOSPHORYLATION; PLURIPOTENTIAL CELLS; SURFACE EXPRESSION; TRANSGENIC MICE; KINASE P56LCK; MOUSE EMBRYOS; LYMPHOCYTES-T	A mutant mouse strain without CD8 (Lyt-2 and Lyt-3) expression on the cell surface has been generated by disrupting the Lyt-2 gene using embryonic stem cell technology. In these mice, CD8+ T lymphocytes are not present in peripheral lymphoid organs, but the CD4+ T lymphocyte population seems to be unaltered. Cytotoxic response of T lymphocytes from these mice against alloantigens and viral antigens is dramatically decreased. Proliferative response against alloantigens and in vivo help to B lymphocytes, however, are not affected. These data suggest that CD8 is necessary for the maturation and positive selection of class I MHC restricted cytotoxic T lymphocytes but is not required on any of the intermediate thymocyte populations (CD8+CD4-TcR- or CD4+CD8+TcR(low)) during the development of functional class II MHC restricted helper T cells.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV ZURICH, INST PATHOL, CH-8006 ZURICH, SWITZERLAND; ERASMUS UNIV, DEPT IMMUNOL, 3000 DR ROTTERDAM, NETHERLANDS	University of Toronto; University of Toronto; University of Zurich; Erasmus University Rotterdam	FUNGLEUNG, WP (corresponding author), UNIV TORONTO, ONTARIO CANC INST, TORONTO M4X 1K9, ONTARIO, CANADA.		Schilham, Marco W./AAL-7223-2021	Schilham, Marco W./0000-0003-4391-6003; Fung-Leung, Wai-Ping/0000-0001-7013-8855				BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BLANC D, 1988, EUR J IMMUNOL, V18, P613, DOI 10.1002/eji.1830180419; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; BRADLEY A, 1987, PRODUCTION ANALCHIMA; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GORMAN SD, 1988, J IMMUNOL, V140, P3646; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; GUPTA SC, 1986, P NATL ACAD SCI USA, V83, P2604, DOI 10.1073/pnas.83.8.2604; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HIRSCH MS, 1968, J EXP MED, V128, P121, DOI 10.1084/jem.128.1.121; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOSZINOWSKI U, 1975, EUR J IMMUNOL, V5, P245, DOI 10.1002/eji.1830050405; LEDBETTER JA, 1981, J EXP MED, V153, P1503, DOI 10.1084/jem.153.6.1503; LIAW CW, 1986, J IMMUNOL, V137, P1037; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; NAKAUCHI H, 1987, P NATL ACAD SCI USA, V84, P4210, DOI 10.1073/pnas.84.12.4210; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROOST H, 1988, EUR J IMMUNOL, V18, P511, DOI 10.1002/eji.1830180404; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SCHILHAM MW, 1986, J IMMUNOL, V137, P2748; SCHMIDTULLRICH R, 1990, INT IMMUNOL, V2, P247, DOI 10.1093/intimm/2.3.247; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SCOTT DW, 1970, CLIN EXP IMMUNOL, V6, P313; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.immunol.5.1.585; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; WALKER ID, 1984, IMMUNOL REV, V82, P47, DOI 10.1111/j.1600-065X.1984.tb01117.x; WALKER ID, 1984, EUR J IMMUNOL, V14, P906, DOI 10.1002/eji.1830141009; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	51	482	499	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					443	449		10.1016/0092-8674(91)90462-8	http://dx.doi.org/10.1016/0092-8674(91)90462-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1673361				2022-12-24	WOS:A1991FK18200011
J	SCHATTENKERK, JKME; VANGOOL, T; VANKETEL, RJ; BARTELSMAN, JFWM; KUIKEN, CL; TERPSTRA, WJ; REISS, P				SCHATTENKERK, JKME; VANGOOL, T; VANKETEL, RJ; BARTELSMAN, JFWM; KUIKEN, CL; TERPSTRA, WJ; REISS, P			CLINICAL-SIGNIFICANCE OF SMALL-INTESTINAL MICROSPORIDIOSIS IN HIV-1-INFECTED INDIVIDUALS	LANCET			English	Article							AIDS; PATIENT	To assess the importance of microsporidiosis of the small intestine in the pathogenesis of chronic diarrhoea in HIV-1-infected individuals, duodenal biopsy samples from the following three patient groups were prospectively evaluated for bacterial, viral, and parasitic pathogens by standard methods, and for microsporidia by light microscopy: 55 consecutive HIV-1-antibody-positive subjects with unexplained diarrhoea of at least 3 weeks duration (group A); 38 HIV-1-seropositive subjects without diarrhoea (group B) who consecutively underwent upper gastrointestinal endoscopy for various reasons; and 7 patients without known risk factors for HIV infection with chronic unexplained diarrhoea (group C). In groups A and B most subjects had had previous AIDS-defining opportunistic infections and the median peripheral blood CD4 lymphocyte count was less than 0.1 X 10(9)/l. Microsporidia were detected as the single pathogen in 15 of the group A compared with 1 (in whom diarrhoea subsequently developed) of the group B patients (p = 0.001) and none of the group C patients. With the exception of 4 of the group A patients, no other intestinal pathogens were identified in any of the patients. The median peripheral blood CD4 count was significantly lower in patients with detectable microsporidia than in those without microsporidiosis (0.03 X 10(9)/l vs 0.06 X 10(9)/l; p = 0.03); in all patients with microsporidiosis, the CD4 count was equal to or less than 0.1 X 10(9)/l. 13 patients with microsporidiosis were treated with metronidazole, in 10 of whom treatment led to a substantial improvement or disappearance of diarrhoea within days of starting therapy, but did not result in eradication of the parasite in the 5 patients who underwent repeat biopsy. The findings suggest that small-intestinal microsporidiosis is an important cause of chronic unexplained diarrhoea in HIV-1-infected individuals with pronounced cellular immune deficiency. This infection should therefore be added to the list of AIDS-defining opportunistic infections.	ROYAL TROP INST,DEPT INTERNAL MED,AMSTERDAM,NETHERLANDS; ROYAL TROP INST,NH SWELLENGREBEL LAB TROP HYG,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT MED MICROBIOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,NATL AIDS THERAPY EVALUAT CTR,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam			Van Gool, Tom/H-6750-2012					Bryan R. T., 1990, Principles and practice of infectious diseases., P2130; CALI A, 1990, J PROTOZOOL, V37, P145, DOI 10.1111/j.1550-7408.1990.tb05885.x; CROWE S, 1990, 6TH INT C AIDS SAN F, V3, P217; CURRY A, 1988, J CLIN PATHOL, V41, P477, DOI 10.1136/jcp.41.4.477-b; DESPORTES I, 1985, J PROTOZOOL, V32, P250; FRIEDBERG DN, 1990, ARCH OPHTHALMOL-CHIC, V108, P504, DOI 10.1001/archopht.1990.01070060052047; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LUCAS SB, 1989, J CLIN PATHOL, V42, P885, DOI 10.1136/jcp.42.8.885-b; OIRENSTEIN JM, 1990, HUM PATHOL, V21, P475; ORENSTEIN J, 1990, 6TH INT C AIDS SAN F, V1, P252; RIJPSTRA AC, 1988, J INFECT DIS, V157, P827, DOI 10.1093/infdis/157.4.827; Soave R., 1990, Principles and practice of infectious diseases., P2122; TERADA S, 1987, ANN INTERN MED, V107, P61, DOI 10.7326/0003-4819-107-1-61; Van Reken DE, 1990, PRINCIPLES PRACTICE, P398; VANGOOL T, 1990, LANCET, V336, P697, DOI 10.1016/0140-6736(90)92198-Q; ZENDER HO, 1989, AM J CLIN PATHOL, V92, P352, DOI 10.1093/ajcp/92.3.352; 1990, MMWR, V39, P188; 1987, MMWR S1, V36, pS3	18	158	159	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					895	898		10.1016/0140-6736(91)90215-B	http://dx.doi.org/10.1016/0140-6736(91)90215-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672978				2022-12-24	WOS:A1991FG04800013
J	MASTRO, TD; GHAFOOR, A; NOMANI, NK; ISHAQ, Z; ANWAR, F; GRANOFF, DM; SPIKA, JS; THORNSBERRY, C; FACKLAM, RR				MASTRO, TD; GHAFOOR, A; NOMANI, NK; ISHAQ, Z; ANWAR, F; GRANOFF, DM; SPIKA, JS; THORNSBERRY, C; FACKLAM, RR			ANTIMICROBIAL RESISTANCE OF PNEUMOCOCCI IN CHILDREN WITH ACUTE LOWER RESPIRATORY-TRACT INFECTION IN PAKISTAN	LANCET			English	Article							STREPTOCOCCUS-PNEUMONIAE; CO-TRIMOXAZOLE; DEVELOPING-COUNTRIES; NEW-GUINEA; ETIOLOGY; VACCINE; PENICILLIN; SEROTYPES	87 strains of Streptococcus pneumoniae isolated during three winter seasons (1986-89) from the blood of children with acute lower respiratory tract infection (ALRI) in Pakistan were serotyped and tested for susceptibility to a range of antimicrobial agents. 97% of isolates were resistant to at least one antimicrobial drug. 62% had decreased susceptibility to co-trimoxazole (trimethoprim/sulphamethoxazole) (31% were fully resistant) and 39% were resistant to chloramphenicol. All isolates were susceptible to erythromycin, cefaclor, cephalothin, ceftriaxone, cefuroxime, rifampicin, vancomycin, and clindamycin. 29% of isolates were neither vaccine types nor vaccine-related types. Serotype distribution and antimicrobial susceptibility varied significantly during the three winter seasons. No single serotype was found in all three winters. The findings highlight the need for surveillance of antimicrobial resistance and serotype distribution of S pneumoniae in developing countries as a guide both to the choice of agent for treatment of pneumococcal infections, especially ALRI, and to the formulation of new pneumococcal conjugate vaccines for use in young children.	NATL INST HLTH,ISLAMABAD,PAKISTAN; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,DIV INFECT DIS,ST LOUIS,MO 63110; CTR DIS CONTROL,CTR INFECT DIS,HOSP INFECT PROGRAM,ANTIMICROB INVEST BRANCH,ATLANTA,GA 30333	Washington University (WUSTL); Centers for Disease Control & Prevention - USA	MASTRO, TD (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV BACTERIAL DIS,RESP DIS BRANCH,MAILSTOP C-09,ATLANTA,GA 30333, USA.		Anwar, Farooq/K-8137-2019		NIAID NIH HHS [AI-24332] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPELBAUM PC, 1987, EUR J CLIN MICROBIOL, V6, P367, DOI 10.1007/BF02013089; BROOME CV, 1981, REV INFECT DIS, V3, P277; CAMPBELL H, 1988, LANCET, V2, P1182; CHRETIEN J, 1984, NEW ENGL J MED, V310, P982, DOI 10.1056/NEJM198404123101509; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; ELMOUZAN MI, 1988, TROP GEOGR MED, V40, P213; GHAFOOR A, 1990, REV INFECT DIS, V12, pS907; GREENWOOD BM, 1970, LANCET, V1, P360; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; KEELEY DJ, 1990, B WORLD HEALTH ORGAN, V68, P185; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; LINARES J, 1983, EUR J CLIN MICROBIOL, V2, P473, DOI 10.1007/BF02013907; LINARES J, 1984, J ANTIMICROB CHEMOTH, V13, P353, DOI 10.1093/jac/13.4.353; MONTO AS, 1989, REV INFECT DIS, V11, P498; ONYEMELUKWE GC, 1982, J INFECTION, V5, P157, DOI 10.1016/S0163-4453(82)91772-8; OTIN CL, 1988, J ANTIMICROB CHEMOTH, V22, P659, DOI 10.1093/jac/22.5.659; PALLARES R, 1988, NEW ENGL J MED, V318, P124; RILEY ID, 1981, ARCH DIS CHILD, V56, P354, DOI 10.1136/adc.56.5.354; RILEY ID, 1986, LANCET, V2, P877; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005; SHANN F, 1984, LANCET, V2, P537; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553; WARD J, 1981, REV INFECT DIS, V3, P254; WEINBERG GA, 1990, B WORLD HEALTH ORGAN, V68, P179; WEINBERG GA, 1989, J INFECT DIS, V160, P634, DOI 10.1093/infdis/160.4.634; 1986, WHORSD85; 1986, B WORLD HEALTH ORGAN, V64, P929; 1988, WHOARI893; 1985, LANCET, V2, P699; 1988, LANCET, V1, P1142; 1986, WHORSD8626; 1988, METHODS DILUTION ANT	34	109	110	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					156	159		10.1016/0140-6736(91)90813-5	http://dx.doi.org/10.1016/0140-6736(91)90813-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670799				2022-12-24	WOS:A1991ET67900015
J	RODGERS, GP; DOVER, GJ; NOGUCHI, CT; SCHECHTER, AN; NIENHUIS, AW				RODGERS, GP; DOVER, GJ; NOGUCHI, CT; SCHECHTER, AN; NIENHUIS, AW			HEMATOLOGIC RESPONSES OF PATIENTS WITH SICKLE-CELL DISEASE TO TREATMENT WITH HYDROXYUREA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NHLBI,CLIN HEMATOL BRANCH,BETHESDA,MD 20205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University	RODGERS, GP (corresponding author), NIDDK,CHEM BIOL LAB,BLDG 10,9N-318,BETHESDA,MD, USA.			Schechter, Alan N/0000-0002-5235-9408	NHLBI NIH HHS [HL-28028] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028028, R37HL028028] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKHATTI A, 1987, NEW ENGL J MED, V317, P415, DOI 10.1056/NEJM198708133170704; ALTER BP, 1985, BLOOD, V66, P373; ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P853, DOI 10.1073/pnas.81.3.853; BERTLES JF, 1968, J CLIN INVEST, V47, P1731, DOI 10.1172/JCI105863; BRITTENHAM GM, 1985, BLOOD, V65, P183; BURNS ER, 1986, AM J CLIN PATHOL, V85, P337, DOI 10.1093/ajcp/85.3.337; CHARACHE S, 1987, BLOOD, V69, P109; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428; Dover G J, 1989, Prog Clin Biol Res, V316B, P295; DOVER GJ, 1986, BLOOD, V67, P735; DOVER GJ, 1978, NEW ENGL J MED, V299, P1428, DOI 10.1056/NEJM197812282992603; DOVER GJ, 1987, BLOOD, V69, P341; Forsythe GE., 1977, COMPUTER METHODS MAT; HUMPHRIES RK, 1985, J CLIN INVEST, V75, P547, DOI 10.1172/JCI111731; LAVELLE D, 1986, BLOOD, V67, P1083; LETVIN NL, 1984, NEW ENGL J MED, V310, P869, DOI 10.1056/NEJM198404053101401; LEY TJ, 1983, BLOOD, V62, P370; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; McDonagh K T, 1989, Prog Clin Biol Res, V316B, P307; MILLER BA, 1987, NEW ENGL J MED, V316, P244, DOI 10.1056/NEJM198701293160504; NAGEL RL, 1985, NEW ENGL J MED, V312, P880, DOI 10.1056/NEJM198504043121403; NOGUCHI CT, 1983, J CLIN INVEST, V72, P846, DOI 10.1172/JCI111055; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; NOGUCHI CT, 1985, J CLIN INVEST, V75, P1632, DOI 10.1172/JCI111870; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; REMINGTON RD, 1970, STATISTICS APPLICATI; RODGERS GP, 1985, J LAB CLIN MED, V106, P30; RODGERS GP, 1989, HEMOGLOBIN SWITCHI B, V316, P281; Schechter A. N., 1987, MOL BASIS BLOOD DIS, P179; SHINAR E, 1987, BLOOD, V70, P158; VEITH R, 1985, NEW ENGL J MED, V313, P1571, DOI 10.1056/NEJM198512193132503	32	246	251	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 12	1990	322	15					1037	1045		10.1056/NEJM199004123221504	http://dx.doi.org/10.1056/NEJM199004123221504			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX869	1690857				2022-12-24	WOS:A1990CX86900004
J	INOUE, K; HOSHIJIMA, K; SAKAMOTO, H; SHIMURA, Y				INOUE, K; HOSHIJIMA, K; SAKAMOTO, H; SHIMURA, Y			BINDING OF THE DROSOPHILA SEX-LETHAL GENE-PRODUCT TO THE ALTERNATIVE SPLICE SITE OF TRANSFORMER PRIMARY TRANSCRIPT	NATURE			English	Article									KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 606,JAPAN	Kyoto University								AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELOTE JM, 1989, GENE, V82, P161, DOI 10.1016/0378-1119(89)90041-3; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HODGKIN J, 1989, CELL, V56, P905, DOI 10.1016/0092-8674(89)90619-3; INGOLIA TD, 1980, CELL, V21, P669, DOI 10.1016/0092-8674(80)90430-4; INOUE K, 1989, GENE DEV, V3, P1472, DOI 10.1101/gad.3.9.1472; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; MAINE EM, 1985, CELL, V43, P521, DOI 10.1016/0092-8674(85)90181-3; MCKEOWN M, 1987, CELL, V48, P489, DOI 10.1016/0092-8674(87)90199-1; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIYAKE T, 1987, MOL GEN GENET, V207, P29, DOI 10.1007/BF00331487; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NOCERA PPD, 1983, P NATL ACAD SCI USA, V80, P7095; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WOLFNER MF, 1988, TRENDS GENET, V4, P333, DOI 10.1016/0168-9525(88)90052-2; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	24	287	293	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 29	1990	344	6265					461	463		10.1038/344461a0	http://dx.doi.org/10.1038/344461a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW478	1690860				2022-12-24	WOS:A1990CW47800073
J	HANSEN, SW				HANSEN, SW			AUTONOMIC NEUROPATHY AFTER TREATMENT WITH CISPLATIN, VINBLASTINE, AND BLEOMYCIN FOR GERM-CELL CANCER	BRITISH MEDICAL JOURNAL			English	Article											HANSEN, SW (corresponding author), RIGSHOSP,FINSEN INST,DEPT ONCOL,DK-2100 COPENHAGEN O,DENMARK.							EWING DJ, 1986, CLIN ENDOCRINOL META, V15, P855, DOI 10.1016/S0300-595X(86)80078-0; HANSEN SW, 1989, J CLIN ONCOL, V7, P1457, DOI 10.1200/JCO.1989.7.10.1457; MCLEOD JG, 1987, ANN NEUROL, V21, P419, DOI 10.1002/ana.410210502; PAGE MM, 1978, LANCET, V1, P14; SAMUELS BL, 1987, CANCER CHEMOTH PHARM, V19, P253	5	44	44	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1990	300	6723					511	512		10.1136/bmj.300.6723.511	http://dx.doi.org/10.1136/bmj.300.6723.511			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ878	1690581	Green Published, Bronze			2022-12-24	WOS:A1990CQ87800021
J	WILLIAMS, GT; SMITH, CA; SPOONCER, E; DEXTER, TM; TAYLOR, DR				WILLIAMS, GT; SMITH, CA; SPOONCER, E; DEXTER, TM; TAYLOR, DR			HEMATOPOIETIC COLONY STIMULATING FACTORS PROMOTE CELL-SURVIVAL BY SUPPRESSING APOPTOSIS	NATURE			English	Article									CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT EXPTL HAEMATOL,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	WILLIAMS, GT (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT ANAT,VINCENT DR,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		Williams, Gwyn/GQY-7555-2022	Williams, Gwyn/0000-0003-4556-9930	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKSHI A, 1985, CELL, V41, P899; BRONCHUD MH, 1988, BRIT J CANCER, V58, P64, DOI 10.1038/bjc.1988.163; BURGESS AW, 1977, J BIOL CHEM, V252, P1998; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LIU YJ, IN PRESS NATURE; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1970, J CELL PHYSIOL, V76, P89, DOI 10.1002/jcp.1040760113; PARAN M, 1968, J CELL PHYSIOL, V72, P247, DOI 10.1002/jcp.1040720312; PRATT RM, 1976, DEV BIOL, V54, P135, DOI 10.1016/0012-1606(76)90292-X; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; RUSSELL JH, 1980, J IMMUNOL, V124, P1100; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPOONCER E, 1989, CURR TOP MICROBIOL, V149, P109; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONWANGENHEIM HR, 1977, BIOMED EXPRESS, V27, P337; WELTE K, 1985, P NATL ACAD SCI USA, V82, P1526, DOI 10.1073/pnas.82.5.1526; WHETTON AD, 1983, NATURE, V303, P629, DOI 10.1038/303629a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	28	1056	1069	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1990	343	6253					76	79		10.1038/343076a0	http://dx.doi.org/10.1038/343076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG614	1688645				2022-12-24	WOS:A1990CG61400059
J	KAUFMANN, H; ORIBE, E; OLIVER, JA				KAUFMANN, H; ORIBE, E; OLIVER, JA			PLASMA ENDOTHELIN DURING UPRIGHT TILT - RELEVANCE FOR ORTHOSTATIC HYPOTENSION	LANCET			English	Article							VASOVAGAL SYNCOPE; POSTURAL CHANGE; CELLS; VASOPRESSIN	Since plasma endothelin concentration increases with upright posture and decreases with volume expansion, a study was conducted to test whether activation of the baroreceptor reflex releases endothelin into plasma. The effect of passive upright tilt on the plasma concentrations of endothelin and vasopressin was examined in: (1) normal subjects; (2) patients with impaired baroreceptor reflex due to primary autonomic failure; (3) patients with normal afferent baroreceptor function but acute inhibition of vasoconstrictor sympathetic outflow (ie, with vasovagal syncope); and (4) patients with hypophysial diabetes insipidus. In normal subjects, upright tilt did not change arterial pressure and significantly increased the plasma concentrations of endothelin and vasopressin. In patients with autonomic failure, upright tilt induced a considerable fall in arterial pressure, no rise in plasma endothelin, and a slight increase in plasma vasopressin. In subjects with vasovagal syncope, arterial pressure dropped and the plasma concentrations of endothelin and vasopressin rose. In the subjects with diabetes insipidus, arterial pressure fell slightly, without change in plasma concentration of endothelin. The results suggest that activation of the baroreceptor reflex induces the release of endothelin into plasma, probably from the neurohypophysis, and they raise the possibility that impaired endothelin release contributes to the orthostatic hypotension of patients with primary autonomic failure.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University	KAUFMANN, H (corresponding author), CUNY MT SINAI SCH MED,DEPT NEUROL,AUTONOM NERVOUS SYST LAB,BOX 1137,NEW YORK,NY 10029, USA.			Kaufmann, Horacio/0000-0002-1851-9981	NCRR NIH HHS [RR-71] Funding Source: Medline; NINDS NIH HHS [NS-07245] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANNISTER R, 1989, AUTONOMIC FAILURE TX, P1; BRIGDEN W, 1950, CLIN SCI, V9, P75; DAVIES R, 1976, CLIN SCI MOL MED, V51, P267, DOI 10.1042/cs0510267; EMORI T, 1989, BIOCHEM BIOPH RES CO, V160, P93, DOI 10.1016/0006-291X(89)91625-2; KALA R, 1974, SCAND J CLIN LAB INV, V33, P87, DOI 10.3109/00365517409114202; KAUFMANN H, 1990, NEUROLOGY, V40, P1115, DOI 10.1212/WNL.40.7.1115; KAUFMANN H, 1990, Society for Neuroscience Abstracts, V16, P221; KAUFMANN H, 1990, Neurology, V40, P211; MILLER M, 1969, ENDOCRINOLOGY, V84, P557, DOI 10.1210/endo-84-3-557; ROSS CA, 1985, J COMP NEUROL, V242, P511, DOI 10.1002/cne.902420405; SAWCHENKO PE, 1981, SCIENCE, V214, P685, DOI 10.1126/science.7292008; SCHERRER U, 1990, NEW ENGL J MED, V322, P602, DOI 10.1056/NEJM199003013220906; SHICHIRI M, 1990, JAMA-J AM MED ASSOC, V263, P661, DOI 10.1001/jama.1990.03440050055027; TOMITA K, 1990, J CLIN INVEST, V85, P2014, DOI 10.1172/JCI114667; WALLIN BG, 1982, J AUTONOM NERV SYST, V6, P287; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZAWA T, 1990, SCIENCE, V247, P462, DOI 10.1126/science.2405487; YOSHIZUMI M, 1989, BIOCHEM BIOPH RES CO, V161, P859, DOI 10.1016/0006-291X(89)92679-X; ZEIDEL ML, 1989, AM J PHYSIOL, V257, pC1101, DOI 10.1152/ajpcell.1989.257.6.C1101; ZERBE RL, 1983, AM J MED, V74, P265, DOI 10.1016/0002-9343(83)90625-3	20	135	141	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1542	1545		10.1016/0140-6736(91)92370-H	http://dx.doi.org/10.1016/0140-6736(91)92370-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683970				2022-12-24	WOS:A1991GW03600002
J	BENZER, A; MITTERSCHIFFTHALER, G; MAROSI, M; LUEF, G; PUHRINGER, F; DELARENOTIERE, K; LEHNER, H; SCHMUTZHARD, E				BENZER, A; MITTERSCHIFFTHALER, G; MAROSI, M; LUEF, G; PUHRINGER, F; DELARENOTIERE, K; LEHNER, H; SCHMUTZHARD, E			PREDICTION OF NON-SURVIVAL AFTER TRAUMA - INNSBRUCK COMA SCALE	LANCET			English	Note							SCORES	421 severely injured patients admitted to a major trauma centre in Innsbruck during the ten years, 1981 to 1990, were investigated retrospectively for early prediction of survival by means of the Innsbruck Coma Scale (ICS). All 79 patients scoring 0 or 1 died within 21 days. The findings of this study indicate that the ICS allows a highly accurate prediction of non-survival in patients with scores of 0 or 1 even at the time of first examination after trauma.	UNIV HOSP INNSBRUCK,DEPT NEUROL,A-6020 INNSBRUCK,AUSTRIA	Medical University of Innsbruck	BENZER, A (corresponding author), UNIV HOSP INNSBRUCK,DEPT ANAESTHESIA,ANICHSTR 35,A-6020 INNSBRUCK,AUSTRIA.							[Anonymous], 1988, Crit Care Med, V16, P807; CHANG RWS, 1988, INTENS CARE MED, V14, P558, DOI 10.1007/BF00263530; JACOBS P, 1990, CRIT CARE MED, V11, P1282; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; TEASDALE G, 1974, LANCET, V2, P81	5	65	67	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1991	338	8773					977	978		10.1016/0140-6736(91)91840-Q	http://dx.doi.org/10.1016/0140-6736(91)91840-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK974	1681344				2022-12-24	WOS:A1991GK97400006
J	PANDEY, MR; DAULAIRE, NMP; STARBUCK, ES; HOUSTON, RM; MCPHERSON, K				PANDEY, MR; DAULAIRE, NMP; STARBUCK, ES; HOUSTON, RM; MCPHERSON, K			REDUCTION IN TOTAL UNDER-5 MORTALITY IN WESTERN NEPAL THROUGH COMMUNITY-BASED ANTIMICROBIAL TREATMENT OF PNEUMONIA	LANCET			English	Article							CHILDREN; INFECTION; IMPACT; GROWTH	Pneumonia is a leading cause of death among children world wide but those at highest risk in developing countries have limited access to clinical services; effective and low-cost alternatives are a global public health priority. We have done a controlled intervention trial among 13404 children under five in Jumla, Nepal, which relied exclusively on indigenous community health workers to detect and treat pneumonia according to the World Health Organisation decision strategy, with a five-day home-treatment course of oral co-trimoxazole. No other health services were provided, and referral of children to hospital was not practicable. During the three-year study, 2101 deaths were recorded. The programme led to a 28% reduction in the risk of death from all causes by the third year of services (relative risk 0.72, 95% confidence interval 0.63-0.82), with a significant trend (p < 0.02) of lower mortality with greater duration of the programme. The greatest benefit was among infants. In addition to reduction in deaths due to pneumonia, there was a significant reduction in deaths due to diarrhoea and measles, indicating that reduction in pneumonia morbidity had considerable carry-over effect. Our findings show that indigenous community workers can effectively detect and treat pneumonia, and reduce overall child mortality, even without other primary care activities.	INT CTR PREVENT & TREATMENT MAJOR CHILDHOOD DIS, POB 168, HANOVER, NH 03755 USA; MRIGENDRA MED TRUST, Kathmandu, NEPAL; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 7HT, ENGLAND; JOHN SNOW INC, BOSTON, MA USA	University of London; London School of Hygiene & Tropical Medicine								BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; DAULAIRE NMP, 1990, ALRI CHILD SURVIVAL; FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009; Gadomski A., 1990, Health Policy and Planning, V5, P235, DOI 10.1093/heapol/5.3.235; KHAN AJ, 1990, B WORLD HEALTH ORGAN, V68, P577; LAUNER LJ, 1990, AM J EPIDEMIOL, V131, P322, DOI 10.1093/oxfordjournals.aje.a115501; Leowski J, 1986, World Health Stat Q, V39, P138; MANTEL N, 1968, BIOMETRICS, V24, P997, DOI 10.2307/2528886; MARTORELL R, 1975, AM J DIS CHILD, V129, P1296, DOI 10.1001/archpedi.1975.02120480022007; Martorell R, 1984, POPUL DEV REV, V10, P49, DOI 10.2307/2807955; MCCORD C, 1978, TROP DOCT, V8, P220, DOI 10.1177/004947557800800420; MOSLEY WH, 1988, CHILD SURVIVAL PROGR; MTANGO FDE, 1986, T ROY SOC TROP MED H, V80, P851, DOI 10.1016/0035-9203(86)90241-5; PANDEY MR, 1989, ANN TROP PAEDIATR, V9, P212, DOI 10.1080/02724936.1989.11748635; ROWLAND MGM, 1988, AM J CLIN NUTR, V47, P134, DOI 10.1093/ajcn/47.1.134; SELWYN BJ, 1990, REV INFECT DIS, V12, pS870; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; SHRESTHA MP, 1982, JUMLA COMMUNITY HLTH; ZUMRAWI FY, 1987, HUM NUTR-CLIN NUTR, V41C, P453; 1985, WHORSD85151985 DOC; 1990, WHOARI9051990 DOC; 1986, WHORSD8515REV21686 D; 1990, RATIONAL USE DRUGS M	25	90	90	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	1991	338	8773					993	997		10.1016/0140-6736(91)91847-N	http://dx.doi.org/10.1016/0140-6736(91)91847-N			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK974	1681351				2022-12-24	WOS:A1991GK97400013
J	HOLLOWELL, JG; HILL, PD; DUFFY, PG; RANSLEY, PG				HOLLOWELL, JG; HILL, PD; DUFFY, PG; RANSLEY, PG			BLADDER FUNCTION AND DYSFUNCTION IN EXSTROPHY AND EPISPADIAS	LANCET			English	Article								Bladder exstrophy and epispadias are congenital abnormalities of the urinary bladder. Evaluation of bladder function before and after bladder-neck reconstruction has not been done in patients with these conditions. We report the preliminary results of a prospective study of lower-urinary-tract function in 36 children (10 girls, 26 boys; age range 1.5-16 years) with bladder exstrophy and epispadias. Children's bladder function was measured by cystometry and cystography, and their upper urinary tracts were examined by ultrasound imaging. Normal bladder function was seen in children with primary epispadias but this was severely impaired in children who had had conventional bladder-neck surgery for continence, implying that this may not be the optimal treatment. Contrary to current assumption, children with closed exstrophy bladders are not capable of normal function, and the abnormalities we identified may be a major cause of upper-urinary-tract damage and may impair development of bladder capacity. Although unrecognised in the past, involuntary bladder contractions are a primary cause of urine leakage persisting in children with exstrophy and epispadias after continence surgery. Detailed functional testing should become a routine part of the evaluation of children with exstrophy and epispadias.	HOSP SICK CHILDREN,DEPT UROL,LONDON WC1N 3JL,ENGLAND; ST PETERS HOSP,DEPT PAEDIAT UROL,LONDON WC2A 2EX,ENGLAND; ST PETERS HOSP,DEPT MED PHYS,LONDON WC2A 2EX,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of London; University College London								ANSELL JS, 1979, J UROLOGY, V121, P650, DOI 10.1016/S0022-5347(17)56924-4; BLOOM DA, 1991, DIAL PED UROL, V14, P2; DECTER RM, 1988, J UROLOGY, V140, P1202, DOI 10.1016/S0022-5347(17)42002-7; GEARHART JP, 1988, J UROLOGY, V139, P790, DOI 10.1016/S0022-5347(17)42639-5; HOLLOWELL JG, IN PRESS BR J UROL; JEFFS RD, 1986, CAMPELLS UROLOGY, V2, P1882; OSTERLING JE, 1987, J UROLOGY, V137, P258; RANSLEY PG, 1988, PAEDIAT SURG, P620	8	36	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					926	928		10.1016/0140-6736(91)91784-R	http://dx.doi.org/10.1016/0140-6736(91)91784-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681276				2022-12-24	WOS:A1991GJ89900014
J	LANG, DM; ALPERN, MB; VISINTAINER, PF; SMITH, ST				LANG, DM; ALPERN, MB; VISINTAINER, PF; SMITH, ST			INCREASED RISK FOR ANAPHYLACTOID REACTION FROM CONTRAST-MEDIA IN PATIENTS ON BETA-ADRENERGIC BLOCKERS OR WITH ASTHMA	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE REACTIONS; BLOCKADE; IMMUNOTHERAPY; ANTAGONISTS; HISTAMINE; HYPERSENSITIVITY; EPINEPHRINE; EXERCISE; RELEASE; AGENTS	Objective: To determine whether greater risk for anaphylactoid reaction from intravenous urographic contrast media exists in patients receiving beta-adrenergic blockers or in asthmatic patients. Design: Case-control study. Setting: Tertiary care, referral-based medical center. Patients: Of 28 978 intravenous urographic contrast media procedures done from July 1987 to June 1988, 49 patients experienced moderate to severe anaphylactoid reaction. Medical records from these 49 reactors were compared with those from a control group matched for gender, age, and date and type of contrast study who received intravenous urographic contrast media without adverse reaction. Main Results: Patients exposed to beta-adrenergic blockers or with asthma comprised 39% (19 of 49) of reactors, compared to 16% (13 of 83) of matched controls (odds ratio, 3.43; 95% Cl, 1.45 to 8.15; P = 0.005). Exposure to beta-blockers was 27% among reactors and 12% in matched controls (odds ratio, 2.67; Cl, 1.01 to 7.05; P = 0.036). Asthma was found in 12% of reactors and 4% of controls; after correction for beta-blocker use, asthma was also associated with increased risk for anaphylactoid reaction (odds ratio, 4.54; Cl, 1.03 to 20.05; P = 0.046). Compared with nonasthmatic patients not taking beta-blockers, asthmatic patients were at greater risk for anaphylactoid reaction with bronchospasm (P = 0.02). Five of 13 reactors receiving beta-blockers became hypotensive, and three needed hospitalization. Compared with nonasthmatic patients not taking beta-blockers, patients exposed to beta-blocking drugs were almost nine times (odds ratio, 8.7; Cl, 0.81 to 93.5; P = 0.075) more likely to be hospitalized after an anaphylactoid reaction. Conclusion: Increased risk for moderate to severe anaphylactoid reaction from intravenous urographic contrast media exists in patients receiving beta-adrenergic blockers or with asthma. These patients are appropriate target populations for efforts to reduce risk before intravenous urographic contrast media are administered.	HENRY FORD HOSP, DETROIT, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital				Visintainer, Paul/0000-0002-2491-1242				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ANSELL G, 1980, INVEST RADIOL, V15, pS32, DOI 10.1097/00004424-198011001-00010; AWAI LE, 1984, ANN ALLERGY, V53, P48; BARRETTBEE K, 1978, BIOCHEM BIOPH RES CO, V84, P998, DOI 10.1016/0006-291X(78)91682-0; BENITAH E, 1986, THERAPIE, V41, P139; BERKELMAN RL, 1986, ANN INTERN MED, V104, P134, DOI 10.7326/0003-4819-104-1-134_1; BUTCHERS PR, 1980, BRIT J PHARMACOL, V71, P663, DOI 10.1111/j.1476-5381.1980.tb10987.x; CAPELLIER G, 1989, PRESSE MED, V18, P181; CORNAILLE G, 1985, PRESSE MED, V14, P790; DAVIS PB, 1986, J ALLERGY CLIN IMMUN, V77, P667, DOI 10.1016/0091-6749(86)90406-9; ENRIGHT T, 1989, ANN ALLERGY, V62, P302; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FRISHMAN WH, 1988, MED CLIN N AM, V72, P37, DOI 10.1016/S0025-7125(16)30786-6; GREENBERGER PA, 1985, ARCH INTERN MED, V145, P2197, DOI 10.1001/archinte.145.12.2197; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V80, P698, DOI 10.1016/0091-6749(87)90290-9; HAAS F, 1988, AM REV RESPIR DIS, V137, P833, DOI 10.1164/ajrccm/137.4.833; HAMILTON G, 1985, CAN MED ASSOC J, V133, P122; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; HIATT WR, 1985, CLIN PHARMACOL THER, V37, P2, DOI 10.1038/clpt.1985.2; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; JACOBSON PD, 1988, JAMA-J AM MED ASSOC, V260, P1586, DOI 10.1001/jama.260.11.1586; KALIMO K, 1980, ANN ALLERGY, V45, P253; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KALINER M, 1984, INVEST RADIOL, V19, P116, DOI 10.1097/00004424-198403000-00007; KAPLAN AP, 1989, J ALLERGY CLIN IMMUN, V84, P129, DOI 10.1016/0091-6749(89)90186-3; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; KING BF, 1989, MAYO CLIN PROC, V64, P976, DOI 10.1016/S0025-6196(12)61226-9; KLEINBAUM DG, 1982, LIFETIME LEARNING PU, V53, P379; LARSSON K, 1985, EUR J RESPIR DIS, V66, P1; LASSER EC, 1977, RADIOLOGY, V125, P1; LAXENAIRE M C, 1984, Annales Francaises d'Anesthesie et de Reanimation, V3, P453, DOI 10.1016/S0750-7658(84)80146-X; LIEBERMAN P, 1986, CLIN REV ALLERG, V4, P229; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; MATSUMURA Y, 1976, J ALLERGY CLIN IMMUN, V58, P387, DOI 10.1016/0091-6749(76)90119-6; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MOTULSKY HJ, 1982, NEW ENGL J MED, V307, P18, DOI 10.1056/NEJM198207013070104; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; NISAM MR, 1978, J APPL PHYSIOL, V44, P455, DOI 10.1152/jappl.1978.44.3.455; PSATY BM, 1990, JAMA-J AM MED ASSOC, V263, P1653, DOI 10.1001/jama.263.12.1653; ROSENFIELD AT, 1977, INVEST RADIOL, V12, P295, DOI 10.1097/00004424-197705000-00016; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SHEREFF RH, 1973, J ALLERGY CLIN IMMUN, V52, P328, DOI 10.1016/0091-6749(73)90091-2; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; SULLIVAN TJ, 1988, CURRENT THERAPY ALLE, V3, P91; SVENTIVANYI A, 1968, J ALLERGY, V42, P203; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TOOGOOD JH, 1987, CAN MED ASSOC J, V136, P929; TUNG R, 1982, J IMMUNOL, V128, P2067; WILLIAMS ME, 1985, NEW ENGL J MED, V312, P823, DOI 10.1056/NEJM198503283121304; ZALOGA GP, 1986, ANN INTERN MED, V105, P65, DOI 10.7326/0003-4819-105-1-65; 1988, FDA DRUG B       NOV, P30	53	129	134	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					270	276		10.7326/0003-4819-115-4-270	http://dx.doi.org/10.7326/0003-4819-115-4-270			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1677239				2022-12-24	WOS:A1991GA76400005
J	SAMUEL, BU; CHERIAN, T; SRIDHARAN, G; MUKUNDAN, P; JOHN, TJ				SAMUEL, BU; CHERIAN, T; SRIDHARAN, G; MUKUNDAN, P; JOHN, TJ			IMMUNE-RESPONSE TO INTRADERMALLY INJECTED INACTIVATED POLIOVIRUS VACCINE	LANCET			English	Note							POLIOMYELITIS; IMMUNIZATION	Immune response to intradermal inoculation of a fractional dose of inactivated poliovirus vaccine (IPV) was measured in 8 adults and 10 children who were previously immune. A striking 4-fold to 1024-fold antibody booster response to all 3 poliovirus serotypes was found in 15 subjects and a similar response to 2 poliovirus serotypes occurred in the other 3 children. Induration and erythema of 3 mm diameter or above, indicative of a cell-mediated immune response, was seen in 12 subjects. Intradermal inoculation of IPV may be a useful technique for secondary immunisation programmes against polio and its use for primary immunisation merits investigation.	CHRISTIAN MED COLL & HOSP,INDIAN COUNCIL MED RES,CTR VIROL,VELLORE 632004,TAMIL NADU,INDIA	Christian Medical College & Hospital (CMCH) Vellore; Indian Council of Medical Research (ICMR)								BEALE AJ, 1990, LANCET, V335, P839, DOI 10.1016/0140-6736(90)90945-2; MCBEAN AM, 1987, PEDIATR INFECT DIS J, V6, P881, DOI 10.1097/00006454-198710000-00001; SULEKHA C, 1990, INT J EPIDEMIOL, V19, P177, DOI 10.1093/ije/19.1.177; TURK JL, 1980, RES MONOGRAPHS IMMUN, V1, P45	4	38	40	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					343	344		10.1016/0140-6736(91)90480-D	http://dx.doi.org/10.1016/0140-6736(91)90480-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677699				2022-12-24	WOS:A1991GA60700005
J	NAROD, SA; FEUNTEUN, J; LYNCH, HT; WATSON, P; CONWAY, T; LYNCH, J; LENOIR, GM				NAROD, SA; FEUNTEUN, J; LYNCH, HT; WATSON, P; CONWAY, T; LYNCH, J; LENOIR, GM			FAMILIAL BREAST-OVARIAN CANCER LOCUS ON CHROMOSOME-17Q12-Q23	LANCET			English	Note							LINKAGE ANALYSIS	Familial breast cancer has been linked to the D17S74 locus on chromosome 17q. To confirm this finding and to investigate whether ovarian cancer is also linked to this locus, five large families with a hereditary predisposition to cancer of the breast and ovary were investigated. Three families were positive for linkage. For the largest family the lod score was 2.72. These findings suggest that the chromosomal region 17q12-q23, previously shown to contain a gene for early-onset breast cancer, is also associated with a proportion of hereditary ovarian cancers.	INT AGCY RES CANC,150 COURS ALBERT THOMAS,F-69372 LYONS,FRANCE; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA; CREIGHTON UNIV,SCH MED,DEPT PREVENT MED,OMAHA,NE 68178; MCGILL UNIV,CTR HUMAN GENET,MONTREAL H3G 1A4,QUEBEC,CANADA; INST GUSTAVE ROUSSY,CNRS,UA 1158,F-94805 VILLEJUIF,FRANCE	World Health Organization; International Agency for Research on Cancer (IARC); McGill University; McGill University; Creighton University; McGill University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Feunteun, Jean/AAZ-1267-2020; Narod, Steven A/AAA-6112-2022	Feunteun, Jean/0000-0003-1212-9189				BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; FERRELL RE, 1989, CANCER GENET CYTOGEN, V38, P241, DOI 10.1016/0165-4608(89)90665-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LYNCH HT, 1981, GENETICS BREAST CANC; Nakamura Y, 1988, GENOMICS, V2, P302, DOI 10.1016/0888-7543(88)90018-3; NAROD SA, 1989, HUM GENET, V83, P353, DOI 10.1007/BF00291380; OTT J, 1985, ANAL HUMAN GENETIC L; ROBERTSON M, 1989, NATURE, V342, P222, DOI 10.1038/342222a0	10	523	536	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					82	83						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676470				2022-12-24	WOS:A1991FW16100005
J	HUTCHINSON, CM; WILSON, C; REICHART, CA; MARSIGLIA, VC; ZENILMAN, JM; HOOK, EW				HUTCHINSON, CM; WILSON, C; REICHART, CA; MARSIGLIA, VC; ZENILMAN, JM; HOOK, EW			LYMPHOCYTE-CD4 CONCENTRATIONS IN PATIENTS WITH NEWLY IDENTIFIED HIV-INFECTION ATTENDING STD CLINICS - POTENTIAL IMPACT ON PUBLICLY FUNDED HEALTH-CARE RESOURCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; HOMOSEXUAL MEN; SEXUAL-BEHAVIOR; UNITED-STATES; MEDICAL-CARE; AIDS; COHORT; ANTIBODY; COSTS	Since January 1990, human immunodeficiency virus (HIV)-infected patients attending two sexually transmitted disease clinics in Baltimore, Md, have been offered T-lymphocyte subset evaluations. From January through September, CD4+ lymphocyte concentrations were measured in 223 newly diagnosed HIV-infected patients; 50% had fewer than 500 CD4+ T cells and 12% had fewer than 200 CD4+ T cells per cubic millimeter. Most patients were asymptomatic, and, even among patients with fewer than 200 CD4+ T cells, 54% had no symptoms or signs suggestive of advanced HIV infection. Homosexually active men had significantly lower mean CD4+ lymphocyte concentrations than intravenous drug users. Given the substantial numbers of patients with CD4+ concentrations that qualified them for zidovudine therapy, we also assessed their mechanisms of paying for health care. Only 24% of HIV-infected patients had private insurance. Seventy-two percent of patients with fewer than 200 CD4+ T cells either had no insurance or relied on public assistance for health care. Thus, although 50% of asymptomatic individuals identified by routine voluntary HIV screening in an inner-city sexually transmitted disease clinic may benefit from therapy for their disease, 75% of those qualifying for presently recommended therapy either depend on publicly funded health care or have no means of payment for care.	JOHNS HOPKINS UNIV HOSP,DEPT MED,600 N WOLFE ST,BALTIMORE,MD 21205; BALTIMORE MARYLAND CITY HLTH DEPT,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University								ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; BUCHANAN RJ, 1988, AM J PUBLIC HEALTH, V78, P462; CATES W, 1988, AM J PUBLIC HEALTH, V78, P1533, DOI 10.2105/AJPH.78.12.1533; CHEUNG TW, 1990, JAMA-J AM MED ASSOC, V263, P1067, DOI 10.1001/jama.1990.03440080039013; COATES T, 1988, AIDS S1, V2, P239; DROTMAN DP, 1989, ANN INTERN MED, V110, P680, DOI 10.7326/0003-4819-110-9-680; ERICKSON B, 1990, SEX TRANSM DIS, V17, P194, DOI 10.1097/00007435-199010000-00009; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; FOX R, 1987, AIDS, V1, P241; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; GIORGI JV, 1989, CLIN IMMUNOL IMMUNOP, V52, P10, DOI 10.1016/0090-1229(89)90188-8; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GOEDERT JJ, 1984, LANCET, V2, P711; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; JACOBSEN PB, 1990, J CONSULT CLIN PSYCH, V58, P31, DOI 10.1037/0022-006X.58.1.31; LO B, 1989, ANN INTERN MED, V110, P727; MAKADON HJ, 1990, J ACQ IMMUN DEF SYND, V3, P123; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; QUINN TC, 1990, ARCH INTERN MED, V150, P1297, DOI 10.1001/archinte.150.6.1297; RANGO NA, 1990, NEW YORK STATE J MED, V90, P116; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; ROGERS MF, 1983, ANN INTERN MED, V99, P151, DOI 10.7326/0003-4819-99-2-151; SCHECHTER MT, 1988, AM J PUBLIC HEALTH, V78, P1535, DOI 10.2105/AJPH.78.12.1535; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; SCITOVSKY AA, 1990, J ACQ IMMUN DEF SYND, V3, P904; STEVENS CE, 1986, JAMA-J AM MED ASSOC, V255, P2167, DOI 10.1001/jama.255.16.2167; VANGRIENSVEN GJP, 1988, AM J PUBLIC HEALTH, V78, P1575, DOI 10.2105/AJPH.78.12.1575; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZENILMAN JM, 1990, 30TH INT C ANT AG CH; 1990, AM J MED, V89, P335; 1990, MMWR, V39, P137; 1989, MMWR, V381, P1; [No title captured]; 1990, MMWR, V39, P1	41	27	27	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					253	256		10.1001/jama.266.2.253	http://dx.doi.org/10.1001/jama.266.2.253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FU896	1676076				2022-12-24	WOS:A1991FU89600035
J	HATANO, M; ROBERTS, CWM; MINDEN, M; CRIST, WM; KORSMEYER, SJ				HATANO, M; ROBERTS, CWM; MINDEN, M; CRIST, WM; KORSMEYER, SJ			DEREGULATION OF A HOMEOBOX GENE, HOX11, BY THE T(10-14) IN T-CELL LEUKEMIA	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING MOTIF; CHROMOSOME-TRANSLOCATION; MESSENGER-RNA; PROTEINS; SEQUENCE; DROSOPHILA; REGION; HELIX; BREAKPOINTS	Molecular cloning of the t(10;14)(q24;q11) recurrent breakpoint of T cell acute lymphoblastic leukemia has demonstrated a transcript for the candidate gene TCL3. Characterization of this gene from chromosome segment l0q24 revealed it to be a new homeobox, HOX11. The HOX11 homeodomain is most similar to that of the murine gene Hlx and possesses a markedly glycine-rich variable region and an acidic carboxyl terminus. HOX11, while expressed in liver, was not detected in normal thymus or T cells. This lineage-restricted homeobox gene is deregulated upon translocation into the T cell receptor locus where it may act as an oncogene.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; PEDIAT ONCOL GRP, ST LOUIS, MO USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Roberts, Charles/N-2541-2018	Roberts, Charles/0000-0003-1135-1896	NATIONAL CANCER INSTITUTE [U10CA030969, P01CA049712, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 30969, CA 21765, 1 PO1 CA49712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; BAKHSHI A, 1985, CELL, V41, P89; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUBE ID, 1986, BLOOD, V67, P1181; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HANES S, 1990, CELL, V57, P1275; HATANO M, UNPUB; HAVILAND DL, 1991, J IMMUNOL, V146, P362; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; MAUILIO F, 1986, NATURE, V324, P664; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RAIMONDI SC, 1988, BLOOD, V72, P1560; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VISVADER J, 1991, ONCOGENE, V6, P187; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	43	392	397	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	1991	253	5015					79	82		10.1126/science.1676542	http://dx.doi.org/10.1126/science.1676542			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1676542				2022-12-24	WOS:A1991FV17700039
J	PRICE, M; LEMAISTRE, M; PISCHETOLA, M; DILAURO, R; DUBOULE, D				PRICE, M; LEMAISTRE, M; PISCHETOLA, M; DILAURO, R; DUBOULE, D			A MOUSE GENE RELATED TO DISTAL-LESS SHOWS A RESTRICTED EXPRESSION IN THE DEVELOPING FOREBRAIN	NATURE			English	Article							LIMB DEVELOPMENT; DROSOPHILA; MURINE; HOMEODOMAIN; EMBRYOGENESIS; ORGANIZATION; HINDBRAIN; PATTERN; EN-1	MANY genes known to be involved in embryogenesis and morphogenesis of the fruitfly Drosophila melanogaster encode proteins with a highly conserved region of 60 amino acids called the homeodomain 1. Mammalian counterparts for most of these genes have been identified, including those homologous to the Drosophila homeotic genes 2,3 or to genes such as evenskipped 4, engrailed 5,6 or caudal 7. We have isolated a murine homeobox gene that encodes a homeodomain similar to that encoded by the Drosophila Distalless (Dll) gene 8. Dll has a crucial role in Drosophila limb morphogenesis, partially specifying pattern along the proximo-distal axis of the limb 8,9. The murine counterpart is expressed in a restricted region of the developing brain, within the diencephalon and the adjacent telencephalic regions.			PRICE, M (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,W-6900 HEIDELBERG,GERMANY.		Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; duboule, denis/0000-0001-9961-2960				BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; GAUNT SJ, 1988, DEVELOPMENT S, V104, P71; GLOVER DM, 1989, DNA CLONING PRACTICA; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; LUMSDEN A, 1990, TRENDS NEUROSCI, V8, P335; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; Niimi K, 1962, TOKUSHIMA J EXP MED, V8, P203; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; RUGH R, 1968, MOUSE ITS REPRODUCTI; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; WILKINSON DG, 1990, TRENDS NEUROSCI, V13, P335, DOI 10.1016/0166-2236(90)90145-Z; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	22	276	286	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					748	751		10.1038/351748a0	http://dx.doi.org/10.1038/351748a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1676488				2022-12-24	WOS:A1991FU20100065
J	[Anonymous]				[Anonymous]			HIV IN CHILDREN	LANCET			English	Editorial Material																		HONIGSBAUM N, 1991, HIV AIDS CHILDREN; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; 1991, JAMA-J AM MED ASSOC, V265, P1637; 1991, LANCET, V337, P253	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1030	1030						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673180				2022-12-24	WOS:A1991FJ13500019
J	PICARDO, M; SCHOR, SL; GREY, AM; HOWELL, A; LAIDLAW, I; REDFORD, J; SCHOR, AM				PICARDO, M; SCHOR, SL; GREY, AM; HOWELL, A; LAIDLAW, I; REDFORD, J; SCHOR, AM			MIGRATION STIMULATING ACTIVITY IN SERUM OF BREAST-CANCER PATIENTS	LANCET			English	Article							FIBROBLAST PHENOTYPE; SKIN FIBROBLASTS; SCATTER FACTOR; FETAL; COLLAGEN; PURIFICATION; CELLS	An assay to measure the ability to stimulate migration of fibroblasts into collagen gel was carried out on serum from treated and untreated breast cancer patients and from healthy controls. Migration stimulating activity was found in the serum of 10 (83%) of 12 untreated breast cancer patients immediately before surgical resection of the primary tumour and in 9 (75%) of them 4 days after resection; in 13 (93%) of 14 patients 1-13 years after tumour resection who had received adjuvant treatment; and in 2 (10%) of 20 healthy women matched for age. The migration stimulating activity in cancer patients' serum was indistinguishable from the migration stimulating factor produced in vitro by fetal and cancer patient skin fibroblasts in its behaviour in various biochemical fractionation procedures. The presence of this activity in the serum of treated breast cancer patients clearly distinguishes it from other oncofetal proteins, which all seem to be produced by tumours.	UNIV MANCHESTER,DEPT CELL & STRUCT BIOL,COUPLAND 3 BLDG,MANCHESTER M13 9PL,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND	University of Manchester; Christie NHS Foundation Trust; Christie Hospital				Howell, Anthony/0000-0002-6233-719X				AZZARONE B, 1984, INT J CANCER, V33, P759, DOI 10.1002/ijc.2910330608; DECKER M, 1989, CANCER RES, V49, P3499; DURNING P, 1984, LANCET, V1, P890; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; HAGGIE J, 1987, LANCET, V1, P1477; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; OTTMAN R, 1983, LANCET, V2, P556; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P1079; SCHOR SL, 1985, J CELL SCI, V73, P235; SCHOR SL, 1979, J CELL SCI, V38, P267; SCHOR SL, 1987, BIOESSAYS, V7, P200, DOI 10.1002/bies.950070503; SCHOR SL, 1988, J CELL SCI, V90, P391; SCHOR SL, 1980, J CELL SCI, V41, P159; SCHOR SL, 1987, EXP CELL BIOL, V55, P11; SCHOR SL, 1986, INT J CANCER, V37, P831, DOI 10.1002/ijc.2910370606; SCHOR SL, 1987, BREAST CANCER SCI CL, P142; SCHOR SL, 1988, IN VITRO CELL DEV, V25, P137; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WARN RM, 1989, NATURE, V340, P186, DOI 10.1038/340186a0	20	19	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					130	133		10.1016/0140-6736(91)90798-T	http://dx.doi.org/10.1016/0140-6736(91)90798-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670786				2022-12-24	WOS:A1991ET67900002
J	SPRENT, J; GAO, EK; WEBB, SR				SPRENT, J; GAO, EK; WEBB, SR			T-CELL REACTIVITY TO MHC MOLECULES - IMMUNITY VERSUS TOLERANCE	SCIENCE			English	Article											SPRENT, J (corresponding author), SCRIPPS CLIN & RES FDN,RES INST,DEPT IMMUNOL,LA JOLLA,CA 92037, USA.				NATIONAL CANCER INSTITUTE [R37CA038355, R01CA038355, P01CA025803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021487] Funding Source: NIH RePORTER; NCI NIH HHS [CA38355, CA25803] Funding Source: Medline; NIAID NIH HHS [AI21487] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE R, 1989, ANNU REV IMMUNOL, V7, P683, DOI 10.1146/annurev.iy.07.040189.003343; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BURGERT HG, 1989, J EXP MED, V170, P1887, DOI 10.1084/jem.170.6.1887; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; BYRNE JA, 1988, J IMMUNOL, V141, P3249; Carbone F. R., 1989, Fundamental immunology., P541; CROUSE DA, 1985, SURV IMMUNOL RES, V4, P120; DEWAAL LP, 1981, EUR J IMMUNOL, V11, P258, DOI 10.1002/eji.1830110317; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FINK P, 1978, IMMUNOL REV, V42, P3; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FORD WL, 1975, PROG ALLERGY, V19, P1, DOI 10.1159/000313381; GAO EK, 1990, J EXP MED, V171, P1101, DOI 10.1084/jem.171.4.1101; GAO EK, 1989, J EXP MED, V170, P1947, DOI 10.1084/jem.170.6.1947; GAO EK, UNPUB; HAAS W, 1984, EUR J IMMUNOL, V14, P383, DOI 10.1002/eji.1830140421; JANEWAY C, 1989, IMMUNOL REV, V109, P59; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JENKINSON EJ, 1985, TRANSPLANTATION, V39, P331, DOI 10.1097/00007890-198503000-00030; JENKINSON EJ, 1982, EUR J IMMUNOL, V12, P583, DOI 10.1002/eji.1830120710; KANAGAWA O, 1989, J EXP MED, V170, P901, DOI 10.1084/jem.170.3.901; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P119; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; MILLER RG, 1986, IMMUNOL TODAY, V7, P112, DOI 10.1016/0167-5699(86)90151-9; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OTTEN G, 1986, EUR J IMMUNOL, V16, P217, DOI 10.1002/eji.1830160302; PARKIN IG, 1988, IMMUNOLOGY, V64, P97; PIERRES A, 1984, J IMMUNOL, V132, P2775; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; ROSENBERG AS, 1987, J EXP MED, V165, P1296, DOI 10.1084/jem.165.5.1296; SCHUURMAN HJ, 1986, J IMMUNOL, V137, P2440; SCOLLAY R, 1985, RECOGNITION REGULATI, P3; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHIMONKEVITZ RP, 1988, J EXP MED, V168, P143, DOI 10.1084/jem.168.1.143; SINGER A, 1987, IMMUNOL REV, V98, P143, DOI 10.1111/j.1600-065X.1987.tb00523.x; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SPRENT J, 1990, J IMMUNOL, V144, P2946; SPRENT J, 1986, J EXP MED, V163, P998, DOI 10.1084/jem.163.4.998; SPRENT J, 1971, CELL IMMUNOL, V2, P171, DOI 10.1016/0008-8749(71)90036-0; SPRENT J, 1988, J EXP MED, V167, P556, DOI 10.1084/jem.167.2.556; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; SPRENT J, 1978, IMMUNOL REV, V42, P108, DOI 10.1111/j.1600-065X.1978.tb00260.x; SPRENT J, 1985, J EXP MED, V162, P2068, DOI 10.1084/jem.162.6.2068; SPRENT J, 1976, CELL IMMUNOL, V21, P278, DOI 10.1016/0008-8749(76)90057-5; SPRENT J, UNPUB; STEINMAN RM, 1983, J EXP MED, V157, P613, DOI 10.1084/jem.157.2.613; VONBOEHMER H, 1984, EUR J IMMUNOL, V14, P1048, DOI 10.1002/eji.1830141116; VONBOEHMER H, 1989, IMMUNOL TODAY, V10, P57, DOI 10.1016/0167-5699(89)90307-1; WEBB SR, 1989, IMMUNOL REV, V107, P141, DOI 10.1111/j.1600-065X.1989.tb00007.x; WEBB SR, 1990, J EXP MED, V171, P953, DOI 10.1084/jem.171.3.953; WEBB SR, UNPUB; WIDERA G, 1987, CELL, V51, P175, DOI 10.1016/0092-8674(87)90145-0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	71	153	153	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 15	1990	248	4961					1357	1363		10.1126/science.1694041	http://dx.doi.org/10.1126/science.1694041			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ501	1694041				2022-12-24	WOS:A1990DJ50100029
J	STALEY, JP; KIM, PS				STALEY, JP; KIM, PS			ROLE OF A SUBDOMAIN IN THE FOLDING OF BOVINE PANCREATIC TRYPSIN-INHIBITOR	NATURE			English	Article									MIT,DEPT BIOL,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	STALEY, JP (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.							CREIGHTON TE, 1974, J MOL BIOL, V87, P603, DOI 10.1016/0022-2836(74)90106-5; CREIGHTON TE, 1981, J MOL BIOL, V151, P211, DOI 10.1016/0022-2836(81)90230-8; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1977, J MOL BIOL, V113, P313, DOI 10.1016/0022-2836(77)90144-9; CREIGHTON TE, 1974, J MOL BIOL, V87, P579, DOI 10.1016/0022-2836(74)90105-3; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; DEMARCO A, 1977, J MAGN RESON, V26, P527, DOI 10.1016/0022-2364(77)90104-4; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EIGENBROT C, UNPUB PROTEIN ENG; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GOLDENBERG DP, 1984, J MOL BIOL, V179, P527, DOI 10.1016/0022-2836(84)90078-0; GOODMAN EM, IN PRESS CURRENT RES; LESK AM, 1981, P NATL ACAD SCI-BIOL, V78, P4304, DOI 10.1073/pnas.78.7.4304; MARKS CB, 1987, PROTEIN STRUCTURE FO, V2, P335; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; PARDI A, 1983, EUR J BIOCHEM, V137, P445, DOI 10.1111/j.1432-1033.1983.tb07848.x; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P359; ROSEN H, 1957, ARCH BIOCHEM BIOPHYS, V67, P10, DOI 10.1016/0003-9861(57)90241-2; STATES DJ, 1980, NATURE, V286, P630, DOI 10.1038/286630a0; STATES DJ, 1987, J MOL BIOL, V195, P731, DOI 10.1016/0022-2836(87)90192-6; STATES DJ, 1984, J MOL BIOL, V174, P411, DOI 10.1016/0022-2836(84)90345-0; WAGNER G, 1987, J MOL BIOL, V196, P227, DOI 10.1016/0022-2836(87)90524-9; WAGNER G, 1976, BIOPHYS STRUCT MECH, V2, P139, DOI 10.1007/BF00863706; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; WLODAWER A, 1987, J MOL BIOL, V198, P469, DOI 10.1016/0022-2836(87)90294-4	27	110	110	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 12	1990	344	6267					685	688		10.1038/344685a0	http://dx.doi.org/10.1038/344685a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY719	1691452				2022-12-24	WOS:A1990CY71900095
J	ROSENGARTEN, R; WISE, KS				ROSENGARTEN, R; WISE, KS			PHENOTYPIC SWITCHING IN MYCOPLASMAS - PHASE VARIATION OF DIVERSE SURFACE LIPOPROTEINS	SCIENCE			English	Article											ROSENGARTEN, R (corresponding author), UNIV MISSOURI,DEPT MOLEC MICROBIOL & IMMUNOL,COLUMBIA,MO 65212, USA.							ANDERSEN H, 1987, J GEN MICROBIOL, V133, P181; Barile MF, 1979, MYCOPLASMAS, V2, P425; BOYER MJ, 1989, INFECT IMMUN, V57, P245, DOI 10.1128/IAI.57.1.245-254.1989; BRICKER TM, 1988, INFECT IMMUN, V56, P295, DOI 10.1128/IAI.56.2.295-301.1988; DEEB BJ, 1967, J BACTERIOL, V93, P1416, DOI 10.1128/JB.93.4.1416-1424.1967; DELGIUDICE RA, 1980, CURR MICROBIOL, V4, P75, DOI 10.1007/BF02602896; DONELSON JE, 1989, MOBILE DNA, P763; DUNCAN JR, 1978, AM J VET RES, V34, P363; FERRELL RV, 1989, MOL MICROBIOL, V3, P957, DOI 10.1111/j.1365-2958.1989.tb00245.x; GOIS M, 1974, J MED MICROBIOL, V7, P105, DOI 10.1099/00222615-7-1-105; GOURLAY RN, 1983, ARCH VIROL, V77, P81, DOI 10.1007/BF01314867; HAY RJ, 1989, NATURE, V339, P487, DOI 10.1038/339487a0; HAYASHI R, 1973, J BIOL CHEM, V248, P2296; KOTANI H, 1986, J CLIN MICROBIOL, V23, P783, DOI 10.1128/JCM.23.4.783-785.1986; KRAUSE DC, 1983, INFECT IMMUN, V39, P830, DOI 10.1128/IAI.39.2.830-836.1983; LISS A, 1983, INFECT IMMUN, V41, P1245, DOI 10.1128/IAI.41.3.1245-1251.1983; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; ROSENGARTEN R, UNPUB; ROSS RF, 1973, ANN NY ACAD SCI, V225, P347, DOI 10.1111/j.1749-6632.1973.tb45662.x; SEIFERT HS, 1988, MICROBIOL REV, V52, P327, DOI 10.1128/MMBR.52.3.327-336.1988; SOLL DR, 1989, MOBILE DNA, P791; STOCKER BAD, 1949, J HYG-CAMBRIDGE, V47, P398, DOI 10.1017/S002217240001473X; Tully J.G., 1983, METHODS MYCOPLASMOLO, P173; VALDIVIESOGARCIA A, 1982, VET REC, V110, P470, DOI 10.1136/vr.110.20.470; WATSON HL, 1988, INFECT IMMUN, V56, P1358, DOI 10.1128/IAI.56.5.1358-1363.1988; WHITTLESTONE P, 1979, MYCOPLASMAS, V2, P133; WOODS JP, 1989, MOL MICROBIOL, V3, P43, DOI 10.1111/j.1365-2958.1989.tb00102.x; WU HC, 1986, CURR TOP MICROBIOL, V125, P127	28	134	138	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1990	247	4940					315	318		10.1126/science.1688663	http://dx.doi.org/10.1126/science.1688663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ669	1688663				2022-12-24	WOS:A1990CJ66900033
J	RIGAU, J; PIQUE, JM; RUBIO, E; PLANAS, R; TARRECH, JM; BORDAS, JM				RIGAU, J; PIQUE, JM; RUBIO, E; PLANAS, R; TARRECH, JM; BORDAS, JM			EFFECTS OF LONG-TERM SULINDAC THERAPY ON COLONIC POLYPOSIS	ANNALS OF INTERNAL MEDICINE			English	Note									BARCELONA UNIV, HOSP CLIN, DEPT GASTROENTEROL, VILLARROEL 170, E-08036 BARCELONA, SPAIN; HOSP GERMANS TRIAS & PUJOL BADALONA, DEPT GASTROENTEROL, BADALONA, SPAIN; HOSP GEN GRANOLLERS, DEPT MED, GRANOLLERS, SPAIN; HOSP GEN GRANOLLERS, DEPT SURG, GRANOLLERS, SPAIN	University of Barcelona; Hospital Germans Trias i Pujol								BENGOECHEA O, 1987, AM J SURG PATHOL, V11, P323, DOI 10.1097/00000478-198704000-00010; CAPPELL MS, 1989, DIS COLON RECTUM, V32, P641, DOI 10.1007/BF02555767; GONZAGA RAF, 1985, LANCET, V1, P751; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; NICHOLLS RJ, 1988, BRIT MED J, V296, P1707, DOI 10.1136/bmj.296.6638.1707-a; NICHOLSON ML, 1991, GUT, V32, P413, DOI 10.1136/gut.32.4.413; SAPERAS E, 1990, AM J GASTROENTEROL, V85, P138; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119	10	210	218	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1991	115	12					952	954		10.7326/0003-4819-115-12-952	http://dx.doi.org/10.7326/0003-4819-115-12-952			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU417	1659272				2022-12-24	WOS:A1991GU41700007
J	CAIRNS, HS; LEAKER, B; WOODHOUSE, CRJ; RUDGE, CJ; NEILD, GH				CAIRNS, HS; LEAKER, B; WOODHOUSE, CRJ; RUDGE, CJ; NEILD, GH			RENAL-TRANSPLANTATION INTO ABNORMAL LOWER URINARY-TRACT	LANCET			English	Article							ILEAL CONDUITS; DIVERSION; CHILDREN; FATE	Because doubts remain about the safety and efficacy of renal transplantation for patients with primary urological abnormalities, we have studied the outcome of transplantation in a large group of such patients. Between 1977 and 1989, 69 renal transplants were completed in 62 patients with abnormal lower urinary tracts (29 primary vesicoureteric reflux, 13 posterior urethral valves or bladder outflow obstruction, 6 vesicoureteric tuberculosis, 5 neuropathic bladders, and 9 miscellaneous causes). Graft survival in this urological group was similar to that in 150 allograft recipients (157 grafts) with end-stage renal failure of a non-urological cause. No aetiological subgroup had poorer graft survival than the others, although patients with recurrent urinary-tract infections and a history of outflow obstruction tended to have worse graft function. 9 patients (10 transplants) had renal transplantation into a urinary diversion (8 ileal conduits, 1 rectal bladder). These patients had graft survival and renal function comparable with those of the whole urological group. We found no effect of immunosuppressive treatment (cyclosporin or azathioprine), type of kidney donor (living or cadaveric), or donor or recipient age on graft survival time or renal function. Thus, renal transplantation in patients with abnormal lower urinary tracts is safe and effective; patients with ileal conduits do well and have few substantial difficulties. Preoperative assessment of bladder emptying and urodynamics are important in these patients.	UNIV LONDON UNIV COLL,INST UROL & NEPHROL,LONDON WC1E 6BT,ENGLAND	University of London; University College London			Neild, Guy/K-2513-2013					BARNETT M, 1985, J UROLOGY, V134, P654, DOI 10.1016/S0022-5347(17)47370-8; CHURCHILL BM, 1988, J UROLOGY, V140, P1129, DOI 10.1016/S0022-5347(17)41979-3; DUNN M, 1979, BRIT J UROL, V51, P458, DOI 10.1111/j.1464-410X.1979.tb03578.x; GLASS NR, 1985, J UROLOGY, V133, P666, DOI 10.1016/S0022-5347(17)49137-3; MACGREGOR P, 1986, J UROLOGY, V135, P686, DOI 10.1016/S0022-5347(17)45819-8; PITTS WR, 1979, J UROLOGY, V122, P154; REINBERG Y, 1988, J UROLOGY, V140, P1491, DOI 10.1016/S0022-5347(17)42082-9; SCHWARZ GR, 1975, J UROLOGY, V114, P285, DOI 10.1016/S0022-5347(17)67009-5; SHAPIRO SR, 1975, J UROLOGY, V114, P289, DOI 10.1016/S0022-5347(17)67010-1	9	47	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1991	338	8779					1376	1379		10.1016/0140-6736(91)92247-Y	http://dx.doi.org/10.1016/0140-6736(91)92247-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682747				2022-12-24	WOS:A1991GR77300014
J	OKAMOTO, T; MURAYAMA, Y; HAYASHI, Y; INAGAKI, M; OGATA, E; NISHIMOTO, I				OKAMOTO, T; MURAYAMA, Y; HAYASHI, Y; INAGAKI, M; OGATA, E; NISHIMOTO, I			IDENTIFICATION OF A GS ACTIVATOR REGION OF THE BETA-2-ADRENERGIC RECEPTOR THAT IS AUTOREGULATED VIA PROTEIN KINASE-A-DEPENDENT PHOSPHORYLATION	CELL			English	Article							BETA-ADRENERGIC-RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTOR; GTP-BINDING PROTEINS; GROWTH FACTOR-II; ADENYLATE-CYCLASE; PHOSPHOLIPID-VESICLES; DISTINCT PATHWAYS; PERTUSSIS-TOXIN; LYMPHOMA-CELLS; BASIC RESIDUES	We have localized a G protein activator region of the human beta-2-adrenergic receptor to region beta-III-2 (from Arg259 to Lys273). The synthetic beta-III-2, corresponding to the C-terminal end of the third cytoplasmic loop, activates G(s) at nanomolar concentrations and weakly activates G(i). Beta-III-2 activates adenylyl cyclase at nanomolar concentrations in wild-type S49 lymphoma membranes, but not in membranes of unc mutant S49 cells, in which G(s) is uncoupled from beta-adrenergic stimulation. Phosphorylation of beta-III-2 by cAMP-dependent protein kinase A, which is involved in the desensitization of the beta-adrenergic receptor from G(s), drastically reduces the effect of beta-III-2 on G(s) while potentiating its action on G(i), resulting in a total loss of adenylyl cyclase-stimulating activity. These findings indicate that this receptor sequence is a multipotential G protein activator whose G protein specificity is regulated by protein kinase A.	SUNTORY BIOMED CTR,TOKYO,GUMMA 37005,JAPAN; AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Suntory Holdings Ltd; Aichi Cancer Center	OKAMOTO, T (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,LIFE SCI LAB,BUNKYO KU,TOKYO 113,JAPAN.		Inagaki, Masaki/B-9920-2016					ABRAMSON SN, 1985, J BIOL CHEM, V260, P4580; ASANO T, 1984, J BIOL CHEM, V259, P9351; Beavo J A, 1974, Methods Enzymol, V38, P299; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BLAKE AD, 1987, BIOCHEM BIOPH RES CO, V147, P168, DOI 10.1016/S0006-291X(87)80102-X; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CLARK RB, 1986, BIOCHEM J, V235, P399, DOI 10.1042/bj2350399; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HILDEBRANDT JD, 1982, J BIOL CHEM, V257, P4723; HOUSE C, 1987, J BIOL CHEM, V262, P772; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; MORISHITA R, 1990, BIOCHEM BIOPH RES CO, V172, P249, DOI 10.1016/S0006-291X(05)80201-3; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; ROSS EM, 1977, P NATL ACAD SCI USA, V74, P3715, DOI 10.1073/pnas.74.9.3715; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WONG SKF, 1990, J BIOL CHEM, V265, P6219	38	256	266	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					723	730		10.1016/0092-8674(91)90067-9	http://dx.doi.org/10.1016/0092-8674(91)90067-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657404				2022-12-24	WOS:A1991GQ40700009
J	REBAY, I; FLEMING, RJ; FEHON, RG; CHERBAS, L; CHERBAS, P; ARTAVANISTSAKONAS, S				REBAY, I; FLEMING, RJ; FEHON, RG; CHERBAS, L; CHERBAS, P; ARTAVANISTSAKONAS, S			SPECIFIC EGF REPEATS OF NOTCH MEDIATE INTERACTIONS WITH DELTA AND SERRATE - IMPLICATIONS FOR NOTCH AS A MULTIFUNCTIONAL RECEPTOR	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; GAMMA-CARBOXYGLUTAMIC ACID; NEURONAL PRECURSOR CELLS; NEUROGENIC LOCUS NOTCH; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE PROTEIN; NEGATIVE COMPLEMENTATION; GENETIC INTERACTIONS; LDL RECEPTOR; FACTOR-IX	The neurogenic loci Notch and Delta, which both encode EGF-homologous transmembrane proteins, appear to function together in mediating cell-cell communication and have been shown to interact at the cell surface in vitro. To examine the role of the EGF repeats in this interaction, we performed an extensive deletion mutagenesis of the extracellular domain of Notch. We find that of the 36 EGF repeats of Notch, only two, 11 and 12, are both necessary and sufficient to mediate interactions with Delta. Furthermore, this Delta binding ability is conserved in the corresponding two repeats from the Xenopus Notch homolog. We report a novel molecular interaction between Notch and Serrate, another EGF-homologous transmembrane protein containing a region of striking similarity to Delta, and show that the same two EGF repeats of Notch also constitute a Serrate binding domain. These results suggest that Notch may act as a multifunctional receptor whose 36 EGF repeats form a tandem array of discrete ligand-binding units, each of which may potentially interact with several different proteins during development.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511; INDIANA UNIV,DEPT BIOL,PROGRAM MOLEC CELLULAR & DEV BIOL,BLOOMINGTON,IN 47405	Yale University; Indiana University System; Indiana University Bloomington	REBAY, I (corresponding author), YALE UNIV,DEPT CELL BIOL,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511, USA.				NIGMS NIH HHS [GM20093, GM37813] Funding Source: Medline; NINDS NIH HHS [NS26084] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS026084] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTON AK, 1989, DEV GENET, V10, P261, DOI 10.1002/dvg.1020100315; APPELLA E, 1987, J BIOL CHEM, V262, P4437; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ARTAVANISTSAKON.S, 1991, IN PRESS, V7, P427; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BOUROUIS M, 1983, EMBO J, V2, P1099, DOI 10.1002/j.1460-2075.1983.tb01552.x; BRAND M, 1990, ROUX ARCH DEV BIOL, V198, P275, DOI 10.1007/BF00377394; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DAVIS LD, 1991, IN PRESS J BIOL CHEM; DELACONCHA A, 1988, GENETICS, V118, P499; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FOSTER GG, 1975, GENETICS, V81, P99; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HANDFORD PA, 1990, EMBO J, V9, P479; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HAYS TS, 1989, MOL CELL BIOL, V9, P875, DOI 10.1128/MCB.9.3.875; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOMORIYA A, 1984, P NATL ACAD SCI-BIOL, V81, P1351, DOI 10.1073/pnas.81.5.1351; KOPCZYNSKI CC, 1989, DEVELOPMENT, V107, P623; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LINDSLEY PL, 1968, PUBLICATION NUMBER C, V627; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Maniatis T, 1989, DECONTAMINATION DILU; MARKOPOULOU K, 1989, J NEUROGENET, V6, P11, DOI 10.3109/01677068909107097; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MORITA T, 1984, J BIOL CHEM, V259, P5698; MOSS RE, 1985, THESIS HARVARD U; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; PORTIN P, 1975, GENETICS, V81, P121; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SHEPARD SB, 1989, GENETICS, V122, P429; SUGO T, 1984, J BIOL CHEM, V259, P5705; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS U, 1991, DEVELOPMENT, V111, P749; VASSIN H, 1985, J NEUROGENET, V2, P291, DOI 10.3109/01677068509102325; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WELSHONS WJ, 1965, SCIENCE, V150, P1122, DOI 10.1126/science.150.3700.1122; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	655	710	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					687	699		10.1016/0092-8674(91)90064-6	http://dx.doi.org/10.1016/0092-8674(91)90064-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657403				2022-12-24	WOS:A1991GQ40700006
J	SHERMOEN, AW; OFARRELL, PH				SHERMOEN, AW; OFARRELL, PH			PROGRESSION OF THE CELL-CYCLE THROUGH MITOSIS LEADS TO ABORTION OF NASCENT TRANSCRIPTS	CELL			English	Article							EARLY DROSOPHILA DEVELOPMENT; INSITU HYBRIDIZATION; RNA-POLYMERASE; MELANOGASTER; DIVISION; EMBRYOS; PHOSPHORYLATION; EMBRYOGENESIS; SEGMENTATION; PATTERNS	Nascent transcripts of the Drosophila Ubx gene were detected by in situ hybridization. Following onset of expression, the progress of RNA polymerase (1.4 kb/min) across the gene was visualized as the successive appearance of hybridization signals from different positions within the transcription unit. Nascent transcripts disappeared at mitosis. Hybridization signals reappeared in the next cell cycle first with a 5' probe, and later, following a delay consistent with the transcription rate, with a 3' probe. Nascent transcripts were observed continuously in expressing cells of a mutant embryo in which cells are blocked in interphase. We conclude that progression through mitosis causes abortion of nascent transcripts and suggest that periodic abortion of transcription contributes to regulation of expression of large genes.	UNIV CALIF SAN FRANCISCO,INST CARDIOVASC,PROGRAM EXCELLENCE MOLEC BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SHERMOEN, AW (corresponding author), UNIV CALIF SAN FRANCISCO,INST CARDIOVASC,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			O'Farrell, Patrick/0000-0003-0011-2734	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL43821] Funding Source: Medline; NIGMS NIH HHS [R01 GM037193-10, R01 GM37193, R01 GM037193] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAM M, 1985, EMBO J, V4, P1687; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FOE VE, 1983, J CELL SCI, V61, P31; FOE VE, 1989, DEVELOPMENT, V107, P1; HARTENSTEIN V, 1990, DEV BIOL, V138, P147, DOI 10.1016/0012-1606(90)90184-K; HIRAOKA Y, 1990, J CELL BIOL, V111, P2815, DOI 10.1083/jcb.111.6.2815; IRVINE KD, 1991, DEVELOPMENT, V111, P407; JACK JW, 1979, P NATL ACAD SCI USA, V76, P1368, DOI 10.1073/pnas.76.3.1368; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEE M, 1987, NATURE, V327, P287; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEMAIRE MF, 1990, MOL CELL BIOL, V10, P6059, DOI 10.1128/MCB.10.11.6059; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; MERRILL PT, 1988, DEVELOPMENT, V104, P495; MINDEN JS, 1989, J CELL BIOL, V109, P505, DOI 10.1083/jcb.109.2.505; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; OCONNOR MB, 1988, EMBO J, V7, P435, DOI 10.1002/j.1460-2075.1988.tb02831.x; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR JH, 1960, ANN NY ACAD SCI, V90, P409, DOI 10.1111/j.1749-6632.1960.tb23259.x; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4	30	313	315	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					303	310		10.1016/0092-8674(91)90182-X	http://dx.doi.org/10.1016/0092-8674(91)90182-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1680567	Green Accepted			2022-12-24	WOS:A1991GL47000010
J	CRUICKSHANK, JK; COOPER, J; BURNETT, M; MACDUFF, J; DRUBRA, U				CRUICKSHANK, JK; COOPER, J; BURNETT, M; MACDUFF, J; DRUBRA, U			ETHNIC-DIFFERENCES IN FASTING PLASMA C-PEPTIDE AND INSULIN IN RELATION TO GLUCOSE-TOLERANCE AND BLOOD-PRESSURE	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; BETA-CELL; POPULATION; DISEASE; HYPERINSULINEMIA; BIMODALITY; PREVALENCE; RESISTANCE; DEFICIENCY; SECRETION	The frequency of non-insulin-dependent diabetes mellitus (NIDDM) and of high blood pressure (or hypertension) is higher in some ethnic groups than in others for reasons that remain unclear. To investigate the mechanisms leading to these ethnic differences, plasma C-peptide and insulin concentrations were measured after overnight fast and during an oral glucose tolerance test in subjects aged 45-74 years sampled from the practice lists of two north west London health centres. Ethnic group was defined by grandparental origin as Afro-Caribbean in 106, Gujerati Indian in 107, and white European in 101. The total age-adjusted prevalence of NIDDM was 29% in the Afro-Caribbean, 30% in the Gujerati, and 3% in the white groups, respectively. Fasting C-peptide and insulin concentrations increased from the subgroup with normal glucose tolerance, through impaired glucose tolerance, to new NIDDM, and were lower again in subjects with known NIDDM. The odds ratio for new NIDDM was 1.87 (95% confidence interval 1.26-2.77) per 1 SD increase in fasting C-peptide, which was the most powerful independent indicator of new NIDDM (p = 0.0005) and accounted for the effect of ethnic group. Fasting insulin had a similarly strong effect. There was no relation between any index of insulin secretion and blood pressure or hypertension. There were differences among the ethnic groups in the C-peptide response relative to the insulin response. These results suggest that factors determining insulin secretion and its hepatic clearance, possibly including dietary fat, are the main causes of ethnic variation in rates of new NIDDM.	NORTHWICK PK HOSP & CLIN RES CTR,DEPT MED,HARROW HA1 3UJ,MIDDX,ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR,MRC,EPIDEMIOL & MED CARE UNIT,HARROW HA1 3UJ,MIDDX,ENGLAND; RADCLIFFE INFIRM,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND	Imperial College London; Imperial College London; Radcliffe Infirmary; University of Oxford					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBANO JDM, 1972, ACTA ENDOCRINOL-COP, V70, P487, DOI 10.1530/acta.0.0700487; Alleyne S I, 1989, Bull Pan Am Health Organ, V23, P306; BECKLES GLA, 1986, LANCET, V1, P1298; Bennett P H, 1976, Recent Prog Horm Res, V32, P333; CAHILL GF, 1988, NEW ENGL J MED, V318, P1268, DOI 10.1056/NEJM198805123181909; CLARK A, 1988, DIABETES RES, V9, P155; CRUICKSHANK JK, 1990, DIABETIC MED S2, V7, P52; CRUICKSHANK JK, 1989, ETHNIC FACTORS HLTH, P33; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Ferrannini E, 1989, J NEPHROL, V1, P3; HAFFNER SM, 1986, NEW ENGL J MED, V315, P220, DOI 10.1056/NEJM198607243150403; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HUGHES LO, 1989, BRIT MED J, V299, P537, DOI 10.1136/bmj.299.6698.537; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; ORAHILLY SP, 1986, LANCET, V2, P360; POLONSKY KS, 1984, DIABETES, V33, P486, DOI 10.2337/diabetes.33.5.486; POLONSKY KS, 1988, NEW ENGL J MED, V318, P1231, DOI 10.1056/NEJM198805123181903; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSENTHAL M, 1985, J CHRON DIS, V38, P5, DOI 10.1016/0021-9681(85)90003-7; SAAD MF, 1989, LANCET, V1, P1356; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; TEMPLE RC, 1989, LANCET, V1, P293, DOI 10.1016/S0140-6736(89)91306-8; THOMPSON R, 1990, CLIN SCI S22, V78, P29; VERMA NPS, 1986, BRIT MED J, V293, P423, DOI 10.1136/bmj.293.6544.423; WARD WK, 1984, J CLIN INVEST, V74, P1318, DOI 10.1172/JCI111542; WELBORN TA, 1969, DIABETOLOGIA, V5, P263, DOI 10.1007/BF01212096; ZIMMET P, 1978, DIABETES, V27, P793, DOI 10.2337/diabetes.27.8.793	30	130	130	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1991	338	8771					842	847		10.1016/0140-6736(91)91501-K	http://dx.doi.org/10.1016/0140-6736(91)91501-K			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH945	1681214				2022-12-24	WOS:A1991GH94500003
J	KESSEL, M; GRUSS, P				KESSEL, M; GRUSS, P			HOMEOTIC TRANSFORMATIONS OF MURINE VERTEBRAE AND CONCOMITANT ALTERATION OF HOX CODES INDUCED BY RETINOIC ACID	CELL			English	Article							EMBRYONAL CARCINOMA-CELLS; CHICK LIMB BUD; HOMEOBOX-CONTAINING GENES; MOUSE EMBRYOS; EXPRESSION PATTERN; BOX GENE; SPATIAL-DISTRIBUTION; TRANSGENIC MICE; CODING SEQUENCE; DROSOPHILA	Exposure of murine embryos to teratogenic doses of retinoic acid (RA) induced homeotic transformations of vertebrae. Posterior transformations occurred along the complete body axis after RA administration on day 7 of gestation and were accompanied by anterior shifts of Hox gene expression domains in embryos. Anterior transformations of vertebrae in the caudal half of the vertebral column were induced on day 8.5. We suggest that the identity of a vertebral segment is specified by a combination of functionally active Hox genes, a "Hox code." In this concept the sequential activation of Hox genes defines sequentially more posterior axial levels, while mesodermal cells leave the primitive streak. Exogenous RA interferes with the normal estabishment of Hox codes and thus with axial specification.			KESSEL, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM, MOLEK ZELLBIOL ABT, POB 2841, W-3400 GOTTINGEN, GERMANY.							AKAM M, 1988, DEVELOPMENT, V104, P123; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BELLAIRS R, 1986, ANAT EMBRYOL, V174, P1, DOI 10.1007/BF00318331; BOGARAD LD, 1989, DEV BIOL, V133, P537, DOI 10.1016/0012-1606(89)90056-0; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; BREIER G, 1986, EMBO J, V5, P2209, DOI 10.1002/j.1460-2075.1986.tb04486.x; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CHEVALIER A, 1977, VERTEBRATE LIMB SOMI, P420; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; COLBERGPOLEY AM, 1985, NATURE, V314, P713, DOI 10.1038/314713a0; CREECHKRAFT J, 1987, TOXICOL APPL PHARM, V87, P474; DESCHAMPS J, 1987, P NATL ACAD SCI USA, V84, P1304, DOI 10.1073/pnas.84.5.1304; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DOLLE P, 1991, IN PRESS MECH DEV; DRESSLER GR, 1989, DIFFERENTIATION, V41, P193, DOI 10.1111/j.1432-0436.1989.tb00747.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; FAINSOD A, 1987, DEV BIOL, V124, P125, DOI 10.1016/0012-1606(87)90465-9; FIBI M, 1988, DEVELOPMENT, V102, P349; FRISCHER LE, 1986, CELL, V47, P1017, DOI 10.1016/0092-8674(86)90816-0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FUJINAGA M, 1989, TERATOLOGY, V40, P439, DOI 10.1002/tera.1420400505; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1990, DEVELOPMENT, V109, P329; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GREEN EL, 1953, SCIENCE, V117, P81, DOI 10.1126/science.117.3030.81; GREGG BC, 1983, J EMBRYOL EXP MORPH, V731, P135; GRUNEBERG H, 1952, GENETICS MOUSE; GRUNEBERG H, 1950, J GENET, V50, P111; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1987, P NATL ACAD SCI USA, V84, P5306, DOI 10.1073/pnas.84.15.5306; KEYNES R, 1990, NEURON, V2, P1; KIENY M, 1972, DEV BIOL, V28, P142, DOI 10.1016/0012-1606(72)90133-9; KOCHHAR DM, 1973, TERATOLOGY, V7, P289, DOI 10.1002/tera.1420070310; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MAHON KA, 1988, DEVELOPMENT, V104, P187; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MENKES B, 1977, VERTEBRATE LIMB SOMI, P405; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; RUBIN MR, 1987, MOL CELL BIOL, V7, P3836, DOI 10.1128/MCB.7.10.3836; RUSSELL LB, 1956, J EXP ZOOL, V131, P329, DOI 10.1002/jez.1401310308; SATRE MA, 1989, DEV BIOL, V133, P529, DOI 10.1016/0012-1606(89)90055-9; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEARLE AG, 1954, J GENET, V52, P68, DOI 10.1007/BF02981491; SHARPE PT, 1988, DEVELOPMENT, V102, P397; SHENEFELT RE, 1972, TERATOLOGY, V5, P103, DOI 10.1002/tera.1420050115; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P169; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SNOW MHL, 1987, SOMITES DEV EMBRYOS, P301; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TAM PPL, 1987, DEVELOPMENT, V99, P109; TAMARIN A, 1984, J EMBRYOL EXP MORPH, V84, P105; TASSIN MT, 1981, J CRAN GENET DEV BIO, V1, P299; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V90, P1; TIBBLES L, 1988, TERATOLOGY, V37, P113, DOI 10.1002/tera.1420370204; VOGELS R, 1990, IN PRESS DEVELOPMENT, V110; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; YASUDA Y, 1986, TERATOLOGY, V34, P37, DOI 10.1002/tera.1420340106	88	892	909	1	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					89	104		10.1016/0092-8674(91)90574-I	http://dx.doi.org/10.1016/0092-8674(91)90574-I			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1680565	hybrid			2022-12-24	WOS:A1991GJ32000009
J	HUNTER, JO				HUNTER, JO			FOOD ALLERGY - OR ENTEROMETABOLIC DISORDER	LANCET			English	Note							IRRITABLE BOWEL SYNDROME; CONTROLLED TRIAL; DIET; INTOLERANCE; MIGRAINE; DISEASE				HUNTER, JO (corresponding author), ADDENBROOKES HOSP,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.							ATHERTON DJ, 1978, LANCET, V1, P401; Bayliss C E, 1986, Ann Ist Super Sanita, V22, P959; BENTLEY SJ, 1983, LANCET, V2, P295; BOND JH, 1980, GASTROENTEROLOGY, V78, P444; BURKE DA, 1988, BMJ-BRIT MED J, V297, P102, DOI 10.1136/bmj.297.6641.102; DARLINGTON LG, 1986, LANCET, V1, P236; EBRINGER RW, 1979, ANN RHEUM DIS, V37, P145; EGGER J, 1985, LANCET, V1, P540; EGGER J, 1983, LANCET, V2, P865; Hanington E., 1983, Clinical reactions to food, P155; HYAMS JS, 1983, GASTROENTEROLOGY, V84, P30; JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; Jones V. A., 1985, Food and the gut, P208; JONES VA, 1982, LANCET, V2, P1115; JONES VA, 1985, LANCET, V2, P177; LESSOF MH, 1980, Q J MED, V195, P259; LITTLEWOOD J, 1982, LANCET, V1, P983; RAVICH WJ, 1983, GASTROENTEROLOGY, V84, P26; SANDLER M, 1970, BACKGROUND MIGRAINE; SHEPPACH W, 1988, GASTROENTEROLOGY, V95, P1549; VANDERWAAIJ D, 1983, ANTIBIOTIC CHOICE IM; 1984, J R COLL PHYSICIANS, V18	23	33	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					495	496		10.1016/0140-6736(91)90557-6	http://dx.doi.org/10.1016/0140-6736(91)90557-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1678455				2022-12-24	WOS:A1991GC15300017
J	ECK, HP; STAHLHENNIG, C; HUNSMANN, G; DROGE, W				ECK, HP; STAHLHENNIG, C; HUNSMANN, G; DROGE, W			METABOLIC DISORDER AS EARLY CONSEQUENCE OF SIMIAN IMMUNODEFICIENCY VIRUS-INFECTION IN RHESUS MACAQUES	LANCET			English	Note							GLUTAMATE CONCENTRATION; MACROPHAGES; CYSTEINE; PLASMA	To establish whether the high plasma glutamate and low acid-soluble thiol (mainly cysteine) concentrations previously found in patients with HIV-1 infection are a consequence of the infection or a risk factor for its development, a closely related animal model, rhesus and fascicularis macaques infected with simian immunodeficiency virus (SIV(mac251)), was studied. The 23 infected macaques had significantly lower mean plasma thiol and higher glutamate concentrations than 18 uninfected controls (p < 0.001). The changes were apparent by 1 week after infection. Thus, abnormal plasma glutamate and thiol concentrations are, at least in this model, a direct and early consequence of the retroviral infection.	GERMAN PRIMATE CTR,DEPT VIROL & IMMUNOL,GOTTINGEN,GERMANY	Deutsches Primatenzentrum (DPZ)	ECK, HP (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,INST IMMUNOL & GENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.							BUHL R, 1989, LANCET, V2, P1294; CRANAGE MP, 1990, ANIMAL MODELS AIDS, P103; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DROGE W, 1988, BIOL CHEM H-S, V369, P143, DOI 10.1515/bchm3.1988.369.1.143; DROGE W, 1988, J CANCER RES CLIN, V114, P124, DOI 10.1007/BF00417824; ECK HP, 1989, BIOL CHEM H-S, V370, P109, DOI 10.1515/bchm3.1989.370.1.109; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; FENDRICH C, 1989, AIDS, V3, P305, DOI 10.1097/00002030-198905000-00010; STAHLHENNIG C, 1990, AIDS, V4, P611, DOI 10.1097/00002030-199007000-00001; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628	10	59	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					346	347		10.1016/0140-6736(91)90482-5	http://dx.doi.org/10.1016/0140-6736(91)90482-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677701				2022-12-24	WOS:A1991GA60700007
J	WAKABAYASHI, A; BRENNER, M; KAYALEH, RA; BERNS, MW; BARKER, SJ; RICE, SJ; TADIR, Y; DELLABELLA, L; WILSON, AF				WAKABAYASHI, A; BRENNER, M; KAYALEH, RA; BERNS, MW; BARKER, SJ; RICE, SJ; TADIR, Y; DELLABELLA, L; WILSON, AF			THORACOSCOPIC CARBON-DIOXIDE LASER TREATMENT OF BULLOUS EMPHYSEMA	LANCET			English	Note							DRAINAGE; BULLAE	A new technique of thoracoscopic laser ablation of pulmonary bullae suitable for patients with multiple bullae and diffuse emphysema was developed and assessed in 22 patients. 20 of 22 patients survived. Pre-operative and postoperative functional evaluation is available for the 11 patients followed up for more than a month; at 1 to 3 months postoperatively there were increases in FVC (mean 2.0 litres pre-operatively to 2.7 litres postoperatively, p < 0.001), in FEV1 (0.74 to 1.06 litres, p = 0.01), and in maximum exercise treadmill times (5.4 min to 8.0 min, p < 0.01). Postoperative air leaks lasted a mean of 13 days and usually resolved spontaneously. Other complications were bleeding (1 patient) and unilateral acute lung injury (1 patient). These early results suggest that selected patients with diffuse emphysema and pulmonary bullae may benefit from thoracoscopic carbon dioxide laser ablation.	UNIV CALIF IRVINE,IRVINE MED CTR,DEPT SURG,DIV PULM & CRIT CARE MED,101 CITY DR S,ORANGE,CA 92668; BECKMAN LASER INST & MED CLIN,IRVINE,CA; UNIV CALIF IRVINE,IRVINE MED CTR,DEPT PULM & CRIT CARE MED,ORANGE,CA 92668; UNIV CALIF IRVINE,IRVINE MED CTR,DEPT RADIOL,ORANGE,CA 92668; UNIV CALIF IRVINE,IRVINE MED CTR,DEPT ANESTHESIA,ORANGE,CA 92668	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine				Berns, Michael/0000-0002-9640-2885				BRANTIGAN OC, 1959, AM REV RESPIR DIS, V80, P194; FITZGERALD MX, 1974, J THORAC CARDIOV SUR, V68, P566; Gaensler E A, 1986, J Thorac Imaging, V1, P75, DOI 10.1097/00005382-198603000-00009; GUNSTENSEN J, 1973, J THORAC CARDIOV SUR, V65, P920; HEAD JR, 1948, J THORAC CARDIOVASC, V40, P443; LAROS CD, 1986, J THORAC CARDIOV SUR, V91, P63; MACARTHUR AM, 1977, THORAX, V32, P668, DOI 10.1136/thx.32.6.668; OBRIEN CJ, 1986, AUST NZ J SURG, V56, P241, DOI 10.1111/j.1445-2197.1986.tb06142.x; VENN GE, 1988, THORAX, V43, P998, DOI 10.1136/thx.43.12.998; WAKABAYASHI A, 1990, ANN THORAC SURG, V50, P786	10	120	122	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					881	883		10.1016/0140-6736(91)90206-5	http://dx.doi.org/10.1016/0140-6736(91)90206-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672970	Green Submitted			2022-12-24	WOS:A1991FG04800005
J	MCKEIGUE, PM; SHAH, B; MARMOT, MG				MCKEIGUE, PM; SHAH, B; MARMOT, MG			RELATION OF CENTRAL OBESITY AND INSULIN RESISTANCE WITH HIGH DIABETES PREVALENCE AND CARDIOVASCULAR RISK IN SOUTH ASIANS	LANCET			English	Article							CORONARY HEART-DISEASE; FAT DISTRIBUTION; NORTHWEST LONDON; ADIPOSE-TISSUE; SERUM-LIPIDS; MORTALITY; MEN; ADULTS; WOMEN; DIET	The hypothesis that the high mortality from coronary heart disease (CHD) in South Asians settled overseas compared with other populations is due to metabolic disturbances related to insulin resistance was tested in a population survey of 3193 men and 561 women aged 40-69 years in London, UK. The sample was assembled from industrial workforces and general practitioners' lists. In comparison with the European group, the South Asian group had a higher prevalence of diabetes (19% vs 4%), higher blood pressures, higher fasting and post-glucose serum insulin concentrations, higher plasma triglyceride, and lower HDL cholesterol concentrations. Mean waist-hip girth ratios and trunk skinfolds were higher in the South Asian than in the European group. Within each ethnic group waist-hip ratio was correlated with glucose intolerance, insulin, blood pressure, and triglyceride. These results confirm the existence of an insulin resistance syndrome, prevalent in South Asian populations and associated with a pronounced tendency to central obesity in this group. Control of obesity and greater physical activity offer the best chances for prevention of diabetes and CHD in South Asian people.	UNIV COLL & MIDDLESEX SCH MED,DEPT COMMUNITY MED,LONDON,ENGLAND	University of London; University College London			Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		[Anonymous], 1985, WHO TECH REP SER, V727, P1; BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; BECKLES GLA, 1986, LANCET, V1, P1298; BOLINDER J, 1983, DIABETES, V32, P117, DOI 10.2337/diabetes.32.2.117; DONAHUE RP, 1987, LANCET, V1, P821; DUCIMETIERE P, 1986, INT J OBESITY, V10, P229; Duncan I.W., 1982, PROCEDURE PROPOSED C; ELLIOTT P, 1988, CONTROL CLIN TRIALS, V9, pS1, DOI 10.1016/0197-2456(88)90028-1; HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1985, LANCET, V2, P1086; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; MORRISON JA, 1981, JAMA-J AM MED ASSOC, V245, P939, DOI 10.1001/jama.245.9.939; OLEFSKY J, 1974, J CLIN INVEST, V53, P64, DOI 10.1172/JCI107560; PEEPLES LH, 1989, METABOLISM, V38, P1029, DOI 10.1016/0026-0495(89)90017-6; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SEIDELL JC, 1988, EUR J CLIN INVEST, V18, P243, DOI 10.1111/j.1365-2362.1988.tb01253.x; SLACK J, 1977, BRIT MED J, V2, P353, DOI 10.1136/bmj.2.6083.353; STERN MP, 1981, AM J EPIDEMIOL, V113, P546, DOI 10.1093/oxfordjournals.aje.a113131; YKIJARVINEN H, 1988, DIABETES, V37, P1271, DOI 10.2337/diabetes.37.9.1271; ZIMMET P, 1977, DIABETOLOGIA, V13, P111, DOI 10.1007/BF00745137; 1989, LANCET, V1, P589; 1990, MORTALITY GEOGRAP DS	30	1184	1190	3	56	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					382	386		10.1016/0140-6736(91)91164-P	http://dx.doi.org/10.1016/0140-6736(91)91164-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671422				2022-12-24	WOS:A1991EX60500002
J	TANAKA, K; OSHIMURA, M; KIKUCHI, R; SEKI, M; HAYASHI, T; MIYAKI, M				TANAKA, K; OSHIMURA, M; KIKUCHI, R; SEKI, M; HAYASHI, T; MIYAKI, M			SUPPRESSION OF TUMORIGENICITY IN HUMAN COLON-CARCINOMA CELLS BY INTRODUCTION OF NORMAL CHROMOSOME-5 OR CHROMOSOME-18	NATURE			English	Article							FAMILIAL POLYPOSIS COLI; COLORECTAL CARCINOMAS; CONSTITUTIONAL HETEROZYGOSITY; GENE; ASSIGNMENT; TUMORS; ARM	DEVELOPMENT of colon carcinomas can be associated with allelic deletions on several chromosomes, including 5q and 18q (refs 1-10). The APC gene11-13 on 5q and the DCC gene14 on 18q have been identified as potential tumor suppressor genes, whose suppression contributes to colon carcinogenesis. To investigate the role of genes in these deleted regions, we have now introduced a single normal human chromosome into a human colon carcinoma cell line, COKFu, through microcell hybridization15-20. Several clones of hybrid cells containing normal chromosome 5, and others containing normal chromosome 18, were obtained. The morphology of the hybrid cells was markedly altered: the hybrids with chromosome 5 exhibited a closely packed polygonal morphology, and the hybrid cells with chromosome 18 were flattened. The cloning efficiency of the hybrid cells in soft agar was reduced from 0.46 to 0% of that of the parental carcinoma cells, and the tumorigenicity of these hybrid cells in athymic nude mice was completely suppressed. The growth properties of the hybrid cells with chromosome 11 were not substantially changed. These results strongly suggest that the genes on normal chromosome 5 and 18 function as tumor suppressors in colon carcinogenesis.	TOTTORI UNIV,FAC MED,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN	Tottori University	TANAKA, K (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,3-18-22 HONKOMAGOME,BUNKYO KU,TOKYO 113,JAPAN.							ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DIETZSCH E, 1986, NUCLEIC ACIDS RES, V14, P1923, DOI 10.1093/nar/14.4.1923; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1989, CARCINOGENESIS, V2, P12; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MIYAKI M, 1990, CANCER RES, V50, P7166; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; NISHISHO I, 1987, JPN J HUM GENET, V32, P1, DOI 10.1007/BF01876521; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; SASAKI M, 1989, CANCER RES, V49, P4402; SAXSON PJ, 1986, EMBO J, V5, P3461; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	25	184	192	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					340	342		10.1038/349340a0	http://dx.doi.org/10.1038/349340a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1670965				2022-12-24	WOS:A1991EU50100056
J	[Anonymous]				[Anonymous]			SURGEONS AND HIV	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					169	169						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670803				2022-12-24	WOS:A1991ET67900021
J	DOTTI, CG; PARTON, RG; SIMONS, K				DOTTI, CG; PARTON, RG; SIMONS, K			POLARIZED SORTING OF GLYPIATED PROTEINS IN HIPPOCAMPAL-NEURONS	NATURE			English	Article							CELLS; CULTURE	Our recent studies suggested that neurons and epithelial cells sort viral glycoproteins in a similar manner. The apical influenza virus haemagglutinin was preferentially delivered to the axon of hippocampal neurons in culture, whereas the basolateral vesicular stomatitis virus glycoprotein was sorted to the dendrites. 1 To investigate whether other membrane proteins showed similar sorting in neurons and epithelial cells, we have analysed the localization of a glypiated (glycosylphosphatidylinositol-anchored) protein, Thy-1, in hippocampal neurons in culture. In MDCk and other epithelial cells, endogenous glycosylphosphatidylinositol (GPI)-anchored proteins, as well as mutated exogenous proteins containing the GPI-attachment signal, undergo preferential delivery to the apical surface 2-4. This polarized sorting of GPI-anchored proteins has been been proposed to occur by the same mechanisms as the sorting of glycolipids to the apical surface 5,6. We report here that the neuronal GPI-protein Thy-1 is present in hippocampal neurons in culture and is exclusively located on the axonal surface. This finding further strengthens our hypothesis that the mechanisms of sorting of surface components may be similar in neurons and epithelial cells.			DOTTI, CG (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Dotti, Carlos G/I-5533-2015; Parton, Robert G/C-5673-2009	Dotti, Carlos G/0000-0003-4052-1719; Parton, Robert G/0000-0002-7494-5248; Simons, Kai/0000-0002-9231-9996				BANKER GA, 1988, INTRINSIC DETERMINAN, P61; BARTLETT WP, 1984, J NEUROSCI, V4, P1954; BENNETT MK, 1988, EMBO J, V7, P4075, DOI 10.1002/j.1460-2075.1988.tb03301.x; CACERES A, 1984, DEV BRAIN RES, V13, P314, DOI 10.1016/0165-3806(84)90167-6; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; LAEMMLI V, 1979, NATURE, V257, P418; LISANTI M, 1989, J CELL BIOL, V109, P2140; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MASON D, 1980, BIOCHEM J, V147, P1; MORRIS RJ, 1985, J NEUROCYTOL, V14, P427, DOI 10.1007/BF01217754; ROTHMAN S, 1981, J COMP NEUROL, V195, P141, DOI 10.1002/cne.901950108; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSON JM, 1990, J CELL SCI, V96, P143	20	218	220	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					158	160		10.1038/349158a0	http://dx.doi.org/10.1038/349158a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1670898				2022-12-24	WOS:A1991ER41800059
J	NAWY, S; JAHR, CE				NAWY, S; JAHR, CE			SUPPRESSION BY GLUTAMATE OF CGMP-ACTIVATED CONDUCTANCE IN RETINAL BIPOLAR CELLS	NATURE			English	Article											NAWY, S (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,L474,PORTLAND,OR 97201, USA.			Nawy, Scott/0000-0003-4679-6756				ATTWELL D, 1987, J PHYSIOL-LONDON, V387, P125, DOI 10.1113/jphysiol.1987.sp016567; COBBS WH, 1985, NATURE, V317, P64, DOI 10.1038/317064a0; COPENHAGEN DR, 1983, VISION RES, V23, P363, DOI 10.1016/0042-6989(83)90083-4; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; ERTEL E A, 1989, Biophysical Journal, V55, p458A; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; KAWAMURA S, 1989, J GEN PHYSIOL, V94, P649, DOI 10.1085/jgp.94.4.649; MATTHEWS G, 1987, P NATL ACAD SCI USA, V84, P299, DOI 10.1073/pnas.84.1.299; MATTHEWS HR, 1985, NATURE, V313, P582, DOI 10.1038/313582a0; MURAKAMI M, 1975, VISION RES, V15, P456, DOI 10.1016/0042-6989(75)90101-7; NAWY S, 1990, NEUROSCI LETT, V108, P279, DOI 10.1016/0304-3940(90)90654-R; NAWY S, 1987, NATURE, V325, P56, DOI 10.1038/325056a0; PFAFFINGER P, 1988, J NEUROSCI, V8, P3343; SATHER WA, 1987, P NATL ACAD SCI USA, V84, P9290, DOI 10.1073/pnas.84.24.9290; SHIELLS RA, 1981, NATURE, V294, P592, DOI 10.1038/294592a0; SLAUGHTER MM, 1981, SCIENCE, V211, P182, DOI 10.1126/science.6255566; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; TRUSSELL LO, 1987, J NEUROSCI, V7, P3306; WERBLIN FS, 1978, J PHYSIOL-LONDON, V280, P449, DOI 10.1113/jphysiol.1978.sp012394; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	23	380	387	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 19	1990	346	6281					269	271		10.1038/346269a0	http://dx.doi.org/10.1038/346269a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP456	1695713				2022-12-24	WOS:A1990DP45600065
J	GOLD, MR; LAW, DA; DEFRANCO, AL				GOLD, MR; LAW, DA; DEFRANCO, AL			STIMULATION OF PROTEIN TYROSINE PHOSPHORYLATION BY THE LYMPHOCYTE-B ANTIGEN RECEPTOR	NATURE			English	Article									UNIV CALIF SAN FRANCISCO, GEORGE WILLIAMS HOOPER FDN, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Gold, Michael/AAF-2081-2021	Gold, Michael/0000-0003-1222-3191				ASHWELL JD, 1984, J EXP MED, V159, P881, DOI 10.1084/jem.159.3.881; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; COGGESHALL KM, 1984, J IMMUNOL, V133, P3382; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; FAHEY KA, 1987, J IMMUNOL, V138, P3935; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLD MR, 1987, J IMMUNOL, V139, P3604; HARNETT MM, 1988, J IMMUNOL, V140, P3135; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HSI ED, 1989, J BIOL CHEM, V264, P10836; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; NEL AE, 1985, J IMMUNOL, V135, P3448; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; PAGE DM, 1988, J IMMUNOL, V140, P3717; PATEL MD, 1987, J BIOL CHEM, V262, P5831; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RALPH P, 1979, IMMUNOL REV, V48, P107, DOI 10.1111/j.1600-065X.1979.tb00300.x; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	24	397	407	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	1990	345	6278					810	813		10.1038/345810a0	http://dx.doi.org/10.1038/345810a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL646	1694265				2022-12-24	WOS:A1990DL64600059
J	MOSES, MA; SUDHALTER, J; LANGER, R				MOSES, MA; SUDHALTER, J; LANGER, R			IDENTIFICATION OF AN INHIBITOR OF NEOVASCULARIZATION FROM CARTILAGE	SCIENCE			English	Article									CHILDRENS HOSP MED CTR,DEPT SURG,BOSTON,MA 02115; MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; MIT,HARVARD MIT DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139	Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT)					NEI NIH HHS [EY05333, EY06047] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005333] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AUERBACH R, 1985, MICROVASC RES, V29, P401, DOI 10.1016/0026-2862(85)90028-7; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BREM H, 1975, J EXP MED, V141, P427, DOI 10.1084/jem.141.2.427; Brem H., 1988, ADV NEUROONCOLOGY, P89; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; DAMORE P, 1986, PROG CLIN BIOL RES, V221, P269; DAMORE PA, 1984, J CELL BIOL, V99, P1545, DOI 10.1083/jcb.99.4.1545; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EISENSTEIN R, 1975, AM J PATHOL, V81, P337; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; GABRIELIDES C, 1987, BIOCHIM BIOPHYS ACTA, V924, P238, DOI 10.1016/0304-4165(87)90092-4; GLASER BM, 1980, NATURE, V288, P483, DOI 10.1038/288483a0; HITIHARPER J, 1978, SCIENCE, V199, P991, DOI 10.1126/science.203038; JOHNSONWINT B, 1980, ANAL BIOCHEM, V104, P175, DOI 10.1016/0003-2697(80)90295-X; KALEBIC T, 1983, SCIENCE, V221, P281, DOI 10.1126/science.6190230; LANGER R, 1980, P NATL ACAD SCI-BIOL, V77, P4331, DOI 10.1073/pnas.77.7.4331; LANGER R, 1976, SCIENCE, V193, P70, DOI 10.1126/science.935859; LEE A, 1983, SCIENCE, V221, P1185, DOI 10.1126/science.6193581; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LUTTY GA, 1983, INVEST OPHTH VIS SCI, V24, P52; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MOSES MJ, UNPUB; MURRAY JB, 1986, J BIOL CHEM, V261, P4154; PATZ A, 1982, AM J OPHTHALMOL, V94, P715, DOI 10.1016/0002-9394(82)90297-5; PAULI BU, 1981, J NATL CANCER I, V67, P65; RIFKIN DB, 1982, PATHOBIOLOGY ENDOTHE, P191; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SUDHALTER J, UNPUB; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; THURGIERSSON UP, 1982, J NATL CANCER I, V69, P1049; 1989, NIH ID A20595 NAT BI	36	421	474	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 15	1990	248	4961					1408	1410		10.1126/science.1694043	http://dx.doi.org/10.1126/science.1694043			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ501	1694043				2022-12-24	WOS:A1990DJ50100039
J	RAO, Y; JAN, LY; JAN, YN				RAO, Y; JAN, LY; JAN, YN			SIMILARITY OF THE PRODUCT OF THE DROSOPHILA NEUROGENIC GENE BIG BRAIN TO TRANSMEMBRANE CHANNEL PROTEINS	NATURE			English	Article									UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	RAO, Y (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				BRAND M, 1988, ROUX ARCH DEV BIOL, V197, P457, DOI 10.1007/BF00385679; BROEKHUYSE RM, 1979, EXP EYE RES, V29, P303, DOI 10.1016/0014-4835(79)90009-5; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DELACONCHA A, 1988, GENETICS, V118, P499; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; EHRING GR, 1988, GAP JUNCTIONS, P335; FITZGERALD PG, 1983, J CELL BIOL, V97, P1491, DOI 10.1083/jcb.97.5.1491; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; JIMENEZ F, 1982, ROUX ARCH DEV BIOL, V191, P191, DOI 10.1007/BF00848335; JOHNSON RG, 1988, GAP JUNCTIONS, P81; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KNUST E, 1987, EMBO J, V6, P4113, DOI 10.1002/j.1460-2075.1987.tb02757.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHMANN R, 1981, ROUX ARCH DEV BIOL, V190, P226, DOI 10.1007/BF00848307; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; Lindsley D. L., 1967, GENETIC VARIATIONS D; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P4378; PAUL DL, 1983, J CELL BIOL, V96, P625, DOI 10.1083/jcb.96.3.625; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANDAL NN, 1988, NUCLEIC ACIDS RES, V16, P9347, DOI 10.1093/nar/16.19.9347; SAS DF, 1985, J CELL BIOL, V100, P216, DOI 10.1083/jcb.100.1.216; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STELLER H, 1986, MOL CELL BIOL, V6, P1640, DOI 10.1128/MCB.6.5.1640; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1987, P NATL ACAD SCI USA, V84, P4500, DOI 10.1073/pnas.84.13.4500; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; VERMA DPS, 1986, PLANT MOL BIOL, V7, P51, DOI 10.1007/BF00020131; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255	40	142	145	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 10	1990	345	6271					163	167		10.1038/345163a0	http://dx.doi.org/10.1038/345163a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC833	1692392				2022-12-24	WOS:A1990DC83300068
J	CAWTHORN, SJ; PARUMS, DV; GIBBS, NM; AHERN, RP; CAFFAREY, SM; BROUGHTON, CIM; MARKS, CG				CAWTHORN, SJ; PARUMS, DV; GIBBS, NM; AHERN, RP; CAFFAREY, SM; BROUGHTON, CIM; MARKS, CG			EXTENT OF MESORECTAL SPREAD AND INVOLVEMENT OF LATERAL RESECTION MARGIN AS PROGNOSTIC FACTORS AFTER SURGERY FOR RECTAL-CANCER	LANCET			English	Article									ROYAL SURREY CTY HOSP,DEPT SURG,GUILDFORD CU2 5TH,SURREY,ENGLAND; ROYAL SURREY CTY HOSP,DEPT PATHOL,GUILDFORD,ENGLAND; ROYAL MARSDEN HOSP,DEPT COMP,LONDON,ENGLAND	Royal Surrey County Hospital; Royal Surrey County Hospital; Royal Marsden NHS Foundation Trust				A'Hern, Roger/0000-0003-0593-8391				ASTLER VB, 1954, ANN SURG, V139, P846, DOI 10.1097/00000658-195406000-00015; BENTZEN SM, 1988, BRIT J CANCER, V58, P195, DOI 10.1038/bjc.1988.192; CAWTHORN SJ, 1986, BRIT J SURG, V73, P58, DOI 10.1002/bjs.1800730124; DAWSON PM, 1987, BRIT J SURG, V74, P366, DOI 10.1002/bjs.1800740514; DEMASCAREL A, 1981, SURG GYNECOL OBSTET, V153, P511; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; DUKES CE, 1958, BRIT J CANCER, V12, P309, DOI 10.1038/bjc.1958.37; DUKES CE, 1930, BRIT J SURG, V17, P643; Gabriel WB, 1935, BRIT J SURG, V23, P395, DOI 10.1002/bjs.1800239017; GOLIGHER JC, 1951, BRIT J SURG, V39, P199, DOI 10.1002/bjs.18003915504; GRICOUROFF G, 1967, CANCER-AM CANCER SOC, V20, P673, DOI 10.1002/1097-0142(1967)20:5<673::AID-CNCR2820200517>3.0.CO;2-G; HEALD RJ, 1986, LANCET, V1, P1479; HEALD RJ, 1988, J ROY SOC MED, V81, P503, DOI 10.1177/014107688808100904; HOJO K, 1982, AM J SURG, V144, P350, DOI 10.1016/0002-9610(82)90018-6; JASS JR, 1987, LANCET, V1, P1303; KODNER IJ, 1989, ANN SURG, V209, P194, DOI 10.1097/00000658-198902000-00010; KOKAL WA, 1989, ANN SURG, V209, P188, DOI 10.1097/00000658-198902000-00009; MORSON BC, 1963, BMJ-BRIT MED J, P13, DOI 10.1136/bmj.2.5348.13; PHILLIPS RKS, 1984, BRIT J SURG, V71, P17, DOI 10.1002/bjs.1800710105; QUIRKE P, 1986, LANCET, V2, P996, DOI 10.1016/s0140-6736(86)92612-7; RAO AR, 1981, CANCER-AM CANCER SOC, V48, P1492, DOI 10.1002/1097-0142(19810915)48:6<1492::AID-CNCR2820480636>3.0.CO;2-K; SILVERMAN DT, 1977, AM J SURG, V133, P289, DOI 10.1016/0002-9610(77)90531-1; UMPLEBY HC, 1984, BRIT J SURG, V71, P659, DOI 10.1002/bjs.1800710902; WILLIAMS NS, 1988, BRIT J SURG, V75, P649, DOI 10.1002/bjs.1800750710; WOOD CB, 1981, BRIT J SURG, V68, P326, DOI 10.1002/bjs.1800680512; 1984, BRIT J SURG, V71, P21	26	264	267	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 5	1990	335	8697					1055	1059		10.1016/0140-6736(90)92631-Q	http://dx.doi.org/10.1016/0140-6736(90)92631-Q			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC568	1691810				2022-12-24	WOS:A1990DC56800003
J	WOLFF, JA; MALONE, RW; WILLIAMS, P; CHONG, W; ACSADI, G; JANI, A; FELGNER, PL				WOLFF, JA; MALONE, RW; WILLIAMS, P; CHONG, W; ACSADI, G; JANI, A; FELGNER, PL			DIRECT GENE-TRANSFER INTO MOUSE MUSCLE INVIVO	SCIENCE			English	Article									VICAL INC,SAN DIEGO,CA 92121; UNIV WISCONSIN,WAISMAN CTR MENTAL RETARDAT & HUMAN DEV,DEPT GENET,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	WOLFF, JA (corresponding author), UNIV WISCONSIN,WAISMAN CTR MENTAL RETARDAT & HUMAN DEV,DEPT PEDIAT,MADISON,WI 53706, USA.		Malone, Robert/AAI-5317-2021	Malone, Robert/0000-0003-0340-7490	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003352] Funding Source: NIH RePORTER; NICHD NIH HHS [HD00669-05, HD03352] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACSADI G, UNPUB; AUSBEL FM, 1989, CURRENT PROTOCOLS MO; BENVENISTY N, 1986, P NATL ACAD SCI USA, V83, P9551, DOI 10.1073/pnas.83.24.9551; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUBENSKY TW, 1984, P NATL ACAD SCI-BIOL, V81, P7529, DOI 10.1073/pnas.81.23.7529; EGLITIS MA, 1988, BIOTECHNIQUES, V6, P608; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FELGNER PL, 1989, FOCUS, V11, P21; FELGNER PL, 1989, NATURE, V331, P461; FINN GK, 1989, MOL CELL BIOL, V9, P4009, DOI 10.1128/MCB.9.9.4009; Franzini-Armstrong C, 1986, MYOLOGY, P125; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAVITRANO M, 1989, CELL, V57, P717, DOI 10.1016/0092-8674(89)90787-3; LEDLEY FD, 1987, J PEDIATR-US, V110, P1, DOI 10.1016/S0022-3476(87)80278-0; Malone, 1989, FOCUS, V11, P61; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MANNINO RJ, 1988, BIOTECHNIQUES, V6, P682; NICOLAU C, 1983, P NATL ACAD SCI-BIOL, V80, P1068, DOI 10.1073/pnas.80.4.1068; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PAUZA CD, 1989, J VIROL, V63, P3700, DOI 10.1128/JVI.63.9.3700-3707.1989; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RALSTON E, 1989, SCIENCE, V244, P1066, DOI 10.1126/science.2543074; REID TR, IN PRESS J BIOL CHEM; RUBIO R, 1972, Z ZELLFORSCH MIK ANA, V124, P57, DOI 10.1007/BF00981941; SEEGER C, 1984, P NATL ACAD SCI-BIOL, V81, P5849, DOI 10.1073/pnas.81.18.5849; SHIMOHAMA S, IN PRESS MOL BRAIN R; WU GY, 1988, J BIOL CHEM, V263, P14621	32	2999	3820	20	199	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 23	1990	247	4949					1465	1468		10.1126/science.1690918	http://dx.doi.org/10.1126/science.1690918			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV282	1690918				2022-12-24	WOS:A1990CV28200037
J	LONGMORE, GD; LODISH, HF				LONGMORE, GD; LODISH, HF			AN ACTIVATING MUTATION IN THE MURINE ERYTHROPOIETIN RECEPTOR INDUCES ERYTHROLEUKEMIA IN MICE - A CYTOKINE RECEPTOR SUPERFAMILY ONCOGENE	CELL			English	Article							FOCUS-FORMING VIRUS; LEUKEMIA-VIRUS; MEMBRANE GLYCOPROTEIN; GROWTH-FACTOR; FRIEND-VIRUS; MYELOPROLIFERATIVE SYNDROME; EXPRESSION CLONING; CSF-1 RECEPTOR; POINT MUTATION; MULTI-CSF	A point mutation at codon 129 of the murine erythropoietin receptor (cEpoR) results in constitutive activation. We have generated a recombinant spleen focus-forming retrovirus in which the env gene is replaced by the cEpoR cDNA. Mice infected with this virus (but not by viruses expressing the wild-type EpoR) develop erythrocytosis and splenomegaly. From the spleen of infected animals we have isolated clonal, growth factor-independent, proerythroblast cell lines that express cEpoR, do not express the putative oncogene spi-1, and have rearranged and inactivated expression of the p53 suppressor oncogene. These cells induce erythroleukemia upon injection into mice. This demonstrates that oncogenic point mutations exist in a member of the cytokine receptor superfamily. The activated erythropoietin receptor does not transform cultured fibroblasts, suggesting why oncogenic mutations in other members of this receptor superfamily have not been detected.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT)	LONGMORE, GD (corresponding author), NINE CAMBRIDGE CTR, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.				NHLBI NIH HHS [HL32262] Funding Source: Medline; NIA NIH HHS [AG00294] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000294] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; CHANG JM, 1989, BLOOD, V73, P1487; CHATIS PA, 1984, J VIROL, V52, P248, DOI 10.1128/JVI.52.1.248-254.1984; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAVID YB, 1988, ONCOGENE, V3, P179; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRASER JK, 1989, EXP HEMATOL, V17, P10; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P140; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; GRAU GE, 1986, J IMMUNOL, V136, P686; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HANKINS WD, 1980, CELL, V22, P693; HARLOW E, 1988, ANTIBODIES LABORATOR; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; ISHIBASHI T, 1987, J CLIN INVEST, V79, P286, DOI 10.1172/JCI112796; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOPITO RR, 1985, J CELL BIOCHEM, V29, P1, DOI 10.1002/jcb.240290102; KOURY MJ, 1986, J CELL PHYSIOL, V126, P259, DOI 10.1002/jcp.1041260216; KRANTZ SB, 1991, BLOOD, V77, P419; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LI JP, 1986, J VIROL, V57, P534, DOI 10.1128/JVI.57.2.534-538.1986; LI JP, 1987, J VIROL, V61, P2782, DOI 10.1128/JVI.61.9.2782-2792.1987; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LINEMEYER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1401, DOI 10.1073/pnas.78.3.1401; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; RUTA M, 1983, P NATL ACAD SCI-BIOL, V80, P4704, DOI 10.1073/pnas.80.15.4704; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SRINIVAS RV, 1983, VIROLOGY, V125, P274, DOI 10.1016/0042-6822(83)90201-5; TROXLER DH, 1977, J VIROL, V22, P361, DOI 10.1128/JVI.22.2.361-372.1977; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P307; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; WOLFF L, 1986, P NATL ACAD SCI USA, V83, P3376, DOI 10.1073/pnas.83.10.3376; WOLFF L, 1982, J VIROL, V43, P472, DOI 10.1128/JVI.43.2.472-481.1982; WOLFF L, 1985, J VIROL, V53, P570, DOI 10.1128/JVI.53.2.570-578.1985; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	70	135	136	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1089	1102		10.1016/0092-8674(91)90286-8	http://dx.doi.org/10.1016/0092-8674(91)90286-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1662116				2022-12-24	WOS:A1991GX16400008
J	SEERY, JP				SEERY, JP			ACHLORHYDRIA AND GASTRIC CARCINOGENESIS	LANCET			English	Article							HUMAN STOMACH; PATHOGENESIS	The association between achlorhydria and gastric carcinogenesis can be explained by a simple hypothesis based on the known cytological properties of neoplastic cells and the physiology of the stomach. Normal gastric secretions might ensure the rapid elimination of carcinomatous cells. Achlorhydria could be an important permissive factor in the development of gastric carcinoma.			SEERY, JP (corresponding author), ROYAL INFIRM,DEPT CLIN PHARMACOL,LAURISTON PL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							BARET MK, 1967, NEOPLASMS STOMACH, P29; FLEMING S, 1991, J PATHOL, V164, P95, DOI 10.1002/path.1711640202; HILL MJ, 1986, MICROBIAL METABOLISM, P221; LEACH SA, 1987, CARCINOGENESIS, V8, P1907, DOI 10.1093/carcin/8.12.1907; LICHT WR, 1988, CARCINOGENESIS, V9, P2227, DOI 10.1093/carcin/9.12.2227; MIRVISH SS, 1975, TOXICOL APPL PHARM, V31, P325, DOI 10.1016/0041-008X(75)90255-0; NEWBOLD KM, 1989, LANCET, V1, P131; NEWBOLD KM, 1988, J PATHOL, V155, P311, DOI 10.1002/path.1711550406; SANDERS MJ, 1985, NATURE, V313, P52, DOI 10.1038/313052a0; SEERY JP, 1991, MED HYPOTHESES, V35, P179, DOI 10.1016/0306-9877(91)90229-R; SOLL AH, 1990, NEW ENGL J MED, V322, P909; SVENDSEN JH, 1986, SCAND J GASTROENTERO, V21, P16, DOI 10.3109/00365528609034615	12	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1991	338	8781					1508	1509		10.1016/0140-6736(91)92312-P	http://dx.doi.org/10.1016/0140-6736(91)92312-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1683930				2022-12-24	WOS:A1991GV07700016
J	CHAN, HSL; HADDAD, G; THORNER, PS; DEBOER, G; LIN, YP; ONDRUSEK, N; YEGER, H; LING, V				CHAN, HSL; HADDAD, G; THORNER, PS; DEBOER, G; LIN, YP; ONDRUSEK, N; YEGER, H; LING, V			P-GLYCOPROTEIN EXPRESSION AS A PREDICTOR OF THE OUTCOME OF THERAPY FOR NEUROBLASTOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REQUIRING PROLONGED OBSERVATION; MULTIDRUG RESISTANCE GENE; METASTATIC NEURO-BLASTOMA; CARCINOMA CELL-LINES; MONOCLONAL-ANTIBODIES; PROGNOSTIC FACTORS; 30 CHILDREN; IV-S; CHEMOTHERAPY; MDR1	Background and Methods. Multidrug resistance in chemotherapy for cancer is characterized by increased genetic expression of P-glycoprotein, which acts as an ATP-dependent drug-efflux pump. To determine whether P-glycoprotein levels are of prognostic value in such cases, we measured these levels immunohistochemically in a retrospective study of sequential tumor samples from 67 children with neuroblastoma. Results. P-glycoprotein was not detected in pretreatment samples from either of the 2 patients with Stage I disease, any of the 21 with Stage II disease, or any of the 8 with Stage IVS disease, but it was detected in the samples from 1 of the 17 patients with Stage III disease (6 percent) and 12 of the 19 with Stage IV disease (63 percent). Of the 44 patients with nonlocalized neuroblastoma (Stage III, IVS, or IV), 26 of the 31 who were negative for P-glycoprotein had a complete response to primary treatment, as compared with 6 of the 13 who were positive for P-glycoprotein (84 percent vs. 46 percent, P = 0.0232 by Fisher's exact test). Log-rank analysis of outcome, with simultaneous stratification according to tumor stage and age, showed that the group that was negative for P-glycoprotein had significantly longer relapse-free survival (P = 0.0011) and overall survival (P = 0.0373) than the group that was positive. Conclusions. Expression of P-glycoprotein before treatment may predict the success or failure of therapy for nonlocalized neuroblastoma. Neuroblastoma may be a promising tumor to treat with anticancer drug therapy combined with a chemosensitizing agent capable of reversing P-glycoprotein-mediated multidrug resistance.	HOSP SICK CHILDREN,DEPT PEDIAT,DIV IMMUNOL & CANC,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT PATHOL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M5S 1A1,ONTARIO,CANADA; ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO M4X 1K9,ONTARIO,CANADA; ONTARIO CANC INST,DEPT BIOSTAT,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	CHAN, HSL (corresponding author), HOSP SICK CHILDREN,DEPT PEDIAT,DIV HEMATOL ONCOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.				NCI NIH HHS [CA-37130] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL DR, 1985, J CLIN ONCOL, V3, P311, DOI 10.1200/JCO.1985.3.3.311; BOURHIS J, 1989, J NATL CANCER I, V81, P1401, DOI 10.1093/jnci/81.18.1401; BRADLEY G, 1989, CANCER RES, V49, P2790; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; CHABNER BA, 1989, J NATL CANCER I, V81, P910, DOI 10.1093/jnci/81.12.910; CHAN HSL, 1988, LAB INVEST, V59, P870; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHRISTIANSEN H, 1988, BRIT J CANCER, V57, P121, DOI 10.1038/bjc.1988.24; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; Deacon J M, 1985, Prog Clin Biol Res, V175, P525; EVANS AE, 1987, CANCER, V59, P1853, DOI 10.1002/1097-0142(19870601)59:11<1853::AID-CNCR2820591102>3.0.CO;2-F; FINKLESTEIN JZ, 1979, MED PEDIATR ONCOL, V6, P179, DOI 10.1002/mpo.2950060211; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERLACH JH, 1987, J CLIN ONCOL, V5, P1452, DOI 10.1200/JCO.1987.5.9.1452; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GERLACH JH, 1986, CANCER SURV, V5, P25; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128; GREEN AA, 1981, CANCER, V48, P2310, DOI 10.1002/1097-0142(19811115)48:10<2310::AID-CNCR2820481029>3.0.CO;2-W; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HANN HWL, 1981, NEW ENGL J MED, V305, P425, DOI 10.1056/NEJM198108203050803; HAYES FA, 1981, CANCER, V48, P1715, DOI 10.1002/1097-0142(19811015)48:8<1715::AID-CNCR2820480805>3.0.CO;2-Y; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LAUG WE, 1978, PEDIATRICS, V62, P77; LING V, 1989, JNCI-J NATL CANCER I, V81, P84, DOI 10.1093/jnci/81.2.84; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; MA DDF, 1987, LANCET, V1, P135; MANCINI AF, 1984, MED PEDIATR ONCOL, V12, P155, DOI 10.1002/mpo.2950120302; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; ONEILL JA, 1985, J PEDIATR SURG, V20, P708, DOI 10.1016/S0022-3468(85)80029-4; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PHILIP T, 1991, J CLIN ONCOL, V9, P1037, DOI 10.1200/JCO.1991.9.6.1037; POLLARDKNIGHT D, 1990, ANAL BIOCHEM, V185, P353, DOI 10.1016/0003-2697(90)90307-U; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; TREUNER J, 1984, LANCET, V1, P333; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; ZELTZER PM, 1983, LANCET, V2, P361	43	437	446	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1991	325	23					1608	1614		10.1056/NEJM199112053252304	http://dx.doi.org/10.1056/NEJM199112053252304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR770	1682809	Bronze			2022-12-24	WOS:A1991GR77000004
J	HEALY, B				HEALY, B			ORAL-ADMINISTRATION OF ACYCLOVIR APPEARS INEFFECTIVE IN TREATING ACUTE INFECTIOUS-MONONUCLEOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, J INFECT DIS, V164, P788	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2955	2955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1668176				2022-12-24	WOS:A1991GR77500008
J	PUTKONEN, P; THORSTENSSON, R; GHAVAMZADEH, L; ALBERT, J; HILD, K; BIBERFELD, G; NORRBY, E				PUTKONEN, P; THORSTENSSON, R; GHAVAMZADEH, L; ALBERT, J; HILD, K; BIBERFELD, G; NORRBY, E			PREVENTION OF HIV-2 AND SIVSM INFECTION BY PASSIVE-IMMUNIZATION IN CYNOMOLGUS MONKEYS	NATURE			English	Article							MACACA-FASCICULARIS; IMMUNODEFICIENCY; VIRUS; GLYCOPROTEIN; PROTECTION; CHIMPANZEES; MACAQUES; LEUKEMIA; GP71	INFECTION of macaques with simian immunodeficiency virus (SIV) 1,2 and human immunodeficiency virus type 2 (HIV-2) 3,4 are useful models for studies of immunotherapy and vaccination against HIV as well as for testing of antiviral drugs. Vaccine research showing protective immunity in immunized monkeys 4-10 has indicated that it will be possible to develop a vaccine for prevention of human HIV infection, although many hurdles remain. The design of an HIV vaccine would be helped if the basis of the protective immunity could be elucidated. Passive immune prophylaxis offers a means to determine the relative role of antibodies in protection against infection. We have studied whether a transfer of antibodies can prevent HIV-2 and SIV(sm) (SIV of sooty mangabey origin) infection in cynomolgus monkeys. Sera with high antibody titres were collected, heat-treated and injected into naive animals 6 h before challenge with 10-100 monkey-infectious doses of live homologous virus. All control animals treated with normal monkey serum (n = 6) or no serum (n = 39) became infected by the challenge virus, whereas five out of seven animals pretreated with antibody-containing serum at a dose of 9 ml kg-1 resisted infection. Thus passively transferred antibodies can protect against a low-dose lentivirus challenge in a nonhuman primate.	NATL BACTERIOL LAB,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN	Karolinska Institutet	PUTKONEN, P (corresponding author), NATL BACTERIOL LAB,DEPT IMMUNOL,S-10521 STOCKHOLM,SWEDEN.							ALBERT J, 1990, J CLIN MICROBIOL, V28, P1560, DOI 10.1128/JCM.28.7.1560-1564.1990; ALBERT J, 1990, AIDS, V4, P291, DOI 10.1097/00002030-199004000-00002; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BIBERFELD G, 1988, AIDS, V2, P195; BJORLING E, IN PRESS P NATN ACAD; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; DENORONHA F, 1978, VIROLOGY, V85, P617, DOI 10.1016/0042-6822(78)90467-1; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; HUNSMANN G, 1975, VIROLOGY, V66, P327, DOI 10.1016/0042-6822(75)90203-2; KATAOKA R, 1990, BLOOD, V76, P1657; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; NORRBY E, 1991, AIDS RES HUM RETROV, V7, P279, DOI 10.1089/aid.1991.7.279; PRINCE AM, 1988, P NATL ACAD SCI USA, V85, P6944, DOI 10.1073/pnas.85.18.6944; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P366; PUTKONEN P, 1991, AIDS RES HUM RETROV, V7, P271, DOI 10.1089/aid.1991.7.271; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P359; PUTKONEN P, 1990, AIDS, V4, P783, DOI 10.1097/00002030-199008000-00010; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; THORSTENSSON R, 1991, J ACQ IMMUN DEF SYND, V4, P374	20	203	210	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					436	438		10.1038/352436a0	http://dx.doi.org/10.1038/352436a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1677743				2022-12-24	WOS:A1991FZ34600067
J	LAMMIE, PJ; HITCH, WL; ALLEN, EMW; HIGHTOWER, W; EBERHARD, ML				LAMMIE, PJ; HITCH, WL; ALLEN, EMW; HIGHTOWER, W; EBERHARD, ML			MATERNAL FILARIAL INFECTION AS RISK FACTOR FOR INFECTION IN CHILDREN	LANCET			English	Note							BRUGIA-PAHANGI; ANTIGENS; RESPONSES; PARASITE; JIRDS	Familial clustering of filarial infection was investigated through random house-to-house surveys of 643 individuals in Leogane, Haiti, an area with endemic Bancroftian filariasis. Children of infected mothers were 2.4 to 2.9 times more likely to be infected than were those of amicrofilaraemic mothers. Filarial-specific cellular responsiveness in amicrofilaraemic children born to infected mothers was lower than that in amicrofilaraemic children born to amicrofilaraemic mothers. No effect of paternal infection status was seen. The findings show that maternal infection is a risk factor for filarial infection in children and is associated with altered parasite-specific immune reactivity.			LAMMIE, PJ (corresponding author), CTR DIS CONTROL, CTR INFECT DIS,DIV PARASIT DIS,PARASIT DIS BRANCH, F13, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.				PHS HHS [YO2-00005-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		FRANKENBURG S, 1988, J IMMUNOL METHODS, V112, P177, DOI 10.1016/0022-1759(88)90355-9; KLEI TR, 1986, T ROY SOC TROP MED H, V80, P214, DOI 10.1016/0035-9203(86)90014-3; LAMMIE PJ, 1988, AM J TROP MED HYG, V38, P125, DOI 10.4269/ajtmh.1988.38.125; LAMMIE PJ, 1983, J IMMUNOL, V130, P1386; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; Ottesen E A, 1984, Trans R Soc Trop Med Hyg, V78 Suppl, P9, DOI 10.1016/0035-9203(84)90309-2; OTTESEN EA, 1981, ACTA TROP, V38, P205; PIESSENS WF, 1980, J CLIN INVEST, V65, P172, DOI 10.1172/JCI109648; RACCURT CP, 1988, T ROY SOC TROP MED H, V82, P721, DOI 10.1016/0035-9203(88)90214-3; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862	10	94	94	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	1991	337	8748					1005	1006		10.1016/0140-6736(91)92661-K	http://dx.doi.org/10.1016/0140-6736(91)92661-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673168				2022-12-24	WOS:A1991FJ13500005
J	HIBBS, ML; XU, H; STACKER, SA; SPRINGER, TA				HIBBS, ML; XU, H; STACKER, SA; SPRINGER, TA			REGULATION OF ADHESION TO ICAM-1 BY THE CYTOPLASMIC DOMAIN OF LFA-1 INTEGRIN BETA-SUBUNIT	SCIENCE			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; COMPLEMENT RECEPTOR TYPE-3; AMINO-ACID SEQUENCE; ALPHA-SUBUNIT; VONWILLEBRAND-FACTOR; CLONING; CD2; HOMOLOGY; FAMILY; CHAIN	Interactions between cytotoxic lymphocytes and their targets require the T cell antigen receptor (TCR) and the integrin lymphocyte function-associated molecule-1 (LFA-1, CD11a/CD18). LFA-1 is not constitutively avid for its counterreceptors, intercellular adhesion molecules (ICAMs)-1 and -2. Cross-linking of the TCR transiently converts LFA-1 to a high avidity state and thus provides a mechanism for regulating cellular adhesion and de-adhesion in an antigen-specific manner. Truncation of the cytoplasmic domain of the beta, but not the alpha, subunit of LFA-1 eliminated binding to ICAM-1 and sensitivity to phorbol esters. Thus, LFA-1 binding to ICAM-1 was found to be regulated by the cytoplasmic domain of the beta-subunit of LFA-1.	HARVARD UNIV, SCH MED, CTR BLOOD RES, 800 HUNTINGTON AVE, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School			Hibbs, Margaret L/D-7013-2011	Hibbs, Margaret L/0000-0002-3751-6751; Stacker, Steven/0000-0003-4096-9273	NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER; NCI NIH HHS [CA31798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HIBBS ML, UNPUB; KAUFMANN Y, UNPUB; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WILSON RW, 1989, NUCLEIC ACIDS RES, V17, P5397, DOI 10.1093/nar/17.13.5397	25	255	256	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1991	251	5001					1611	1613		10.1126/science.1672776	http://dx.doi.org/10.1126/science.1672776			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	1672776				2022-12-24	WOS:A1991FD89000038
J	GLAICHENHAUS, N; SHASTRI, N; LITTMAN, DR; TURNER, JM				GLAICHENHAUS, N; SHASTRI, N; LITTMAN, DR; TURNER, JM			REQUIREMENT FOR ASSOCIATION OF P56LCK WITH CD4 IN ANTIGEN-SPECIFIC SIGNAL TRANSDUCTION IN T-CELLS	CELL			English	Article							TYROSINE-PROTEIN-KINASE; MAJOR HISTOCOMPATIBILITY COMPLEX; PHORBOL-MYRISTATE ACETATE; CLASS-I MOLECULES; LYMPHOCYTES-T; TRANSGENIC MICE; GENE-TRANSFER; MOUSE CD4; RECEPTOR; ACTIVATION	The T cell-specific transmembrane glycoprotein CD4 interacts with class II MHC molecules via its external domain and is associated with the tyrosine kinase p56lck via a cysteine motif in its cytoplasmic domain. We have assessed the ability of CD4 to synergize with the antigen-specific T cell receptor (TCR) for induction of transmembrane signals that result in lymphokine production. Mutant CD4 molecules were introduced into T cells that lacked endogenous CD4 but expressed TCRs specific for lysozyme peptides or the superantigen SEA bound to A(b) or A(bm12) class II MHC molecules. With either ligand, T cell activation occurred only when CD4 was associated with p56lck. These results demonstrate that residues within the cytoplasmic domain of CD4 are required for its coreceptor function in TCR-mediated signal transduction and strongly support the notion that the association of CD4 with p56lck is critical in this process.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	GLAICHENHAUS, N (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.							ACRES RB, 1986, J BIOL CHEM, V261, P6210; ACRES RB, 1987, J IMMUNOL, V139, P2268; ANDERSON P, 1988, J IMMUNOL, V140, P1732; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BIDDISON WE, 1984, J EXP MED, V159, P783, DOI 10.1084/jem.159.3.783; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; CHUCK RS, 1990, P NATL ACAD SCI USA, V87, P5021, DOI 10.1073/pnas.87.13.5021; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; JANEWAY CA, 1989, TODAY, V10, P234; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; MACDONALD HR, 1990, J EXP MED, V171, P1381, DOI 10.1084/jem.171.4.1381; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARNES JR, 1989, ADV IMMUNOL, V44, P265; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; RONCHESE F, 1987, J IMMUNOL, V139, P629; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHASTRI N, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P249; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONHOEGEN P, 1989, J EXP MED, V170, P1879, DOI 10.1084/jem.170.6.1879; WASSMER P, 1985, J IMMUNOL, V135, P2237; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	53	447	462	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					511	520		10.1016/0092-8674(91)90235-Q	http://dx.doi.org/10.1016/0092-8674(91)90235-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1671341				2022-12-24	WOS:A1991EX36100007
J	GERBERDING, JL; LITTELL, C; TARKINGTON, A; BROWN, A; SCHECTER, WP				GERBERDING, JL; LITTELL, C; TARKINGTON, A; BROWN, A; SCHECTER, WP			RISK OF EXPOSURE OF SURGICAL PERSONNEL TO PATIENTS BLOOD DURING SURGERY AT SAN-FRANCISCO-GENERAL-HOSPITAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	GERBERDING, JL (corresponding author), SAN FRANCISCO GEN HOSP,MED SERV,5H-22,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.							BROUGH SJ, 1988, BRIT J SURG, V75, P317, DOI 10.1002/bjs.1800750408; Centers for Disease Control reports include, 1988, MMWR, V37, P229; EMANUEL EJ, 1988, NEW ENGL J MED, V318, P1686, DOI 10.1056/NEJM198806233182511; FOURNIER AM, 1989, ARCH SURG-CHICAGO, V124, P1038; GERBERDING JL, 1987, J INFECT DIS, V156, P861, DOI 10.1093/infdis/156.6.861; GOLDMAN B, 1988, CAN MED ASSOC J, V138, P736; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; LAFFERTY K, 1987, BRIT MED J, V295, P392, DOI 10.1136/bmj.295.6594.392-a; LOWENFELS AB, 1989, ARCH SURG-CHICAGO, V124, P1284; MATTA H, 1988, BRIT MED J, V297, P597, DOI 10.1136/bmj.297.6648.597; SHANSON DC, 1988, J HOSP INFECT, V11, P218, DOI 10.1016/0195-6701(88)90190-9; 1986, SUGI SUPPLEMENTAL LI, P269; 1986, MMWR, V35, P221	13	321	326	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 21	1990	322	25					1788	1793		10.1056/NEJM199006213222506	http://dx.doi.org/10.1056/NEJM199006213222506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ232	1693174				2022-12-24	WOS:A1990DJ23200006
J	BURKLY, LC; LO, D; FLAVELL, RA				BURKLY, LC; LO, D; FLAVELL, RA			TOLERANCE IN TRANSGENIC MICE EXPRESSING MAJOR HISTOCOMPATIBILITY MOLECULES EXTRATHYMICALLY ON PANCREATIC-CELLS	SCIENCE			English	Article									UNIV PENN,SCH VET MED,REPROD PHYSIOL LAB,PHILADELPHIA,PA 19104; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	University of Pennsylvania; Howard Hughes Medical Institute; Yale University	BURKLY, LC (corresponding author), BIOGEN INC,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BILL J, 1988, P NATL ACAD SCI USA, V85, P9184, DOI 10.1073/pnas.85.23.9184; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BOTTAZZO GF, 1986, IMMUNOL REV, V94, P137, DOI 10.1111/j.1600-065X.1986.tb01168.x; BOTTAZZO GF, 1985, NEW ENGL J MED, V313, P353, DOI 10.1056/NEJM198508083130604; BOTTAZZO GF, 1983, LANCET, V2, P1115; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BURGERT HG, 1989, J EXP MED, V170, P1887, DOI 10.1084/jem.170.6.1887; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; COLIGAN JE, 1981, NATURE, V291, P35, DOI 10.1038/291035a0; COWING C, 1985, IMMUNOL TODAY, V6, P72, DOI 10.1016/0167-5699(85)90018-0; CRISPE IN, 1985, NATURE, V317, P627, DOI 10.1038/317627a0; DEAN BM, 1985, DIABETOLOGIA, V28, P464, DOI 10.1007/BF00280892; FINK PJ, 1984, J EXP MED, V159, P436, DOI 10.1084/jem.159.2.436; FLAVELL RA, 1986, SCIENCE, V233, P437, DOI 10.1126/science.3726537; FRELINGER J, 1984, IMMUNOL REV, V81, P21, DOI 10.1111/j.1600-065X.1984.tb01103.x; GAO EK, 1989, J EXP MED, V170, P1947, DOI 10.1084/jem.170.6.1947; GASPARI AA, 1988, J IMMUNOL, V141, P2216; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KANAGAWA O, UNPUB; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; LO D, UNPUB; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MADSEN JC, 1988, NATURE, V332, P161, DOI 10.1038/332161a0; MANGER B, 1985, J IMMUNOL, V135, P3669; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MARRACK P, 1988, CELL, V53, P627, DOI 10.1016/0092-8674(88)90578-8; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MATZINGER P, 1987, J CELL IMMUN, V29, P1; MICHIE SA, 1988, J EXP MED, V168, P1929, DOI 10.1084/jem.168.5.1929; MILLER J, 1990, J IMMUNOL, V144, P334; MILLER JFAP, 1989, IMMUNOL REV, V107, P109, DOI 10.1111/j.1600-065X.1989.tb00005.x; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; NAPARSTEK Y, 1982, NATURE, V300, P262, DOI 10.1038/300262a0; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PARHAM P, 1988, NATURE, V333, P500, DOI 10.1038/333500a0; PHILLIPS ML, 1986, P NATL ACAD SCI USA, V83, P5634, DOI 10.1073/pnas.83.15.5634; PUJOLBORRELL R, 1987, NATURE, V326, P304, DOI 10.1038/326304a0; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; QUILL H, 1987, J IMMUNOL, V138, P3704; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROSSINI AA, 1985, ANNU REV IMMUNOL, V3, P289; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; WIDERA G, 1987, CELL, V51, P175, DOI 10.1016/0092-8674(87)90145-0	60	111	115	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 15	1990	248	4961					1364	1368		10.1126/science.1694042	http://dx.doi.org/10.1126/science.1694042			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ501	1694042				2022-12-24	WOS:A1990DJ50100030
J	ROSEN, MK; STANDAERT, RF; GALAT, A; NAKATSUKA, M; SCHREIBER, SL				ROSEN, MK; STANDAERT, RF; GALAT, A; NAKATSUKA, M; SCHREIBER, SL			INHIBITION OF FKBP ROTAMASE ACTIVITY BY IMMUNOSUPPRESSANT FK506 - TWISTED AMIDE SURROGATE	SCIENCE			English	Article									HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University			Standaert, Robert F/D-9467-2013; Standaert, Robert F./AAI-1532-2021	Standaert, Robert F/0000-0002-5684-1322; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, R37GM038627] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKIN D, 1989, TETRAHEDRON LETT, V30, P671, DOI 10.1016/S0040-4039(01)80278-1; BEVERIDGE T, 1986, CYCLOSPORIN, P269; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FINDLAY JA, 1980, CAN J CHEM, V58, P579, DOI 10.1139/v80-090; FISCHER G, 1989, FEBS LETT, V250, P267, DOI 10.1016/0014-5793(89)80735-5; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISHER G, 1989, NATURE, V337, P476; GALARDY RE, 1982, INT J PEPT PROT RES, V19, P123; GALAT A, UNPUB; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARDING MW, TRANSPLANTATION, pS29; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HATANAKA H, 1989, J ANTIBIOT, V42, P620, DOI 10.7164/antibiotics.42.620; JOHNSON F, 1968, CHEM REV, V68, P375, DOI 10.1021/cr60254a001; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MARTEL RR, 1977, CAN J PHYSIOL PHARM, V55, P48, DOI 10.1139/y77-007; NAKATSUKA M, IN PRESS J AM CHEM S; QUESNIAUX VFJ, 1988, TRANSPLANTATION, V46, pS23; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCOTT AI, 1986, TETRAHEDRON, V42, P3269, DOI 10.1016/S0040-4020(01)87391-9; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, UNPUB; STARZL TE, 1989, LANCET, V2, P1000; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; WENGER RM, 1986, PROG CHEM ORGANIC NA, V50, P123; YOSHIMURA N, 1989, TRANSPLANTATION, V47, P356, DOI 10.1097/00007890-198902000-00035; YOSHIMURA N, 1989, TRANSPLANTATION, V47, P351, DOI 10.1097/00007890-198902000-00034; 1989, NY TIMES        1018, P1	36	190	197	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 18	1990	248	4957					863	866		10.1126/science.1693013	http://dx.doi.org/10.1126/science.1693013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DD972	1693013				2022-12-24	WOS:A1990DD97200043
J	FILBIN, MT; WALSH, FS; TRAPP, BD; PIZZEY, JA; TENNEKOON, GI				FILBIN, MT; WALSH, FS; TRAPP, BD; PIZZEY, JA; TENNEKOON, GI			ROLE OF MYELIN PO PROTEIN AS A HOMOPHILIC ADHESION MOLECULE	NATURE			English	Article									UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT EXPTL PATHOL,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	FILBIN, MT (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205, USA.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARCLAY AN, 1988, T CELL RECEPTORS, P53; BRAUN PE, 1984, MYELIN, P97; FILBIN MT, IN PRESS J NEUROCHEM; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; JONES GE, 1979, J NEUROL SCI, V43, P465, DOI 10.1016/0022-510X(79)90025-X; JONES GE, 1981, J CELL SCI, V48, P291; KIRSCHNER DA, 1980, NATURE, V283, P207, DOI 10.1038/283207a0; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; PIZZEY JA, 1985, J NEUROL SCI, V69, P207, DOI 10.1016/0022-510X(85)90134-0; PIZZEY JA, 1988, J CELL BIOL, V107, P2307, DOI 10.1083/jcb.107.6.2307; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; RUTISHAUSER U, 1982, P NATL ACAD SCI-BIOL, V79, P685, DOI 10.1073/pnas.79.2.685; SIEBER F, 1981, J CELL BIOL, V90, P55, DOI 10.1083/jcb.90.1.55; STOLL G, 1989, J NEUROSCI, V9, P2327; STOLL PM, 1989, CELL, V59, P313; TRAPP BD, 1988, J CELL BIOL, V107, P675, DOI 10.1083/jcb.107.2.675; TRAPP BD, 1982, J CELL BIOL, V92, P877, DOI 10.1083/jcb.92.3.877; TRAPP BD, 1979, P NATL ACAD SCI USA, V76, P3552, DOI 10.1073/pnas.76.7.3552	19	306	307	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 26	1990	344	6269					871	872		10.1038/344871a0	http://dx.doi.org/10.1038/344871a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA751	1691824				2022-12-24	WOS:A1990DA75100059
J	DOBSON, DE; KAMBE, A; BLOCK, E; DION, T; LU, H; CASTELLOT, JJ; SPIEGELMAN, BM				DOBSON, DE; KAMBE, A; BLOCK, E; DION, T; LU, H; CASTELLOT, JJ; SPIEGELMAN, BM			1-BUTYRYL-GLYCEROL - A NOVEL ANGIOGENESIS FACTOR SECRETED BY DIFFERENTIATING ADIPOCYTES	CELL			English	Article									HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; TUFTS UNIV,SCH HLTH SCI,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111; EK SHRIVER CTR,MASS SPECT LAB,WALTHAM,MA 02254	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Tufts University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042420, R37DK031405, R01DK031405] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30290] Funding Source: Medline; NIDDK NIH HHS [DK42420, DK31405] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BANCHER E, 1973, INT J VITAM NUTR RES, V43, P510; BANDA MJ, 1982, P NATL ACAD SCI-BIOL, V79, P7773, DOI 10.1073/pnas.79.24.7773; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BENEZRA D, 1978, AM J OPHTHALMOL, V86, P455, DOI 10.1016/0002-9394(78)90289-1; BIRKHAHN RH, 1977, AM J CLIN NUTR, V30, P2078, DOI 10.1093/ajcn/30.12.2078; CASTELLOT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P5597, DOI 10.1073/pnas.79.18.5597; CASTELLOT JJ, 1986, J CELL PHYSIOL, V127, P323, DOI 10.1002/jcp.1041270221; CASTELLOT JJ, 1980, P NATL ACAD SCI-BIOL, V77, P6007, DOI 10.1073/pnas.77.10.6007; DUNN BE, 1981, ANAT REC, V199, P33, DOI 10.1002/ar.1091990105; FETT JW, 1985, BIOCHEMISTRY-US, V25, P3527; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; GOLDSMITH HS, 1984, JAMA-J AM MED ASSOC, V252, P2034, DOI 10.1001/jama.252.15.2034; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1978, DIFFERENTIATION DEV, P13; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; Jaffe E. A, 1984, BIOL ENDOTHELIAL CEL; KULL FC, 1987, SCIENCE, V236, P843, DOI 10.1126/science.2437656; KURIHARCUCH W, 1978, P NATL ACAD SCI USA, V75, P6107, DOI 10.1073/pnas.75.12.6107; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; MCAUSLAN BR, 1979, EXP CELL RES, V119, P181, DOI 10.1016/0014-4827(79)90347-1; Moriyusu M, 1984, CHEM ABSTR, V99; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; RAJU KS, 1984, CANCER RES, V44, P1579; REICH E, 1974, P351; RIFKIN DB, 1984, CANCER INVASION META, P187; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SALMON JA, 1982, METHOD ENZYMOL, V86, P477; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; TAUB M, 1980, J CELL PHYSIOL, V105, P369, DOI 10.1002/jcp.1041050220; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WAGNER RC, 1975, MICROVASC RES, V10, P286, DOI 10.1016/0026-2862(75)90033-3; WANG CS, 1981, J BIOL CHEM, V256, P198; WASSERMANN F., 1965, HANDBOOK PHYSIOL, V5, P87; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; WRIGHT TM, 1988, P NATL ACAD SCI USA, V85, P1869, DOI 10.1073/pnas.85.6.1869; ZICHE M, 1982, JNCI-J NATL CANCER I, V69, P475	43	112	141	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 20	1990	61	2					223	230		10.1016/0092-8674(90)90803-M	http://dx.doi.org/10.1016/0092-8674(90)90803-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DA752	1691958				2022-12-24	WOS:A1990DA75200005
J	ELICES, MJ; OSBORN, L; TAKADA, Y; CROUSE, C; LUHOWSKYJ, S; HEMLER, ME; LOBB, RR				ELICES, MJ; OSBORN, L; TAKADA, Y; CROUSE, C; LUHOWSKYJ, S; HEMLER, ME; LOBB, RR			VCAM-1 ON ACTIVATED ENDOTHELIUM INTERACTS WITH THE LEUKOCYTE INTEGRIN VLA-4 AT A SITE DISTINCT FROM THE VLA-4 FIBRONECTIN BINDING-SITE	CELL			English	Article									BIOGEN INC, CAMBRIDGE, MA 02142 USA	Biogen	ELICES, MJ (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR VIROL, BOSTON, MA 02115 USA.			takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM38903] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; BEDNARCZYK J, 1990, IN PRESS J IMMUNOL; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOYD AW, 1988, P NATL ACAD SCI USA, V85, P3095, DOI 10.1073/pnas.85.9.3095; CLAYBERGER C, 1987, J IMMUNOL, V138, P1510; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1986, J IMMUNOL, V137, P245; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; GODFREY HP, 1988, J IMMUNOL, V141, P1508; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; HAMANN A, 1988, J IMMUNOL, V140, P693; HARLAN JM, 1985, BLOOD, V65, P513; HASKARD D, 1986, J IMMUNOL, V137, P2901; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HSI BL, 1987, PLACENTA, V8, P209, DOI 10.1016/0143-4004(87)90024-5; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIEFEL V, 1989, BLOOD, V73, P2219; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; LEEUWENBERG JFM, 1989, EUR J IMMUNOL, V19, P715, DOI 10.1002/eji.1830190422; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MENTZER SJ, 1986, J CELL PHYSIOL, V126, P285, DOI 10.1002/jcp.1041260219; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PALS ST, 1988, J IMMUNOL, V140, P1851; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; POBER JS, 1986, J IMMUNOL, V137, P1893; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; VANNOESEL C, 1988, NATURE, V333, P850, DOI 10.1038/333850a0; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321	51	1780	1879	2	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 23	1990	60	4					577	584		10.1016/0092-8674(90)90661-W	http://dx.doi.org/10.1016/0092-8674(90)90661-W			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CQ723	1689216				2022-12-24	WOS:A1990CQ72300008
J	WALLNY, HJ; RAMMENSEE, HG				WALLNY, HJ; RAMMENSEE, HG			IDENTIFICATION OF CLASSICAL MINOR HISTOCOMPATIBILITY ANTIGEN AS CELL-DERIVED PEPTIDE	NATURE			English	Article									MAX PLANCK INST BIOL, IMMUNGENET ABT, CORRENSSTR 42, W-7400 TUBINGEN, GERMANY	Max Planck Society								BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; BEVAN MJ, 1975, NATURE, V256, P419, DOI 10.1038/256419a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CLAVERIE JM, 1986, ANN INST PASTEUR IMM, VD137, P425; COUNCE S, 1956, ANN SURG, V144, P198, DOI 10.1097/00000658-195608000-00009; DEPLAEN E, 1988, P NATL ACAD SCI USA, V85, P2274; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GRAFF RJ, 1979, ORIGINS INBRED MICE, P667; KLEIN J, 1983, IMMUNOGENETICS, V17, P553, DOI 10.1007/BF00366126; Klein J., 1986, NATURAL HIST MAJOR H; KRAUSPE R, 1986, ANAL BIOCHEM, V153, P242, DOI 10.1016/0003-2697(86)90088-6; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LOVELAND B, 1986, IMMUNOL TODAY, V7, P223, DOI 10.1016/0167-5699(86)90109-X; RAMMENSEE HG, 1989, IMMUNOGENETICS, V30, P296, DOI 10.1007/BF02421334; RAMMENSEE HG, 1986, NATURE, V319, P502, DOI 10.1038/319502a0; RUSCH E, 1983, TRANSPLANT P, V15, P2093; SNELL GD, 1948, J GENET, V49, P87, DOI 10.1007/BF02986826; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WETTSTEIN PJ, 1989, HUMAN IMMUNOGENETICS, P339; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	21	199	200	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	1990	343	6255					275	278		10.1038/343275a0	http://dx.doi.org/10.1038/343275a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ682	1689009				2022-12-24	WOS:A1990CJ68200076
J	KLEIN, RS; FREEMAN, K; TAYLOR, PE; STEVENS, CE				KLEIN, RS; FREEMAN, K; TAYLOR, PE; STEVENS, CE			OCCUPATIONAL RISK FOR HEPATITIS-C VIRUS-INFECTION AMONG NEW-YORK-CITY DENTISTS	LANCET			English	Article							NON-B-HEPATITIS; NON-A; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; ANTIBODIES; EPIDEMIOLOGY; TRANSMISSION; PREVALENCE	Health-care workers have an occupational risk of infection with hepatitis C virus (HCV). However, neither the magnitude of this risk nor the practices associated with it have been defined. Since dentists have numerous patients and are exposed to blood, they are likely to have the maximum risk. Therefore, we have assessed occupational risk for HCV infection among dentists in the New York City area. Individuals who admitted present or previous intravenous drug use or (men) who were homosexual or bisexual were excluded. Demographic, occupational, and behavioural data were recorded, and sera were tested for antibodies to HCV (anti-HCV). Anti-HCV was found in 8 (1.75%) of 456 dentists compared with 1 (0.14%) of 723 controls (odds ratio [OR] 12.9, 95% confidence interval [Cl] 1.7 to 573). Anti-HCV was found in 4 (9.3%) of 43 oral surgeons compared with 4 (0.97%) of 413 other dentists (OR 10.5, 95% Cl 1.9 to 58). Seropositive dentists claimed to have treated more intravenous drug users in the week (p = 0.04) or month (p = 0.03) before the study than did seronegative dentists. Our findings show that dentists are at increased risk for hepatitis C infection. All health-care workers should regard patients as potentially infected with a communicable bloodborne agent.	MONTEFIORE MED CTR,DEPT BIOSTAT,BRONX,NY 10467; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT SOCIAL MED,BRONX,NY 10461; NEW YORK BLOOD CTR,WOLF SZMUNESS LAB EPIDEMIOL,NEW YORK,NY 10021	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; New York Blood Center	KLEIN, RS (corresponding author), MONTEFIORE MED CTR,DEPT MED,DIV INFECT DIS,111 E 210TH ST,BRONX,NY 10467, USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ABE K, 1987, J INFECT DIS, V155, P1078, DOI 10.1093/infdis/155.5.1078; AHTONE J, 1980, LANCET, V1, P1142; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1978, LANCET, V1, P459; ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; BRUIX J, 1989, LANCET, V2, P1004; COLOMBO M, 1989, LANCET, V2, P1006; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1989, LANCET, V2, P294; FRANCIS DP, 1984, AM J MED, V76, P69, DOI 10.1016/0002-9343(84)90752-6; KATMITSUKASA H, 1989, LANCET, V2, P987; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; MOSLEY JW, 1975, JAMA-J AM MED ASSOC, V9, P967; SCHIFF ER, 1986, J AM DENT ASSOC, V113, P390, DOI 10.14219/jada.archive.1986.0210; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; TABOR E, 1978, LANCET, V1, P463, DOI 10.1016/s0140-6736(78)90132-0; TABOR E, 1983, J MED PRIMATOL, V12, P305; TABOR E, 1980, NEW ENGL J MED, V303, P139; WANG JT, 1991, LANCET, V337, P48, DOI 10.1016/0140-6736(91)93365-G; 1987, MMWR S2S, V36; 1988, MMWR, V37, P387; 1988, MMWR, V37, P377	28	148	153	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1539	1542		10.1016/0140-6736(91)92369-D	http://dx.doi.org/10.1016/0140-6736(91)92369-D			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683969				2022-12-24	WOS:A1991GW03600001
J	SEGIL, N; ROBERTS, SB; HEINTZ, N				SEGIL, N; ROBERTS, SB; HEINTZ, N			MITOTIC PHOSPHORYLATION OF THE OCT-1 HOMEODOMAIN AND REGULATION OF OCT-1 DNA-BINDING ACTIVITY	SCIENCE			English	Article							HISTONE H2B GENE; GEL-ELECTROPHORESIS; ESCHERICHIA-COLI; POU DOMAIN; CELL; PURIFICATION; PROTEINS	Oct-1 is a transcription factor involved in the cell cycle regulation of histone H2B gene transcription and in the transcription of other cellular housekeeping genes. Oct-1 is hyperphosphorylated as cells enter mitosis, and mitosis-specific phosphorylation is reversed as cells exit mitosis. A mitosis-specific phosphorylation site in the homeodomain of Oct-1 was phosphorylated in vitro by protein kinase A. Phosphorylation of this site correlated with inhibition of Oct-1 DNA binding activity in vivo and in vitro. The inhibition of Oct-1 DNA binding during mitosis suggests a mechanism by which the general inhibition of transcription during mitosis might occur.			SEGIL, N (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOL LAB,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032544, F32GM013752] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 13752, GM 32544] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; DAVIDSON D, 1964, EXP CELL RES, V35, P317, DOI 10.1016/0014-4827(64)90098-9; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HARLOW E, 1988, ANTIBODIES LABORATOR; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LABELLA F, 1991, MOL CELL BIOL, V11, P5825, DOI 10.1128/MCB.11.12.5825; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SAHASRABUDDHE CG, 1984, EXP CELL RES, V153, P439, DOI 10.1016/0014-4827(84)90612-8; Schreiber E., 1989, TISSUE SPECIFIC GENE, P33; SEGIL N, 1991, COLD SPRING HARB SYM, V56, P285; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TERASIMA T, 1963, EXP CELL RES, V30, P344, DOI 10.1016/0014-4827(63)90306-9; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	26	222	225	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1814	1816		10.1126/science.1684878	http://dx.doi.org/10.1126/science.1684878			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1684878				2022-12-24	WOS:A1991GW31600051
J	YU, VC; DELSERT, C; ANDERSEN, B; HOLLOWAY, JM; DEVARY, OV; NAAR, AM; KIM, SY; BOUTIN, JM; GLASS, CK; ROSENFELD, MG				YU, VC; DELSERT, C; ANDERSEN, B; HOLLOWAY, JM; DEVARY, OV; NAAR, AM; KIM, SY; BOUTIN, JM; GLASS, CK; ROSENFELD, MG			RXR-BETA - A COREGULATOR THAT ENHANCES BINDING OF RETINOIC ACID, THYROID-HORMONE, AND VITAMIN-D RECEPTORS TO THEIR COGNATE RESPONSE ELEMENTS	CELL			English	Article							HUMAN OSTEOCALCIN GENE; DNA-BINDING; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; MOLECULAR-CLONING; MAMMALIAN-CELLS; SEQUENCE; PROTEINS; IDENTIFICATION; TRANSCRIPTION	The retinoic acid receptor (RAR) requires coregulators to bind effectively to response elements in target genes. A strategy of sequential screening of expression libraries with a retinoic acid response element and RAR identified a cDNA encoding a coregulator highly related to RXR-alpha. This protein, termed RXR-beta, forms heterodimers with RAR, preferentially increasing its DNA binding and transcriptional activity on promoters containing retinoic acid, but not thyroid hormone or vitamin D, response elements. Remarkably, RXR-beta also heterodimerizes with the thyroid hormone and vitamin D receptors, increasing both DNA binding and transcriptional function on their respective response elements. RXR-alpha also forms heterodimers with these receptors. These observations suggest that retinoid X receptors meet the criteria for biochemically characterized cellular coregulators and serve to selectively target the high affinity binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate DNA response elements.	UNIV CALIF SAN DIEGO,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,MOLEC PATHOL GRP,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	YU, VC (corresponding author), UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093, USA.		Yu, Victor/A-7899-2015; Glass, Christopher/AAI-3933-2021	Yu, Victor/0000-0003-3270-4734; Glass, Christopher/0000-0003-4344-3592				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1991, MOL ASPECTS CELLULAR, V6, P299; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HE X, 1989, NATURE, V343, P38; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUROKAWA R, 1991, BIOCHIM BIOPHYS ACTA, V1095, P63; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9781; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LIPKIN SM, 1991, IN PRESS P NATL ACAD; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; OZONO K, 1990, J BIOL CHEM, V265, P21881; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SPORN MB, 1983, CANCER RES, V43, P3034; STUDIER FW, 1986, J MOL BIOL, V189, P13; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	78	1237	1264	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1251	1266		10.1016/0092-8674(91)90301-E	http://dx.doi.org/10.1016/0092-8674(91)90301-E			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1662118				2022-12-24	WOS:A1991GX16400023
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FOOD LABELING REFORM INITIATIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3263	3263						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU964	1660082				2022-12-24	WOS:A1991GU96400003
J	SMITH, WC; HARLAND, RM				SMITH, WC; HARLAND, RM			INJECTED XWNT-8 RNA ACTS EARLY IN XENOPUS EMBRYOS TO PROMOTE FORMATION OF A VEGETAL DORSALIZING CENTER	CELL			English	Article							MESODERM-INDUCING FACTOR; MESSENGER-RNA; CELL LINEAGE; AMPHIBIAN DEVELOPMENT; LAEVIS EMBRYOS; GROWTH-FACTOR; INDUCTION; EXPRESSION; AXIS; PATTERN	Expression cloning from a pool of gastrula cDNAs identified the Wnt family member Xwnt-8 as having dorsal axis-inducing activity in Xenopus embryos. Microinjected Xwnt-8 mRNA was able to rescue the development of a dorsally complete anterior-posterior axis in embryos ventralized by exposure to UV light. Axis induction was observed in embryos injected in either marginal or vegetal blastomeres at the 32-cell stage. Vegetal blastomeres receiving Xwnt-8 mRNA contributed progeny not to the induced dorsal axis, but to the endoderm, a result consistent with Xwnt-8 causing cells to act as a Nieuwkoop center (the vegetal-inducing component of normal dorsal axis formation), rather than as a Spemann organizer (the induced dorsal marginal zone component that directly forms the dorsal mesoderm). Xwnt-8, which is normally expressed ventrally in midgastrula and neurula embryos, appears to mimic, when injected, maternally encoded dorsal mesoderm-inducing factors that act early in development.			SMITH, WC (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOTERENBROOD EC, 1973, ROUX ARCH DEV BIOL, V173, P319, DOI 10.1007/BF00575837; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CONDIE BG, 1987, DEVELOPMENT, V101, P93; COOKE J, 1987, DEVELOPMENT, V99, P197; DALE L, 1985, J EMBRYOL EXP MORPH, V89, P289; DALE L, 1987, DEVELOPMENT, V100, P279; DALE L, 1987, DEVELOPMENT, V99, P527; Dawid I.B., 1990, Current Topics in Developmental Biology, V24, P261, DOI 10.1016/S0070-2153(08)60090-3; ELINSON RP, 1988, DEV BIOL, V128, P185, DOI 10.1016/0012-1606(88)90281-3; FRANK D, 1991, IN PRESS DEVELOPMENT; GERHART J, 1986, ANNU REV CELL BIOL, V2, P201, DOI 10.1146/annurev.cb.02.110186.001221; GERHART J, 1989, DEVELOPMENT, V107, P37; Gerhart J, 1980, BIOL REGULATION DEV, V2; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GIMLICH RL, 1983, NATURE, V306, P471, DOI 10.1038/306471a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HARLAND RM, 1991, IN PRESS METH CELL B, V36; HAUSEN P, 1991, EARLY DEV XENOPUS; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; JONES EA, 1987, DEVELOPMENT, V101, P557; KAGEURA H, 1990, DEV BIOL, V142, P432, DOI 10.1016/0012-1606(90)90365-P; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON AP, 1991, ADV DEV BIOL, V1, P31; MOODY SA, 1987, DEV BIOL, V122, P300, DOI 10.1016/0012-1606(87)90296-X; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1973, ADV MORPHOGEN, V10, P2; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Sambrook J., 1989, MOL CLONING LAB MANU; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67; Spemann H., 1938, EMBRYONIC DEV INDUCT; STEWART RM, 1990, DEVELOPMENT, V109, P363; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; VIZE PD, 1991, METHOD CELL BIOL, V36, P361; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7	59	544	558	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					753	765		10.1016/0092-8674(91)90070-F	http://dx.doi.org/10.1016/0092-8674(91)90070-F			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657405				2022-12-24	WOS:A1991GQ40700012
J	WINGARD, JR; MERZ, WG; RINALDI, MG; JOHNSON, TR; KARP, JE; SARAL, R				WINGARD, JR; MERZ, WG; RINALDI, MG; JOHNSON, TR; KARP, JE; SARAL, R			INCREASE IN CANDIDA-KRUSEI INFECTION AMONG PATIENTS WITH BONE-MARROW TRANSPLANTATION AND NEUTROPENIA TREATED PROPHYLACTICALLY WITH FLUCONAZOLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TORULOPSIS-GLABRATA; FUNGEMIA; FREQUENCY; CANCER; FEVER; COLONIZATION; THERAPY	Background. In early 1990 fluconazole was introduced as a prophylactic antifungal agent after bone marrow transplantation. During the same year Candida krusei emerged as the chief candida pathogen among patients with bone marrow transplants. Methods. To determine whether there was a correlation between the introduction of fluconazole and the increased incidence of C. krusei, we conducted a retrospective study based on the medical, mycologic, and autopsy records of all adult inpatients who had undergone bone marrow transplantation (n = 296) or who had leukemia (n = 167) at the study center during 1989 and 1990. Results. The 84 patients who received antifungal prophylaxis with fluconazole had a sevenfold greater frequency of C. krusei infection than the 335 patients who did not receive fluconazole (8.3 percent vs. 1.2 percent, P = 0.002), despite having a lower frequency of disseminated C. albicans and C. tropicalis infections (0 vs. 6.0 percent, P = 0.02). Ten of the 11 C. krusei infections were controlled by a combination of amphotericin B and flucytosine. Colonization by C. krusei was found in 40.5 percent of the patients who received fluconazole but in only 16.7 percent of those who did not receive it (P < 0.0001). Colonization was independently associated with the prophylactic use of both fluconazole (odds ratio, 3.50; P < 0.001) and norfloxacin (odds ratio, 2.53; P = 0.04). C. krusei was not susceptible to fluconazole in vitro. Conclusions. In patients at high risk for disseminated candida infections, suppression of bacterial flora and the more common candida pathogens may permit some less pathogenic, but natively resistant candida species, such as C. krusei, to emerge as systemic pathogens.	JOHNS HOPKINS MED INST,DEPT LAB MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,CTR ONCOL,BALTIMORE,MD 21205; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284; NCI,OFF DIRECTOR,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	WINGARD, JR (corresponding author), EMORY UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BONE MARROW TRANSPLANT PROGRAM,ATLANTA,GA 30322, USA.			Wingard, John/0000-0001-7478-5398	NCI NIH HHS [CA15396, CA06973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973, P01CA015396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISNER J, 1976, AM J MED, V61, P23, DOI 10.1016/0002-9343(76)90026-7; CALDERONE RA, 1987, REV INFECT DIS, V9, pS400; DICK JD, 1980, ANTIMICROB AGENTS CH, V18, P158, DOI 10.1128/AAC.18.1.158; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; HARVEY RL, 1987, ARCH INTERN MED, V147, P2117, DOI 10.1001/archinte.147.12.2117; HORN R, 1985, REV INFECT DIS, V7, P646; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; KARP JE, 1991, REV INFECT DIS, V13, P592; KING RD, 1980, INFECT IMMUN, V27, P667, DOI 10.1128/IAI.27.2.667-674.1980; KOMSHIAN SV, 1989, REV INFECT DIS, V11, P379; MCILROY MA, 1991, J INFECT DIS, V163, P420, DOI 10.1093/infdis/163.2.420; MERZ WG, 1984, J CLIN MICROBIOL, V20, P1194, DOI 10.1128/JCM.20.6.1194-1195.1984; MERZ WG, 1986, J CLIN MICROBIOL, V24, P581, DOI 10.1128/JCM.24.4.581-584.1986; PERSONS DA, 1991, NEW ENGL J MED, V325, P1315; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; Rinaldi M. G., 1988, DIAGNOSTIC PROCEDURE, P325; SANDFORD GR, 1980, J INFECT DIS, V142, P503, DOI 10.1093/infdis/142.4.503; WILEY JM, 1990, J CLIN ONCOL, V8, P280, DOI 10.1200/JCO.1990.8.2.280; WINGARD JR, 1987, AM J MED, V83, P1103, DOI 10.1016/0002-9343(87)90949-1; WINGARD JR, 1979, ANN INTERN MED, V91, P539, DOI 10.7326/0003-4819-91-4-539; 1989, AM J MED, V86, P668	21	813	830	1	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1274	1277		10.1056/NEJM199110313251803	http://dx.doi.org/10.1056/NEJM199110313251803			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1669837				2022-12-24	WOS:A1991GM04100003
J	MEADE, TW; COOPER, J; MILLER, GJ; HOWARTH, DJ; STIRLING, Y				MEADE, TW; COOPER, J; MILLER, GJ; HOWARTH, DJ; STIRLING, Y			ANTITHROMBIN-III AND ARTERIAL-DISEASE	LANCET			English	Note							HEMOSTATIC VARIABLES	Cross-sectional studies suggest that both low and high antithrombin III levels are associated with the risk of arterial disease, principally ischaemic heart disease (IHD). The prospective relation between antithrombin III and subsequent death from arterial disease has been investigated in 893 men in the Northwick Park Heart Study. Antithrombin III levels were directly correlated with high rather than low levels of factor VII activity and of plasma fibrinogen. There were more deaths from arterial disease in the low and high thirds of the antithrombin III distribution than in the middle third.			MEADE, TW (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,MRC,EPIDEMIOL & MED CARE UNIT,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.							BANERJEE RN, 1974, THROMB DIATH HAEMOST, V31, P339, DOI 10.1055/s-0038-1649168; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; FULLER JH, 1979, BMJ-BRIT MED J, V2, P964, DOI 10.1136/bmj.2.6196.964; HAINES AP, 1980, THROMB RES, V19, P139, DOI 10.1016/0049-3848(80)90413-2; INNERFIELD I, 1976, AM J CLIN PATHOL, V65, P64; JORDAN RE, 1982, J BIOL CHEM, V257, P400; MEADE TW, 1990, BRIT J HAEMATOL, V74, P77, DOI 10.1111/j.1365-2141.1990.tb02541.x; MEADE TW, 1977, BRIT MED BULL, V33, P283, DOI 10.1093/oxfordjournals.bmb.a071448; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1987, THROMB DIATH HAEMO, P37; MEADE TW, 1987, HAEMOSTASIS THROMBOS, P697; MEILAHN E, 1988, AM J EPIDEMIOL, V128, P908; OBRIEN JR, 1975, THROMB DIATH HAEMOST, V34, P483, DOI 10.1055/s-0038-1651407; ROSENBERG RD, 1984, REV HAEMATOLOGY; YUE RH, 1976, THROMB HAEMOSTASIS, V35, P598, DOI 10.1055/s-0038-1647958	15	57	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1991	338	8771					850	851		10.1016/0140-6736(91)91503-M	http://dx.doi.org/10.1016/0140-6736(91)91503-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH945	1681216				2022-12-24	WOS:A1991GH94500005
J	TAMPE, R; CLARK, BR; MCCONNELL, HM				TAMPE, R; CLARK, BR; MCCONNELL, HM			ENERGY-TRANSFER BETWEEN 2 PEPTIDES BOUND TO ONE MHC CLASS-II MOLECULE	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGEN; RECOGNITION	The 17-amino acid peptide from chicken ovalbumin, Ova(323-339), was labeled at the amino terminus with fluorescein [FOva(323-339)] and near the carboxyl terminus with Texas Red [AcOva(323-338)KTR]. Fluorescence spectroscopy was carried out on resolved electrophoretic bands on nonreducing polyacrylamide gels derived from incubation mixtures containing major histocompatibility complex (MHC) class II molecules IA(d) and the FOva(323-339)- and AcOva(323-338)KTR-labeled peptides. Energy transfer between fluorescein and Texas Red was observed in the "floppy" alpha-beta heterodimer band, but not in the "compact" alpha-beta heterodimer band. Energy transfer was detected between the truncated peptides FOva(323-328)CONH2 and AcOva(331-338)KTR in both the compact alpha-beta and floppy alpha-beta gel bands. The energy-transfer data suggest that the two binding sites of floppy alpha-beta arise from splitting apart a putative large, single binding site region in compact alpha-beta.	ANERGEN INC,REDWOOD CITY,CA 94063		TAMPE, R (corresponding author), STANFORD UNIV,STAUFFER LAB PHYS CHEM,STANFORD,CA 94305, USA.		Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160	NIAID NIH HHS [2R37 AI 13587-16] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013587] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAYANI H, 1989, J EXP MED, V170, P1609, DOI 10.1084/jem.170.5.1609; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; DORMAIR K, 1990, P NATL ACAD SCI USA, V87, P4143; DORNMAIR K, UNPUB; DORNMAIR K, 1990, COLD SPRING HARB SYM, V54, P409; FOSTER T, 1946, NATURWISSENSCHAFTEN, V6, P166; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OHNO S, 1991, P NATL ACAD SCI USA, V88, P3065, DOI 10.1073/pnas.88.8.3065; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; PERUTZ MF, 1972, NATURE, V237, P495, DOI 10.1038/237495a0; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; TAMPE R, 1991, P NATL ACAD SCI USA, V88, P4661, DOI 10.1073/pnas.88.11.4661; TAMPE R, UNPUB	17	40	42	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					87	89		10.1126/science.1656526	http://dx.doi.org/10.1126/science.1656526			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1656526				2022-12-24	WOS:A1991GH60500032
J	VENTO, S; GAROFANO, T; DIPERRI, G; DOLCI, L; CONCIA, E; BASSETTI, D				VENTO, S; GAROFANO, T; DIPERRI, G; DOLCI, L; CONCIA, E; BASSETTI, D			IDENTIFICATION OF HEPATITIS-A VIRUS AS A TRIGGER FOR AUTOIMMUNE CHRONIC HEPATITIS TYPE-1 IN SUSCEPTIBLE INDIVIDUALS	LANCET			English	Article							CHRONIC ACTIVE HEPATITIS; ASIALOGLYCOPROTEIN RECEPTOR PROTEIN; AUTOANTIBODIES; LYMPHOCYTES; AUTOREACTIVITY; ANTIBODIES; ANTIGENS; MEASLES; LECTIN	To identify factors contributing to the pathogenesis of autoimmune chronic active hepatitis (CAH) healthy relatives of 13 patients with the disorder were followed prospectively for 4 years. 58 relatives were monitored for various serological markers and for T-lymphocyte migration inhibitory activity every 2 months. 3 cases of subclinical acute hepatitis A occurred during the study. In 2 of the 3 subjects, before hepatitis A virus (HAV) infection, there was a defect in suppressor-inducer T lymphocytes specifically controlling immune responses to the asialoglycoprotein receptor, an antigen expressed on the hepatocyte surface. In these 2 subjects, specific helper T cells and antibodies to the asialoglycoprotein receptor persisted and increased after acute hepatitis A, and autoimmune CAH type 1 developed within 5 months. Thus, in susceptible individuals HAV is a trigger for autoimmune CAH.	BORGO TRENTO CITY HOSP,DEPT MICROBIOL,VERONA,ITALY; UNIV VERONA,BORGO TRENTO HOSP,DEPT INFECT DIS,I-37100 VERONA,ITALY	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	VENTO, S (corresponding author), A PUGLIESE HOSP,INFECT DIS UNIT,I-88100 CATANZARO,ITALY.		Vento, Sandro/I-1662-2017	Vento, Sandro/0000-0003-0084-4062				ALLISON AC, 1971, LANCET, V2, P135; ESTEBAN JI, 1989, LANCET, V2, P294; FENZI G, 1978, J ENDOCRINOL INVEST, V1, P17, DOI 10.1007/BF03346766; HARFORD J, 1981, P NATL ACAD SCI-BIOL, V78, P1557, DOI 10.1073/pnas.78.3.1557; HARFORD J, 1984, GLYCOCONJUGATES, V4, P27; JOHNSON AH, 1980, 8TH INT HIST TEST WO, P285; LONGO A, 1980, 8TH INT HIST TEST WO, P283; MACKAY IR, 1962, Q J MED, V31, P485; MCFARLANE BM, 1985, J IMMUNOL METHODS, V77, P219, DOI 10.1016/0022-1759(85)90034-1; MCFARLANE BM, 1986, J HEPATOL, V3, P196, DOI 10.1016/S0168-8278(86)80026-5; MCFARLANE IG, 1984, CLIN EXP IMMUNOL, V55, P347; MIELI VERGANI G., 1979, Clinical and Experimental Immunology, V38, P16; MIELIVERGANI G, 1989, LANCET, V2, P688; OBRIEN CJ, 1986, LANCET, V1, P350; ROBERTSON DAF, 1987, LANCET, V2, P9; SPIESS M, 1985, J BIOL CHEM, V260, P1979; TERASAKI PI, 1974, DHEW NIH75545 PUBL, P67; TREICHEL U, 1990, HEPATOLOGY, V11, P606, DOI 10.1002/hep.1840110413; TREICHEL U, 1989, HEPATOLOGY, V10, P637; VALLBRACHT A, 1986, HEPATOLOGY, V6, P1308, DOI 10.1002/hep.1840060614; VENTO S, 1986, GASTROENTEROLOGY, V91, P810, DOI 10.1016/0016-5085(86)90680-3; VENTO S, 1987, LANCET, V1, P886; Vento S, 1990, Prog Liver Dis, V9, P335; VENTO S, 1988, J CLIN LAB IMMUNOL, V25, P1; VENTO S, 1984, LANCET, V1, P1200; VENTO S, 1988, J AUTOIMMUN, V1, P299, DOI 10.1016/0896-8411(88)90034-0	26	199	204	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1183	1187		10.1016/0140-6736(91)92858-Y	http://dx.doi.org/10.1016/0140-6736(91)92858-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673738				2022-12-24	WOS:A1991FM26100003
J	DOE, CQ; CHULAGRAFF, Q; WRIGHT, DM; SCOTT, MP				DOE, CQ; CHULAGRAFF, Q; WRIGHT, DM; SCOTT, MP			THE PROSPERO GENE SPECIFIES CELL FATES IN THE DROSOPHILA CENTRAL-NERVOUS-SYSTEM	CELL			English	Article							ACHAETE-SCUTE COMPLEX; EMBRYONIC-DEVELOPMENT; NEURONAL DEVELOPMENT; GLIAL PATHWAYS; AXON PATHWAYS; GROWTH CONES; PROTEIN; NEUROGENESIS; EXPRESSION; LOCALIZATION	The molecular mechanisms used to generate neuronal diversity are largely unknown. To identify genes controlling cell fate in the Drosophila central nervous system, we screened for mutations that alter expression of homeobox genes in the developing central nervous system (indicating changes in cell fates). We also screened "enhancer trap" lines to identify genes expressed in neuronal stem cells (neuroblasts). The prospero gene was discovered in both screens. Prospero is expressed in a subset of neuroblasts, sensory neuron precursors, and identified glial precursors. It is not expressed in neurons. Neuroblasts lacking prospero function generate abnormal cell lineages, producing incorrectly specified progeny that differentiate into neurons showing axon pathfinding defects. Prospero is therefore a novel type of gene expressed in neuroblasts and known to specify neuronal fate.	UNIV COLORADO,HOWARD HUGHES MED INST,BOULDER,CO 80309; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	DOE, CQ (corresponding author), UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801, USA.				PHS HHS [18163, 27056] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPOSORTEGA JA, 1991, IN PRESS ANN REV NEU, V14; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; Doe C Q, 1990, Semin Cell Biol, V1, P211; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DOE CQ, 1991, IN PRESS DETERMINANT; ENGELS WR, 1986, FOCUS, V8, P6; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HUFF R, 1989, DEV BIOL, V134, P146, DOI 10.1016/0012-1606(89)90085-7; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JACOBS JR, 1989, J NEUROSCI, V9, P2421; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; ROBERTSON HM, 1988, GENETICS, V118, P461; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; Sambrook J., 1989, MOL CLONING LAB MANU; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; SMOUSE D, 1988, GENE DEV, V2, P830, DOI 10.1101/gad.2.7.830; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5	49	393	398	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					451	464		10.1016/0092-8674(91)90463-9	http://dx.doi.org/10.1016/0092-8674(91)90463-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1673362				2022-12-24	WOS:A1991FK18200012
J	MORRIS, AJ; MADHOK, R; STURROCK, RD; CAPELL, HA; MACKENZIE, JF				MORRIS, AJ; MADHOK, R; STURROCK, RD; CAPELL, HA; MACKENZIE, JF			ENTEROSCOPIC DIAGNOSIS OF SMALL-BOWEL ULCERATION IN PATIENTS RECEIVING NONSTEROIDAL ANTIINFLAMMATORY DRUGS	LANCET			English	Note								15 patients with rheumatoid arthritis who were receiving non-steroidal anti-inflammatory drugs (NSAIDs) and who had chronic occult gastrointestinal bleeding underwent extended small bowel examination with a Sonde enteroscope. 7 patients (47%) were found to have jejunal or ileal ulceration. Small bowel enteroscopy may be a valuable technique for the investigation of undiagnosed gastrointestinal bleeding.	GLASGOW ROYAL INFIRM,GASTROINTESTINAL INVEST UNIT,GLASGOW G4 0SF,SCOTLAND; GLASGOW ROYAL INFIRM,CTR RHEUMAT DIS,GLASGOW G4 0SF,SCOTLAND	University of Glasgow; University of Glasgow								Bjarnason I., 1988, RECENT ADV GASTROENT, P23; KENT TH, 1969, AM J PATHOL, V54, P237; LEWIS BS, 1988, GASTROENTEROLOGY, V94, P1117, DOI 10.1016/0016-5085(88)90001-7; MADHOK R, 1986, Q J MED, V255, P53; UPADHYAY R, 1990, ANN RHEUM DIS, V49, P359, DOI 10.1136/ard.49.6.359	5	131	134	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					520	520		10.1016/0140-6736(91)91300-J	http://dx.doi.org/10.1016/0140-6736(91)91300-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671893				2022-12-24	WOS:A1991EZ87400007
J	GRAZIANO, JH; BLUM, C				GRAZIANO, JH; BLUM, C			LEAD-EXPOSURE FROM LEAD CRYSTAL	LANCET			English	Note								In a study of the elution of lead (Pb) from crystal decanters and glasses, port containing 89-mu-g Pb/l was placed in decanters and the Pb content of the wine rose steadily to 3518-mu-g/l after 4 months. Wines and spirits stored in crystal decanters for a long time contained Pb at concentrations up to 21 530-mu-g/l. In a short-term experiment white wine eluted small amounts of Pb from crystal glasses within minutes.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University	GRAZIANO, JH (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032, USA.							DELEACY EA, 1987, MED J AUSTRALIA, V147, P622; Elias RW, 1985, DIETARY ENV LEAD HUM, P79; Fernandez F., 1982, ATOM SPECTROSC, V3, P130; Nriagu J.O., 1985, DIETARY ENV LEAD HUM, P1; PLANCHES LTD, 1848, LEAD DISEASES TREATI, P37; 1988, NATURE EXTENT LEAD P, pI28	6	41	41	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					141	142						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670790				2022-12-24	WOS:A1991ET67900006
J	WOJCIECHOWSKI, AP; FARRALL, M; CULLEN, P; WILSON, TME; BAYLISS, JD; FARREN, B; GRIFFIN, BA; CASLAKE, MJ; PACKARD, CJ; SHEPHERD, J; THAKKER, R; SCOTT, J				WOJCIECHOWSKI, AP; FARRALL, M; CULLEN, P; WILSON, TME; BAYLISS, JD; FARREN, B; GRIFFIN, BA; CASLAKE, MJ; PACKARD, CJ; SHEPHERD, J; THAKKER, R; SCOTT, J			FAMILIAL COMBINED HYPERLIPEMIA LINKED TO THE APOLIPOPROTEIN AI-CIII-AIV GENE-CLUSTER ON CHROMOSOME-11Q23-Q24	NATURE			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; CORONARY HEART-DISEASE; DNA POLYMORPHISMS; LINKAGE ANALYSIS; LIPID-LEVELS; DEFICIENCY; HUMANS	Familial combined hyperlipidaemia (FCHL) is a common inherited disorder of lipid metabolism with a prevalence of 0.5-2.0% (refs 1,2). It is estimated to cause 10% of premature coronary heart disease 1,3. The underlying metabolic and genetic defects in FCHL have not been identified, but a population study has suggested an association between FCHL and an XmnI restriction fragment length polymorphism (RFLP) within the apolipoprotein AI-CIII-AIV gene cluster 4. Here we confirm this association and show that it results from linkage disequilibrium between FChl and the 6.6-kilobase (kb) allele of the XmnI RFLP. Subsequent analysis in seven FChl families, ascertained through a proband carrying the 6.6 kb XmnI allele, demonstrated linkage to the AI-CIII-AIV cluster on 11q23-q24, z = 6.86 with no recombinants. This assignment will facilitate the identification of the mutation that causes hyperlipidaemia in these families.	NORTHWICK PK HOSP & CLIN RES CTR,MRC,CLIN RES CTR,DIV MOLEC MED,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND; GLASGOW ROYAL INFIRM,INST PATHOL BIOCHEM,GLASGOW G4 0SF,SCOTLAND	Imperial College London; Medical Research Council Clinical Trials Unit; University of Glasgow				Thakker, Rajesh/0000-0002-1438-3220				BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BRESLOW JL, 1989, J CLIN INVEST, V84, P373, DOI 10.1172/JCI114176; BRUNZELL JD, 1976, METABOLISM, V25, P313, DOI 10.1016/0026-0495(76)90089-5; CHIVOT L, 1990, ATHEROSCLEROSIS, V82, P205, DOI 10.1016/0021-9150(90)90042-H; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GRIFFIN BA, 1990, ATHEROSCLEROSIS, V83, P59, DOI 10.1016/0021-9150(90)90131-2; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; HAYDEN MR, 1987, AM J HUM GENET, V40, P421; KESSLING AM, 1985, CLIN GENET, V28, P296; LANDER ES, 1988, MAPPING COMPLEX GENE, P171; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LAW A, 1986, LANCET, V1, P1301; NIKKILA EA, 1973, LANCET, V1, P954; NORUM RA, 1982, NEW ENGL J MED, V306, P1513, DOI 10.1056/NEJM198206243062503; OTT J, 1985, Genetic Epidemiology, V2, P79, DOI 10.1002/gepi.1370020108; ROSE HG, 1973, AM J MED, V54, P148, DOI 10.1016/0002-9343(73)90218-0; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; WILSON TME, IN PRESS NUCLEIC ACI; WINDLER E, 1985, J LIPID RES, V26, P556; 1980, NIH801527 PUBL, V1	24	175	176	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					161	164		10.1038/349161a0	http://dx.doi.org/10.1038/349161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1670899				2022-12-24	WOS:A1991ER41800060
J	MASTERSON, WJ; RAPER, J; DOERING, TL; HART, GW; ENGLUND, PT				MASTERSON, WJ; RAPER, J; DOERING, TL; HART, GW; ENGLUND, PT			FATTY-ACID REMODELING - A NOVEL REACTION SEQUENCE IN THE BIOSYNTHESIS OF TRYPANOSOME GLYCOSYL PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS	CELL			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University				Hart, Gerald/0000-0001-7812-4351; Raper, Jayne/0000-0002-8723-9748	NIAID NIH HHS [AI21334] Funding Source: Medline; NIGMS NIH HHS [5T32GM07309] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANGS JD, 1988, J BIOL CHEM, V263, P17697; BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; Mead J. F., 1986, LIPIDS CHEM BIOCH NU; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, IN PRESS J BIOL CHEM; NIJSSEN JG, 1986, BIOCHIM BIOPHYS ACTA, V875, P450, DOI 10.1016/0005-2760(86)90064-0; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; Stahl E., 1969, THIN LAYER CHROMATOG; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595	29	191	193	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 13	1990	62	1					73	80		10.1016/0092-8674(90)90241-6	http://dx.doi.org/10.1016/0092-8674(90)90241-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DN533	1694728				2022-12-24	WOS:A1990DN53300012
J	MANCA, F; HABESHAW, JA; DALGLEISH, AG				MANCA, F; HABESHAW, JA; DALGLEISH, AG			HIV ENVELOPE GLYCOPROTEIN, ANTIGEN SPECIFIC T-CELL RESPONSES, AND SOLUBLE CD4	LANCET			English	Article									MRC,CTR CLIN RES,DIV IMMUNOL,RETROVIRUS RES GRP,HARROW HA1 3UJ,MIDDX,ENGLAND		MANCA, F (corresponding author), UNIV GENOA,SAN MARTINO HOSP,DEPT IMMUNOL,I-16126 GENOA,ITALY.		Dalgleish, Angus/AAZ-4450-2020	Dalgleish, Angus/0000-0003-3511-3059				BIDDISON WE, 1984, J EXP MED, V159, P783, DOI 10.1084/jem.159.3.783; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHIRMULE N, 1990, BLOOD, V75, P152; CLAPHAM PR, 1987, VIROLOGY, V158; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DALGLEISH AG, 1989, ADV HUMAN RETROVIRUS, V51, P307; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DIAMOND DC, 1988, J IMMUNOL, V141, P3715; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GELDERBLOM HR, 1989, ARCH VIROL, V106, P1, DOI 10.1007/BF01311033; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; GOWDA SD, 1989, J IMMUNOL, V142, P773; HABESHAW JA, 1989, J ACQ IMMUN DEF SYND, V2, P457; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; JOUAULT T, 1989, AIDS, V3, P125, DOI 10.1097/00002030-198903000-00002; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; PATTERSON S, 1987, J GEN VIROL, V68, P1177, DOI 10.1099/0022-1317-68-4-1177; RIVAS A, 1988, J IMMUNOL, V140, P2912; SHALABY MR, 1987, CELL IMMUNOL, V110, P140, DOI 10.1016/0008-8749(87)90108-0; SHEARER GM, 1986, J IMMUNOL, V137, P2514; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SPICKETT G, 1989, J VIROL METHODS, V24, P67, DOI 10.1016/0166-0934(89)90008-6; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091; ZARLING JM, 1988, AIDS S, V2, P3113	36	96	96	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 7	1990	335	8693					811	815		10.1016/0140-6736(90)90935-X	http://dx.doi.org/10.1016/0140-6736(90)90935-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CY371	1690832				2022-12-24	WOS:A1990CY37100003
J	HEAPHY, S; DINGWALL, C; ERNBERG, I; GAIT, MJ; GREEN, SM; KARN, J; LOWE, AD; SINGH, M; SKINNER, MA				HEAPHY, S; DINGWALL, C; ERNBERG, I; GAIT, MJ; GREEN, SM; KARN, J; LOWE, AD; SINGH, M; SKINNER, MA			HIV-1 REGULATOR OF VIRION EXPRESSION (REV) PROTEIN BINDS TO AN RNA STEM-LOOP STRUCTURE LOCATED WITHIN THE REV RESPONSE ELEMENT REGION	CELL			English	Article											HEAPHY, S (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Skinner, Michael A/B-7112-2012	Skinner, Michael/0000-0002-0050-4167				ATHERTON E, 1986, J CHEM SOC CHEM COMM, P1763, DOI 10.1039/c39860001763; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DRYLAND A, 1986, J CHEM SOC P1, V128, P125; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; Galfre G, 1981, Methods Enzymol, V73, P3; HEAPHY S, 1987, PROTEIN ENG, V1, P425, DOI 10.1093/protein/1.5.425; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KNIGHT DM, 1987, SCIENCE, V236, P837, DOI 10.1126/science.3033827; MALIM MH, 1989, P NATL ACAD SCI USA, V86, P8222, DOI 10.1073/pnas.86.21.8222; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; VARTIKAR JV, 1989, J MOL BIOL, V209, P221, DOI 10.1016/0022-2836(89)90274-X; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	33	331	344	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1990	60	4					685	693		10.1016/0092-8674(90)90671-Z	http://dx.doi.org/10.1016/0092-8674(90)90671-Z			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CQ723	1689218				2022-12-24	WOS:A1990CQ72300018
J	AUGUSTIN, S; MULLER, MW; SCHWEYEN, RJ				AUGUSTIN, S; MULLER, MW; SCHWEYEN, RJ			REVERSE SELF-SPLICING OF GROUP-II INTRON RNAS INVITRO	NATURE			English	Article											AUGUSTIN, S (corresponding author), UNIV VIENNA,INST MIKROBIOL & GENET,ALTHANSTR 14,A-1090 VIENNA,AUSTRIA.							CECH TR, 1985, INT REV CYTOL, V93, P3, DOI 10.1016/S0074-7696(08)61370-4; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JARRELL KA, 1988, J BIOL CHEM, V263, P3432; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MULLER MW, 1988, NUCLEIC ACIDS RES, V16, P7383, DOI 10.1093/nar/16.15.7383; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; SCHMEIZER C, 1987, CELL, V51, P753, DOI 10.1016/0092-8674(87)90098-5; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WOLF K, 1987, ENDOCYT CELL RES, V4, P103; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9	15	91	94	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1990	343	6256					383	386		10.1038/343383a0	http://dx.doi.org/10.1038/343383a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK918	1689013				2022-12-24	WOS:A1990CK91800067
J	HEALY, B				HEALY, B			ASPIRIN AND WARFARIN EFFECTIVE IN PREVENTING STROKE AND EMBOLISM IN PATIENTS WITH ATRIAL-FIBRILLATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, CIRCULATION, V84, P527	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2955	2955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1668176				2022-12-24	WOS:A1991GR77500006
J	HEALY, B				HEALY, B			CURRENTLY LICENSED IMMUNOASSAYS DO NOT ACCURATELY DISTINGUISH ANTIBODIES TO HERPES-SIMPLEX VIRUS SUBTYPES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, ANN INTERN MED, V115, P520	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2955	2955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1668176				2022-12-24	WOS:A1991GR77500007
